<SEC-DOCUMENT>0001683168-21-000475.txt : 20210210
<SEC-HEADER>0001683168-21-000475.hdr.sgml : 20210210
<ACCEPTANCE-DATETIME>20210210171530
ACCESSION NUMBER:		0001683168-21-000475
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		80
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210210
DATE AS OF CHANGE:		20210210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37487
		FILM NUMBER:		21615061

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>aethlon_10q-123120.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt"><A HREF="#a_019">Table of Contents</A></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 10-Q</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Mark One)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the quarterly period ended December
31, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">OR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the transition period from _____to_____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">COMMISSION FILE NUMBER 001-37487</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">AETHLON MEDICAL,
INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEVADA</FONT></TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-3632859</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation or organization)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9635 GRANITE RIDGE DRIVE, SUITE 100, SAN
DIEGO, CA 92123</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices,
including Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(858) 459-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant's telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol</FONT></TD>
    <TD STYLE="width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AEMD</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nasdaq Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. YES &#9746; NO &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant has submitted
electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this
chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES&nbsp;&nbsp;
&#9746; NO&nbsp;&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo;, &ldquo;smaller reporting company&rdquo;, and &ldquo;emerging
growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer &#9744;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company &#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company &#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to section 13(a) of the Exchange Act. &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act). YES &#9744; NO &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of February 4, 2021, the registrant had outstanding 12,123,524
shares of common stock, $0.001 par value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_019"></A>TABLE OF CONTENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">FINANCIAL INFORMATION</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 85%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">FINANCIAL STATEMENTS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">CONDENSED CONSOLIDATED BALANCE SHEETS AT DECEMBER 31,&nbsp;2020 (UNAUDITED) AND MARCH&nbsp;31, 2020</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED DECEMBER 31, 2020 AND 2019 (UNAUDITED)</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&rsquo; EQUITY FOR THE THREE&nbsp;AND NINE MONTHS ENDED DECEMBER 31, 2020 AND 2019 (UNAUDITED)</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED DECEMBER 31, 2020 AND 2019 (UNAUDITED)</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">CONTROLS AND PROCEDURES</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">OTHER INFORMATION</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">LEGAL PROCEEDINGS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1A.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">RISK FACTORS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_015">DEFAULTS UPON SENIOR SECURITIES</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_016">MINE SAFETY DISCLOSURES</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_017">OTHER INFORMATION</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_018">EXHIBITS</A></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_001"></A>PART I. FINANCIAL INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_002"></A>ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A>CONDENSED CONSOLIDATED BALANCE SHEETS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">December 31, <BR> 2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">March 31, <BR> 2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 66%">Cash</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">12,131,593</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">9,604,780</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114,849</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">206,729</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">75,829</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">229,604</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,322,271</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,041,113</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">166,751</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,484</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Right-of-use lease asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">136,426</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Patents, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,092</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,504</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,726</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 1pt">Deposits</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,159</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,159</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,669,749</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,387,686</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">175,422</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">285,036</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Due to related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131,746</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,707</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Lease liability, current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,698</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,557</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">860,697</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">472,420</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,235,563</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,067,720</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Lease liability, less current portion</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">42,540</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,235,563</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,110,260</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Commitments and Contingencies (Note 13)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Stockholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt">Common stock, par value $0.001 per share; 30,000,000 shares authorized; 12,123,524 and 9,366,873 shares issued and outstanding as of December 31, 2020 and March 31, 2020, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,368</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129,207,491</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,426,563</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(117,650,120</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(112,026,381</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Total Aethlon Medical, Inc. stockholders&rsquo; equity before noncontrolling interests</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,569,496</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,409,550</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(135,310</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(132,124</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,434,186</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,277,426</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,669,749</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,387,686</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Three and Nine Month Periods Ended
December 31, 2020 and 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months <BR> Ended <BR> December 31, <BR> 2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months <BR> Ended <BR> December 31, <BR> 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Nine Months <BR> Ended <BR> December 31, <BR> 2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Nine Months <BR> Ended <BR> December 31, <BR> 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>REVENUES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 40%; text-align: left">Government contract revenue</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">624,871</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">413,458</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">624,871</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">443,458</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">OPERATING EXPENSES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">624,979</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">609,933</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,845,659</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,979,848</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Payroll and related expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,523,650</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">406,421</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,520,805</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,609,942</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">919,830</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">273,510</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,883,802</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">998,465</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,068,459</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,289,864</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,250,266</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,588,255</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">OPERATING LOSS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,443,588</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(876,406</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,625,395</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,144,797</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">OTHER EXPENSE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest and other debt expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">802</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">126</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,530</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,232</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">(Gain) on share for warrant exchanges</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55,593</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(51,190</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Loss on debt extinguishment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">447,011</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total other expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">802</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(55,467</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,530</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">450,053</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">NET LOSS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,444,390</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(820,939</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,626,925</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,594,850</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 1pt">LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,498</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,358</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,186</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,808</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 1pt">NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC.</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,442,892</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(819,581</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,623,739</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,591,042</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 1pt">BASIC AND DILUTED LOSS PER COMMON SHARE</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.20</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.28</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.50</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2.52</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 1pt">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING &ndash; BASIC AND DILUTED</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,093,361</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,887,883</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,265,725</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,821,557</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&rsquo;
EQUITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Three and Nine Months Ended December
31, 2020 and 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1pt solid">ATTRIBUTABLE TO AETHLON MEDICAL, INC.</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">COMMON STOCK</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: center">ADDITIONAL PAID IN</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: center">ACCUMULATED</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: center">NON-<BR> CONTROLLING</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: center">TOTAL</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">SHARES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">AMOUNT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">CAPITAL</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">DEFICIT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">INTERESTS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">EQUITY</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt; width: 22%">BALANCE - MARCH 31, 2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9,366,873</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">9,368</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">121,426,563</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(112,026,381</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(132,124</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">9,277,426</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Issuances of common stock for cash under at the market program</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,685,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,686</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,258,183</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,260,869</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Issuance of common shares upon vesting of restricted stock units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,920</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,269</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,251</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84,207</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,410,283</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(863</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,411,146</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">BALANCE - JUNE 30, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,070,393</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,072</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">128,744,684</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(113,436,664</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(132,987</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,187,105</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Issuance of common shares upon vesting of restricted stock units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,920</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(16,145</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(16,128</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">167,042</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">167,042</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,770,564</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(825</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,771,389</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">BALANCE - SEPTEMBER 30, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,088,313</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,089</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">128,895,581</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(115,207,228</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(133,812</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">13,566,630</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Issuance of common shares upon vesting of restricted stock units and net stock option exercise</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,211</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(66,048</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(66,012</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">377,958</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">377,958</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,442,892</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,498</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,444,390</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">BALANCE - DECEMBER 31, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,123,524</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,125</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">129,207,491</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(117,650,120</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(135,310</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,434,186</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Continued on following page</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1pt solid">ATTRIBUTABLE TO AETHLON MEDICAL, INC.</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">COMMON STOCK</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: center">ADDITIONAL PAID IN</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: center">ACCUMULATED</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: center">NON-<BR> CONTROLLING</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: center">TOTAL</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">SHARES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">AMOUNT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">CAPITAL</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">DEFICIT</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">INTERESTS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">EQUITY</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt; width: 22%">BALANCE - MARCH 31, 2019</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,266,979</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,267</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">108,076,275</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(105,652,433</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(126,031</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,299,078</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Issuances of common stock for cash under at the market program</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,087</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,619</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,622</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Loss on debt extinguishment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">447,011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">447,011</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Issuance of common shares upon vesting of restricted stock units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,539</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,775</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,771</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">326,536</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">326,536</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,066,424</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(860</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,067,284</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">BALANCE - JUNE 30, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,273,605</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,274</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">108,862,666</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(107,718,857</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(126,891</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,018,192</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Issuances of common stock for cash under at the market program</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59,340</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">60</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">386,552</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">386,612</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Issuance of common shares upon vesting of restricted stock units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,236</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,448</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,445</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Issuance of common shares upon warrant exchanges</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,078</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,402</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,403</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">326,536</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">326,536</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,705,037</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,589</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,706,626</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">BALANCE - SEPTEMBER 30, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,337,259</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,339</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">109,571,708</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(109,423,894</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(128,480</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">20,672</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Proceeds from the issuance of common stock, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,432,056</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,432</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,560,802</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,564,234</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Issuance of common shares upon vesting of restricted stock units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,439</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,772</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,769</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Issuances of common stock upon warrant exchanges</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,914</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55,596</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55,593</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Par value of DTC roundup of shares following reverse split</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,946</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">Stock-based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,576</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102,576</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(819,581</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,358</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(820,939</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt">BALANCE &ndash; DECEMBER 31, 2019</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,779,614</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,781</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">114,172,714</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(110,243,475</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(129,838</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,804,182</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A>CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Nine Months Ended December 31, 2020
and 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Nine Months <BR> Ended <BR> December 31, 2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Nine Months <BR> Ended <BR> December 31, 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Cash flows used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 66%; text-align: left">Net loss</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(5,626,925</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(4,594,850</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,775</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,992</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">629,207</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">755,648</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Loss on debt extinguishment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">447,011</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Gain on share for warrant exchanges</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(51,190</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Accretion of right-of-use lease asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,723</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">862</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Amortization of debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,287</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,880</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(206,729</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">153,775</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169,691</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left">Accounts payable and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">278,663</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(271,533</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Due to related parties</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20,039</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,558</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,526,309</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,577,253</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash flows used in investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Purchases of property and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(54,630</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(148,064</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(54,630</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(148,064</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash flows provided by (used in) financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from the issuance of common stock, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,260,869</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,987,468</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Principal payments on convertible notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(992,591</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Tax withholding payments or tax
    equivalent payments for net share settlement of restricted stock units and net stock option exercise</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(106,391</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(38,981</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,154,478</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,955,896</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net increase in cash and restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,573,539</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,579</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and restricted cash at beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,604,780</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,828,074</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Cash and restricted cash at end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,178,319</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,058,653</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Supplemental disclosures of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash paid during the period for:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">Interest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">83,332</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Supplemental disclosures of non-cash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Initial recognition of right-of-use lease asset and lease liability</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">228,694</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Par value of shares issued for round up following reverse stock split</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Par value of shares issued for vested restricted
    stock units and net stock option exercise</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">71</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt; text-align: left">Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left">Cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,131,593</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,058,653</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Restricted cash</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46,726</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Cash and restricted cash</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,178,319</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,058,653</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">See accompanying notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AETHLON MEDICAL, INC. AND SUBSIDIARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A>NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (UNAUDITED)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">December 31, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. NATURE OF BUSINESS AND BASIS OF PRESENTATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ORGANIZATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon Medical, Inc. and its subsidiary
(collectively, &ldquo;Aethlon&rdquo;, the &ldquo;Company&rdquo;, &ldquo;we&rdquo; or &ldquo;us&rdquo;), is a medical technology
company focused on developing products to diagnose and treat life and organ threatening diseases. The Aethlon Hemopurifier&reg;,
or Hemopurifier, is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections.
In cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression,
seed the spread of metastasis and inhibit the benefit of leading cancer therapies. The U.S. Food and Drug Administration, or FDA,
has designated the Hemopurifier as a &ldquo;Breakthrough Device&rdquo; for&nbsp;two independent indications:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the treatment of life-threatening viruses that are not addressed with approved therapies.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the Hemopurifier can be a substantial
advance in the treatment of patients with advanced and metastatic cancer through the clearance of exosomes that promote the growth
and spread of tumors through multiple mechanisms. We are currently preparing for the initiation of clinical trials in patients
with advanced and metastatic cancers. We are initially focused on the treatment of solid tumors, including head and neck cancer,
gastrointestinal cancers and other cancers. As we advance our clinical trials, we are in close contact with our clinical sites
to navigate and assess the impact of the COVID-19 global pandemic on our clinical trials and current timelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 4, 2019, the FDA approved our
Investigational Device Exemption, or IDE, application to initiate an Early Feasibility Study, or EFS, of the Hemopurifier in patients
with head and neck cancer in combination with standard of care pembrolizumab (Keytruda) (NCT # 04453046).&nbsp; The primary endpoint
for the EFS, which is designed to enroll 10-12 subjects at a single center, will be safety, with secondary endpoints including
measures of exosome clearance and characterization, as well as response and survival rates. This study, which will be conducted
at the UPMC Hillman Cancer Center in Pittsburgh, PA, has been approved by the Institutional Review Board, or IRB, and is now open
for patient enrollment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also believe the Hemopurifier can be
a part of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed
with an already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used to treat
individuals infected with human immunodeficiency virus, or HIV, Hepatitis C, and Ebola.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, <I>in vitro,</I> the Hemopurifier
has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus,
Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, and the
reconstructed Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government
or non-government research institutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2020, the FDA approved a supplement
to the Company&rsquo;s open IDE for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients
with SARS-CoV-2/COVID-19 in a New Feasibility Study. <FONT STYLE="background-color: white">That study&rsquo;s plan is to enroll
up to 40 subjects at up to 20 centers in the U.S. Subjects will have established laboratory diagnosis of COVID-19, be admitted
to an intensive care unit, or ICU and will have acute lung injury and/or severe or life threatening disease, among other criteria.
Endpoints for this study, in addition to safety, will include reduction in circulating virus as well as clinical outcomes (NCT
# 04595903). The first sites for this trial, Hoag Memorial Hospital Presbyterian in Newport Beach, CA and Hoag Hospital &ndash;
Irvine in Irvine, CA now have IRB approval and are preparing to open for patient enrollment. Under Single Patient Emergency Use
regulations, the Company has also recently treated a patient with COVID-19 who successfully completed eight daily treatments with
the Hemopurifier.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also the majority owner of Exosome
Sciences, Inc., or ESI, a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases.
Included among ESI&rsquo;s activities is the advancement of a TauSome&trade; biomarker candidate to diagnose chronic traumatic
encephalopathy, or CTE, in the living. ESI previously documented TauSome levels in former NFL players to be nine times higher than
same age-group control subjects. Through ESI, we are also developing exosome based biomarkers in patients with, or at risk for,
a number of cancers. We consolidate ESI&rsquo;s activities in our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Successful outcomes of human trials will
also be required by the regulatory agencies of certain foreign countries where we plan to sell the Hemopurifier. Some of our patents
may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications
and/or other patents issued more recently will help protect the proprietary nature of the Hemopurifier treatment technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the foregoing, we are monitoring
closely the impact of the COVID-19 global pandemic on our business and have taken steps designed to protect the health and safety
of our employees while continuing our operations. Given the level of uncertainty regarding the duration and impact of the COVID-19
pandemic on capital markets and the U.S. economy, we are unable to assess the impact of the worldwide spread of SARS-CoV-2 and
the resulting COVID-19 pandemic on our timelines and future access to capital. We are continuing to monitor the spread of COVID-19
and its potential impact on our operations. The full extent to which the COVID-19 pandemic will impact our business, results of
operations, financial condition, clinical trials, and preclinical research will depend on future developments that are highly uncertain,
including actions taken to contain or treat COVID-19 and their effectiveness, as well as the economic impact on national and international
markets.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our executive offices are located at 9635
Granite Ridge Drive, Suite 100, San Diego, California 92123. Our telephone number is (858) 459-7800. Our website address is www.aethlonmedical.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the Nasdaq Capital Market under
the symbol &ldquo;AEMD.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">REVERSE STOCK SPLIT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the approval of a reverse stock
split at our 2019 Annual Meeting of Stockholders&rsquo; held on October 14, 2019, our Board of Directors approved a 1-for-15 reverse
stock split. Accordingly, 15 shares of outstanding common stock then held by stockholders were combined into one share of common
stock. Any fractional shares resulting from the reverse split were rounded up to the next whole share. Authorized common stock
remained at 30,000,000 shares. The accompanying unaudited condensed consolidated financial statements and accompanying notes have
been retroactively revised to reflect such reverse stock split as if it had occurred on April 1, 2019. All shares and per share
amounts have been revised accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended December 31, 2020, there were no
changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended March 31,
2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis of Presentation and Use of Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP,
for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission,
or SEC Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto
for the fiscal year ended March 31, 2020, included in the Company's Annual Report on Form 10-K filed with the SEC on June 25, 2020.
The accompanying unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its majority-owned
subsidiary. All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed
consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are
necessary to present fairly the condensed consolidated financial statements as of and for the three and nine months ended December
31, 2020, and the condensed consolidated statement of cash flows for the nine months ended December 31, 2020. Estimates were made
relating to useful lives of fixed assets, impairment of assets, share-based compensation expense and accruals for clinical trial
and research and development expenses. Actual results could differ materially from those estimates. The accompanying condensed
consolidated balance sheet at March 31, 2020 has been derived from the audited consolidated balance sheet at March 31, 2020, contained
in the above referenced 10-K. The results of operations for the three and nine months ended December 31, 2020 are not necessarily
indicative of the results to be expected for the full year or any future interim periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reclassifications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year balances within the unaudited condensed consolidated
financial statements have been reclassified to conform to the current year presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Restricted Cash</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To comply with the terms of our new laboratory and office lease
(see Note 13), we caused our bank to issue a standby letter of credit, or the L/C, in the amount of $46,726 in favor of the landlord.
The L/C is in lieu of a security deposit. In order to support the L/C, we agreed to have our bank withdraw $46,726 from our operating
accounts and to place that amount in a restricted certificate of deposit. We have classified that amount as restricted cash, a
long-term asset, on our balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LIQUIDITY AND GOING CONCERN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management expects existing cash as of
December 31, 2020 to be sufficient to fund the Company&rsquo;s operations for at least twelve months from the issuance date of
these condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. LOSS PER COMMON SHARE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing
net loss by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is
computed similar to basic loss per share, except that the denominator is increased to include the number of additional dilutive
common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were
dilutive. Since we had net losses for all periods presented, basic and diluted loss per share are the same, and additional potential
common shares have been excluded, as their effect would be antidilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020, and 2019, an aggregate
of 2,626,485 and 3,779,301 potential common shares, respectively, consisting of shares underlying outstanding stock options, warrants
and unvested restricted stock units, were excluded, as their inclusion would be antidilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. RESEARCH AND DEVELOPMENT EXPENSES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development costs are
expensed as incurred. We incurred research and development expenses during the three and nine month periods ended December 31,
2020 and 2019, which are included in various operating expense line items in the accompanying condensed consolidated statements
of operations. Our research and development expenses in those periods were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 65%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three months ended</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">461,176</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">218,571</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nine months ended</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,367,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">692,022</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. <FONT STYLE="text-transform: uppercase">Recent Accounting
Pronouncements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not expect the adoption of any recent accounting pronouncement
to have a material impact on our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. CONVERTIBLE NOTES PAYABLE, NET</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2019, all of our previously outstanding
convertible notes, in the aggregate amount of $992,591, were paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the nine months ended December 31,
2019, we recorded interest expense of $23,759 related to the contractual interest rates of our convertible notes and interest expense
of $30,287 related to the amortization of the note discount for a total interest expense of $54,046 related to our convertible
notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended December 31,
2019, prior to paying off the notes, we reduced the conversion price on the convertible notes from $45.00 per share to $10.20 per
share. The modification of the convertible notes was evaluated under ASC 470-50-40 and the instruments were determined to be substantially
different, and the transaction qualified for extinguishment accounting. Under the extinguishment accounting we recorded a loss
on debt extinguishment of $447,011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6. EQUITY TRANSACTIONS&nbsp;IN THE NINE MONTHS ENDED DECEMBER
31, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock Sales Agreement with H.C. Wainwright &amp; Co.,
LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 28, 2016, we entered into a Common
Stock Sales Agreement, or the Agreement, with H.C. Wainwright &amp; Co., LLC, or Wainwright, which established an at-the-market
equity program pursuant to which we may offer and sell shares of our common stock from time to time as set forth in the Agreement.
The Agreement provided for the sale of shares of our common stock having an aggregate offering price of up to $12,500,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 30, 2020, we executed Amendment
No. 2 to the Agreement with Wainwright, effective as of the same date. The amendment provides that references in the Agreement
to the registration statement shall refer to the registration statement on Form S-3 (File No. 333-237269), originally filed with
the SEC on March 19, 2020, declared effective by the SEC on March 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms and conditions set
forth in the Agreement, Wainwright agreed to use its commercially reasonable efforts consistent with its normal trading and sales
practices to sell the shares under the Agreement from time to time, based upon our instructions. We provided Wainwright with customary
indemnification rights under the Agreement, and Wainwright is entitled to a commission at a fixed rate equal to three percent of
the gross proceeds per share sold. In addition, we agreed to pay certain expenses incurred by Wainwright in connection with the
Agreement, including up to $50,000 of the fees and disbursements of their counsel. The Agreement will terminate upon the sale of
all of the shares under the Agreement, unless terminated earlier by either party as permitted under the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of the shares, if any, under the
Agreement will be made in transactions that are deemed to be &ldquo;at the market offerings&rdquo; as defined in Rule 415 under
the Securities Act of 1933, as amended, or the Securities Act, including sales made by means of ordinary brokers&rsquo; transactions,
including on the Nasdaq Capital Market, at market prices or as otherwise agreed with Wainwright. We have no obligation to sell
any of the shares, and, at any time, we may suspend offers under the Agreement or terminate the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the three months ended June 30, 2020,
we raised aggregate net proceeds of $7,260,869, net of $224,825 in commissions to Wainwright and $8,472 in other offering expenses,
under the Agreement, through the sale of 2,685,600 shares at an average price of $2.70 per share of net proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Restricted Stock Unit Grants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2012, as amended through July 16, 2020,
our Board of Directors established the Non-Employee Directors Compensation Program, to provide for cash and equity compensation
for persons serving as non-employee directors of the Company. Under this program, each new director receives either stock options
or a grant of restricted stock units, or RSUs, as well as an annual grant of RSUs at the beginning of each fiscal year. The RSUs
are subject to vesting and represent the right to be issued on a future date shares of our common stock upon vesting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 3, 2020, pursuant to the terms
of the Company&rsquo;s Non-Employee Directors Compensation Program, the Compensation Committee of the Board of Directors granted
RSUs to each non-employee director of the Company. The Non-Employee Directors Compensation Program provided for a grant of RSUs
with a grant date fair value of $35,000, priced at the average of the closing prices for the five trading days ending on the date
of grant, which was $1.41 per share, so that the total number of RSUs to be granted to each non-employee director for fiscal year
2020 would be 24,822 shares of our common stock.&nbsp;&nbsp;On April 3, 2020, each eligible director was granted an RSU for 23,893
shares under the Company&rsquo;s 2010 Stock Plan, or the 2010 Plan, as the number of shares that remained available for grant under
the 2010 Plan was not sufficient for each director&rsquo;s full RSU grant. The Compensation Committee also granted to each eligible
director a contingent grant under our 2020 Equity Incentive Plan, or the 2020 Plan, for the remaining portion of the annual RSU
grants, or 929 RSU&rsquo;s to each eligible director, contingent upon stockholder approval of the 2020 Plan at the Company&rsquo;s
2020 Annual Meeting of Stockholders, or the Annual Meeting. These grants are subject to vesting as follows: 50% of the RSUs subject
to the grants will vest on December 31, 2020 and 50% of the RSUs will vest on March 31, 2021, subject in each case to the continuous
service of each director, through such vesting dates, as well as approval of the 2020 Plan by the stockholders at the Annual Meeting,
which was obtained at the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2020, 29,866 vested RSUs held by
our non-employee directors were exchanged into the same number of shares of our common stock. All five non-employee directors elected
to return 40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resulting
in 11,947 of the vested RSUs being cancelled in exchange for $24,251 in aggregate cash proceeds to those independent directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2020, 29,866 vested RSUs held
by our non-employee directors were exchanged into the same number of shares of our common stock. All five non-employee directors
elected to return 40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances,
resulting in 11,947 of the vested RSUs being cancelled in exchange for $16,128 in aggregate cash proceeds to those independent
directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also in September 2020, our stockholders
approved the 2020 Plan at the Annual Meeting, at which point the grants of 929 RSUs to each of our eligible independent directors
for a total of 4,645 RSUs were considered effective and no longer contingent as of that date (See Note 9).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, 32,189 vested RSUs held
by our non-employee directors were exchanged into the same number of shares of our common stock. All five non-employee directors
elected to return 40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances,
resulting in 12,876 of the vested RSUs being cancelled in exchange for $31,802 in aggregate cash proceeds to those independent
directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RSUs outstanding that have vested as of,
and are expected to vest subsequent to, December 31, 2020 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of RSUs</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Vested</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 83%; text-align: left; padding-bottom: 1pt">Expected to vest</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; border-bottom: Black 1pt solid; text-align: right">32,189</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">32,189</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7. RELATED PARTY TRANSACTIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended December
31, 2020, we accrued unpaid fees of $69,292 owed to our non-employee directors as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of entering into a Separation Agreement on October
30, 2020 with our former Chief Executive Officer, or CEO, Timothy Rodell, M.D., or the Separation Agreement, we paid out accrued
vacation of $20,260 to Dr. Rodell in the three months ended December 2020 (see Note 8 and Note 13). That accrued vacation was previously
recorded in the due to related parties account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amounts due to related parties were comprised
of the following items:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">December 31, <BR>2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">March 31, <BR>2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Accrued Board fees</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">69,292</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">69,750</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accrued vacation to all employees</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">62,454</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">41,957</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total due to related parties</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">131,746</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">111,707</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8. OTHER CURRENT LIABILITIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other current liabilities were comprised of the following items:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">March 31,</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 66%; text-align: left">Accrued separation expenses for former executive</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">400,578</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accrued professional fees</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">460,119</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">472,420</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total other current liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">860,697</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">472,420</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9. STOCK COMPENSATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables summarize share-based compensation expenses
relating to RSUs and stock options and the effect on basic and diluted loss per common share during the three and nine month periods
ended December 31, 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months <BR> Ended <BR> December 31, <BR> 2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months<BR> Ended<BR> December 31, <BR> 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Nine Months <BR> Ended <BR> December 31,<BR> 2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Nine Months<BR> Ended <BR> December 31,<BR> 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1pt">Vesting of stock options and restricted stock units</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">377,958</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">102,576</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">629,207</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">755,648</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total stock-based compensation expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">377,958</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">102,576</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">629,207</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">755,648</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Weighted average number of common shares outstanding &ndash; basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,093,361</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,887,883</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">11,265,725</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,821,557</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Basic and diluted loss per common share attributable to stock-based compensation expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.03</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.04</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.06</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.41</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All of the stock-based compensation expense
recorded during the nine months ended December 31, 2020 and 2019, which totaled $629,207 and $755,648, respectively, is included
in payroll and related expense in the accompanying condensed consolidated statements of operations.&nbsp; Stock-based compensation
expense recorded during the nine months ended December 31, 2020 and 2019 represented an impact on basic and diluted loss per common
share of $(0.06) and $(0.41), respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We review share-based compensation on a
quarterly basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative
effect of adjusting the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed.
The effect of forfeiture adjustments for the nine months ended December 31, 2020 was insignificant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock Option Activity and Approval of 2020 Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From February 2020 through May 2020, our
compensation committee granted options to purchase 521,476 shares of our common stock that were contingent upon stockholder approval
of the 2020 Plan. Upon approval of the 2020 Plan at the Annual Meeting, these option grants were considered effective and no longer
contingent as of that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2020 Plan approved by our stockholders
at the Annual Meeting, authorizes up to 1,842,556 shares for issuance pursuant to stock option grants, RSUs or other forms of stock-based
compensation. No future grants will be made under the 2010 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We issued an option to purchase shares
239,122 shares of our common stock pursuant to the 2020 Plan to our Chief Executive Officer during the three months ended December
31, 2020, in connection with the appointment of Dr. Fisher as our Chief Executive Officer, effective as of October 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Separation Agreement
and pursuant to Dr. Rodell&rsquo;s employment agreement with the Company, the vesting was accelerated on 50% of outstanding and
unvested options to purchase shares of our common stock held by Dr. Rodell as of the Separation Date of October 30, 2020, such
that the accelerated stock options were fully vested and exercisable as of the Separation Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, Dr. Rodell elected to
net exercise a portion of his stock options. As a result, we issued Dr. Rodell an aggregate of 15,896 shares of our common stock
and we paid the estimated withholding taxes of $34,209 related to the net exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options outstanding that were vested as
of December 31, 2020 and options that are expected to vest subsequent to December 31, 2020 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<BR> Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Exercise<BR> Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Remaining<BR> Contractual<BR> Term in<BR> Years</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 55%">Vested</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">34,509</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">32.53</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">5.84</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Expected to vest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">567,814</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">1.51</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">9.67</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">602,323</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of stock option activity during the nine months ended
December 31, 2020 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of<BR> Exercise Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average <BR> Exercise<BR> Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 50%; text-align: left">Stock options outstanding at March 31, 2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">51,124</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$18.75 - $187.50</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">44.12</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,896</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">$1.28</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">770,094</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.28 &ndash; $2.45</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.45</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Cancelled/Expired</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(202,999</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.28 - $187.50</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">6.76</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Stock options outstanding at December 31, 2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">602,323</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.28 - $187.50</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">3.29</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Stock options exercisable at December 31, 2020</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">34,509</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.28 - $187.50</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">32.53</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 31, 2020, our outstanding stock
options had no intrinsic value since the closing price on that date of $2.47 per share was below the weighted average exercise
price of our outstanding stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2020, there was approximately
$2,240,000 of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted
average period of 1.48 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10. WARRANTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the nine months ended December 31, 2020 and 2019, we
did not issue any warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of warrant activity during the nine months ended December
31, 2020 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Range of<BR> Exercise<BR> Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted<BR> Average<BR> Exercise<BR> Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants outstanding at March 31, 2020</FONT></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">2,021,368</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.50 - $125.25</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">5.21</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled/Expired</FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(29,395</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$90.75 &ndash; $135.00</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">97.17</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants outstanding at December 31, 2020</FONT></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,991,973</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.50 &ndash; $99.00</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">5.23</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants exercisable at December 31, 2020</FONT></TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,991,973</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$1.50 &ndash; $99.00</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">5.23</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11. GOVERNMENT CONTRACTS AND RELATED REVENUE RECOGNITION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have recognized revenue under the following two contracts/grants
with the National Cancer Institute, or NCI, part of the National Institutes of Health, or NIH, over the past two years:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Phase 2 Melanoma Cancer Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 12, 2019, the NCI awarded
to us an SBIR Phase II Award Contract, for NIH/NCI Topic 359, entitled &ldquo;A Device Prototype for Isolation of Melanoma Exosomes
for Diagnostics and Treatment Monitoring&rdquo;, or the Award Contract. The Award Contract amount is $1,860,561 and runs for the
period from September 16, 2019 through September 15, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The work to be performed pursuant to this
Award Contract focuses on melanoma exosomes. This work follows from our completion of a phase I contract for the Topic 359 solicitation
that ran from September 2017 through June 2018, as described below. Following on the phase I work, the deliverables in the phase
II program involve the design and testing of a pre-commercial prototype of a more advanced version of the exosome isolation platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period ended December 31, 2020,
we completed all of the milestones relevant to that time period. As a result, we recorded $436,427 of government contract revenue
on the Phase 2 Melanoma Cancer Contract in the nine months ended December 31, 2020.&nbsp;&nbsp; Of the total revenue recognized
during the current period relating to this grant, a total of $117,849 was invoiced to the NCI during the three months ended December
31, 2020 and we recorded $318,578 which had previously been recognized as deferred revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Breast Cancer Grant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the nine months ended December 31, 2020,
we completed and submitted the final reports applicable to this NCI grant (number 1R43CA232977-01). The title of this Small Business
Innovation Research, or SBIR, Phase I grant is &ldquo;The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from
the Blood Circulation,&rdquo; or the Breast Cancer Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This NCI Phase I grant period originally
ran from September 14, 2018 through August 31, 2019. In August 2019, we applied for and received a no cost, twelve month extension
on this grant; through August 31, 2020. The total amount of the firm grant was $298,444. The grant called for two subcontractors
to work with us. Those subcontractors were University of Pittsburgh and Massachusetts General Hospital. As of December 31, 2020,
we have received all of the funds allocated to the Breast Cancer Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended December 31,
2020, we recorded the remaining $188,444 of revenue related to the Breast Cancer Grant, as we achieved two of the three milestones
related to the Breast Cancer Grant. We concluded in our final report to the SBIR that our pre-clinical results demonstrated that
our work under the grant provided support that the Hemopurifier has the capacity to clear exosomes from breast cancer patients.
That amount previously was recorded as deferred revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020, we received all
of the funds allocated to the Breast Cancer Grant and have submitted the final reports applicable to this grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Subaward with University of Pittsburgh</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we are completing the logistical
elements of documentation and billing the University of Pittsburgh in connection with a cost reimbursable subaward arrangement
under an NIH project entitled &ldquo;Depleting Exosomes to Improve Responses to Immune Therapy in HNNCC.&rdquo; Our share of the
award is $256,750. We have not recorded any revenues as of December 31, 2020 related to the subaward. We anticipate billing and
recognizing revenue under this subaward in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">12. SEGMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We operate our businesses principally through
two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic
business activities. Our reportable segments have been determined based on the nature of the potential products being developed.
We record discrete financial information for ESI and our chief operating decision maker reviews ESI&rsquo;s operating results in
order to make decisions about resources to be allocated to the ESI segment and to assess its performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aethlon&rsquo;s revenue is generated primarily
from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead
to the ESI segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following tables set forth certain information regarding
our segments:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">Nine Months Ended December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Revenues:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; width: 66%">Aethlon</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">624,871</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">443,458</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total Revenues</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">624,871</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">443,458</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Operating Losses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5,609,464</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(4,125,758</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(15,931</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(19,039</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total Operating Loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,625,395</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,144,797</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net Losses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(5,610,994</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(4,575,811</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(15,931</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(19,039</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Net Loss Before Non-Controlling Interests</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,626,925</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,594,850</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>Cash:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,131,396</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,058,456</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">197</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">197</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total Cash</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,131,593</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,058,653</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,669,552</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,682,294</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">197</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">197</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,669,749</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,682,491</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Capital Expenditures:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">54,630</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">148,064</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Capital Expenditures</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">54,630</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">148,064</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Depreciation and Amortization:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">28,775</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15,992</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total Depreciation and Amortization</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">28,775</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,992</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Interest Expense:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Aethlon</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,530</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(54,232</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1pt">ESI</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total Interest Expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,530</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(54,232</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">13. COMMITMENTS AND CONTINGENCIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONTRACTUAL OBLIGATIONS AND COMMITMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no material changes to
our contractual obligations and commitments outside the ordinary course of business from those disclosed under the heading &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations-Contractual Obligations and Commitments&rdquo; as contained
in our Annual Report on Form 10-K for the year ended March 31, 2020, filed by us with the SEC on June 25, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 30, 2020, we entered into a Separation Agreement
with Timothy Rodell, M.D., our former Chief Executive Officer, or the Separation Agreement. Under this agreement, we agreed to
pay Dr. Rodell a total of $444,729 and to cover his medical insurance costs over a twelve-month period that began on November 1,
2020, all in accordance with the terms of his employment agreement with the Company. We also paid Dr. Rodell accrued vacation in
the amount of $20,260 in November 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The total expense accrued at December 31, 2020 relating to the
Separation Agreement, was $400,578 (see Note 7 and Note 8).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 30, 2020, we entered into an
Executive Employment Agreement, or Agreement, with Charles J. Fisher Jr., M.D. The Agreement provides Dr. Fisher with (i) an initial
annualized base salary of $430,000 per year; (ii) eligibility for a discretionary annual cash bonus, (iii) eligibility for a one-time
cash bonus and additional equity grant upon attaining a specified performance goal, (iv) eligibility to participate in and receive
additional stock options or equity award grants under the Company&rsquo;s equity incentive plans from time to time, in the discretion
of the Board or the Compensation Committee, and in accordance with the terms and conditions of such plans; and (iv) severance payments
in the event that Dr. Fisher&rsquo;s employment is terminated by the Company for any reason other than Cause (as defined in the
Agreement) or if it is terminated by Dr. Fisher for Good Reason (as defined in the Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LEASE COMMITMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently lease approximately 2,600
square feet of executive office space at 9635 Granite Ridge Drive, Suite 100, San Diego<I>, </I>California 92123 under a 39-month
gross plus utilities lease that commenced on December 1, 2014 and expires on August 31, 2021. The current rental rate under the
lease extension is $8,265 per month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also rent approximately 1,700 square
feet of laboratory space at 11585 Sorrento Valley Road, Suite 109, San Diego, California 92121 at the rate of $6,148 per month
on a one-year lease that originally was to expire on November 30, 2020. In December 2020, we entered into a short-term lease extension
running from December 1, 2020 through the completion date of our construction of our planned new laboratory space which is adjacent
to our current laboratory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rent expense, which is included in general
and administrative expenses, approximated $50,000 and $44,000 for the three month periods ended December 31, 2020 and 2019, respectively.
For the nine month periods ended December 31, 2020 and 2019, rent expense approximated $144,000 and $130,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Future minimum lease payments under the Granite Ridge Lease
as of December 31, 2020, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 83%">January 1, 2021 through March 31, 2021</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">25,663</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">April 1, 2021 through August 31, 2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">43,670</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Total future minimum lease payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,333</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: discount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,635</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total lease liability</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">67,698</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year ended March 31,
2020, we adopted ASU Topic 842 on April 1, 2019 utilizing the alternative transition method allowed for under this guidance. As
a result, we recorded lease liabilities and right-of-use lease assets of $228,694 on our balance sheet as of April 1, 2019. The
lease liabilities represent the present value of the remaining lease payments of our corporate headquarters lease, discounted using
our incremental borrowing rate as of April 1, 2019. The corresponding right-of-use lease assets are recorded based on the lease
liabilities and the cumulative difference between rent expense and amounts paid under its corporate headquarters lease. We also
elected the short-term lease recognition exemption for its laboratory lease. For the laboratory lease that qualified as short-term,
we did not recognize right-of-use assets or lease liabilities at adoption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, we entered into an agreement
to lease approximately 2,823 square feet of office space and 1,807 square feet of laboratory space. The agreement carries a term
of 63 months and we will commence paying rent when we take occupancy of those spaces, which is expected to occur in the second
quarter of 2021. Upon taking occupancy of the space, we will record lease liabilities and right-of-use lease assets related to
this agreement on our balance sheet. We estimate that the present value of the contractual payments under the lease agreement to
be approximately $806,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the new lease agreement required
us to post a standby letter of credit in favor of the landlord in the amount of $46,726 in lieu of a security deposit. We arranged
for our bank to issue the standby letter of credit in the three months ended December 31, 2020 and transferred a like amount to
a restricted certificate of deposit which secured the bank&rsquo;s risk in issuing that letter of credit. We have classified that
restricted certificate of deposit on our balance sheet as restricted cash .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LEGAL MATTERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, claims are made against
us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent
uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from
selling one or more products or engaging in other activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The occurrence of an unfavorable outcome
in any specific period could have a material adverse effect on our results of operations for that period or future periods. We
are not presently a party to any pending or threatened legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">14. SUBSEQUENT EVENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has evaluated events subsequent
to December 31, 2020 through the date that the accompanying condensed consolidated financial statements were filed with the SEC
for transactions and other events which may require adjustment of and/or disclosure in such financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2021, we hired two senior executives,
Guy Cipriani as Senior Vice President, Chief Business Officer, and Steven LaRosa, M.D., as Chief Medical Officer and entered into
employment agreements with each executive. Mr. Cipriani will oversee business development and partnerships, while also contributing
to fundraising and corporate development. Mr. Cipriani&rsquo;s initial annual base salary is $340,000 and Mr. Cipriani also is
eligible for a discretionary annual cash bonus.&nbsp; Mr. Cipriani also is eligible for reimbursement of relocation expenses in
the aggregate amount of up to $75,000. &nbsp;Dr. LaRosa will be responsible for the clinical development of Aethlon's Hemopurifier&reg;,
including leading clinical operations and regulatory strategy. In addition to a one-time signing bonus of $100,000, subject to
repayment if Dr. LaRosa leaves Aethlon prior to two years with the Company, Dr. LaRosa&rsquo;s initial annual base salary is $400,000.
Dr. LaRosa also is eligible for a discretionary annual cash bonus and relocation expense reimbursement of up to $50,000.&nbsp;
Upon commencement of employment each of Mr. Cipriani and Dr. LaRosa was granted an option to purchase 120,883 shares of the Company&rsquo;s
Common Stock, with an exercise price equal to the fair market value on the date of grant, subject to a four-year vesting schedule
and other terms and conditions of the Company&rsquo;s 2020 Equity Incentive Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A NAME="a_008"></A>ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following discussion of our financial
condition and results of operations should be read in conjunction with, and is qualified in its entirety by, the condensed consolidated
financial statements and notes thereto included in Item 1 in this Quarterly Report on Form 10-Q. This item contains forward-looking
statements that involve risks and uncertainties. Actual results may differ materially from those indicated in such forward-looking
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FORWARD LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All statements, other than statements of
historical fact, included in this Form 10-Q are, or may be deemed to be, &quot;forward-looking statements&quot; within the meaning
of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act
of 1934, as amended, or the Exchange Act. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties
and other factors which may cause our actual results, performance, or achievements to be materially different from any future results,
performance, or achievements expressed or implied by such forward-looking statements contained in this Form 10-Q. Potential risks
and uncertainties include, without limitation, completion of our capital-raising activities, our ability to maintain our Nasdaq
listing, U.S. Food and Drug Administration, approval of our products, other regulations, patent protection of our proprietary technology,
product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors detailed
herein and in other of our filings with the Securities and Exchange Commission, or the Commission. The forward-looking statements
are made as of the date of this Form 10-Q, and we assume no obligation to update the forward-looking statements, or to update the
reasons actual results could differ from those projected in such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a medical technology company focused
on developing products to diagnose and treat life and organ threatening diseases. The Aethlon Hemopurifier&reg;, or Hemopurifier,
is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier
is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis
and inhibit the benefit of leading cancer therapies. The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier
as a &ldquo;Breakthrough Device&rdquo; for two independent indications:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the treatment of life-threatening viruses that are not addressed with approved therapies.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe the Hemopurifier can be a substantial
advance in the treatment of patients with advanced and metastatic cancer through the clearance of exosomes that promote the growth
and spread of tumors through multiple mechanisms. We are currently preparing for the initiation of clinical trials in patients
with advanced and metastatic cancers. We are initially focused on the treatment of solid tumors, including head and neck cancer,
gastrointestinal cancers and other cancers. As we advance our clinical trials, we are in close contact with our clinical sites
to navigate and assess the impact of the global COVID-19 pandemic on our clinical trials and current timelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 4, 2019, the FDA approved our
Investigational Device Exemption, or IDE, application to initiate an Early Feasibility Study, or EFS, of the Hemopurifier in patients
with head and neck cancer in combination with standard of care pembrolizumab (Keytruda) (NCT # 04453046). The primary endpoint
for the EFS, which is designed to enroll 10-12 subjects at a single center, will be safety, with secondary endpoints including
measures of exosome clearance and characterization, as well as response and survival rates. This study, which will be conducted
at the UPMC Hillman Cancer Center in Pittsburgh, PA, has been approved by the Institutional Review Board, or IRB, and is now open
for patient enrollment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also believe the Hemopurifier can be
part of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed
with an already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used to treat
individuals infected with human immunodeficiency virus, or HIV, Hepatitis-C, and Ebola.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, <I>in-vitro</I>, the Hemopurifier
has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus,
Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, and the
reconstructed Spanish flu virus of 1918. In several cases, these validations were conducted in collaboration with leading government
or non-government research institutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 17, 2020, the FDA approved a supplement
to the Company&rsquo;s open IDE for the Company&rsquo;s Hemopurifier in viral disease to allow for the testing of the Hemopurifier
in patients with SARS-CoV-2/COVID-19 in a New Feasibility Study. <FONT STYLE="background-color: white">That study&rsquo;s plan
is to enroll up to 40 subjects at up to 20 centers in the U.S.&nbsp; Subjects will have established laboratory diagnosis of COVID-19,
be admitted to an intensive care unit, or ICU and will have acute lung injury and/or severe or life threatening disease among other
criteria. Endpoints for this study, in addition to safety, will include reduction in circulating virus as well as clinical outcomes
(NCT # 04595903). The first sites for this trial, Hoag Memorial Hospital Presbyterian in Newport Beach, CA and Hoag Hospital &ndash;
Irvine in Irvine, CA now have IRB approval and are preparing to open for patient enrollment. Under Single Patient Emergency Use
regulations, the Company has also recently treated a patient with COVID-19, who successfully completed eight daily treatments with
the Hemopurifier.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also the majority owner of Exosome
Sciences, Inc., or ESI, a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases.
Included among ESI&rsquo;s activities is the advancement of a TauSome&trade; biomarker candidate to diagnose chronic traumatic
encephalopathy, or CTE, in the living. ESI previously documented TauSome levels in former NFL players to be nine times higher than
same age-group control subjects. Through ESI, we are also developing exosome based biomarkers in patients with, or at risk for,
a number of cancers. We consolidate ESI&rsquo;s activities in our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Successful outcomes of human trials will
also be required by the regulatory agencies of certain foreign countries where we plan to sell the Hemopurifier. Some of our patents
may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications
and/or other patents issued more recently will help protect the proprietary nature of the Hemopurifier treatment technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We were formed on March 10, 1999. Our executive
offices are located at 9635 Granite Ridge Drive, Suite 100, San Diego, California 92123. Our telephone number is (858) 459-7800.
Our website address is www.aethlonmedical.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the Nasdaq Capital Market under
the symbol &ldquo;AEMD.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>COVID-19 Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2020, the World Health Organization
declared COVID-19 a global pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply
chains and created significant volatility and disruption of financial markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are monitoring closely the impact of
the COVID-19 global pandemic on our business and have taken steps designed to protect the health and safety of our employees while
continuing our operations, including clinical trials. Given the level of uncertainty regarding the duration and impact of the COVID-19
pandemic on capital markets and the U.S. economy, we are unable to assess the impact of the worldwide spread of SARS-CoV-2 and
the resulting COVID-19 pandemic on our future access to capital. Further, while we have not experienced significant disruptions
to our manufacturing supply chain, business, results of operations, financial condition, clinical trials, or preclinical research
to date, we are unable to assess the potential impact this pandemic could have on our manufacturing supply chain, business, results
of operations, financial condition, clinical trials, or preclinical research in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we continue to actively advance our
clinical trials, we remain in close contact with our clinical sites and are assessing the impact of COVID-19 on our trials, expected
timelines and costs on an ongoing basis. We will assess any potential delays in our ability to timely ship clinical trial materials,
including internationally, due to transportation interruptions. The extent of the impact of COVID-19 on our operational and financial
performance will depend on certain developments, including the duration and spread of the outbreak, impact on our clinical trials,
employees and vendors, all of which are uncertain and cannot be predicted. Given these uncertainties, we cannot reasonably estimate
the related impact to our business, operating results and financial condition, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WHERE YOU CAN FIND MORE INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to the informational requirements
of the Exchange Act, and must file reports, proxy statements and other information with the Commission. The Commission maintains
a web site (http://www.sec.gov) that contains reports, proxy and information statements and other information regarding registrants,
like us, which file electronically with the Commission. Our headquarters are located at 9635 Granite Ridge Drive, Suite 100, San
Diego, CA 92123. Our phone number at that address is (858) 459-7800. Our website is http://www.aethlonmedical.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RESULTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THREE MONTHS ENDED DECEMBER 31, 2020 COMPARED TO THE THREE MONTHS
ENDED DECEMBER 31, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Government Contract Revenues</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recorded $624,871 in government contract revenue in the three
months ended December 31, 2020. This revenue resulted from work performed under our government contracts with NIH as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months<BR> Ended 12/31/20</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Three Months<BR> Ended 12/31/19</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change in <BR> Dollars</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 55%; text-align: left">Phase 2 Melanoma Cancer Contract</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">436,427</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">413,458</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">22,969</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Breast Cancer Grant</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">188,444</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">158,444</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Government Contract and Grant Revenue</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">624,871</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">443,458</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">181,413</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have recognized revenue under the following two contracts/grants
with the National Cancer Institute, or NCI, part of the National Institutes of Health, or NIH, over the past two years:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Phase 2 Melanoma Cancer Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 12, 2019, the NCI awarded
to us an SBIR Phase II Award Contract, for NIH/NCI Topic 359, entitled &ldquo;A Device Prototype for Isolation of Melanoma Exosomes
for Diagnostics and Treatment Monitoring&rdquo;, or the Award Contract. The Award Contract amount is $1,860,561 and runs for the
period from September 16, 2019 through September 15, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The work to be performed pursuant to this
Award Contract focuses on melanoma exosomes. This work follows from our completion of a phase I contract for the Topic 359 solicitation
that ran from September 2017 through June 2018, as described below. Following on the phase I work, the deliverables in the phase
II program involve the design and testing of a pre-commercial prototype of a more advanced version of the exosome isolation platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period ended December 31, 2020,
we completed all of the milestones relevant to that time period. As a result, we recorded $436,427 of government contract revenue
on the Phase 2 Melanoma Cancer Contract in the three months ended December 31, 2020.&nbsp;&nbsp; Of the total revenue recognized
during the current period relating to this grant, a total of $117,849 was invoiced to the NCI during the three months ended December
31, 2020 and we recorded $318,578 which had previously been recognized as deferred revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Breast Cancer Grant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the three months ended December 31,
2020, we completed and submitted the final reports applicable to this NCI grant (number 1R43CA232977-01). The title of this Small
Business Innovation Research, or SBIR, Phase I grant is &ldquo;The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes
from the Blood Circulation,&rdquo; or the Breast Cancer Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This NCI Phase I grant period originally
ran from September 14, 2018 through August 31, 2019. In August 2019, we applied for and received a no cost, twelve-month extension
on this grant; through August 31, 2020. The total amount of the firm grant was $298,444. The grant called for two subcontractors
to work with us. Those subcontractors were University of Pittsburgh and Massachusetts General Hospital. As of December 31, 2020,
we have received all of the funds allocated to the Breast Cancer Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended December
31, 2020, we recorded the remaining $188,444 of revenue related to the Breast Cancer Grant as we achieved two of the three milestones
related to the Breast Cancer Grant and concluded in our final report that our work under the grant provided nonclinical support
that the Hemopurifier has the capacity to clear exosomes from breast cancer patients. That amount previously was recorded as deferred
revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Subaward with University of Pittsburgh</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we are completing the logistical
elements of documentation and billing the University of Pittsburgh in connection with a cost reimbursable subaward arrangement
under an NIH project entitled &ldquo;Depleting Exosomes to Improve Responses to Immune Therapy in HNNCC.&rdquo; Our share of the
award is $256,750. We have not recorded any revenues as of December 31, 2020 related to the subaward. We anticipate billing and
recognizing revenue under this subaward in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consolidated operating expenses for the
three months ended December 31, 2020 were $3,068,459, compared to $1,289,864 for the three months ended December 31, 2019. This
increase of $1,778,595, or 137.9%, in the 2020 period was due to increases in payroll and related expenses of $1,117,229, in general
and administrative expenses of $646,320, and in professional fees of $15,046.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The $1,117,229 increase in payroll and
related expenses was due to the combination of an $841,847 increase in our cash-based compensation expense and a $275,382 increase
in stock-based compensation expense. The largest factor in the cash-based compensation increase was a result of recording an aggregate
of $593,272 related to severance costs associated with the Separation Agreement. Additional factors were a $125,000 increase in
year-end bonus payments, increased headcount and salary increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The $646,320 increase in general and administrative
expenses was primarily due to a $360,703 increase in our clinical trial expenses, a $132,542 increase in subcontractor expenses
associated with our government contracts and grants, a $130,019 increase in lab supplies, in connection with our ongoing effort
to continue to build an inventory of Hemopurifiers for our clinical trials, and to a $39,667 increase in our insurance expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The $15,046 increase in our professional
fees was primarily due to a $28,421 increase in contract labor, predominantly research scientists hired on a consulting basis,
and a $23,151 increase in our legal fees, which were partially offset by a $35,189 decrease in our accounting fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other Income (Expense)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We had $802 of other expense during the
three months ended December 31, 2020. In the three months ended December 31, 2019, other expense consisted of interest expense
and a gain on share for warrant exchanges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table breaks out the various components of our
other expense for both periods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Three Months <BR> Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Three Months <BR> Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">12/31/20</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">12/31/19</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 55%; text-align: left">(Gain) on Share for Warrant Exchanges</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(55,593</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">55,593</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Interest Expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">802</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">126</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">676</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Other Expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">802</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(55,467</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">56,269</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gain on Share for Warrant Exchanges</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was no warrant exchange activity
during the three months ended December 31, 2020. During the three months ended December 31, 2019, we agreed with two accredited
investors to issue 2,914 shares of our common stock to these investors in exchange for the cancellation of outstanding warrants
then held by the investors to purchase 29,141 shares of our common stock. We measured the fair value of the shares issued and the
fair value of the warrants exchanged for those shares and recorded a gain of $55,593 on those exchanges based on the changes in
fair value between the instruments exchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interest Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We had $802 in interest expense in the
three months ended December 31, 2020. Interest expense was $126 for the three months ended December 31, 2019. The various components
of our interest expense are shown in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Three Months <BR> Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Three Months<BR> Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">12/31/20</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">12/31/19</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 55%; text-align: left">Interest Expense</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">802</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">126</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">676</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net Loss</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the changes in revenues
and expenses noted above, our net loss increased to approximately $2,447,000 in the three month period ended December 31, 2020,
from approximately $821,000 in the three month period ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted loss attributable to
common stockholders were ($0.20) for the three month period ended December 31, 2020, compared to ($0.28) for the three month period
ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NINE MONTHS ENDED DECEMBER 31, 2020 COMPARED TO THE NINE MONTHS
ENDED DECEMBER 31, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Government Contract Revenues</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recorded $624,871 in government contract
revenue in the nine months ended December 31, 2020. This revenue resulted from work performed under our government contracts with
NIH as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Nine Months<BR> Ended 12/31/20</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Nine Months<BR> Ended 12/31/19</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change in <BR> Dollars</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 55%; text-align: left">Phase 2 Melanoma Cancer Contract</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">436,427</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">413,458</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">22969</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Breast Cancer Grant</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">188,444</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">158,444</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Government Contract and Grant Revenue</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">624,871</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">443,458</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">181,413</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have recognized revenue under the following two contracts/grants
with the National Cancer Institute, or NCI, part of the National Institutes of Health, or NIH, over the past two years:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Phase 2 Melanoma Cancer Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 12, 2019, the NCI awarded
to us an SBIR Phase II Award Contract, for NIH/NCI Topic 359, entitled &ldquo;A Device Prototype for Isolation of Melanoma Exosomes
for Diagnostics and Treatment Monitoring&rdquo;, or the Award Contract. The Award Contract amount is $1,860,561 and runs for the
period from September 16, 2019 through September 15, 2021. The work to be performed pursuant to this Award Contract focuses on
melanoma exosomes. This work follows from our completion of a phase I contract for the Topic 359 solicitation that ran from September
2017 through June 2018, as described below. Following on the phase I work, the deliverables in the phase II program involve the
design and testing of a pre-commercial prototype of a more advanced version of the exosome isolation platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the period ended December 31, 2020,
we completed all of the milestones relevant to that time period. As a result, we recorded $436,427 of government contract revenue
on the Phase 2 Melanoma Cancer Contract in the nine months ended December 31, 2020.&nbsp;&nbsp; Of the total revenue recognized
during the current period relating to this grant, a total of $117,849 was invoiced to the NCI during the three months ended December
31, 2020 and we recorded $318,578 which had previously been recognized as deferred revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Breast Cancer Grant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the nine months ended December 31, 2020,
we completed and submitted the final reports applicable to this NCI grant (number 1R43CA232977-01). The title of this Small Business
Innovation Research, or SBIR, Phase I grant is &ldquo;The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from
the Blood Circulation,&rdquo; or the Breast Cancer Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This NCI Phase I grant period originally
ran from September 14, 2018 through August 31, 2019. In August 2019, we applied for and received a no cost, twelve month extension
on this grant; through August 31, 2020. The total amount of the firm grant was $298,444. The grant called for two subcontractors
to work with us. Those subcontractors were University of Pittsburgh and Massachusetts General Hospital. As of December 31, 2020,
we have received all of the funds allocated to the Breast Cancer Grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended December 31,
2020, we recorded the remaining $188,444 of revenue related to the Breast Cancer Grant as we achieved two of the three milestones
related to the Breast Cancer Grant and concluded in our final report that our work under the grant provided nonclinical support
that the Hemopurifier has the capacity to clear exosomes from breast cancer patients. That amount previously was recorded as deferred
revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Subaward with University of Pittsburgh</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we are completing the logistical
elements of documentation and billing the University of Pittsburgh in connection with a cost reimbursable subaward arrangement
under an NIH project entitled &ldquo;Depleting Exosomes to Improve Responses to Immune Therapy in HNNCC.&rdquo; Our share of the
award is $256,750. We have not recorded any revenues as of December 31, 2020 related to the subaward. We anticipate billing and
recognizing revenue under this subaward in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consolidated operating expenses for the
nine months ended December 31, 2020 were $6,250,266, compared to $4,588,255 for the nine months ended December 31, 2019. This increase
of $1,662,011, or 36.2%, in the 2020 period was due to increases in payroll and related expenses of $910,863 and in general and
administrative expenses of $885,337, which were partially offset by a decrease in professional fees of $134,189.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The $910,863 increase in payroll and related
expenses in the nine months ended December 31, 2020 was due to a $934,726 increase in our cash-based compensation expense, which
was partially offset by a $23,865 reduction in stock-based compensation expense. The largest factor in the cash-based compensation
increase was a result of recording an aggregate of $593,272 related to severance costs associated with the Separation Agreement.
Additional factors were a $125,000 increase in year-end bonus payments and our headcount and salary increases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The $885,337 increase in general and administrative
expenses in the nine months ended December 31, 2020 was primarily due to a $441,246 increase in our clinical trial expenses, a
$67,542 increase in subcontractor expenses associated with our government contracts and grants, a $318,100 increase in lab supplies,
in connection with our ongoing effort to continue to build an inventory of Hemopurifiers for our clinical trials, and to a $60,958
increase in our insurance expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The $134,189 decrease in our professional
fees was due to a $116,432 decrease in our accounting fees, a $92,820 decrease in our legal fees, and a $23,610 decrease in other
consulting fees, which were partially offset by a $102,243 increase in contact labor, predominantly research scientists hired on
a consulting basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other expense during the nine months ended
December 31, 2020 consisted of interest expense and during the nine months ended December 31, 2019, consisted of interest expense,
a gain on share for warrant exchanges and a loss on debt extinguishment. Other expense for the nine months ended December 31, 2020
was $1,530, compared to other expense of $450,053 for the nine months ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table breaks out the various components of our
other expense for both periods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Nine Months <BR> Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Nine Months <BR> Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">12/31/20</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">12/31/19</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 55%; text-align: left">Loss on Debt Extinguishment</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">447,011</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(447,011</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gain on Share for Warrant Exchanges</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(51,190</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">51,190</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Interest Expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,530</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">54,232</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(52,702</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Other Expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,530</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">450,053</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(448,523</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Loss on Debt Extinguishment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no losses on debt extinguishment
during the nine months ended December 31, 2020. During the nine months ended December 31, 2019, we reduced the conversion price
on our then outstanding convertible notes from $45.00 per share to $10.20 per share. The modification of the convertible notes
was evaluated under ASC 470-50-40 and the instruments were determined to be substantially different, and the transaction qualified
for extinguishment accounting. Under the extinguishment accounting we recorded a loss on debt extinguishment of $447,011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gain on Share for Warrant Exchanges</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There was no warrant exchange activity
during the nine months ended December 31, 2020. During the nine months ended December 31, 2019, we agreed with seven accredited
investors to issue 3,992 shares of our common stock to these investors in exchange for the cancellation of outstanding warrants
then held by the investors to purchase 39,900 shares of our common stock. We measured the fair value of the shares issued and the
fair value of the warrants exchanged for those shares and recorded a gain of $51,190 on those exchanges based on the changes in
fair value between the instruments exchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interest Expense</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total interest expense was $1,530 for the
nine months ended December 31, 2020, and $54,232 for the nine months ended December 31, 2019, a decrease of $52,702. The various
components of our interest expense are shown in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Nine Months <BR> Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Nine Months<BR> Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">12/31/20</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">12/31/19</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Change</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 55%; text-align: left">Interest Expense</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">1,530</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">23,945</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">(22,415</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Amortization of Note Discounts</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,287</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(30,287</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Interest Expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,530</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">54,232</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(52,702</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The $52,702 decrease in our total interest
expense in the nine months ended December 2020 was due to the payment in full of our convertible notes in July 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net Loss</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the changes in revenues
and expenses noted above, our net loss increased to approximately $5,630,000 in the nine month period ended December 31, 2020,
from approximately $4,595,000 in the nine month period ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic and diluted loss attributable to
common stockholders were ($0.50) for the nine month period ended December 31, 2020, compared to ($2.52) for the nine month period
ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LIQUIDITY AND CAPITAL RESOURCES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2020, we had a cash
balance of $12,131,593 and current working capital of $11,086,708. This compares to a cash balance of $9,604,780 and working capital
of $8,973,393 at March 31, 2020. We expect our existing cash as of December 31, 2020 to be sufficient to fund the Company&rsquo;s
operations for at least twelve months from the issuance date of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The primary source of our increase in cash
during the nine months ended December 31, 2020 resulted from our Common Stock Sales Agreement with H.C. Wainwright &amp; Co., LLC,
or Wainwright. The cash raised from that activity is described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock Sales Agreement with Wainwright</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 28, 2016, we entered into a Common
Stock Sales Agreement, or the Agreement, with Wainwright, which established an at-the-market equity program pursuant to which we
may offer and sell shares of our common stock from time to time as set forth in the Agreement. The Agreement provided for the sale
of shares of our common stock having an aggregate offering price of up to $12,500,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 30, 2020, we executed Amendment
No. 2 to the Agreement with Wainwright, effective as of the same date. The amendment provides that references in the Agreement
to the registration statement shall refer to the registration statement on Form S-3 (File No. 333-237269), originally filed with
the SEC on March 19, 2020, declared effective by the SEC on March 30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms and conditions set
forth in the Agreement Wainwright agreed to use its commercially reasonable efforts consistent with its normal trading and sales
practices to sell the shares under the Agreement from time to time, based upon our instructions. We provided Wainwright with customary
indemnification rights under the Agreement, and Wainwright is entitled to a commission at a fixed rate equal to three percent of
the gross proceeds per share sold. In addition, we agreed to pay certain expenses incurred by Wainwright in connection with the
Agreement, including up to $50,000 of the fees and disbursements of their counsel. The Agreement will terminate upon the sale of
all of the shares under the Agreement, unless terminated earlier by either party as permitted under the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of the Shares, if any, under the
Agreement will be made in transactions that are deemed to be &ldquo;at the market offerings&rdquo; as defined in Rule 415 under
the Securities Act, including sales made by means of ordinary brokers&rsquo; transactions, including on the Nasdaq Capital Market,
at market prices or as otherwise agreed with Wainwright. We have no obligation to sell any of the Shares, and, at any time, we
may suspend offers under the Agreement or terminate the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the nine months ended December 31, 2020,
we raised aggregate net proceeds of $7,260,869, net of $224,825 in commissions to Wainwright and $8,472 in other offering expenses,
under the Agreement through the sale of 2,685,600 shares at an average price of $2.70 per share of net proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future capital requirements will depend
upon many factors, including progress with pre-clinical testing and clinical trials, the number and breadth of our clinical programs,
the time and costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims and other proprietary rights,
the time and costs involved in obtaining regulatory approvals, competing technological and market developments, as well as our
ability to establish collaborative arrangements, effective commercialization, marketing activities and other arrangements. We expect
to continue to incur increasing negative cash flows and net losses for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash Flows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash flows from operating, investing and financing activities,
as reflected in the accompanying Condensed Consolidated Statements of Cash Flows, are summarized as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid">(In thousands) <BR> For the nine months ended</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">December 31, <BR> 2020</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">December 31, <BR> 2019</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Cash provided by (used in):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left">Operating activities</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(4,526</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(3,577</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(55</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(148</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Financing activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,154</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,956</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash and cash equivalents</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,573</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">231</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NET CASH USED IN OPERATING ACTIVITIES.
We used cash in our operating activities due to our losses from operations. Net cash used in operating activities was approximately
$4,526,000 in the nine month period ended December 31, 2020, compared to approximately $3,577,000 in the nine month period ended
December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NET CASH USED IN INVESTING ACTIVITIES.
We used approximately $55,000 of cash to purchase laboratory and office equipment in the nine months ended December 31, 2020, compared
to approximately $148,000 in the nine month period ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NET CASH PROVIDED BY/(USED IN) FINANCING
ACTIVITIES. During the nine months ended December 31, 2020, we raised approximately $7,261,000 from the issuance of common stock.
That source of cash from our financing activities was partially offset by the use of approximately $106,000 to pay for the tax
withholding on restricted stock units and on a net stock option exercise by our former Chief Executive Officer, for an aggregate
increase of cash provided by financing activities of approximately $7,154,000. During the nine months ended December 31, 2019,
we raised approximately $4,987,000 from the issuance of common stock, which was offset by the use of approximately $993,000 to
pay off our then outstanding convertible notes and approximately $39,000 to pay for the tax withholding on restricted stock units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this filing, we plan
to invest significantly into purchases of our raw materials and in our contract manufacturing arrangement, subject to successfully
raising additional capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CRITICAL ACCOUNTING POLICIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Use of Estimates</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial
statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires us to
make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements. These estimates and assumptions affect the reported amounts of
expenses during the reporting period. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience
and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however,
actual results may differ from these estimates under different future conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that the estimates and assumptions
that are most important to the portrayal of our financial condition and results of operations, in that they require the most difficult,
subjective or complex judgments, form the basis for the accounting policies deemed to be most critical to us. These critical accounting
estimates relate to revenue recognition, stock purchase warrants issued with notes payable, beneficial conversion feature of convertible
notes payable, impairment of intangible assets and long lived assets, stock compensation, deferred tax asset valuation allowance,
and contingencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There have been no changes to our critical accounting policies
as disclosed in our Form 10-K for the year ended March 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">OFF-BALANCE SHEET ARRANGEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December&nbsp;31, 2020, we did not have any off-balance
sheet arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_009"></A>ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a smaller reporting company as defined
by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations
and therefore are not required to provide the information requested by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_010"></A>ITEM 4. CONTROLS AND PROCEDURES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DISCLOSURE CONTROLS AND PROCEDURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the supervision and with the participation
of our management, including our Chief Executive Officer and our Chief Financial Officer, we evaluated the effectiveness of the
design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act)
as of the end of the period covered by this Quarterly Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on such evaluation, our Chief Executive
Officer and Chief Financial Officer concluded that, as of the end of such period, our disclosure controls and procedures are effective
in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports
that we file or submit under the Securities Exchange Act of 1934, as amended, and are effective in ensuring that information required
to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is accumulated
and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow
timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There have been no changes in our internal
control over financial reporting during the last fiscal quarter that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_011"></A>PART II. OTHER INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_012"></A>ITEM 1. LEGAL PROCEEDINGS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, claims are made against
us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent
uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from
selling one or more products or engaging in other activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The occurrence of an unfavorable outcome
in any specific period could have a material adverse effect on our results of operations for that period or future periods. We
are not presently a party to any pending or threatened legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_013"></A>ITEM 1A. RISK FACTORS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">RISK FACTOR SUMMARY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">Below
is a summary of the principal factors that make an investment in our securities speculative or risky. This summary does not address
all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that
we face, can be found below under the heading &ldquo;<I>Risk Factors</I>&rdquo; and should be carefully considered, together with
other information in this Quarterly Report on Form 10-Q and our other filings with the SEC before making investment decisions regarding
our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have incurred significant operating
losses since our inception and have not generated any revenue. We expect to incur continued losses for the foreseeable future and
may never achieve or maintain profitability.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We will require substantial additional
funding to sustain our operations. If we are unable to raise capital on favorable terms when needed, we could be forced to delay,
reduce or eliminate our research or device development programs or any future commercialization efforts.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">To achieve the levels of production necessary
to commercialize our Hemopurifier and any other future products, we will need to secure large-scale manufacturing agreements with
contract manufacturers which comply with good manufacturing practice standards and other standards prescribed by various federal,
state and local regulatory agencies in the U.S. and any other country of use. We have limited experience coordinating and overseeing
the manufacture of medical device products on a large-scale.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our Hemopurifier product may be made unmarketable
prior to commercialization by us by new scientific or technological developments by others with new treatment modalities that are
more efficacious and/or more economical than our products. Any one of our competitors could develop a more effective product which
would render our technology obsolete.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our Hemopurifier product is subject to
extensive government regulations related to development, testing, manufacturing and commercialization in the U.S. and other countries.
If we fail to comply with these extensive regulations of the U.S. and foreign agencies, the commercialization of our products could
be delayed or prevented entirely.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As a public company with limited financial
resources undertaking the launch of new medical technologies, we may have difficulty attracting and retaining executive management
and directors.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We will need to significantly expand our
operations to implement our longer-term business plan and growth strategies. We will also be required to manage multiple relationships
with various strategic partners, technology licensors, customers, manufacturers and suppliers, consultants and other third parties.
The time and costs to effectuate these steps may place a significant strain on our management personnel, systems and resources,
particularly given the limited amount of financial resources and skilled employees that may be available at the time.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our business prospects will depend on
our ability to complete studies, clinical trials, obtain satisfactory results, obtain required regulatory approvals and successfully
commercialize our Hemopurifier product candidate. Delays in successfully completing the clinical trials could jeopardize our ability
to obtain regulatory approval.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If we are unable to adequately address
these and other risks we face, our business, financial condition, operating results and prospects may be adversely affected.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our business could be adversely affected
by the effects of health pandemics or epidemics, including the COVID-19 pandemic.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">RISK FACTORS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a smaller reporting company as defined
by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations
and therefore are not required to provide the information requested by this item. For a discussion of our potential risks and uncertainties,
please see the information listed in the item captioned &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the fiscal
year ended March 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>*Delays in successfully completing
our planned clinical trials could jeopardize our ability to obtain regulatory approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business prospects will depend on our
ability to complete studies, clinical trials, including our EFS trial in 10 to 12 patients, obtain satisfactory results, obtain
required regulatory approvals and successfully commercialize our Hemopurifier product candidate. Completion of our clinical trials,
announcement of results of the trials and our ability to obtain regulatory approvals could be delayed for a variety of reasons,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">slow patient enrollment;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">serious adverse events related to our
medical device candidates;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">unsatisfactory results of any clinical
trial;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the failure of our principal third-party
investigators to perform our clinical trials on our anticipated schedules; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">different interpretations of our pre-clinical
and clinical data, which could initially lead to inconclusive results; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">delays resulting from the coronavirus
pandemic.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our development costs will increase if
we have material delays in any clinical trial or if we need to perform more or larger clinical trials than planned. If the delays
are significant, or if any of our product candidates do not prove to be safe or effective or do not receive required regulatory
approvals, our financial results and the commercial prospects for our product candidates will be harmed. Furthermore, our inability
to complete our clinical trials in a timely manner could jeopardize our ability to obtain regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>*The approval requirements for medical products used to
fight bioterrorism are still evolving, and any products we develop for such uses may not meet these requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are advancing product
candidates under governmental policies that regulate the development and commercialization of medical treatment countermeasures
against bioterror and pandemic threats. While we intend to pursue FDA market clearance to treat infectious bioterror and pandemic
threats, it is often not feasible to conduct human studies against these deadly high threat pathogens. For example, the Hemopurifier
is an investigational device that has not yet received FDA approval for any indication. We continue to investigate the potential
for the use of the Hemopurifier in viral diseases under an open IDE and our FDA Breakthrough Designation for &ldquo;&hellip;the
treatment of life-threatening glycosylated viruses that are not addressed with an approved therapy.&rdquo; We currently have an
open FDA approved Expanded Access Protocol for the treatment of Ebola infected patients in the U.S. and a corresponding HealthCanada
approval in Canada. Based on our studies to date, the Hemopurifier can potentially clear many viruses that are pathogenic in humans,
including HCV, HIV and Ebola. We do have preclinical data suggesting that it could clear a closely related coronavirus (MERS).
Additionally, we have a very limited supply of Hemopurifiers and therefore any use in this pandemic will be only investigational
in a very small number of patients, even if it appears that the device can help those patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Thus, we may not be
able to demonstrate the effectiveness of our treatment countermeasures through controlled human efficacy studies. Additionally,
a change in government policies could impair our ability to obtain regulatory approval and the FDA may not approve any of our product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*<B><I>Should any of our potential products,
including the Hemopurifier, be approved for commercialization, adverse changes in reimbursement policies and procedures by payors
may impact our ability to market and sell our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Healthcare costs have
risen significantly over the past decade, and there have been and continue to be proposals by legislators, regulators and third-party
payors to decrease costs. Third-party payors are increasingly challenging the prices charged for medical products and services
and instituting cost containment measures to control or significantly influence the purchase of medical products and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For example, in the
U.S., the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or
collectively, PPACA, among other things, reduced and/or limited Medicare reimbursement to certain providers. However, on December
14, 2018, a Texas U.S. District Court Judge ruled that the Affordable Care Act is unconstitutional in its entirety because the
&ldquo;individual mandate&rdquo; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. Additionally, on December
18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional
and remanded the case back to the District Court to determine whether the remaining provisions of the PPACA are invalid as well.
The United States Supreme Court is currently reviewing this case, but it is unclear when a decision will be made. The Budget Control
Act of 2011, as amended by subsequent legislation, further reduces Medicare&rsquo;s payments to providers by two percent through
fiscal year 2030. The Coronavirus Aid, Relief and Economic Security Act, or CARES Act, and other COVID-19 relief legislation have,
among other things, temporarily suspended the two percent Medicare sequester from May 1, 2020 through March 31,2021. These reductions
may reduce providers&rsquo; revenues or profits, which could affect their ability to purchase new technologies. Furthermore, the
healthcare industry in the U.S. has experienced a trend toward cost containment as government and private insurers seek to control
healthcare costs by imposing lower payment rates and negotiating reduced contract rates with service providers. Legislation could
be adopted in the future that limits payments for our products from governmental payors. It is possible that additional governmental
action is taken to address the COVID-19 pandemic. It is also possible that additional health reform measures will be implemented
as a result of the new Presidential administration. In addition, commercial payors such as insurance companies, could adopt similar
policies that limit reimbursement for medical device manufacturers&rsquo; products. Therefore, it is possible that our product
or the procedures or patient care performed using our product will not be reimbursed at a cost-effective level. We face similar
risks relating to adverse changes in reimbursement procedures and policies in other countries where we may market our products.
Reimbursement and healthcare payment systems vary significantly among international markets. Our inability to obtain international
reimbursement approval, or any adverse changes in the reimbursement policies of foreign payors, could negatively affect our ability
to sell our products and have a material adverse effect on our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_014"></A>ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We did not issue or sell any unregistered securities during
the three months ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_015"></A>ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no disclosure applicable to this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_016"></A>ITEM 4. MINE SAFETY DISCLOSURES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no disclosure applicable to this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_017"></A>ITEM 5. OTHER INFORMATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no disclosure applicable to this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_018"></A>ITEM 6. EXHIBITS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) Exhibits. The following documents are filed as part of this
report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by Reference</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit<BR>
Number</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit Description</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC File No.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit<BR>
Number</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed<BR>
Herewith</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 36%"><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000101968716006120/aethlon_s1-ex0301.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles of Incorporation.</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-3</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-211151</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 5, 2016</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000168316819002910/aethlon_8k-ex0301.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Bylaws of the Company.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 12, 2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000101968714004876/aethlon_s1-ex0401.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Certificate.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-201334</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000101968712003217/aethlon_8k-ex0401.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant dated August 29, 2012.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-21846</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 6, 2012</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000101968713000435/aemd_10q-ex401.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant dated October, November and December 2012. </FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-21846</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February 12, 2013</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000101968713003054/aethlon_10q-ex401.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant dated June 14, 2013.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-21846</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 13, 2013</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000101968714002585/aethlon_8k-ex0401.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant dated June 24, 2014.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-21846</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000101968714002828/aethlon_8k-ex401.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant dated July 24, 2014.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-21846</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 28, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000101968714004132/aemd_10q-ex0403.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant dated August and September 2014.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Q</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-21846</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 10, 2014</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000101968715002499/aemd_8k-ex0401.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant to Purchase Common Stock dated June 25, 2015.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-21846</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 24, 2015</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000101968715002528/aemd_8k-ex0401.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Purchase Agent Warrant dated June 25, 2015.</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">000-21846</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 26, 2015</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000168316817000627/aethlon_ex0401.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant Agreement dated March 27, 2017.</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 22, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000168316817002401/aethlon_s1a-ex0429.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant dated _______, 2017.</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-219589</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.29</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 18, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000168316817002459/aethlon_s1a2-ex0430.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Placement Agent Warrant dated _______, 2017.</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-219589</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.30</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 22, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000168316819003944/aethlon_ex0414.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant to Purchase Common Stock.</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-234712</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 11, 2019</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14 </FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000168316819003944/aethlon_ex0415.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriter Warrant.</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1/A</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-234712</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 11, 2019</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000168316820000188/aethlon_ex0401.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Common Stock Purchase Warrant.</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January 17, 2020</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by Reference</FONT></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit<BR>
Number</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit Description</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC File No.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit<BR>
Number</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed<BR>
Herewith</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 7%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 35%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 11%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 11%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 18%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 7%; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000168316820003665/aethlon_8k-ex1001.htm" STYLE="-sec-extract: exhibit">Separation Agreement between the Company and Dr. Rodell, dated October 30, 2020.</A></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 3, 2020</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/882291/000168316820003665/aethlon_8k-ex1002.htm" STYLE="-sec-extract: exhibit">Employment Agreement between the Company and Dr. Fisher, dated October 30, 2020.</A></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-K</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-37487</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 3, 2020</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="aethlon_ex1003.htm">Lease, by and between the Company and San Diego Inspire 1, LLC. and San Diego Inspire 2, LLC, effective December 7, 2020.</A></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="aethlon_ex1004.htm">Eighth Amendment to Standard Industrial Net Lease, by and between the Company and San Diego Inspire 1, LLC., effective December 7, 2020.</A></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="aethlon_ex1005.htm">Executive Employment Agreement between the Company and Guy Cipriani, dated January 1, 2021.</A></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="aethlon_ex1006.htm">Executive Employment Agreement between the Company and Steven P. LaRosa, MD, dated January 4, 2021.</A></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A HREF="aethlon_ex3101.htm">Certification of our Chief Executive Officer, pursuant to Securities Exchange Act rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.</A></U></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A HREF="aethlon_ex3102.htm">Certification of our Chief Financial Officer, pursuant to Securities Exchange Act rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002.</A></U></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A HREF="aethlon_ex3201.htm">Statement of our Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).</A></U></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U><A HREF="aethlon_ex3202.htm">Statement of our Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).</A></U></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Instance Document</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Schema Document</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Calculation Linkbase Document</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Definition Linkbase Document</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Label Linkbase Document</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL Presentation Linkbase Document</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;___________________</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8px">&nbsp;</TD>
    <TD STYLE="width: 16px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">++</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedules will be furnished to the SEC upon request.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AETHLON MEDICAL, INC.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: February 10, 2021</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ JAMES B. FRAKES</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JAMES B. FRAKES</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHIEF FINANCIAL OFFICER</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHIEF ACCOUNTING OFFICER</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>aethlon_ex1003.htm
<DESCRIPTION>LEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 10.3</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>LEASE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SOVA CENTRAL SCIENCE DISTRICT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SAN DIEGO INSPIRE 1, LLC</B>,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<BR>
a Delaware limited liability company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SAN DIEGO INSPIRE 2, LLC</B>,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<BR>
a Delaware limited liability company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">collectively, as Landlord,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AETHLON MEDICAL, INC.</B>,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">a Nevada corporation,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">as Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: center"><B>Page</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: middle; text-align: right">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: left; width: 0.5in">1.</TD>
    <TD STYLE="vertical-align: middle; text-align: left">PREMISES, BUILDING, PROJECT, AND COMMON AREAS</TD>
    <TD STYLE="vertical-align: middle; text-align: right; width: 0.5in">6</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">2.</TD>
    <TD STYLE="text-align: left">LEASE TERM; OPTION TERM</TD>
    <TD STYLE="text-align: right">8</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">3.</TD>
    <TD STYLE="text-align: left">BASE RENT</TD>
    <TD STYLE="text-align: right">10</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">4.</TD>
    <TD STYLE="text-align: left">ADDITIONAL RENT</TD>
    <TD STYLE="text-align: right">10</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">5.</TD>
    <TD STYLE="text-align: left">USE OF PREMISES</TD>
    <TD STYLE="text-align: right">16</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">6.</TD>
    <TD STYLE="text-align: left">SERVICES AND UTILITIES</TD>
    <TD STYLE="text-align: right">22</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">7.</TD>
    <TD STYLE="text-align: left">REPAIRS</TD>
    <TD STYLE="text-align: right">25</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">8.</TD>
    <TD STYLE="text-align: left">ADDITIONS AND ALTERATIONS</TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">9.</TD>
    <TD STYLE="text-align: left">COVENANT AGAINST LIENS</TD>
    <TD STYLE="text-align: right">27</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">10.</TD>
    <TD STYLE="text-align: left">INSURANCE</TD>
    <TD STYLE="text-align: right">28</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">11.</TD>
    <TD STYLE="text-align: left">DAMAGE AND DESTRUCTION</TD>
    <TD STYLE="text-align: right">30</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">12.</TD>
    <TD STYLE="text-align: left">NONWAIVER</TD>
    <TD STYLE="text-align: right">31</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">13.</TD>
    <TD STYLE="text-align: left">CONDEMNATION</TD>
    <TD STYLE="text-align: right">31</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">14.</TD>
    <TD STYLE="text-align: left">ASSIGNMENT AND SUBLETTING</TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">15.</TD>
    <TD STYLE="text-align: left">SURRENDER OF PREMISES; OWNERSHIP AND REMOVAL OF TRADE FIXTURES</TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">16.</TD>
    <TD STYLE="text-align: left">HOLDING OVER</TD>
    <TD STYLE="text-align: right">37</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">17.</TD>
    <TD STYLE="text-align: left">ESTOPPEL CERTIFICATES</TD>
    <TD STYLE="text-align: right">37</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">18.</TD>
    <TD STYLE="text-align: left">SUBORDINATION</TD>
    <TD STYLE="text-align: right">37</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">19.</TD>
    <TD STYLE="text-align: left">DEFAULTS; REMEDIES</TD>
    <TD STYLE="text-align: right">38</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">20.</TD>
    <TD STYLE="text-align: left">COVENANT OF QUIET ENJOYMENT</TD>
    <TD STYLE="text-align: right">41</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">21.</TD>
    <TD STYLE="text-align: left">SECURITY DEPOSIT</TD>
    <TD STYLE="text-align: right">41</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">22.</TD>
    <TD STYLE="text-align: left">SUBSTITUTION OF OTHER PREMISES (AS TO OFFICE PREMISES ONLY)</TD>
    <TD STYLE="text-align: right">42</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">23.</TD>
    <TD STYLE="text-align: left">SIGNS</TD>
    <TD STYLE="text-align: right">43</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">24.</TD>
    <TD STYLE="text-align: left">COMPLIANCE WITH LAW</TD>
    <TD STYLE="text-align: right">43</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">25.</TD>
    <TD STYLE="text-align: left">LATE CHARGES</TD>
    <TD STYLE="text-align: right">44</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">26.</TD>
    <TD STYLE="text-align: left">LANDLORD&rsquo;S RIGHT TO CURE DEFAULT; PAYMENTS BY TENANT</TD>
    <TD STYLE="text-align: right">44</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">27.</TD>
    <TD STYLE="text-align: left">PROJECT CONTROL BY LANDLORD; ENTRY BY LANDLORD</TD>
    <TD STYLE="text-align: right">45</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">28.</TD>
    <TD STYLE="text-align: left">TENANT PARKING</TD>
    <TD STYLE="text-align: right">46</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: left">29.</TD>
    <TD STYLE="text-align: left">MISCELLANEOUS PROVISIONS</TD>
    <TD STYLE="text-align: right">46</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 1; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: middle; text-align: justify; width: 12%">EXHIBITS</TD>
    <TD STYLE="vertical-align: bottom; width: 88%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: justify">Exhibit 1.1.1-1</TD>
    <TD STYLE="text-align: justify">Premises</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: justify">Exhibit 1.1.1-2</TD>
    <TD STYLE="text-align: justify">Work Letter</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: justify">Exhibit 1.3</TD>
    <TD STYLE="text-align: justify">First Offer Space</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: justify">Exhibit 2.1</TD>
    <TD STYLE="text-align: justify">Form of Notice of Lease Term Dates</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: justify">Exhibit 5.2</TD>
    <TD STYLE="text-align: justify">Rules and Regulations</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: justify">Exhibit 5.3.1.1</TD>
    <TD STYLE="text-align: justify">Environmental Questionnaire</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: justify">Exhibit 17</TD>
    <TD STYLE="text-align: justify">Form of Tenant&rsquo;s Estoppel Certificate</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: justify">Exhibit 21.1</TD>
    <TD STYLE="text-align: justify">Form of Letter of Credit&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD STYLE="text-align: justify">Exhibit 27.3</TD>
    <TD STYLE="text-align: justify">Restricted Shaft Space&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: middle; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="text-decoration: underline; vertical-align: middle">Index of Defined Terms<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: 400"></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 0.5in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>11555 Building</TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>11575 Building</TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Abatement Period</TD>
    <TD STYLE="text-align: right">2</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Accountant</TD>
    <TD STYLE="text-align: right">15</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>ADA</TD>
    <TD STYLE="text-align: right">21</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Additional Insureds</TD>
    <TD STYLE="text-align: right">29</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Additional Rent</TD>
    <TD STYLE="text-align: right">10</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Advocate Arbitrators</TD>
    <TD STYLE="text-align: right">9</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Alterations</TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Applicable Laws</TD>
    <TD STYLE="text-align: right">43</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Bank Prime Loan</TD>
    <TD STYLE="text-align: right">44</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Base Rent</TD>
    <TD STYLE="text-align: right">10</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>BMBL</TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>BOMA</TD>
    <TD STYLE="text-align: right">7</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Brokers</TD>
    <TD STYLE="text-align: right">49</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Builder&rsquo;s All Risk</TD>
    <TD STYLE="text-align: right">27</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Building Common Areas</TD>
    <TD STYLE="text-align: right">6</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Building Hours</TD>
    <TD STYLE="text-align: right">22</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>CASp Report</TD>
    <TD STYLE="text-align: right">44</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>CC&amp;Rs</TD>
    <TD STYLE="text-align: right">21</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Claims</TD>
    <TD STYLE="text-align: right">21</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Clean-up</TD>
    <TD STYLE="text-align: right">20</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Closure Letter</TD>
    <TD STYLE="text-align: right">20</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Code</TD>
    <TD STYLE="text-align: right">10</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Common Areas</TD>
    <TD STYLE="text-align: right">6</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Company</TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Comparable Buildings</TD>
    <TD STYLE="text-align: right">9</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Comparable Transactions</TD>
    <TD STYLE="text-align: right">8</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Contemplated Effective Date</TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Contemplated Transfer Space</TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>DHHS</TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Direct Expenses</TD>
    <TD STYLE="text-align: right">11</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Environmental Assessment</TD>
    <TD STYLE="text-align: right">19</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Environmental Laws</TD>
    <TD STYLE="text-align: right">18</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Environmental Questionnaire</TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Environmental Report</TD>
    <TD STYLE="text-align: right">20</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Estimate</TD>
    <TD STYLE="text-align: right">15</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Estimate Statement</TD>
    <TD STYLE="text-align: right">15</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Estimated Direct Expenses</TD>
    <TD STYLE="text-align: right">15</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Existing Hazardous Materials</TD>
    <TD STYLE="text-align: right">19</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Expense Year</TD>
    <TD STYLE="text-align: right">11</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Fair Rental Value</TD>
    <TD STYLE="text-align: right">8</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: middle">
    <TD>First Offer Commencement Date</TD>
    <TD STYLE="text-align: right; width: 0.5in">7</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>First Offer Notice</TD>
    <TD STYLE="text-align: right">7</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Force Majeure</TD>
    <TD STYLE="text-align: right">48</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Future Shaft Areas</TD>
    <TD STYLE="text-align: right">46</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Future Shaft Wall</TD>
    <TD STYLE="text-align: right">46</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Hazardous Materials</TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Hazardous Materials Claims</TD>
    <TD STYLE="text-align: right">18</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Holidays</TD>
    <TD STYLE="text-align: right">22</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>HVAC</TD>
    <TD STYLE="text-align: right">23</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>HVAC Electric</TD>
    <TD STYLE="text-align: right">22</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Independent Accountants</TD>
    <TD STYLE="text-align: right">16</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Intention to Transfer Notice</TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>L/C Security</TD>
    <TD STYLE="text-align: right">41</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Lab Premises</TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Landlord</TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Landlord Indemnitees</TD>
    <TD STYLE="text-align: right">21</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Landlord Parties</TD>
    <TD STYLE="text-align: right">28</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Lease</TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Lease Expiration Date</TD>
    <TD STYLE="text-align: right">8</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Lease Term</TD>
    <TD STYLE="text-align: right">8</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Lease Year</TD>
    <TD STYLE="text-align: right">8</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Lender</TD>
    <TD STYLE="text-align: right">21</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Lines</TD>
    <TD STYLE="text-align: right">50</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Mail</TD>
    <TD STYLE="text-align: right">48</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Material Service Interruption</TD>
    <TD STYLE="text-align: right">25</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Net Worth</TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Neutral Arbitrator</TD>
    <TD STYLE="text-align: right">9</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>New Improvements</TD>
    <TD STYLE="text-align: right">29</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Notices</TD>
    <TD STYLE="text-align: right">48</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Office Premises</TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Operating Expenses</TD>
    <TD STYLE="text-align: right">11</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Option Conditions</TD>
    <TD STYLE="text-align: right">8</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Option Rent</TD>
    <TD STYLE="text-align: right">8</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Option Term</TD>
    <TD STYLE="text-align: right">8</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Original Tenant</TD>
    <TD STYLE="text-align: right">7</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Outside Agreement Date</TD>
    <TD STYLE="text-align: right">9</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>PCBs</TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Permitted Transfer</TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Permitted Transferee</TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Permitted Use</TD>
    <TD STYLE="text-align: right">16</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Premises</TD>
    <TD STYLE="text-align: right">1</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: middle">
    <TD>Project</TD>
    <TD STYLE="text-align: right; width: 0.5in">6</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Project Common Areas</TD>
    <TD STYLE="text-align: right">6</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Proposition 13</TD>
    <TD STYLE="text-align: right">13</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Recapture Notice</TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Regulations</TD>
    <TD STYLE="text-align: right">10</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>REIT</TD>
    <TD STYLE="text-align: right">47</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Release</TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Renovations</TD>
    <TD STYLE="text-align: right">50</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Rent</TD>
    <TD STYLE="text-align: right">10</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Rent Commencement Date</TD>
    <TD STYLE="text-align: right">8</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Restricted Shaft Space</TD>
    <TD STYLE="text-align: right">46</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Review Period</TD>
    <TD STYLE="text-align: right">15</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Rules and Regulations</TD>
    <TD STYLE="text-align: right">16</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Service Interruption</TD>
    <TD STYLE="text-align: right">25</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Service Interruption Notice</TD>
    <TD STYLE="text-align: right">25</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Statement</TD>
    <TD STYLE="text-align: right">15</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Subject Space</TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Summary</TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Tax Expenses</TD>
    <TD STYLE="text-align: right">13</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Tenant</TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Tenant Parties</TD>
    <TD STYLE="text-align: right">17</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Tenant&rsquo;s Share</TD>
    <TD STYLE="text-align: right">14</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Tenant&rsquo;s Subleasing Costs</TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Third Parties</TD>
    <TD STYLE="text-align: right">29</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Transfer Notice</TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Transfer Premium</TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Transferee</TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Transfers</TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD>Underlying Documents</TD>
    <TD STYLE="text-align: right">11</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1in 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SOVA SCIENCE DISTRICT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>LEASE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Lease (the &ldquo;<B>Lease</B>&rdquo;),
dated as of the date set forth in <U>Section&nbsp;1</U> of the Summary of Basic Lease Information (the &ldquo;<B>Summary</B>&rdquo;),
below, is made by and between <B>SAN DIEGO INSPIRE 1, LLC,</B> a Delaware limited liability company, and <B>SAN DIEGO INSPIRE 2,
LLC,</B> a Delaware limited liability company (collectively, &ldquo;<B>Landlord</B>&rdquo;), and <B>AETHLON MEDICAL, INC.</B>,
a Nevada corporation (&ldquo;<B>Tenant</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>SUMMARY
OF BASIC LEASE INFORMATION</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">TERMS OF LEASE</FONT></P></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
                                                <P STYLE="margin-top: 0; margin-bottom: 0">D<FONT STYLE="font-family: Times New Roman, Times, Serif">ESCRIPTION</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dated as of:</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">November 24, 2020</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Premises<BR>
(<U>Article 1</U>).</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Buildings:</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">That (i) certain life sciences building containing approximately 26,486 rentable square feet of space located at 11555 Sorrento Valley Road, San Diego, California 92121 (the &ldquo;<B>11555 Building</B>&rdquo;), and (ii) certain life sciences building containing approximately 22,131 rentable square feet of space located at 11575 Sorrento Valley Road, San Diego, California 92121 (the &ldquo;<B>11575 Building</B>&rdquo;).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Premises:</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately 4,630 rentable square feet of space, consisting of (i) approximately 2,823 rentable square feet in the 11555 Building and commonly known as Suite 203 (the &ldquo;<B>Office Premises</B>&rdquo;), and (ii)&nbsp;1,807 rentable square feet in the 11575 Building and commonly known as Suite 200 (the &ldquo;<B>Lab Premises</B>&rdquo;), as further set forth in <B><U>Exhibit&nbsp;1.1.1-1</U></B> to the Lease.&nbsp;&nbsp;The Office Premises and the Lab Premises are hereinafter referred to together as the &ldquo;<B>Premises</B>.&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lease Term<BR>
(<U>Article 2</U>).</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Length of Term:</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Five (5) years, three (3) months (i.e., sixty-three (63) months).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intentionally Blank:</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 1in; text-indent: -0.5in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rent Commencement Date:</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The date upon which the Premises (both the Office Premises and the Lab Premises) are Ready for Occupancy (as defined in the Work Letter attached as <B><U>Exhibit 1.1.1-2</U></B>); provided, however, if Tenant commences to conduct business from either the Office Premises or the Lab Premises before such date, the Rent Commencement Date as to that portion of the Premises will occur on such date Tenant commences to conduct business therefrom.&nbsp;&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 24%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 26%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lease Expiration Date:</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The last day of the sixty-third (63<SUP>rd</SUP>) full calendar month after the Rent Commencement Date of the Lab Premises.&nbsp;&nbsp;If, at Tenant&rsquo;s election, the Rent Commencement Date is different for the Office Premises and the Lab Premises (e.g., Tenant decides to commence business from the Office Premises before the Lab Premises are Ready for Occupancy), the Lease Expiration Date will nevertheless be co-terminous as stated in the preceding sentence </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Option Term:</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">One (1) renewal term of five (5) years.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Base Rent (<U>Article 3</U>):</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The sum of the Base Rent payable for the Office Premises and the Lab Premises, as follows:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Base
Rent for Office</FONT></P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Premises:<BR>
                                         <BR> <U>Lease Year</U></FONT> <SUP>1</SUP></P></TD>
    <TD STYLE="width: 24%; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR> <BR></FONT></P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Annual<BR> <U>Base Rent</U></FONT></P></TD>
    <TD STYLE="width: 26%; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR> &nbsp;</FONT></P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Monthly<BR> Installment<BR> <U>of Base Rent</U></FONT></P></TD>
    <TD STYLE="width: 25%; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
                                               <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Monthly
                                         Base<BR> Rent<BR> per Rentable<BR> <U>Square Foot</U></FONT> <SUP>2</SUP></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1<SUP>3</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$72,155.88</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$6,012.99</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$2.13</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$74,188.44</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$6,182.37</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$2.19</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$76,221.00</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$6,351.75</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$2.25</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$78,592.32</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$6,549.36</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$2.32</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$80,963.64</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$6,746.97</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$2.39</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">6 (mos. 61, 62 and 63)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$83,334.96</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$6,944.58</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$2.46</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">__________________________</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

















<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif">If
the Rent Commencement Date does not occur on the first day of a calendar month, then Lease Year 1 shall include the first twelve
(12) full calendar months of the Lease Term and any partial calendar month in which the Rent Commencement Date occurs, and the
Base Rent for such partial calendar month shall be prorated in accordance with <U>Section 3.1</U> below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif">Monthly
Base Rent per rentable square foot has been rounded off to the nearest cent using conventional rounding principles. In addition,
in order to amortize (at an interest rate of 8%) the cost of the emergency generator allocated to Tenant based on 10% usage of
such generator, the amount of $0.08 has been added to the Monthly Base Rate per Rentable Square Foot.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif">Provided
Tenant is not in default of the terms of this Lease after expiration of any applicable notice and cure period, Tenant shall be
entitled to receive a Base Rent abatement for the second (2<SUP>nd</SUP>), third (3<SUP>rd</SUP>) and fourth (4<SUP>th</SUP>)
full calendar months of the Lease Term (the &ldquo;<B>Abatement Period</B>&ldquo;) in an aggregate amount not to exceed Seventeen
Thousand, Three Hundred Sixty-One Dollars and Forty-Five Cents ($17,361.45); the abatement amount does not include the amortized
cost of the generator. Tenant shall be obligated to pay Tenant&rsquo;s Share of Direct Expenses attributable to such period, and
Tenant shall pay to Landlord the sum of $225.84 for each month within such period for the amortized cost of the emergency generator
allocated to Tenant.</FONT></P>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 25%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
                                   <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Base Rent for Lab</FONT></P>
                                   <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Premises:<BR> <BR> <U>Lease Year</U></FONT> <SUP>4</SUP></P></TD>
    <TD STYLE="text-align: center; width: 24%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR> <BR></FONT></P>
                                   <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
                                   <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                   <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Annual<BR> <U>Base Rent</U></FONT></P></TD>
    <TD STYLE="text-align: center; width: 26%"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                   <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR> &nbsp;</FONT></P>
                                   <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Monthly<BR> Installment<BR> <U>of Base Rent</U></FONT></P></TD>
    <TD STYLE="text-align: center; width: 25%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
                                   <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Monthly Base<BR> Rent<BR> per Rentable<BR> <U>Square Foot</U></FONT> <SUP>5</SUP></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 7.9pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1
    </FONT><SUP>6</SUP></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$88,470.72</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$7,372.56</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$4.08</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 7.9pt; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$91,072.80</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$7,589.40</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$4.20</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$93,674.88</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$7,806.24</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$4.32</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$96,493.80</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$8,041.15</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$4.45</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$99,312.72</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$8,276.06</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$4.58</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">6 (mos. 61, 62 and 63)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$102,348.48</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$8,529.04</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">$4.72</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment of Rent:</FONT></TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Rent checks shall be made payable to and sent to the following
        lockbox address:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Diego Inspire 1, LLC and San Diego Inspire 2, LLC<BR>
        P.O. Box 894412<BR>
        Los Angeles, CA 90189-4422</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Or wired or sent via ACH to:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Citibank, N. A. New York<BR>
        Account Name: San Diego Inspire Holdings, LLC<BR>
        Account Number 6794041847<BR>
        Routing Number: 021000089<BR>
        Origin is outside of U.S.: Swift code CITIUS33</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant Improvement Allowance:</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Landlord shall construct improvements in the Premises in accordance with the terms of the Tenant Work Letter attached hereto as <B><U>Exhibit 1.1.1-2</U></B>.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin: 0">__________________________</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>4</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif">If
the Rent Commencement Date does not occur on the first day of a calendar month, then Lease Year 1 shall include the first twelve
(12) full calendar months of the Lease Term and any partial calendar month in which the Rent Commencement Date occurs, and the
Base Rent for such partial calendar month shall be prorated in accordance with <U>Section 3.1</U> below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>5</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif">Monthly
Base Rent per rentable square foot has been rounded off to the nearest cent using conventional rounding principles. In addition,
in order to amortize (at an interest rate of 8%) the cost of the emergency generator allocated to Tenant based on 10% usage of
such generator, the amount of $0.08 has been added to the Monthly Base Rate per Rentable Square Foot. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>6</SUP> <FONT STYLE="font-family: Times New Roman, Times, Serif">Provided
Tenant is not in default of the terms of this Lease after expiration of any applicable notice and cure period, Tenant shall be
entitled to receive a Base Rent abatement for the second (2<SUP>nd</SUP>), third (3<SUP>rd</SUP>) and fourth (4<SUP>th</SUP>)
full calendar months of the Lease Term (the &ldquo;<B>Abatement Period</B>&ldquo;) in an aggregate amount not to exceed Twenty-One
Thousand, Six Hundred Eighty-Four Dollars ($21,684.00) ); the abatement amount does not include the amortized cost of the generator.
Tenant shall be obligated to pay Tenant&rsquo;s Share of Direct Expenses attributable to such period, and Tenant shall pay to
Landlord the sum of $144.56 for each month within such period for the amortized cost of the emergency generator allocated to Tenant.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: center; width: 25%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 24%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 26%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 25%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NNN Lease:</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In addition to the Base Rent, Tenant shall be responsible to pay Tenant&rsquo;s Share of Direct Expenses in accordance with the terms of <U>Article 4</U> of the Lease.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in; text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant&rsquo;s Share<BR>
(<U>Article 4</U>):</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Approximately (i) 10.66% of the 11555 Building, (ii) 8.17% of the 11575 Building, and (iii) 3.58% of the Project, based on the calculations set forth in <U>Section 4.2.6</U> below of this Lease.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permitted Use<BR>
(<U>Article 5</U>):</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Premises shall be used only for general office<I>, </I>laboratory, research and development, administrative offices and, incidental and accessory thereto, storage uses and other lawful uses reasonably related to and incidental to such specified uses, all (i) consistent with comparable life sciences projects in the San Diego, California area<I>,</I> and (ii) in compliance with, and subject to, Applicable Laws (as defined below).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Security Deposit<BR>
(<U>Article 21</U>): </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A letter of credit in the amount of Forty-Six Thousand, Seven Hundred Twenty-Six Dollars ($46,726.00)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Guarantor<BR>
<BR>
</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">None</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parking Pass Ratio<BR>
(<U>Article 28</U>):</FONT></TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Two and one-half (2.5) unreserved parking
        spaces for every 1,000 rentable square feet of the Premises (i.e., 12 parking spaces), subject to the terms of <U>Article&nbsp;28</U>
        of the Lease.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Address of Tenant<BR>
(<U>Section&nbsp;29.18</U>):</FONT></TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For periods prior to the Rent Commencement Date:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.<BR>
        9635 Granite Ridge Drive, Suite 100<BR>
        San Diego, CA 92123<BR>
        Attention CFO</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After the Rent Commencement Date:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.<BR>
        11555 Sorrento Valley Road, Suite 203</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Diego, CA 92121<BR>
        Attention CFO</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">And in each case, with a copy to:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cooley LLP<BR>
        4401 Eastgate Mall<BR>
        San Diego, California 92121-1909<BR>
        Attention: Michael Levinson</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: center; width: 25%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 24%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 26%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; width: 25%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Address
        of Landlord<BR>
        (<U>Section&nbsp;29.18</U>):</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">See <U>Section&nbsp;29.18</U> of the Lease.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><P STYLE="margin-top: 0; margin-bottom: 0">14. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Broker(s)</P>
                    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(<U>Section&nbsp;29.24</U>):</P></TD>
    <TD COLSPAN="2" STYLE="text-align: justify">Newmark of Southern California, Inc. dba Newmark<BR>
Knight Frank <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(representing Landlord exclusively)</P>
             <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
             <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">JLL Life Sciences Group (representing Tenant exclusively)</P>
</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>PREMISES, BUILDING, PROJECT, AND COMMON AREAS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Premises, Building, Project and Common Areas</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.1.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>The Premises</U></B>. Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the premises set forth
in <U>Section&nbsp;2.2</U> of the Summary (the &ldquo;<B>Premises</B>&rdquo;). The outline of the Premises is set forth in <B><U>Exhibit&nbsp;1.1.1-1</U></B>
attached hereto. The parties hereto agree that the lease of the Premises is upon and subject to the terms, covenants and conditions
herein set forth, and Tenant covenants as a material part of the consideration for this Lease to keep and perform each and all
of such terms, covenants and conditions by it to be kept and performed and that this Lease is made upon the condition of such performance.
The parties hereto hereby acknowledge that the purpose of <B><U>Exhibit&nbsp;1.1.1-1</U></B> is to show the approximate location
of the Office Premises in the 11555 Building and the Lab Premises in the 11575 Building only, and such Exhibit is not meant to
constitute an agreement, representation or warranty as to the construction of the Premises, the precise area thereof or the specific
location of the &ldquo;Common Areas,&rdquo; as that term is defined in <U>Section&nbsp;1.1.3</U> below, or the elements thereof
or of the accessways to the Premises or the &ldquo;Project&rdquo;, as that term is defined in <U>Section&nbsp;1.1.2</U> below.
Tenant shall accept the Premises in its presently existing &ldquo;as-is&rdquo; condition and Landlord shall not be obligated to
provide or pay for any improvement work or services related to the improvement of the Premises except as otherwise expressly set
forth in this Lease or in the Tenant Work Letter attached hereto as <B><U>Exhibit 1.1.1-2</U></B>. The Premises shall exclude Common
Areas, including without limitation exterior faces of exterior walls, the entry, vestibules and main lobby of the Building, elevator
lobbies and common lavatories, the common stairways and stairwells, elevators and elevator wells, boiler room, sprinkler rooms,
elevator rooms, mechanical rooms, loading and receiving areas, electric and telephone closets, janitor closets, and pipes, ducts,
conduits, wires and appurtenant fixtures and equipment serving exclusively or in common with other parts of the Building. Notwithstanding
anything to the contrary in this Lease, Landlord shall, at its sole expense, deliver the Premises to Tenant with &nbsp;the plumbing,
electrical systems, fire sprinkler system, lighting, air conditioning and heating systems and all other building systems serving
the Premises in good operating condition and repair. If it is determined that either the Premises or the Project, or both, are
not in compliance with Applicable Laws when the Premises are, or were, delivered to Tenant, Landlord shall thereafter promptly
make such alterations as is necessary to cause the Premises and the Project, as applicable, to be in compliance with Applicable
Laws (other than the lack of an elevator to the Office Premises). Any expenses incurred by Landlord to comply with the provisions
of the two preceding sentences shall not be included in any Operating Expenses that may be charged to Tenant in any manner under
this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.1.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>The Building and The Project</U></B>. The Premises are a part of the buildings set forth in <U>Section&nbsp;2.1</U>
of the Summary (collectively, the &ldquo;<B>Building</B>&rdquo;). The term &ldquo;<B>Project</B>&rdquo;, as used in this Lease,
shall mean (i) the Building and the Common Areas, (ii) the land (which is improved with landscaping, parking facilities and other
improvements) upon which the Building and the Common Areas are located, and (iii) the other buildings (i.e., 11535, 11545 and 11585
Sorrento Valley Road) located in a portion of the project known as &ldquo;SOVA Central Science District&rdquo;, and the land upon
which such adjacent buildings are located. Tenant acknowledges and understands that (i) San Diego Inspire 1, LLC is the owner of
the 11575 Building in which the Lab Premises is located, and it is a party to this Lease solely with respect to its ownership of
the 11575 Building, and (ii) San Diego Inspire 2, LLC is the owner of the 11555 Building in which the Office Premises is located,
and it is a party to this Lease solely with respect to its ownership of the 11555 Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.1.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Common Areas</U></B>. Tenant shall have the non-exclusive right to use in common with other tenants in the Project,
and subject to the rules and regulations referred to in <U>Article 5</U> of this Lease, those portions of the Project which are
provided, from time to time, for use in common by Landlord, Tenant and any other tenants of the Project (such areas, together with
such other portions of the Project designated by Landlord, in its discretion, including certain areas designated for the exclusive
use of certain tenants, including Tenant, or to be shared by Landlord and certain tenants, including Tenant, are collectively referred
to herein as the &ldquo;<B>Common Areas</B>&rdquo;). The Common Areas shall consist of the &ldquo;<B>Project Common Areas</B>&rdquo;
and the &ldquo;<B>Building Common Areas</B>&rdquo;. The term &ldquo;<B>Project Common Areas</B>&rdquo;, as used in this Lease,
shall mean the portion of the Project designated as such by Landlord. The term &ldquo;<B>Building Common Areas</B>&rdquo;, as used
in this Lease, shall mean the portions of the Common Areas located within the Building designated as such by Landlord. The manner
in which the Common Areas are maintained and operated shall be at the sole discretion of Landlord and the use thereof shall be
subject to such rules, regulations and restrictions as Landlord may make from time to time in accordance with <U>Section 5.2</U>,
below; provided that, notwithstanding anything to the contrary in this Lease, Landlord shall operate the Project as a first class
life sciences project comparable to other first class life sciences projects in San Diego. Landlord reserves the right to close
temporarily, make alterations or additions to, or change the location of elements of the Project and the Common Areas, provided
that, in connection therewith, Landlord shall perform such closures, alterations, additions or changes in a commercially reasonable
manner and, in connection therewith, shall use commercially reasonable efforts to minimize any material interference with Tenant&rsquo;s
use of and access to the Premises. Notwithstanding anything to the contrary in this Lease, in no event shall Landlord operate,
maintain or make any changes to the Project or any portion thereof that will unreasonably interfere with or limit (a) Tenant&rsquo;s
access to or from the Premises, (b) Tenant&rsquo;s use of the Premises, or (c) Tenant&rsquo;s parking rights under this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Stipulation of Rentable Square Feet of Premises</U></B>. For purposes of this Lease, &ldquo;rentable square feet&rdquo;
of the Premises shall be deemed to be as set forth in <U>Section 2.2</U> of the Summary. For purposes of this Lease, the &ldquo;rentable
square feet&rdquo; of the Premises and the Building and the other buildings in the Project shall be calculated by Landlord pursuant
to the Standard Method for measuring Floor Area in Office Buildings, ANSI Z65.1-2017,or any subsequent updated standard as may
be used by Landlord <B>(</B>&ldquo;<B>BOMA</B>&rdquo;), as modified for the Project pursuant to Landlord&rsquo;s standard rental
area measurements for the Project, to include, among other calculations, a portion of the common areas and service areas of the
Building and other buildings in the Project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Right of First Offer</U></B>. Landlord hereby grants to the Tenant named in the Summary (the &ldquo;<B>Original Tenant</B>&rdquo;)
a one-time right of first offer with respect to certain space located in the Building as more particularly described on <B><U>Exhibit
1.3</U></B> (the &ldquo;<B>First Offer Space&rdquo;)</B>. Notwithstanding the foregoing, such first offer right of Tenant shall
commence only following the expiration or earlier termination of the initial lease (including renewals) of the First Offer Space.
Tenant&rsquo;s right of first offer shall not be applicable during any Option Term. Tenant&rsquo;s right of first offer shall be
on the terms and conditions set forth in this <U>Section 1.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.3.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Procedure for Offer</U></B>. Prior to entering into any lease for all or any portion of the First Offer Space, other
than a lease pursuant to rights held by a Superior Right Holder, Landlord shall provide a written notice to Tenant (the &ldquo;<B>First
Offer Notice</B>&rdquo;), offering to lease to Tenant the applicable portion of the First Offer Space. The First Offer Notice shall
describe the First Offer Space so offered to Tenant and shall set forth the rent, commencement date, rent commencement date and
the other material economic terms upon which Landlord is willing to lease such space to Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.3.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Procedure for Acceptance</U></B>. If Tenant wishes to exercise Tenant&rsquo;s right of first offer with respect to
the space described in the First Offer Notice, then within ten (10) business days of delivery of the First Offer Notice to Tenant,
Tenant shall deliver notice to Landlord of Tenant&rsquo;s election to exercise its right of first offer with respect to the entire
space described in the First Offer Notice on the terms contained in such notice. If Tenant does not so notify Landlord within the
ten (10) business day period, then Landlord shall be free to lease the space described in the First Offer Notice to anyone to whom
Landlord desires on any terms Landlord desires, provided that, prior to entering into a lease of such space on material economic
terms that are more than 3% more favorable to the tenant than the Base Rent set forth in the First Offer Notice, Landlord shall
first deliver another First Offer Notice to Tenant offering such space to Tenant on such reduced terms. Tenant shall respond to
any such &ldquo;re-offer&rdquo; within five (5) business days after delivery of such &ldquo;re-offer&rdquo; notice. Notwithstanding
anything to the contrary contained herein, Tenant must elect to exercise its right of first offer, if at all, with respect to all
of the space offered by Landlord to Tenant at any particular time, and Tenant may not elect to lease only a portion thereof. The
First Offer Space shall be leased by Tenant on all of the terms and conditions of this Lease except as set forth in the First Offer
Notice and this <U>Section 1.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.3.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Construction In First Offer Space</U></B>. Tenant shall take the First Offer Space in its &ldquo;as is&rdquo; condition
unless otherwise set forth in the First Offer Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.3.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Amendment to Lease</U></B>. If Tenant timely exercises Tenant&rsquo;s right to lease the First Offer Space as set
forth herein, then the First Offer Space shall be added to the Premises on the terms set forth herein and, at the election of Landlord
or Tenant, the parties shall promptly thereafter execute an amendment to this Lease for such First Offer Space (but the execution
of such amendment shall not be required for the lease of the First Offer Space to become effective). Tenant shall commence payment
of Rent for the First Offer Space, and the term of the First Offer Space shall commence upon the date (or mechanism for establishing
such date) set forth in the First Offer Notice (the &ldquo;<B>First Offer Commencement Date</B>&rdquo;) and terminate on the date
set forth in the First Offer Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.3.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Termination of Right of First Offer</U></B>. The rights contained in this <U>Section 1.2</U> shall be personal to
the Original Tenant, and may only be exercised by the Original Tenant and any Permitted Transferee (as defined in <U>Section 14.8</U>)
(and not any other assignee, sublessee or other transferee of the Original Tenant&rsquo;s interest in this Lease) if the Original
Tenant or any Permitted Transferee occupies the entire Lab Premises. Except as expressly set forth in this <U>Section 1.3</U>,
the right of first offer granted herein shall terminate as to particular First Offer Space upon the failure by Tenant to exercise
its right of first offer with respect to such First Offer Space as offered by Landlord. Tenant shall not have the right to lease
First Offer Space, as provided in this <U>Section 1.3</U>, if, as of the date of the attempted exercise of any right of first offer
by Tenant, or as of the scheduled date of delivery of such First Offer Space to Tenant, Tenant is in default under this Lease,
after the expiration of any applicable notice and cure period, or Tenant has previously been in default, after the expiration of
any applicable notice an cure period, under this Lease more than once in the twelve (12) months preceding the date Landlord would
otherwise be obligated to give to Tenant the First Offer Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>LEASE TERM; OPTION TERM</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Lease Term</U></B>. The terms and provisions of this Lease shall be effective as of the date of this Lease, except
that in no event shall Tenant have any obligations under this Lease prior to the Rent Commencement Date except as expressly set
forth in this Lease. The term of this Lease (the &ldquo;<B>Lease Term</B>&rdquo;) shall be as set forth in <U>Section&nbsp;3.1</U>
of the Summary, shall commence on the date set forth in <U>Section&nbsp;3.3</U> of the Summary (the &ldquo;<B>Rent Commencement
Date</B>&rdquo;), and shall terminate on the date set forth in <U>Section&nbsp;3.4</U> of the Summary (the &ldquo;<B>Lease Expiration
Date</B>&rdquo;) unless this Lease is sooner terminated as hereinafter provided. For purposes of this Lease, the term &ldquo;<B>Lease
Year</B>&rdquo; shall mean the consecutive twelve (12) month period following and including the Rent Commencement Date and each
subsequent twelve (12) month period during the Lease Term. At any time during the Lease Term, Landlord may deliver to Tenant a
notice in the form as set forth in <B><U>Exhibit&nbsp;2.1</U></B> attached hereto, as a confirmation only of the information set
forth therein, which Tenant shall (absent manifest error) execute and return to Landlord within ten (10) business days of receipt
thereof, but execution of such instrument shall not be a condition to Lease commencement or Tenant&rsquo;s obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Option Term</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Option Right</U></B><I>. </I>Landlord hereby grants to the originally named Tenant herein (the &ldquo;<B>Original
Tenant</B>&rdquo;) and any Permitted Transferee (as defined in <U>Section 14.8</U>) the option to extend the Lease Term for a period
of five (5) years (the &ldquo;<B>Option Term</B>&rdquo;), which option shall be irrevocably exercised only by written notice delivered
by Tenant to Landlord not more than twelve (12) months nor less than nine (9) months prior to the expiration of the initial Lease
Term, provided that the following conditions <B>(</B>the &ldquo;<B>Option Conditions</B>&rdquo;) are satisfied: (i)&nbsp;as of
the date of delivery of such notice, Tenant is not in default under this Lease after the expiration of any applicable notice and
cure period; (ii)&nbsp;as of the end of the Lease Term, Tenant is not in default under this Lease, after the expiration of any
applicable notice and cure period; (iii)&nbsp;Tenant has not previously been in default under this Lease, after the expiration
of any applicable notice and cure period, more than twice; and (iv)&nbsp;the Lease then remains in full force and effect and the
Original Tenant or any Permitted Transferee occupies at least seventy-five (75%) of the Premises at the time the option to extend
is exercised and as of the commencement of the Option Term. Landlord may, at Landlord&rsquo;s option, exercised in Landlord&rsquo;s
sole and absolute discretion, waive any of the Option Conditions in which case the option, if otherwise properly exercised by Tenant,
shall remain in full force and effect. Upon the proper exercise of such option to extend, and provided that Tenant satisfies all
of the Option Conditions (except those, if any, which are waived by Landlord), the Lease Term, as it applies to the Premises, shall
be extended for a period of five (5) years. The rights contained in this <U>Section&nbsp;2.2</U> shall be personal to Original
Tenant, and may be exercised by Original Tenant or any Permitted Transferee occupying the entire Premises (and not by any other
assignee, sublessee or other &ldquo;Transferee&rdquo; (as defined in <U>Section 14.1</U> of this Lease) of Tenant&rsquo;s interest
in this Lease).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Option Rent</U></B>. The annual Base Rent payable by Tenant during the Option Term (the &ldquo;<B>Option Rent</B>&rdquo;)
shall be equal to the &ldquo;Fair Rental Value&rdquo;, as that term is defined below, for the Premises as of the commencement date
of the Option Term. The &ldquo;<B>Fair Rental Value</B>&rdquo;, as used in this Lease, shall be equal to the annual fixed base
rent per rentable square foot at which tenants (pursuant to leases consummated within the twelve (12) month period preceding the
first day of the Option Term), are leasing non-sublease, non-encumbered, non-equity space which is not significantly greater or
smaller in size than the subject space, for a comparable lease term, in an arm&rsquo;s length transaction, which comparable space
is located in the &ldquo;Comparable Buildings&rdquo;, as that term is defined below (transactions satisfying the foregoing criteria
shall be known as the &ldquo;<B>Comparable Transactions</B>&rdquo;), taking into consideration all reasonable factors considered
by landlords and tenants in the determination of fixed annual rent. The term &ldquo;<B>Comparable Buildings</B>&rdquo; shall mean
the Building and those other life sciences buildings which are comparable to the Building in terms of age (based upon the date
of completion of construction or major renovation of to the building), quality of construction, level of services and amenities,
size and appearance, and are located in Sorrento Valley submarket within the City of San Diego, California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Determination of Option Rent</U></B>. In the event Tenant timely and appropriately exercises an option to extend the
Lease Term, Landlord shall notify Tenant of Landlord&rsquo;s determination of the Option Rent no later than five (5) months prior
to the Lease Expiration Date. If Tenant, on or before the date which is ten&nbsp;(10) days following the date upon which Tenant
receives Landlord&rsquo;s determination of the Option Rent, in good faith objects to Landlord&rsquo;s determination of the Option
Rent, then Landlord and Tenant shall attempt to agree upon the Option Rent using their best good-faith efforts. If Landlord and
Tenant fail to reach agreement within ten (10) days following Tenant&rsquo;s objection to the Option Rent (the &ldquo;<B>Outside
Agreement Date</B>&rdquo;), then each party shall make a separate determination of the Option Rent, as the case may be, within
five (5) days, and such determinations shall be submitted to arbitration in accordance with <U>Sections&nbsp;2.2.3.1</U> through
<U>2.2.3.7</U>, below. If Tenant fails to object to Landlord&rsquo;s determination of the Option Rent within the time period set
forth herein, then Tenant shall be deemed to have accepted Landlord&rsquo;s determination of Option Rent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.2.3.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If Landlord and Tenant fail to reach agreement prior to the Outside Agreement Date, then Landlord and Tenant shall each
appoint one arbitrator who shall be, at the option of the appointing party, a qualified real estate broker or appraiser who shall
have been active over the ten (10) year period ending on the date of such appointment in the leasing of other comparable life sciences
buildings located in the city of San Diego. The determination of the arbitrators shall be limited solely to the issue of whether
Landlord&rsquo;s or Tenant&rsquo;s submitted Option Rent is the closest to the actual Option Rent, taking into account the requirements
of <U>Section&nbsp;2.2.2</U> of this Lease, as determined by the arbitrators. Each such arbitrator shall be appointed within fifteen
(15) days after the Outside Agreement Date. Landlord and Tenant may consult with their selected arbitrators prior to appointment
and may select an arbitrator who is favorable to their respective positions. The arbitrators so selected by Landlord and Tenant
shall be deemed &ldquo;<B>Advocate Arbitrators</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.2.3.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The two (2) Advocate Arbitrators so appointed shall be specifically required pursuant to an engagement letter to, within
ten (10) days of the date of the appointment of the last appointed Advocate Arbitrator, agree upon and appoint a third arbitrator
(&ldquo;<B>Neutral Arbitrator</B>&rdquo;) who shall be qualified under the same criteria set forth hereinabove for qualification
of the two Advocate Arbitrators, except that neither Landlord or Tenant or either party&rsquo;s Advocate Arbitrator may, directly
or indirectly, consult with the Neutral Arbitrator prior or subsequent to his or her appearance. The Neutral Arbitrator shall be
retained via an engagement letter jointly prepared by Landlord&rsquo;s counsel and Tenant&rsquo;s counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.2.3.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The three arbitrators shall, within thirty (30) days of the appointment of the Neutral Arbitrator, reach a decision as to
whether the parties shall use Landlord&rsquo;s or Tenant&rsquo;s submitted Option Rent, and shall notify Landlord and Tenant thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.2.3.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The decision of the majority of the three arbitrators shall be binding upon Landlord and Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.2.3.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Intentionally Blank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.2.3.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the two (2) Advocate Arbitrators fail to agree upon and appoint the Neutral Arbitrator, then either party may petition
the then-President of the San Diego Real Estate Board to appoint such Advocate Arbitrator subject to the criteria in <U>Section&nbsp;2.2.3.1</U>
of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.2.3.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The cost of the Neutral Arbitrator shall be paid by Landlord and Tenant equally and each of Landlord and Tenant shall pay
the cost of its respective Advocate Arbitrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.2.3.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that the Option Rent shall not have been determined pursuant to the terms hereof prior to the commencement
of the Option Term, Tenant shall be required to pay the Option Rent initially provided by Landlord to Tenant, and upon the final
determination of the Option Rent, the payments made by Tenant shall be reconciled with the actual amounts of Option Rent due, and
the appropriate party shall make any corresponding payment to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">2.2.3.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The terms of the Lease during any Option Term shall be the same as the terms during the initial Lease Term, other than as
expressly set forth in this <U>Section 2.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>BASE RENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Payment of Rent</U></B>. Tenant shall pay, without prior notice or demand, in accordance with <U>Section 4.1</U> of
the Summary or at such place as Landlord may from time to time designate in writing, by a check for currency which, at the time
of payment, is legal tender for private or public debts in the United States of America or pursuant to wire or electronic payment
instructions provided by Landlord, base rent (&ldquo;<B>Base Rent</B>&rdquo;) as set forth in <U>Section&nbsp;4</U> of the Summary,
payable in equal monthly installments as set forth in <U>Section&nbsp;4</U> of the Summary, in advance, on or before the first
day of each and every calendar month during the Lease Term, without any setoff or deduction whatsoever. Base Rent for the first
full month of the Lease Term shall be paid at the time of Tenant&rsquo;s execution of this Lease. If any Rent payment date (including
the Rent Commencement Date) falls on a day of the month other than the first day of such month or if any payment of Rent is for
a period which is shorter than one month, the Rent for any fractional month shall accrue on a daily basis for the period from the
date such payment is due to the end of such calendar month or to the end of the Lease Term at a rate per day which is equal to
1/365 of the applicable annual Rent. All other payments or adjustments required to be made under the terms of this Lease that require
proration on a time basis shall be prorated on the same basis. Base Rent and Additional Rent shall together be denominated &ldquo;<B>Rent</B>&rdquo;.
Without limiting the foregoing, Tenant&rsquo;s obligation to pay Rent shall be absolute, unconditional and independent of any Landlord
covenants and shall not be discharged or otherwise affected by any law or regulation now or hereafter applicable to the Premises,
or any other restriction on Tenant&rsquo;s use, or (except as expressly provided herein) any casualty or taking, or any failure
by Landlord to perform any covenant contained herein, or any other occurrence; and Tenant assumes the risk of the foregoing and
waives all rights now or hereafter existing to terminate or cancel this Lease or quit or surrender the Premises or any part thereof,
or to assert any defense in the nature of constructive eviction to any action seeking to recover rent. Tenant&rsquo;s covenants
contained herein are independent and not dependent, and Tenant hereby waives the benefit of any statute or judicial law to the
contrary. Notwithstanding anything to the contrary in this Lease, Tenant may at its election pay any Rent (as defined below) to
Landlord by electronic transfer (including ACH), and Tenant shall use the ACH information set forth in <U>Section 4</U> of the
Summary in order to effect such payments of Rent using electronic transfer of funds through its bank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Rents from Real Property</U></B>. Landlord and Tenant hereby agree that it is their intent that all Base Rent, Additional
Rent and other rent and charges payable to the Landlord under this Lease (hereinafter individually and collectively referred to
as &ldquo;<B>Rent</B>&rdquo;) shall qualify as &ldquo;rents from real property&rdquo; within the meaning of Section 856(d) of the
Internal Revenue Code of 1986, as amended (the &ldquo;<B>Code</B>&rdquo;), and the Department of the U.S. Treasury Regulations
promulgated thereunder (the &ldquo;<B>Regulations</B>&rdquo;). Should the Code or the Regulations, or interpretations thereof by
the Internal Revenue Service contained in revenue rulings or other similar public pronouncements, be changed so that any Rent no
longer so qualifies as &ldquo;rent from real property&rdquo; for purposes of Section 856(d) of the Code and the Regulations promulgated
thereunder, such Rent shall be adjusted in such manner as the Landlord may require so that it will so qualify; provided, however,
that any adjustments required pursuant to this <U>Section 7.3</U> shall be made so as to produce the equivalent (in economic terms)
Rent as payable prior to such adjustment and in no event shall Tenant be obligated to incur any additional Rent by virtue of such
adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">4.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>ADDITIONAL RENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>General Terms</U></B>. In addition to paying the Base Rent specified in <U>Article 3</U> of this Lease, Tenant shall
pay &ldquo;<B>Tenant&rsquo;s Share</B>&rdquo; of the annual &ldquo;<B>Direct Expenses</B>&rdquo; as those terms are defined in
<U>Sections 4.2.6</U> and <U>4.2.2</U> of this Lease, respectively. Such payments by Tenant, together with any and all other amounts
payable by Tenant to Landlord pursuant to the terms of this Lease other than Base Rent, are hereinafter collectively referred to
as the &ldquo;<B>Additional Rent</B>&rdquo;. All amounts due under this <U>Article 4</U> as Additional Rent shall be payable for
the same periods and in the same manner as the Base Rent. Without limitation on other obligations of Tenant which survive the expiration
of the Lease Term, the obligations of Tenant to pay the Additional Rent provided for in this <U>Article 4</U> shall survive the
expiration of the Lease Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Definitions of Key Terms Relating to Additional Rent</U></B>. As used in this <U>Article&nbsp;4</U>, the following
terms shall have the meanings hereinafter set forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Intentionally Omitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Direct Expenses</B>&rdquo; shall mean &ldquo;<B>Operating Expenses</B>&rdquo; and &ldquo;<B>Tax Expenses</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Expense Year</B>&rdquo; shall mean each calendar year in which any portion of the Lease Term falls, through and
including the calendar year in which the Lease Term expires, provided that Landlord, upon notice to Tenant, may change the Expense
Year from time to time to any other twelve (12) consecutive month period, and, in the event of any such change, Tenant&rsquo;s
Share of Direct Expenses shall be equitably adjusted for any Expense Year involved in any such change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Operating Expenses</B>&rdquo; shall mean all expenses, costs and amounts of every kind and nature which Landlord
pays or accrues during any Expense Year because of or in connection with the ownership, management, maintenance, security, repair,
replacement, restoration or operation of the Project, or any portion thereof. Without limiting the generality of the foregoing,
Operating Expenses shall specifically include any and all of the following: (i) the cost of supplying all utilities, the cost of
operating, repairing, maintaining, and renovating the utility, telephone, mechanical, sanitary, storm drainage, and elevator systems,
and the cost of maintenance and service contracts in connection therewith; (ii) the cost of licenses, certificates, permits and
inspections and the cost of contesting any governmental enactments which may affect Operating Expenses, and the costs incurred
in connection with any federal, state or municipal governmentally mandated transportation demand management program or similar
program; (iii) the cost of all insurance carried by Landlord in connection with the Project; (iv) the cost of landscaping, re-lamping,
and all supplies, tools, equipment and materials used in the operation, repair and maintenance of the Project, or any portion thereof;
(v) the cost of parking area operation, repair, restoration, and maintenance; (vi) fees and other costs, including management,
consulting fees, legal fees and accounting fees, of all contractors and consultants in connection with the management, operation,
maintenance and repair of the Project; (vii) payments under any equipment rental agreements and the fair rental value of any management
office space; (viii) subject to item (f), below, wages, salaries and other compensation and benefits, including taxes levied thereon,
of all persons engaged in the operation, maintenance and security of the Project; (ix) intentionally omitted (x) operation, repair,
maintenance and replacement of all systems and equipment and components thereof of the Project; (xi) the cost of janitorial, alarm,
security and other services, replacement of wall and floor coverings, ceiling tiles and fixtures in common areas, maintenance and
replacement of curbs and walkways, repair to roofs and re-roofing; (xii) amortization (including reasonable interest on the unamortized
cost) over such period of time as Landlord shall reasonably determine, of the cost of acquiring or the rental expense of personal
property used in the maintenance, operation and repair of the Project, or any portion thereof; (xiii) the cost of capital improvements
or other costs incurred in connection with the Project (A) which are, in good faith, intended to reduce expenses in the operation
or maintenance of the Project, or any portion thereof, or to reduce current or future Operating Expenses or to enhance the safety
or security of the Project or its occupants, (B) that are required to comply with any mandatory energy conservation programs, (C)
which are replacements or modifications of nonstructural items located in the Common Areas required to keep the Common Areas in
the same good order or condition as on the Lease Commencement Date, or (D) that are required under any federal, state or municipal
governmental law or regulation that was not in force or effect as of the Rent Commencement Date; provided, however, that the costs
of any capital improvement shall be amortized (including reasonable interest on the amortized cost as reasonably determined by
Landlord) over such period of time as Landlord shall reasonably determine; and (xiv) costs, fees, charges or assessments imposed
by, or resulting from any mandate imposed on Landlord by, any federal, state or municipal government for fire and police protection,
trash removal, community services, or other services which do not constitute &ldquo;Tax Expenses&rdquo; as that term is defined
in <U>Section&nbsp;4.2.5</U>, below, (xv)&nbsp;cost of tenant relation programs reasonably established by Landlord, and (xvi)&nbsp;payments
under any easement, license, operating agreement, declaration, restrictive covenant, or instrument pertaining to the sharing of
costs by the Building, including, without limitation, any covenants, conditions, restrictions, and reciprocal easement agreements
affecting the Project, and any agreements with governmental agencies affecting the Project (any of the foregoing that now or hereafter
affect the Property, collectively, the &ldquo;<B>Underlying Documents</B>&rdquo;). In the event that Landlord or Landlord&rsquo;s
managers or agents perform services for the benefit of the Building off-site which would otherwise be performed on-site (e.g.,
accounting), the cost of such services shall be reasonably allocated among the properties benefitting from such service and shall
be included in Operating Expenses. Notwithstanding the foregoing, for purposes of this Lease, <B>Operating Expenses shall not,
however, include</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>costs, including legal fees, space planners&rsquo; fees, advertising and promotional expenses, and brokerage fees incurred
in connection with the original construction or development (or any defects), or original or future leasing of the Project, and
costs, including permit, license and inspection costs, incurred with respect to the installation of tenant improvements made for
tenants or incurred in renovating or otherwise improving, decorating, painting or redecorating vacant space for tenants of the
Project (excluding, however, such costs relating to any common areas of the Project);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>except as set forth in items (xii), (xiii), and (xiv) above, depreciation, interest and principal payments on mortgages
and other debt costs, if any, penalties and interest, and costs of capital improvements (as distinguished from repairs or replacements);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>costs for which Landlord is reimbursed by any tenant or occupant of the Project (other than as Direct Expenses) or by insurance
by its carrier or any tenant&rsquo;s carrier or by anyone else, and electric power costs for which any tenant directly contracts
with the local public service company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any bad debt loss, rent loss, or reserves for bad debts or rent loss;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>costs associated with the operation of the business of the partnership or entity which constitutes Landlord, as the same
are distinguished from the costs of operation of the Project (which shall specifically include, but not be limited to, accounting
costs associated with the operation of the Project). Costs associated with the operation of the business of the partnership or
entity which constitutes Landlord include without limitation costs of partnership accounting and legal matters, costs of defending
any lawsuits with any mortgagee (except as the actions of Tenant may be in issue), costs of selling, syndicating, financing, mortgaging
or hypothecating any of Landlord&rsquo;s interest in the Project, and costs incurred in connection with any disputes between Landlord
and its employees, between Landlord and Project management, or between Landlord and other tenants or occupants;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the wages and benefits of any employee who does not devote substantially all of his or her employed time to the Project
unless such wages and benefits are prorated to reflect time spent on operating and managing the Project vis-a-vis time spent on
matters unrelated to operating and managing the Project; provided, that in no event shall Operating Expenses for purposes of this
Lease include wages and/or benefits attributable to personnel above the level of Project manager;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(g)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amount paid as ground rental for the Project by Landlord;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(h)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>except for a property management fee, overhead and profit increment paid to Landlord or to subsidiaries or affiliates of
Landlord for services in the Project to the extent the same exceeds the costs of such services rendered by qualified, first-class
unaffiliated third parties on a competitive basis;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any compensation paid to clerks, attendants or other persons in commercial concessions operated by Landlord, provided that
any compensation paid to any concierge at the Project shall be includable as an Operating Expense;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(j)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all items and services for which Tenant or any other tenant in the Project reimburses Landlord (other than as Direct Expenses)
or which Landlord provides selectively to one or more tenants (other than Tenant) without reimbursement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(k)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>rent for any office space occupied by Project management personnel to the extent the size or rental rate of such office
space exceeds the size or fair market rental value of office space occupied by management personnel of comparable buildings in
the vicinity of the Building, with adjustment where appropriate for the size of the applicable project;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(l)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>costs incurred to comply with laws relating to the removal of Hazardous Materials;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(m)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Landlord&rsquo;s general overhead expenses not related to the Project;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(n)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>legal fees, accountants&rsquo; fees (other than normal bookkeeping expenses) and other expenses incurred in connection with
disputes of tenants or other occupants of the Project or associated with the enforcement of the terms of any leases with tenants
or the defense of Landlord&rsquo;s title to or interest in the Project or any part thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(o)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any reserves;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(p)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>capital expenditures except as expressly set forth above and then only to the extent that they are capitalized over the
useful life of such item (as such useful life is reasonably determined by Landlord).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(q)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>costs of Landlord's charitable or political contributions, or of fine art maintained at the Project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(r)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>costs incurred in the sale or refinancing of the Project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(s)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>penalties, fines, interest or other similar charges incurred by Landlord (1) due to the violation by Landlord, its employees,
agents or contractors or any tenant of the terms and conditions of any lease of space in the Project or any legal requirement,
(2) incurred as a result of Landlord's inability or failure to make payment of taxes and/or to file any tax or informational returns
when due or (3) due to the gross negligence or willful misconduct of Landlord or its employees, officers, directors, contractors
or agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(t)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any costs incurred to remove, study, test or remediate hazardous materials that exist in or about the Project prior to the
date of this Lease; and costs incurred to remove, remedy, contain, or treat hazardous material, which hazardous material is brought
into the Project or onto the Project after the date hereof by Landlord or any other tenant of the Project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Landlord is not
furnishing any particular work or service (the cost of which, if performed by Landlord, would be included in Operating Expenses)
to a tenant who has undertaken to perform such work or service in lieu of the performance thereof by Landlord, Operating Expenses
shall be deemed to be increased by an amount equal to the additional Operating Expenses which would reasonably have been incurred
during such period by Landlord if it had at its own expense furnished such work or service to such tenant. If the Project is not
at least one hundred percent (100%) occupied during all or a portion of any Expense Year, Landlord shall make an appropriate adjustment
to the components of Operating Expenses for such year to determine the amount of Operating Expenses that would have been incurred
had the Project been one hundred percent (100%) occupied; and the amount so determined shall be deemed to have been the amount
of Operating Expenses for such year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Taxes</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.5.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Tax Expenses</B>&rdquo; shall mean all federal, state, county, or local governmental or municipal taxes, fees,
charges or other impositions of every kind and nature, whether general, special, ordinary or extraordinary (including, without
limitation, real estate taxes, general and special assessments, transit taxes, payments in lieu of taxes, business improvement
district charges, leasehold taxes or taxes based upon the receipt of rent, including gross receipts or sales taxes applicable to
the receipt of rent, unless required to be paid by Tenant, personal property taxes imposed upon the fixtures, machinery, equipment,
apparatus, systems and equipment, appurtenances, furniture and other personal property used in connection with the Project, or
any portion thereof), which shall be paid or accrued during any Expense Year (without regard to any different fiscal year used
by such governmental or municipal authority) because of or in connection with the ownership, leasing and operation of the Project,
or any portion thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.5.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Tax Expenses shall include, without limitation: (i) Any tax on the rent, right to rent or other income from the Project,
or any portion thereof, or as against the business of leasing the Project, or any portion thereof; (ii) any assessment, tax, fee,
levy or charge in addition to, or in substitution, partially or totally, of any assessment, tax, fee, levy or charge previously
included within the definition of real property tax, it being acknowledged by Tenant and Landlord that Proposition 13 was adopted
by the voters of the State of California in the June 1978 election (&ldquo;<B>Proposition 13</B>&rdquo;) and that assessments,
taxes, fees, levies and charges may be imposed by governmental agencies for such services as fire protection, street, sidewalk
and road maintenance, refuse removal and for other governmental services formerly provided without charge to property owners or
occupants, and, in further recognition of the decrease in the level and quality of governmental services and amenities as a result
of Proposition 13, Tax Expenses shall also include any governmental or private assessments or the Project's contribution towards
a governmental or private cost-sharing agreement for the purpose of augmenting or improving the quality of services and amenities
normally provided by governmental agencies; and it being further acknowledged that the voters of the State of California may amend,
modify or reject Proposition 13 during the Lease Term resulting in increases in real property taxes assessed or levied against
the Project, (iii) any assessment, tax, fee, levy, or charge allocable to or measured by the area of the Premises or the Rent payable
hereunder, including, without limitation, any business or gross income tax or excise tax with respect to the receipt of such rent,
or upon or with respect to the possession, leasing, operating, management, maintenance, alteration, repair, use or occupancy by
Tenant of the Premises, or any portion thereof; and (iv) any assessment, tax, fee, levy or charge, upon this transaction or any
document to which Tenant is a party, creating or transferring an interest or an estate in the Premises or the improvements thereon.
If at any time during the Lease Term there shall be assessed on Landlord, in addition to or lieu of the whole or any part of the
ad valorem tax on real or personal property, a capital levy or other tax on the gross rents or other measures of building operations,
or a governmental income, franchise, excise or similar tax, assessment, levy, charge or fee measured by or based, in whole or in
part, upon building valuation, gross rents or other measures of building operations or benefits of governmental services furnished
to the Building, then any and all of such taxes, assessments, levies, charges and fees, to the extent so measured or based, shall
be included within the term Tax Expenses, but only to the extent that the same would be payable if the Building and Land were the
only property of Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.2.5.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any costs and expenses (including, without limitation, reasonable and actual attorneys&rsquo; and consultants&rsquo; fees)
incurred in attempting to protest, reduce or minimize Tax Expenses shall be included in Tax Expenses in the Expense Year such expenses
are incurred. Tax refunds shall be credited against Tax Expenses and refunded to Tenant regardless of when received, based on the
Expense Year to which the refund is applicable, provided that in no event shall the amount to be refunded to Tenant for any such
Expense Year exceed the total amount paid by Tenant as on account of Tax Expenses under this <U>Article 4</U> for such Expense
Year. The foregoing sentence shall survive the expiration or earlier termination of this Lease. If Tax Expenses for any period
during the Lease Term or any extension thereof are increased after payment thereof for any reason, including, without limitation,
error or reassessment by applicable governmental or municipal authorities, Tenant shall pay Landlord upon demand Tenant&rsquo;s
Share of any such increased Tax Expenses. Notwithstanding anything to the contrary contained in this Lease, there shall be excluded
from Tax Expenses (i) all excess profits taxes, franchise taxes, gift taxes, capital stock taxes, inheritance and succession taxes,
estate taxes, transfer tax or fee, federal and state income taxes, and other taxes to the extent applicable to Landlord&rsquo;s
general or net income (as opposed to rents, receipts or income attributable to operations at the Project), (ii) any items included
as Operating Expenses, and (iii) any items paid by Tenant under <U>Section&nbsp;4.5</U> of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Tenant&rsquo;s Share</B>&rdquo; is based upon the following, as applicable: (i)&nbsp;for the 11555 Building, the
ratio that the rentable square feet of the Premises bears to the rentable square feet of the 11555 Building (i.e., 2,823 &divide;
26,486), (ii) for the 11575 Building, the ratio that the rentable square feet of the Premises bears to the rentable square feet
of the 11575 Building (i.e., 1,807 &divide; 22,131) and (ii) for the Project, the ratio that the rentable square feet of the Premises
bears to the rentable square feet of the Project (i.e., 4,630 &divide; 129,411). Initially, Tenant&rsquo;s Share shall mean the
applicable percentages set forth in <U>Section&nbsp;7</U> of the Summary, subject to adjustment in the event that Tenant expands
the Premises within the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Allocation of Direct Expenses</U></B>. The parties acknowledge that the Building is a part of a multi-building project
and that the costs and expenses incurred in connection with the Project (i.e., the Direct Expenses) should be shared among the
tenants of the Building and the tenants of the other buildings in the Project. Accordingly, as set forth in <U>Section 4.2</U>
above, Direct Expenses (which consist of Operating Expenses and Tax Expenses) are determined annually for the Project as a whole,
and a portion of the Direct Expenses, which portion shall be determined by Landlord on an equitable basis, shall be allocated to
the tenants of the Building (as opposed to the tenants of any other buildings in the Project). Such portion of Direct Expenses
allocated to the tenants of the Building shall include all Direct Expenses attributable solely to the Building and an equitable
portion of the Direct Expenses attributable to the Project as a whole. Further, Landlord shall have the right, from time to time,
to allocate equitably some or all of the Direct Expenses for the Building or the Project among different portions or occupants
of the Building or Project, in Landlord&rsquo;s reasonable discretion, in a manner reflecting commercially reasonable cost pools
for such Direct Expenses so allocated. The Direct Expenses within each cost pool shall be allocated and charged to the tenants
within such cost pool in an equitable manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Calculation and Payment of Additional Rent</U></B>. Tenant shall pay to Landlord, in the manner set forth in <U>Section&nbsp;4.4.1</U>
below and as Additional Rent, Tenant&rsquo;s Share of Direct Expenses for each Expense Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.4.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Statement of Actual Direct Expenses and Payment by Tenant</U></B>. Landlord shall endeavor to give to Tenant within
six (6) months following the end of each Expense Year, a statement (the &ldquo;<B>Statement</B>&rdquo;) which shall state the Direct
Expenses (and itemized details therefor) incurred or accrued for such preceding Expense Year, and which shall indicate the amount
of Tenant&rsquo;s Share of Direct Expenses. Upon receipt of the Statement for each Expense Year commencing or ending during the
Lease Term, Tenant shall pay, with its next installment of Base Rent due, the full amount of Tenant&rsquo;s Share of Direct Expenses
for such Expense Year, less the amounts, if any, paid during such Expense Year as &ldquo;<B>Estimated Direct Expenses</B>&rdquo;,
as that term is defined in <U>Section&nbsp;4.4.2</U>, below, and if Tenant paid more as Estimated Direct Expenses than the actual
Tenant&rsquo;s Share of Direct Expenses, Tenant shall receive a credit in the amount of Tenant&rsquo;s overpayment against Rent
next due under this Lease or, if Landlord elects, Landlord shall reimburse such overpayment amount to Tenant. The failure of Landlord
to timely furnish the Statement for any Expense Year shall not prejudice Landlord or Tenant from enforcing its rights under this
<U>Article 4</U>. Even though the Lease Term has expired and Tenant has vacated the Premises, when the final determination is made
of Tenant&rsquo;s Share of Direct Expenses for the Expense Year in which this Lease terminates, Tenant shall pay to Landlord such
amount within thirty (30) days, and if Tenant paid more as Estimated Direct Expenses than the actual Tenant&rsquo;s Share of Direct
Expenses, Landlord shall, within thirty (30) days, pay to Tenant the amount of the overpayment. The provisions of this <U>Section&nbsp;4.4.1</U>
shall survive the expiration or earlier termination of the Lease Term except that in no event shall Tenant owe any Additional Rent
to Landlord with respect to any statement first delivered more than twelve (12) months after the end of the calendar year in which
this Lease terminates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.4.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>Statement
of Estimated Direct Expenses</U></B>. In addition, Landlord shall endeavor to give Tenant a yearly expense estimate statement
(the &ldquo;<B>Estimate Statement</B>&rdquo;) which shall set forth Landlord&rsquo;s reasonable estimate (the &ldquo;<B>Estimate</B>&rdquo;)
of what the total amount of Direct Expenses (and itemized details therefor) for the then-current Expense Year shall be and the
estimated Tenant&rsquo;s Share of Direct Expenses (the &ldquo;<B>Estimated Direct Expenses</B>&rdquo;). The failure of Landlord
to timely furnish the Estimate Statement for any Expense Year shall not preclude Landlord from enforcing its rights to collect
any Estimated Direct Expenses under this <U>Article 4</U>, nor shall Landlord be prohibited from revising any Estimate Statement
or Estimated Direct Expenses theretofore delivered to the extent necessary. Thereafter, Tenant shall pay, with its next installment
of Base Rent due, a fraction of the Estimated Direct Expenses for the then-current Expense Year (reduced by any amounts paid pursuant
to the last sentence of this <U>Section&nbsp;4.4.2</U>). Such fraction shall have as its numerator the number of months which
have elapsed in such current Expense Year, including the month of such payment, and twelve (12) as its denominator. Until a new
Estimate Statement is furnished (which Landlord shall have the right to deliver to Tenant at any time), Tenant shall pay monthly,
with the monthly Base Rent installments, an amount equal to one-twelfth (1/12) of the total Estimated Direct Expenses set forth
in the previous Estimate Statement delivered by Landlord to Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.4.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Audit Rights</U></B>. Tenant shall have the right, at Tenant's cost, after reasonable notice to Landlord, to have
Tenant's authorized employees or agents inspect, at Landlord's or its property manager&rsquo;s California office during normal
business hours, Landlord's books, records and supporting documents concerning the Direct Expenses set forth in any statement delivered
by Landlord to Tenant for a particular calendar year pursuant to <U>Section 4.4.1</U> above; provided, however, Tenant shall have
no right to conduct such inspection or object to or otherwise dispute the amount of the Direct Expenses set forth in any such statement,
unless Tenant notifies Landlord of such inspection request, completes such inspection, and demands an audit as set forth below
within six (6) months immediately following Landlord's delivery of the particular statement in question (the &ldquo;<B>Review Period</B>&rdquo;);
provided, further, that notwithstanding any such timely inspection, objection, dispute, and/or audit, and as a condition precedent
to Tenant's exercise of its right of inspection, objection, dispute, and/or audit as set forth in this <U>Section 4.4.3</U>, Tenant
shall not be permitted to withhold payment of, and Tenant shall timely pay to Landlord, the full amounts as required by the provisions
of this <U>Article&nbsp;4</U> in accordance with such statement. However, such payment may be made under protest pending the outcome
of any audit. In connection with any such inspection by Tenant, Landlord and Tenant shall reasonably cooperate with each other
so that such inspection can be performed pursuant to a mutually acceptable schedule, in an expeditious manner and without undue
interference with Landlord's operation and management of the Project. If, after such inspection and/or request for documentation,
Tenant disputes the amount of the Direct Expenses set forth in the statement, Tenant shall have the right, but not the obligation,
within the Review Period, to cause an independent certified public accountant which is not paid on a contingency basis and which
is mutually approved by Landlord and Tenant (the &ldquo;<B>Accountant</B>&rdquo;) to complete an audit of Landlord's books and
records to determine the proper amount of the disputed Direct Expenses incurred and amounts payable by Tenant for the calendar
year which is the subject of such statement. Such audit by the Accountant shall be final and binding upon Landlord and Tenant.
If Landlord and Tenant cannot mutually agree as to the identity of the Accountant within thirty (30) days after Tenant notifies
Landlord that Tenant desires an audit to be performed, then Landlord may submit to Tenant the names of at least three (3) certified
public accountants with at least ten (10) years of experience in auditing life science office and research and development buildings
in the San Diego market and who do not currently represent Landlord or any of its affiliates (&ldquo;<B>Independent Accountants</B>&rdquo;)
and Tenant shall select one (1) of the Independent Accountants as the Accountant within ten (10) days thereafter. The cost of the
Accountant shall be paid by Tenant unless it is subsequently determined that Landlord's original statement which was the subject
of such audit was in error to Tenant's disadvantage by five percent (5%) or more of the total Operating Expenses which was the
subject of such audit. If the Additional Rent due with respect to Operating Expenses is finally determined to be less or more than
the Additional Rent paid by Tenant on account of Landlord&rsquo;s calculation of Operating Expenses, Landlord shall either promptly
refund to Tenant the difference or credit same against Rent next due from Tenant or Tenant shall promptly pay to Landlord the difference,
as applicable. The payment by Tenant of any amounts pursuant to this <U>Article 4</U> shall not preclude Tenant from questioning
the correctness of any statement provided by Landlord at any time during the Review Period, but the failure of Tenant to object
thereto, conduct and complete its inspection and have the Accountant conduct and complete the audit as described above prior to
the expiration of the Review Period shall be conclusively deemed Tenant's approval of the statement in question and the amount
of Operating Expenses shown thereon. In connection with any inspection and/or audit conducted by Tenant pursuant to this <U>Section
4.4.3</U>. Tenant agrees to keep, and to cause all of Tenant's employees and consultants and the Accountant to keep, all of Landlord's
books and records and the audit, and all information pertaining thereto and the results thereof, strictly confidential (except
to the extent disclosure is required in accordance with applicable law), and in connection therewith, Tenant shall cause such employees,
consultants and the Accountant to execute such reasonable confidentiality agreements as Landlord may require prior to conducting
any such inspections and/or audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Taxes and Other Charges for Which Tenant Is Directly Responsible</U></B>. Tenant shall be liable for and shall pay
ten (10) days before delinquency, taxes levied against Tenant&rsquo;s equipment, furniture, fixtures and any other personal property
located in or about the Premises. If any such taxes on Tenant&rsquo;s equipment, furniture, fixtures and any other personal property
are levied against Landlord or Landlord&rsquo;s property or if the assessed value of Landlord&rsquo;s property is increased by
the inclusion therein of a value placed upon such equipment, furniture, fixtures or any other personal property and if Landlord
pays the taxes based upon such increased assessment, which Landlord shall have the right to do regardless of the validity thereof
but only under proper protest if requested by Tenant, Tenant shall upon demand (together with reasonable back-up evidencing the
same) repay to Landlord the taxes so levied against Landlord or the proportion of such taxes resulting from such increase in the
assessment, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">5.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>USE OF PREMISES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Permitted Use</U></B>. Tenant shall use the Premises solely for the Permitted Use set forth in <U>Section&nbsp;8</U>
of the Summary (&ldquo;<B>Permitted Use</B>&rdquo;) and Tenant shall not use or permit the Premises or the Project to be used for
any other purpose or purposes whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Prohibited Uses</U></B>. Tenant further covenants and agrees that Tenant shall not use, or suffer or permit any person
or persons claiming by, through, or under Tenant to use, the Premises or any part thereof for any use or purpose contrary to the
provisions of the Rules and Regulations attached hereto as <B><U>Exhibit 5.2</U></B>, as the same may be amended by Landlord from
time to time in a non-discriminatory, commercially reasonable manner (the &ldquo;<B>Rules and Regulations</B>&rdquo;), or in violation
of Applicable Laws or any Underlying Documents (with respect to which a copy was furnished to Tenant prior thereto). Tenant shall
not do or permit anything to be done in or about the Premises which will in any way damage the reputation of the Project or obstruct
or interfere with the rights of other tenants or occupants of the Building, or injure or annoy them or use or allow the Premises
to be used for any improper, unlawful or objectionable purpose, nor shall Tenant cause, maintain or permit any nuisance in, on
or about the Premises. Tenant shall comply with, and Tenant&rsquo;s rights and obligations under the Lease and Tenant&rsquo;s use
of the Premises shall be subject and subordinate to, all Underlying Documents (with respect to which a copy was furnished to Tenant
prior thereto). Tenant shall only place equipment within the Premises with floor loading consistent with the Building's structural
design, and such equipment shall be placed in a location designed to carry the weight of such equipment. Tenant shall cause any
equipment or machinery to be installed in the Premises so as to reasonably prevent sounds or vibrations therefrom from extending
into the Common Areas or other offices in the Project.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Hazardous Materials</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Tenant&rsquo;s Obligations</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3.1.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Prohibitions</U></B>. As a material inducement to Landlord to enter into this Lease with Tenant, Tenant has fully
and accurately completed Landlord&rsquo;s Pre-Leasing Environmental Exposure Questionnaire (the &ldquo;<B>Environmental Questionnaire</B>&rdquo;),
which is attached as <B><U>Exhibit 5.3.1.1</U></B>. Tenant hereby represents, warrants and covenants that except for general office
supplies within the Premises which are of a kind typically used in normal office areas in the ordinary course of business, for
use in the manner for which they were designed and only in accordance with all Applicable Laws, and then only in such amounts as
may be normal for general office use, Tenant shall not use or allow another person or entity to use any part of the Premises for
the storage, use, treatment, manufacture or sale of Hazardous Materials and except for those chemicals or materials, and their
respective quantities, specifically listed on the Environmental Questionnaire, and neither Tenant nor Tenant&rsquo;s subtenants
or assigns, or any of their respective employees, contractors and subcontractors of any tier, entities with a contractual relationship
with such parties (other than Landlord), or any entity acting as an agent or sub-agent of such parties or any of the foregoing
(collectively, &ldquo;<B>Tenant Parties</B>&rdquo;) will produce, use, store or generate any &ldquo;Hazardous Materials&rdquo;,
as that term is defined below, on, under or about the Premises, nor cause or permit any Hazardous Material to be brought upon,
placed, stored, manufactured, generated, blended, handled, recycled, used or &ldquo;Released&rdquo;, as that term is defined below,
on, in, under or about the Premises or Project. If any information provided to Landlord by Tenant on the Environmental Questionnaire,
or otherwise relating to information concerning Hazardous Materials is false, incomplete, or misleading in any material respect,
the same shall be deemed a default by Tenant under this Lease. Upon Landlord&rsquo;s request, or in the event of any material change
in Tenant&rsquo;s use of Hazardous Materials at the Premises, Tenant shall deliver to Landlord an updated Environmental Questionnaire.
Landlord&rsquo;s prior written consent shall be required for any Hazardous Materials use for the Premises not described on the
initial Environmental Questionnaire, such consent not to be unreasonably withheld, conditioned or delayed. Tenant shall not install
or permit any underground storage tank on the Premises. In addition, Tenant agrees that it: (i)&nbsp;shall not cause or suffer
to occur, the Release (as defined below) of any Hazardous Materials at, upon, under or within the Premises or any contiguous or
adjacent premises; and (ii)&nbsp;shall not engage in activities at the Premises that give rise to, or lead to the imposition of,
liability upon Tenant or Landlord or the creation of an environmental lien or use restriction upon the Premises. For purposes of
this Lease, &ldquo;<B>Hazardous Materials</B>&rdquo; means all flammable explosives, petroleum and petroleum products, oil, radon,
radioactive materials, toxic pollutants, asbestos, polychlorinated biphenyls (&ldquo;<B>PCBs</B>&rdquo;), medical waste, chemicals
known to cause cancer or reproductive toxicity, pollutants, contaminants, hazardous wastes, toxic substances or related materials,
including without limitation any chemical, element, compound, mixture, solution, substance, object, waste or any combination thereof,
which is or may hereafter be determined to be hazardous to human health, safety or to the environment due to its radioactivity,
ignitability, corrosiveness, reactivity, explosiveness, toxicity, carcinogenicity, infectiousness or other harmful or potentially
harmful properties or effects, or defined as, regulated as or included in, the definition of &ldquo;hazardous substances&rdquo;,
&ldquo;hazardous wastes&rdquo;, &ldquo;hazardous materials&rdquo;, or &ldquo;toxic substances&rdquo; under any Environmental Laws.
The term &ldquo;Hazardous Materials&rdquo; for purposes of this Lease shall also include any mold, fungus or spores, whether or
not the same is defined, listed, or otherwise classified as a &ldquo;hazardous material&rdquo; under any Environmental Laws, if
such mold, fungus or spores may pose a risk to human health or the environment or negatively impact the value of the Premises.
Hazardous Materials shall also include any &ldquo;biohazardous waste,&rdquo; &ldquo;medical waste,&rdquo; or other waste under
California Health and Safety Code Division 20, Chapter 6.1 (Medical Waste Management Act). For purposes of this Lease, &ldquo;<B>Release</B>&rdquo;
or &ldquo;<B>Released</B>&rdquo; or &ldquo;<B>Releases</B>&rdquo; shall mean any release, deposit, discharge, emission, leaking,
spilling, seeping, migrating, injecting, pumping, pouring, emptying, escaping, dumping, disposing, or other movement of Hazardous
Materials into the environment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything
contained herein to the contrary, in no event shall Tenant or anyone claiming by through or under Tenant perform work at or above
the risk category Biosafety Level 2 as established by the Department of Health and Human Services (&ldquo;<B>DHHS</B>&rdquo;) and
as further described in the DHHS publication Biosafety in Microbiological and Biomedical Laboratories (5<SUP>th</SUP> Edition)
(as it may be or may have been further revised, the &ldquo;<B>BMBL</B>&rdquo;) or such nationally recognized new or replacement
standards as Landlord may reasonable designate. Tenant shall comply with all applicable provisions of the standards of the BMBL
to the extent applicable to Tenant&rsquo;s operations in the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3.1.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Notices to Landlord</U></B>. Unless Tenant is required by Applicable Laws to give earlier notice to Landlord, Tenant
shall notify Landlord in writing as soon as possible but in no event later than five (5)&nbsp;days after (i)&nbsp;Tenant becomes
aware of any actual, alleged or threatened Release of any Hazardous Material in, on, under, from, about or in the vicinity of the
Premises (whether past or present), regardless of the source or quantity of any such Release, or (ii)&nbsp;Tenant becomes aware
of any regulatory actions, inquiries, inspections, investigations, directives, or any cleanup, compliance, enforcement or abatement
proceedings (including any threatened or contemplated investigations or proceedings) relating to or potentially affecting the Premises,
or (iii)&nbsp;Tenant becomes aware of any claims by any person or entity relating to any Hazardous Materials in, on, under, from,
about or in the vicinity of the Premises, whether relating to damage, contribution, cost recovery, compensation, loss or injury.
Collectively, the matters set forth in clauses&nbsp;(i), (ii) and (iii) above are hereinafter referred to as &ldquo;<B>Hazardous
Materials Claims</B>&rdquo;. Tenant shall promptly forward to Landlord copies of all orders, notices, permits, applications and
other communications and reports in connection with any Hazardous Materials Claims. Additionally, Tenant shall promptly advise
Landlord in writing of Tenant&rsquo;s discovery of any occurrence or condition on, in, under or about the Premises that could subject
Tenant or Landlord to any liability, or restrictions on ownership, occupancy, transferability or use of the Premises under any
&ldquo;Environmental Laws&rdquo;, as that term is defined below. Tenant shall not enter into any legal proceeding or other action,
settlement, consent decree or other compromise with respect to any Hazardous Materials Claims without first notifying Landlord
of Tenant&rsquo;s intention to do so and affording Landlord the opportunity to join and participate, as a party if Landlord so
elects, in such proceedings and in no event shall Tenant enter into any agreements which are binding on Landlord or the Project
without Landlord&rsquo;s prior written consent. Landlord shall have the right to appear at and participate in, any and all legal
or other administrative proceedings concerning any Hazardous Materials Claim. For purposes of this Lease, &ldquo;<B>Environmental
Laws</B>&rdquo; means all applicable present and future laws relating to the protection of human health, safety, wildlife or the
environment, including, without limitation, (i)&nbsp;all requirements pertaining to reporting, licensing, permitting, investigation
and/or remediation of emissions, discharges, Releases, or threatened Releases of Hazardous Materials, whether solid, liquid, or
gaseous in nature, into the air, surface water, groundwater, or land, or relating to the manufacture, processing, distribution,
use, treatment, storage, disposal, transport, or handling of Hazardous Materials; and (ii)&nbsp;all requirements pertaining to
the health and safety of employees or the public. Environmental Laws include, but are not limited to, the Comprehensive Environmental
Response, Compensation and Liability Act of 1980, 42&nbsp;USC &sect;&nbsp;9601, et seq., the Hazardous Materials Transportation
Authorization Act of 1994, 49&nbsp;USC &sect;&nbsp;5101, et seq., the Solid Waste Disposal Act, as amended by the Resource Conservation
and Recovery Act of 1976, and Hazardous and Solid Waste Amendments of 1984, 42&nbsp;USC &sect;&nbsp;6901, et seq., the Federal
Water Pollution Control Act, as amended by the Clean Water Act of 1977, 33&nbsp;USC &sect;&nbsp;1251, et seq., the Clean Air Act
of 1966, 42&nbsp;USC &sect;&nbsp;7401, et seq., the Toxic Substances Control Act of 1976, 15&nbsp;USC &sect;&nbsp;2601, et seq.,
the Safe Drinking Water Act of 1974, 42&nbsp;USC &sect;&sect;&nbsp;300f through 300j, the Occupational Safety and Health Act of
1970, as amended, 29&nbsp;USC &sect;&nbsp;651 et seq., the Oil Pollution Act of 1990, 33&nbsp;USC &sect;&nbsp;2701 et seq., the
Emergency Planning and Community Right-To-Know Act of 1986, 42&nbsp;USC &sect;&nbsp;11001 et seq., the National Environmental Policy
Act of 1969, 42&nbsp;USC &sect;&nbsp;4321 et seq.; oil and hazardous materials as defined in any federal, state or local law, as
such Applicable Laws are in effect as of the Rent Commencement Date, or thereafter amended, adopted, published or promulgated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3.1.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Releases of Hazardous Materials</U></B>. If any Release of any Hazardous Material in, on, under, from or about the
Premises by Tenant or any one acting under Tenant (e.g., employees of Tenant or any subtenant) in violation of, or requiring any
Clean-Up (as defined below), in addition to notifying Landlord as specified above, Tenant, at its own sole cost and expense, shall
(i)&nbsp;immediately comply with any and all reporting requirements imposed pursuant to any and all Environmental Laws, (ii)&nbsp;provide
a written certification to Landlord indicating that Tenant has complied with all applicable reporting requirements, (iii)&nbsp;take
any and all necessary investigation, corrective, remedial and other Clean-up action in accordance with any and all applicable Environmental
Laws, utilizing an environmental consultant approved by Landlord, all in accordance with the provisions and requirements of this
<U>Section 5.3</U>, including, without limitation, <U>Section&nbsp;5.3.4</U>, and (iv)&nbsp;take any such additional investigative,
remedial and corrective actions as Landlord shall in its reasonable discretion deem necessary such that the Premises and Project
are remediated to a condition allowing unrestricted use of the Premises (i.e., to a level that will allow any future use of the
Premises, including residential, without any engineering controls or deed restrictions), all in accordance with the provisions
and requirements of this <U>Section 5.3</U>. Landlord may, as required by any and all Environmental Laws, report the Release of
any Hazardous Material to the appropriate governmental authority, identifying Tenant as the responsible party. Tenant shall deliver
to Landlord copies of all administrative orders, notices, demands, directives or other communications directed to Tenant from any
governmental authority with respect to any Release of Hazardous Materials in, on, under, from, or about the Premises, together
with copies of all investigation, assessment, and remediation plans and reports prepared by or on behalf of Tenant in response
to any such regulatory order or directive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3.1.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Indemnification</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">5.3.1.4.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>In General</U></B>. Without limiting in any way Tenant&rsquo;s obligations under any other provision of this Lease,
Tenant shall be solely responsible for and shall protect, defend, indemnify and hold the Landlord Parties harmless from and against
any and all claims, judgments, losses, damages, costs, expenses, penalties, enforcement actions, taxes, fines, remedial actions,
liabilities (including, without limitation, actual attorneys&rsquo; fees, litigation, arbitration and administrative proceeding
costs, expert and consultant fees and laboratory costs) including, without limitation, consequential damages and sums paid in settlement
of claims, which arise during or after the Lease Term, whether foreseeable or unforeseeable, directly or indirectly arising out
of or attributable to the presence, use, generation, manufacture, treatment, handling, refining, production, processing, storage,
Release or presence of Hazardous Materials in, on, under or about the Premises or Project by any Tenant Party, except to the extent
such liabilities result from the negligence or willful misconduct of Landlord following the Rent Commencement Date. The foregoing
obligations of Tenant shall include, without limitation: (i)&nbsp;the costs of any required or necessary removal, repair, cleanup
or remediation of the Premises and Project, and the preparation and implementation of any closure, removal, remedial or other required
plans; (ii)&nbsp;judgments for personal injury or property damages; and (iii)&nbsp;all costs and expenses incurred by Landlord
in connection therewith. It is the express intention of the parties to this Lease that Tenant assumes all such liabilities, and
holds Landlord harmless from all such liabilities, associated with the environmental condition of the Premises, arising on or after
the date Tenant takes possession of the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">5.3.1.4.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Limitations</U></B>. Notwithstanding anything in this Lease to the contrary, Tenant&rsquo;s indemnity of Landlord
shall not be applicable to claims based upon, and in no event shall Tenant have any liability for or be deemed to be in default
because of, Existing Hazardous Materials except to the extent that Tenant&rsquo;s acts caused or exacerbated the subject claim.
&ldquo;<B>Existing Hazardous Materials</B>&rdquo; shall mean Hazardous Materials located on the Property as of the Rent Commencement
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3.1.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Compliance with Environmental Laws</U></B>. Without limiting the generality of Tenant&rsquo;s obligation to comply
with Applicable Laws as otherwise provided in this Lease, Tenant shall, at its sole cost and expense, comply with all Environmental
Laws with respect to its use of the Premises other than with respect to any Existing Hazardous Materials. Tenant shall obtain and
maintain any and all necessary permits, licenses, certifications and approvals appropriate or required for the use, handling, storage,
and disposal of any Hazardous Materials used, stored, generated, transported, handled, blended, or recycled by Tenant on the Premises.
Landlord shall have a continuing right, without obligation, to require Tenant to obtain, and to review and inspect any and all
such permits, licenses, certifications and approvals, together with copies of any and all Hazardous Materials management plans
and programs, any and all Hazardous Materials risk management and pollution prevention programs, and any and all Hazardous Materials
emergency response and employee training programs respecting Tenant&rsquo;s use of Hazardous Materials. Upon request of Landlord,
Tenant shall deliver to Landlord a narrative description explaining the nature and scope of Tenant&rsquo;s activities involving
Hazardous Materials and showing to Landlord&rsquo;s satisfaction compliance with all Environmental Laws and the terms of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Assurance of Performance</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3.2.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Environmental Assessments In General</U></B>. Landlord may, but shall not be required to, engage from time to time
such contractors as Landlord determines to be appropriate to perform &ldquo;Environmental Assessments&rdquo;, as that term is defined
below, to ensure Tenant&rsquo;s compliance with the requirements of this Lease with respect to Hazardous Materials. For purposes
of this Lease, &ldquo;<B>Environmental Assessment</B>&rdquo; means an assessment including, without limitation: (i)&nbsp;an environmental
site assessment conducted in accordance with the then-current standards of the American Society for Testing and Materials and meeting
the requirements for satisfying the &ldquo;all appropriate inquiries&rdquo; requirements; and (ii)&nbsp;sampling and testing of
the Premises based upon potential recognized environmental conditions or areas of concern or inquiry identified by the environmental
site assessment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3.2.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Costs of Environmental Assessments</U></B>. All costs and expenses incurred by Landlord in connection with any such
Environmental Assessment initially shall be paid by Landlord; provided that if any such Environmental Assessment shows that Tenant
has failed to comply with the provisions of this <U>Section 5.3</U>, then all of the reasonable costs and expenses of such Environmental
Assessment shall be reimbursed by Tenant as Additional Rent within thirty (30)&nbsp;days after receipt of written demand therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Tenant&rsquo;s Obligations upon Surrender</U></B>. At the expiration or earlier termination of the Lease Term, Tenant,
at Tenant&rsquo;s sole cost and expense, shall: (i)&nbsp;cause an Environmental Assessment of the Premises to be conducted in accordance
with <U>Section 15.3</U>; (ii)&nbsp;cause all Hazardous Materials to be removed from the Premises and disposed of in accordance
with all Environmental Laws and as necessary to allow the Premises to be used for any purpose; and (iii)&nbsp;cause to be removed
all containers installed or used by any Tenant Parties to store any Hazardous Materials on the Premises, and cause to be repaired
any damage to the Premises caused by such removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Clean-up</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3.4.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Environmental Reports; Clean-Up</U></B>. If any written report, including any report containing results of any Environmental
Assessment (an &ldquo;<B>Environmental Report</B>&rdquo;) shall indicate (i)&nbsp;the presence of any Hazardous Materials brought
into the Premises by Tenant as to which Tenant has a removal or remediation obligation under this <U>Section 5.3</U>, and (ii)&nbsp;that
as a result of same, the investigation, characterization, monitoring, assessment, repair, closure, remediation, removal, or other
clean-up (the &ldquo;<B>Clean-up</B>&rdquo;) of any Hazardous Materials is required, Tenant shall immediately prepare and submit
to Landlord within thirty (30)&nbsp;days after receipt of the Environmental Report a comprehensive plan, subject to Landlord&rsquo;s
written approval, specifying the actions to be taken by Tenant to perform the Clean-up so that the Premises are restored to the
conditions required by this Lease. Upon Landlord&rsquo;s approval of the Clean-up plan, Tenant shall, at Tenant&rsquo;s sole cost
and expense, without limitation of any rights and remedies of Landlord under this Lease, immediately implement such plan with a
consultant reasonably acceptable to Landlord and proceed to Clean-Up Hazardous Materials in accordance with all applicable laws
and as required by such plan and this Lease. If, within thirty (30)&nbsp;days after receiving a copy of such Environmental Report,
Tenant fails either (a)&nbsp;to complete such Clean-up, or (b)&nbsp;with respect to any Clean-up that cannot be completed within
such 30-day period, fails to proceed with diligence to prepare the Clean-up plan and complete the Clean-up as promptly as practicable,
then Landlord shall have the right, but not the obligation, and without waiving any other rights under this Lease, to carry out
any Clean-up recommended by the Environmental Report or required by any governmental authority having jurisdiction over the Premises,
and recover all of the costs and expenses thereof from Tenant as Additional Rent, payable within ten (10)&nbsp;days after receipt
of written demand therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3.4.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>No Rent Abatement</U></B>. Tenant shall continue to pay all Rent due or accruing under this Lease during any Clean-up,
and shall not be entitled to any reduction, offset or deferral of any Base Rent or Additional Rent due or accruing under this Lease
during any such Clean-up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3.4.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Surrender of Premises</U></B>. Tenant shall complete any Clean-up prior to surrender of the Premises upon the expiration
or earlier termination of this Lease, and shall fully comply with all Environmental Laws and requirements of any governmental authority
with respect to such completion, including, without limitation, fully comply with any requirement to file a risk assessment, mitigation
plan or other information with any such governmental authority in conjunction with the Clean-up prior to such surrender. Tenant
shall obtain and deliver to Landlord a letter or other written determination from the overseeing governmental authority confirming
that the Clean-up has been completed in accordance with all requirements of such governmental authority and that no further response
action of any kind is required for the unrestricted use of the Premises (&ldquo;<B>Closure Letter</B>&rdquo;). Upon the expiration
or earlier termination of this Lease, Tenant shall also be obligated to close all permits obtained in connection with Hazardous
Materials in accordance with Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3.4.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Failure to Timely Clean-Up</U></B>. Should any Clean-up for which Tenant is responsible not be completed, or should
Tenant not receive the Closure Letter and any governmental approvals required under Environmental Laws in conjunction with such
Clean-up prior to the expiration or earlier termination of this Lease, and Tenant&rsquo;s failure to receive the Closure Letter
is prohibiting Landlord from leasing the Premises or any part thereof to a third party, or prevents the occupancy or use of the
Premises or any part thereof by a third party, then Tenant shall be liable to Landlord as a holdover tenant (as more particularly
provided in <U>Article&nbsp;16</U>) until Tenant has fully complied with its obligations under this <U>Section 5.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Confidentiality</U></B>. Unless compelled to do so by applicable law, Tenant agrees that Tenant shall not disclose,
discuss, disseminate or copy any information, data, findings, communications, conclusions and reports regarding the environmental
condition of the Premises to any Person (other than Tenant&rsquo;s consultants, attorneys, property managers and employees that
have a need to know such information), including any governmental authority, without the prior written consent of Landlord. In
the event Tenant reasonably believes that disclosure is compelled by Applicable Laws, it shall provide Landlord ten (10)&nbsp;days&rsquo;
advance notice of disclosure of confidential information so that Landlord may attempt to obtain a protective order. Tenant may
additionally release such information to bona fide prospective purchasers or lenders or investors, directors, shareholders and
consultants, subject to any such parties&rsquo; written agreement to be bound by the terms of this <U>Section 5.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Copies of Environmental Reports</U></B>. Within thirty (30)&nbsp;days of receipt thereof, Tenant shall provide Landlord
with a copy of any and all environmental assessments, audits, studies and reports regarding Tenant&rsquo;s activities with respect
to the Premises, or ground water beneath the Land, or the environmental condition or Clean-up thereof. Tenant shall be obligated
to provide Landlord with a copy of such materials without regard to whether such materials are generated by Tenant or prepared
for Tenant, or how Tenant comes into possession of such materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Signs, Response Plans, Etc</U></B>. Tenant shall be responsible for posting on the Premises any signs required under
applicable Environmental Laws. Tenant shall also complete and file any business response plans or inventories required by any applicable
Environmental Laws. Tenant shall concurrently file a copy of any such business response plan or inventory with Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.3.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Survival</U></B>. Each covenant, agreement, representation, warranty and indemnification made by Tenant set forth
in this <U>Section 5.3</U> shall survive the expiration or earlier termination of this Lease and shall remain effective until all
of Tenant&rsquo;s obligations under this <U>Section 5.3</U> have been completely performed and satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Premises Compliance with ADA</U></B>. Notwithstanding any other provision herein to the contrary, Tenant shall be
responsible for all liabilities, costs and expenses arising out of or in connection with the compliance of the Premises with the
Americans with Disabilities Act, 42 U.S.C. &sect;&nbsp;1210 I, et seq., and any state and local accessibility laws, codes, ordinances
and rules (collectively, and together with regulations promulgated pursuant thereto, the &ldquo;<B>ADA</B>&rdquo;), and Tenant
shall indemnify, save, defend (at Landlord&rsquo;s option and with counsel reasonably acceptable to Landlord) and hold Landlord
and its affiliates, employees, agents and contractors; and any lender, mortgagee or beneficiary (each, a &ldquo;<B>Lender</B>&rdquo;
and, collectively with Landlord its partners and subpartners, and their respective officers, members, directors, shareholders,
agents, property managers, employees and independent contractors, the &ldquo;<B>Landlord Indemnitees</B>&rdquo;) harmless from
and against any demands, claims, liabilities, losses, costs, expenses, actions, causes of action, damages or judgments, and all
reasonable expenses (including reasonable attorneys&rsquo; fees, charges and disbursements) incurred in investigating or resisting
the same (collectively, &ldquo;<B>Claims</B>&rdquo;) arising out of any such failure of the Premises to comply with the ADA. Notwithstanding
anything to the contrary in this Lease, in no event shall Tenant be obligated to make any physical alterations to the Premises
or the Project, or any portion thereof, in order to comply with Applicable Laws except to the extent caused by voluntary Alterations
made by Tenant to the Premises after the Rent Commencement Date. The provisions of this Section shall survive the expiration or
earlier termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Rules and Regulations, CC&amp;Rs, Parking Facilities and Common Areas</U>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.5.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Tenant shall have the non-exclusive right, in common with others, to use the Common Areas, subject to the Rules and Regulations.
The manner in which the Common Areas are maintained and operated shall be at the sole discretion of Landlord and the use thereof
shall be subject to the Rules and Regulations, as Landlord may make from time to time in a non-discriminatory, commercially reasonable
manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.5.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Lease is subject to any recorded covenants, conditions or restrictions on the Project or Property (the &ldquo;<B>CC&amp;Rs</B>&rdquo;),
as the same may be amended, amended and restated, supplemented or otherwise modified from time to time; provided that any such
amendments, restatements, supplements or modifications do not materially modify Tenant&rsquo;s rights or obligations hereunder.
Tenant shall comply with the CC&amp;Rs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.5.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Tenant shall have a non-exclusive, irrevocable license to use throughout the Lease Term the number of unreserved parking
passes set forth in <U>Section 2.11</U> of the Summary in at such locations in the parking facilities serving the Building as may
be determined by Landlord from time to time in common with the other occupants of the Building, on an unreserved basis at no cost
to Tenant. Tenant shall use only such parking facilities to park Tenant&rsquo;s vehicles. In no event shall Tenant park or store
any items other than automotive vehicles at such parking facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.5.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Tenant agrees not to unreasonably overburden the parking facilities and agrees to cooperate with Landlord and other tenants
in the use of the parking facilities. Landlord may reasonably allocate parking spaces among Tenant and other tenants of the Building
or the Project provided that Tenant shall be entitled to use throughout the Lease Term the number of unreserved parking passes
set forth in <U>Section 2.11</U> of the Summary. Nothing in this Section, however, is intended to create an affirmative duty on
Landlord&rsquo;s part to monitor parking.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">5.5.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Landlord reserves the right to modify the Common Areas, including the right to add or remove exterior and interior landscaping
and to subdivide real property, in accordance with the terms and conditions of this Lease. Tenant acknowledges that Landlord specifically
reserves the right to allow the exclusive use of corridors and restroom facilities located on specific floors to one or more tenants
occupying such floors; provided, however, that Tenant shall not be deprived of the use of the corridors reasonably required to
serve the Premises or of restroom facilities serving the floor upon which the Premises are located. Landlord reserves the right
to close temporarily, make alterations or additions to, or change the location of elements of the Project and the Common Areas;
provided, however, Landlord will give to Tenant prior reasonable notice of any closure necessitated by such alterations, additions
or changes and use commercially reasonable efforts to minimize any disruption to Tenant&rsquo;s use of the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">6.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>SERVICES AND UTILITIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Landlord Provided Services</U></B>. Landlord shall provide the following services on all days (unless otherwise stated
below) during the Lease Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.1.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Landlord shall provide HVAC when necessary for normal comfort in the Building Common Areas from 8:00&nbsp;A.M. to 6:00&nbsp;P.M.
Monday through Friday, and on Saturdays from 9:00&nbsp;A.M. to 1:00&nbsp;P.M. (collectively, the &ldquo;<B>Building Hours</B>&rdquo;),
except for the date of observance of New Year&rsquo;s Day, Independence Day, Labor Day, Memorial Day, Thanksgiving Day, Christmas
Day and, at Landlord&rsquo;s discretion, other locally or nationally recognized holidays which are observed by other buildings
comparable to and in the vicinity of the Building (collectively, the &ldquo;<B>Holidays</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.1.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Landlord shall provide adequate electrical wiring and facilities for connection to Tenant&rsquo;s lighting fixtures and
incidental use equipment, provided that the connected electrical load of the incidental use equipment and the connected electrical
load of Tenant&rsquo;s lighting fixtures does not exceed Tenant&rsquo;s Share of the per floor limits of the electrical system
of the Building. Tenant shall bear the cost of replacement of lamps, starters and ballasts for non-Building standard lighting fixtures
within the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.1.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Landlord shall provide city water from the regular Building outlets for drinking, lavatory and toilet purposes in the Building
Common Areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.1.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Landlord shall provide a dumpster and/or trash compactor at the Building for use by Tenant and other tenants for ordinary
office waste (and not for Hazardous Materials) and janitorial, trash services and cleaning to Building Common Areas consistent
with Comparable Buildings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.1.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Intentionally Omitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.1.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Landlord agrees to provide and maintain utility connections to the Building and, where applicable, Common Areas, for electricity,
water and sewer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.1.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the provisions of this Article, Landlord shall furnish the electric energy that Tenant shall reasonably require
in the Premises for the purposes permitted under this Lease. Except for electric energy required to operate motors on the air handlers
providing HVAC (the &ldquo;<B>HVAC Electric</B>&rdquo;), such electric energy shall be furnished through a meter or meters and
related equipment installed, serviced, maintained, monitored and, as appropriate from time to time, upgraded by Landlord, in each
case at Tenant&rsquo;s expense, measuring the amount of electric energy furnished to the Premises; provided, however, that Landlord
shall pay for the cost of installing any such new meters for the Premises. Tenant shall pay for electric energy (for which it is
liable for payment under this Article) within ten (10) days after receipt of any bills related thereto. The amount charged for
electric energy furnished to the Premises, excluding HVAC Electric, shall be one hundred percent (100%) of Landlord&rsquo;s cost
(including those charges applicable to or computed on the basis of electric consumption, demand and hours of use, any sales or
other taxes regularly passed on to Landlord by such public utility company, fuel rate adjustments and surcharges, weighted in each
case to reflect differences in consumption or demand applicable to each rate level). Tenant and its authorized representatives
may have access to such meter or meters (if any) on at least three (3) days&rsquo; prior notice to Landlord for the purpose of
verifying Landlord&rsquo;s meter readings (if any). From time to time during the Lease Term, Landlord may, in its sole discretion,
(a) install or eliminate such meters, (b) increase or reduce the number of such meters, (e) vary the portions of the Premises that
such meters serve or (d) replace any or all of such meters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Tenant Provided Services and Utilities</U></B>. Except as otherwise expressly set forth in <U>Section&nbsp;6.1</U>,
above, Tenant will be responsible, at its sole cost and expense, for the furnishing of all services and utilities to the Premises,
including without limitation electricity, water, telephone, janitorial and Premises security services. Tenant acknowledges that
(i) electricity is, or will be, separately submetered to the Office Premises and the Lab Premises, and (ii) water will not be separately
submetered and will be charged to Tenant as part of Tenant&rsquo;s Share of Operating Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Tenant shall be solely responsible for performing all janitorial and trash services and other cleaning of the Premises,
all in compliance with Applicable Laws. In the event such service is provided by a third party janitorial service, and not by employees
of Tenant, such service shall be a janitorial service approved in advance by Landlord (Landlord shall provide Tenant with a list
of approved vendors upon Tenant&rsquo;s request). The janitorial and cleaning of the Premises shall be adequate to maintain the
Premises in a manner consistent with Comparable Buildings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to Applicable Laws and except in the event of an emergency, Tenant shall have access to the Building, the Premises
and the Common Areas of the Building, other than Common Areas requiring access with a Building engineer, twenty-four (24) hours
per day, seven (7) days per week, every day of the year; provided, however, that Tenant shall only be permitted to have access
to and use of the limited-access areas of the Building during the normal operating hours of such portions of the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tenant shall cooperate
fully with Landlord at all times and abide by all non-discriminatory, commercially reasonable regulations and requirements that
Landlord may reasonably prescribe for the proper functioning and protection of the HVAC, electrical, mechanical and plumbing systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Tenant shall pay for all water (including the cost to service, repair and replace reverse osmosis, de-ionized and other
treated water), gas, heat, light, power, telephone, internet service, cable television, other telecommunications and other utilities
supplied to the Premises, together with any fees, surcharges and taxes thereon, utilities and services provided to the Premises
that are separately metered shall be paid by Tenant directly to the supplier of such utility or service. If any such utility is
not separately metered to Tenant, Tenant shall pay Tenant&rsquo;s Share of all charges of such utility jointly metered with other
premises as Additional Rent or, in the alternative, Landlord may, at its option, monitor the usage of such utilities by Tenant
and charge Tenant with the cost of monitoring such metering equipment, provided that Landlord shall pay for the cost of the initial
purchase and installation (only) of any such metering equipment. To the extent that Tenant uses more than Tenant&rsquo;s Pro Rata
Share of any utilities that are not separately metered and billed directly to Tenant, then Tenant shall pay Landlord the cost of
such excess consumption as reasonably determined by Landlord. In the event that the Building or the Project is less than fully
occupied, Tenant acknowledges that Landlord may extrapolate utility usage that vary depending on the occupancy of the Building
or Project, as applicable, by dividing (a) the total cost of utility usage by (b) the Rentable Area of the Building or Project
(as applicable) that is occupied, then multiplying (y) the resulting quotient by (z) ninety-five percent (95%) of the total Rentable
Area of the Building or Project (as applicable). Tenant shall pay Tenant&rsquo;s Share of the product of (y) and (z), subject to
adjustment based on actual usage as reasonably determined by Landlord; provided, however, that Landlord shall not recover more
than one hundred percent (100%) of such utility costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For the Office Premises, Landlord shall furnish the heating, ventilating and air conditioning used for the Office Premises
as reasonably required (except as this Lease otherwise provides in <U>Sections 6.2.8</U> and <U>6.4</U> below) for Tenant&rsquo;s
reasonably comfortable occupancy of the Office Premises. For the Lab Premises, Tenant shall (a) maintain and operate the heating,
ventilating and air conditioning systems used for the Permitted Use only (&ldquo;<B>HVAC</B>&rdquo;) and (b) subject to clause
(a) above, furnish HVAC as reasonably required (except as this Lease otherwise provides) for reasonably comfortable occupancy of
the Lab Premises twenty-four (24) hours a day, every day during the Lease Term, subject to casualty, eminent domain or as otherwise
specified in this Article. Notwithstanding anything to the contrary in this Section (other than as expressly set forth in <U>Section&nbsp;6.4</U>
below), Landlord shall have no liability, and Tenant shall have no right or remedy, on account of any interruption or impairment
in HVAC services. If requested in writing by Landlord, Tenant shall provide Landlord copies of HVAC maintenance contracts and HVAC
maintenance reports on a quarterly basis. In the event Landlord determines that Tenant is not properly maintaining the HVAC, Landlord
may take over the responsibilities in (a) and (b) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For any utilities serving the Premises for which Tenant is billed directly by such utility provider, Tenant agrees to furnish
to Landlord (a) if expressly requested by Landlord from time to time, any invoices or statements for such utilities within thirty
(30) days after Tenant&rsquo;s receipt thereof and (b) within thirty (30) days after Landlord&rsquo;s request, any other utility
usage information reasonably requested by Landlord. Tenant shall retain records of utility usage at the Premises, including invoices
and statements from the utility provider, for at least sixty (60) months, or such other shorter period of time as may be requested
by Landlord. Tenant acknowledges that any utility information for the Premises, the Building and the Project may be shared with
third parties, including Landlord&rsquo;s consultants and governmental authorities. In the event that Tenant fails to comply with
this Section, Tenant hereby authorizes Landlord to collect utility usage information directly from the applicable utility providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Tenant, at its sole cost, shall furnish and install all replacement lighting tubes, lamps, bulbs and ballasts required in
the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Tenant&rsquo;s use of electric energy in the Premises shall not at any time exceed the capacity of any of the electrical
conductors and equipment in or otherwise serving the Premises. In order to ensure that such capacity is not exceeded, and to avert
a possible adverse effect upon the Project&rsquo;s distribution of electricity via the Project&rsquo;s electric system, Tenant
shall not, without Landlord&rsquo;s prior written consent in each instance (which consent Landlord may condition upon the availability
of electric energy in the Project as allocated by Landlord to various areas of the Project) connect any fixtures, appliances or
equipment (other than normal business machines) to the Building&rsquo;s or Project&rsquo;s electric system or make any alterations
or additions to the electric system of the Premises existing on the date hereof. Should Landlord grant such consent, all additional
risers, distribution cables or other equipment required therefor shall be provided by Landlord and the cost thereof shall be paid
by Tenant to Landlord on demand (or, at Tenant&rsquo;s option, shall be provided by Tenant pursuant to plans and contractors approved
by Landlord, and otherwise in accordance with the provisions of this Lease). Landlord shall have the right to require Tenant to
pay sums on account of such cost prior to the installation of any such risers or equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Landlord reserves the right, upon at least two (2) business days&rsquo; prior written notice to Tenant absent exigent circumstances
in which the giving of such notice is not reasonably possible, to stop service of the elevator, plumbing, ventilation, air conditioning
and electric systems, when Landlord deems any such stoppage as reasonably necessary due to accident, emergency or the need to make
repairs, alterations or improvements, until such repairs, alterations or improvements shall have been completed, and Landlord shall
further have no responsibility or liability for failure to supply elevator facilities, plumbing, ventilation, air conditioning
or electric service when prevented from doing so by Force Majeure or Landlord&rsquo;s negligence; a failure by a third party to
deliver gas, oil or another suitable fuel supply; or Landlord&rsquo;s inability by exercise of reasonable diligence to obtain gas,
oil or another suitable fuel. If any such repairs, alterations or improvements might require or cause an interruption in electrical
service to the Premises or any portion thereof, Landlord will give to Tenant at least three (3) business days prior written notice
whenever practicable. Without limiting the foregoing, it is expressly understood and agreed that any covenants on Landlord&rsquo;s
part to furnish any service pursuant to any of the terms, covenants, conditions, provisions or agreements of this Lease, or to
perform any act or thing for the benefit of Tenant, shall not be deemed breached if Landlord is unable to furnish or perform the
same by virtue of Force Majeure or Landlord&rsquo;s negligence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Capacities; Overstandard Tenant Use</U></B>. Tenant&rsquo;s use of electricity and any other utility serving the Premises
shall never exceed the capacity of the feeders to the Project. If Tenant desires to use heat, ventilation or air conditioning with
respect to the Office Premises during hours other than those for which Landlord is obligated to supply such utilities pursuant
to the terms of <U>Section 6.1</U> of this Lease, Tenant shall give Landlord such prior notice, if any, as Landlord shall from
time to time reasonably establish as appropriate, of Tenant&rsquo;s desired use in order to supply such utilities, and Landlord
shall supply such utilities to Tenant at such hourly cost per zone to Tenant (which shall be treated as Additional Rent) as Landlord
shall from time to time establish based upon its reasonably estimated out-of-pocket costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Interruption of Use</U></B>. Tenant agrees that, to the extent permitted pursuant to Applicable Laws, Landlord shall
not be liable for damages, by abatement of Rent or otherwise, for failure to furnish or delay in furnishing any service required
to be provided by Landlord under this Lease, or for any diminution in the quality or quantity thereof, when such failure or delay
or diminution is occasioned, in whole or in part, by breakage, repairs, replacements, or improvements, by any strike, lockout
or other labor trouble, by inability to secure electricity, gas, water, or other fuel at the Building or Project after reasonable
effort to do so, by any riot or other dangerous condition, emergency, accident or casualty whatsoever, by act or default of Tenant
or other parties, or by any other cause; and such failures or delays or diminution shall never be deemed to constitute an eviction
or disturbance of Tenant&rsquo;s use and possession of the Premises or relieve Tenant from paying Rent or performing any of its
obligations under this Lease. Furthermore, Landlord shall not be liable under any circumstances for a loss of, or injury to, property
or for injury to, or interference with, Tenant&rsquo;s business, including, without limitation, loss of profits, however occurring,
through or in connection with or incidental to a failure to furnish any of the services or utilities as set forth in this <U>Article
6</U>. Notwithstanding anything to the contrary in this Lease, in the event that there shall be an interruption, curtailment or
suspension of any service required to be provided by Landlord pursuant to <U>Section 6.1</U> (and no reasonably equivalent alternative
service or supply is provided by Landlord) that shall materially interfere with Tenant&rsquo;s use and enjoyment of a material
portion of the Premises, or if Tenant is unable to use the Premises or its parking rights hereunder (whether by lack of services,
lack of utilities, lack of access, repairs or construction, or any other reason, and provided that such inability to use is not
caused by Tenant and provided that such inability to use is caused by the acts or omissions of Landlord) and Tenant actually ceases
to use the affected portion of the Premises or parking (any such event, a &ldquo;<B>Service Interruption</B>&rdquo;), and if (i)
such Service Interruption shall continue for eight (8) consecutive business days following receipt by Landlord of written notice
from Tenant describing such Service Interruption (the &ldquo;<B>Service Interruption Notice</B>&rdquo;), and (ii) such Service
Interruption shall not have been caused, in whole or in part, by reasons beyond Landlord&rsquo;s reasonable control or by an act
or omission in violation of this Lease by any Tenant Party or by any negligence of Tenant any Tenant Parties, (a Service Interruption
that satisfies the foregoing conditions being referred to hereinafter as a &ldquo;<B>Material Service Interruption</B>&rdquo;)
then, as liquidated damages and Tenant&rsquo;s sole remedy at law or equity, Tenant shall be entitled to an equitable abatement
of Base Rent and Tenant&rsquo;s Share of Direct Expenses, based on the nature and duration of the Material Service Interruption,
the area of the Premises or parking affected, and the then current Rent amounts, for the period that shall begin on the commencement
of such Material Service Interruption and that shall end on the day such Material Service Interruption shall cease. To the extent
a Material Service Interruption is caused by an event covered by <U>Articles&nbsp;11</U> or <U>13</U> of this Lease, then Tenant&rsquo;s
right to abate rent shall be governed by the terms of such <U>Article&nbsp;11</U> or <U>13</U>, as applicable, and the provisions
of this paragraph shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Intentionally Blank</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">7.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>REPAIRS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tenant shall, at Tenant&rsquo;s
own expense, keep the Premises, including all improvements, fixtures, furnishings, and systems and equipment within the Premises
(or, provided that Landlord provides access to Tenant, any systems and equipment outside of the Premises but exclusively serving
the Premises), in good order, repair and condition at all times during the Lease Term. In addition, Tenant shall, at Tenant&rsquo;s
own expense, but under the supervision and subject to the prior reasonable approval of Landlord, and within any reasonable period
of time specified by Landlord, promptly and adequately repair all damage to the Premises and replace or repair all damaged, broken,
or worn fixtures and appurtenances, except for damage caused by ordinary wear and tear; provided however, that if Tenant fails
to make such repairs within applicable notice and cure periods, Landlord may, but need not, make such repairs and replacements,
and Tenant shall pay Landlord the cost thereof, including a management fee of five percent (5%) of such costs. Without limitation,
Tenant shall be responsible for repair and maintenance of all electrical, plumbing, heating, ventilating and air-conditioning systems
and other utility services serving the Premises from the Building connection point to the Premises (but only to the extent such
electrical, plumbing, heating, ventilating and air-conditioning systems and other utility services serve Tenant exclusively and
only to the extent that Landlord provides access to Tenant), and Tenant shall secure, pay for, and keep in force contracts with
appropriate and reputable service companies reasonably approved by Landlord providing for the regular maintenance of such systems.
Notwithstanding the foregoing, Landlord shall be responsible for repairs to the exterior walls, foundation and roof (including
roof membrane) of the Building, the structural portions of the floors of the Building, and the base building systems and equipment
of the Building and Common Areas, and all portions of the Project outside the Premises and not exclusively leased to other tenants,
except to the extent that such repairs are required due to the negligence or willful misconduct of Tenant; provided, however, that
if such repairs are due to the negligence or willful misconduct of Tenant, Landlord shall nevertheless make such repairs at Tenant&rsquo;s
expense, or, if covered by Landlord&rsquo;s insurance, Tenant shall only be obligated to pay any deductible in connection therewith.
Subject to the terms of <U>Article 27</U>, below, Landlord may, but shall not be required to, enter the Premises at all reasonable
times and upon reasonable prior notice to make such repairs, alterations, improvements or additions to the Premises or to the Project
or to any equipment located in the Project as Landlord shall desire or deem necessary or as Landlord may be required to do by governmental
or quasi-governmental authority or court order or decree. Tenant hereby waives and releases its right to make repairs at Landlord&rsquo;s
expense under Sections 1941 and 1942 of the California Civil Code or under any similar law, statute or ordinance now or hereafter
in effect. Tenant&rsquo;s obligation hereunder shall include maintenance and repair of all telecommunications wire and cabling
with the Building&rsquo;s network cabling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">8.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>ADDITIONS AND ALTERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Landlord&rsquo;s Consent to Alterations</U></B>. Tenant may not make any improvements, alterations, additions or changes
to the Premises or any mechanical, plumbing, HVAC facilities or other utility or Building systems pertaining to the Premises (collectively,
the &ldquo;<B>Alterations</B>&rdquo;) without first procuring the prior written consent of Landlord to such Alterations, which
consent shall be requested by Tenant not less than fifteen (15) business days prior to the commencement thereof. Landlord shall
not unreasonably withhold or delay its consent to any proposed Alterations, provided that such Alterations (1) are not visible
from the outside of the Building, (2) do not violate any certificate of occupancy for the Building or any other permits or licenses
relating to the Project and (3) do not materially adversely affect any service required to be furnished to Tenant or to any other
tenant or occupant of the Building (4) do not adversely affect any Building systems or Common Areas, (5) do not reduce the value
or utility of the Building, and (6) otherwise comply with the terms and conditions of this <U>Article 8</U>.. Notwithstanding the
foregoing, Tenant shall be permitted to make Alterations following ten (10) business days&rsquo; notice to Landlord, but without
Landlord&rsquo;s prior consent, to the extent that such Alterations (i) are purely cosmetic in nature (such as painting, carpeting
and the like), (ii) do not affect the Building systems or equipment, (iii) are not visible from the exterior of the Building, and
(iv) cost less than $35,000.00 for a particular job of work<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Work Affecting Air Distribution or Ventilation Systems</U></B>. Prior to commencing any Alterations affecting air
distribution or disbursement from ventilation systems serving Tenant or the Building, including without limitation the installation
of Tenant&rsquo;s exhaust systems, Tenant shall provide Landlord with a third party report from a consultant, and in a form reasonably
acceptable to Landlord, showing that such work will not adversely affect the ventilation systems or air quality of the Building
(or of any other tenant in the Building) and shall, upon completion of such work, provide Landlord with a certification reasonably
satisfactory to Landlord from such consultant confirming that no such adverse effects have resulted from such work.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Manner of Construction</U></B>. Landlord may impose, as a condition of its consent to any and all Alterations or repairs
of the Premises or about the Premises, such commercially reasonable, non-discriminatory requirements as Landlord in its reasonable
discretion may deem desirable, including, but not limited to, the requirement that Tenant utilize for such purposes only contractors,
subcontractors, materials, mechanics and materialmen selected by Tenant and approved by Landlord (which approval shall not be unreasonably
withheld, conditioned or delayed) and the requirement that upon Landlord&rsquo;s request (subject to the terms of <U>Section&nbsp;8.5</U>,
below), Tenant shall, at Tenant&rsquo;s expense, remove such Alterations upon the expiration or any early termination of the Lease
Term. Tenant shall construct such Alterations and perform such repairs in a good and workmanlike manner, in conformance with any
and all Applicable Laws and, where required by Applicable Law, pursuant to a valid building permit. Tenant shall not use (and upon
notice from Landlord shall cease using) contractors, services, workmen, labor, materials or equipment that, in Landlord&rsquo;s
reasonable judgment, would disturb labor harmony with the workforce or trades engaged in performing other work, labor or services
in or about the Building or the Common Areas. Upon completion of any Alterations (or repairs), Tenant shall deliver to Landlord
final lien waivers from all contractors, subcontractors, design professionals, service providers, suppliers and materialmen who
performed such work and whose labor, supplies or services give rise to a lien under California law. In addition to Tenant&rsquo;s
obligations under <U>Article 9</U> of this Lease, upon completion of any Alterations that cost more than $35,000, Tenant shall
deliver to the Project construction manager a reproducible copy of the &ldquo;<B>as built</B>&rdquo; drawings of the Alterations
in CAD format as well as copies of all permits, approvals and other documents issued by any governmental agency in connection with
the Alterations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Payment for Improvements</U></B>. If Tenant orders any work directly from Landlord, Tenant shall pay to Landlord an
amount equal to five percent (5%) of the cost of such work to compensate Landlord for all overhead, general conditions, fees and
other costs and expenses arising from Landlord&rsquo;s involvement with such work. If Tenant does not order any work directly from
Landlord, Tenant shall reimburse Landlord for Landlord&rsquo;s reasonable, actual, out-of-pocket costs and expenses actually incurred
in connection with Landlord&rsquo;s review of any proposed Alterations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Construction Insurance</U></B>. In addition to the requirements of <U>Article 10</U> of this Lease, in the event that
Tenant makes any Alterations, prior to the commencement of such Alterations, Tenant shall provide Landlord with evidence that Tenant
or Tenant&rsquo;s general contractor carries &ldquo;<B>Builder&rsquo;s All Risk</B>&rdquo; insurance (to the extent that the cost
of the work shall exceed $100,000.00) in an amount reasonably approved by Landlord covering the construction of such Alterations,
and such other insurance as Landlord may reasonably require, it being understood and agreed that all of such Alterations shall
be insured by Tenant pursuant to <U>Article 10</U> of this Lease immediately upon completion thereof. In addition, Tenant&rsquo;s
contractors and subcontractors shall be required to carry Commercial General Liability Insurance, Auto Liability Insurance, and
Workers&rsquo; Compensation Insurance in amounts reasonably approved by Landlord and otherwise in accordance with the requirements
of <U>Article 10</U> of this Lease and such Commercial General Liability and Auto Liability insurance shall name Tenant and the
Landlord Parties (as defined below) as additional insureds on a primary and non-contributory basis for both ongoing and completed
operations. If commercially reasonable under the circumstances, Tenant shall maintain and require its contractors and subcontractors
to maintain products-completed operations coverage for not less than the greater of ten (10) years after substantial completion
of any Alterations or the greater time under which a claim may be properly brought under the applicable statute of limitations
or repose. Landlord may, in its discretion, require Tenant to obtain and record a statutory form of lien bond, or obtain performance
and payment bonds, or some alternate form of security satisfactory to Landlord in an amount sufficient to ensure the lien-free
completion of such Alterations and naming Landlord as a co-obligee, in each case in form and substance reasonably satisfactory
to Landlord. In addition, Tenant&rsquo;s contractors and subcontractors shall be required to carry workers compensation insurance
with a waiver of subrogation in favor of Landlord Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Landlord&rsquo;s Property</U></B>. All Alterations which may be installed or placed in or about the Premises, from
time to time, shall be at the sole cost of Tenant and shall be and become the property of Landlord and remain in place at the Premises
following the expiration or earlier termination of this Lease. Notwithstanding the foregoing to the contrary, Landlord may, by
written notice to Tenant given at the time that Landlord consents to the Alterations<I>,</I> require Tenant, at Tenant&rsquo;s
expense, to remove any such Alterations within the Premises and to repair any damage to the Premises and Building caused by such
removal and return the affected portion of the Premises to a building standard tenant improved condition as determined by Landlord.
If Tenant fails to complete any required removal and/or to repair any damage caused by the removal of any Alterations in the Premises
and return the affected portion of the Premises to a building standard tenant improved condition as reasonably determined by Landlord,
Landlord may do so and may charge the actual and reasonable cost thereof to Tenant. Tenant hereby protects, defends, indemnifies
and holds Landlord harmless from any liability, cost, obligation, expense or claim of lien in any manner relating to the installation,
placement, removal or financing of any such Alterations, improvements, fixtures and/or equipment in, on or about the Premises,
which obligations of Tenant shall survive the expiration or earlier termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">9.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>COVENANT AGAINST LIENS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Within ten (10) business
days following a request in writing by Landlord, Tenant shall keep the Project and Premises free from any liens or encumbrances
arising out of the work performed, materials or services furnished or obligations incurred by or on behalf of Tenant (which expressly
excludes the Landlord Work), and shall protect, defend, indemnify and hold Landlord harmless from and against any claims, liabilities,
judgments or costs (including, without limitation, reasonable attorneys&rsquo; fees and costs) arising out of same or in connection
therewith. Tenant shall give Landlord notice at least twenty (20) days prior to the commencement of any work, services or obligations
related to the Premises giving rise to any such liens or encumbrances (or such additional time as may be necessary under Applicable
Laws) to afford Landlord the opportunity of posting and recording appropriate notices of non-responsibility (to the extent applicable
pursuant to then Applicable Laws). Tenant shall remove any such lien or encumbrance by statutory lien bond or otherwise within
ten (10) business days after notice by Landlord, and if Tenant shall fail to do so, Landlord may pay the amount necessary to remove
such lien or encumbrance, without being responsible for investigating the validity thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">10.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>INSURANCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Indemnification and Waiver</U></B>. To the maximum extent permitted pursuant to Applicable Laws, Tenant hereby assumes
all risk of damage to property or injury to persons in, upon or about the Premises from any cause whatsoever (including, but not
limited to, any personal injuries resulting from a slip and fall in, upon or about the Premises) and agrees that, to the extent
permitted pursuant to Applicable Laws, Landlord, its lenders, partners, subpartners, the Additional Insureds, and each of their
respective officers, agents, servants, employees, and independent contractors (collectively, &ldquo;<B>Landlord Parties</B>&rdquo;)
shall not be liable for, and are hereby released from any responsibility for, any damage either to person or property or resulting
from the loss of use thereof, which damage is sustained by Tenant or by other persons claiming through Tenant. Tenant shall indemnify,
defend, protect, and hold harmless the Landlord Parties from any and all loss, cost, damage, injury, expense and liability (including
without limitation court costs and reasonable attorneys&rsquo; fees) during the Lease Term, or any period of Tenant&rsquo;s occupancy
of the Premises prior to the commencement or after the expiration of the Lease Term, incurred in connection with or arising from
(i) any cause in, on or about the Premises (including, but not limited to, a slip and fall), provided that the terms of the foregoing
indemnity shall not apply to the extent of any gross negligence or willful misconduct of Landlord, (ii) any negligent acts or omissions
of Tenant or of any person claiming by, through or under Tenant, or of the contractors, agents, servants, employees, invitees,
guests or licensees of Tenant or any such person, in, on or about the Project, or (iii) any breach of the terms of this Lease by
Tenant, either prior to, during, or after the expiration of the Lease Term. Should Landlord be named as a defendant in any suit
brought against Tenant in connection with or arising out of Tenant&rsquo;s occupancy of the Premises, Tenant shall pay to Landlord
its reasonable costs and expenses incurred in such suit, including without limitation, its actual professional fees such as reasonable
appraisers&rsquo;, accountants&rsquo; and attorneys&rsquo; fees. Notwithstanding anything to the contrary in this Lease, (a)&nbsp;except
for Section 10.5 below, in no event shall Landlord be exculpated in any manner to the extent of the gross negligence, willful misconduct
or breach of this Lease by or of Landlord or any officer, employee, director, manager, tenant, contractor or agent of Landlord,
and (b)&nbsp;neither Landlord nor Tenant shall have any liability to the other for any consequential, indirect, special or punitive
damages, except for the indemnification obligation of Tenant set forth in Article 16. The provisions of this <U>Section&nbsp;10.1</U>
shall survive the expiration or sooner termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Tenant&rsquo;s Compliance With Landlord&rsquo;s Property Insurance</U></B>. Tenant shall, at Tenant&rsquo;s expense,
comply with all commercially reasonable, non-discriminatory insurance company requirements pertaining to the use of the Premises.
If Tenant&rsquo;s conduct or use of the Premises for any purpose other than a Permitted Use causes any increase in the premium
for such insurance policies then Tenant shall reimburse Landlord for any such increase. Tenant, at Tenant&rsquo;s expense, shall
comply with all rules, orders, regulations or requirements of the American Insurance Association (formerly the National Board of
Fire Underwriters) and with any similar body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Tenant&rsquo;s Insurance</U></B>. Tenant shall maintain, at its cost and expense, the following coverages with limits
of not less than the greater of (i) those set forth hereunder, and (ii) those required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.3.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Commercial General Liability Insurance issued on terms no less broad than the most current ISO CG 00 01 occurrence form
covering the insured against claims of bodily injury, personal and advertising injury and property damage (including loss of use
thereof) arising out of Tenant&rsquo;s operations, products/completed operations, social or host liquor liability (if applicable),
and &ldquo;insured contracts&rdquo; (as defined by the most current ISO CG 00 01 form), including a Separation of Insureds provision
with no exclusion for cross-liability, and including the Additional Insureds (as defined hereunder) as additional insureds with
respect to both ongoing and completed operations coverage on a primary and non-contributory basis, for limits of liability of not
less than:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">$1,000,000 each occurrence</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">$2,000,000 annual aggregate</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">per location</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">$1,000,000 personal and advertising injury</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">$2,000,000 products-completed operations</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Commercially reasonable deductible or self-insured</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">retention
        (but not in excess of $25,000).</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">$25,000 self-insured retention on product liability.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.3.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Property Insurance covering (i) all office furniture, business and trade fixtures, office equipment, free-standing cabinet
work, movable partitions, merchandise and all other items of Tenant&rsquo;s property on the Premises installed by, for, or at the
expense of Tenant, and (ii) the Tenant Improvements described in <B><U>Exhibit 1.1.1-2</U></B> and any other tenant improvements
that exist in the Premises as of the Rent Commencement Date (the &ldquo;<B>New Improvements</B>&rdquo;). Such insurance shall be
written on an &ldquo;<B>all risks</B>&rdquo; of physical loss or damage basis, for the full replacement cost value (subject to
reasonable deductible amounts) new without deduction for depreciation of the covered items and in amounts that meet any co-insurance
clauses of the policies of insurance and shall include coverage for damage or other loss caused by fire or other peril including,
but not limited to, hail, windstorm, flood, earthquake, terrorism, vandalism and malicious mischief, theft, water damage of any
type, including sprinkler leakage, earthquake sprinkler leakage, bursting or stoppage of pipes, and explosion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.3.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Business Income Interruption for one (1) year plus Extra Expense insurance in such amounts as will reimburse Tenant for
actual direct or indirect loss of earnings and continuing expenses, including rent, attributable to the risks outlined in <U>Section
10.3.2</U> above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.3.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Auto Liability Insurance covering liability arising out of any auto, including owned (if any), non-owned, leased, and hired
autos, with a limit of not less than $1,000,000 combined single limit each accident for bodily injury and property damage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.3.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Worker&rsquo;s Compensation and Employer&rsquo;s Liability or other similar insurance pursuant to all applicable state and
local statutes and regulations, together with Employer&rsquo;s Liability Insurance with limits of not less than $1,000,000 bodily
injury (each accident), $1,000,000 bodily injury by disease (each employee), and $1,000,000 bodily injury by disease (policy limit)
or such greater amounts as may be required by Tenant&rsquo;s Umbrella/Excess Liability policy in order to effect such coverage.
The policy will include a waiver of subrogation in favor of the Landlord Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.3.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Umbrella and/or Excess Liability Insurance policy in excess of Commercial General Liability, Auto Liability, and Employer&rsquo;s
Liability Insurance policies, concurrent to, and at least as broad as the underlying primary insurance policies, which must &ldquo;drop
down&rdquo; over reduced or exhausted aggregate limits as to such underlying policies and contain a &ldquo;follow form&rdquo; statement.
The limits must be no less than $1,000,000 each occurrence and $1,000,000 in the aggregate. Such Umbrella/Excess Liability policy
must be endorsed to provide that this insurance is primary to, and non-contributory with, any other insurance on which the Additional
Insureds are an insured, whether such other insurance is primary, excess, contingent, self-insurance, or insurance on any other
basis. This endorsement must cause the Umbrella/Excess coverage to be vertically exhausted, whereby such coverage is not subject
to any &ldquo;Other Insurance&rdquo; clause under this Umbrella and/or Excess Liability policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.3.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tenant&rsquo;s Agents/Contractors</U>. In the case of Tenant&rsquo;s contractors, subcontractors, and any vendors/consultants
brought on to the property for any Alterations (collectively, for purposes of this <U>Article 10</U>, Tenant&rsquo;s &ldquo;<B>Third
Parties</B>&rdquo;), Tenant shall cause such Third Parties to obtain and maintain such insurance as is required under <U>Sections&nbsp;10.3.1</U>,
<U>10.3.4</U>, and <U>10.3.5</U> herein, unless granted written approval from Landlord to waive such requirements. Such Third Parties&rsquo;
coverage under <U>Sections&nbsp;10.3.1</U> and <U>10.3.4</U> shall include Tenant and the Additional Insureds each as additional
insureds on a primary and non-contributory basis for both ongoing and completed operations. Additionally, the commercial general
liability limit required to be carried by any contractor or subcontractors of Tenant shall be not less than the following: (x)
general contractors &ndash; $5,000,000, (y)&nbsp;any subcontractors for work costing $250,000 or more &ndash; $2,000,000, and (z)
any subcontractors for work costing less than $250,000 &ndash; $1,000,000. The foregoing limits may be satisfied by a combination
of primary and/or excess policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Form of Policies</U></B>. The minimum limits of policies of insurance required of Tenant and its agents/contractors
under this Lease shall in no event limit the liability of Tenant under this Lease. Such insurance shall name Landlord, its subsidiaries
and affiliates, Longfellow Property Management Services CA Inc.; Longfellow Strategic Value Fund, LLC; San Diego Inspire Holdings,
LLC; LSVF Americas, LP; LSVF Pacific, LP; Longfellow Capital Partners II, LP; Longfellow Real Estate Partners, LLC; Invesco CMI
Investments, LP; and any other party the Landlord so specifies (collectively, the &ldquo;<B>Additional Insureds</B>&rdquo;), as
additional insureds under the policies listed in <U>Sections 10.3.1</U>, <U>10.3.2</U>, <U>10.3.3</U>, <U>10.3.4</U> and <U>10.3.6</U>.
All insurance policies required to be maintained by Tenant shall (i) be issued by an insurance company having a rating of not less
than A:VIII in Best&rsquo;s Insurance Guide or which is otherwise acceptable to Landlord and licensed to do business in the State
of California; (ii) be primary insurance as to all claims thereunder and provide that any insurance carried by Landlord is excess
and is non-contributing with any insurance required of Tenant; (iii) be in form and content reasonably acceptable to Landlord (Tenant
shall provide full and complete copies of any policies that Landlord reasonably requests); (iv) be endorsed with waiver of subrogation
endorsements in favor of the Additional Insureds; (v) not contain deductible or self-insured retention in excess of $25,000 unless
otherwise approved by Landlord in writing; and (vi) if generally commercially available in California, provide that said insurer
shall provide thirty&nbsp;(30) days&rsquo; written notice to Landlord and any mortgagee of Landlord, to the extent such names are
furnished to Tenant prior to the cancellation of such policy (ten&nbsp;(10) days&rsquo; for non-payment of premium). Tenant shall
deliver said policy or policies or certificates thereof to Landlord on or before the earlier to occur of (A)&nbsp;the Rent Commencement
Date, and (B)&nbsp;the date upon which Tenant is first provided access to the Premises, and at least ten&nbsp;(10) days before
the expiration dates thereof. In the event Tenant shall fail to procure such insurance, or to deliver such policies or certificate
within ten&nbsp;(10) days after written notice from Landlord, Landlord may, at its option, procure such policies for the account
of Tenant, and the cost thereof shall be paid to Landlord within five&nbsp;(5) days after delivery to Tenant of bills therefor.
Landlord and the Additional Insureds will not be responsible for any deductibles or self-insured retentions related to any insurance
under this <U>Article 10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Subrogation</U></B>. Landlord and Tenant intend that their respective property loss risks shall be borne by reasonable
insurance carriers to the extent above provided, and Landlord and Tenant hereby agree to look solely to, and seek recovery only
from, their respective insurance carriers in the event of a property loss to the extent that such coverage is agreed to be provided
hereunder. The parties each hereby waive all rights and claims against each other for such losses, and waive all rights of subrogation
of their respective insurers, provided such waiver of subrogation shall not affect the right of the insured to recover thereunder.
The parties agree that their respective insurance policies are now, or shall specify that the waiver of subrogation shall not affect
the right of the insured to recover thereunder. Tenant will waive, and cause its Third Parties to waive, all causes of action or
claims they may have against the Additional Insureds for any liability and workers compensation claims they incur in relation to
the Lease or any Alterations, or any other work or activities performed in connection with the Project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Additional Insurance Obligations</U></B>. Landlord reserves the right to require such other insurance, written in
such other amounts, terms, and conditions, against other insurable hazards that at the time are commonly insured against in the
case of projects similar in nature, construction type, and geographic location to the Project and/or as otherwise required by any
mortgage lender provided that any such lender requirements are consistent with the requirements of other landlords of comparable
life science projects in the Sorrento Valley market. Tenant shall carry and maintain during the entire Lease Term, at Tenant&rsquo;s
sole cost and expense, such increased amounts of insurance provided they are consistent with the requirements of other landlords
of comparable life science projects in the Sorrento Valley market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Landlord&rsquo;s Insurance</U>.</B> Landlord shall maintain its usual liability insurance as well as property insurance
for the Building (excluding any Alterations and Tenant Improvements).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">11.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>DAMAGE AND DESTRUCTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Repair of Damage to Premises by Landlord</U></B>. Tenant shall promptly notify Landlord of any damage to the Premises
resulting from fire or any other casualty. If the Premises or any Common Areas serving or providing access to the Premises shall
be damaged by fire or other casualty, Landlord shall promptly and diligently, subject to reasonable delays for insurance adjustment
or other matters beyond Landlord&rsquo;s reasonable control, and subject to all other terms of this <U>Article 11</U>, restore
such Common Areas and the Premises to substantially the same condition as existed prior to the casualty, except for modifications
required by zoning and building codes and other laws or by the holder of a mortgage on the Building or Project or any other modifications
to the Common Areas deemed desirable by Landlord, which are consistent with the character of the Project, provided that access
to the Premises shall not be materially impaired. To the extent permitted pursuant to Applicable Laws, Landlord shall not be liable
for any inconvenience or annoyance to Tenant or its visitors, or injury to Tenant&rsquo;s business resulting in any way from such
damage or the repair thereof; provided however, that if such fire or other casualty shall have damaged the Premises or Common Areas
necessary to Tenant&rsquo;s occupancy, and the Premises are not occupied by Tenant as a result thereof, then during the time and
to the extent the Premises are unfit for occupancy, the Rent shall be abated in proportion to the ratio that the amount of rentable
square feet of the Premises which is unfit for occupancy for the Permitted Use bears to the total rentable square feet of the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Landlord&rsquo;s Option to Repair</U></B>. Notwithstanding the terms of <U>Section&nbsp;11.1</U> of this Lease, Landlord
may elect not to rebuild and/or restore the Premises, Building and/or Project, and instead terminate this Lease, by notifying Tenant
in writing of such termination within sixty (60) days after the date of discovery of the damage, such notice to include a termination
date giving Tenant sixty (60) days to vacate the Premises, but Landlord may so elect only if the Building or Project shall be damaged
by fire or other casualty or cause, whether or not the Premises are affected, and one or more of the following conditions is present:
(i) in Landlord&rsquo;s reasonable judgment, repairs cannot reasonably be completed within one hundred eighty (180) days after
the date of discovery of the damage (when such repairs are made without the payment of overtime or other premiums); (ii) the holder
of any mortgage on the Building or Project or ground lessor with respect to the Building or Project shall require that the insurance
proceeds or any portion thereof be used to retire the mortgage debt, or shall terminate the ground lease, as the case may be; (iii)
such damage is not fully covered by Landlord&rsquo;s insurance policies; (iv) Landlord decides to rebuild the Building or Common
Areas so that they will be substantially different structurally or architecturally; (v) the damage occurs during the last twelve
(12<I>) </I>months of the Lease Term; or (vi) any owner of any other portion of the Project, other than Landlord, does not intend
to repair the damage to such portion of the Project; provided, however, that if Landlord does not elect to terminate this Lease
pursuant to Landlord&rsquo;s termination right as provided above, and the repairs cannot, in the reasonable opinion of Landlord,
be completed within one hundred eighty (180) days after being commenced, Tenant may elect, no earlier than sixty (60) days after
the date of the damage and not later than ninety (90) days after the date of such damage, to terminate this Lease by written notice
to Landlord effective as of the date specified in the notice, which date shall not be less than thirty (30) days nor more than
sixty (60) days after the date such notice is given by Tenant. Notwithstanding the provisions of this <U>Section 11.2</U>, Tenant
shall have the right to terminate this Lease under this <U>Section 11.2</U> only if each of the following conditions is satisfied:
(a) the damage to the Project by fire or other casualty was not caused by the negligence or intentional act of Tenant or any Tenant
Party; (b) as a result of the damage, Tenant cannot reasonably conduct business from the Premises; and, (c) as a result of the
damage to the Project, Tenant does not occupy or use the Premises at all. In addition, Tenant may terminate this Lease if the damage
to the Premises occurs during the last twelve (12) months of the Lease Term, and, as a result of such damage, Tenant cannot reasonably
conduct business from the Premises for a period of at least one-half (1/2<I>) </I>of the then-remaining term. In no event shall
Landlord have any obligation to undertake restoration on account of any casualty except to the extent of the insurance proceeds
actually received by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Waiver of Statutory Provisions</U></B>. The provisions of this Lease, including this <U>Article 11</U>, constitute
an express agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, all or any part of the
Premises, the Building or the Project, and any statute or regulation of the State of California, including, without limitation,
Sections 1932(2) and 1933(4) of the California Civil Code, with respect to any rights or obligations concerning damage or destruction
in the absence of an express agreement between the parties, and any other statute or regulation, now or hereafter in effect, shall
have no application to this Lease or any damage or destruction to all or any part of the Premises, the Building or the Project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">12.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>NONWAIVER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No provision of this
Lease shall be deemed waived by either party hereto unless expressly waived in a writing signed thereby. The waiver by either party
hereto of any breach of any term, covenant or condition herein contained shall not be deemed to be a waiver of any subsequent breach
of same or any other term, covenant or condition herein contained. The subsequent acceptance of Rent hereunder by Landlord shall
not be deemed to be a waiver of any preceding breach by Tenant of any term, covenant or condition of this Lease, other than the
failure of Tenant to pay the particular Rent so accepted, regardless of Landlord&rsquo;s knowledge of such preceding breach at
the time of acceptance of such Rent. No acceptance of a lesser amount than the Rent herein stipulated shall be deemed a waiver
of Landlord&rsquo;s right to receive the full amount due, nor shall any endorsement or statement on any check or payment or any
letter accompanying such check or payment be deemed an accord and satisfaction, and Landlord may accept such check or payment without
prejudice to Landlord&rsquo;s right to recover the full amount due. No receipt of monies by Landlord from Tenant after the termination
of this Lease shall in any way alter the length of the Lease Term or of Tenant&rsquo;s right of possession hereunder, or after
the giving of any notice shall reinstate, continue or extend the Lease Term or affect any notice given Tenant prior to the receipt
of such monies, it being agreed that after the service of notice or the commencement of a suit, or after final judgment for possession
of the Premises, Landlord may receive and collect any Rent due, and the payment of said Rent shall not waive or affect said notice,
suit or judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">13.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>CONDEMNATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the whole or substantially all of the Premises, Building or Project shall be taken by power of eminent domain or condemned
by any competent authority for any public or quasi-public use or purpose, or if all reasonable access to the Building is so taken
or condemned, or if Landlord shall grant a deed or other instrument in lieu of such taking by eminent domain or condemnation, Landlord
shall have the option to terminate this Lease effective as of the date possession is required to be surrendered to the authority.
Tenant shall not because of such taking assert any claim against Landlord or the authority for any compensation because of such
taking and Landlord shall be entitled to the entire award or payment in connection therewith, except that Tenant shall have the
right to file any separate claim available to Tenant for any taking of Tenant&rsquo;s personal property and fixtures belonging
to Tenant and removable by Tenant upon expiration of the Lease Term pursuant to the terms of this Lease, and for moving expenses,
so long as such claims do not diminish the award available to Landlord, its ground lessor with respect to the Building or Project
or its mortgagee, and such claim is payable separately to Tenant. All Rent shall be apportioned as of the date of such termination.
If any part of the Premises shall be taken, and this Lease shall not be so terminated, the Rent shall be proportionately abated.
Notwithstanding anything to the contrary contained in this <U>Article 13</U>, in the event of a temporary taking of all or any
portion of the Premises for a period of one hundred and eighty (180) days or less, and provided that such temporary taking does
not materially preclude or unreasonably diminish Tenant&rsquo;s ability to conduct business from the Premises, then this Lease
shall not terminate but the Base Rent and Tenant&rsquo;s Share of Direct Expenses shall be abated for the period of such taking
in proportion to the ratio that the amount of rentable square feet of the Premises taken bears to the total rentable square feet
of the Premises. Tenant hereby waives any and all rights it might otherwise have pursuant to Section 1265.130 of The California
Code of Civil Procedure. Landlord shall be entitled to receive the entire award made in connection with any such temporary taking,
provided, however, that Tenant shall be entitled to a share of the award for any loss of fixtures and improvements and for moving
and other reasonable expenses that do not otherwise reduce Landlord&rsquo;s recovery. If this Lease does not terminate on account
of any such eminent domain or condemnation proceeding, then Landlord shall, to the extent practicable, restore the affected area
of the Premises, Building or Project. In no event shall Landlord have any obligation to undertake restoration on account of any
condemnation or eminent domain proceeding except to the extent of the award actually received by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">14.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>ASSIGNMENT AND SUBLETTING</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Transfers</U></B>. Tenant shall not, without the prior written consent of Landlord, assign, mortgage, pledge, hypothecate,
encumber, or permit any lien to attach to, or otherwise transfer, this Lease or any interest hereunder, permit any assignment,
or other transfer of this Lease or any interest hereunder by operation of law, sublet the Premises or any part thereof, or enter
into any license or concession agreements or otherwise permit the occupancy or use of the Premises or any part thereof by any persons
other than Tenant and its employees and contractors (all of the foregoing are hereinafter sometimes referred to collectively as
&ldquo;<B>Transfers</B>&rdquo; and any person to whom any Transfer is made or sought to be made is hereinafter sometimes referred
to as a &ldquo;<B>Transferee</B>&rdquo;). If Tenant desires Landlord&rsquo;s consent to any Transfer, Tenant shall notify Landlord
in writing, which notice (the &ldquo;<B>Transfer Notice</B>&rdquo;) shall include (i) the proposed effective date of the Transfer,
which shall not be less than twenty (20) days nor more than one hundred eighty (180) days after the date of delivery of the Transfer
Notice, (ii) a description of the portion of the Premises to be transferred (the &ldquo;<B>Subject Space</B>&rdquo;), (iii) all
of the terms of the proposed Transfer and the consideration therefor, including calculation of the &ldquo;<B>Transfer Premium</B>&rdquo;,
as that term is defined in <U>Section&nbsp;14.3</U> below, in connection with such Transfer, the name and address of the proposed
Transferee, and a copy of all existing executed and/or proposed documentation pertaining to the proposed Transfer, and (iv) provided
that Landlord executes a commercially reasonable non-disclosure agreement, current financial statements of the proposed Transferee
certified by an officer, partner or owner thereof, business credit and personal references and history of the proposed Transferee
and any other information reasonably required by Landlord which will enable Landlord to determine the financial responsibility,
character, and reputation of the proposed Transferee, nature of such Transferee&rsquo;s business and proposed use of the Subject
Space. Any Transfer made without Landlord&rsquo;s prior written consent shall, at Landlord&rsquo;s option, be null, void and of
no effect, and shall, at Landlord&rsquo;s option, constitute a default by Tenant under this Lease. Whether or not Landlord consents
to any proposed Transfer, Tenant shall pay Landlord&rsquo;s reasonable review and processing fees, as well as any reasonable professional
fees (including, without limitation, attorneys&rsquo;, accountants&rsquo;, architects&rsquo;, engineers&rsquo; and consultants&rsquo;
fees) incurred by Landlord, not to exceed the sum of $4,000, within thirty (30) days after written request by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Landlord&rsquo;s Consent</U></B>. Landlord shall not unreasonably withhold, condition or delay its consent to any
proposed sublet of the Subject Space or assignment of this Lease on the terms specified in the Transfer Notice. If Landlord fails
to reasonably object to a proposed assignment, sublease or other Transfer within twenty (20) days after Tenant&rsquo;s request,
and provided that Tenant provides Landlord with a reminder notice and Landlord fails to reasonably object within two (2) business
days after the giving of such reminder notice, then Landlord shall be deemed to have consented thereto. Without limitation as to
other reasonable grounds for withholding consent, the parties hereby agree that it shall be reasonable under this Lease and under
any Applicable Law for Landlord to withhold consent to any proposed sublet or assignment where one or more of the following apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">14.2.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Transferee is of a character or reputation or engaged in a business which is not consistent with the quality of the
Building or the Project;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">14.2.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Transferee is either a governmental agency or instrumentality thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">14.2.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Transferee is not a party of reasonable financial worth and/or financial stability in light of the responsibilities
to be undertaken in connection with the Transfer on the date consent is requested;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">14.2.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The proposed Transfer would cause a violation of another lease for space in the Project, or would give an occupant of the
Project a right to cancel its lease (provided that Landlord notifies Tenant in writing of any such restriction upon request from
Tenant from time to time); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">14.2.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Either the proposed Transferee, or any person or entity which directly or indirectly, controls, is controlled by, or is
under common control with, the proposed Transferee, is negotiating with Landlord or has negotiated with Landlord during the three
(3) month period immediately preceding the date Landlord receives the Transfer Notice to lease space in the Project and Landlord
(or an affiliate within the SOVA Science District) has space available for such proposed Transferee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">14.2.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In Landlord&rsquo;s reasonable determination, the sub-rent, additional rent or other amounts received or accrued by Tenant
from subleasing, assigning or otherwise Transferring all or any portion of the Premises is based on the income or profits of any
person, or the assignment or sublease could cause any portion of the amounts received by Landlord pursuant to this Lease to fail
to qualify as &ldquo;rents from real property&rdquo; within the meaning of section 856(d) of the Internal Revenue Code of 1986,
as amended (the &ldquo;<B>Code</B>&rdquo;), or any similar or successor provision thereto or which would cause any other income
of Landlord to fail to qualify as income described in section 856(c)(2) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Landlord consents
to any Transfer pursuant to the terms of this <U>Section&nbsp;14.2</U> (and does not exercise any recapture rights Landlord may
have under <U>Section&nbsp;14.4</U> of this Lease), Tenant may within six (6) months after Landlord&rsquo;s consent, but not later
than the expiration of said six-month period, enter into such Transfer of the Premises or portion thereof, upon substantially the
same terms and conditions as are set forth in the Transfer Notice furnished by Tenant to Landlord pursuant to <U>Section&nbsp;14.1</U>
of this Lease, provided that if there are any changes in the terms and conditions from those specified in the Transfer Notice (i)
such that Landlord would initially have been entitled to refuse its consent to such Transfer under this <U>Section&nbsp;14.2</U>,
Tenant shall again submit the Transfer to Landlord for its approval and other action under this <U>Article 14</U> (including Landlord&rsquo;s
right of recapture, if any, under <U>Section&nbsp;14.4</U> of this Lease). Notwithstanding anything to the contrary in this Lease,
if Tenant or any proposed Transferee claims that Landlord has withheld or delayed its consent in violation of this <U>Section&nbsp;14.2</U>
or otherwise has breached its obligations under this <U>Article 14</U>, their sole remedies shall be a suit for contract damages
(other than damages for injury to, or interference with, Tenant&rsquo;s business including, without limitation, loss of profits,
however occurring) or declaratory judgment and an injunction for the relief sought, and Tenant hereby waives all other remedies,
including, without limitation, any right at law or equity to terminate this Lease, on its own behalf and, to the extent permitted
under all Applicable Laws, on behalf of the proposed Transferee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Transfer Premium</U></B>. If Landlord consents to a Transfer, as a condition thereto which the parties hereby agree
is reasonable, Tenant shall pay to Landlord fifty percent (50%) of any &ldquo;<B>Transfer Premium</B>&rdquo;, as that term is defined
in this <U>Section&nbsp;14.3</U>, received by Tenant from such Transferee. &ldquo;<B>Transfer Premium</B>&rdquo; shall mean all
rent, additional rent or other consideration payable by such Transferee in connection with the Transfer in excess of the Rent and
Additional Rent payable by Tenant under this Lease during the term of the Transfer on a per rentable square foot basis if less
than all of the Premises is transferred, after deducting the reasonable third party expenses incurred by Tenant for (i)&nbsp;any
design and construction costs incurred on account of changes, alterations and improvements to the Premises in connection with the
Transfer, (ii)&nbsp;any free base rent and tenant improvement allowances reasonably provided to the Transferee in connection with
the Transfer (provided that such free rent and tenant improvement allowances shall be deducted only to the extent the same is included
in the calculation of total consideration payable by such Transferee), (iii)&nbsp;any brokerage commissions and/or marketing expenses
in connection with the Transfer, and (iv) legal fees and disbursements reasonably incurred in connection with the Transfer (collectively,
&ldquo;<B>Tenant&rsquo;s Subleasing Costs</B>&rdquo;). &ldquo;<B>Transfer Premium</B>&rdquo; shall also include, but not be limited
to, any lump sum payment, key money, bonus money or other cash consideration paid by Transferee to Tenant in connection with such
Transfer, and any payment in excess of fair market value for services rendered by Tenant to Transferee or for assets, fixtures,
inventory, equipment, or furniture transferred by Tenant to Transferee in connection with such Transfer. The determination of the
amount of Landlord&rsquo;s applicable share of the Transfer Premium shall be made on a monthly basis as rent or other consideration
is received by Tenant under the Transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Landlord&rsquo;s Option as to Subject Space</U></B>. Notwithstanding anything to the contrary contained in this <U>Article
14</U>, in the event Tenant contemplates a Transfer of more than twenty-five percent (25%) of either the Office Premises or the
Lab Premises for a proposed term (including options to extend) of more than twenty-four (24) months (unless such Transfer is proposed
during the final twenty-four (24) months of the Lease Term, in which case it is proposed for all or substantially all of the balance
of the Lease Term), Tenant shall give Landlord notice (the &ldquo;<B>Intention to Transfer Notice</B>&rdquo;) of such contemplated
Transfer (whether or not the contemplated Transferee or the terms of such contemplated Transfer have been determined). The Intention
to Transfer Notice shall specify the portion of and amount of rentable square feet of the Premises which Tenant intends to Transfer
(the &ldquo;<B>Contemplated Transfer Space</B>&rdquo;), the contemplated date of commencement of the Contemplated Transfer (the
&ldquo;<B>Contemplated Effective Date</B>&rdquo;), and the contemplated length of the term of such contemplated Transfer, and shall
specify that such Intention to Transfer Notice is delivered to Landlord pursuant to this <U>Section&nbsp;14.4</U> in order to allow
Landlord to elect to recapture the Contemplated Transfer Space. Thereafter, Landlord shall have the option, by giving written notice
to Tenant (a &ldquo;<B>Recapture Notice</B>&rdquo;) within fifteen (15) days after receipt of any Intention to Transfer Notice,
to recapture the Contemplated Transfer Space. Such recapture shall cancel and terminate this Lease with respect to such Contemplated
Transfer Space as of the Contemplated Effective Date. In the event of a recapture by Landlord, if this Lease shall be canceled
with respect to less than the entire Premises, the Rent reserved herein shall be prorated on the basis of the number of rentable
square feet retained by Tenant in proportion to the number of rentable square feet contained in the Premises, and this Lease as
so amended shall continue thereafter in full force and effect, and upon request of either party, the parties shall execute written
confirmation of the same. Landlord and Tenant shall share equally in the costs to demise any such portion of the Premises recaptured
by Landlord pursuant to this <U>Section 14.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Effect of Transfer</U></B>. If Landlord consents to a Transfer, (i) the terms and conditions of this Lease shall in
no way be deemed to have been waived or modified, (ii) such consent shall not be deemed consent to any further Transfer by either
Tenant or a Transferee, (iii) Tenant shall deliver to Landlord, promptly after execution, an original executed copy of all documentation
pertaining to the Transfer in form reasonably acceptable to Landlord, (iv) Tenant shall furnish upon Landlord&rsquo;s request a
complete statement, certified by an independent certified public accountant, or Tenant&rsquo;s chief financial officer, setting
forth in detail the computation of any Transfer Premium Tenant has derived and shall derive from such Transfer, and (v) no Transfer
relating to this Lease or agreement entered into with respect thereto, whether with or without Landlord&rsquo;s consent, shall
relieve Tenant or any guarantor of the Lease from any liability under this Lease, including, without limitation, in connection
with the Subject Space. Landlord or its authorized representatives shall have the right at all reasonable times to audit the books,
records and papers of Tenant relating to any Transfer, and shall have the right to make copies thereof. If the Transfer Premium
respecting any Transfer shall be found understated, Tenant shall, within thirty (30) days after demand, pay the deficiency, and
if understated by more than two percent (2%), Tenant shall pay Landlord&rsquo;s costs of such audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Sublease/Transfer Restrictions</U></B>. Notwithstanding anything contained herein to the contrary and without limiting
the generality of <U>Section 14.1</U> above, Tenant shall not: (a) sublet all or part of the Premises or assign or otherwise Transfer
this Lease on any basis such that the rental or other amounts to be paid by the subtenant or assignee thereunder would be based,
in whole or in part, on the income or profits derived by the business activities of the subtenant or assignee; (b) sublet all or
part of the Premises or assign this Lease to any person or entity in which, under Section 856(d)(2)(B) of the Code, Longfellow
Atlantic REIT, Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), or any affiliate of the Company owns, directly
or indirectly (by applying constructive ownership rules set forth in Section 856(d) (5) of the Code), a ten percent (10%) or greater
interest; or (c) sublet all or part of the Premises or assign this Lease in any other manner or otherwise derive any income which
could cause any portion of the amounts received by Landlord pursuant hereto or any sublease to fail to qualify as &ldquo;rents
from real property&rdquo; within the meaning of Section 856(d) of the Code, or which could cause any other income received by Landlord
to fail to qualify as income described in Section 856(c) (2) of the Code. The requirements of this <U>Section 14.4</U> shall likewise
apply to any further subleasing, assignment or other Transfer by any subtenant or assignee. All references herein to Section 856
of the Code also shall refer to any amendments thereof or successor provisions thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Occurrence of Default</U></B>. Any Transfer hereunder shall be subordinate and subject to the provisions of this Lease,
and if this Lease shall be terminated during the term of any Transfer, Landlord shall have the right to (and each sublease shall
provide Landlord with the ability to): (i) treat such Transfer as cancelled and repossess the Subject Space by any lawful means,
or (ii) require that such Transferee attorn to and recognize Landlord as its landlord under any such Transfer. If Tenant shall
be in default under this Lease, Landlord is hereby irrevocably authorized, as Tenant&rsquo;s agent and attorney-in-fact, to direct
any Transferee to make all payments under or in connection with the Transfer directly to Landlord (which Landlord shall apply towards
Tenant&rsquo;s obligations under this Lease) until such default is cured. Such Transferee shall rely on any representation by Landlord
that Tenant is in default hereunder, without any need for confirmation thereof by Tenant. Upon any assignment, the assignee shall
assume in writing all obligations and covenants of Tenant thereafter to be performed or observed under this Lease. No collection
or acceptance of rent by Landlord from any Transferee shall be deemed a waiver of any provision of this <U>Article 14</U> or the
approval of any Transferee or a release of Tenant from any obligation under this Lease, whether theretofore or thereafter accruing.
In no event shall Landlord&rsquo;s enforcement of any provision of this Lease against any Transferee be deemed a waiver of Landlord&rsquo;s
right to enforce any term of this Lease against Tenant or any other person. If Tenant&rsquo;s obligations hereunder have been guaranteed,
Landlord&rsquo;s consent to any Transfer shall not be effective unless the guarantor also consents to such Transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Permitted Transfers</U></B>. &ldquo;<B>Permitted Transfer</B>&rdquo; means (a) an assignment of this Lease or a subletting
of all or a portion of the Premises to an affiliate of Tenant (an entity which controls (as defined below), is controlled by or
is under common control with, Tenant), (b) an assignment of this Lease to an entity which acquires all or substantially all of
the assets of Tenant, and (c) an assignment of this Lease to an entity which is the resulting entity of a merger or consolidation
of Tenant. The term &ldquo;control&rdquo; and similar phrases, as used in this subsection, means the ownership, directly or indirectly,
of more than fifty percent (50%) of the voting securities of, or possession of the right to vote, in the ordinary direction of
its affairs, of more than fifty percent (50%) of the voting interest in, any person or entity. &ldquo;<B>Permitted Transferee</B>&rdquo;
means (i) any transferee with respect to a Permitted Transfer pursuant to Clauses (a) or (b) above, and (ii) the resulting Tenant
arising from or in connection with a Permitted Transfer pursuant to Clause (c) above. Notwithstanding anything to the contrary
in this Lease, a Permitted Transfer shall not be deemed an assignment, sublease or Transfer under this Lease, shall not require
Landlord&rsquo;s consent and shall not trigger any recapture or rent-sharing provisions of this Lease, provided that (A) following
the closing of such Permitted Transfer, Tenant notifies Landlord of such Permitted Transfer and promptly supplies Landlord with
any documents or information reasonably requested by Landlord regarding such Permitted Transfer or such Permitted Transferee, (B)
such Permitted Transfer is not a subterfuge by Tenant to avoid its obligations under this Lease, (C) with respect to a Permitted
Transfer pursuant to clauses (b) or (c) above, the Permitted Transferee shall have a tangible net worth (not including goodwill
as an asset) computed in accordance with generally accepted accounting principles (&ldquo;<B>Net Worth</B>&rdquo;) at least equal
to the Net Worth of Tenant on the day preceding the effective date of such Permitted Transfer. No such permitted assignment or
subletting or other Transfer permitted with or without Landlord&rsquo;s consent pursuant to this <U>Article 14</U> shall serve
to release Tenant from any of its obligations under this Lease. Any Permitted Transferee in connection with a Permitted Transfer
shall be deemed the original Tenant for all purposes of this Lease (including without limitation options to renew or expand, right
of first offer and signage rights).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">15.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>SURRENDER OF PREMISES; OWNERSHIP AND REMOVAL OF TRADE FIXTURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Surrender of Premises</U></B>. No act or thing done by Landlord or any agent or employee of Landlord during the Lease
Term shall be deemed to constitute an acceptance by Landlord of a surrender of the Premises unless such intent is specifically
acknowledged in writing by Landlord. The delivery of keys to the Premises to Landlord or any agent or employee of Landlord shall
not constitute a surrender of the Premises or effect a termination of this Lease, whether or not the keys are thereafter retained
by Landlord, and notwithstanding such delivery Tenant shall be entitled to the return of such keys at any reasonable time upon
request until this Lease shall have been properly terminated. The voluntary or other surrender of this Lease by Tenant, whether
accepted by Landlord or not, or a mutual termination hereof, shall not work a merger, and at the option of Landlord shall operate
as an assignment to Landlord of all subleases or subtenancies affecting the Premises or terminate any or all such sublessees or
subtenancies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Removal of Tenant Property by Tenant</U></B>. Upon the expiration of the Lease Term, or upon any earlier termination
of this Lease, Tenant shall, subject to the provisions of this <U>Article 15</U>, quit and surrender possession of the Premises
to Landlord in as good order and condition as when Tenant took possession and as thereafter improved by Landlord and/or Tenant,
reasonable wear and tear and repairs which are specifically made the responsibility of Landlord hereunder, and casualty, excepted.
Upon such expiration or termination, Tenant shall, without expense to Landlord, remove or cause to be removed from the Premises
all Alterations that Tenant is required to remove in accordance with <U>Section 8.3</U> of this Lease, any debris and rubbish,
and such items of furniture, equipment, free-standing cabinet work, movable partitions and other articles of personal property
owned by Tenant or installed or placed by Tenant at its expense in the Premises, and such similar articles of any other persons
claiming under Tenant (unless Landlord, in its sole discretion, waives the requirement that any item of personal property be removed),
and Tenant shall repair at its own expense all damage to the Premises and Building resulting from such removal. Tenant&rsquo;s
personal property includes only those items that are not built into the Premises and that have not been constructed or installed
by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Environmental Assessment</U></B>. Prior to the expiration of the Lease (or within thirty (30) days after any earlier
termination), Tenant shall clean and otherwise decommission all interior surfaces (including floors, walls, ceilings, and counters),
piping, supply lines, waste lines and plumbing in or serving the Premises, and all exhaust or other ductwork in or serving the
Premises, in each case that has carried, released or otherwise been exposed to any Hazardous Materials due to Tenant&rsquo;s use
or occupancy of the Premises, and shall otherwise clean the Premises so as to permit the Environmental Assessment called for by
this <U>Section 15.3</U> to be issued. Prior to the expiration of this Lease (or within thirty (30) days after any earlier termination),
Tenant, at Tenant&rsquo;s expense, shall obtain for Landlord a report (an &ldquo;<B>Environmental Assessment</B>&rdquo;) addressed
to Landlord (and, at Tenant&rsquo;s election, Tenant) by a reputable licensed environmental engineer or industrial hygienist that
is designated by Tenant and acceptable to Landlord in Landlord&rsquo;s reasonable discretion, which report shall be based on the
environmental engineer&rsquo;s inspection of the Premises and shall state, to Landlord&rsquo;s reasonable satisfaction, that (a)
the Hazardous Materials described in the first sentence of this paragraph, to the extent, if any, existing prior to such decommissioning,
have been removed in accordance with Applicable Laws; (b) all Hazardous Materials described in the first sentence of this paragraph,
if any, have been removed in accordance with Applicable Laws from the interior surfaces of the Premises (including floors, walls,
ceilings, and counters), piping, supply lines, waste lines and plumbing, and all such exhaust or other ductwork in the Premises,
may be reused by a subsequent tenant or disposed of in compliance with Applicable Laws without incurring special costs or undertaking
special procedures for demolition, disposal, investigation, assessment, cleaning or removal of such Hazardous Materials and without
giving notice in connection with such Hazardous Materials; and (c) the Premises may be reoccupied for office, research and development,
or laboratory use, demolished or renovated without incurring special costs or undertaking special procedures for disposal, investigation,
assessment, cleaning or removal of Hazardous Materials described in the first sentence of this paragraph and without giving notice
in connection with Hazardous Materials. Further, for purposes of clauses (b) and (c), &ldquo;special costs&rdquo; or &ldquo;special
procedures&rdquo; shall mean costs or procedures, as the case may be, that would not be incurred but for the nature of the Hazardous
Materials as Hazardous Materials instead of non-hazardous materials. The report shall also include reasonable detail concerning
the clean-up measures taken, the clean-up locations, the tests run and the analytic results. Tenant shall submit to Landlord the
identity of the applicable consultants and the scope of the proposed Environmental Assessment for Landlord&rsquo;s reasonable review
and approval at least 30 days prior to commencing the work described therein or at least 60 days prior to the expiration of the
Lease Term, whichever is earlier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Tenant fails to
perform its obligations under this <U>Section 15.3</U>, without limiting any other right or remedy, Landlord may, on five (5) business
days&rsquo; prior written notice to Tenant perform such obligations at Tenant&rsquo;s expense if Tenant has not commenced to do
so within said five day period, and Tenant shall within 10 days of written demand reimburse Landlord for all reasonable out-of-pocket
costs and expenses incurred by Landlord in connection with such work. Tenant&rsquo;s obligations under this <U>Section 15.2</U>
shall survive the expiration or earlier termination of this Lease. In addition, at Landlord&rsquo;s election, Landlord may inspect
the Premises and/or the Project for Hazardous Materials at Landlord&rsquo;s cost and expense within sixty (60) days of Tenant&rsquo;s
surrender of the Premises at the expiration or earlier termination of this Lease. Tenant shall pay for all such costs and expenses
incurred by Landlord in connection with such inspection if such inspection reveals that a release or threat of release of Hazardous
Materials exists at the Project or Premises as a result of the acts or omission of Tenant, its officers, employees, contractors,
and agents (except to the extent resulting from (i) Hazardous Materials existing in the Premises as at the delivery of possession
to Tenant (in which event Landlord shall be responsible for any Clean-up, as provided in this Lease), or (ii) the acts or omissions
of Landlord or Landlord&rsquo;s agents, employees or contractors).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">16.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>HOLDING OVER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Tenant holds over
after the expiration of the Lease Term or earlier termination thereof, with the express written consent of Landlord, such tenancy
shall be from month-to-month only, and shall not constitute a renewal hereof or an extension for any further term. If Tenant holds
over after the expiration of the Lease Term of earlier termination thereof, without the express written consent of Landlord, such
tenancy shall be deemed to be a tenancy by sufferance only, and shall not constitute a renewal hereof or an extension for any further
term. In either case, Base Rent shall be payable at a monthly rate equal to (x) one twenty five percent (125%) of the Base Rent
applicable during the last rental period of the Lease Term for the first thirty (30) days of such hold over, and (y) one hundred
fifty percent (150%) of the Base Rent applicable during the last rental period of the Lease Term for each day thereafter. Such
month-to-month tenancy or tenancy by sufferance, as the case may be, shall be subject to every other applicable term, covenant
and agreement contained herein, including without limitation the obligation to pay Additional Rent. Nothing contained in this <U>Article
16</U> shall be construed as consent by Landlord to any holding over by Tenant, and Landlord expressly reserves the right to require
Tenant to surrender possession of the Premises to Landlord as provided in this Lease upon the expiration or other termination of
this Lease. The provisions of this <U>Article 16</U> shall not be deemed to limit or constitute a waiver of any other rights or
remedies of Landlord provided herein or at law. If Tenant fails to surrender the Premises on or before thirty (30) days after the
expiration or earlier termination of this Lease, in addition to any other liabilities to Landlord accruing therefrom, Tenant shall
protect, defend, indemnify and hold Landlord harmless from all loss, costs (including reasonable attorneys&rsquo; fees) and liability
resulting from such failure, including, without limiting the generality of the foregoing, any claims made by any succeeding tenant
founded upon such failure to surrender and/or any lost profits and consequential or indirect damages to Landlord resulting therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">17.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>ESTOPPEL CERTIFICATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tenant shall execute,
acknowledge and deliver to Landlord an estoppel certificate, which, as submitted by Landlord, shall be substantially in the form
of <B><U>Exhibit&nbsp;17</U></B>, attached hereto (or such other form as may be reasonably required by any prospective mortgagee
or purchaser of the Project, or any portion thereof), indicating therein any exceptions thereto that may exist at that time, and
shall also contain any other information reasonably requested by Landlord or Landlord&rsquo;s mortgagee or prospective mortgagee.
Any such certificate may be relied upon by any prospective mortgagee or purchaser of all or any portion of the Project. Tenant
shall execute and deliver whatever other instruments may be reasonably required for such purposes. Failure of Tenant to timely
execute, acknowledge and deliver such estoppel certificate or other instruments shall constitute an acceptance of the Premises
and an acknowledgment by Tenant that statements included in the estoppel certificate are true and correct, without exception. At
any time during the Lease Term, within ten (10) business days following a request in writing by Landlord, provided that Landlord
executes a commercially reasonable non-disclosure agreement, Landlord may require Tenant to provide Landlord with a current financial
statement and financial statements of the two (2) years prior to the current financial statement year. Such statements shall be
prepared in accordance with generally accepted accounting principles and, if such is the normal practice of Tenant, shall be audited
by an independent certified public accountant. If no audited financial statement is prepared, such statement will be certified
by the CFO or Treasurer of Tenant. Upon request from Tenant from time to time, Landlord shall promptly furnish a similar commercially
reasonable estoppel certificate to Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">18.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>SUBORDINATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Lease shall be
subject and subordinate to all future ground or underlying leases of the Building or Project and to the lien of any mortgage, trust
deed or other encumbrances now or hereafter in force against the Building or Project or any part thereof, if any, and to all renewals,
extensions, modifications, consolidations and replacements thereof, and to all advances made or hereafter to be made upon the security
of such mortgages or trust deeds, unless the holders of such mortgages, trust deeds or other encumbrances, or the lessors under
such ground lease or underlying leases require in writing that this Lease be superior thereto. Tenant covenants and agrees that
in the event any proceedings are brought for the foreclosure of any such mortgage or deed in lieu thereof (or if any ground lease
is terminated), to attorn, without any deductions or set-offs whatsoever, to the lienholder or purchaser or any successors thereto
upon any such foreclosure sale or deed in lieu thereof (or to the ground lessor), if so requested to do so by such purchaser or
lienholder or ground lessor. Notwithstanding any other provision of this Lease to the contrary, no holder of any such mortgage,
trustee deed or other encumbrance and no such ground lessor, shall be obligated to perform or liable in damages for failure to
perform any of Landlord&rsquo;s obligations under this Lease unless and until such holder shall foreclose such mortgage, trust
deed or other encumbrance, or the lessors under such ground lease or underlying leases otherwise acquire title to the Property,
and then shall only be liable for Landlord&rsquo;s obligations arising or accruing after such foreclosure or acquisition of title,
provided the foregoing shall not release any such holder or ground lessor from performing ongoing obligations of Landlord from
and after the date of such foreclosure or acquisition of title, such as repair and maintenance obligations. No such holder shall
ever be obligated to perform or be liable in damages for any of Landlord&rsquo;s obligations arising or accruing before such foreclosure
or acquisition of title. Tenant shall, within ten (10) business days of request by Landlord, execute such further instruments or
assurances as Landlord may reasonably deem necessary to evidence or confirm the subordination or superiority of this Lease to any
such mortgages, trust deeds, ground leases or underlying leases. Tenant waives the provisions of any current or future statute,
rule or law which may give or purport to give Tenant any right or election to terminate or otherwise adversely affect this Lease
and the obligations of Tenant hereunder in the event of any foreclosure proceeding or sale. The subordination of this Lease to
future mortgages, deeds of trust, master leases or similar instruments shall be subject to Tenant&rsquo;s receipt of a commercially
reasonable non-disturbance agreement from the beneficiary or lessor thereunder which provides in substance that so long as Tenant
is not in default under this Lease past applicable cure periods, its use and occupancy of the Premises shall not be disturbed notwithstanding
any default of Landlord under such mortgage, deed of trust, master lease or similar instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Landlord&rsquo;s interest
herein may be assigned as security at any time to any Mortgagee. Notwithstanding the foregoing or anything to the contrary herein,
no Mortgagee succeeding to the interest of Landlord hereunder shall be (i) liable in any way to Tenant for any act or omission,
neglect or default on the part of Landlord under this Lease, (ii) responsible for any monies owing by or on deposit with Landlord
to the credit of Tenant (except to the extent any such deposit is actually received by such mortgagee or ground lessor), (iii)
subject to any counterclaim or setoff which theretofore accrued to Tenant against Landlord, (iv) bound by any amendment or modification
of this Lease subsequent to such mortgage (provided that Landlord notifies Tenant of such mortgage prior to such amendment or modification),
or by any previous prepayment of Rent for more than one (1) month, which was not approved in writing by the Mortgagee, (v) liable
beyond such Mortgagee&rsquo;s interest in the Project, or (vi) responsible for the payment or performance of any work to be done
by Landlord under this Lease to render the Premises ready for occupancy by Tenant or for the payment of any tenant improvements
allowances. Nothing in clause (i), above, shall be deemed to relieve any Mortgagee succeeding to the interest of Landlord hereunder
of its obligation to comply with the obligations of Landlord under this Lease from and after the date of such succession.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No Mortgagee shall,
either by virtue of the Mortgage or any assignment of leases executed by Landlord for the benefit of such Mortgagee, be or become
a mortgagee in possession or be or become subject to any liability or obligation under the Lease or otherwise until such Mortgagee
shall have acquired the interest of Landlord in the Property, by foreclosure or otherwise, or in fact have taken possession of
the Property as a mortgagee in possession and then such liability or obligation of Mortgagee under the Lease shall extend only
to those liability or obligations accruing subsequent to the date that such Mortgagee has acquired the interest of Landlord in
the Premises, or in fact taken possession of the Property as a mortgagee in possession.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">19.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>DEFAULTS; REMEDIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Events of Default</U></B>. The occurrence of any of the following shall constitute a default of this Lease by Tenant:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">19.1.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Any
failure by Tenant to pay any Rent or any other charge required to be paid under this Lease, or any part thereof, when due and
such failure shall continue for five (5) business days after notice of such failure is given to Tenant, except that if Landlord
shall have given two (2) such notices in any twelve (12) month period, Tenant shall not be entitled to any further notice of its
delinquency in the payment of Rent or any other charge required to be paid under this Lease until such time as twelve (12) consecutive
months shall have elapsed without Tenant having defaulted in any such payment; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">19.1.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Any
failure by Tenant to observe or perform any other provision, covenant or condition of this Lease to be observed or performed by
Tenant where such failure continues for thirty (30) days after written notice thereof from Landlord to Tenant; provided that if
the nature of such default is such that the same cannot reasonably be cured within a thirty (30) day period, Tenant shall not
be deemed to be in default if it diligently commences such cure within such period and thereafter diligently proceeds to rectify
and cure such default; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">19.1.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Abandonment of the Premises by Tenant pursuant to Section 1951.35 of the California Civil Code; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">19.1.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The failure by Tenant to observe or perform according to the provisions of <U>Sections&nbsp;5.1 </U>or <U>5.2</U> or <U>Articles
14</U>, <U>17</U> or <U>18</U> of this Lease where such failure continues for more than two (2) business days after notice from
Landlord;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">19.1.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If a receiver, guardian, conservator, trustee in bankruptcy or similar officer shall be appointed by a court of competent
jurisdiction to take charge of all or any part of Tenant&rsquo;s or any guarantor&rsquo;s property and such appointment is not
discharged within 90&nbsp;days thereafter or if a petition including, without limitation, a petition for reorganization or arrangement
is filed by Tenant or any guarantor under any bankruptcy law or is filed against Tenant or any guarantor and, in the case of a
filing against Tenant only, the same shall not be dismissed within 90&nbsp;days from the date upon which it is filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The notice periods
provided herein are in lieu of, and not in addition to, any notice periods provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Remedies Upon Default</U></B>. Upon the occurrence of any event of default by Tenant beyond applicable notice and
cure periods, Landlord shall have, in addition to any other remedies available to Landlord at law or in equity (all of which remedies
shall be distinct, separate and cumulative), the option to pursue any one or more of the following remedies, each and all of which
shall be cumulative and nonexclusive, without any notice or demand whatsoever. Tenant hereby waives, for Tenant and for all those
claiming under Tenant, any and all rights now or hereafter existing to redeem by order or judgment of any court or by any legal
process or writ, Tenant&rsquo;s right of occupancy of the Premises after any termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">19.2.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Terminate this Lease (pursuant to Section 1951.2 of the California Civil Code), in which event Tenant shall immediately
surrender the Premises to Landlord, and if Tenant fails to do so, Landlord may, without prejudice to any other remedy which it
may have for possession or arrearages in rent, enter upon and take possession of the Premises and expel or remove Tenant and any
other person who may be occupying the Premises or any part thereof, without being liable for prosecution or any claim or damages
therefor; and Landlord may recover from Tenant the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The worth at the time of award of the unpaid rent which has been earned at the time of such termination; plus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The worth at the time of award of the amount by which the unpaid rent which would have been earned after termination until
the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The worth at the time of award of the amount by which the unpaid rent for the balance of the Lease Term after the time of
award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any other amount necessary to compensate Landlord for all the detriment proximately caused by Tenant&rsquo;s failure to
perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, specifically
including but not limited to, brokerage commissions and advertising expenses incurred, expenses of remodeling the Premises or any
portion thereof for a new tenant, whether for the same or a different use, and any special concessions made to obtain a new tenant;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At Landlord&rsquo;s election, such other amounts in addition to or in lieu of the foregoing as may be permitted from time
to time by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &ldquo;<B>rent</B>&rdquo;
as used in this <U>Section 19.2</U> shall be deemed to be and to mean all sums of every nature required to be paid by Tenant pursuant
to the terms of this Lease, whether to Landlord or to others. As used in <U>Sections 19.2.1(i)</U> and <U>(ii)</U>, above, the
&ldquo;worth at the time of award&rdquo; shall be computed by allowing interest at the rate set forth in <U>Article 25</U> of this
Lease, but in no case greater than the maximum amount of such interest permitted by law. As used in <U>Section 19.2.1(iii)</U>
above, the &ldquo;<B>worth at the time of award</B>&rdquo; shall be computed by discounting such amount at the discount rate of
the Federal Reserve Bank of San Francisco at the time of award plus one percent (1%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">19.2.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Landlord shall have the remedy described in California Civil Code Section 1951.4 (lessor may continue lease in effect after
lessee&rsquo;s breach and abandonment and recover rent as it becomes due, if lessee has the right to sublet or assign, subject
only to reasonable limitations). Accordingly, if Landlord does not elect to terminate this Lease on account of any default by Tenant,
Landlord may, from time to time, without terminating this Lease, enforce all of its rights and remedies under this Lease, including
the right to recover all rent as it becomes due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">19.2.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Landlord shall at all times have the rights and remedies (which shall be cumulative with each other and cumulative and in
addition to those rights and remedies available under this <U>Section 19.2</U>, or any law or other provision of this Lease), without
prior demand or notice except as required by Applicable Law, to seek any declaratory, injunctive or other equitable relief, and
specifically enforce this Lease, or restrain or enjoin a violation or breach of any provision hereof. The provisions of this <U>Section
19.2.6</U> are not dependent upon the occurrence of a default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">19.2.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Any obligation imposed by law upon Landlord to relet the Premises after any termination of the Lease shall be subject to
the reasonable requirements of Landlord to lease to high quality tenants on such terms as Landlord may from time to time deem appropriate
and to develop the Building in a harmonious manner with an appropriate mix of uses, tenants, floor areas and terms of tenancies,
and the like, and Landlord shall not be obligated to relet the Premises to any party to whom Landlord or its affiliate may desire
to lease other available space in the Building.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">19.2.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Nothing herein shall limit or prejudice the right of Landlord to prove and obtain in a proceeding for bankruptcy, insolvency,
arrangement or reorganization, by reason of the termination, an amount equal to the maximum allowed by a statute of law in effect
at the time when, and governing the proceedings in which, the damages are to be proved, whether or not the amount is greater to,
equal to, or less than the amount of the loss or damage which Landlord has suffered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Subleases of Tenant</U></B>. Whether or not Landlord elects to terminate this Lease on account of any default by Tenant,
as set forth in this <U>Article 19</U>, Landlord shall have the right to terminate any and all subleases, licenses, concessions
or other consensual arrangements for possession entered into by Tenant and affecting the Premises or may, in Landlord&rsquo;s sole
discretion, succeed to Tenant&rsquo;s interest in such subleases, licenses, concessions or arrangements. In the event of Landlord&rsquo;s
election to succeed to Tenant&rsquo;s interest in any such subleases, licenses, concessions or arrangements, Tenant shall, as of
the date of notice by Landlord of such election, have no further right to or interest in the rent or other consideration receivable
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Efforts to Relet</U></B>. No re-entry or repossession, repairs, maintenance, changes, alterations and additions, reletting,
appointment of a receiver to protect Landlord&rsquo;s interests hereunder, or any other action or omission by Landlord shall be
construed as an election by Landlord to terminate this Lease or Tenant&rsquo;s right to possession, or to accept a surrender of
the Premises, nor shall same operate to release Tenant in whole or in part from any of Tenant&rsquo;s obligations hereunder, unless
express written notice of such intention is sent by Landlord to Tenant. Tenant hereby irrevocably waives any right otherwise available
under any law to redeem or reinstate this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Landlord Default</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">19.5.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>General</U></B>. Notwithstanding anything to the contrary set forth in this Lease, Landlord shall not be in default
in the performance of any obligation required to be performed by Landlord pursuant to this Lease unless Landlord fails to perform
such obligation within thirty (30) days after the receipt of notice from Tenant specifying in detail Landlord&rsquo;s failure to
perform; provided, however, if the nature of Landlord&rsquo;s obligation is such that more than thirty (30) days are required for
its performance, then Landlord shall not be in default under this Lease if it shall commence such performance within such thirty
(30) day period and thereafter diligently pursue the same to completion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">20.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>COVENANT OF QUIET ENJOYMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Landlord covenants
that Tenant, on paying the Rent, charges for services and other payments herein reserved and on keeping, observing and performing
all the other terms, covenants, conditions, provisions and agreements herein contained on the part of Tenant to be kept, observed
and performed, shall, during the Lease Term, peaceably and quietly have, hold and enjoy the Premises subject to the terms, covenants,
conditions, provisions and agreements hereof without interference by any persons lawfully claiming by or through Landlord. The
foregoing covenant is in lieu of any other covenant express or implied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">21.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>SECURITY DEPOSIT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> Concurrently with Tenant&rsquo;s execution of this Lease, Tenant shall deposit with Landlord a letter of credit (the &ldquo;<B>L/C
Security</B>&rdquo;) in the amount set forth in <U>Section&nbsp;9</U> of the Summary as security for the faithful performance by
Tenant of all of its obligations under this Lease as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Tenant shall provide Landlord, and maintain in full force and effect throughout the Term and until the date that is ninety
(90) days after the Lease Expiration Date, an evergreen letter of credit substantially in the form of <B><U>Exhibit 21.1</U></B>
issued by an issuer reasonably satisfactory to Landlord (and Landlord hereby approves First Republic Bank as an issuer), in the
amount set forth in <U>Section&nbsp;9</U> of the Summary. If at any time during the Term (i) Landlord determines in its reasonable
discretion that the financial condition of such issuer has changed in any materially adverse way from the financial condition of
such issuer as of the date of execution of this Lease including, without limitation, if such issuer is declared insolvent or is
placed into receivership or conservatorship by the Federal Deposit Insurance Corporation, or any successor or similar entity, if
a trustee, receiver or liquidator is appointed for such issuer, if the credit rating of the long-term debt of the issuer of the
letter of credit (according to Moody&rsquo;s, Standard &amp; Poor&rsquo;s or similar national rating agency reasonably identified
by Landlord) is downgraded to a grade below investment grade, if the issuer enters into any supervisory agreement with any governmental
authority or fails to meet any capital requirements imposed by applicable law, Landlord may require the L/C Security to be replaced
by an L/C Security issued by a different issuer, in which event Tenant shall within twenty&nbsp;(20) days after written notice
from Landlord deliver to Landlord a replacement L/C Security issued by a commercial bank or savings and loan association reasonably
acceptable to Landlord and that meets all other requirements of this Article. If Tenant has actual notice, or Landlord notifies
Tenant at any time, that any issuer of the L/C Security has become insolvent or placed into FDIC receivership, then Tenant shall
promptly deliver to Landlord (without the requirement of further notice from Landlord) substitute L/C Security issued by a commercial
bank or savings and loan association reasonably acceptable to Landlord and that meets all other requirements of this Article. As
used herein with respect to the issuer of the L/C Security, &ldquo;insolvent&rdquo; shall mean the determination of insolvency
as made by such issuer&rsquo;s primary bank regulator (i.e., the state bank supervisor for state chartered banks; the OCC or OTS,
respectively, for federally chartered banks or thrifts; or the Federal Reserve for its member banks).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Landlord may draw upon the L/C Security, and hold and apply the proceeds for the payment of any Rent or any other sum in
default, or to compensate Landlord for any other loss or damage that Landlord may suffer by reason of Tenant&rsquo;s default, if:
(i) a default beyond applicable notice and cure periods exists (or would have existed with the giving of notice and passage of
applicable cure periods, but only if transmittal of a default notice is stayed or barred by applicable bankruptcy or other similar
law); (ii) as of the date forty-five (45) days before any L/C Security expires Tenant has not delivered to Landlord an amendment
or replacement for such L/C Security, reasonably satisfactory to Landlord, extending the expiry date to the date that is sixty
(60) days after the then-current Lease Expiration Date; (iii) Tenant fails to pay any bank charges for Landlord&rsquo;s transfer
of the L/C Security when due, after the expiration of any applicable notice and cure period; or (iv) the issuer of the L/C Security
ceases, or announces that it will cease, to maintain an office in the city where Landlord may present drafts under the L/C Security
(and fails to permit drawing upon the L/C Security by overnight courier or facsimile). This Section does not limit any other provisions
of this Lease allowing Landlord to draw the L/C Security under specified circumstances. In the event of any such draw upon the
L/C Security, Tenant shall within 10 business days thereafter provide Landlord with a replacement letter of credit, or amendment
to the existing letter of credit increasing the amount of such letter of credit, in the amount of L/C Security, and in the form,
required hereunder, and Tenant&rsquo;s failure to do so shall be a material breach of this Lease. Landlord shall hold the proceeds
of any draw not applied as set forth above as a cash Security Deposit as further described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If Landlord transfers its interest in the Premises, then Landlord shall transfer the L/C Security to the transferee of its
interest and notify Tenant of such transfer, and Tenant shall at Tenant&rsquo;s expense, within fifteen (15) business days after
receiving a request from Landlord, deliver (and, if the issuer requires, Landlord shall consent to) an amendment to the L/C Security
naming Landlord&rsquo;s grantee as substitute beneficiary. If the required Security Deposit changes while L/C Security is in force,
then Tenant shall deliver (and, if the issuer requires, Landlord shall consent to) a corresponding amendment to the L/C Security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If and to the extent Landlord is holding the proceeds of the L/C Security in cash from time to time, such cash shall be
held by Landlord as security for the faithful performance by Tenant of all of the terms, covenants and conditions of this Lease
to be kept and performed by Tenant during the period commencing on the Execution Date and ending upon the expiration or termination
of Tenant&rsquo;s obligations under this Lease. If Tenant defaults (beyond applicable notice and cure periods) with respect to
any provision of this Lease, including any provision relating to the payment of Rent, then Landlord may (but shall not be required
to) use, apply or retain all or any part of the Security Deposit for the payment of any Rent or any other sum in default, or to
compensate Landlord for any other loss or damage that Landlord may suffer by reason of Tenant&rsquo;s default as provided in this
Lease. The provisions of this Article shall survive the expiration or earlier termination of this Lease. In the event of bankruptcy
or other debtor-creditor proceedings against Tenant, any cash security then being held by Landlord shall be deemed to be applied
first to the payment of Rent and other charges due Landlord for all periods prior to the filing of such proceedings. Landlord shall
deliver or credit to any purchaser of Landlord&rsquo;s interest in the Premises the funds then held hereunder by Landlord, and
thereupon (and upon confirmation by the transferee of such funds, whether expressly or by written assumption of this Lease, generally)
Landlord shall be discharged from any further liability with respect to such funds. This provision shall also apply to any subsequent
transfers. If Tenant shall fully and faithfully perform every provision of this Lease to be performed by it, then the cash security,
if any, or any balance thereof, shall be returned to Tenant (or, at Landlord&rsquo;s option, to the last assignee of Tenant&rsquo;s
interest hereunder) within sixty (60) days after the expiration or earlier termination of this Lease. If and to the extent the
security held by Landlord hereunder shall be in cash, Landlord shall hold such cash in an account at a banking organization selected
by Landlord; <U>provided</U>, however, that Landlord shall not be required to maintain a separate account for the cash security,
but may intermingle it with other funds of Landlord. Landlord shall be entitled to all interest and/or dividends, if any, accruing
on such cash security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If, at any time, Tenant is obligated to deliver to Landlord a replacement letter of credit pursuant to the terms of this
Section 21 but Tenant is unable to do so despite its good faith, commercially reasonable efforts to deliver a replacement letter
of credit, then Tenant shall be permitted (in lieu thereof) to deliver to Landlord a cash security deposit to Landlord in such
amount. In such event, Landlord shall hold such security deposit in accordance with Section 21(d) above and this <U>Section 21(e)</U>.
Further, Tenant hereby waives the provisions of Section 1950.7 of the California Civil Code, or any successor statute, and all
other provisions of law, now or hereafter in effect, which (i) establish the time frame by which a landlord must refund a security
deposit under a lease, and/or (ii) provide that a landlord may claim from a security deposit only those sums reasonably necessary
to remedy defaults in the payment of rent, to repair damage caused by a tenant or to clean the premises, it being agreed that Landlord
may, in addition, claim those sums specified in this Section above and/or those sums reasonably necessary to compensate Landlord
for any loss or damage caused by Tenant&rsquo;s default of this Lease (beyond applicable notice and cure periods), as amended hereby,
including, but not limited to, all damages or rent due upon termination of Lease pursuant to Section 1951.2 of the California Civil
Code. Notwithstanding anything to the contrary contained in this Section 21(e), Landlord may, from time to time (but not more often
than once in any twelve (12) month period), require Tenant to attempt to obtain a replacement letter of credit in lieu of a cash
security deposit, and Tenant will use good faith, commercially reasonable efforts to deliver a replacement letter of credit in
lieu of a cash security deposit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">22.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>SUBSTITUTION OF OTHER PREMISES (AS TO OFFICE PREMISES ONLY)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Landlord shall have
the right at any time <B>as to the Office Premises only</B>, upon giving Tenant not less than thirty (30) days&rsquo; prior written
notice, to provide and furnish Tenant with comparable space elsewhere in the 11555 Building of at least the same size as the Office
Premises with at least the same number of private offices and to place Tenant in such space. If the total rentable square footage
of the new space exceeds the total of the original Office Premises, Tenant&rsquo;s Rent shall not be increased. The total rentable
square footage of the new space shall not be less than the total of the original Office Premises<I>. </I>In the event of any such
relocation of Tenant, Landlord shall pay for all of the following verified reasonable direct costs actually incurred solely due
to any such relocation: the costs of relocating furniture, files and equipment, telephone installation, computer wiring and cabling,
and reasonable costs of new stationery and business cards; provided, however, Tenant shall not be entitled to any compensation
for damages for any interference with or interruption of its business during or resulting from such relocation<I>.</I> However,
Landlord shall make reasonable efforts to minimize such interference. If Landlord relocates Tenant to such new space, this Lease
and each and all of its terms, covenants and conditions shall remain in full force and effect and be deemed applicable to such
new space, and such new space shall thereafter be deemed to be the &ldquo;Office Premises&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">23.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>SIGNS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">23.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Signage</U></B>. Tenant shall not install any signage (including, without limitation, any signs identifying Tenant&rsquo;s
name or advertising Tenant&rsquo;s merchandise or otherwise) in or about the Premises that is visible from the exterior of the
Premises or in any other part of the Project except as expressly permitted in this <U>Section 23.1</U>. Landlord shall add Tenant
to any relevant multi-tenant lobby directories. Such signage shall comply with Landlord&rsquo;s then-current Building standard
signage program. Subject to Landlord&rsquo;s prior written approval, which approval shall not be unreasonably withheld, conditioned
or delayed, and provided all signs are in keeping with the quality, design and style of the Building and Project, Tenant, at its
sole cost and expense, may install one sign identifying Tenant (and Tenant&rsquo;s subsidiary, Exosome Sciences, Inc., so long
as such subsidiary does not have any employees and remains an affiliate of Tenant) at the entry to each of the Office Premises
and Lab Premises, which identification signs shall be consistent with building standard signage as determined by Landlord. All
permitted signs shall be maintained by Tenant at its expense in a first-class and safe condition and appearance. Upon the expiration
or earlier termination of this Lease, Tenant shall remove all of its signs at Tenant&rsquo;s sole cost and expense. Tenant shall
repair any damage to the Premises or Project, inside or outside, resulting from the erection, maintenance or removal of any signs.
Tenant&rsquo;s signage must also comply with all Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">23.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Prohibited Signage and Other Items</U></B>. Any signs, notices, logos, pictures, names or advertisements which are
installed and that have not been separately approved by Landlord may be removed without notice by Landlord at the sole expense
of Tenant. Except as expressly permitted pursuant to <U>Section 23.1</U>, above, Tenant may not install any signs on the exterior
or roof of the Project or the Common Areas. Any signs, displays, window coverings, window lettering, or blinds (even if the same
are located behind the Landlord-approved window coverings for the Building), or other items or Alterations visible from the exterior
of the Premises or Building, shall be subject to the prior approval of Landlord, in its sole reasonable discretion. Tenant shall
not place or install any projections, antennae, aerials, or similar devices inside or outside of the Building, without the prior
written approval of Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">24.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>COMPLIANCE WITH LAW</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tenant shall not do
anything or suffer anything to be done by any Tenant Party in or about the Premises or the Project which will in any way conflict
with any law, statute, ordinance or other federal, state or local governmental rule, regulation or requirement now in force or
which may hereafter be enacted or promulgated (collectively, &ldquo;<B>Applicable Laws</B>&rdquo;). At its sole cost and expense,
Tenant shall promptly comply with all such Applicable Laws which relate to (i)&nbsp;Tenant&rsquo;s use of the Premises, (ii)&nbsp;&nbsp;any
Alterations, or (iii)&nbsp;the Building, but in no event shall Tenant be obligated to make any alterations outside of the Premises
to the extent such obligations are triggered by Tenant&rsquo;s particular use of the Premises as opposed to office and laboratory
use, generally. Tenant shall be responsible, at its sole cost and expense, to make all alterations to the Premises as are required
to comply with the Applicable Laws to the extent required in this <U>Article 24</U>. Notwithstanding the foregoing terms of this
<U>Article 24</U> to the contrary, Tenant may defer such compliance with Applicable Laws while Tenant contests, in a court of proper
jurisdiction, in good faith, the applicability of such Applicable Laws to the Premises or Tenant&rsquo;s specific use or occupancy
of the Premises; provided, however, Tenant may only defer such compliance if such deferral shall not (a)&nbsp;prohibit Tenant from
obtaining or maintaining a certificate of occupancy for the Premises, (b)&nbsp;prohibit Landlord from obtaining or maintaining
a certificate of occupancy for the Building or any portion thereof, (c)&nbsp;unreasonably and materially affect the safety of the
employees and/or invitees of Landlord or of any tenant in the Building (including Tenant), (d)&nbsp;create a significant health
hazard for the employees and/or invitees of Landlord or of any tenant in the Building (including Tenant), (e)&nbsp;otherwise materially
and adversely affect Tenant&rsquo;s use of or access to the Buildings or the Premises, or (f)&nbsp;impose material obligations,
liability, fines, or penalties upon Landlord or any other tenant of the Building, or would materially and adversely affect the
use of or access to the Building by Landlord or other tenants or invitees of the Building. The judgment of any court of competent
jurisdiction or the admission of Tenant in any judicial action, regardless of whether Landlord is a party thereto, that Tenant
has violated any of said governmental measures, shall be conclusive of that fact as between Landlord and Tenant. Landlord shall
comply with all Applicable Laws relating to the Common Areas of the Building, provided that compliance with such Applicable Laws
is not the responsibility of Tenant under this Lease, and provided further that Landlord&rsquo;s failure to comply therewith would
prohibit Tenant from obtaining or maintaining a certificate of occupancy for the Premises, or would unreasonably and materially
affect the safety of Tenant&rsquo;s employees or create a significant health hazard for Tenant&rsquo;s employees, or would otherwise
materially and adversely affect Tenant&rsquo;s use of or access to the Premises. Landlord shall be permitted to include in Operating
Expenses any costs or expenses incurred by Landlord under this <U>Article&nbsp;24</U> to the extent not prohibited by the terms
of <U>Section&nbsp;4.2.7</U> above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of Section
1938 of the California Civil Code, Landlord hereby discloses to Tenant, and Tenant hereby acknowledges, that neither the Premises,
the Building nor the Common Areas have undergone inspection by a Certified Access Specialist (CASp). Pursuant to California Civil
Code Section 1938, Tenant is hereby notified as follows: <B>&ldquo;A Certified Access Specialist (CASp) can inspect the subject
premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards
under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or
lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential
occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for
the time and manner of any CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs
necessary to correct violations of construction-related accessibility standards within the subject premises.&rdquo;</B> If Tenant
requests to perform a CASp inspection of the Premises, Tenant shall, at its cost, retain a CASp approved by Landlord (provided
that Landlord may designate the CASp, at Landlord&rsquo;s option) to perform the inspection of the Premises at a time agreed upon
by the parties. Tenant shall provide Landlord with a copy of any report or certificate issued by the CASp (the &ldquo;<B>CASp Report</B>&rdquo;).
Landlord and Tenant agree that any modifications necessary to correct violations of construction related accessibility standards
identified in the CASp Report shall be the responsibility of Tenant. Tenant agrees to keep the information in the CASp Report confidential
except as necessary for the Tenant to complete such modifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">25.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>LATE CHARGES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any installment
of Rent or any other sum due from Tenant shall not be received by Landlord or Landlord&rsquo;s designee within five (5) business
days after the date due, then Tenant shall pay to Landlord a late charge equal to five percent (5%) of the overdue amount plus
any reasonable attorneys&rsquo; fees incurred by Landlord by reason of Tenant&rsquo;s failure to pay Rent and/or other charges
when due hereunder. Notwithstanding the foregoing, Landlord shall not charge Tenant a late charge for the first (1<SUP>st</SUP>)
late payment in any twelve (12) month period unless Tenant fails to timely pay such amount within five (5) business days following
notice from Landlord that such amount is past due. The late charge shall be deemed Additional Rent and the right to require it
shall be in addition to all of Landlord&rsquo;s other rights and remedies hereunder or at law and shall not be construed as liquidated
damages or as limiting Landlord&rsquo;s remedies in any manner. In addition to the late charge described above, any Rent or other
amounts owing hereunder which are not paid when due shall bear interest from the date when due until paid at a rate per annum equal
to the lesser of (i) the annual &ldquo;<B>Bank Prime Loan</B>&rdquo; rate cited in the Federal Reserve Statistical Release Publication
H.15, published on the first Tuesday of each calendar month (or such other comparable index as Landlord and Tenant shall reasonably
agree upon if such rate ceases to be published) plus three (3) percentage points, and (ii) the highest rate permitted by Applicable
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">26.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>LANDLORD&rsquo;S RIGHT TO CURE DEFAULT; PAYMENTS BY TENANT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">26.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Landlord&rsquo;s Cure</U></B>. All covenants and agreements to be kept or performed by Tenant under this Lease shall
be performed by Tenant at Tenant&rsquo;s sole cost and expense and without any reduction of Rent, except to the extent, if any,
otherwise expressly provided herein. If Tenant shall fail to perform any obligation under this Lease, and such failure shall continue
in excess of the time allowed under <U>Section&nbsp;19.1.2</U> above, unless a specific time period is otherwise stated in this
Lease, Landlord may, but shall not be obligated to, make any such payment or perform any such act on Tenant&rsquo;s part without
waiving its rights based upon any default of Tenant after the expiration of any applicable notice and cure period and without releasing
Tenant from any obligations hereunder. Tenant&rsquo;s obligations under this <U>Section&nbsp;26.1</U> shall survive the expiration
or sooner termination of the Lease Term. Except as may be specifically provided to the contrary in this Lease, Tenant shall pay
to Landlord, within twenty (20) days after delivery by Landlord to Tenant of statements therefor: (i) sums equal to expenditures
reasonably made and obligations incurred by Landlord in connection with the remedying by Landlord of Tenant&rsquo;s defaults pursuant
to the provisions of <U>Section&nbsp;26.1</U>; (ii) sums equal to all losses, costs, liabilities, damages and expenses referred
to in <U>Article 10</U> of this Lease; and (iii) sums equal to all expenditures made and obligations incurred by Landlord in collecting
or attempting to collect the Rent or in enforcing or attempting to enforce any rights of Landlord under this Lease or pursuant
to law, including, without limitation, all reasonable legal fees and other amounts so expended. Tenant&rsquo;s obligations under
this <U>Section&nbsp;26.1</U> shall survive the expiration or sooner termination of the Lease Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">27.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>PROJECT CONTROL BY LANDLORD; ENTRY BY LANDLORD</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">27.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Project Control</U></B>. Landlord reserves full control over the Building and the Project to the extent not inconsistent
with Tenant&rsquo;s enjoyment of the Premises as provided by this Lease. This reservation includes Landlord&rsquo;s right to subdivide
the Project; convert the Building to condominium units; change the size of the Project by selling all or a portion of the Project
or adding real property and any improvements thereon to the Project; grant assessments and licenses to third parties; maintain
or establish ownership of the Building separate from fee title to the Property; make additions to or reconstruct portions of the
Building and the Project; install, use, maintain, repair, replace and relocate for service to the Premises and other parts of the
Building or the Project pipes, ducts, conduits, wires and appurtenant fixtures, wherever located in the Premises, the Building
or elsewhere at the Project; and alter or relocate any other Common Area or facility, including private drives, lobbies and entrances.
Landlord&rsquo;s right pursuant to this <U>Section 27.1</U>, including without limitation the rights to construct, maintain, relocate,
alter, improve, or adjust the Building or the Project shall be subject to the condition that (i) the exercise of any of such rights
shall not materially and adversely interfere with Tenant&rsquo;s use of the Premises or materially decrease the number of Tenant&rsquo;s
parking spaces, (ii) Landlord shall provide reasonable prior notice to Tenant before exercising any such rights which may materially
and adversely interfere with Tenant&rsquo;s use of the Premises, provided that such use of the Premises is in accordance with the
Permitted Use, and (iii) Landlord shall use reasonable efforts to minimize to the extent possible any interference with Tenant&rsquo;s
business, provided that such business is in accordance with the Permitted Use, including, when reasonable, scheduling such work
after business hours or on weekends. Possession of areas of the Premises necessary for utilities, services, safety and operation
of the Building is reserved to Landlord. Notwithstanding the foregoing, Landlord shall provide Tenant reasonable prior notice of
required access to the Premises for such activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">27.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Entry by Landlord</U></B>. Landlord reserves the right at all reasonable times and upon not less than one (1) business
day&rsquo;s prior notice to Tenant which may be given by telephone or electronic mail (except in the case of an emergency or with
respect to regularly scheduled services) to enter the Premises to (i) inspect them; (ii) show the Premises to prospective purchasers,
or to current or prospective mortgagees, ground or underlying lessors or insurers or, during the last twelve (12) months of the
Lease Term, to prospective tenants; (iii) post notices of nonresponsibility (to the extent applicable pursuant to then Applicable
Law); or (iv) provided that it is in accordance with the express provisions of this Lease, alter, improve or repair the Premises
or the Building, or for structural alterations, repairs or improvements to the Building or the Building&rsquo;s systems and equipment.
Provided that Landlord employs commercially reasonable efforts to minimize interference with the conduct of Tenant&rsquo;s business
in connection with entries into the Premises, Landlord may make any such entries without creating a default by Landlord and shall
take such reasonable steps as required to accomplish the stated purposes. In an emergency, Landlord shall have the right to use
any means that Landlord may deem proper to open the doors in and to the Premises. Landlord also shall have the right at any time,
without the same constituting an actual or constructive eviction and without incurring any liability to Tenant therefor, to change
the arrangement or location of entrances or passageways, doors and doorways, and corridors, elevators, stairs, toilets, or other
public parts of the Building and to change the name, address, number or designation by which the Premises is commonly known, provided
any such change does not (A) unreasonably reduce, interfere with or deprive Tenant of access to the Premises, or (B) reduce the
rentable area (except by a <I>de minimis</I> amount) of the Premises. Any entry into the Premises by Landlord in the manner hereinbefore
described shall not be deemed to be a forcible or unlawful entry into, or a detainer of, the Premises, or an actual or constructive
eviction of Tenant from any portion of the Premises and the Base Rent (and any other item of Rent) shall under no circumstances
abate while said repairs, alterations, improvements, additions or restorations are being made, by reason of loss or interruption
of business of Tenant, or otherwise. If Tenant shall not be present when for any reason entry into the Premises shall be necessary
or permissible, Landlord or Landlord&rsquo;s agents, representatives, contractors or employees may enter the same without rendering
Landlord or such agents liable therefor if during such entry Landlord or Landlord&rsquo;s agents shall accord reasonable care under
the circumstances to Tenant&rsquo;s Property, and without in any manner affecting this Lease. Tenant shall, at all times during
the Term, be responsible for ensuring that Landlord has any and all keys, cards, codes or other means necessary to access the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">27.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Restricted Shaft Space</U></B>. Landlord further reserves the right to the areas designated as &ldquo;<B>Restricted
Shaft Space</B>&rdquo; and &ldquo;<B>Future Shaft Wall</B>&rdquo; on <B><U>Exhibit 27.3</U></B> attached hereto, within the Office
Premises for the future installation of additional shaft walls and risers for the tenants or occupants of floors beneath the applicable
floor of the Office Premises. Upon the giving of such notice, the designated areas on <B><U>Exhibit 27.3</U></B> (the &ldquo;<B>Future
Shaft Areas</B>&rdquo;) shall be treated as Common Areas. Tenant shall not make any Alterations in the Future Shaft Areas and shall
remove any of Tenant&rsquo;s property from the same upon reasonable prior notice from Landlord<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">28.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>TENANT PARKING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the Term, Landlord
shall provide Tenant with parking passes for use by standard size automobiles and small utility vehicles in an amount equal to
the number of parking passes set forth in <U>Section&nbsp;10</U> of the Summary, which parking passes shall pertain to the on-site
and/or off-site, as the case may be, parking facility (or facilities) which serve the Project. All such parking shall be on a first-come,
first-serve basis in common with others entitled to use the same. Tenant&rsquo;s continued right to use the parking passes is conditioned
upon Tenant abiding by all rules and regulations which are prescribed from time to time for the orderly operation and use of the
parking facility where the parking passes provide access (including any sticker or other identification system established by Landlord
and the prohibition of vehicle repair and maintenance activities in the parking facilities), and Tenant shall cooperate in seeing
that any Tenant Parties and Tenant visitors also comply with such rules and regulations. Tenant&rsquo;s use of the parking passes
for parking at the Project shall be at Tenant&rsquo;s sole risk and Tenant acknowledges and agrees that Landlord shall have no
liability whatsoever for damage to the vehicles of Tenant, its employees and/or visitors, or for other personal injury or property
damage or theft relating to or connected with the parking rights granted herein or any of Tenant&rsquo;s, its employees&rsquo;
and/or visitors&rsquo; use of the parking facilities. Landlord shall have the right to assign its obligations under this <U>Article&nbsp;28</U>
to an affiliate of Landlord or a third-party parking manager or operator, in which case Tenant shall make any payments due under
this <U>Article&nbsp;28</U> directly to such other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none">29.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>MISCELLANEOUS PROVISIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Terms; Captions</U></B>. The words &ldquo;<B>Landlord</B>&rdquo; and &ldquo;<B>Tenant</B>&rdquo; as used herein shall
include the plural as well as the singular. The necessary grammatical changes required to make the provisions hereof apply either
to corporations or partnerships or individuals, men or women, as the case may require, shall in all cases be assumed as though
in each case fully expressed. The captions of Articles and Sections are for convenience only and shall not be deemed to limit,
construe, affect or alter the meaning of such Articles and Sections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Binding Effect</U></B>. Subject to all other provisions of this Lease, each of the covenants, conditions and provisions
of this Lease shall extend to and shall, as the case may require, bind or inure to the benefit not only of Landlord and of Tenant,
but also of their respective heirs, personal representatives, successors or assigns, provided this clause shall not permit any
assignment by Tenant contrary to the provisions of <U>Article 14</U> of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.3<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>No Air Rights</U></B>. No rights to any view or to light or air over any property, whether belonging to Landlord
or any other person, are granted to Tenant by this Lease. If at any time any windows of the Premises are temporarily darkened
or the light or view therefrom is obstructed by reason of any repairs, improvements, maintenance or cleaning in or about the Project,
the same shall be without liability to Landlord and without any reduction or diminution of Tenant&rsquo;s obligations under this
Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.4<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Modification of Lease</U></B>. Should any current or prospective mortgagee or ground lessor for the Building or Project
require a modification of this Lease, which modification will not cause an increased cost or expense to Tenant or in any other
way adversely change the rights or obligations of Tenant hereunder, then and in such event, Tenant agrees that this Lease may be
so modified and agrees to execute whatever documents are reasonably required therefor and to deliver the same to Landlord within
ten (10) business days following a request therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.5<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Transfer of Landlord&rsquo;s Interest</U></B>. Tenant acknowledges that Landlord has the right to transfer all or
any portion of its interest in the Project or Building and in this Lease, and Tenant agrees that in the event of any such transfer,
Landlord shall automatically be released from all liability under this Lease and Tenant agrees to look solely to such transferee
for the performance of Landlord&rsquo;s obligations hereunder after the date of transfer and such transferee shall be deemed to
have fully assumed and be liable for all obligations of this Lease to be performed by Landlord and Tenant shall attorn to such
transferee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.6<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Prohibition Against Recording</U></B>. Landlord and Tenant agree not to record this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.7<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Landlord&rsquo;s Title</U></B>. Landlord&rsquo;s title is and always shall be paramount to the title of Tenant. Nothing
herein contained shall empower Tenant to do any act which can, shall or may encumber the title of Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.8<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Relationship of Parties</U></B>. Nothing contained in this Lease shall be deemed or construed by the parties hereto
or by any third party to create the relationship of principal and agent, partnership, joint venturer or any association between
Landlord and Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.9<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Application of Payments</U></B>. Landlord shall have the right to apply payments received from Tenant pursuant to
this Lease, regardless of Tenant&rsquo;s designation of such payments, to satisfy any obligations of Tenant hereunder, in such
order and amounts as Landlord, in its sole discretion, may elect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.10<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Time of Essence</U></B>. Time is of the essence with respect to the performance of every provision of this Lease in
which time of performance is a factor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.11<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Partial Invalidity</U></B>. If any term, provision or condition contained in this Lease shall, to any extent, be invalid
or unenforceable, the remainder of this Lease, or the application of such term, provision or condition to persons or circumstances
other than those with respect to which it is invalid or unenforceable, shall not be affected thereby, and each and every other
term, provision and condition of this Lease shall be valid and enforceable to the fullest extent possible permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.12<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>No Warranty</U></B>. In executing and delivering this Lease, Tenant has not relied on any representations, including,
but not limited to, any representation as to the amount of any item comprising Additional Rent or the amount of the Additional
Rent in the aggregate or that Landlord is furnishing the same services to other tenants, at all, on the same level or on the same
basis, or any warranty or any statement of Landlord which is not expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.13<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Landlord Exculpation</U></B>. The liability of Landlord or the Landlord Parties to Tenant for any default by Landlord
under this Lease or arising in connection herewith or with Landlord&rsquo;s operation, management, leasing, repair, renovation,
alteration or any other matter relating to the Project or the Premises shall be limited solely and exclusively to an amount which
is equal to the interest of Landlord in the Project. Neither Landlord, nor any of the Landlord Parties shall have any personal
liability therefor, and Tenant hereby expressly waives and releases such personal liability on behalf of itself and all persons
claiming by, through or under Tenant. The limitations of liability contained in this <U>Section&nbsp;29.13</U> shall inure to the
benefit of Landlord&rsquo;s and the Landlord Parties&rsquo; present and future partners, beneficiaries, officers, directors, trustees,
shareholders, agents and employees, and their respective partners, heirs, successors and assigns. Under no circumstances shall
any present or future partner of Landlord (if Landlord is a partnership), or trustee or beneficiary (if Landlord or any partner
of Landlord is a trust), have any liability for the performance of Landlord&rsquo;s obligations under this Lease. Notwithstanding
any contrary provision herein, neither Landlord nor the Landlord Parties shall be liable under any circumstances for consequential
or indirect damages, including without limitation injury or damage to, or interference with, Tenant&rsquo;s business, loss of profits,
loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, in each case, however occurring.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.14<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Entire Agreement</U></B>. It is understood and acknowledged that there are no oral agreements between the parties
hereto affecting this Lease and this Lease constitutes the parties&rsquo; entire agreement with respect to the leasing of the Premises
and supersedes and cancels any and all previous negotiations, arrangements, brochures, agreements and understandings, if any, between
the parties hereto or displayed by Landlord to Tenant with respect to the subject matter thereof, and none thereof shall be used
to interpret or construe this Lease. None of the terms, covenants, conditions or provisions of this Lease can be modified, deleted
or added to except in writing signed by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.15<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>REIT</U>.</B> Tenant acknowledges that the Company, an affiliate of Landlord, elects to be taxed as a real estate
investment trust (a &ldquo;<B>REIT</B>&rdquo;) under the Code. Tenant hereby agrees to modifications of this Lease required to
retain or clarify the Company&rsquo;s status as a REIT, provided such modifications: (a) are reasonable, (b) do not adversely affect
Tenant&rsquo;s use of the Premises as herein permitted or any rights or obligations of Tenant hereunder, and (c) do not increase
the Base Rent, Additional Rent and other sums to be paid by Tenant or Tenant&rsquo;s other obligations pursuant to this Lease,
or reduce any rights of Tenant under this Lease, then Landlord may submit to Tenant an amendment to this Lease incorporating such
required modifications, and Tenant shall execute, acknowledge and deliver such amendment to Landlord within ten (10) days after
Tenant&rsquo;s receipt thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.16<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Right to Lease</U></B>. Landlord reserves the absolute right to effect such other tenancies in the Project as Landlord
in the exercise of its sole business judgment shall determine to best promote the interests of the Building or Project. Tenant
does not rely on the fact, nor does Landlord represent, that any specific tenant or type or number of tenants shall, during the
Lease Term, occupy any space in the Building or Project.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.17<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Force Majeure</U></B>. Any prevention, delay or stoppage due to strikes, lockouts, labor disputes, acts of God, acts
of war, terrorist acts, governmental action or inaction, inability to obtain services, labor, or materials or reasonable substitutes
therefor, governmental actions, civil commotions, fire or other casualty, and other causes beyond the reasonable control of the
party obligated to perform, except with respect to the obligations imposed with regard to Rent and other charges to be paid by
Tenant pursuant to this Lease (collectively, a &ldquo;<B>Force Majeure</B>&rdquo;), notwithstanding anything to the contrary contained
in this Lease, shall excuse the performance of such party for a period equal to any such prevention, delay or stoppage and, therefore,
if this Lease specifies a time period for performance of an obligation of either party, that time period shall be extended by the
period of any delay in such party&rsquo;s performance caused by a Force Majeure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.18<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Notices</U></B>. All notices, demands, statements, designations, approvals or other communications (collectively,
&ldquo;<B>Notices</B>&rdquo;) given or required to be given by either party to the other hereunder or by law shall be in writing,
shall be (A) sent by United States certified or registered mail, postage prepaid, return receipt requested (&ldquo;<B>Mail</B>&rdquo;),
(B) delivered by a nationally recognized overnight courier, or (D) delivered personally. Any Notice shall be sent, transmitted,
or delivered, as the case may be, to Tenant at the appropriate address set forth in <U>Section&nbsp;11</U> of the Summary, or to
such other place as Tenant may from time to time designate in a Notice to Landlord, and to Landlord at the addresses set forth
below, or to such other places as Landlord may from time to time designate in a Notice to Tenant. Any Notice will be deemed given
the date of actual or attempted but refused or failed delivery. As of the date of this Lease, any Notices to Landlord must be sent,
transmitted, or delivered, as the case may be, to the following addresses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">San Diego Inspire 1, LLC/San Diego Inspire 2, LLC<BR>
c/o Longfellow Real Estate Partners<BR>
260 Franklin Street, Suite 1920<BR>
Boston, MA 02110<BR>
Attention: Asset Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">San Diego Inspire 1, LLC/San Diego Inspire 2, LLC<BR>
c/o Longfellow Property Management Services CA Inc.<BR>
11772 Sorrento Valley Road, Suite 250<BR>
San Diego, CA 92121<BR>
Attention: Property Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in">DLA Piper LLP (US)<BR>
401 B Street, Suite 1700<BR>
San Diego, CA 92101<BR>
Attention: Joseph&nbsp;A. Delaney, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.19<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Joint and Several</U></B>. If there is more than one Tenant, the obligations imposed upon Tenant under this Lease
shall be joint and several.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.20<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Authority</U></B>. If Tenant is a corporation, trust or partnership, Tenant hereby represents and warrants that Tenant
(a) is a duly formed and existing entity qualified to do business in the State of Nevada and is qualified as a foreign entity authorized
to do business in the State of California and (b) has full right and authority to execute and deliver this Lease, and (c) each
person signing on behalf of Tenant is authorized to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.21<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Attorneys&rsquo; Fees</U></B>. In the event that either Landlord or Tenant should bring suit for the possession of
the Premises, for the recovery of any sum due under this Lease, or because of the breach of any provision of this Lease or for
any other relief against the other, then all costs and expenses, including reasonable attorneys&rsquo; fees, incurred by the prevailing
party therein shall be paid by the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.22<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Governing Law; WAIVER OF TRIAL BY JURY</U></B>. This Lease shall be construed and enforced in accordance with the
laws of the State of California. IN ANY ACTION OR PROCEEDING ARISING HEREFROM, LANDLORD AND TENANT HEREBY CONSENT TO (I) THE JURISDICTION
OF ANY COMPETENT COURT WITHIN THE STATE OF CALIFORNIA, (II) SERVICE OF PROCESS BY ANY MEANS AUTHORIZED BY CALIFORNIA LAW, AND (III)
IN THE INTEREST OF SAVING TIME AND EXPENSE, TRIAL WITHOUT A JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY EITHER OF
THE PARTIES HERETO AGAINST THE OTHER OR THEIR SUCCESSORS IN RESPECT OF ANY MATTER ARISING OUT OF OR IN CONNECTION WITH THIS LEASE,
THE RELATIONSHIP OF LANDLORD AND TENANT, TENANT'S USE OR OCCUPANCY OF THE PREMISES, AND/OR ANY CLAIM FOR INJURY OR DAMAGE, OR ANY
EMERGENCY OR STATUTORY REMEDY. IN THE EVENT LANDLORD COMMENCES ANY SUMMARY PROCEEDINGS OR ACTION FOR NONPAYMENT OF BASE RENT OR
ADDITIONAL RENT, TENANT SHALL NOT INTERPOSE ANY COUNTERCLAIM OF ANY NATURE OR DESCRIPTION (UNLESS SUCH COUNTERCLAIM SHALL BE MANDATORY)
IN ANY SUCH PROCEEDING OR ACTION, BUT SHALL BE RELEGATED TO AN INDEPENDENT ACTION AT LAW.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.23<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Submission of Lease</U></B>. Submission of this instrument for examination or signature by Tenant does not constitute
a reservation of, option for or option to lease, and it is not effective as a lease or otherwise until execution and delivery by
both Landlord and Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.24<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Brokers</U></B>. Landlord and Tenant hereby warrant to each other that they have had no dealings with any real estate
broker or agent in connection with the negotiation of this Lease, excepting only the real estate brokers or agents specified in
<U>Section&nbsp;14</U> of the Summary (the &ldquo;<B>Brokers</B>&rdquo;), whose commissions shall be paid by Landlord, and that
they know of no other real estate broker or agent who is entitled to a commission in connection with this Lease. Each party agrees
to indemnify and defend the other party against and hold the other party harmless from any and all claims, demands, losses, liabilities,
lawsuits, judgments, costs and expenses (including without limitation reasonable attorneys&rsquo; fees) with respect to any leasing
commission or equivalent compensation alleged to be owing on account of any dealings with any real estate broker or agent, other
than the Brokers, occurring by, through, or under the indemnifying party. The terms of this <U>Section 29.24</U> shall survive
the expiration or earlier termination of the Lease Term. Landlord shall pay a commission to the Brokers pursuant to a separate
written agreement between Landlord and the Brokers<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.25<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Project or Building Name, Address and Signage</U></B>. Landlord shall have the right at any time to change the name
and/or address of the Project or Building and to install, affix and maintain any and all signs on the exterior and on the interior
of the Project or Building as Landlord may, in Landlord&rsquo;s sole discretion, desire. Tenant shall not use the name of the Project
or Building or use pictures or illustrations of the Project or Building in advertising or other publicity or for any purpose other
than as the address of the business to be conducted by Tenant in the Premises, without the prior written consent of Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.26<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Counterparts</U></B>. This Lease may be executed in counterparts with the same effect as if both parties hereto had
executed the same document. Both counterparts shall be construed together and shall constitute a single lease. Delivery by fax
or by electronic mail file attachment of any executed counterpart to this Lease will be deemed the equivalent of the delivery of
the original executed instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.27<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Intentionally Blank</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.28<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>Development of the Project</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">29.28.1<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><B>Subdivision</B>. Landlord reserves the right to subdivide all or a portion of the Building or Project. Tenant agrees
to execute and deliver, upon demand by Landlord and in the form requested by Landlord, any additional documents needed to conform
this Lease to the circumstances resulting from a subdivision and any all maps in connection therewith. Notwithstanding anything
to the contrary set forth in this Lease, the separate ownership of any buildings and/or Common Areas by an entity other than Landlord
shall not affect the calculation of Direct Expenses or Tenant&rsquo;s payment of Tenant&rsquo;s Share of Direct Expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">29.28.2<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><B>Construction of Property and Other Improvements</B>. Tenant acknowledges that portions of the Project may be under construction
following Tenant&rsquo;s occupancy of the Premises, and that such construction may result in levels of noise, dust, obstruction
of access, etc. which are in excess of that present in a fully constructed project. Tenant hereby waives any and all rent offsets
or claims of constructive eviction which may arise in connection with such construction. However, Tenant hereby acknowledges that
Landlord is currently renovating or may during the Lease Term renovate, improve, alter, or modify (collectively, the &ldquo;<B>Renovations</B>&rdquo;)
the Project, the Building and/or the Premises. Landlord shall use commercially reasonable efforts to complete any Renovations in
a manner which does not materially, adversely affect Tenant&rsquo;s use of or access to the Premises. Notwithstanding the foregoing,
Tenant hereby agrees that such Renovations shall in no way constitute a constructive eviction of Tenant nor entitle Tenant to any
abatement of Rent. Landlord shall have no responsibility and shall not be liable to Tenant for any injury to or interference with
Tenant&rsquo;s business arising from the Renovations, nor shall Tenant be entitled to any compensation or damages from Landlord
for loss of the use of the whole or any part of the Premises or of Tenant&rsquo;s personal property or improvements resulting from
the Renovations, or for any inconvenience or annoyance occasioned by such Renovations, provided that the foregoing shall not limit
Landlord&rsquo;s liability, if any, pursuant to applicable law for personal injury and property damage to the extent caused by
the gross negligence or willful misconduct of Landlord, its agents, employees or contractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.29<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>No Violation</U></B>. Tenant hereby warrants and represents that neither its execution of nor performance under this
Lease shall cause Tenant to be in violation of any agreement, instrument, contract, law, rule or regulation by which Tenant is
bound, and Tenant shall protect, defend, indemnify and hold Landlord harmless against any claims, demands, losses, damages, liabilities,
costs and expenses, including, without limitation, reasonable attorneys&rsquo; fees and costs, arising from Tenant&rsquo;s breach
of this warranty and representation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.30<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Communications and Computer Lines</U></B>. Tenant may install, maintain, replace, remove or use any communications
or computer wires and cables serving the Premises (collectively, the &ldquo;<B>Lines</B>&rdquo;), provided that Tenant shall obtain
Landlord&rsquo;s prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed), use an experienced
and qualified contractor approved in writing by Landlord, and comply with all of the other provisions of <U>Articles 7</U> and
<U>8</U> of this Lease. Tenant shall pay all costs in connection therewith. Landlord reserves the right, upon notice to Tenant
prior to the expiration or earlier termination of this Lease, to require that Tenant, at Tenant&rsquo;s sole cost and expense,
remove any Lines located in or serving the Premises (that would adversely affect any future tenant of the Premises) prior to the
expiration or earlier termination of this Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.31<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Transportation Management</U></B>. Tenant shall fully comply with all present or future mandatory governmental programs
intended to manage parking, transportation or traffic in and around the Project and/or the Building, and in connection therewith,
Tenant shall take responsible action for the transportation planning and management of all employees located at the Premises by
working directly with Landlord, any governmental transportation management organization or any other transportation-related committees
or entities. Such programs may include, without limitation: (i) restrictions on the number of peak-hour vehicle trips generated
by Tenant; (ii) increased vehicle occupancy; (iii) implementation of an in-house ridesharing program and an employee transportation
coordinator; (iv) working with employees and any Project, Building or area-wide ridesharing program manager; (v) instituting employer-sponsored
incentives (financial or in-kind) to encourage employees to rideshare; and (vi) utilizing flexible work shifts for employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.32<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B><U>Special Appurtenant Right</U></B>. Tenant shall have the right in common with others to connect to and use the following
system:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 40.5pt">(a)<I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I>100
KW emergency generator (the &ldquo;<B>Special System</B>&rdquo;) to be located adjacent to the Building (in a location as reasonably
determined by Landlord), subject to the following provisions. Landlord shall use its best efforts to cause, on or before the Rent
Commencement Date, the Special System to be installed and the Lab Premises connected to the central distribution point for the
Special System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(1) Tenant&rsquo;s use of the
Special System shall be at Tenant&rsquo;s sole risk to the extent permitted pursuant to Applicable Laws (Landlord making no representation
or warranty regarding the sufficiency of the Special System for Tenant&rsquo;s use);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(2) Tenant&rsquo;s use of the
Special System shall be undertaken by Tenant in compliance with all Applicable Laws, including Environmental Laws, and Tenant shall
obtain any and all permits required in connection with such use by Tenant (but Landlord shall obtain and maintain all required
permits (e.g., APCD permit) for the installation of the emergency generator);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(3) Landlord shall be responsible
for connecting to the central distribution point for the Special System in connection with the Tenant Improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(4) The costs to operate and
maintain the Special System shall be included in Operating Expenses. Tenant use of the Special System shall not exceed Tenant&rsquo;s
Share (i.e., ten percent (10%) since Tenant will occupy approximately ten percent (10%) of the Building) of the capacity available
to tenants of any such Special System;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(5) The use of the Special System
shall be subject to the Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(6) Tenant acknowledges and agrees,
except as expressly set forth in this Lease, that there are no warranties of any kind, whether express or implied, made by Landlord
or otherwise with respect to the Special Systems or any services (if any) provided in the Special System, and Tenant disclaims
any and all such warranties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(7) Landlord shall maintain the
Special System and any equipment connection with the Special System to Tenant&rsquo;s automatic transfer switch in good working
condition, and Landlord shall from time to time, as recommended by the manufacturer, test the operational and electrical load capacity
of the Special System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
Landlord and Tenant have caused this Lease to be executed the day and date first above written as a sealed California instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>LANDLORD</U>:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SAN DIEGO INSPIRE 1, LLC,<BR></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a Delaware limited liability company</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By:___________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify; text-indent: -15pt">Name: ______________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">Its:________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SAN DIEGO INSPIRE 2, LLC,<BR>
        a Delaware limited liability company</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:___________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify; text-indent: -15pt">Name: ______________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">Its:________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">&nbsp;</P></TD>
    <TD STYLE="width: 48%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>TENANT</U>:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AETHLON MEDICAL, INC.,<BR></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a Nevada corporation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/
        Charles
        Fisher&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify; text-indent: -15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify; text-indent: -15pt">Name:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Charles
        Fisher&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify; text-indent: -15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify; text-indent: -15pt">Its:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CEO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/
        Jim
        Frakes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">Name:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jim Frakes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">Its:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
Landlord and Tenant have caused this Lease to be executed the day and date first above written as a sealed California instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>LANDLORD</U>:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SAN DIEGO INSPIRE 1, LLC,<BR></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a Delaware limited liability company</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By: <U>/s/ Jamison Peschel</U>____________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify; text-indent: -15pt">Name:
        <U>Jamison Peschel</U>_________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">Its:<U>Authorized Signatory</U>________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SAN DIEGO INSPIRE 2, LLC,<BR>
        a Delaware limited liability company</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:<U>/s/ Jamison Peschel</U>_______________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify; text-indent: -15pt">Name:
        <U>Jamison Peschel</U>____________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">Its: <U>Authorized Signatory</U>__________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">&nbsp;</P></TD>
    <TD STYLE="width: 48%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>TENANT</U>:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AETHLON MEDICAL, INC.,<BR></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a Nevada corporation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By:<U>______________________________________</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify; text-indent: -15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify; text-indent: -15pt">Name:_________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify; text-indent: -15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30pt; text-align: justify; text-indent: -15pt">Its:___________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By:______________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">Name:_________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15pt">Its:___________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>EXHIBIT
1.1.1-1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>PREMISES</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="image_001.gif" ALT="" STYLE="height: 367px; width: 625px"></B></P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Demo
Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="image_002.gif" ALT="" STYLE="height: 362px; width: 605px"></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Conceptual
Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">***</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 1.1.1-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>EXHIBIT
1.1.1-2</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>WORK LETTER</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">Landlord at Landlord&rsquo;s sole cost (whether or not the cost estimates set forth on <B>Attachment&nbsp;#1</B>
hereto, solely for the scope of work covered thereby, are exceeded) shall (i)&nbsp;perform improvements to the Premises in accordance
with the improvements described and budgeted in <B>Attachment #1</B> hereto (the &ldquo;<B>Tenant Improvements</B>&rdquo;), in
accordance with Applicable Laws, (ii)&nbsp;cause all mechanical, plumbing, electrical, HVAC and life-safety systems serving the
Premises and the Buildings to be in good working order and condition at the time of Landlord&rsquo;s delivery of the Premises to
Tenant, (iii)&nbsp;cause all window blinds within the Office Premises to be in good working order and condition, and (iv)&nbsp;include
new interior paint and carpet within the Office Premises (collectively, &ldquo;<B>Landlord&rsquo;s Work</B>&rdquo;). Landlord shall
enter into a direct contract for Landlord&rsquo;s Work with a general contractor selected by Landlord. In addition, Landlord shall
have the right to select and approve of any subcontractors used in connection with Landlord&rsquo;s Work. Tenant acknowledges that
Landlord may complete the Landlord&rsquo;s Work for the Lab Premises prior to the Landlord&rsquo;s Work for the Office Premises.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">Landlord may, but shall not be obligated to, approve any changes to Landlord&rsquo;s Work (&ldquo;<B>Change
Orders</B>&rdquo;) that are requested by Tenant. Landlord shall have any necessary revisions to the plans for Landlord&rsquo;s
Work for a Change Order prepared at Tenant&rsquo;s sole cost and expense (provided that Landlord furnishes Tenant with a reasonable
estimate of the cost and expense thereof prior to incurring any cost or expense, and Tenant does not retract its request for such
Change Order within one (1) business day after Tenant&rsquo;s receipt of such estimate), and Tenant shall reimburse Landlord upon
demand for the cost of preparing any such revisions. In addition, Landlord shall notify Tenant in writing of Landlord&rsquo;s estimate
of the cost of completing the work set forth in the Change Orders (&ldquo;<B>Excess Cost</B>&rdquo;), which shall be subject to
Tenant&rsquo;s approval (in its sole and absolute discretion), and if Tenant fails to approve such Excess Cost within two (2) business
days; then such Change Order shall be deemed retracted by Tenant. Landlord reserves the right to require Tenant to pay to Landlord
the amount of the estimated Excess Cost before continuing with Landlord&rsquo;s Work, and any delay in the completion of Landlord&rsquo;s
Work due to a delay by Tenant in making such payment shall be deemed a Delay (as hereinafter defined). If Tenant fails to pay the
amount so demanded by Landlord within two (2) business days after such demand, Landlord reserves the right to withdraw its approval
of the applicable Change Order and to proceed with Landlord&rsquo;s Work without regard to any changes encompassed by such Change
Order. Furthermore, if upon completion of Landlord&rsquo;s Work, Landlord determines that the Excess Cost in connection with Change
Orders exceeds the amount of Excess Cost theretofore paid by Tenant to Landlord, Tenant shall, within five (5) business days after
Landlord&rsquo;s demand, pay the balance of the Excess Cost to Landlord. Subject to the notice and opportunity to cure described
in subparagraph (iv) below, any delay in Tenant&rsquo;s approval of any Change Orders or the completion of Landlord&rsquo;s Work
caused by Change Orders shall be deemed a Delay.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD STYLE="text-align: justify">If and as long as Tenant does not interfere in any way with the construction process (by causing
disharmony, scheduling or coordination difficulties, etc.), Tenant may, with prior approval of Landlord, which approval shall not
be unreasonably withheld, conditioned or delayed, and at Tenant&rsquo;s sole risk and expense, enter the Premises prior to the
Rent Commencement Date for the purpose of installing Tenant&rsquo;s movable furnishings, business fixtures and equipment. Any independent
contractor of Tenant (or any employee or agent of Tenant) performing any work in the Premises prior to the Rent Commencement Date
shall subject to the insurance provisions of the Lease. Neither Tenant nor any Tenant independent contractor shall interfere in
any way with construction of, nor damage, Landlord&rsquo;s Work or the common areas or other parts of the Project, and each shall
do all things reasonably requested by Landlord to expedite construction of Landlord&rsquo;s Work. Without limitation, Tenant shall
require each Tenant independent contractor to adjust and coordinate any work or installation in or to the Premises to meet the
schedule or requirements of other work being performed by or for Landlord throughout the Project which shall in all cases have
precedence. If Tenant or any Tenant independent contractor fails so to adjust to the schedule or requirements of Landlord, then
Landlord may immediately by notice to Tenant terminate permission previously granted to Tenant to enter the Premises prior to the
Rent Commencement Date. Neither Tenant nor any Tenant independent contractor shall cause any labor disharmony. In all events, Tenant
shall indemnify Landlord against any claim, loss or cost arising out of any interference with, or damage to, Landlord&rsquo;s Work
or any other work in the Building, or any delay thereto, or any increase in the cost thereof on account in whole or in part of
any act, omission, neglect or default by Tenant or any Tenant independent contractor. Without limiting the generality of the foregoing,
to the extent that the commencement or performance of Landlord&rsquo;s Work is delayed on account in whole or in part of any act,
omission, neglect, or default by Tenant or any Tenant independent contractor (and provided that Landlord notifies Tenant of such
potential delay in accordance with subparagraph (iv) below and Tenant fails to cure same within one (1) business day), then such
delay shall constitute a Delay (as defined below).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 1.1.1-2-<!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Any requirements of any such
Tenant independent contractor for services from Landlord or Landlord&rsquo;s Contractor, such as hoisting, electrical or mechanical
needs, shall be paid for in advance by Tenant and arranged between such Tenant independent contractor and Landlord or Landlord&rsquo;s
contractor. Should the work of any Tenant independent contractor depend on the installed field conditions of any item of Landlord&rsquo;s
Work, such Tenant independent contractor shall ascertain such field conditions after installation of such item of Landlord&rsquo;s
Work. Neither Landlord nor Landlord&rsquo;s contractor shall ever be required or obliged to alter the method, time or manner for
performing Landlord&rsquo;s Work or work elsewhere in the Project, on account of the work of any such Tenant independent contractor.
Should Landlord&rsquo;s contractor, including subcontractors working under such contractor, damage or delay the work of any Tenant
independent contractor, then such Tenant independent contractor, by entering on the Premises, shall be deemed to have agreed not
to prosecute any claim against Landlord, but shall look solely to Landlord&rsquo;s contractor (or such contractor&rsquo;s subcontractors)
that allegedly caused the damage or delay. If any such Tenant independent contractor ever makes a claim against any Indemnitee
directly, then Tenant shall indemnify such Indemnitee in the manner provided in the Lease against such claim so long as such Tenant
independent contractor&rsquo;s loss was not caused solely and directly by the negligence or willful and wrongful act of such Indemnitee.
Tenant shall cause each Tenant independent contractor performing work on the Premises to clean up regularly and remove its debris
from the Premises. If any Tenant independent contractor fails so to clean up, then Landlord may cause its contractor to clean up
and remove debris, and a Change Order shall be issued requiring Tenant to pay all actual, reasonable costs (including administrative
costs) of such cleanup and removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(iv)</TD><TD STYLE="text-align: justify">If Landlord shall be delayed in substantially completing Landlord&rsquo;s Work as a result of the
occurrence of any of the following (provided that in each such case Landlord notifies Tenant of such potential delay and Tenant
fails to cure same with one (1) business day) (a &ldquo;<B>Delay</B>&rdquo;):</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Tenant&rsquo;s failure to furnish information in accordance with this Work Letter or to respond
to any request by Landlord for any approval or information within any time period prescribed, or if no time period is prescribed,
then within two (2) business days of such request; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Tenant&rsquo;s request for materials, finishes or installations that have long lead times after
having first been informed by Landlord that such materials, finishes or installations will cause a Delay; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">A Change Order; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The performance or nonperformance by a person or entity employed by on or behalf of Tenant in the
completion of any work in the Premises (all such work and such persons or entities being subject to prior approval of Landlord);
or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Any written request by Tenant that Landlord delay the completion of any component of Landlord&rsquo;s
Work; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Tenant&rsquo;s failure to pay any amounts as and when due under this Work Letter;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">Any delay resulting from Tenant&rsquo;s having taken possession of the Premises for any reason
prior to substantial completion of Landlord&rsquo;s Work; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">Any other delay appropriately chargeable to Tenant, its agents, employees or independent contractors
and for which Landlord gives to Tenant written notice of such delay and two (2) business days&rsquo; opportunity for Tenant to
cure or resolve such delay (but any such other delay will be limited to the extent of any delay following such the two (2) business
days without any cure or resolution of such delay).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 1.1.1-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">then, for
purposes of determining the Rent Commencement Date, the date of substantial completion shall be deemed to be the day that Landlord&rsquo;s
Work would have been substantially completed absent any such Delay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(v)</TD><TD STYLE="text-align: justify">Landlord&rsquo;s Work shall be deemed to be substantially completed on the date that Landlord&rsquo;s
Work has been completed pursuant to the Plans (or would have been so completed absent any Delay), with the exception of any Punch
List Items (as defined below), and the acquisition of a certificate of occupancy or its legal equivalent allowing occupancy of
the Premises (such date &ldquo;<B>Ready For Occupancy</B>&rdquo;). &ldquo;<B>Punch List Items</B>&rdquo; shall mean only commercially
reasonable punch list items, the non-completion of which does not unreasonably interfere with Tenant's use or occupancy of the
Premises, and which punch list items shall be corrected promptly by Landlord (within thirty (30) days following Landlord's receipt
of written notice thereof from Tenant) without unreasonable interference with Tenant's use of or access to or from the Premises.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Rent Commencement Date for
the Office Premises and the Lab Premises shall be the same date, unless Tenant decides or elects to commence the conduct of its
business from either the Office Premises or the Lab Premises on an earlier date than the other. In this regard, Tenant acknowledges
and agrees that the dates upon which the Office Premises and Lab Premises are Ready For Occupancy may not be the same date, but
the Rent Commencement Date will nevertheless be the same for both the Office Premises and the Lab Premises unless Tenant commences
to conduct business from one of the Premises--either the Office Premises or Lab Premises&mdash;before the date upon which both
the Office Premises and Lab Premises are Ready For Occupancy. The adjustment of the Rent Commencement Date and, accordingly, the
postponement of Tenant&rsquo;s obligation to pay Base Rent and other sums due under the Lease shall be Tenant&rsquo;s sole remedy
that Tenant might otherwise have against Landlord by reason of the Premises not being Ready For Occupancy by Tenant on the Estimated
Delivery Date (as defined below). Landlord shall give Tenant at least ten (10) days prior written notice of the date that Landlord
reasonably anticipates that the Landlord&rsquo;s Work will be substantially complete; provided, however, Landlord&rsquo;s failure
to accurately estimate such date shall in no event affect the actual date of substantial completion or any other obligations of
Landlord or Tenant under the Lease. After the Landlord&rsquo;s Work is substantially completed and prior to Tenant&rsquo;s move-in
into the Premises, following two (2) days&rsquo; advance written notice from Tenant to Landlord, Landlord shall cause the contractor
to inspect the Premises and complete a punch list of unfinished items of the Landlord&rsquo;s Work. Authorized representatives
for Landlord and Tenant shall execute said punch list.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(vi)</TD><TD STYLE="text-align: justify">Tenant has designated James Frakes as its sole representative with respect to the matters set forth
in this Work Letter, who, until further notice to Landlord, shall have full authority and responsibility to act on behalf of Tenant
as required in this Work Letter. Landlord has designated Peter Fritz as its sole representative with respect to the matters set
forth in this Work Letter, who, until further notice to Tenant, shall have full authority and responsibility to act on behalf of
Landlord as required in this Work Letter.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(vii)</TD><TD STYLE="text-align: justify">This Work Letter shall not be deemed applicable to any additional space added to the original Premises
at any time or from time to time, whether by any options under the Lease or otherwise, or to any portion of the original Premises
or any additions to the Premises in the event of a renewal or extension of the original Lease Term, whether by any options under
the Lease or otherwise, unless expressly so provided in the Lease or any written amendment or supplement to the Lease. All capitalized
terms used in this Work Letter but not defined herein shall have the same meanings ascribed to such terms in the Lease.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 1.1.1-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Attachment #1 to</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>WORK LETTER</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 500px; width: 625px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 1.1.1-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 811px; width: 627px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 1.1.1-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_003.jpg" ALT="" STYLE="height: 811px; width: 627px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 1.1.1-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_004.jpg" ALT="" STYLE="height: 811px; width: 627px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 1.1.1-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_005.jpg" ALT="" STYLE="height: 811px; width: 627px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 1.1.1-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_006.jpg" ALT="" STYLE="height: 811px; width: 627px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 1.1.1-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_007.jpg" ALT="" STYLE="height: 811px; width: 627px"></FONT></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 1.1.1-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_008.jpg" ALT="" STYLE="height: 811px; width: 627px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 1.1.1-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>EXHIBIT
1.</U></B></FONT><B><U>3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FIRST OFFER SPACE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Suites 204 (excluding 204A) and 218 in the
11575 Building, as depicted below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_003.gif" ALT="" STYLE="height: 621px; width: 478px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Note: The Lab Premises are designated as
Suite 200 but constitute Suites 200, 201 and 203 in the above depiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 72; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 1.3-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>EXHIBIT
2.1<BR>
<BR>
form of NOTICE OF LEASE TERM DATES</U></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">To:</TD><TD STYLE="text-align: justify"><U>_______________________</U><BR>
<U>_______________________</U><BR>
<U>_______________________</U><BR>
<U>_______________________</U><BR>
<BR>
</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">Re:</TD><TD STYLE="text-align: justify">Lease dated <U>____________</U>, 20<U>__</U> between <U>____________________</U>, a _<U>____________________</U>
(&ldquo;<B>Landlord</B>&rdquo;), and <U>_______________________</U>, a _<U>______________________</U> (&ldquo;<B>Tenant</B>&rdquo;)
concerning Suite <U>______</U> on floor(s) <U>__________</U> of the building located at <B>[INSERT BUILDING ADDRESS]</B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with
the Lease (the &ldquo;<B>Lease</B>&rdquo;), we wish to advise you and/or confirm as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD>The Lease Term shall commence on or has commenced on <U>_____________</U> for a term of <U>_______________</U> ending on <U>_______________</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD>The Rent Commencement Date occurred on <U>___________</U>__..</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD>Your rent checks should be made payable to <U>__________</U> at <U>______________</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 51%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Landlord&rdquo;:</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SAN DIEGO INSPIRE 1, LLC,<BR>
        a Delaware limited liability company</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By: ________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify"><U><BR>
</U>Its: ____________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Agreed to and Accepted as<BR>
of <U>_____</U>, 20__.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Tenant&rdquo;:</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"><U><BR></U>&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">_________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">a
________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By:_______________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U><BR>
</U>Its: _______________________________</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U></U></B></FONT></P>

<!-- Field: Page; Sequence: 73; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 2.1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>EXHIBIT
5.2</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U><BR>
</U></B></FONT><B><U>RULES AND REGULATIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tenant shall faithfully
observe and comply with the following Rules and Regulations. Landlord shall not be responsible to Tenant for the nonperformance
of any of said Rules and Regulations by or otherwise with respect to the acts or omissions of any other tenants or occupants of
the Project. In the event of any conflict between the Rules and Regulations and the other provisions of this Lease, the latter
shall control. Any consent, approval or waiver required of Landlord under these rules and regulations shall not be unreasonably
withheld, conditioned or delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><BR>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><BR>
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not alter any lock or install any new or additional locks or bolts on any doors or windows of the Premises without obtaining
Landlord&rsquo;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed. If Tenant shall affix
additional locks on doors then Tenant shall furnish Landlord with copies of keys or pass cards or similar devices for said locks.
Tenant shall bear the cost of any lock changes or repairs required by Tenant. Initial keys will be furnished by Landlord for the
Premises, and any additional keys required by Tenant must be obtained from Landlord at a reasonable cost to be established by Landlord.
Upon the termination of this Lease, Tenant shall restore to Landlord all keys of stores, offices, and toilet rooms, either furnished
to, or otherwise procured by, Tenant and in the event of the loss of keys so furnished, Tenant shall pay to Landlord the cost of
replacing same or of changing the lock or locks opened by such lost key if Landlord shall deem it necessary to make such changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
doors opening to public corridors shall be kept closed at all times except for normal ingress and egress to the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord
reserves the right to close and keep locked all entrance and exit doors of the Building during such hours as are customary for
comparable buildings in the vicinity of the Building. Tenant, its employees and agents must be sure that the doors to the Building
are securely closed and locked when leaving the Premises if it is after the normal hours of business for the Building. Any tenant,
its employees, agents or any other persons entering or leaving the Building at any time when it is so locked, or any time when
it is considered to be after normal business hours for the Building, may be required to sign the Building register. Access to the
Building may be refused unless the person seeking access has proper identification or has a previously arranged pass for access
to the Building. Landlord will furnish passes to persons for whom Tenant requests same in writing. Tenant shall be responsible
for all persons for whom Tenant requests passes and shall be liable to Landlord for all acts of such persons. Landlord and its
agents shall in no case be liable for damages for any error with regard to the admission to or exclusion from the Building of any
person. In case of invasion, mob, riot, public excitement, or other commotion, Landlord reserves the right to prevent access to
the Building or the Project during the continuance thereof by any means it deems appropriate for the safety and protection of life
and property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
furniture, freight or equipment of any kind shall be brought into the Building without prior notice to Landlord. All moving activity
into or out of the Building shall be scheduled with Landlord and done only at such time and in such manner as Landlord designates.
Landlord shall have the right to prescribe the weight, size and position of all safes and other heavy property brought into the
Building and also the times and manner of moving the same in and out of the Building. Safes and other heavy objects shall, if considered
necessary by Landlord, stand on supports of such thickness as is necessary to properly distribute the weight. Landlord will not
be responsible for loss of or damage to any such safe or property in any case. Any damage to any part of the Building, its contents,
occupants or visitors by moving or maintaining any such safe or other property shall be the sole responsibility and expense of
Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
furniture, packages, supplies, equipment or merchandise will be received in the Building or carried up or down in the elevators,
except between such hours, in such specific elevator and by such personnel as shall be designated by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
requirements of Tenant will be attended to only upon application at the management office for the Project or at such office location
designated by Landlord. Employees of Landlord shall not perform any work or do anything outside their regular duties unless under
special instructions from Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 5.2-<!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
sign, advertisement, notice or handbill shall be exhibited, distributed, painted or affixed by Tenant on any part of the Premises
or the Building without the prior written consent of Landlord. Tenant shall not disturb, solicit, peddle, or canvass any occupant
of the Project and shall cooperate with Landlord and its agents of Landlord to prevent same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
toilet rooms, urinals, wash bowls and other apparatus shall not be used for any purpose other than that for which they were constructed,
and no foreign substance of any kind whatsoever shall be thrown therein. The expense of any breakage, stoppage or damage resulting
from the violation of this rule shall be borne by the tenant who, or whose servants, employees, agents, visitors or licensees shall
have caused same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discharge
of industrial sewage to the Building plumbing system shall only be permitted if Tenant, at its sole expense, shall have obtained
all necessary permits and licenses therefor, including without limitation permits from state and local authorities having jurisdiction
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not overload the floor of the Premises, nor mark, drive nails or screws, or drill into the partitions, woodwork or drywall
or in any way deface the Premises or any part thereof without Landlord&rsquo;s prior written consent; provided, however, that Landlord&rsquo;s
prior written consent shall not be required for the hanging of normal and customary office artwork and personal items. Tenant shall
not purchase spring water, ice, towel, linen, maintenance or other like services from any person or persons not included on an
approved list that Landlord shall provide to Tenant upon request. Landlord reserves the right to have Landlord&rsquo;s structural
engineer review Tenant&rsquo;s floor loads on the Building at Landlord&rsquo;s expense, unless such study reveals that Tenant has
exceeded the floor loads, in which case Tenant shall pay the cost of such survey.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
for vending machines intended for the sole use of Tenant&rsquo;s employees and invitees, no vending machine or machines other than
fractional horsepower office machines shall be installed, maintained or operated upon the Premises without the written consent
of Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not use or keep in or on the Premises, the Building, or the Project any kerosene, gasoline or other inflammable or combustible
fluid, chemical, substance or material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not without the prior written consent of Landlord use any method of heating or air conditioning other than that supplied
by Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not use, keep or permit to be used or kept, any foul or noxious gas or substance in or on the Premises, or permit or allow
the Premises to be occupied or used in a manner offensive or objectionable to Landlord or other occupants of the Project by reason
of noise, odors, or vibrations, or interfere with other tenants or those having business therein, whether by the use of any musical
instrument, radio, phonograph, or in any other way. Tenant shall not throw anything out of doors, windows or skylights or down
passageways.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not bring into or keep within the Project, the Building or the Premises any animals, birds, aquariums, or, except in areas
designated by Landlord, bicycles or other vehicles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
cooking shall be done or permitted on the Premises, nor shall the Premises be used for the storage of merchandise, for lodging
or for any improper, objectionable or immoral purposes. Notwithstanding the foregoing, Underwriters&rsquo; laboratory-approved
equipment and microwave ovens may be used in the Premises for heating food and brewing coffee, tea, hot chocolate and similar beverages
for employees and visitors, provided that such use is in accordance with all applicable federal, state, county and city laws, codes,
ordinances, rules and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Premises shall not be used for manufacturing or for the storage of merchandise except as such storage may be incidental to the
use of the Premises provided for in the Summary. Tenant shall not occupy or permit any portion of the Premises to be occupied as
an office for a messenger-type operation or dispatch office, public stenographer or typist, or for the manufacture or sale of liquor,
narcotics, or tobacco in any form, or as a medical office, or as a barber or manicure shop, or as an employment bureau without
the express prior written consent of Landlord. Tenant shall not engage or pay any employees on the Premises except those actually
working for such tenant on the Premises nor advertise for laborers giving an address at the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 5.2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Landlord
reserves the right to exclude or expel from the Project any person who, in the judgment of Landlord, is intoxicated or under the
influence of liquor or drugs, or who shall in any manner do any act in violation of any of these Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant,
its employees and agents shall not loiter in or on the entrances, corridors, sidewalks, lobbies, courts, halls, stairways, elevators,
vestibules or any Common Areas for the purpose of smoking tobacco products or for any other purpose, nor in any way obstruct such
areas, and shall use them only as a means of ingress and egress for the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not waste electricity, water or air conditioning and agrees to cooperate fully with Landlord to ensure the most effective
operation of the Building&rsquo;s heating and air conditioning system, and shall refrain from attempting to adjust any controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall store all its trash and garbage within the interior of the Premises. No material shall be placed in the trash boxes or receptacles
if such material is of such nature that it may not be disposed of in the ordinary and customary manner of removing and disposing
of trash and garbage in San Diego, California without violation of any law or ordinance governing such disposal. All trash, garbage
and refuse disposal shall be made only through entry-ways and elevators provided for such purposes at such times as Landlord shall
designate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall comply with all safety, fire protection and evacuation procedures and regulations established by Landlord or any governmental
agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
persons employed by Tenant to do janitorial work shall be subject to the prior written approval of Landlord, and while in the Building
and outside of the Premises, shall be subject to and under the control and direction of the Building manager (but not as an agent
or servant of such manager or of Landlord), and Tenant shall be responsible for all acts of such persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
awnings or other projection shall be attached to the outside walls of the Building without the prior written consent of Landlord,
and no curtains, blinds, shades or screens shall be attached to or hung in, or used in connection with, any window or door of the
Premises other than Landlord standard drapes. All electrical ceiling fixtures hung in the Premises or spaces along the perimeter
of the Building must be fluorescent and/or of a quality, type, design and a warm white bulb color approved in advance in writing
by Landlord. Neither the interior nor exterior of any windows shall be coated or otherwise sunscreened without the prior written
consent of Landlord. Tenant shall abide by Landlord&rsquo;s regulations concerning the opening and closing of window coverings
which are attached to the windows in the Premises, if any, which have a view of any interior portion of the Building or Building
Common Areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">25.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
sashes, sash doors, skylights, windows, and doors that reflect or admit light and air into the halls, passageways or other public
places in the Building shall not be covered or obstructed by Tenant, nor shall any bottles, parcels or other articles be placed
on the windowsills.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">26.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
must comply with requests by Landlord concerning the informing of their employees of items of importance to Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">27.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
smoking is permitted in the Building or on the Project. Tenant must comply with the State of California &ldquo;No-Smoking&rdquo;
law set forth in California Labor Code Section 6404.5, and any local &ldquo;No-Smoking&rdquo; ordinance which may be in effect
from time to time and which is not superseded by such state law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">28.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
hereby acknowledges that Landlord shall have no obligation to provide guard service or other security measures for the benefit
of the Premises, the Building or the Project. Tenant hereby assumes all responsibility for the protection of Tenant and its agents,
employees, contractors, invitees and guests, and the property thereof, from acts of third parties, including keeping doors locked
and other means of entry to the Premises closed, whether or not Landlord, at its option, elects to provide security protection
for the Project or any portion thereof. Tenant further assumes the risk that any safety and security devices, services and programs
which Landlord elects, in its sole discretion, to provide may not be effective, or may malfunction or be circumvented by an unauthorized
third party, and Tenant shall, in addition to its other insurance obligations under this Lease, obtain its own insurance coverage
to the extent Tenant desires protection against losses related to such occurrences. Tenant shall cooperate in any reasonable safety
or security program developed by Landlord or required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 5.2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">29.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
non-standard office equipment of any electrical or mechanical nature shall be placed by Tenant in the Premises in settings approved
by Landlord, to absorb or prevent any vibration, noise and annoyance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">30.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
shall not use in any space or in the public halls of the Building, any hand trucks except those equipped with rubber tires and
rubber side guards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">31.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
auction, liquidation, fire sale, going-out-of-business or bankruptcy sale shall be conducted in the Premises without the prior
written consent of Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">32.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
tenant shall use or permit the use of any portion of the Premises for living quarters, sleeping apartments or lodging rooms.<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Landlord reserves the right at any time
to change or rescind any one or more of these Rules and Regulations, or to make such other and further reasonable Rules and Regulations
as in Landlord&rsquo;s judgment, acting in a non-discriminatory and commercially reasonable manner, may from time to time be necessary
for the management, safety, care and cleanliness of the Premises, Building, the Common Areas and the Project, and for the preservation
of good order therein, as well as for the convenience of other occupants and tenants therein. Landlord may waive any one or more
of these Rules and Regulations for the benefit of any particular tenants, but no such waiver by Landlord shall be construed as
a waiver of such Rules and Regulations in favor of any other tenant, nor prevent Landlord from thereafter enforcing any such Rules
or Regulations against any or all tenants of the Project. Tenant shall be deemed to have read these Rules and Regulations and to
have agreed to abide by them as a condition of its occupancy of the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 77; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 5.2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>EXHIBIT
5.3.1.1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><U>ENVIRONMENTAL
QUESTIONNAIRE</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ENVIRONMENTAL QUESTIONNAIRE<BR>
FOR COMMERCIAL AND INDUSTRIAL PROPERTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Property Name:</B>_________________________________________________________________________________________<BR>
<BR>
<B>Property Address:_______________________________________________________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B><U>Instructions</U></B>: The following
questionnaire is to be completed by the Lessee representative with knowledge of the planned operations for the specified building/location.
Please print clearly and attach additional sheets as necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>1.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>PROCESS
INFORMATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Describe planned use, and include brief
description of manufacturing processes employed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_____________________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_____________________________________________________________________________________________________</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 7.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_____________________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 7.5in"><U><BR> <B>2.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HAZARDOUS
MATERIALS</B></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Are hazardous materials used or stored?
If so, continue with the next question. If not, go to <U>Section&nbsp;3.0</U>.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">2.1</TD><TD>Are any of the following materials handled on the Property?</TD>
    <TD STYLE="width: 0.5in">Yes No</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">(A material is handled if it is used, generated, processed,
produced, packaged, treated, stored, emitted, discharged, or disposed.) If so, complete this section. If this question is not applicable,
skip this section and go on to <U>Section&nbsp;5.0</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Explosives</FONT></TD>
    <TD STYLE="text-align: justify; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Fuels</FONT></TD>
    <TD STYLE="text-align: justify; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Oils</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Solvents</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Oxidizers</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Organics/Inorganics</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Acids</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Bases</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Pesticides</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Gases</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;PCBs</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Radioactive Materials</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Other (please specify)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2-2.</TD><TD>If any of the groups of materials checked in <U>Section&nbsp;2.1</U>, please list the specific material(s), use(s), and quantity
of each chemical used or stored on the site in the Table below. If convenient, you may substitute a chemical inventory and list
the uses of each of the chemicals in each category separately.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 78; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 5.3.1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: Black 1.5pt double; border-bottom: Black 1.5pt double; border-left: Black 1.5pt double; border-right: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Material</B></FONT></TD>
    <TD STYLE="border-top: Black 1.5pt double; border-right: Black 1pt solid; border-bottom: Black 1.5pt double; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Physical State (Solid, Liquid, or Gas)</B></FONT></TD>
    <TD STYLE="border-top: Black 1.5pt double; border-right: Black 1pt solid; border-bottom: Black 1.5pt double; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Usage</B></FONT></TD>
    <TD STYLE="border-top: Black 1.5pt double; border-right: Black 1pt solid; border-bottom: Black 1.5pt double; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Container Size</B></FONT></TD>
    <TD STYLE="border-top: Black 1.5pt double; border-right: Black 1pt solid; border-bottom: Black 1.5pt double; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Containers</B></FONT></TD>
    <TD STYLE="border-top: Black 1.5pt double; border-right: Black 1.5pt double; border-bottom: Black 1.5pt double; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Quantity</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1.5pt double; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1.5pt double; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1.5pt double; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1.5pt double; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1.5pt double; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1.5pt double; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1.5pt double; border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1.5pt double; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1.5pt double; border-bottom: Black 1.5pt double; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; border-right: Black 1.5pt double; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">2-3.</TD>
    <TD>Describe the planned
storage area location(s) for these materials. Please include site maps and drawings as appropriate.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_____________________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_____________________________________________________________________________________________________</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 7.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_____________________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>3.0</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>HAZARDOUS
WASTES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD>Are hazardous wastes generated?</TD>
    <TD STYLE="width: 0.5in">Yes No</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If yes, continue with the next question.
If not, skip this section and go to <U>Section&nbsp;4.0</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.1</TD><TD>Are any of the following wastes generated, handled, or disposed of (where applicable) on the Property?</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Hazardous wastes</FONT></TD>
    <TD STYLE="text-align: justify; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Industrial Wastewater</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Waste oils</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;PCBs</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Air emissions</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Sludges</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Regulated Wastes</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Other (please specify)</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3-2.</TD><TD>List and quantify the materials identified in Question&nbsp;3-1 of this section.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WASTE GENERATED</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RCRA listed Waste?</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SOURCE</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>APPROXIMATE MONTHLY QUANTITY</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WASTE CHARACTERIZATION</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DISPOSITION</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0"></TD>
    <TD STYLE="width: 0.5in">3-3</TD>
    <TD>Please include name,
location, and permit number (e.g. EPA ID No.) for transporter and disposal facility, if applicable). Attach separate pages as necessary.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transporter/Disposal Facility Name</B></FONT></TD>
    <TD STYLE="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Facility Location</B></FONT></TD>
    <TD STYLE="width: 37%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transporter (T) or Disposal (D) Facility</B></FONT></TD>
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Permit Number</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%"></TD>
    <TD STYLE="width: 0.5in">3-4.</TD>
    <TD>Are pollution controls or monitoring employed in the process to prevent or minimize the release of wastes into the environment?</TD>
    <TD STYLE="width: 0.5in">Yes
No</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 5.3.1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3-5.</TD><TD>If so, please describe.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">_____________________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_____________________________________________________________________________________________________</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 7.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_____________________________________________________________________________________________________</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"><B>4.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>USTS/ASTS</U></B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.1</TD><TD>Are underground storage tanks (USTs), aboveground storage tanks (ASTs), or associated pipelines used for the storage of petroleum
products, chemicals, or liquid wastes present on site (lease renewals) or required for planned operations (new tenants)?&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Yes___&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No___</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If not, continue with <U>Section&nbsp;5.0</U>. If
yes, please describe capacity, contents, age, type of the USTs or ASTs, as well any associated leak detection/spill prevention
measures. Please attach additional pages if necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Capacity</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Contents</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Year Installed</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Type (Steel, Fiberglass, etc.)</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Associated Leak Detection / Spill Prevention Measures<SUP>*</SUP></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><SUP>&nbsp;</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><SUP>*</SUP>Note:&nbsp;&nbsp;&nbsp;&nbsp;The
following are examples of leak detection / spill prevention measures:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Integrity testing</FONT></TD>
    <TD STYLE="text-align: justify; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Inventory reconciliation</FONT></TD>
    <TD STYLE="text-align: justify; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Leak detection system</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Overfill spill protection</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Secondary containment</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cathodic protection</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4-2.</TD><TD>Please provide copies of written tank integrity test results and/or monitoring documentation, if available.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">4-3.</TD><TD>Is the UST/AST registered and permitted with the appropriate regulatory agencies?<BR>
If so, please attach a copy of the required permits.</TD>
    <TD STYLE="width: 0.5in">Yes No</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4-4.</TD><TD>If this Questionnaire is being completed for a lease renewal, and if any of the USTs/ASTs have leaked, please state the substance
released, the media(s) impacted (e.g., soil, water, asphalt, etc.), the actions taken, and all remedial responses to the incident.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 7.5in"><U><BR></U></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">_____________________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_____________________________________________________________________________________________________</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 7.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_____________________________________________________________________________________________________</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%"></TD>
    <TD STYLE="width: 0.5in">4-5.</TD>
    <TD>If this Questionnaire is being completed for a lease renewal, have USTs/ASTs been removed from the Property?</TD>
    <TD STYLE="width: 0.5in">Yes No</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If yes, please provide any official closure letters
or reports and supporting documentation (e.g., analytical test results, remediation report results, etc.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 0%"></TD>
    <TD STYLE="width: 0.5in">4-6.</TD>
    <TD>For Lease renewals, are there any above or below ground pipelines on site used to transfer chemicals or wastes?</TD>
    <TD STYLE="width: 0.5in">Yes No</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD>
    <TD>&nbsp;</TD>
    <TD>For new tenants, are installations of this type required
for the planned operations?</TD>
    <TD>Yes No</TD></TR>
</TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 5.3.1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If yes to either question, please describe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 7.5in"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">_____________________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_____________________________________________________________________________________________________</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 7.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_____________________________________________________________________________________________________</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>5.0</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>ASBESTOS
CONTAINING BUILDING MATERIALS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please be advised that an asbestos survey
may have been performed at the Property. If provided, please review the information that identifies the locations of known asbestos
containing material or presumed asbestos containing material. All personnel and appropriate subcontractors should be notified of
the presence of these materials, and informed not to disturb these materials. Any activity that involves the disturbance or removal
of these materials must be done by an appropriately trained individual/contractor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>6.0</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>REGULATORY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%"></TD>
    <TD STYLE="width: 0.5in">6-1.</TD>
    <TD>Does the operation have or require a National Pollutant Discharge Elimination System (NPDES) or equivalent permit?</TD>
    <TD STYLE="width: 0.5in">Yes No</TD></TR>
<TR STYLE="vertical-align: top">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD>If so, please attach a copy of this permit.</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%"></TD>
    <TD STYLE="width: 0.5in">6-2.</TD>
    <TD>a Hazardous Materials Business Plan been developed for the site?</TD>
    <TD STYLE="width: 0.5in">Yes No</TD></TR>
<TR STYLE="vertical-align: top">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD>If so, please attach a copy.</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CERTIFICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I am familiar with the real property described
in this questionnaire. By signing below, I represent and warrant that the answers to the above questions are complete and accurate
to the best of my knowledge. I also understand that Lessor will rely on the completeness and accuracy of my answers in assessing
any environmental liability risks associated with the property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">Signature:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_________________________________</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;__________________________________</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;__________________________________</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;__________________________________</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Telephone:&nbsp;&nbsp;__________________________________</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 5.3.1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>EXHIBIT
17</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SOVA Science District</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>FORM
OF TENANT&rsquo;S ESTOPPEL CERTIFICATE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned as
Tenant under that certain Lease (the &ldquo;<B>Lease</B>&rdquo;) made and entered into as of _<U>__________</U>, 20<U>_ &nbsp;</U>
by and between <U>_______________</U> as Landlord, and the undersigned as Tenant, for Premises on the ______________ floor(s) of
the office building located at <B>[INSERT BUILDING ADDRESS]</B>, San Diego, California, certifies as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attached
hereto as <B><U>Exhibit&nbsp;A</U></B> is a true and correct copy of the Lease and all amendments and modifications thereto. The
documents contained in <B><U>Exhibit&nbsp;A</U></B> represent the entire agreement between the parties as to the Premises.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned currently occupies the Premises described in the Lease, the Lease Term commenced on <U>__________</U>, and the Lease
Term expires on <U>___________</U>, and the undersigned has no option to terminate or cancel the Lease or to purchase all or any
part of the Premises, the Building and/or the Project, except as expressly set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Base
Rent became payable on <U>____________</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Lease is in full force and effect and has not been modified, supplemented or amended in any way except as provided in <B><U>Exhibit&nbsp;A</U></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tenant
has not transferred, assigned, or sublet any portion of the Premises nor entered into any license or concession agreements with
respect thereto except as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intentionally
Omitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
monthly installments of Base Rent, all Additional Rent and all monthly installments of estimated Additional Rent have been paid
when due through <U>___________</U>. The current monthly installment of Base Rent is $<U>_____________________</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the best of the undersigned&rsquo;s knowledge, all conditions of the Lease to be performed by Landlord necessary to the enforceability
of the Lease have been satisfied and Landlord is not in default thereunder. In addition, the undersigned has not delivered any
notice to Landlord regarding a default by Landlord thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
rental has been paid more than thirty (30) days in advance and no security has been deposited with Landlord except as provided
in the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date hereof, to the undersigned&rsquo;s knowledge, there are no existing defenses or offsets or claims or any basis for
a claim, that the undersigned has against Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Tenant is a corporation or partnership, each individual executing this Estoppel Certificate on behalf of Tenant hereby represents
and warrants that Tenant is a duly formed and existing entity qualified to do business in California and that Tenant has full right
and authority to execute and deliver this Estoppel Certificate and that each person signing on behalf of Tenant is authorized to
do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no actions pending against the undersigned under the bankruptcy or similar laws of the United States or any state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the undersigned&rsquo;s knowledge, (a)&nbsp;all tenant improvement work to be performed by Landlord under the Lease has been completed
in accordance with the Lease and has been accepted by the undersigned and all reimbursements and allowances due to the undersigned
under the Lease in connection with any tenant improvement work have been paid in full and (b)&nbsp;all work (if any) in the common
areas required by the Lease to be completed by Landlord has been completed and all parking spaces required by the Lease have been
furnished and/or all parking ratios required by the Lease have been met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 82; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 17-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned acknowledges
that this Estoppel Certificate may be delivered to Landlord or to a prospective mortgagee or prospective purchaser, and acknowledges
that said prospective mortgagee or prospective purchaser will be relying upon the statements contained herein in making the loan
or acquiring the property of which the Premises are a part and that receipt by it of this certificate is a condition of making
such loan or acquiring such property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Executed at <U>______________</U>
on the <U>____ </U>day of <U>___________</U>, 20<U>__</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&ldquo;Tenant&rdquo;:</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.75in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">___________________________________________,<BR>
a __________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By: ________________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify"><U><BR>
</U>Its: ____________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20pt; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">By:
________________________________________</P>
        <P STYLE="margin: 0pt 0 0pt 20pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><U><BR>
</U>Its: ____________________________________</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 17-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>EXHIBIT
21.1<BR></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U></U></B><U>FORM LETTER OF CREDIT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note: Landlord acknowledges that (i)
Tenant intends to use First Republic Bank as the issuer of the Letter of Credit, and (ii) Landlord has reviewed and approved a
proposed form of Letter of Credit to be issued by First Republic Bank.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IRREVOCABLE STANDBY LETTER OF CREDIT NO. ______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DATE: _______________, 20___</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BENEFICIARY:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">______________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">______________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">______________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">APPLICANT:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">______________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">______________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">______________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AMOUNT: US$__________________ ($___________and 00/100 U.S. DOLLARS)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EXPIRATION DATE: _______________, 20____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LOCATION: AT OUR COUNTERS IN ____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 21.1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DEAR SIR/MADAM:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WE HEREBY ESTABLISH
OUR IRREVOCABLE STANDBY LETTER OF CREDIT NO. <U>________________</U> IN YOUR FAVOR AVAILABLE BY YOUR DRAFT IN THE FORM OF &ldquo;ANNEX
1&rdquo; ATTACHED DRAWN ON US AT SIGHT AND ACCOMPANIED BY THE FOLLOWING DOCUMENTS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A DATED STATEMENT SIGNED BY AN AUTHORIZED
OFFICER OF THE BENEFICIARY READING AS FOLLOWS:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WE
ARE ENTITLED TO DRAW ON THE LETTER OF CREDIT PURSUANT TO THE TERMS OF THAT CERTAIN LEASE BY AND BETWEEN <U>_______________</U>,
AS LANDLORD, AND _____________________, AS TENANT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.25pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.25pt; text-align: center">OR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.25pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_<U>________________</U>
HEREBY CERTIFIES THAT IT HAS RECEIVED NOTICE FROM <U>_____________ </U>THAT THE LETTER OF CREDIT NO. <U>___________</U> WILL NOT
BE RENEWED, AND THAT IT HAS NOT RECEIVED A REPLACEMENT OF THIS LETTER OF CREDIT FROM <U>________________________</U> SATISFACTORY
TO <U>_________________</U> AT LEAST FORTY-FIVE (45) DAYS PRIOR TO THE EXPIRATION DATE OF THIS LETTER OF CREDIT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THE LEASE MENTIONED
IN THIS LETTER OF CREDIT IS FOR IDENTIFICATION PURPOSES ONLY AND IT IS NOT INTENDED THAT SAID AGREEMENT BE INCORPORATED HEREIN
OR FORM PART OF THIS LETTER OF CREDIT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">DRAFT(S) AND DOCUMENTS
MUST INDICATE THE NUMBER AND DATE OF THIS LETTER OF CREDIT. PARTIAL DRAWINGS ARE PERMITTED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS LETTER OF CREDIT
SHALL BE AUTOMATICALLY EXTENDED FOR AN ADDITIONAL PERIOD OF ONE YEAR, WITHOUT AMENDMENT OR CONDITION, FROM THE PRESENT OR EACH
FUTURE EXPIRATION DATE UNLESS AT LEAST FORTY-FIVE (45) DAYS PRIOR TO THE THEN CURRENT EXPIRATION DATE WE NOTIFY YOU AND THE APPLICANT
BY REGISTERED MAIL/OVERNIGHT COURIER SERVICE AT THE ABOVE ADDRESSES THAT THIS LETTER OF CREDIT WILL NOT BE EXTENDED BEYOND THE
CURRENT EXPIRATION DATE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS LETTER OF CREDIT
MAY BE TRANSFERRED (AND THE PROCEEDS HEREOF ASSIGNED), AT THE EXPENSE OF THE APPLICANT (WHICH PAYMENT SHALL NOT BE A CONDITION
TO ANY TRANSFER), ONE OR MORE TIMES BUT IN EACH INSTANCE ONLY IN THE FULL AMOUNT AVAILABLE TO BE DRAWN UNDER THE LETTER OF CREDIT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ALL DEMANDS FOR PAYMENT
SHALL BE MADE BY PRESENTATION OF THE DATED CERTIFICATION PRIOR TO <U>______</U> A.M. <U>____________</U> TIME, ON A BUSINESS DAY
AT OUR OFFICE (THE &ldquo;BANK&rsquo;S OFFICE&rdquo;) AT: <U>_________________________________</U>, ATTENTION: STANDBY LETTER OF
CREDIT SECTION OR BY FACSIMILE TRANSMISSION AT: (<U>___</U>) <U>_____________</U>; AND SIMULTANEOUSLY UNDER TELEPHONE ADVICE TO:
(<U>___</U>) <U>__________</U>, ATTENTION: STANDBY LETTER OF CREDIT NEGOTIATION SECTION WITH ORIGINALS TO FOLLOW BY OVERNIGHT COURIER
SERVICE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">PAYMENT AGAINST CONFORMING
PRESENTATIONS HEREUNDER SHALL BE MADE BY BANK IN IMMEDIATELY AVAILABLE U.S. FUNDS DURING NORMAL BUSINESS HOURS OF THE BANK&rsquo;S
OFFICE WITHIN TWO (2) BUSINESS DAYS AFTER PRESENTATION NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THE UNIFORM CUSTOMS AND PRACTICE
FOR DOCUMENTARY CREDITS (1997 REVISION), INTERNATIONAL CHAMBER OF COMMERCE, PUBLICATION NO. 600.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WE HEREBY CERTIFY THAT
THIS IS AN UNCONDITIONAL AND IRREVOCABLE CREDIT AND AGREE WITH THE DRAWERS, ENDORSERS AND BONAFIDE HOLDERS THAT THE DRAFTS DRAWN
UNDER AND IN ACCORDANCE WITH THE TERMS AND CONDITIONS OF THIS LETTER OF CREDIT SHALL BE DULY HONORED UPON PRESENTATION TO THE DRAWEE,
IF NEGOTIATED ON OR BEFORE THE EXPIRATION DATE OF THIS CREDIT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">EXCEPT TO THE EXTENT
INCONSISTENT WITH THE EXPRESS TERMS HEREOF, THIS LETTER OF CREDIT IS SUBJECT TO THE UNIFORM CUSTOMS AND PRACTICE FOR DOCUMENTARY
CREDITS (1997 REVISION), INTERNATIONAL CHAMBER OF COMMERCE, PUBLICATION NO. 600.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">______________________________</TD>
    <TD STYLE="width: 50%">______________________________</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>AUTHORIZED SIGNATURE</TD>
    <TD>AUTHORIZED SIGNATURE</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 21.1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>ANNEX 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<DIV STYLE="padding: 1pt 24pt 1pt 28pt; border: Black 4.5pt double">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.25in"><B>BILL OF EXCHANGE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.25in">DATE:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">AT&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
SIGHT OF THIS BILL OF EXCHANGE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">PAY TO THE ORDER OF __________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">US ___________________________DOLLARS (US $________________)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>DRAWN UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>CREDIT NUMBER NO.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DATED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>T</B>O:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>...............................................................</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Authorized Signature</B></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 21.1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXHIBIT &ldquo;A&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DATE:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 40%">TO: _________________________</TD>
    <TD STYLE="width: 5%">RE:</TD>
    <TD STYLE="width: 55%">STANDBY LETTER OF CREDIT</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_________________________</TD>
    <TD>&nbsp;</TD>
    <TD>NO.________________</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>ISSUED BY __________________</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LADIES AND GENTLEMEN:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">FOR VALUE RECEIVED, THE UNDERSIGNED BENEFICIARY
HEREBY IRREVOCABLY TRANSFERS TO:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 30%">(NAME OF TRANSFEREE)</TD>
    <TD STYLE="width: 70%">______________________________________</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>(ADDRESS)</TD>
    <TD>______________________________________</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>______________________________________</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ALL RIGHTS OF THE UNDERSIGNED
BENEFICIARY TO DRAW UNDER THE ABOVE LETTER OF CREDIT UP TO ITS AVAILABLE AMOUNT AS SHOWN ABOVE AS OF THE DATE OF THIS TRANSFER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">BY THIS TRANSFER, ALL
RIGHTS OF THE UNDERSIGNED BENEFICIARY IN SUCH LETTER OF CREDIT ARE TRANSFERRED TO THE TRANSFEREE. TRANSFEREE SHALL HAVE THE SOLE
RIGHTS AS BENEFICIARY THEREOF, INCLUDING SOLE RIGHTS RELATING TO ANY AMENDMENTS, WHETHER INCREASES OR EXTENSIONS OR OTHER AMENDMENTS,
AND WHETHER NOW EXISTING OR HEREAFTER MADE. ALL AMENDMENTS ARE TO BE ADVISED DIRECT TO THE TRANSFEREE WITHOUT NECESSITY OF ANY
CONSENT OF OR NOTICE TO THE UNDERSIGNED BENEFICIARY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THE ORIGINAL OF SUCH
LETTER OF CREDIT IS RETURNED HEREWITH, AND WE ASK YOU TO ENDORSE THE TRANSFER ON THE REVERSE THEREOF, AND</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FORWARD IT DIRECTLY
TO THE TRANSFEREE WITH YOUR CUSTOMARY NOTICE OF TRANSFER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">SINCERELY,</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">SIGNATURE AUTHENTICATED</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">_____________________________</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">________________________________________</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(BENEFICIARY&rsquo;S NAME) </FONT></TD>
    <TD STYLE="padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Name of Bank)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">_____________________________</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">________________________________________</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;SIGNATURE OF BENEFICIARY</FONT></TD>
    <TD STYLE="padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(authorized signature)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 21.1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>EXHIBIT 27.3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>Restricted Shaft Space</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_004.gif" ALT="" STYLE="height: 361px; width: 711px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note: Two (2) Future Shaft Areas are depicted (marked by an
elongated x) along the exterior wall within the Premises</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 88; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">Exhibit 27.3-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>aethlon_ex1004.htm
<DESCRIPTION>EIGHTH AMENDMENT TO STANDARD INDUSTRIAL NET LEASE BETWEEN SAN DIEGO INSPIRE 1, LLC AND AETHLON MEDICAL, INC.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 10.4</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0.5in">eighth
AMENDMENT TO STANDARD INDUSTRIAL NET lease<BR>
BETWEEN<BR>
SAN DIEGO INSPIRE 1, LLC<BR>
AND<BR>
AETHLON MEDICAL, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS EIGHTH AMENDMENT
TO STANDARD INDUSTRIAL NET LEASE</B> (this &ldquo;<B>Eighth Amendment</B>&rdquo;) is dated as of November&nbsp;9, 2020, by and
between <B>SAN DIEGO INSPIRE&nbsp;1, LLC</B>, a Delaware limited liability company (&ldquo;<B>Landlord</B>&rdquo;), and <B>AETHLON
MEDICAL, INC.</B>, a Nevada corporation (&ldquo;<B>Tenant</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">RECITALS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Landlord (as successor-in-interest to AGP Sorrento Business Complex, L.P., a Delaware limited partnership, who, in turn,
is successor-in-interest to Sorrento Business Complex, a California limited partnership) and Tenant are parties to that certain
Standard Industrial Net Lease dated as of September&nbsp;28, 2009 (the &ldquo;<B>Original Lease</B>&rdquo;), as amended by that
certain (i) First Amendment to Standard Industrial Net Lease dated as of October&nbsp;4, 2011 (the &ldquo;<B>First Amendment</B>&rdquo;),
(ii) Second Amendment to Standard Industrial Net Lease dated as of October&nbsp;10, 2014 (the &ldquo;<B>Second Amendment</B>&rdquo;),
(iii)&nbsp;Third Amendment to Standard Industrial Net Lease dated as of October&nbsp;21, 2015 (the &ldquo;<B>Third Amendment</B>&rdquo;),
(iv) Fourth Amendment to Standard Industrial Net Lease dated as of October&nbsp;5, 2016 (the &ldquo;<B>Fourth Amendment</B>&rdquo;),
(v) Fifth Amendment to Standard Industrial Net Lease dated October&nbsp;16, 2017 (the &ldquo;<B>Fifth Amendment</B>&rdquo;), (vi)
Sixth Amendment to Standard Industrial Net Lease dated September&nbsp;18, 2018 (the &ldquo;<B>Sixth Amendment</B>&rdquo;), and
(vi) Seventh Amendment to Standard Industrial Net Lease dated September&nbsp;9, 2019 (the &ldquo;<B>Seventh Amendment</B>&rdquo;)
(all such lease amendments together with the Original Lease, hereinafter simply the &ldquo;<B>Lease</B>&rdquo;), with respect to
certain premises containing approximately 1,703 rentable square feet (the &ldquo;<B>Existing Premises</B>&rdquo;) identified as
Suite 109 in that certain building located at 11585 Sorrento Valley Road, San Diego, California 92121 (the &ldquo;<B>Building</B>&rdquo;),
which is part of a larger complex known as Inspire&nbsp;1 consisting of the Building and other buildings (the &ldquo;<B>Project</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">B.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Pursuant to the Seventh Amendment, the Expiration Date was previously extended from December&nbsp;1, 2019 to November&nbsp;30,
2020 (such extended term referred to in the Seventh Amendment as the &ldquo;<B>Seventh Amendment Extended Term</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">C.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Contemporaneously with this Eighth Amendment, Landlord and Tenant have executed and delivered a certain new lease (the &ldquo;<B>New
Lease</B>&rdquo;) whereby Landlord is leasing to Tenant, and Tenant is leasing from Landlord, certain premises consisting of approximately
(i)&nbsp;2,833 rentable square feet in the building located at 11555 Sorrento Valley Road, San Diego, California 92121, and a Building,
and (ii)&nbsp;1,807 rentable square feet in the building located at 11575 Sorrento Valley Road, San Diego, California 92121 (collectively,
the &ldquo;<B>New Premises</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">D.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Landlord and Tenant now desire to amend the Lease to extend the Lease Term until the New Premises are Ready for Occupancy
(as defined in the New Lease) so that Tenant may relocate from the Existing Premises to the New Premises and modify other provisions
of the Lease, all as more particularly set forth herein. Landlord and Tenant estimate that the Lease Term will be extended approximately
seven (7) months in order to afford Landlord time to build out the New Premises as contemplated by the New Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>,
in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, Landlord and Tenant agree that the Lease is amended as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><U>Defined Terms</U></FONT></B>.
Capitalized terms used and not otherwise defined herein shall have the same meanings ascribed to them in the Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><FONT STYLE="font-variant: small-caps"><U>Term of the Lease</U></FONT></B>. Effective as of the date hereof,
the Lease Term is hereby extended to the date upon which the New Premises are Ready for Occupancy (which period may be referred
to as the &ldquo;<B>Eighth Amendment Extended Term</B>&rdquo;) so that the Eighth Amendment Extended Term shall commence December&nbsp;1,
2020 and expire unless terminated sooner pursuant to the terms of the Existing Lease, on the date four (4) days after the New Premises
are Ready for Occupancy (the &ldquo;<B>Eighth Amendment Extended Expiration Date</B>&rdquo;). All references to &ldquo;<B>Lease
Term</B>&rdquo; in the Lease and this Eighth Amendment shall be deemed references to the Lease Term as extended by this Eighth
Amendment and all references to &ldquo;<B>Expiration Date</B>&rdquo; shall be deemed references to the Eighth Amendment Extended
Expiration Date. Tenant shall not have any right to extend the Lease Term beyond the Eighth Amendment Extended Expiration Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><U>Condition of the Premises</U></FONT></B>.
Landlord shall have no obligation whatsoever to construct leasehold improvements for Tenant or to repair or refurbish the Premises.
Tenant hereby agrees to continue to accept the Premises in its &ldquo;<B>AS IS</B>&rdquo; condition, and Tenant hereby acknowledges
that the Premises is suited for the use intended by Tenant and is in good and satisfactory condition as of the date of this Amendment.
Tenant acknowledges that neither Landlord nor Landlord&rsquo;s agents has made any representation or warranty as to the condition
of the Premises or the Building or its suitability for Tenant&rsquo;s purposes. Tenant represents and warrants to Landlord that
(a)&nbsp;its sole intended use of the Premises is for uses set forth in <U>Section 1.8</U> of the Original Lease, and (b)&nbsp;it
does not intend to use the Premises for any other purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><U>Base Rent</U></FONT></B>.
In addition to Additional Rent and all other costs and expenses payable by Tenant pursuant to the Lease, Tenant shall pay the following
Minimum Monthly Rent (as defined in the Lease) for the Premises during the Eighth Amendment Extended Term in accordance with the
terms of <U>Article&nbsp;4</U> of the Original Lease:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #D9D9D9">
    <TD STYLE="width: 33%; border: Black 1pt solid; text-align: center"><B>EIGHTH AMENDMENT EXTENDED TERM</B></TD>
    <TD STYLE="width: 35%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><B>MINIMUM MONTHLY INSTALLMENT OF <BR>
&nbsp;RENT</B></TD>
    <TD STYLE="width: 32%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><B>MINIMUM MONTHLY RENT PER RENTABLE SQUARE FOOT</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center">12/1/2020 &ndash; 6/30/21 (estimated)</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">$6,147.83</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center">$3.61</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><U>Additional Rent</U></FONT></B>.
During the Eighth Amendment Extended Term and in addition to the monthly Base Rent set forth in <U>Section&nbsp;4</U> of this Eighth
Amendment, Tenant shall continue to pay all Additional Rent for the Premises, including without limitation, Tenant&rsquo;s Share
of Operating Costs in accordance with the terms of Article&nbsp;6 of the Original Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><U>Security Deposit</U></FONT></B>.
Tenant has previously deposited with Landlord the sum of Three Thousand Two Hundred Fifty Dollars and Sixty-Five Cents ($3,250.65)
as a Security Deposit under the Lease. Landlord shall continue to hold such Security Deposit during the Eighth Amendment Extended
Term in accordance with the terms and conditions of <U>Article&nbsp;5</U> of the Original Lease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><U>Address for Rent Payment</U></FONT></B>.
<U>Section 4.5</U> of the Original Lease is hereby amended and restated as follows: Tenant shall make all payments of Minimum Monthly
Rent, Additional Rent and other amounts due under the Lease in immediately available funds or by wire transfer of funds. Such payments
all be initiated by Tenant to an account designated from time to time by Landlord no later than 12:00 noon, San Diego, California
time on the date such sums or payments are respectively due. Any payment received after such time shall be deemed to have been
made after the due date. Tenant shall use the following address for rent payments:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: left">San Diego Inspire&nbsp;1, LLC<BR>
P.O. Box 894412<BR>
Los Angeles, CA 90189-4412</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: left">Or Tenant may wire rent payments to:<BR>
<BR>
Citibank NA, New York<BR>
Account Name: San Diego Inspire Holdings, LLC<BR>
Account Number: 6794041847<BR>
Routing Number: 021000089<BR>
Origin is outside the U.S.: Swift code CITIUS33</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><U>Address</U></FONT></B>.
<U>Section&nbsp;1.1</U> and <U>Section&nbsp;24.19</U> of the Original Lease are hereby amended to provide that notices to Landlord
shall be given at the following addresses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Address of Landlord</U>:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 60%; padding-left: 8.25pt">SAN DIEGO INSPIRE 1, LLC<BR>
c/o Longfellow Real Estate Partners<BR>
260 Franklin Street, Suite 1920<BR>
Boston, MA 02110<BR>
Attn:&nbsp;&nbsp;Asset Management</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 7.9pt"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">With copies to:<BR> <BR> San Diego Inspire 1, LLC<BR> c/o Longfellow Property Management Services CA Inc.<BR> 11772 Sorrento Valley Rd., Suite 250<BR> San Diego, CA 92121<BR> Attn:&nbsp;&nbsp;Property Management</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><U>Brokers</U></FONT></B>.
Tenant represents and warrants to Landlord that it has not engaged any broker, finder or other person who would be entitled to
any commission or fees in respect of the negotiation, execution or delivery of this Eighth Amendment, other than Newmark of Southern
California, Inc., dba Newmark Knight Frank (&ldquo;<B>Newmark Knight Frank</B>&rdquo;) serving exclusively as Landlord&rsquo;s
agent and JLL Life Sciences Group (&ldquo;<B>JLL</B>&rdquo;) serving exclusively as Tenant&rsquo;s agent and whose commissions
shall be paid by Landlord pursuant to a separate agreement based on the New Lease and without any commissions attributable to this
Eight Amendment. Tenant shall indemnify, defend and hold harmless Landlord against any loss, cost, liability or expense incurred
by Landlord as a result of any claim asserted by any broker (other than Newmark Knight Frank and JLL), finder or other person on
the basis of any arrangements or agreements made or alleged to have been made by or on behalf of Tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><U>Disclosures and Utility
Usage Information</U></FONT></B>. For purposes of Section 1938(a) of the California Civil Code, Landlord hereby discloses to Tenant,
and Tenant hereby acknowledges, that the Premises have not undergone inspection by a Certified Access Specialist (CASp). As required
by Section 1938(e) of the California Civil Code, Landlord hereby states as follows: &ldquo;<B>A Certified Access Specialist (CASp)
can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related
accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial
property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the
occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree
on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost
of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.&rdquo;</B>
In furtherance of the foregoing, Landlord and Tenant hereby agree as follows: (a) any CASp inspection requested by Tenant shall
be conducted, at Tenant&rsquo;s sole cost and expense, by a CASp designated by Landlord, subject to Landlord&rsquo;s reasonable
rules and requirements; (b) Tenant, at its sole cost and expense, shall be responsible for making any improvements or repairs within
the Premises to correct violations of construction-related accessibility standards; and (c) if anything done by or for Tenant in
its use or occupancy of the Premises shall require any improvements or repairs to the Building or the Center (outside the Premises)
to correct violations of construction-related accessibility standards, then Tenant shall reimburse Landlord upon demand, as Additional
Rent, for the cost to Landlord of performing such improvements or repairs. If Tenant is billed directly by a public utility with
respect to Tenant&rsquo;s electrical usage at the Premises, upon request, Tenant shall provide monthly electrical utility usage
for the Premises to Landlord for the period of time requested by Landlord (in electronic or paper format) or, at Landlord&rsquo;s
option, provide any written authorization or other documentation required for Landlord to request information regarding Tenant&rsquo;s
electricity usage with respect to the Premises directly from the applicable utility company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><U>Continuing Effectiveness</U></FONT></B>.
The Lease, except as amended hereby, remains unamended, and, as amended hereby, remains in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><U>Counterparts</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">.
</FONT>This Eighth Amendment may be executed in counterparts, each of which shall constitute an original, and all of which, together,
shall constitute one document. Either party may execute this Eighth Amendment using electronic signature technology (i.e., via
DocuSign or other electronic signature technology) or by such party&rsquo;s signature transmitted by facsimile (&ldquo;<B>fax</B>&rdquo;)
or email. Copies of this Eighth Amendment executed and delivered by means of faxed or emailed signatures shall have the same force
and effect as copies hereof executed and delivered with original signatures. All parties hereto may rely upon faxed or emailed
signatures as if such signatures were originals. All parties hereto agree that a faxed or emailed signature page may be introduced
into evidence in any proceeding arising out of or related to this Eighth Amendment as if it were an original signature page.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><U>Execution by Both Parties</U></FONT></B>.
Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option to lease, and
it is not effective as an amendment to lease or otherwise until execution by and delivery to both Landlord and Tenant, and execution
and delivery hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><U>No Further Modification</U></FONT></B>.
Except as set forth in this Eighth Amendment, all of the terms and provisions of the Lease shall remain unmodified and in full
force and effect. This Eighth Amendment contains the entire understanding between the parties with respect to the matters contained
herein. In the event of any conflict between the terms and conditions of the Lease and the terms and conditions of this Eighth
Amendment, the terms and conditions of this Eighth Amendment shall prevail. No representations, warranties, covenants or agreements
have been made concerning or affecting the subject matter of this Eighth Amendment, except as are contained herein and in the Lease.
This Eighth Amendment may not be changed orally, but only by an agreement in writing signed by the party against whom enforcement
of any waiver, change or modification or discharge is sought.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase"><B>15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><U>Authorization</U></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps">.</FONT>
The parties signing on behalf of Tenant each hereby represents and warrants that such party has the capacity set forth on the signature
pages hereof and has full power and authority to bind Tenant to the terms hereof. Two (2) authorized officers must sign on behalf
of the Tenant and this Amendment must be executed by the president or vice-president and the secretary or assistant secretary of
Tenant, unless the bylaws or a resolution of the board of directors shall otherwise provide. In such case, the bylaws or a certified
copy of the resolution of Tenant, as the case may be, must be furnished to Landlord.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(SIGNATURES ON NEXT PAGE)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF,
</B>the parties hereto have executed this Eighth Amendment as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="text-transform: uppercase"><B>&ldquo;landlord&rdquo;</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>SAN DIEGO INSPIRE 1, LLC,<BR>
        </B>a Delaware limited liability company</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By: <I><U>/s/ Jamison Peschel&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></I><U></U><BR></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Print Name: <U>Jamison Peschel&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title: <U>Authorized Signatory&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P></TD>
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&ldquo;<B>TENANT&rdquo;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>AETHLON MEDICAL, INC.</B>,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">a Nevada corporation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By: <I><U>/s/ Charles Fisher&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></I><BR>
<BR>
Print Name: <U>Charles Fisher&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
<BR>
Title: <U>CEO&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">By: <I><U>/s/ Jim Frakes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></I><BR>
<BR>
Print Name: <U>Jim Frakes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><BR>
<BR>
Title: <U>Chief Financial Officer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>4
<FILENAME>aethlon_ex1005.htm
<DESCRIPTION>EXECUTIVE EMPLOYMENT AGREEMENT - CIPRIANI
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 10.5</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>AETHLON
MEDICAL, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>EXECUTIVE
</B></FONT><B>EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>for</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GUY F. CIPRIANI</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Executive Employment
Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of January 1, 2020 (the &ldquo;<B>Effective Date</B>&rdquo;),
by and between <B>Guy F. Cipriani</B> (&ldquo;<B>Employee</B>&rdquo;) and Aethlon Medical, Inc. (the &ldquo;<B>Company</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Employment by the Company.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Start Date and Position.</B> Employee&rsquo;s employment with the Company shall begin on January 4, 2020 or such date as
otherwise agreed to by Employee and the Company (such actual date employment begins (the &ldquo;<B>Start Date</B>&rdquo;)). Employee
shall serve as the Company&rsquo;s Senior Vice President, Chief Business Officer, reporting to the Chief Executive Officer. During
the term of Employee&rsquo;s employment with the Company, Employee will devote Employee&rsquo;s best efforts and substantially
all of Employee&rsquo;s business time and attention to the business of the Company, except for as permitted in <U>Section 4.1</U>
below and except for approved vacation periods and reasonable periods of illness or other incapacities permitted by the Company&rsquo;s
general employment policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Duties and Location.</B> Employee shall perform such duties as are customarily associated with the position of Senior Vice
President, Chief Business Officer and such other duties as are assigned to Employee by the Company. Employee&rsquo;s primary office
location will be initially be Employee&rsquo;s residence in Bellingham, Washington; provided that Employee will be required to
relocate to and primarily work at the Company&rsquo;s office located in San Diego, California by no later than September 1, 2021
(or such other time as mutually agreed between Employee and the CEO). Subject to the terms of this Agreement, the Company reserves
the right to (i) reasonably require Employee to perform Employee&rsquo;s duties at places other than Employee&rsquo;s primary office
location from time to time and to require reasonable business travel, and (ii) modify Employee&rsquo;s job title and duties as
it deems necessary and appropriate in light of the Company&rsquo;s needs and interests from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Board of Directors. </B>Employee will continue to serve as a director on the Company&rsquo;s Board of Directors (&ldquo;<B><I>Board</I></B>&rdquo;)
until such time the Company engages a new independent director, or earlier if requested by the Company. Employee agrees that, upon
the Company&rsquo;s request, Employee will resign from the Board and take all steps necessary to effectuate such resignation from
the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Policies and Procedures.</B> The employment relationship between the parties shall be governed by the general employment
policies and practices of the Company, except that when the terms of this Agreement differ from or are in conflict with the Company&rsquo;s
general employment policies or practices, this Agreement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Compensation</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Base Salary.</B> For services to be rendered hereunder, Employee shall receive a base salary at the rate of $340,000 per
year, less standard payroll deductions and withholdings and payable in accordance with the Company&rsquo;s regular payroll schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Annual Bonus. </B>Employee will be eligible for an annual discretionary bonus with a target amount of 40% of Employee&rsquo;s
then-current annual base salary (the &ldquo;<B>Annual Bonus</B>&rdquo;). Whether Employee receives an Annual Bonus for any given
year, and the amount of any such Annual Bonus, will be determined in the discretion of the Board (or the Compensation Committee
thereof), based upon the Company&rsquo;s and Employee&rsquo;s achievement of objectives and milestones to be determined on an annual
basis by the Board (or Compensation Committee thereof). No Annual Bonus is guaranteed and, in addition to the other conditions
for earning such compensation, Employee must remain an employee in good standing of the Company on the scheduled Annual Bonus payment
date in order to be eligible for any Annual Bonus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Relocation Assistance. </B>Subject to Employee&rsquo;s relocation to San Diego, California by no later than September 1,
2021, Employee will be eligible to receive relocation benefits as specified herein (the &ldquo;<B><I>Relocation Assistance</I></B>&rdquo;).
The Relocation Assistance is provided subject to the terms of the Company&rsquo;s reimbursement policies and procedures. Employee
will be reimbursed an aggregate amount of up to $75,000 of relocation expenses, including, without limitation, reimbursement for
documented moving expenses, temporary housing costs and commuting costs, and for the selling commission and closing costs in connection
with the sale of Employee&rsquo;s current residence that Employee incurs, which will become payable to Employee in accordance with
the Company&rsquo;s reimbursement policies and procedures. The taxable relocation costs pursuant to this paragraph shall be &ldquo;grossed
up&rdquo; to compensate Employee in full for taxes incurred on such costs. If Employee&rsquo;s employment terminates under any
circumstances other than due to Employee&rsquo;s resignation for Good Reason or a termination without Cause by the Company, Employee
agrees to repay to the Company, within thirty (30) days of Employee&rsquo;s employment termination date: (i) 100% of the the Relocation
Assistance if such termination occurs before the first anniversary of the Start Date, and (ii) 50% of the gross amount of the Relocation
Assistance if such termination occurs before the second anniversary of the Start Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Standard Company Benefits.</B> Employee shall, in accordance with Company policy and the terms and conditions of the applicable
Company benefit plan documents, be eligible to participate in the benefit, fringe, and retirement benefit programs provided by
the Company to its executive employees from time to time. Any such benefits shall be subject to the terms and conditions of the
governing benefit plans and policies and may be changed by the Company in its discretion. To the extent Employee is not eligible
for the Company&rsquo;s healthcare benefits on the Start Date, Company will reimburse Employee for the cost of COBRA to maintain
his healthcare benefits from his prior employer until such time as Employee is eligible for the Company&rsquo;s benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>2.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Expenses. </B>The Company will reimburse Employee for reasonable travel, entertainment or other expenses incurred by Employee
in furtherance or in connection with the performance of Employee&rsquo;s duties hereunder, in accordance with the Company&rsquo;s
expense reimbursement policy as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>2.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Equity; Change in Control Acceleration. </B>Subject to approval by the Board, under the Company&rsquo;s 2020 Equity Incentive
Plan (the &ldquo;<B>Plan</B>&rdquo;), the Company will grant Employee an option to purchase 120,883 shares (the &ldquo;<B>Option</B>&rdquo;)
of the Company&rsquo;s Common Stock, at fair market value as determined by the Board as of the date of grant. The Option will be
subject to the terms and conditions of the Plan and Employee&rsquo;s Option grant agreement. Employee&rsquo;s Option grant agreement
will include a four-year vesting schedule, under which 25% of Employee&rsquo;s shares will vest after twelve months of employment,
with the remaining shares vesting monthly thereafter, subject to Employee&rsquo;s continuous service with the Company on each such
vesting date. Notwithstanding anything to the contrary set forth in the Plan, any prior equity incentive plans or any award agreement,
effective upon consummation of a Change in Control (as defined under the Plan), the vesting and exercisability of all unvested
time-based vesting equity awards then held by Employee shall accelerate such that all shares subject to the Option, and any additional
unvested time-based equity awards granted to Employee, shall become immediately vested and exercisable by Employee upon such Change
in Control and shall remain exercisable, if applicable, following the Change in Control, as set forth in the applicable equity
award documents. With respect to any performance-based vesting equity award, such award, if any, shall continue to be governed
in all respects by the terms of the applicable equity award documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Confidential Information Obligations</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Confidential Information Agreement.</B> As a condition of employment, Employee shall execute and abide by the Company&rsquo;s
standard form of Confidential Information and Invention Assignment Agreement (the &ldquo;<B>Confidential Information Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Third-Party Agreements and Information.</B> Employee represents and warrants that Employee&rsquo;s employment by the Company
does not conflict with any prior employment or consulting agreement or other agreement with any third party, and that Employee
will perform Employee&rsquo;s duties to the Company without violating any such agreement. Employee represents and warrants that
Employee does not possess confidential information arising out of prior employment, consulting, or other third party relationships,
that would be used in connection with Employee&rsquo;s employment by the Company, except as expressly authorized by that third
party. During Employee&rsquo;s employment by the Company, Employee will use in the performance of Employee&rsquo;s duties only
information that is generally known and used by persons with training and experience comparable to Employee&rsquo;s own, common
knowledge in the industry, otherwise legally in the public domain, or obtained or developed by the Company or by Employee in the
course of Employee&rsquo;s work for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Outside Activities and Non-Competition During Employment</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Outside Activities.</B> During Employee&rsquo;s employment with the Company, Employee may engage in civic and not-for-profit
activities so long as such activities do not interfere with the performance of Employee&rsquo;s duties hereunder or present a conflict
of interest with the Company or its affiliates. Subject to the restrictions set forth herein, and only with prior written disclosure
to and consent of the Board, Employee may engage in other types of business or public activities. The Board may rescind such consent,
if the Board determines, in its sole discretion, that such activities compromise or threaten to compromise the Company&rsquo;s
or its affiliates&rsquo; business interests or conflict with Employee&rsquo;s duties to the Company or its affiliates. Employee
and Company agree that Employee may from time to time provide consulting services to his former employer, Microbion Corporation.
Such consulting services to Microbion Corporation are anticipated to constitute five (5) hours or less of Employee&rsquo;s time
on a monthly basis. Such consulting services shall not interfere, individually or in the aggregate, with the performance of Employee&rsquo;s
obligations, duties and responsibilities hereunder or under the Confidential Information Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Non-Competition During Employment.</B> During Employee&rsquo;s employment with the Company, Employee will not, without the
express written consent of the Board, directly or indirectly serve as an officer, director, stockholder, employee, partner, proprietor,
investor, joint ventures, associate, representative or consultant of any person or entity engaged in, or planning or preparing
to engage in, business activity competitive with any line of business engaged in (or planned to be engaged in) by the Company or
its affiliates; provided, however, that Employee may purchase or otherwise acquire up to (but not more than) one percent (1%) of
any class of securities of any enterprise (without participating in the activities of such enterprise) if such securities are listed
on any national or regional securities exchange. In addition, Employee will be subject to certain restrictions (including restrictions
continuing after Employee&rsquo;s employment ends) under the terms of the Confidential Information Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Termination of Employment; Severance Benefits</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At-Will Employment.</B> Employee&rsquo;s employment relationship is at-will. Either Employee or the Company may terminate
the employment relationship at any time, with or without Cause (as defined below) or advance notice. Upon termination of Employee&rsquo;s
employment for any reason, Employee shall resign from all positions and terminate any relationships as an employee, advisor, officer
or director with the Company and any of its affiliates, each effective on the employment termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Termination Without Cause or Resignation for Good Reason. </B>In the event Employee&rsquo;s employment with the Company
is terminated by the Company without Cause (and other than as a result of Employee&rsquo;s death or disability) or Employee resigns
for Good Reason, then provided such termination constitutes a &ldquo;separation from service&rdquo; (as defined under Treasury
Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a &ldquo;<B>Separation from Service</B>&rdquo;),
and provided that Employee satisfies the Release Requirement in <U>Section 6</U> below, and remains in compliance with the terms
of this Agreement and the Confidential Information Agreement, the Company shall provide Employee with the following severance benefits
(collectively, the &ldquo;<B>Severance Benefits</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Severance Payments</B>. Severance pay in the form of continuation of Employee&rsquo;s final monthly base salary for a period
of twelve (12) months following termination, subject to required payroll deductions and tax withholdings (the &ldquo;<B>Severance
Payments</B>&rdquo;). Subject to <U>Section 7</U> below, the Severance Payments shall be made on the Company&rsquo;s regular payroll
schedule in effect following Employee&rsquo;s employment termination date; provided, however that any such payments that are otherwise
scheduled to be made prior to the Release Effective Date (as defined below) shall instead accrue and be made on the first regular
payroll date following the Release Effective Date. For such purposes, Employee&rsquo;s final base salary will be calculated prior
to giving effect to any reduction in base salary that would give rise to Employee&rsquo;s right to resign for Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Health Care Continuation Coverage Payments. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>COBRA Premiums. </B>If Employee timely elects continued coverage under COBRA, the Company will pay Employee&rsquo;s COBRA
premiums to continue Employee&rsquo;s coverage (including coverage for Employee&rsquo;s eligible dependents, if applicable) (&ldquo;<B>COBRA
Premiums</B>&rdquo;) through the period starting on the employment termination date and ending twelve (12) months after the employment
termination date (the &ldquo;<B>COBRA Premium Period</B>&rdquo;); provided, however, that the Company&rsquo;s provision of such
COBRA Premium benefits will immediately cease if during the COBRA Premium Period Employee becomes eligible for group health insurance
coverage through a new employer or Employee ceases to be eligible for COBRA continuation coverage for any reason, including plan
termination. In the event Employee becomes covered under another employer&rsquo;s group health plan or otherwise ceases to be eligible
for COBRA during the COBRA Premium Period, Employee must immediately notify the Company of such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Special Cash Payments in Lieu of COBRA Premiums</B>. Notwithstanding the foregoing, if the Company determines, in its sole
discretion, that it cannot pay the COBRA Premiums without potentially incurring financial costs or penalties under applicable law
(including, without limitation, Section 2716 of the Public Health Service Act), regardless of whether Employee or Employee&rsquo;s
dependents elect or are eligible for COBRA coverage, the Company instead shall pay to Employee, on the first day of each calendar
month following the employment termination date, a fully taxable cash payment equal to the applicable COBRA premiums for that month
(including the amount of COBRA premiums for Employee&rsquo;s eligible dependents), subject to applicable tax withholdings (such
amount, the &ldquo;<B>Special Cash Payment</B>&rdquo;), for the remainder of the COBRA Premium Period. Employee may, but is not
obligated to, use such Special Cash Payments toward the cost of COBRA premiums or toward premium costs under an individual health
plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Termination for Cause; Resignation Without Good Reason; Death or Disability. </B>Employee will not be eligible for, or entitled
to any severance benefits, including (without limitation) the Severance Benefits listed in <U>Section 5.2</U> above, if the Company
terminates Employee&rsquo;s employment for Cause, Employee resigns Employee&rsquo;s employment without Good Reason, or Employee&rsquo;s
employment terminates due to Employee&rsquo;s death or disability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Conditions to Receipt of Severance Benefits. </B>To be eligible for the Severance Benefits pursuant to <U>Section 5.2</U>
above, Employee must satisfy the following release requirement (the &ldquo;<B>Release Requirement</B>&rdquo;): return to the Company
a signed and dated general release of all known and unknown claims in a termination agreement acceptable to the Company (the &ldquo;<B>Release</B>&rdquo;)
within the applicable deadline set forth therein, but in no event later than forty-five (45) calendar days following Employee&rsquo;s
employment termination date, and permit the Release to become effective and irrevocable in accordance with its terms (such effective
date of the Release, the &ldquo;<B>Release Effective Date</B>&rdquo;). No Severance Benefits will be paid hereunder prior to the
Release Effective Date. Accordingly, if Employee breaches the preceding sentence and/or refuses to sign and deliver to the Company
an executed Release or signs and delivers to the Company the Release but exercises Employee&rsquo;s right, if any, under applicable
law to revoke the Release (or any portion thereof), then Employee will not be entitled to any severance, payment or benefit under
this Agreement. Employee shall also resign from all positions and terminate any relationships as an employee, advisor, officer
or director with the Company and any of its affiliates, each effective on the employment termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 409A. </B>It is intended that all of the severance benefits and other payments payable under this Agreement satisfy,
to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1(b)(4),
1.409A-1(b)(5) and 1.409A-1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those
provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that
complies with Section 409A. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation
Section 1.409A-2(b)(2)(iii)), Employee&rsquo;s right to receive any installment payments under this Agreement (whether severance
payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each
installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to
the contrary in this Agreement, if Employee is deemed by the Company at the time of Employee&rsquo;s Separation from Service to
be a &ldquo;specified employee&rdquo; for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon Separation
from Service set forth herein and/or under any other agreement with the Company are deemed to be &ldquo;deferred compensation&rdquo;,
then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution
under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided to
Employee prior to the earliest of (i) the expiration of the six-month and one day period measured from the date of Employee&rsquo;s
Separation from Service with the Company, (ii) the date of Employee&rsquo;s death or (iii) such earlier date as permitted under
Section 409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable
Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section shall be paid in a lump sum to Employee, and
any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due
on any amounts so deferred. If the Company determines that any severance benefits provided under this Agreement constitutes &ldquo;deferred
compensation&rdquo; under Section 409A, for purposes of determining the schedule for payment of the severance benefits, the effective
date of the Release will not be deemed to have occurred any earlier than the sixtieth (60th) date following the Separation From
Service, regardless of when the Release actually becomes effective. In addition to the above, to the extent required to comply
with Section 409A and the applicable regulations and guidance issued thereunder, if the applicable deadline for Employee to execute
(and not revoke) the applicable Release spans two calendar years, payment of the applicable severance benefits shall not commence
until the beginning of the second calendar year. To the extent required to avoid accelerated taxation and/or tax penalties under
Code Section 409A, amounts reimbursable to Employee under this Agreement shall be paid to Employee on or before the last day of
the year following the year in which the expense was incurred and the amount of expenses eligible for reimbursement (and in-kind
benefits provided to Employee) during any one year may not effect amounts reimbursable or provided in any subsequent year. The
Company makes no representation that any or all of the payments described in this Agreement will be exempt from or comply with
Code Section 409A and makes no undertaking to preclude Code Section 409A from applying to any such payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Definitions</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>8.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Cause</B>. For purposes of this Agreement, &ldquo;<B>Cause</B>&rdquo; means the occurrence of any one or more of the following:
(i) Employee&rsquo;s conviction of or plea of guilty or <I>nolo contendere</I> to any felony or a crime of moral turpitude; (ii)
Employee&rsquo;s willful and continued failure or refusal to follow lawful and reasonable instructions of the Board and/or the
Company or lawful and reasonable policies and regulations of the Company or its affiliates; (iii) Employee&rsquo;s willful and
continued failure to faithfully and diligently perform the assigned duties of Employee&rsquo;s employment with the Company or its
affiliates; (iv) unprofessional, unethical, immoral or fraudulent conduct by Employee; (v) conduct by Employee that materially
discredits the Company or any affiliate or is materially detrimental to the reputation, character and standing of the Company or
any affiliate; or (vi) Employee&rsquo;s material breach of this Agreement, the Confidential Information Agreement, or any applicable
Company policies. An event described in <U>Section 8.1(ii)</U> through <U>Section 8.1(vi)</U> herein shall not be treated as &ldquo;Cause&rdquo;
until after Employee has been given written notice of such event, failure, conduct or breach and Employee fails to cure such event,
failure, conduct or breach within 30 calendar days from such written notice; provided, however, that such 30-day cure period shall
not be required if the event, failure, conduct or breach is incapable of being cured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>8.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Good Reason.</B> For purposes of this Agreement, Employee shall have &ldquo;<B>Good Reason</B>&rdquo; for resignation from
employment with the Company if any of the following actions are taken by the Company without Employee&rsquo;s prior written consent:
(i) a material reduction in Employee&rsquo;s base salary, unless pursuant to a salary reduction program applicable generally to
the Company&rsquo;s senior executives; (ii) a material reduction in Employee&rsquo;s duties (including responsibilities and/or
authorities), provided, however<I>, </I>that a change in job position (including a change in title) or reporting line shall not
be deemed a &ldquo;material reduction&rdquo; in and of itself unless Employee&rsquo;s new duties are materially reduced from the
prior duties; or (iii) relocation of Employee&rsquo;s principal place of employment to a place that increases Employee&rsquo;s
one-way commute by more than fifty (50) miles as compared to Employee&rsquo;s then-current principal place of employment immediately
prior to such relocation, provided, however, that Employee&rsquo;s relocation from Bellingham, Washington to San Diego, California
as contemplated in <U>Section 1.2</U> will not be considered a relocation of Employee&rsquo;s principal place of employment with
the Company for purposes of this definition). In order for Employee to resign for Good Reason, each of the following requirements
must be met: (iv) Employee must provide written notice to the Board within 30 calendar days after the first occurrence of the event
giving rise to Good Reason setting forth the basis for Employee&rsquo;s resignation, (v) Employee must allow the Company at least
30 calendar days from receipt of such written notice to cure such event, (vi) such event is not reasonably cured by the Company
within such 30 calendar day period (the &ldquo;<B>Cure Period</B>&rdquo;), and (vii) Employee must resign from all positions Employee
then holds with the Company not later than 30 calendar days after the expiration of the Cure Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Dispute Resolution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>9.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Agreement to Arbitrate</B>. To ensure the timely and economical resolution of disputes that may arise between Employee and
the Company, both Employee and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. &sect;1-16, and
to the fullest extent permitted by applicable law, Employee and the Company will submit solely to final, binding and confidential
arbitration any and all disputes, claims, or causes of action arising from or relating to: <B>(i)</B> the negotiation, execution,
interpretation, performance, breach or enforcement of this Agreement; or <B>(ii)</B> Employee&rsquo;s employment with the Company
(including but not limited to all statutory claims); or <B>(iii)</B> the termination of Employee&rsquo;s employment with the Company
(including but not limited to all statutory claims). <FONT STYLE="text-transform: uppercase"><B>By agreeing to this arbitration
procedure, both EMPLOYEE and the Company waive the right to resolve any such disputes through a trial by jury or judge or through
an administrative proceeding.</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>9.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Arbitrator Authority</B>. The arbitrator shall have the sole and exclusive authority to determine whether a dispute, claim
or cause of action is subject to arbitration under this Section and to determine any procedural questions which grow out of such
disputes, claims or causes of action and bear on their final disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>9.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Individual Capacity Only</B>. All claims, disputes, or causes of action under this Section, whether by Employee or the Company,
must be brought solely in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any
purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity.&nbsp;&nbsp;
The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative
or class proceeding.&nbsp; To the extent that the preceding sentences in this Section are found to violate applicable law or are
otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than
by arbitration.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>9.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Arbitration Process</B>. Any arbitration proceeding under this Section shall be presided over by a single arbitrator and
conducted by Judicial Arbitration and Mediation Services, Inc. (&ldquo;<B>JAMS</B>&rdquo;) in San Diego, California, or as otherwise
agreed to by Employee and the Company, under the then applicable JAMS rules for the resolution of employment disputes (available
upon request and also currently available at&nbsp;<U>http://www.jamsadr.com/rules-employment-arbitration/</U>).&nbsp;&nbsp;Employee
and the Company both have the right to be represented by legal counsel at any arbitration proceeding, at each party&rsquo;s own
expense.&nbsp;&nbsp;The arbitrator shall: <B>(i)</B> have the authority to compel adequate discovery for the resolution of the
dispute; <B>(ii)</B> issue a written arbitration decision, to include the arbitrator&rsquo;s essential findings and conclusions
and a statement of the award; and <B>(iii)</B> be authorized to award any or all remedies that Employee or the Company would be
entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the amount of court fees that
would be required of Employee if the dispute were decided in a court of law.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>9.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Excluded Claims</B>. This Section shall not apply to any action or claim that cannot be subject to mandatory arbitration
as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004,
as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent
such claims are not permitted by applicable law to be submitted to mandatory arbitration and such applicable law is not preempted
by the Federal Arbitration Act or otherwise invalid (collectively, the &ldquo;<B>Excluded Claims</B>&rdquo;). In the event Employee
intends to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court,
while any other claims will remain subject to mandatory arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>9.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Injunctive Relief and Final Orders</B>. Nothing in this Section is intended to prevent either Employee or the Company from
obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award
in any arbitration proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction
and enforced accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>General Provisions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>10.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notices.</B> Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery
(including personal delivery by fax) or the next day after sending by overnight carrier, to the Company at its primary office location
and to Employee at the address as listed on the Company payroll.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>10.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Severability.</B> Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect
under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other
provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent
possible in keeping with the intent of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>10.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Waiver.</B> Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall
not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>10.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Complete Agreement.</B> This Agreement, together with the Confidential Information Agreement, constitutes the entire agreement
between Employee and the Company with regard to the subject matter hereof and is the complete, final, and exclusive embodiment
of the Company&rsquo;s and Employee&rsquo;s agreement with regard to this subject matter. This Agreement is entered into without
reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes, extinguishes,
and replaces in their entirety all other or prior agreements, whether oral or written, with respect to Employee&rsquo;s employment
compensation, benefits, and terms with the Company or its affiliates or predecessors. It cannot be modified or amended except in
a writing signed by a duly authorized member of the Board, with the exception of those changes expressly reserved to the Company&rsquo;s
discretion in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>10.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Counterparts.</B> This Agreement may be executed in separate counterparts, any one of which need not contain signatures
of more than one party, but both of which taken together will constitute one and the same Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>10.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Headings.</B> The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute
a part hereof nor to affect the meaning thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>10.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Successors and Assigns.</B> This Agreement is intended to bind and inure to the benefit of and be enforceable by Employee
and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Employee may not assign
any of Employee&rsquo;s duties hereunder and Employee may not assign any of Employee&rsquo;s rights hereunder without the written
consent of the Company, which shall not be withheld unreasonably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>10.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Tax Withholding. </B>All payments and awards contemplated or made pursuant to this Agreement will be subject to withholdings
of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Employee acknowledges
and agrees that the Company has neither made any assurances nor any guarantees concerning the tax treatment of any payments or
awards contemplated by or made pursuant to this Agreement. Employee has had the opportunity to retain a tax and financial advisor
and fully understands the tax and economic consequences of all payments and awards made pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>10.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Choice of Law.</B> All questions concerning the construction, validity and interpretation of this Agreement will be governed
by the laws of the State of California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>10.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Conditions Precedent. </B>This offer is subject to satisfactory proof of Employee&rsquo;s identity and right to work in
the United States and other applicable pre-employment screenings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[<B><I><U>Signature Page
to Follow</U></I></B>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>In
Witness Whereof</B></FONT>, the Parties have executed this Agreement to become effective as of the Effective Date written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><B>AETHLON MEDICAL, INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>By: <U>/s/ Charles J. Fisher, Jr.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt">Charles J. Fisher, Jr., MD</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt">Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><B>EMPLOYEE</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Signature: <U>/s/ Guy F. Cipriani&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 40pt">Guy F. Cipriani</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>5
<FILENAME>aethlon_ex1006.htm
<DESCRIPTION>EXECUTIVE EMPLOYMENT AGREEMENT - LAROSA
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 10.6</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>AETHLON
MEDICAL, INC. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>EXECUTIVE
</B></FONT><B>EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>for</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>STEVEN P. LAROSA, MD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Executive Employment
Agreement (this &ldquo;<B>Agreement</B>&rdquo;) is made and entered into as of January 4, 2021 (the &ldquo;<B>Effective Date</B>&rdquo;),
by and between <B>Steven P. LaRosa, MD</B> (&ldquo;<B>Employee</B>&rdquo;) and Aethlon Medical, Inc. (the &ldquo;<B>Company</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Employment by the Company.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Start Date and Position.</B> Employee&rsquo;s employment with the Company shall begin on January 4, 2021 or such date as
otherwise agreed to by Employee and the Company (such actual date employment begins (the &ldquo;<B>Start Date</B>&rdquo;)). Employee
shall serve as the Company&rsquo;s Chief Medical Officer, reporting to the Chief Executive Officer. During the term of Employee&rsquo;s
employment with the Company, Employee will devote Employee&rsquo;s best efforts and substantially all of Employee&rsquo;s business
time and attention to the business of the Company, except for as permitted in Section 7.1 below and except for approved vacation
periods and reasonable periods of illness or other incapacities permitted by the Company&rsquo;s general employment policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Duties and Location.</B> Employee shall perform such duties as are customarily associated with the position of Chief Medical
Officer and such other duties as are assigned to Employee by the Company. Employee&rsquo;s primary office location will be initially
be Employee&rsquo;s residence in Boston, Massachusetts; provided that Employee will be required to relocate to and primarily work
at the Company&rsquo;s office located in San Diego, California by no later than September 1, 2021 (or such other time as mutually
agreed between Employee and the Company). Subject to the terms of this Agreement, the Company reserves the right to (i) reasonably
require Employee to perform Employee&rsquo;s duties at places other than Employee&rsquo;s primary office location from time to
time and to require reasonable business travel, and (ii) modify Employee&rsquo;s job title and duties as it deems necessary and
appropriate in light of the Company&rsquo;s needs and interests from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Policies and Procedures.</B> The employment relationship between the parties shall be governed by the general employment
policies and practices of the Company, except that when the terms of this Agreement differ from or are in conflict with the Company&rsquo;s
general employment policies or practices, this Agreement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Compensation</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Base Salary.</B> For services to be rendered hereunder, Employee shall receive a base salary at the rate of $400,000 per
year, less standard payroll deductions and withholdings and payable in accordance with the Company&rsquo;s regular payroll schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Annual Bonus. </B>Employee will be eligible for an annual discretionary bonus with a target amount of 40% of Employee&rsquo;s
then-current annual base salary (the &ldquo;<B>Annual Bonus</B>&rdquo;). Whether Employee receives an Annual Bonus for any given
year, and the amount of any such Annual Bonus, will be determined in the discretion of the Company&rsquo;s Board of Director&rsquo;s
(or the Compensation Committee thereof) (the &ldquo;<B><I>Board</I></B>&rdquo;), based upon the Company&rsquo;s and Employee&rsquo;s
achievement of objectives and milestones to be determined on an annual basis by the Board (or Compensation Committee thereof).
No Annual Bonus is guaranteed and, in addition to the other conditions for earning such compensation, Employee must remain an employee
in good standing of the Company on the scheduled Annual Bonus payment date in order to be eligible for any Annual Bonus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Relocation Assistance. </B>Subject to Employee&rsquo;s relocation to San Diego, California by no later than September 1,
2021, Employee will be eligible to receive relocation benefits as specified herein (the &ldquo;<B><I>Relocation Assistance</I></B>&rdquo;).
The Relocation Assistance is provided subject to the terms of the Company&rsquo;s reimbursement policies and procedures. Employee
will be reimbursed a gross amount of up to $50,000 of documented relocation expenses that Employee incurs and which are eligible
for reimbursement (as specified under the Company&rsquo;s reimbursement policies and procedures), which will become payable to
Employee in accordance with the Company&rsquo;s reimbursement policies and procedures. Relocation Assistance benefits are taxable
income, subject to withholding, such that Employee&rsquo;s net Relocation Assistance benefit received may be less than Employee&rsquo;s
incurred expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Signing Bonus.</B> Upon the commencement of Employee&rsquo;s employment with the Company, Employee will receive a one-time
signing bonus in the amount of $100,000 (the &ldquo;<B>Signing Bonus</B>&rdquo;), subject to applicable payroll deductions and
withholdings. The Signing Bonus will be paid to Employee as an advance in a single lump sum in accordance with the Company&rsquo;s
standard payroll processes within 30 days after the Start Date, and is provided to Employee prior to Employee&rsquo;s earning of
such Signing Bonus. Employee will not earn the Signing Bonus unless Employee remains actively and continuously employed with the
Company through the second anniversary of the Start Date. If Employee&rsquo;s employment terminates under any circumstances, Employee
agrees to repay to the Company, within thirty (30) days of Employee&rsquo;s employment termination date: (i) 100% of the gross
amount of the Signing Bonus if such termination occurs before the first year anniversary of the Start Date, and (ii) 50% of the
gross amount of the Signing Bonus if such termination occurs before the second year anniversary of the Start Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Standard Company Benefits. </B>Employee shall, in accordance with Company policy and the terms and conditions of the applicable
Company benefit plan documents, be eligible to participate in the benefit and fringe benefit programs provided by the Company to
its employees from time to time. Any such benefits shall be subject to the terms and conditions of the governing benefit plans
and policies and may be changed by the Company in its discretion. To the extent Employee is not eligible for the Company&rsquo;s
healthcare benefits on the Start Date, Company will reimburse Employee for the cost of COBRA to maintain his healthcare benefits
from his prior employer until such time as Employee is eligible for the Company&rsquo;s benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Expenses. </B>The Company will reimburse Employee for reasonable travel, entertainment or other expenses incurred by Employee
in furtherance or in connection with the performance of Employee&rsquo;s duties hereunder, in accordance with the Company&rsquo;s
expense reimbursement policy as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Equity; Change in Control Acceleration. </B>Subject to approval by the Board, under the Company&rsquo;s 2020 Equity Incentive
Plan (the &ldquo;<B>Plan</B>&rdquo;), the Company will grant Employee an option to purchase 120,883 shares (the &ldquo;<B>Option</B>&rdquo;)
of the Company&rsquo;s Common Stock, at fair market value as determined by the Board as of the date of grant. The Option will be
subject to the terms and conditions of the Plan and Employee&rsquo;s Option grant agreement. Employee&rsquo;s Option grant agreement
will include a four-year vesting schedule, under which 25% of Employee&rsquo;s shares will vest after twelve months of employment,
with the remaining shares vesting monthly thereafter, subject to Employee&rsquo;s continuous service with the Company on each such
vesting date. Notwithstanding anything to the contrary set forth in the Plan, any prior equity incentive plans or any award agreement,
effective upon consummation of a Change in Control (as defined under the Plan), the vesting and exercisability of all unvested
time-based vesting equity awards then held by Employee shall accelerate such that all shares subject to the Option, and any additional
unvested time-based equity awards granted to Employee, shall become immediately vested and exercisable by Employee upon such Change
in Control and shall remain exercisable, if applicable, following the Change in Control, as set forth in the applicable equity
award documents. With respect to any performance-based vesting equity award, such award, if any, shall continue to be governed
in all respects by the terms of the applicable equity award documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> Confidential Information Obligations</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Confidential Information Agreement.</B> As a condition of employment, Employee shall execute and abide by the Company&rsquo;s
standard form of Confidential Information and Invention Assignment Agreement (the &ldquo;<B>Confidential Information Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Third-Party Agreements and Information.</B> Employee represents and warrants that Employee&rsquo;s employment by the Company
does not conflict with any prior employment or consulting agreement or other agreement with any third party, and that Employee
will perform Employee&rsquo;s duties to the Company without violating any such agreement. Employee represents and warrants that
Employee does not possess confidential information arising out of prior employment, consulting, or other third party relationships,
that would be used in connection with Employee&rsquo;s employment by the Company, except as expressly authorized by that third
party. During Employee&rsquo;s employment by the Company, Employee will use in the performance of Employee&rsquo;s duties only
information that is generally known and used by persons with training and experience comparable to Employee&rsquo;s own, common
knowledge in the industry, otherwise legally in the public domain, or obtained or developed by the Company or by Employee in the
course of Employee&rsquo;s work for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Outside Activities and Non-Competition During Employment</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Outside Activities.</B> During Employee&rsquo;s employment with the Company, Employee may engage in civic and not-for-profit
activities so long as such activities do not interfere with the performance of Employee&rsquo;s duties hereunder or present a conflict
of interest with the Company or its affiliates. Subject to the restrictions set forth herein, and only with prior written disclosure
to and consent of the Board, Employee may engage in other types of business or public activities. The Board may rescind such consent,
if the Board determines, in its sole discretion, that such activities compromise or threaten to compromise the Company&rsquo;s
or its affiliates&rsquo; business interests or conflict with Employee&rsquo;s duties to the Company or its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Non-Competition During Employment.</B> During Employee&rsquo;s employment with the Company, Employee will not, without the
express written consent of the Board, directly or indirectly serve as an officer, director, stockholder, employee, partner, proprietor,
investor, joint ventures, associate, representative or consultant of any person or entity engaged in, or planning or preparing
to engage in, business activity competitive with any line of business engaged in (or planned to be engaged in) by the Company or
its affiliates; provided, however, that Employee may purchase or otherwise acquire up to (but not more than) one percent (1%) of
any class of securities of any enterprise (without participating in the activities of such enterprise) if such securities are listed
on any national or regional securities exchange. In addition, Employee will be subject to certain restrictions (including restrictions
continuing after Employee&rsquo;s employment ends) under the terms of the Confidential Information Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Termination of Employment; Severance Benefits</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>8.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>At-Will Employment.</B> Employee&rsquo;s employment relationship is at-will. Either Employee or the Company may terminate
the employment relationship at any time, with or without Cause (as defined below) or advance notice. Upon termination of Employee&rsquo;s
employment for any reason, Employee shall resign from all positions and terminate any relationships as an employee, advisor, officer
or director with the Company and any of its affiliates, each effective on the employment termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>8.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Termination Without Cause or Resignation for Good Reason. </B>In the event Employee&rsquo;s employment with the Company
is terminated by the Company without Cause (and other than as a result of Employee&rsquo;s death or disability) or Employee resigns
for Good Reason, then provided such termination constitutes a &ldquo;separation from service&rdquo; (as defined under Treasury
Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a &ldquo;<B>Separation from Service</B>&rdquo;),
and provided that Employee satisfies the Release Requirement in Section 9 below, and remains in compliance with the terms of this
Agreement and the Confidential Information Agreement, the Company shall provide Employee with the following severance benefits
(collectively, the &ldquo;<B>Severance Benefits</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>8.2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severance
Payments</B>. Severance pay in the form of continuation of Employee&rsquo;s final monthly base salary for a period of twelve (12)
months following termination, subject to required payroll deductions and tax withholdings (the &ldquo;<B>Severance Payments</B>&rdquo;).
Subject to Section 10 below, the Severance Payments shall be made on the Company&rsquo;s regular payroll schedule in effect following
Employee&rsquo;s employment termination date; provided, however that any such payments that are otherwise scheduled to be made
prior to the Release Effective Date (as defined below) shall instead accrue and be made on the first regular payroll date following
the Release Effective Date. For such purposes, Employee&rsquo;s final base salary will be calculated prior to giving effect to
any reduction in base salary that would give rise to Employee&rsquo;s right to resign for Good Reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><B>8.2.2</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Health
Care Continuation Coverage Payments</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COBRA
Premiums. </B>If Employee timely elects continued coverage under COBRA, the Company will pay Employee&rsquo;s COBRA premiums to
continue Employee&rsquo;s coverage (including coverage for Employee&rsquo;s eligible dependents, if applicable) (&ldquo;<B>COBRA
Premiums</B>&rdquo;) through the period starting on the employment termination date and ending twelve (12) months after the employment
termination date (the &ldquo;<B>COBRA Premium Period</B>&rdquo;); provided, however, that the Company&rsquo;s provision of such
COBRA Premium benefits will immediately cease if during the COBRA Premium Period Employee becomes eligible for group health insurance
coverage through a new employer or Employee ceases to be eligible for COBRA continuation coverage for any reason, including plan
termination. In the event Employee becomes covered under another employer&rsquo;s group health plan or otherwise ceases to be eligible
for COBRA during the COBRA Premium Period, Employee must immediately notify the Company of such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Special
Cash Payments in Lieu of COBRA Premiums</B>. Notwithstanding the foregoing, if the Company determines, in its sole discretion,
that it cannot pay the COBRA Premiums without potentially incurring financial costs or penalties under applicable law (including,
without limitation, Section 2716 of the Public Health Service Act), regardless of whether Employee or Employee&rsquo;s dependents
elect or are eligible for COBRA coverage, the Company instead shall pay to Employee, on the first day of each calendar month following
the employment termination date, a fully taxable cash payment equal to the applicable COBRA premiums for that month (including
the amount of COBRA premiums for Employee&rsquo;s eligible dependents), subject to applicable tax withholdings (such amount, the
&ldquo;<B>Special Cash Payment</B>&rdquo;), for the remainder of the COBRA Premium Period. Employee may, but is not obligated to,
use such Special Cash Payments toward the cost of COBRA premiums or toward premium costs under an individual health plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>8.3</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination
for Cause; Resignation Without Good Reason; Death or Disability. </B>Employee will not be eligible for, or entitled to any severance
benefits, including (without limitation) the Severance Benefits listed in Section 8.2 above, if the Company terminates Employee&rsquo;s
employment for Cause, Employee resigns Employee&rsquo;s employment without Good Reason, or Employee&rsquo;s employment terminates
due to Employee&rsquo;s death or disability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Conditions to Receipt of Severance Benefits. </B>To be eligible for the Severance Benefits pursuant to Section 8.2 above,
Employee must satisfy the following release requirement (the &ldquo;<B>Release Requirement</B>&rdquo;): return to the Company a
signed and dated general release of all known and unknown claims in a termination agreement acceptable to the Company (the &ldquo;<B>Release</B>&rdquo;)
within the applicable deadline set forth therein, but in no event later than forty-five (45) calendar days following Employee&rsquo;s
employment termination date, and permit the Release to become effective and irrevocable in accordance with its terms (such effective
date of the Release, the &ldquo;<B>Release Effective Date</B>&rdquo;). No Severance Benefits will be paid hereunder prior to the
Release Effective Date. Accordingly, if Employee breaches the preceding sentence and/or refuses to sign and deliver to the Company
an executed Release or signs and delivers to the Company the Release but exercises Employee&rsquo;s right, if any, under applicable
law to revoke the Release (or any portion thereof), then Employee will not be entitled to any severance, payment or benefit under
this Agreement. Employee shall also resign from all positions and terminate any relationships as an employee, advisor, officer
or director with the Company and any of its affiliates, each effective on the employment termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 409A. </B>It is intended that all of the severance benefits and other payments payable under this Agreement satisfy,
to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1(b)(4),
1.409A-1(b)(5) and 1.409A-1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those
provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that
complies with Section 409A. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation
Section 1.409A-2(b)(2)(iii)), Employee&rsquo;s right to receive any installment payments under this Agreement (whether severance
payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each
installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to
the contrary in this Agreement, if Employee is deemed by the Company at the time of Employee&rsquo;s Separation from Service to
be a &ldquo;specified employee&rdquo; for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon Separation
from Service set forth herein and/or under any other agreement with the Company are deemed to be &ldquo;deferred compensation&rdquo;,
then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution
under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided to
Employee prior to the earliest of (i) the expiration of the six-month and one day period measured from the date of Employee&rsquo;s
Separation from Service with the Company, (ii) the date of Employee&rsquo;s death or (iii) such earlier date as permitted under
Section 409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable
Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section shall be paid in a lump sum to Employee, and
any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due
on any amounts so deferred. If the Company determines that any severance benefits provided under this Agreement constitutes &ldquo;deferred
compensation&rdquo; under Section 409A, for purposes of determining the schedule for payment of the severance benefits, the effective
date of the Release will not be deemed to have occurred any earlier than the sixtieth (60th) date following the Separation From
Service, regardless of when the Release actually becomes effective. In addition to the above, to the extent required to comply
with Section 409A and the applicable regulations and guidance issued thereunder, if the applicable deadline for Employee to execute
(and not revoke) the applicable Release spans two calendar years, payment of the applicable severance benefits shall not commence
until the beginning of the second calendar year. To the extent required to avoid accelerated taxation and/or tax penalties under
Code Section 409A, amounts reimbursable to Employee under this Agreement shall be paid to Employee on or before the last day of
the year following the year in which the expense was incurred and the amount of expenses eligible for reimbursement (and in-kind
benefits provided to Employee) during any one year may not effect amounts reimbursable or provided in any subsequent year. The
Company makes no representation that any or all of the payments described in this Agreement will be exempt from or comply with
Code Section 409A and makes no undertaking to preclude Code Section 409A from applying to any such payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Definitions</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>11.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B>Cause. For purposes of this Agreement, &ldquo;<B>Cause</B>&rdquo; means the occurrence of any one or more of the following:
(i) Employee&rsquo;s conviction of or plea of guilty or <I>nolo contendere</I> to any felony or a crime of moral turpitude; (ii)
Employee&rsquo;s willful and continued failure or refusal to follow lawful and reasonable instructions of the Board and/or the
Company or lawful and reasonable policies and regulations of the Company or its affiliates; (iii) Employee&rsquo;s willful and
continued failure to faithfully and diligently perform the assigned duties of Employee&rsquo;s employment with the Company or its
affiliates; (iv) unprofessional, unethical, immoral or fraudulent conduct by Employee; (v) conduct by Employee that materially
discredits the Company or any affiliate or is materially detrimental to the reputation, character and standing of the Company or
any affiliate; or (vi) Employee&rsquo;s material breach of this Agreement, the Confidential Information Agreement, or any applicable
Company policies. An event described in Section 11.1(ii) through Section 11.1(vi) herein shall not be treated as &ldquo;Cause&rdquo;
until after Employee has been given written notice of such event, failure, conduct or breach and Employee fails to cure such event,
failure, conduct or breach within 30 calendar days from such written notice; provided, however, that such 30-day cure period shall
not be required if the event, failure, conduct or breach is incapable of being cured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>11.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></B>Good Reason. For purposes of this Agreement, Employee shall have &ldquo;<B>Good Reason</B>&rdquo; for resignation from
employment with the Company if any of the following actions are taken by the Company without Employee&rsquo;s prior written consent:
(i) a material reduction in Employee&rsquo;s base salary, unless pursuant to a salary reduction program applicable generally to
the Company&rsquo;s senior executives; (ii) a material reduction in Employee&rsquo;s duties (including responsibilities and/or
authorities), provided, however<I>, </I>that a change in job position (including a change in title) or reporting line shall not
be deemed a &ldquo;material reduction&rdquo; in and of itself unless Employee&rsquo;s new duties are materially reduced from the
prior duties; or (iii) relocation of Employee&rsquo;s principal place of employment to a place that increases Employee&rsquo;s
one-way commute by more than fifty (50) miles as compared to Employee&rsquo;s then-current principal place of employment immediately
prior to such relocation, provided, however, that Employee&rsquo;s relocation from Boston, Massachusetts to San Diego, California
as contemplated in Section 1.2 will not be considered a relocation of Employee&rsquo;s principal place of employment with the Company
for purposes of this definition). In order for Employee to resign for Good Reason, each of the following requirements must be met:
(iv) Employee must provide written notice to the Board within 30 calendar days after the first occurrence of the event giving rise
to Good Reason setting forth the basis for Employee&rsquo;s resignation, (v) Employee must allow the Company at least 30 calendar
days from receipt of such written notice to cure such event, (vi) such event is not reasonably cured by the Company within such
30 calendar day period (the &ldquo;<B>Cure Period</B>&rdquo;), and (vii) Employee must resign from all positions Employee then
holds with the Company not later than 30 calendar days after the expiration of the Cure Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Dispute Resolution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>12.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Agreement to Arbitrate</B>. To ensure the timely and economical resolution of disputes that may arise between Employee and
the Company, both Employee and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. &sect;1-16, and
to the fullest extent permitted by applicable law, Employee and the Company will submit solely to final, binding and confidential
arbitration any and all disputes, claims, or causes of action arising from or relating to: <B>(i)</B> the negotiation, execution,
interpretation, performance, breach or enforcement of this Agreement; or <B>(ii)</B> Employee&rsquo;s employment with the Company
(including but not limited to all statutory claims); or <B>(iii)</B> the termination of Employee&rsquo;s employment with the Company
(including but not limited to all statutory claims). <FONT STYLE="text-transform: uppercase"><B>By agreeing to this arbitration
procedure, both EMPLOYEE and the Company waive the right to resolve any such disputes through a trial by jury or judge or through
an administrative proceeding.</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>12.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Arbitrator Authority</B>. The arbitrator shall have the sole and exclusive authority to determine whether a dispute, claim
or cause of action is subject to arbitration under this Section and to determine any procedural questions which grow out of such
disputes, claims or causes of action and bear on their final disposition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>12.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Individual Capacity Only</B>. All claims, disputes, or causes of action under this Section, whether by Employee or the Company,
must be brought solely in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any
purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity.&nbsp;&nbsp;
The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative
or class proceeding.&nbsp; To the extent that the preceding sentences in this Section are found to violate applicable law or are
otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than
by arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>12.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Arbitration Process</B>. Any arbitration proceeding under this Section shall be presided over by a single arbitrator and
conducted by Judicial Arbitration and Mediation Services, Inc. (&ldquo;<B>JAMS</B>&rdquo;) in San Diego, California, or as otherwise
agreed to by Employee and the Company, under the then applicable JAMS rules for the resolution of employment disputes (available
upon request and also currently available at&nbsp;<U>http://www.jamsadr.com/rules-employment-arbitration/</U>).&nbsp;&nbsp;Employee
and the Company both have the right to be represented by legal counsel at any arbitration proceeding, at each party&rsquo;s own
expense.&nbsp;&nbsp;The arbitrator shall: <B>(i)</B> have the authority to compel adequate discovery for the resolution of the
dispute; <B>(ii)</B> issue a written arbitration decision, to include the arbitrator&rsquo;s essential findings and conclusions
and a statement of the award; and <B>(iii)</B> be authorized to award any or all remedies that Employee or the Company would be
entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the amount of court fees that
would be required of Employee if the dispute were decided in a court of law.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>12.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Excluded Claims</B>. This Section shall not apply to any action or claim that cannot be subject to mandatory arbitration
as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004,
as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent
such claims are not permitted by applicable law to be submitted to mandatory arbitration and such applicable law is not preempted
by the Federal Arbitration Act or otherwise invalid (collectively, the &ldquo;<B>Excluded Claims</B>&rdquo;). In the event Employee
intends to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court,
while any other claims will remain subject to mandatory arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>12.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Injunctive Relief and Final Orders</B>. Nothing in this Section is intended to prevent either Employee or the Company from
obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award
in any arbitration proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction
and enforced accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>General Provisions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>13.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notices.</B> Any notices provided must be in writing and will be deemed effective upon the earlier of personal delivery
(including personal delivery by fax) or the next day after sending by overnight carrier, to the Company at its primary office location
and to Employee at the address as listed on the Company payroll.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>13.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Severability.</B> Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect
under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other
provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced in such jurisdiction to the extent
possible in keeping with the intent of the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>13.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Waiver.</B> Any waiver of any breach of any provisions of this Agreement must be in writing to be effective, and it shall
not thereby be deemed to have waived any preceding or succeeding breach of the same or any other provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>13.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Complete Agreement.</B> This Agreement, together with the Confidential Information Agreement, constitutes the entire agreement
between Employee and the Company with regard to the subject matter hereof and is the complete, final, and exclusive embodiment
of the Company&rsquo;s and Employee&rsquo;s agreement with regard to this subject matter. This Agreement is entered into without
reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes, extinguishes,
and replaces in their entirety all other or prior agreements, whether oral or written, with respect to Employee&rsquo;s employment
compensation, benefits, and terms with the Company or its affiliates or predecessors. It cannot be modified or amended except in
a writing signed by a duly authorized member of the Board, with the exception of those changes expressly reserved to the Company&rsquo;s
discretion in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>13.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Counterparts.</B> This Agreement may be executed in separate counterparts, any one of which need not contain signatures
of more than one party, but both of which taken together will constitute one and the same Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>13.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Headings.</B> The headings of the sections hereof are inserted for convenience only and shall not be deemed to constitute
a part hereof nor to affect the meaning thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>13.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Successors and Assigns.</B> This Agreement is intended to bind and inure to the benefit of and be enforceable by Employee
and the Company, and their respective successors, assigns, heirs, executors and administrators, except that Employee may not assign
any of Employee&rsquo;s duties hereunder and Employee may not assign any of Employee&rsquo;s rights hereunder without the written
consent of the Company, which shall not be withheld unreasonably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>13.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Tax Withholding. </B>All payments and awards contemplated or made pursuant to this Agreement will be subject to withholdings
of applicable taxes in compliance with all relevant laws and regulations of all appropriate government authorities. Employee acknowledges
and agrees that the Company has neither made any assurances nor any guarantees concerning the tax treatment of any payments or
awards contemplated by or made pursuant to this Agreement. Employee has had the opportunity to retain a tax and financial advisor
and fully understands the tax and economic consequences of all payments and awards made pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>13.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Choice of Law.</B> All questions concerning the construction, validity and interpretation of this Agreement will be governed
by the laws of the State of California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>13.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Conditions Precedent. </B>This offer is subject to satisfactory proof of Employee&rsquo;s identity and right to work in
the United States and other applicable pre-employment screenings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[<B><I><U>Signature Page
to Follow</U></I></B>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps"><B>In
Witness Whereof</B></FONT>, the Parties have executed this Agreement to become effective as of the Effective Date written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><B>AETHLON MEDICAL, INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>By: <U>/s/ Charles J. Fisher, Jr.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt">Charles J. Fisher, Jr., MD</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt">Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><B>EMPLOYEE</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Signature: <U>/s/ Steven P. LaRosa&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 40pt">Steven P. LaRosa, MD</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>aethlon_ex3101.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a),
AS ADOPTED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Charles J. Fisher, Jr., MD certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on
Form 10-Q of Aethlon Medical, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s)
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5.&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s)
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors
and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: February 10, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 33%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;CHARLES J. FISHER, JR., MD</FONT></TD>
    <TD STYLE="width: 62%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CHARLES J. FISHER, JR., MD</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CHIEF EXECUTIVE OFFICER</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(PRINCIPAL EXECUTIVE OFFICER)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>aethlon_ex3102.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a),
AS ADOPTED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, James Frakes, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1.&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on
Form 10-Q of Aethlon Medical, Inc.;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does
not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3.&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4.&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s)
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5.&nbsp;&nbsp;&nbsp;The registrant's other certifying officer(s)
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors
and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="width: 94%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: February 10, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 33%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;JAMES B. FRAKES</FONT></TD>
    <TD STYLE="width: 62%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">JAMES B. FRAKES</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CHIEF FINANCIAL OFFICER</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(PRINCIPAL FINANCIAL OFFICER)</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>aethlon_ex3201.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO RULE 13a-14(b)
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AND SECTION 1350 OF CHAPTER 63 OF TITLE
18 OF THE UNITED STATES CODE (18 U.S.C. SECTION 1350),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AS ADOPTED PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the Quarterly Report
of Aethlon Medical, Inc., or the Registrant, on Form 10-Q for the fiscal quarter ended December 31, 2020 as filed with the Securities
and Exchange Commission on the date hereof, I, Charles J. Fisher, Jr., MD, Chief Executive Officer of the Registrant, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1. The Quarterly Report on Form 10-Q, to
which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, as amended, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2. The information contained in such Quarterly
Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: February 10, 2021</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ CHARLES J. FISHER, JR., MD</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Charles J. Fisher, Jr.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Aethlon Medical, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This certification accompanies the Form 10-Q to which it relates,
is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Aethlon
Medical, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before
or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>aethlon_ex3202.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CERTIFICATION PURSUANT TO RULE 13a-14(b)
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AND SECTION 1350 OF CHAPTER 63 OF TITLE
18 OF THE UNITED STATES CODE (18 U.S.C. SECTION 1350),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AS ADOPTED PURSUANT TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the Quarterly Report
of Aethlon Medical, Inc., or the Registrant, on Form 10-Q for the fiscal quarter ended December 31, 2020 as filed with the Securities
and Exchange Commission on the date hereof, I, James B. Frakes, Chief Financial Officer of the Registrant, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1. The Quarterly Report on Form 10-Q, to
which this Certification is attached as Exhibit 32.2, fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, as amended, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2. The information contained in such Quarterly
Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Aethlon Medical,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: February 10, 2021</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ JAMES B. FRAKES</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">James B. Frakes</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Aethlon Medical, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This certification accompanies the Form 10-Q to which it relates,
is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Aethlon
Medical, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before
or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#=A<0)O 7<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MV@#OWZ6# Q\NO#CQX;Z-*S^^O#GSY\ZC0Y\.@(#'YP1H4M\NO3OW[\8%(/_
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M=Q[!'O313.]VKQ9-;!QM+?A(<I0\QRYQR5FA4"8ET.EG0E5).IF]0D_>$_/
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M!''M/H.!";5)] RG.8$]K!\TTPB2[\_N^9TF44[:NGOVM>@YQ8R--=;@ "%
M  $"  0"0)A0H4(!"QTJQ,=P74,!!@HFO/A0HT$##0$01'C1XT:2)1D2&&E2
MY<J%]0RPJ\=2YDR:-55:M$FR7L:</1T2".!3Z%"B-0GPFX</)4B#](K.I)CR
MZ=!Y MI-_6A0ZE!Z_B"N:X83XE:3!"R:]1@Q*]:$ WFR96E 'ERZ="N^)3JP
M[DR\>_W^96C08#VO" \"7HA/(%F? QT'5>F8GF(!<Q5/+7CXJ5J(8A7.LVFV
M(\( 3M=B%8@2L4D#!E:_IND9<_]?V!\9U\8-URIN ?XT%T4IT/5*Q^E\>Q0
M&;A6K/SLK>1W>Z9:VC2C$E2=^R$[>=*UO[Y+=U[UU>2_GV_LG2Z]=+^)7B2
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M>/"*^ C*>V@((UO*AFB'XZH/ $ P $  >UA%C$P(!'@#?T" =)"/[T@ ?0"
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MY5/$F ?;>E*N*4D$\ <;W9;*>8@#$(![2+O:,,H=!51[6$OMH$*2Z []D#(
M\()XR*9.8M0F@AZ I"_%$ZHG+$F*% #L7#*2P%1/;9""" M !0#^9,_;Z0U#
MR@PQS=4GG-4F,J0*XA(@4HB'Q VO+$M/48GKO$Q^BH]C10_**:A>+0CHJ5 E
MBE8=8E%.!*#B4;L+E*CJ^PD).8#[C-2)&4ED%=2MZ @YP1Y.3( O>4237-<4
MTH][4Q_^2YOZPHA0E5$3P%/_8\.2$6%"Q,A, *!76ZE)!D$M\&S5+W#7@;K2
M&(*F7P. D96?![T1K<F-=(#,BHS.@EV3CRQ+'ATLG+0DZ-$++Q@.FGV5@T4A
MO0P A0W(+E.*O%(;?K"MDH6*QZ3*],LO[3@ L@Q)6VF/E7R::RL(_8A$!679
M+HT(E=4ZT?BR#NU2K8'8YUE+G.T)^<!/S&3%?<!3$9(/?EV3)7E4=5U3YN'9
MHU49&LO7W)@'$ZM4XH!:GP#5;\6-+"W+NE6>[:P5%G5+"15:"_('9FI8CSBM
M#PE;D[0M#X(-?]A5H9 /886LTS2?6B& ?2!)CBT(ALW;RZV@.QM<NQBH2_.5
MSW4C_Z5B#]ZXR"^M"4]E7&@*5PSP51JIA\_C7>VA70!"6;*=F>L*#-CL/\.]
MW8ME"9"\785PUF-BQ5/MTDMKWE\M7QK)F*)MV&,!G^Y]C=]%"&S-5J(H,/'-
MC0-P#3_EV(AXSR1#+B-+V[[EG>C%HV-9+"F*TR>\2+0]UA,( Q[##9L] .%M
MLF8H20+ VX5Y7OF!'J.=WI1U7@&N%WQ0JL.-C,3%* P;#J=5B;'\4X[MC76P
M%7FXX R>$%C2I4P3X;RU![(E*,E*X->84P"(3GQ1N;4+R7V@8,T)U#2[8!,(
MX/.ED%_#P+113^VA*]&9U!C55:NL"YJ[.<>]!\A=%790 /^UY%B(04G,V^"%
MO0HISHFK\.&I!6(N!@\4U@T$X"VPH$H&!@S]M <;9BL<)J6=P$2Q>XMV(IX2
MCM2-K,Q0U%)!OF&WVMH='AW<@V-D,> V!J,@OI35\6-N-0CMG9"1+&)7H>&/
MD&3T(.05;5!$QF)+KI8M?E8,>16?I(M[D&$$6,5[*"[7J,P$\&6?_-0$.(#B
MRHSB&F.2:P;6&C!?+HAV4.;BVBVCQ  M998 4^7D]5A.3A_J=1HC/6#.T0P3
MOJ!+O>6Z.  M10 RSHET\((E7@A[N <O$ !21HCO-:(:CF*:?&6M8]_=<M_5
M(.&$D-\G7,M3IIU0?H@"LTI62$7_ 9-A(H[HVS0(<JCH:$Y%#!"P8#"!M76(
M!/B"C6YF>JAH##@DCL8 F)#G"0%@#.YG7?(?FJBNQ*SIAIBNH+CIGZ0NP=CI
MG^YIG YJGI[.?*91<9(OZ\75P<C6TGV5EO8)/Q4Y*8M"6R*(>0#@E+UJU6@^
M*8O*+Y@/>2$(KT@'I9@'M . *)L'!("'UZT5"_X(*,8B;[Y5[%@)>_@M++2W
M3:23AZ0<E$"*C,-"QPCLI( U'2EL8+/"/ SLR<C"N1@5A@@*3AT=6J91;GX7
MZ+1EMAC5JRT5J":7+^A?7,:2=0AD6\G<M![H4J%K1NH:%7&)M'B4%/O0W.@/
MHQUG.+5C_[C!8XK!B69(5.T![;:(4I4H7C!QW54VJ59>)(L@D/D J\F1%[D
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M]:&0:J@.___0]IB8AY]_BO<?*O 4_YU"_LH%"  "!Q(L:/ @PH0)"0!@2%"
M@(81%5*L:/$B1HOX_ WD5R\CR) B1Y*L>$\?  3["!+P B98,#!?Y"' *"^8
M@00&2AZ$*" !SZ 7!= #P,^AT*0&(394ZO0IU'H$)CZ<"O7JTJ8L!5+%ZK4D
M4ZX<DR+825$ TJ]J$2*H":_F0'G;$!# )R!8VXQVKQ) ( ##6J%H ?\,#DR2
M:5K#BKT&:%9T(%JKBY7."X"OH(  #35/[EQPWD>N77F: $K1@%G/:A.L/'"
MH#POZ0@#,'%2=<&^Z=[@SHAV=N+>"!$++RXR@ $!]B 2D&Q<Y.5YN;D^7QR6
M\.B2&$PG3(=@;'6E[2(*:$>PF8F?P6K?@RN\+P# X8=/+3S_8<3@]_<WI\<O
M^WX5\6,49OD!&&!2&PTTGE)9P'-::@A"%1L^[-Q36P+K&$? 2O))B!UA^H5'
MW(<EFEB1<@-N1=N)2EUW75"E*40 =RWZ1EY7[*0WD!<'7%8</A@@D(6) NQD
M7X DVKCDB0,FEMEF3/($&F0'BH0 2@DE)R7_1@G4=(![ -ST13!?? &&=*J5
M]U%.89S@H81H,?>ADES:.9]Y*@[DD)5WGD45C%[UZ2=!!ZR$P(6P[;./ NL8
M4 \[G1F@TCKV"!3:B>DPU!R=^1'Z:7&;%B@1J!@I*-I:DY:JD$XIA=E3C6O1
MN*6=1(78J5:KZFJ8IRL.NBN(J";E)6;M_?HIF #L\YI" B2Z%GFS^>E/,P!H
MBJN(P&J;E*@/:48 9]L:1*5 #"9E@GOUY)2FN /=EE>SKUZ5SCHK@8I6 $CN
M5V>[_8*5JT!\^CNJL$*98$(S-2TW<)6$29N0 /(^Y0\\$1)J*Z=Q]LHPQQEU
MV[!S Y\:K%"HS7-L_\=+Q?I4Q-ER.9B^]_&;,LT] :P5RJN^F'/-'D<TSX_-
M?J6/RURF8U;1Q<W<,],?<_5MN .32S+3P[JU\F28Z@Q:.TD+MW35-&\<,'4=
M[QRV4BJY>I;7(LG#LXU2-=0V;F"CS;'3((;L[\CFWLW3NQ(_]"!4/VT+,]UJ
MCOUWRHL+;#:@<#-N4%[["#Z0/U@'E4#B2\IYL\R+3\YPWE""V_'4@8Z>$;'W
M, OQY23!=_BFG7=F]^J'W_PXQV?G'A(!YK5C7K.O*Z4 \=HBCNWO>-^,F.1^
MCJQZ\RX:SVV[RVL,>O7*[UYV[Y%WCQ&GS20=?=7^'&G[9+B/#VKI4*..J?_?
M8/F$X_VBY8\=1.;>S^!R[C>1_PW0)WP2(/ZH!Q)B(4!S7Q' PY1WF8PAR'WO
MN]CW6!2^AO'D $+RDJ5RTAX0 B G#6R/0'*2 'BT*B4)\!*QZM' !K90'R]L
MX$Z\DX 1,B1B)TP >4Z( 8N%)%GP@AC[%(* J %+>Q44W05753H#=6QZZ"-(
M"^^DJI($[BP.%$G$^N7$)$$QBO?*X!5K)3Z>9-%.">N@ @"0K'@Y)6:[DI,=
M1U1&,Q(J?E'B6.K2*!"=X ,UJ)$'>$ZT19*P)B7/&LXC@S(K0_;0D*BII"4%
M:9VB4)",W.,C!A/#.X;YKB0&D$<8O' P$WPAB;C_X4>D[&>M067.*?P(PRJ]
M !1\J/)@7H!++EFA2R+NBR'7VIXK08F@*9**8WW39$-F(@!_", +R11C[*!3
MGG;LA7\0M!1AJ"DF57HA)/6PAV8P-<"!G%,S5&DG ,YY*71J,%R#"< UH;5'
M9;X,C8U;8TGJ$1L!X(,A7JC6DK0F$JL$SSB0:@X[Y/&CYC1')?;  ,*&HLL1
M K&$,&P/1TRX0[C,\(8?*2D*7;A##!R@'GFLC@7Y:2,_G@Z0ZM0DHF3#2@!X
M(98M,H"&2L+ 2*K& !A0 *,44$F5[&.' +"'%XAY$ )\P3/L $PG][5/F7K.
MGY#C8$D:N(UI1L0+\EB2_P'L11*U'7$X4G7**2G2CIK<XPMPFE$PO'0 D#8D
M :Y)J0@;F"4;@JD]EFH@F!H) 'VX#@$F (P]\JF6F'+51#V\'SZIZ$SP*# C
M]TC "9)#4%:<U4:+'$D"4(* ZZDL56\5""SK88)U5-4B'*)HQ@3 #MP&#+<.
M.0IOYT;1-.$6-2Z5[ .W6MD3Y:<^]0$?*0&Z5GWTDIS(54PSU#J2MR@KFV%4
M"VHL\A->,A$A;SN(0J_"C^5<%RN47:Z$*(K .<UO09I,0#/:88"(FH])Z\AF
M15K5UIX0%2KA11$0M:L0HGEFC%K])'Q_NIT7#E& _P0K2>3!KEH%;20!L)0]
M(O_8$]9."*$+2<Y=*9)>7O6PO5=Y;X3W8X WO# !;W@MWS@+33X*@,2=Z4L]
MR%&/#1>3OD^$<(Q+9-0:8\#%3-IP9S$29>8*DE-9M5FH:I( 7;!BQ06AU>T8
M4E#F)5E**JPQCON%C_\86:AI5C* *=*Z.*>JM NIB6[+>18$B%@Q#@X=DLN,
MH"53^,WBHJ9\A=)&+KTQK(?R\4#HY5J*S*X9)QA46>K&$'R26= SM20[=NPG
M\@S+T A"3E 9>2CO%O@I!TY(A:32$G BI!V$4Y-S.^UIYLZCAW^C*%E,/6@%
MAZ21JST+I)7RZF9A !]A\/(@B=P^3CJ99<K=]7V ?3?_U.QXT6:F<T(RO8\L
M02S927%415R* 8$V2]0C^?-\8(SM#8$Y;,W9\=ZD-.4ZFELHS< Q =81 -X@
MT3@"D(>EJEW':\^[.LW1D[WSW7#(@)LDY37(&S&@OH/D1.$@0<N0/9X4>4\<
M-_?^M<07ZFXU)6\D!F#(ORO29ZA</#<(L,<]Z/$%K?6EXFJ)+ #&C,R26Y8
M$*_:R[LM[ "=5B0,]#E6ECU5N!A -HBY1\N5MFF1"X;A1._-R>\6]LTM_3Z-
M@7I!U#9'B)4])%(WR.QX61:N'X8 _I#;T+\>WROW+.G#HOM:Y)%JU*K6NU],
MRMLQ0P![[(362:J=KO6>[933_VSL;-0)MTMH20-\:_,"$3PE4^AY(QE2'Z7=
M/"9#3WK4K(,\AE0L([_4:HI/NB)!*E*+(R_Y\&@;;98'BZ,.3  %6#)@9;FD
M0/Z-&KJ(GO4(M:12FS\IAUC2+X2QY#Y<;TA!AC?Q#YF]4M#=[K_@_E9YW_WD
M5ZY%RC?<<&HA@(D1HIL4%_FESR$Y^@/3^XBK_X("(/=7U-R>U 3]R4Q1"-V1
M 5[^@<3O-0W[@=(^[(3W9=L^I$,!QEONG=\"/L?^(=T#\E'K]%M@R$/1P$>'
M55 &)N &\MX'DDX+1A$\%!Y%>$>J#)Y!0 K:X5J;/9@"KJ!M\5W-^%V,9<C:
MT!%XX?]80=%@B1 4 /2:[OF@:C1@STBA3*G-LIP%^"'>F]W>$C($WJD@%(8*
M$%;>"U[0NQ ;9H@@3T3@G_R%XSW>-/7@NWE=&'H%%=*,$$98N+QA:[U?"?+9
M!8Y("GJ2'-;A5(UARMQA94$;5[0=5,!'(,*4F!5B2."?(2J%(G9,'L*7N.7@
MC]T<P=$)0_@#)7X<'5[B4Q# RZ%<*8K+TQG'!!H?  B@( K %Q(B*D9A7:!<
M_S&-VGF7)V)$+#9$,+8/0SBA!N:B8DR%M/5=&;Y/:J4$&C[$X94,COU&-1K<
M(/*@,OZ8 1R= _9BSW#77NU9[9U%)-Z?%[:BE)UB-TK2,[;_RR8N5Z;IPS5F
MH5!DFD(4%/EUX0X"&CM>8G.<8#CFG_L]T!]:H(FD@W0@HL&YXSN6!"P]AN_%
M8_<,T,P]A$^!'0'RH<QL(T!&Y#)*U-_,8V6Q53&Z"*558#H:7&D%I'A!I$@N
M% %0)/\E630.&)9]Q3#.#NZE@_T]9*#-)+?LHMA99/7 0QQ9CCD>(:6EI&*D
M [4](5$^!3TX1DDB9?-$(W<U"SX&Q3!"A!**HOF!857:H58"2W/46 _5V OM
M!(VXY::X)><0!EWFAY>\P8356$2<F9?TI5N25& *! W=T%/1I6"BV5,59JO\
MA%L>"5W"98VYAA?$D6LT)4]N84MJ_QUP4.59<HN&9:5/0 9M $II6@I3D-I3
MD=I$+(<_R -0V$,])%*T2(MRG),M"H1L[F9H0!!AR%,\<<1L2(ML<D1N_J9L
M#H=NSJ8&$<9N"L ^5$M8 @6I:48 7"=V4H=JEJ8&L6980L1F?@WD)>-G.L5
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EMF$?-F(GMF(O-F,WMF,_-F1'MF1/-F57MF5?!S9F9_9(! 0 .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.gif
M1TE&.#=A70)J 7<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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MAGH/-5JXH/=P!SNN5]Z)9%7#!N&IZFZ".>P^1+88H<?RELN.3DZ+P<E3#Y>
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MU>_L]&N1_(Q2=M;.3W]E\Y_9T(9^];<JUO9_O7$N =@>N6-^]^=_XR)^R0*
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M:18^QA 0LF:J(301HA<?9Q3#*)$U\9 4 8[^N(P:B3^%84A,.1'JT9![\9-
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M0'*3CC<0XYS>H;R?RR'6H3*N CV[V\K8T4VT:PT4L)W+IR$0A*;==)). (
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MU(7_$LIB&!R4ISSTG/,XO_,WW_/=@P_DL "-4=31]1@'@#O'-$#(E/1,O_3
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ME<PJ4 /03J7N>LXH'Z/]1B7X4M)F F'G.R+[.5%R=J@U=)+__-__@P+[  %
MX$""!0D&('! X4*&#0,8A!A18D0""/ =($!@XD:.'3U^!-DQ8\B( 3 F)/#N
MGDJ5SNYAA(F2Y$>-,VW>Q)FS8("'!-G5I+=.9TB>/(<>':@19<J5]YBR; HU
MHTNF"=>Q>[</(8$ \^BIFT?@GKI]& ,X15@T++UY6],V/)" *U=G7[7.38N7
MZ[RF3_<1^ = G3FD 'KV% J '0"MA3G^[.E8\F21!X[6]$G9(V;-G3T;-$KP
M7TUUBS\?=$<O\FF/JGG^8Q=@<?]1Q;+=Q<9M.("YJ[+_S3,78)_ U0+-U;2L
MVZ"Z@TD+NHM,+Z0]=K!E:Y0-8)X[ULJ[KSMPK_OXR\ES(B3/D7-Z]CA##V1G
M3^!P\D6+MR]( 'I!>VVY2B1 '?0.8F>=>00BP*N!PCH0@.0R"B P %3#++1_
M[L.,N8_>&^@UP\8C(#'6V,$(/Q,W.\"TG-8[$0 66X2QI.+6 4I$UB)L*T:"
MVEHM(7@(P,< %MTA(('P$C @L@#<.4X@>C)BC@![[NGI@(>VPBXCSC!+T#Y[
MN 0I+0 "2\LH#CL;\+L2=6331?/.N\_$%]O4\<R?!&IP/-D$I). X X[("P"
MZE&HN(3_$#J T IOTW @I]8#C" MN3LHLN/L$V]!HJR<"[N'Z*'TLS,_(W%.
M.MF[QQD)S\L31E-//?',T02BKKX 5.MS/P23L]+!]7HUZ:I\#AMSO5'?Q--&
MXGITBS/YPK3/3#R[(T#%[M:$]<27CFI2QU>S;>_,T.+T;,E16_0408WN!""K
M@H8UK"9X3+.O(V0ENK##0.&Y9YYWH@M)2[E&,NK9S^PA%TULP6TO(\*&^B_&
M;QFNK]5X\5SU1A<3Q@_A/-U)(+)Y\#$H(153[= <(NWE>"!S\A0+ &<TZG5:
MD$JTTB3ESG6,W?06IGB\T>Z]R6=T@XYQ5*#2J[=-[%8-(!^8_^ )55)X7+KZ
M8<,8M=<C75U\Q^44G0-I).YT-K-EG6A4>S*3)D9Z,I.1XM/5N%N\=2?2JCX-
MQ[;)XXJV*R<ML#K#KUQI-\76X<F=63FJ>:.7]1W(G0-$-'@S+K%#T+-+\0/Z
M[L\2*BS-$^$673.EYV.:-J==). O=6*?/:\ I9P=P@03_/*OA^#^.S:"PA-H
MX;\I+SY=GH<B\GC)WDZ=VLM+1]VSZJ-WK,RBGJ25:0 0IM/UHR(T6J< &@7
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M:EVO_R5#2^>[T6 \VP\J!S6HE@5 !PY877* A\T-QF)2@ 3  'Q0 -(-  ,
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M \C(&(R(!,B'[Q9O'B<^?D<M9]5)SAD(<N=Y>TIVS4" %U2#1%F(,2:4N4^
M"YQ+#3BG<F@&@Z"#$5BI$% "-SX J9'[B+0(@05"#L@'.@CO!:C:#<23'D-M
M)1MVI?^02'&.GZ<8Z^X.G?9<AKB2AC ?,C;]N$#]TS?]GUXEU4]]AC#\NJ_[
M!'BLG!CEUW?]_]PW(7;8 !5!4:V8AWW8AR<1_GLX!X$P@!" BX:@=WB@ 1K8
MA1?@!1XW (-I!S58@:K! "DCM/36<Y@2]YT0>IE%]\D862'1$C))H(B_(/1W
MPLU=$??/03DFTC%68W[=UO/ @/BL!^PEB:<'"  "\1$(8/ @0H3D1FP@<(\
MQ(@$XAT0:/'B17@)YAVHB/&C 0(6[Y$SX.PBA@  5'YLZ?(ES)@R9]*L:?$
MRY<B;?+LZ5+E3HLB#?HL:O0HS0#T+!)%6C-!P00Q#P0MVA$I 8]&K[I41^X
M@HYBQ=8S$,  TK-II?:DL\$B IH$#-#3\/*=UI?E7/!ZQX'<NI@&YO]9-*-F
M03V4 ,P1=NKX,>2/>5L6C&Q9*("E3%4VO>SY\\K&*W."M@@U -N74)'>F]SS
M7MRCK5_.A@D5[=$ \=+B[KE!PP8Z.&?N6]',KDNN,#F@,T?CC#N9(2V64X,!
MW<4%T>V5[N[]XO"?5;\7!8J1<&?RZFT&")J^^\8 B6%21>H,GGW7/)WI%T@
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MRD68>/&"%UD'#=YKY?2I.;Y/QO"%S:CF7:0/OO"U:MJ00H]I6B28=DY?XFR
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ME]!QH/H2$H#BZ'@-&=-&CKB;BPQL/D 2$;UQ$'DR(C/9/'@7:D@I/M!K/KQ
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M88 +T*ECM.--HN['OO_U19+13/OB33^9YG6OQK2+ K@,&TP-"+<W3, #ABR
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M6 #FFA&8=[A@W($.J9IE9X# /GP&$M0[D. =@7[_/KN5/9LV;9"U<5>UES&
MF@3Q5BA(@-H ZA5JI'9D>;5AO>050V^\^['G4*$;B7:<)]GB!G, [G%7&%5L
MV(;1R^)<35 ]SL/[<L>7/U^B7LOT\3L$&0 ?Z'M^ 0/M.8H(6*PC9^!IS+K'
MYG+,(G,T: 8\ QF":L";JJLJ@'P26*T>C5PZ  'U0,S/Q!-SNPW%%0TB *\
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M-MX,D*G=@A+8Q2HU5OI7(I;4B=>L6R.:KB,7'^N5HH4IFJ?![KY[:!W/,"+
M&8VC6OD=^,JB!]*G^ 7@ #IK-EAG3Z?=N2UZ\&)G@370<*GF!-2,]*><&2H7
MSXXTYHB 6#G"."*/=;58HI,V@E!"CA.]%H,#X E7K++)EC$]('LNJ-G8?(X[
M/D[E/FL_I&FXQ^,#1D4H 76L]KLEK0MRSJ-W;JPGM006;]QQQ1/@L!YRUHV(
M@!L;AUQSQC=?O!X#U!X* \\Y+SUST^NI)]5?PVN('8'^8=PAPM5-:%B#U/ZR
M[MUG*YCWLO9YYUI\;$@@9S;YS?_G)ZP7<EI6CUY/6?KIJ:>>Z8FJSU[[MC>:
M9_OO,1+^5P+,78@@Q1T::>WQ4GI[UM_AEYK[^#?6#$91&7)F;(046/9Z'@<W
MN_?1CX ;8(<Y#A6LM:"/(>N@'71R%14ZJ0UF!+1@_?YW0;5<"VDS@@=RH@(/
M#*3!!A*;6(":,T -\LZ  Z&=0-PANX8P;R/O6%=4ED:7%>Y0(G3C80]YDP!G
MC&LJFGG!+OA" QO AEP!#-L/5^@=:37D'S!TQJ(J5)9OZ0=E4/1B$3/XQ8/
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%E0(" #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" 'T G$# 2(  A$! Q$!_\0
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M2[!5!9CT &2:Z*-*,TW(XL5B)TI)1ZGH_P#PN,?] "?_ ,"D_P */^%QC_H
M3_\ @4G^%<<WAG44LOM)C7&W=LS\^/I62RE&*L"K#J",$4Z*P]:_LY7MV9C4
MQ&)I6]I&U_)GH_\ PN,?] "?_P "D_PH_P"%QC_H 3_^!2?X5YO16WU:!E]?
MJ]E_7S/2/^%QC_H 3_\ @4G^%'_"XQ_T )__  *3_"O-Z*/JT ^OU>R_KYGI
M'_"XQ_T )_\ P*3_  H_X7&/^@!/_P"!2?X5YO11]6@'U^KV7]?,](_X7&/^
M@!/_ .!2?X4?\+C'_0 G_P# I/\ "O-Z*/JT ^OU>R_KYGI'_"XQ_P! "?\
M\"D_PH_X7&/^@!/_ .!2?X5YO11]6@'U^KV7]?,](_X7&/\ H 3_ /@4G^%'
M_"XQ_P! "?\ \"D_PKS>BCZM /K]7LOZ^9Z1_P +C'_0 G_\"D_PH_X7&/\
MH 3_ /@4G^%>;T4?5H!]?J]E_7S/2/\ A<8_Z $__@4G^%'_  N,?] "?_P*
M3_"O-Z*/JT ^OU>R_KYGI'_"XQ_T )__  *3_"C_ (7&/^@!/_X%)_A7F]%'
MU: ?7ZO9?U\STC_A<8_Z $__ (%)_A1_PN,?] "?_P "D_PKS>BCZM /K]7L
MOZ^9Z1_PN,?] "?_ ,"D_P */^%QC_H 3_\ @4G^%>< %B H))X '>AE*,58
M%6'4$8(H^K0#Z_5[(]'_ .%QC_H 3_\ @4G^%'_"XQ_T )__  *3_"O.=C;2
MVT[1U..!0RLN-RD9&1D=:/JT ^OU>R/1O^%QC_H 3_\ @4G^%'_"XQ_T )__
M  *3_"O-Z*/JT ^OU>R_KYGI'_"XQ_T )_\ P*3_  H_X7&/^@!/_P"!2?X5
MYO11]6@'U^KV7]?,](_X7&/^@!/_ .!2?X4?\+C'_0 G_P# I/\ "O-Z*/JT
M ^OU>R_KYGI'_"XQ_P! "?\ \"D_PH_X7&/^@!/_ .!2?X5YO11]6@'U^KV7
M]?,](_X7&/\ H 3_ /@4G^%'_"XQ_P! "?\ \"D_PKS>MW3?#]KJ-C;S#4'C
MEFN%M_+,&0&/OGI@4GAZ:5W<J.-K2=DE_7S.K_X7&/\ H 3_ /@4G^%'_"XQ
M_P! "?\ \"D_PKDM*\,W&K1Z@\3D"S!Q\A/F,/X?;@58D\&W(M8YX;B-@VW=
MO&P)E PR?QQ4^QI7M<I8K$-7LOZ^9TO_  N,?] "?_P*3_"C_A<8_P"@!/\
M^!2?X5R;^#]7CMWG>!5B0D,Q;@8SG^5.3P=J<B1./("2J"I+XY./EZ=>1^='
ML:7</K6(_E_ ZK_A<8_Z $__ (%)_A1_PN,?] "?_P "D_PKD(_"NHR21Q@0
MB1U+E"_,:\G+>@X-9=S;R6ES+;S#$D3%6 .>::H4WI<EXVLE=I'H?_"XQ_T
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M*-&@(QGYL]6"_P S4JC2?4MXK$+[*_KYG8?\+C'_ $ )_P#P*3_"C_A<8_Z
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MZW_A<8_Z $__ (%)_A1_PN,?] "?_P "D_PKC[WPS>6-Y;6TDENSW+E$*N<
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ML45B8(0Y<D$E0 W48Z>]<J=;U)H_+:^N"GG>?@N?]9_>^M+9:YJ>FF8V-[-
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M  )6C_A%]=_Y\(__  )6O1:*\W_6;&_W?N_X)M_8>$[/[SSK_A%]=_Y\(_\
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M]%HH_P!9L;_=^[_@A_8>$[/[SSK_ (1?7?\ GPC_ / E:/\ A%]=_P"?"/\
M\"5KT6BC_6;&_P!W[O\ @A_8>$[/[SSK_A%]=_Y\(_\ P)6C_A%]=_Y\(_\
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M4[:V@N+&W$=LNU DZ+^)]Z[:BE_K+C7_ "_=_P $:R3"K:_WGG7_  B^N_\
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M ,^$?_@2M'_"+Z[_ ,^$?_@2M>BT4?ZS8W^[]W_!#^P\)V?WGG7_  B^N_\
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M:\67D$2D%''G,7>TV^8%52BX/3))&:N^&9]6NWUFXN'F-Q)#'Y+30F%0^TY
M4^A[]ZY7D>$71_>:_7JO<LF[U$=?#VJ?E'_\72?;-0_Z%[5/RB_^+K(TV6XT
M_29Y]-M-4.JBW7[6]P"T>_=\Q"G[S#KQQBED\0^)T^Q%4D>%IV0N+(^9*F<!
MBO1?QI_V'A.S^\/KU8U_MNH@Y_X1_5 ?^V?_ ,73_P"T]6W;O[#U?=C&<QY_
M]#K!76/$EA;62HUQ,6NY5G5K0L^-_P H!Z8P>O\ A7H@8$ Y R.F13CDN%2N
MK_>+Z]5;_P" <R-3U4'(T/5P<YZQ]?\ ONI1K6KBV:#^P-3VMU)$>?\ T.NA
MR/4?G1D>H_.JCE&'C>S?WB>+J/>WW','4M5;&="U<X&!DQ]/^^Z=-JFIS*BM
MX>U,+&-J@"/ _P#'ZZ7(]1^=&1ZC\Z7]C8:S6NOF'URIY'*_;-0_Z%[5/RB_
M^+H^V:A_T+VJ?E%_\7759'J/SHR/4?G4?V'A.S^\KZ]5.5^V:A_T+VJ?E%_\
M71]LU#_H7M4_*+_XNNJR/4?G1D>H_.C^P\)V?WA]>JG*_;-0_P"A>U3\HO\
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MZZK(]1^=&1ZC\Z/[#PG9_>'UZJ<K]LU#_H7M4_*+_P"+H^V:A_T+VJ?E%_\
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M $!;/_OW1_P@OAK_ * MG_W[K?HH P/^$%\-?] 6S_[]T?\ ""^&O^@+9_\
M?NM^B@# _P"$%\-?] 6S_P"_='_""^&O^@+9_P#?NM^B@# _X07PU_T!;/\
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MX?\ ^@)IO_@*G^%'_")>'_\ H":;_P" J?X5R>DQ^,8M=\^6&8+/@R+,Z^2
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M - 33?\ P%3_  K7HH R/^$2\/\ _0$TW_P%3_"C_A$O#_\ T!--_P# 5/\
M"M>B@#(_X1+P_P#] 33?_ 5/\*/^$2\/_P#0$TW_ ,!4_P *UZ* ,C_A$O#_
M /T!--_\!4_PH_X1+P__ - 33?\ P%3_  K7HH R/^$2\/\ _0$TW_P%3_"C
M_A$O#_\ T!--_P# 5/\ "M>B@#(_X1+P_P#] 33?_ 5/\*/^$2\/_P#0$TW_
M ,!4_P *UZ* ,C_A$O#_ /T!--_\!4_PH_X1+P__ - 33?\ P%3_  K7HH R
M/^$2\/\ _0$TW_P%3_"C_A$O#_\ T!--_P# 5/\ "M>B@#(_X1+P_P#] 33?
M_ 5/\*/^$2\/_P#0$TW_ ,!4_P *UZ* ,C_A$O#_ /T!--_\!4_PH_X1+P__
M - 33?\ P%3_  K7HH R/^$2\/\ _0$TW_P%3_"C_A$O#_\ T!--_P# 5/\
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MK[5@VK>*8M-UF*[6^-S<2'[$4V$H N2 <X )X!/Y4K[_ -=AV.G_ .$2\/\
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M/^%'_"6Z!_T%[7_OH_X4 :'_  E>H?\ 0LW_ /W_ (?_ (NC_A*]0_Z%F_\
M^_\ #_\ %UG_ /"6Z!_T%[7_ +Z/^%'_  EN@?\ 07M?^^C_ (4 :'_"5ZA_
MT+-__P!_X?\ XNC_ (2O4/\ H6;_ /[_ ,/_ ,76?_PEN@?]!>U_[Z/^%'_"
M6Z!_T%[7_OH_X4 :'_"5ZA_T+-__ -_X?_BZ/^$KU#_H6;__ +_P_P#Q=9__
M  EN@?\ 07M?^^C_ (4?\);H'_07M?\ OH_X4 :'_"5ZA_T+-_\ ]_X?_BZ/
M^$KU#_H6;_\ [_P__%UG_P#"6Z!_T%[7_OH_X4?\);H'_07M?^^C_A0!H?\
M"5ZA_P!"S?\ _?\ A_\ BZ/^$KU#_H6;_P#[_P /_P 76?\ \);H'_07M?\
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MH>O21L6U+RV+L=AE8\9X.?Z=*;)X>\1-$B+K2<3LY)W<H2,+^0/YT)@=;N&
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M]"8AE6]1[U?HH IVNCZ?9,&M;*WA8$L#'& 03U/XTV70],G5EFT^U=6W9#1
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M%S<HK$@\4037$,)MYT,C["2!A3N*CGN"1UK;HL 4444 %%%% !1110 4444
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M 'S6IX237(Q>C72W^L!@!VX"\\ @_3K7144[BL%%%%(84444 %%%% !1110
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MB<CMGCK4M% &#XBAU![W3'L$F=8Y\RJC +CU8Y_QK>HHH6@=;A1110 4444
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M+, !PN["G\<'\JMZ9XF75-9^QQ0%$$+2%G(W9! Z>G/6JMK8#>HHHI %%%%
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M -]BC[;:_P#/S#_WV*S?^$0\/?\ 0#TW_P !D_PH_P"$0\/?] /3?_ 9/\*
M-+[;:_\ /S#_ -]BC[;:_P#/S#_WV*S?^$0\/?\ 0#TW_P !D_PH_P"$0\/?
M] /3?_ 9/\* -+[;:_\ /S#_ -]BC[;:_P#/S#_WV*S?^$0\/?\ 0#TW_P !
MD_PH_P"$0\/?] /3?_ 9/\* -+[;:_\ /S#_ -]BC[;:_P#/S#_WV*S?^$0\
M/?\ 0#TW_P !D_PH_P"$0\/?] /3?_ 9/\* -#[39>9YGG6^_&-VY<X^M.^V
MVO\ S\P_]]BLW_A$?#N<?V)IN>N/LR?X4?\ "(>'O^@'IO\ X#)_A0!I?;;7
M_GYA_P"^Q1]MM?\ GYA_[[%9O_"(>'O^@'IO_@,G^%'_  B'A[_H!Z;_ . R
M?X4 :7VVU_Y^8?\ OL4?;;7_ )^8?^^Q6;_PB'A[_H!Z;_X#)_A1_P (AX>_
MZ >F_P#@,G^% &@US9.5+S6[%3D$LIQ3OMMK_P _,/\ WV*S3X1\.J,MHFF@
M>IMD_P */^$0\/?] /3?_ 9/\* -+[;:_P#/S#_WV*/MMK_S\P_]]BLW_A$/
M#W_0#TW_ ,!D_P */^$0\/?] /3?_ 9/\* -+[;:_P#/S#_WV*/MMK_S\P_]
M]BLW_A$/#W_0#TW_ ,!D_P */^$0\/?] /3?_ 9/\* -+[;:_P#/S#_WV*/M
MMK_S\P_]]BLW_A$/#W_0#TW_ ,!D_P */^$0\/?] /3?_ 9/\* -![JSD4J\
M\#*>H+B@W5F<9GM^.1\XK/'A'PZ>FB::?^W9/\*3_A$O#G/_ !)=-XZ_Z,G^
M% &DMW:+G;/ ,\G#BD:YLF=7::W++T)9<BL__A$/#W_0$TW_ ,!D_P */^$1
M\.@@?V)IN3T'V9/\* -+[;:_\_,/_?8H^VVO_/S#_P!]BLW_ (1#P]_T ]-_
M\!D_PH_X1#P]_P! /3?_  &3_"@#2^VVO_/S#_WV*/MMK_S\P_\ ?8K-_P"$
M0\/?] /3?_ 9/\*/^$0\/?\ 0#TW_P !D_PH T3=V;$%IX"1TRXXJ6.:.8$Q
M2(X'4JP-9/\ PB'AW_H":;_X#)_A5ZPTJQTI'33[.WM4<Y988P@)]3B@"W11
M10 UQN1@.I&*\XL?!GB'2[BZFT\V< :57$8F/[WER<L$R!\P.#NZ=:[;7=:7
M0[.*=K::Y>69((XHL;F9C@=2!6(GCMY;J2VCT2[>XC&7B6X@+*/<;Z5M1WT,
MS2O"/B2SUM;Q[R"-I,&:99F?/RL-I0@ \E3G/:KMWX/OC>ZE>VK6:WMQ:QQI
M<*@1V<??.0#MW#C(R:MIXRNI'9(_#M^S+@L%F@)&>F?GI_\ PE=__P!"SJ7_
M ']A_P#BZ8CG)?!OB8!I8KB!IY(##B2ZD_=+YF0H8#)PO&:O67@[55\*:O8Z
M@UM<W=\8VR9#A]J(IRV.N5/8UH/XVFC,H?0+U3$ 9,SP#8#T)^?BI1XLOB 1
MX:U$@]#YL/\ \71_7XW#J8%IX/\ $UO%:1+=PQ11N2%CF*^2"P).%4!R5R.@
MQFK7ACP-=Z%)>J9(XUNK,Q>9'*Q*2%F).TC'0CGVK3D\87<,9>7PYJ"(.K--
M  /_ !^G#Q9?$ CPSJ6#_P!-8?\ XNCI8.MS$C\):Y#I26]M;:=:-'L206TS
M1M= ?Q,X7(YYQ@_6H+GP;XHNC=QW%_%/%-:HA9YWRTB[>@ PHR#ZUNW/C:>R
MA,UWH%[!$."\D\"@?B7I\?B^\EC62/PYJ#HPRK+- 01['?1UN GA/1M:TO4M
M1DU.:-[6<AH%\]I'7D\$D  8QTKJ:YAO%MZHRWAK40!W,L'_ ,72_P#"5WW_
M $+.I?\ ?V'_ .+H"QTU%<R?%MZJDMX:U$ =298/_BZ/^$LOB,_\(SJ6/^NL
M/_Q= '345S/_  EE]_T+.I?]_8?_ (NC_A++[_H6=2_[^P__ != '345S/\
MPEE]_P!"SJ7_ ']A_P#BZ/\ A++[_H6=2_[^P_\ Q= '345S/_"67W_0LZE_
MW]A_^+H_X2R^_P"A9U+_ +^P_P#Q= '345S/_"67W_0LZE_W]A_^+H_X2R^_
MZ%G4O^_L/_Q= '345S/_  EE]_T+.I?]_8?_ (NC_A++[_H6=2_[^P__ !=
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MX=_Z >G?^ Z_X4 5_/A_Y[1?]]BCSX?^>T7_ 'V*L?\ "&^'?^@'IW_@.O\
MA1_PAOAW_H!Z=_X#K_A0!7\^'_GM%_WV*//A_P">T7_?8JQ_PAOAW_H!Z=_X
M#K_A1_PAOAW_ * >G?\ @.O^% %?SX?^>T7_ 'V*//A_Y[1?]]BK'_"&^'?^
M@'IW_@.O^%'_  AOAW_H!Z=_X#K_ (4 5_/A_P">T7_?8H\^'_GM%_WV*L?\
M(;X=_P"@'IW_ (#K_A1_PAOAW_H!Z=_X#K_A0!7\^'_GM%_WV*//A_Y[1?\
M?8JQ_P (;X=_Z >G?^ Z_P"%'_"&^'?^@'IW_@.O^% %?SX?^>T7_?8H\^'_
M )[1?]]BK'_"&^'?^@'IW_@.O^%'_"&^'?\ H!Z=_P" Z_X4 5_/A_Y[1?\
M?8H\^'_GM%_WV*L?\(;X=_Z >G?^ Z_X4?\ "&^'?^@'IW_@.O\ A0!7\^'_
M )[1?]]BCSX?^>T7_?8JQ_PAOAW_ * >G?\ @.O^%'_"&^'?^@'IW_@.O^%
M%?SX?^>T7_?8H\^'_GM%_P!]BK'_  AOAW_H!Z=_X#K_ (4?\(;X=_Z >G?^
M Z_X4 5_/A_Y[1?]]BCSX?\ GM%_WV*L?\(;X=_Z >G?^ Z_X4?\(;X=_P"@
M'IW_ (#K_A0!7\^'_GM%_P!]BCSX?^>T7_?8JQ_PAOAW_H!Z=_X#K_A1_P (
M;X=_Z >G?^ Z_P"% %?SX?\ GM%_WV*//A_Y[1?]]BK'_"&^'?\ H!Z=_P"
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M?\*/^$-\._\ 0#T[_P !U_PH K^?#_SVB_[[%'GP_P#/:+_OL58_X0WP[_T
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MB]D1[&(Q[E3_ %AV@*QY[$9JN/AS"&&-1F""V$ 4+@!L'+\'DDDG% F=F""
M1T-+7!ZIX!O!9W+:=J+R7$SABDS,$/S \X/8#':NOT>TEL-&L[6=_,EAA5'?
M).X@8)YH6P%VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *JW5W9VDL;74D4;MD(7Z^_-6JS-4T&VU>Z
MMY+O+QPA@8NSY]: +?V*T,@D^S0;P#AM@R,]?Y_K44MIIPP9K>U_=[<%HU^7
MGY<<>O2LA?!X2Z$JWTH&YF(P<Y)8C!SP/F'Y"H9?!32M"S:G,Y145O,7=O*M
MNW=>O:F"\S>>PTZ-"SVMJJAMV3&N WKTZTV>PT^^:X1X86D=0DK* 'P1P">O
M2L&/P1(D91]5FF!E\S]ZF>.??KSUJ?4O"\L]]>7UK=E)IT 10"N&"[02V><=
M>E(%>YLW-S8VA@BN6B3) B5AWZ#%/73[)5*K:6X4DY C7GU_D/RJI+HJS6=E
M TS;K4AO,(R6(!&?US63;^"FAB0/JMQ*\;,R.P.025/KS]W]33Z@CH4T^RCS
MY=K;KD\[8U'O4L"PK"HMQ&(L?+Y>-OX8KFK?P6T4A>;5)YB)#(H((VG<&]?;
M'XUNZ3IXTO3(+-7WB%=H;&,_A2 N4444 %%%% !1110 4444 %%%% !1110
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MJ-]HB8\EB>,?+TKK:-U<?6P4444 %%%% !1110 4444 %%%% !1110 4444
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MV'1XADXZCK3K>:&X@26W=7B<95EZ$4EL!+1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -=2R,H8J2,9'
M45R,7PTTB)V/FW3K(=\J2.&623#9<@C@_,>G' KK9=WE/L^]M./K7GVA#QK;
M&99TF;?*GS7(0A5RY8J W/11GWZ4NH^A?A^%VD17@N?M%XS>48MN\!>4V9P!
MUQ^HJ0?#/26M3#--<2 HR;OE4C<P8D8'!^7''O4%KJ7C>98VFTZ"(B9MRLH)
M:/<@'\7!VES^%5TN?&[3W$YM,/YF$C8*$ "-T&[)&[;3W"_4[;3+!-+TVWLH
MW9T@01JS8R0/7%6JX"X\1^*;35;&QGLE=YB0_E0YW#=C=NW87CG'--@3Q?9:
M@X\NZN9EC8"5Y$^SG@;<+U)ZYZ<YIWOJ)*VAZ#17 WVN>,[*:Y3^ST>/?'';
MRI"&+DCYOEW>OJ14R2>,O.G+P*8Y2"J<9C.1T.>F,\4NEP.XHKBHM4\8[+ O
MIJL[W(6[4HJA(\<E3O.?K7:T %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5&^T>UU&Z
M@GND\SR =J'[ISZCO5ZL37;+4KZ\M$L+AK>,;C)(#]T]N.]+J@(1X-L5N1*K
MR#YF8J O))8YSC/&X_D*C;P/8EH6%Q<9B1$R=K;@K;LG(ZD]Z%N?$JW05H(F
MC+-R$& H+8R=W7 7\ZK7%QXHD:/%J(Q(L;/Y>"4;?\R\GIMZFJ=]1K<GA\"6
M4";4N;@CS/,^?:WKQR/?KUJ;4O"<5[=7=W'.ZSSIM&0,(=NW.0,]/>J0O/%4
MT!6:S6%C+C,8!.W)_P!KITYJ>_O-<L-1OY8HO,LU0/&'4$9"= 0<Y+>U(E;F
MN^C0O96EL7<);8VD'DX&.?SK)M_ MA;Q*@GN'*$E&8@E<E3UQ_L#]:M7UK?W
M=MITW[Q;A6#3)&^U<8)(/MG JC;WOBJ2)'FLH8V5FWI@'<,K@ [O0M^5-7N"
MV);?P/80.7::>5B_F#>0=IW!N./:MO3;%-,T^&TB9F2(;5+8S^E8%O>^*9G/
MFV<42+(>H!++N ]>/ER:V]&^U_V3;_VAN^U;?WFX#.?PI+8?0O4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[FOM)M[BZ0),ZY=0",'Z&DMON'T+U%%% !1110 4444 %%%% !1110 4444
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M$KT'_H,67_?RLB&]T"'Q3<:R/$%GF:$1&$$ 'W)ZFCJ'0V?[&N?^AAUO_O\
MI_\ $4CZ'/(I5]?UIE/4&=.?_'*3_A*]!_Z#%E_W\H_X2O0?^@Q9?]_* '?V
M-<_]##K?_?\ 3_XBC^QKG_H8=;_[_I_\13?^$KT'_H,67_?RC_A*]!_Z#%E_
MW\H =_8US_T,.M_]_P!/_B*K6]NMV)C;^*M6D$)Q(5N8SL^OR5/_ ,)7H/\
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MQ(W[S8,>XP=P]N*A_LG4;:VU"W6![I;V1F4F<KL&WU[9/ITI 7_M/B7U\/\
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M 7_/M??]^KRC9X"_Y]K[_OU>5T^]O[Q_.C>W]X_G0!S&SP%_S[7W_?J\HV>
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MO;^\?SHWM_>/YT <QL\!?\^U]_WZO*-G@+_GVOO^_5Y73[V_O'\Z-[?WC^=
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M_P 11GQ+_P! &U_\& _^(H T**S\^)?^@#:_^# ?_$49\2_] &U_\& _^(H
MT**S\^)?^@#:_P#@P'_Q%&?$O_0!M?\ P8#_ .(H T**S\^)?^@#:_\ @P'_
M ,11GQ+_ - &U_\ !@/_ (B@#0HK/SXE_P"@#:_^# ?_ !%&?$O_ $ ;7_P8
M#_XB@#0HK/SXE_Z -K_X,!_\11GQ+_T ;7_P8#_XB@#0HK/SXE_Z -K_ .#
M?_$49\2_] &U_P#!@/\ XB@#0HK/SXE_Z -K_P"# ?\ Q%&?$O\ T ;7_P &
M _\ B* -"BL_/B7_ * -K_X,!_\ $49\2_\ 0!M?_!@/_B* -"BL_/B7_H V
MO_@P'_Q%&?$O_0!M?_!@/_B* -"BL_/B7_H VO\ X,!_\11GQ+_T ;7_ ,&
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M4,<WF[51-O)P*.@CI:***!A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" ,K G,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BHKJZALK:2XN9%BAB7<[L<!1ZFLS_A+=#.G_;AJ=M]FW^7YF[C
M=UQ]: -BBLF?Q1HMM:074VI6R07!Q$Y?AO6KD^I6=LL337,2+-GRR6X? R<?
M@,T 6J*RK;Q1HUY:3W5OJ,#P0 -))G"J#TYJ&3QEX?AMH;B35;80SDB-MW#$
M<$?7VH VL =J6F)-&\*S*X,;+N#=L=<U576=.>&"9;V QSR>7$P<8=O0>M %
MVBLU_$.E1RW43W\ >S7=."W^K'O^8H3Q%I4DEM&E]"7NAF%0>7'3C\J -*BJ
M=QJ]A:7\%E<744=U<?ZJ)FY?Z5+/>VUK+#%//'').VR)6;!<XS@#OTH FI:H
MSZWIMLET\U[ BVA G)?_ %9/0&H4\2Z1)=P6JZA 9YU#11YY<>WY&@#4HJC9
MZSI^H0S2VEW%+' 2)'5N%QUR:BM/$FD7^S[+J$$N^3RE ;DOC./RH TZ*QYO
M%NAV\J13:I;([DA06]#M/Z@BM<$$ @Y!Z$4 +15?[?:_VA]A^T1_:_+\WR=W
MS;,XSCTS3Y[J"U4-/*D:G."QQG S_(&@"6BJIU&T$-O+]HC\NX8+"V>')Z ?
M6K5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 9GB33)=9\.WVGP.B2W$1C
M5GS@$^N*YFZ^'"-IUK;VMY*LQNX[BZN7?]XVU"ORD+CC/'%=M+*D$322NJ1H
M-S,QP /4UEVGBK1;Z+S+;4877S%BSR/F;[HY]>QZ4T^P^GW_ (G*6W@75=-A
MA^R_V9<2BVFM)!.6 8.Q82]#\QS\PZ'UJRW@W5VBTZP:YM'L=/A812'<)"YC
M9"",8QELYST%=&/%.BM;^>-1@,6UVW \80X8_@:+OQ1HUBA:YOXD&4'&6.6&
M5X [@9J7K&SV_P"'_P Q=;G*V?@?5(O#']FR-:++"\$D;?:'D25HSG# J-JG
MVS6O/X>U#4+&U%VFFPSQZDEVZ6Z'9L4YQG&6;W(%7Y?&&A020)-J,<;3H'0,
MK#*DX!/''/K6I<74%I:O<W$JQP1KN9R> /6J>NK_ *_JPK7T*T.G@M?I/!%Y
M-RW($C-O7: <@\#TP*YNV\$2P:+H]J3:^?IU]]H#C.!'N)*KQUP178I(DD:R
M(P*, 5/J#TI:-OZ[ [-6."N_ M[<7^K2!+'[-> EH3-)BX;<I!?CY, $?+GK
M26O@;58;[2+AI[436F ]P)'+I&&8^4HQAAA@,G!XKM;_ %.TTR*.2\G6)9'$
M:9R=S'H !2WFHVNGHCW<Z1*[;5+'J<$X_($_A2C[MK=!O6Z[G'>*O"&MZKXI
MM]6TV[M4^SA!%YK$;,'+ J%(;/4$GBM_6]!.J:EH][&(5FL;GS&=LYV;6!5?
MQ(_*M:"XBN8$F@D5XY%#*PZ$>M24;:=M1.S^9QNI>"7N&UOR8;.2'4)H9EA=
MW0$JN&W%1D$GG(S5G2O"MW;W.GRZC/!<&RLWB5L'=YK'[V<= OR@]:ZJBDE9
M6_K:PSCO#?A&]TC2=5LY#9I%=)LAMT9Y(E.W!)W8/S'J!6;:> M6BT.\M_M%
MK;W(DBFL=CM((9$[[BH;![#G KT.BF]0/.M0^&5Q=10K#>QIY-@D!4D[9Y-Y
M9]XQ]ULGISS7;/8W,AL3'=M;+;X\V*)05E&,;<GD"K]%-L#@=0\#ZY=^([G7
M+?5K>"ZD<QQH$)V0;2N-W7/).,8SCFJD'P[U4:/;P7-S!/<0W1E DN9'7:8R
MA()&02><5Z314I65AWUN<!:?#_4+.VA@AO8D2.6WE'SNVUD4ARN>F2013+/P
M%JPM5@NKR-8C-"TL<=S,PE"!@[%CR&8D9 XXKT*BGU;%TL9OA[3[C2M!M+*\
MF$T\*;6D#%L_B>:TJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#.U_2O[;T*\
MT[S3%]IB*!\9P:Y.Z\#:IJ=O>2W=S8V]\UM#!;&U5MB&-MP=LC.<CMT%=X2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5PHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/[4\1?\ 0NP?^#$?_$4 ;]%8']J>(O\ H78/_!B/_B*/[4\1?]"[!_X,1_\
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MK'_(W^'?K<_^BZWZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L#PG_JM7_["ES_ .A5OU@>$_\ 5:O_ -A2Y_\
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MM3_\%MQ_\10!NT5A?\)AIO\ SRU/_P %MQ_\11_PF&F_\\M3_P#!;<?_ !%
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M5!W#WH2"*,+LC10HVKM4# ]!6-_PF&F_\\M3_P#!;<?_ !%'_"8:;_SRU/\
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MZH 3%W_>@_[Y/^-&+O\ O0?]\G_&E^VVW_/>/_OJC[;;?\]X_P#OJ@!,7?\
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MV_Y[Q_\ ?5 "8N_[T'_?)_QJ%[MHBXDNK)#&,N&;&T>_/%3_ &VV_P">\?\
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M(<>3C&Q@K9_[Z&/7-;?DW'_/U_Y#%-]!(GQ1BH/)N/\ GZ_\ABCR;C_GZ_\
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M4#)\48J#R;C_ )^O_(8H\FX_Y^O_ "&* )\48J#R;C_GZ_\ (8H\FX_Y^O\
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M^0Q6-X@5X[K0S,_F@ZD@ QMP?+DYXZTP.AHHHH **** "BBB@ HHHH ****
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MU0/8O_88/[A_[Z/^-'V&#^X?^^C_ (T;;K_GI#_WP?\ &C;=?\](?^^#_C0
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M %%%% !1110 4444 %%%% !1110!Q?C_ $[^U[S2;#S5B-PMPF]^@^05E?\
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MG5+@C_OJNEK \)_ZK5_^PI<_^A4 :_VZV_Y[+1]NMO\ GLM6** *_P!NMO\
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M )^F_P"^%H\B?_GZ;_OA://F_P"?5_\ OI?\://F_P"?5_\ OI?\: #R)_\
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M,&+$I(<<=.I]J9*N=91110,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MVZW_ .>GZ&@ WW7_ #RB_P"_A_PHWW7_ #RB_P"_A_PH^W6__/3]#1]NM_\
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MFLOQ!,J6^CI)=-.PU6 EV7!QD^@J:.Q,?BU]42ZA2W=-K1JK;G.._;\>M'5
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M_GU;_OM:L44 5_.G_P"?5O\ OM:/.G_Y]6_[[6K%% %?SI_^?5O^^UH\Z?\
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M^^UJQ10!7\Z?_GU;_OM:/.G_ .?5O^^UJQ10!7\Z?_GU;_OM:/.G_P"?5O\
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M?-$DV<D8)QC&2.]/&B:TH4#3?#N$G:X WS<2,""WW>IR?SJ>G]?UW!_U^/\
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M'.*T4=9$5T.589!]16!<>#K)[<00O+'$9%=E,A8#&,[1V)P 3Z$UT  4  8
MX H6P"T444 %9SZS!'J_]GR1RI(8VE5R!M95QG'.>_I6C67+I-E/JIG>:0W.
MW_5B8X4<9PO;.*6HR@?&U@ID#V]VGE()9<HO[N,]'//0^W/M2KXTL2T:M;W:
M&09&Y!TV@J>O?(Q_2D'AG0V))E9_-/EMFY)\Q1_RS//*CTJ:/0]'^Q-:B;?$
MY).Z?<>%VXSZ =NU4(V1,I@\X9*[=WR\YJCH>MQ:[:R3PQ21*DA3#E<\?0G'
MT/-6;2SALM/CM8BWDQIM!9LG'UJGH6FZ?I\,SZ=,9Q,^7D,OF9([9]J74.AJ
MT444 %%%% !1110!0AUB">XOH528-9$>82G7(S\OK67+XXTV'RS)'<*'0,,J
MH.3DA<9SGY3[>]:_]FQ+?/=1O(DDI'F -P^ 0 1^-4;GPGIEVT9F25A$/D'F
M'"G).?KR>:&!GZQJ,.K:;H-Y;AA'+JD! ;&>I],C\JUCKT0\1KH_DR^:8O-\
MPX"X]LG)_ 5EZ[80Z;9Z+;VX;8-6@;+-DDDG))K1DTK3Y_$D5\\[-?0QG9#Y
MO"@\;MM/2XM;&O1112&%%%% !24M% &$OBVR><1+#=$B5HW)0#9A@NXY.<98
M5'J'C73M-NIX)TFWPY'&W#$8SC+<8W#KBK<WAJPFN#.1*LAD,A*R$!B2#@CN
M,J#CVJ&;PEI]S.+BY:XEN%4 2F4Y!P 2/0G'-#\@+%AKL.H7GV=(+B,M%YJ-
M(H =<XR.<_G6/HVK1Z)X'-]-')(D=Q<95,9YN']> />MC2O#UGHT\TMHUQF4
M ,LDS.HQTP#TK'T:UM;WP.T%].8('N+D-()-A'[^3O0_(2N=-:W NK6*=5*B
M1 P!()&?IQ4U5["TAL;""VM?]1$@5.<\#IS5BF]]!H****0%34M0BTRS:XF6
M1D! Q&N3R:AM]:BN+RXMC!<1O GF$NHPRYQD8)].^*N7-M'=V[P3 E'&" <5
M0LM!@T^YEGMY[K=-)YDBO,6#'Z'H*6H&?_PG.FAH%\JYW3QET4H >-W&,YS\
MI_3-1ZO?QZDN@3QHZ8U949)  RLJ2 @X]Q5R3PAI<C E)A@8P)3ZL<_4;C53
M6;&'3AH$$&[;_:RL2[;F8E)"23W.35::@=/1112 **** "BBB@ HHHH ****
M "BBB@ HHHH **** ,#6/^1O\._6Y_\ 1=;]8&L?\C?X=^MS_P"BZWZ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KEK_P=]MU._O\ SRD\K(T&TX"E
M5 R3C=Z]#74T4 <<?#&LI?RNE\DEH3Q"T\B[UP, D XQUXZ]Z<GAC5WNB\]\
MHC"-PLTGSR9RKGCC' P..*L:QXGFTG6C"ZP&T5%) &9"3GCKQT&.#WZ4V+QI
M'/X@-C%'$]N%C_>+*"VYB>@_B'';I22OH#T*-OX0UDSQO>7L3@-RPFDW[3RW
M/<G\,5:.@:X]YNFN8)+5%V+%Y\BD_,2') Z@$#'0U'<>-)K&\N#<?9);>.>6
M+RH2?-0(N0S<D8/3H*8OQ "M)--;1);$A8E\[YV(/SG.,$=,>M#LUZAMJ1V_
MA'6[>-$CO8$"QJBE97_=L,Y8<?-D<<UHR^&[MM#DLC)'.?/62/S9&^4!1_$0
M>=P)Y!'-5F\>+/=Z='8PQ.ER\:R>9)@H&&>W<>AJQ=^,6L;Z\AEL_-2WEV%D
M< @'8!P>IR_MQ3?Y_H"C;^N__#E*+PIK?GH)=1B^SA$0I&[+A0!E0 ,8.#SP
M>:GD\,ZO]I\S[;'-$IV+$\KKNC#9 + 9!ZY^@I?^%@V7V,2^2&E:18Q$LH)+
M%B.OL1S2GQTG]J-IT=F)+I03M6<8&W&X$XXQFD_Z_K^OQ#^ON_K^K%2?POXB
MD:5EU*(LS!ES-( ?0, .0/;&>]=I$&6%!(07"@,1T)KEI_'UK#;K.+8M'(VV
M,&4!CC.<C^'IQGK74Q2"6%) " ZA@#UYJN@NH^BBBD,*YU]!NQX@GOHS;[)"
M2')(D&55=O3H-I/7K715SY\0RIXAGLW%N((R5"Y(D)"*V[KC!W8Z=:3MU&C$
M;P/?NTYW64?G1"$;-W[K&?WJ\??.>>GUJ=/!4XM ?]&CNTXC,9.P (%R1CJQ
M'/L3UJ)O'-\AG!CLG\B$3_(6_>@Y_=KS]\8YZ_2ID\7ZE]G6Y,-F]N/]9)'G
M"DH& Z]1GGV':JU$=-;V]PVCK!>&-[@Q;'QG:3C'Y5G>#]'NM#T8VEYY*D2,
MR)%R%7L,X&:UK&[COK**YA8-'(H8$=ZL4@Z6"BBB@ HHKBG\=SVVII9W5I$K
M2W$T<)W%5=$Z'<>%YR#F@+':T5R8\87%UH=Y>VEK&)(KQ+:-"=Y8%E4G (]3
MCGGBH++Q^/,\B^M3YX+!@GR%<$@90DD?=YYXH>FX>9V=)7)2>/K9+*[D,2I-
M!((POFAPQ..01U SVH?X@0Q77D26+J2VU?WHYR2 2.PR.3VH#K8L^(XYHX-&
M6XF$S_VM!\X3;QD]JDBT2ZB\9R:F@@2VDCVN<Y=SCTQQ]<_A5#4-2DU73-&N
M94C1O[8B7$;[EX8CKWKL*+:IBO=!1110,***YKQ%XGN-#U'RQ!&]J+;S7D.<
MQL7VKD?W?7TI-V&E<Z6BN8LO&/V[4[*UCMD5;AV4N91D !NW8Y7H>U9T?CNZ
MMY&:_M8UB(/E_*8]WS$ AB2"..3@8X]:;T=OZT)3OL=Q17*V_CRTFF16@,4;
M$KO>50000#D=ASP>]0#X@Q8D<6A:)5C8.9 H&\94'KZ'GZ4=QG5B.873.9@8
M2N!'LY!]<UQUMI,VL^ TM[=(FE%Y<,OF-@#$\G/0_J*U=%\5?VWJI@A@6. 1
M,V6<&3<&P<J.@]#WJ7P9_P BW'_U\7/_ */DI-7T8)FM8Q2P6,$4[*TJ(%=D
M& 3CL*GHHIMWU$E96"BN+C\=3QWRVMW:1+(SS;,,55T5PJMN/ ZD'/I[U,?&
M-U<:1+=V=I'O%W';QH3O+!C@G (Y].>:"K?U_7H==17%VWQ 5%CBO+;-P5+.
M$.S'+ #:22#\O//%6?\ A.[9K6=O*5)HIO)V>8'#'N1CJ/>DW97$M78ZJN<U
M^.:-] 6XF$S_ -JI\P3;QY<G:JI\?PI*L<MDZLR;P/-'0YVGZ?*<^E,N=3DU
M>VT&YE2-&_MHQXC?<N%$JCGOTJK"33.QHHHI#"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@# UC_D;_#OUN?_ $76_6!K'_(W^'?K<_\ HNM^@ HHHH *
M*** "BBB@ HHHH **** "L=O%&GH6R9]@8JCB)MLC9QM0_Q'/'%;%<Y-X+LY
MI8W-S=*L#F2W12O[EB<Y!VY/)S@DBCJ!?G\06EM8QW4T=RBR2^2L9A;?NYXV
M]>QHM_$FE7%K]H6]B5-F\ASM91G'(/2DET""[M88+^66\$4_GDS;3O." ",8
MQSTQ5/\ X0K31?-<1F6-2XD$*[0BMWP,<9H'H7+;Q-I-U;"=+V)8R"W[P[3@
M'&<'MFI4UW2Y'*)?V[,H)(#CC%9K^"[&1XRT]SY:3K<"/<N/,7&&Z9Z#&.E/
MN/!UE/;F(37,1./GC8!A@YZXH["Z%HZGHDTRRFXLGE\O>')4MM^OIUJ2TDTB
M6X5;3[&TRJ'41A=P![C\ZRH_ NGQV\<8N+HM',)UD+*6WC=@]/\ :-6;/PG:
MV>H2W@N+F26565MS#&6 !88 P>.U "0:WHEQIE[JL,:M!"62=Q!\S$'!&,9-
M.M]7T*YC ;[/#M<IY<\80@@9/!]CFH;3P996EE?V@N+F2"^ $B.5VCZ # SW
M]:=J7@^QO61HPT,<:X%M%A(G.<_,,4!W+4E]H5K*8GEL8Y,YV_*#G_&GRZGH
MP,GFW-GG<%?<5^]Z'\OTJA8>#[6VM46:622<X:208^9L8STJ&U\ Z;:Q/&LU
MTR,C1@,RG:&# X./]HT+?4/0L7.MZ#;06UQY221R[_*:*WW8"?>/ XQFK?\
M:6B(S2F>S1\#<QVAN1GGO5.\\&6=]9VMM+//LM=X0D(QPW4<J1QC@]:(O!MC
M%=0S>?<MY"LD2,P(4,!GMD].]+H,L3:GH$=X;>:2S$Q + JOX9/KS6P,;1MQ
MCMBN8E\!V,D21"\O$CC!\L*RY3/4@[<Y.?6NEC011(@)(4 9/4U70G6X^BBB
MD,*R_P"T=-?5Y+5D!NE'S.8N. &QNQUP0<5J5DOX?A?4I+P3SJTAW&,$;=Q
M4GIGD*!0!2'B/0 ?]7M\L^8V;8CRP?\ EH>.%/\ >IT?B30SLB5"@<L0IMR
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MBBB@ HHHH **** "BBB@# UC_D;_  [];G_T76_6!K'_ "-_AWZW/_HNM^@
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M(JM[L74ZFBBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** ,#6/^1O\
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MKD]=T@3^++:]TW^SEAC,(\PW2; JDY!C/0@'@K^-=]_:VG_\_P!:_P#?Y?\
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M;_P&MO\ XJC_ (2;PY_T)3?^ UM_\54'_".7GFR1^9;;H\!OWG )Z#IUJO\
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MJK<:QH^H:MHD-CX4-M+_ &@C%O(@7< K\9#?C^%-CT&^D=$\L*6B$OS'&%/
MS57305\4Z&#U%\!_Y#>@#V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH X+XE_\ 'WH/_76;_P!%URM=IXZTN;6=7T"TMIXX)6>=A))&7 Q'SP"/
MYUG_ /"N=7_Z#5E_X!-_\<H YNBND_X5SJ__ $&K+_P";_XY1_PKG5_^@U9?
M^ 3?_'* .;HKI/\ A7.K_P#0:LO_  ";_P".4?\ "N=7_P"@U9?^ 3?_ !R@
M#FZ*Z3_A7.K_ /0:LO\ P";_ ..4?\*YU?\ Z#5E_P" 3?\ QR@#FZ*Z3_A7
M.K_]!JR_\ F_^.4?\*YU?_H-67_@$W_QR@#$L+PV%XEPJ!RH(VDXZC%6[76?
ML\, -LKSVRLL,N\C:#ZCOU-:'_"N=7_Z#5E_X!-_\<H_X5SJ_P#T&K+_ , F
M_P#CE &5#JAB6S5H$D%J[2#)^\2<\_C5N3Q&;F)DO+..0NA1BC%,C<&]^_\
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M?^ 3?_'* ,O4]5?5)X69-BQ+M49R>N3DUE^%+P6"07+1^8(YI3M#8/WV[UU
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M A'BN=I5>6VB)";&V$KNYSG_ .M658R&7Q;HTA !>_W8'0?(];?_  KG5_\
MH-67_@$W_P <JK/X1U31-8T.Y?4[2;.H(@46K+U1_P#;/8&@#TVBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH P-8_P"1O\._6Y_]%UOU@:Q_R-_A
MWZW/_HNM^@ HHHH **** "BBB@#/U+4WLI;>&"V:YN+@D(@<*, 9))-5#XIL
MXTD%P#%,F 8B0221G (X]:T+_3+74T1;N,N(SN4AV4J>G!!!JO\ \(YI7[O_
M $*/]WG9R>,@*>_H *6H/R*NF>*8=3FM$CMY%%S'YFXD87@G'Z4-XQTI9C$S
MRAP?FS&?E7(&X_[.2.:F_P"$6T@000K:;8X"3&$D=2N1@\@YIL'A+1;8N8;"
M-2Z[6^9CD9!QU]0*;\OZ[ M]2"W\9:?-?2VS+/$4(PTB$ J5W;O85)-XNTRW
MB62=IHT8%LM$1@8R/S'3UIP\(Z*'#_80S!@PW2.W(&!P3Z<5#>>"-$NX'1K4
MJ[)L$GF.64=L9/:GI<"1O%^FJYBW2>?@_NV0J0W.%/H3CBHD\96/GW44R2(;
M=E7 ^8N3@$ #G@G%6%\):,LL<OV(&5""'+L22#D$\\\^M2_\(WI :)_L,0:)
MMRL,@YSGD]^?7-("F?&-B)2IBN!'Y0D$K1D*0<XY[ \8/O21>-M+91Y[20$N
M4PZ="#@<^YZ5<3PSI*0R1"T!20!65G8\#H.3P!49\):(TOF&P0MDG.YNYR>_
MK0#W$C\56337$<J7$'D1B1C+&5XP2>/8+43^,=.$:L@F;?\ <RFT-R!P3]<U
M-+X3T>9666T+!@%8F9\D8(Y.>>":)/".B2NKO8(650@.]N !@=Z'Y O,H7/C
MB&VD/F6,WE;-ZMO&7'/W5[]*OKXJTTV\\SR211P??:2,CN03^8(_"GW'AO2;
MILSVP<;0NTR,%P.GRYQGWZT2^%](GC2.2S#(@("[VP<DDYYYY)ZT!T\QD'B>
MSGO'MS'<1,J[LR1E0>,_RJO/XVTR*P-VHG>,JQ0^60'Q[GU((!JTWA;2&'S6
MI)]3,^?SS3)?!^AS)&DFGH5B38@W-PN2<=?4FA;Z_P!('Y$=_P")QIUQ*9;-
M_L=NJ-/<^8H$8;_9ZG%(WC/2AD+)(7P6P4(X[$D\8/:KMSH&F7=Y]HN+8/*0
M%.7;:P'3*YP?Q%5F\&Z$R*K:>A1&W*I=L ^N,TN@UN-;QAIB@DF?( .!$3N7
MGYAZCY6Y]JVT=9(U=#E6 (/J*P[+PAI]K<7,L@:;SAM"L3A%^;@<_P"T:W$1
M8HU1!A5  'H*K0E7ZCJ***0S USQ5%H>I06DMNSB5-Y<.!M&X#IWZU8D\16S
M60GL@;EGD2)$4[=S,-P&3TXYJ>_T/3]1N%GNX-\B+L!WL 5SG! .",CO4=MH
M%E#I1L'3S8G<RL<E26+;L@CD<],4=/Z_K8.I3C\9:<OFQWQ-I<PNT<D3?-@@
M;N".O%/_ .$RTD,BO+*COR%:,@[>!O\ ]W)'-3?\(KHQ*,;%&9.C,S$]<Y))
MYY]:6;POH]Q+%++9(TD2A4;<P( Z#K2U#J68=3CN=*-_;QRO&4+HI7:S@=,
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M&F9)3M#C !VXY&T=*O+HNN+=?;(I'290J;)+LN&&3NSQ],>E:?\ PEMM_P!
MW6O_  6S?_$T?\);;?\ 0-UK_P %LW_Q-,FQAQZ'XJEL+L7%V!,3B!/M)9-I
M'S;LCGOC-2WVF>*)%"6L@!+DO(UV0#R,;5 X&,C%:_\ PEMM_P! W6O_  6S
M?_$TT^+[1<;K#6%STSITHS_X[0]58?6Y@GPGJGVNSN)H89F1'1QO4X&\%?O*
M>V>1BIH=%\3V]Q,HN ;4N2B1W!4["P.WIP>OS?A6P?&%F&VFPU<,>QT^7/\
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MH!(+>,3$&0*-Y'KCFL3_ (3"TR!]@U?)Z#^SY>?IQ3O^$MMO^@;K7_@MF_\
MB:=R4K&[16%_PEMM_P! W6O_  6S?_$T?\);;?\ 0-UK_P %LW_Q-(8>+-*N
M=6L;>.U1)#'.KLK%1D#_ '@1^8K+&E^(XY<1OMLQL"V\=P$90%(;#!<<G!]L
M'UK4_P"$MMO^@;K7_@MF_P#B:/\ A+;;_H&ZU_X+9O\ XFA: ]3)BTKQ-;6R
M6T+H(L!F(N,$?+RHXZD\YJM9Z%XJM5,:W&V'S&8(+HY\LN6*9Q][!^_UK?\
M^$MMO^@;K7_@MF_^)H_X2VV_Z!NM?^"V;_XFA:#;N2Z;IT]OX62QN%S.(2C+
MYN<D]MW]:A\&:9=Z1H"VM[%'$ZR,55"#A>V2.":7_A+;;_H&ZU_X+9O_ (FF
MCQ?:-D+8:PQ!P<:=*<?^.T+2XC?HK"_X2VV_Z!NM?^"V;_XFC_A+;;_H&ZU_
MX+9O_B: -VBL+_A+;;_H&ZU_X+9O_B:/^$MMO^@;K7_@MF_^)H W:*PO^$MM
MO^@;K7_@MF_^)H_X2VV_Z!NM?^"V;_XF@#=I*P_^$MMO^@;K7_@MF_\ B:/^
M$MMO^@;K7_@MF_\ B: *_B,3K;Z,+IXWD_M:#F-2!C)QUI8M'O(O'$NHK#&+
M62+:TC.&8\=AC(_/%9?B;Q-;SC2L6&K+LU*%SOL)5S@G@9')]JV3XOM%(!L-
M8!/0'3I<G_QVCK<'M8WZ*PO^$MMO^@;K7_@MF_\ B:/^$MMO^@;K7_@MF_\
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M,,;8+<J2<CK6U_P@WAW_ *!4/YM_C1]I2[!T:-^BL#_A!O#O_0*A_-O\:/\
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MO_0*A_-O\:R-<\)Z)8WNAO;:?%&S:E&I()Z;'/KZ@4 =M1110 4444 %%%%
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M&9HM0W6MS#(T<D7W^0,\$=>*>?&FE*Z([3H[_,%:/G9P-_\ NY(YI/;?^O\
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M5_\ /KHG_@3+_P#&Z/-\5_\ /KHG_@3+_P#&Z -ZBL'S?%?_ #ZZ)_X$R_\
MQNCS?%?_ #ZZ)_X$R_\ QN@#=KG->MEM7T"-&D8?VJAR[%CS')W-3>;XK_Y]
M=$_\"9?_ (W61KLGB$WFA?;+?2E3^TH\>5/(3G8_J@[9_2@#M:*** "BBB@
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M_P#\11_PFVB?\_%Q_P" 4_\ \17*?\+ \0?\^6E?]_)/\*/^%@>(/^?+2O\
MOY)_A0!U?_";:)_S\7'_ (!3_P#Q%'_";:)_S\7'_@%/_P#$5RG_  L#Q!_S
MY:5_W\D_PH_X6!X@_P"?+2O^_DG^% '5_P#";:)_S\7'_@%/_P#$4?\ ";:)
M_P _%Q_X!3__ !%<I_PL#Q!_SY:5_P!_)/\ "C_A8'B#_GRTK_OY)_A0!U1\
M:Z)C_CXN?_ *?_XBN8\)W>G>'M0U2XGU266.\F,B0Q:?.B+[XVX#?2F?\+ \
M0?\ /EI7_?R3_"C_ (6!X@_Y\M*_[^2?X4+34.ECJ_\ A-M$_P"?BX_\ I__
M (BC_A-M$_Y^+C_P"G_^(KE/^%@>(/\ GRTK_OY)_A1_PL#Q!_SY:5_W\D_P
MH ZO_A-M$_Y^+C_P"G_^(H_X3;1/^?BX_P# *?\ ^(KE/^%@>(/^?+2O^_DG
M^%'_  L#Q!_SY:5_W\D_PH ZO_A-M$_Y^+C_ , I_P#XBC_A-M$_Y^+C_P
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MPQ+\CUP<4= ZG)T5T'_"$:O_ '(/^_O_ -:C_A"=7_N0?]_?_K4 <_170?\
M"$ZO_<@_[^__ %J/^$)U?^Y!_P!_?_K4 9NG:7)J"3NK!(X4+%B.I SM'OQ5
MK^P0D=N\ESCS2JL%3)0L 5'OUK2L_#GB.P5UM9(D1P0R^;P<C'3'6I3H7B0K
M ,VO[@Y0[ADG&!GCGB@##BTE)M3N+9;D>3;@EIMOI[?6I_\ A&IE@=WF4,)3
M&HQP<$ D^@YK2MO#FNV@!ABLP^6W,S [P>QXYI_]A^)?*DC)MB)&+$E@3R03
M@XX!('% &!JFE/I4\*LY=9%W*2NT\'!XK,\)6(U%8+5I5B$DLOS'_?:NLN_"
M^O7TJ/.+;Y!M4*^ !],53T'P9K^CK$XCM?-21VP9-P(+$^GH:%Y@S(N[?[+=
MRP9)\MBN2N"?PJ&NENO"6N7ER\\PMS(YR<28_I47_"$ZO_<@_P"_O_UJ$#.?
MK6CT&0QV3S2K%]J<KAOX!C.35K_A"-7_ +D'_?W_ .M5[^P_$S1Q1R202I$V
MY5D<,.F,'CD>U &+/HODK>MYXQ:@$*1\S@XY^G-,ATDS:0]ZLN6#8$2C)],G
MG(K:D\-^()7G9Q:_OU". P VC& ...@IYT#7PDB0QV<*.?X& *CK@''2@#.C
M\+RM*J23JO[D2-@9VDG&WWK*T]2GBO1$/5;\#_QQZZH:3XIWJSRV\A5=H\Q@
MW?//'7/>J=KX/UA-?TV]F$!2"Z\Z4^9SC:PXX]2* /0:*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#CM
M6T'6)M?N-1LWRBR1F*/>02 F"0=V -W4$<U1=/%TT9M)!-Y[1$Y$D80<J&RW
MTW8QR*[^BE8=];G&6\?BH7$HGBE6VW+M"3QE^"W0GH,;<@U8T^/Q0=)OUO54
MWD@"PY==H)ZD$= /3K75T4WJ):'GX'BC31<6:+.RV4(\J1'5D=3OZ[OF+#@#
MZ9/6K_V?Q.\:R;[@( 0L8DC$A!/!8],CC-=C10]16.5%MXDN++4HKI@IDA46
MVUEX; W@X/<YQ61_8&OF KY,JR>:"K"YQB $;HR-Q^9N3G]:]!HH&<!<:#K;
M&(P6\P.P*H>X!$2Y/&=V<@>QSZBMN/2M1TOP_#;6CM+,9 9S$0CE<<[2[$9S
MCOZUTE%*V@=;G'0:-JZZ,_VY9;BYEO3-/"DX&^//"J<@ 8QQD4Q[/Q(+J&*U
MMS!8#;^Z,ZMM7))!).<].<^U=I13>H'#6ECXIL-,C)D96@C!V>8KACEMV>I/
M&W%6(+:\\0^$KI+A+AYO/;[,9)=CE>,'<I />NQI*=]0>IQ5YIGB2UU&[;2E
M*VS>6L0$P)V@-_>/J1GUKLX=_DIYO^LVC=CU[T^BETL 4444 %%%% '$W^E:
M_->7D[0>=;W; -!'<[65%.5[@ D<<&J\.@:JNH7,GV&Y6.0QFS)O ?L@#'<&
M&[YO7OUQ7?44+0'J0VH=;:,2;]X'.\@G\<<5-110 4444 %%%% ',:QIM]/X
MLL+FVBE:%4*R2>9A4'<@9X;\#FJVH:9JKZ-;6%ND[/ Y=R9 =X);:-VX=.">
M>]=A122L#U=SA+O1?$<T5RME&(%E5#(LER06=>NP@G@]\X]*MZ[I>L7VI":U
MAE0;DRPN H,8W;TQGJW&#^HKL**?2P+>YFZ#;7%KIBQW*M&=[%(V?>8T)^52
M<G.![UI444"2L%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" ,K G,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[CM*\=-K,#^%=U8VJV5C#;IC$:!>*%L+J3T444 %%%% !1110 4444 %%%%
M!1110 4444 8E]XMTO3]6.FS/,UTH5F2.%GVANF2!Q4+>.=#%U<6ZW+N\!8-
MLB9@S+]Y5(')'<5F:GX2U"?QC<:Q EI-#+'$JK)=S0LA7.3A!AOQIFG>#]4M
M/%R:EYMG!;K+*\OV=W_T@-T#1GY5([L#S0O\P-.S\?:#?HKP73[6W[2T;*&V
MC+8SZ"K-IXPT:^GT^&WO%>34(VDMQ@_,JYS].A_*N=7P'J(TC2[3[3:^99_:
M=YRV#Y@(7'';/-8D'PHUFP<26>HV8D1?*A9R_P"Z0QE7QQUW,2*3O=V_K^M
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M;_T&X_\ OS+_ /$T?\+6\&_]!N/_ +\R_P#Q-;WF:3Z6O_? H\S2?2U_[X%
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M !!<WG]MZ/8VEZUFET9?,=54GY0".M8EMX^GM;9(;J 7D\;2"25#M#HK;00
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M*R#A&VJV\-UR",9]#6K3UL9IZZE2SUWPW<ZK-:'3K#;A&MV2V4F1"NXL1MX
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MV2V<Y_"KIT#2VN3.;&+S2RL6YZJ,*<=.!6W_ &5>?\\#^8H_LJ\_YX'\Q0M
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MD^A(K=_LJ\_YX'\Q1_95Y_SP/YB@#*.EV)-R3:1$W7^O)7/F<8Y_"H8M TN
M((K&%0DGFKC/#XQGKUQQ6W_95Y_SP/YBC^RKS_G@?S% ;F WAC1F\G.G08A^
MX!G YSZ\\\\TYO#FD->/=-80F=R6+\]3P3C.*W?[*O/^>!_,4?V5>?\ / _F
M* ,*;P[I-PBK+80L%C6->O"J<J!SVK;TT!;^W Z!L#\J=_95Y_SP/YBI[+3K
MJ*]A=X2%5LDY% '0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ]OZ[EVBBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6Z&')X'O8[N*"!H# ;9E,K%_W3D(-R\_>^4D9I?^%?WWGNZWL"*0ZHWSEUW
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M( HHHH RO$.E2ZM8I';NJ31R!T<NR[?H5Y[US$?P^NH9%,=Y"?+82*[;B6(
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M8+!>@8CJ>]&JWMY;I;O9^0_FL$"OG+$^F/:GV5_/<:C=6T\(C$(4K@Y+9[T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX;#B&X_UWD;QY7FYST&>O/7-"W VJ*** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]FYU W'VYJEU)>MC6HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M03G/%=M13>NX%>QM196%O:ARX@B6/<1@M@8S^E6***;=W=@E8****0!1110
M5E76B"YN;V?S\27,21+NC#",*2>AZY)&1[5JT4 <X/"DJ64<,.HF.2.5IE<0
M+@,Q.<+G &#T[8IVE>$H]*OHI8[IW@A=Y8XB@XD==K-N[Y&>.U=#10M-@,G6
M]!BUR)HYYG1#$T8"CC)(.??[O3W-8D?P]B22V87P"P2>;L6W4#=NW9'/'I78
MT4+0'JK,**** "BBB@ HHHH **** "J]_;RW5E+#;W#6TKKA954$H?7!ZU8H
MH YG2O!D>F_9-U[),+99]J[ J[Y3DL!VP,@#W-6?#7AH>'_M;&Z^T27+*3MB
M$2J%&!A1QGU/>MVB@+!1110 4444 %%%% !1110 4444 %%%% #6=44L[!5'
M4DX I0<C(Z5S7CK2]3US1H]+TQ(]MS*!<R22;56,<D<<\D <"L*RLO&D36L-
MPLR^1!Y,;0SQ^467(WR _,01C %*^X['H=)TKS:*W\=6\.]!>RJ4*>7+/"9/
M,,9!?/ V!\$#K4.HZ/XUO+N:.1[V2U(BD&V>)!E2I*C')[]<4^HCTY75QE&#
M#U!S064,%+ $]!GK7GUCI_BRTN+821W1@&YEC@GB0!B^?WOK\O\ =I/#6E>*
MFU^RNM<CG,$#2D&::-F0,B\?*>1D&FE<3=CT 3Q-,8A*AE49*!AN ^E*TT:'
M#R(I]"P%><2>']>M!?&QTH-JYEFD35C.H+*Q^55&>3CC## J";P[XLO8(S=)
M)-(!"0TKQAQMD).[!P2!BIOH5;6QZ@K!U#*05/0@]:6O-)=/\:6&G>?%<S1&
M!$7RM\9C5!%\YV@9SOSBMOX=:C?:GI]]->2W4L0G"P-<LK-C:,\KP><U5KMV
MZ$O1+S.PHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:36\N?+F0HV/0C!K'\+^&!X;AG5KQ[N28H"[($PJ+M48'L.M"Z@]E8W:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML_G74:_: #%SG<..?IR.: +M%9A\1Z4(I)#>Q;(WV,1GK[>H]QQ4\^K6-M)
MDUS&K7'^J&?O>_TY'- %RBJMGJ5IJ!D%I.DOE-M?;V/^>].FOK>"X@@EE599
MR5C7NQ')H L4444 %%%% !1110 444UW6-&>1@J*,EF. !0 ZBJ4NL6$.GI?
M2748M9,%) <AL],8ZTL&K6-S=FUAN8WG"[]H/;Z]* +E%1RSQPM&LCA3(VQ
M>YP3C\@:C6^MWO6M%E4W"()&0=0IZ&@"Q1110 4444 %%%% !1110 44C,%4
MLQ  &23VK-M_$>DW=E<7D%_ ]O;9\V0-PGUH TZ*RH?%&C7$END6I6[/<@F(
M;L%L=?IT/6K.FZM8ZO"\NGW4=Q&C%&9#G!':@"Y1110 4444 %%%% !1110
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M<?O(W"Q*N<H<XW'C[PXK2O?%%S%%;3PP1>7]E6[F5\EBI(&U??GK0_/^M/\
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M$-T+Z&&.6$HP\DDJ5=0PZ]P#@U:V8GTN=+1112 **** "BBB@ HHHH ****
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M'')P3CW'YU5M;";T.VHHHI#"BBB@ HHHH *BN;:*[MW@N(UDBD&&5NA%2T4
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M+<; JM,=T66 _> #@\YKJ])O6U'2[>Z>,1O(N64'(![\U9$48)(103U.*<
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MPB+;*6M_-_>/A>&/'"=P:?\ 7YB_K\#I8_"&GQ2QR+)=!E9&?]\<2E6W+O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@Y]_NCCZUB1_#V%)+9A>D+!)YNQ8%"EMV[(]/2A ]M#L**** "BBB@ HHHH
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ME'..#UJO;Z+96S(T<;;U?S S.2<XQW]J%OJ#\B_1110 4444 %%%% !1110
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M4+6V6-I9D42,$3G.XDX&/Q-6:=]+?UT%U"BBBD,**** "BBB@ HHHH ****
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M5T]OXFTRZO4MH;A6,@^5NQ//R_7 S44WB_1X;J&#[9$WF*S%PWRH%&22:?\
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M$=Z%N!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHRYBF91DHG?.>-W2M:_\;WALKF^T^*Q2RMPJM-=2-\TA3<R*!RQR47CN3Z4
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M2^P;CCIS4NQ-^_:N_&-V.<?6G44 %%%% !1110 4444 %%%% !1110 4444
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M.C\(Z'&ULRZ;#NM6W0DY.P\>I]AP:V:* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" ,K G,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYFN)3#(W!&5>,?*W/8<CBL&?PKXA>RDA$UM(UQ (F9YV!AQ*7'(7Y^#C/!-
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M&6V0R[CM*\=-K,#^%=U8VJV5C#;IC$:!>*%L+J3T444 %%%% !1110 4444
M%%%% !1110 4444 8E]XNTO3]6.FS/,UTH5F2.%GVANF2!Q4+>.=#%U<6ZW+
MN\!8-LB9@S+]Y00.2.XK,U/PEJ$_C&XUB!+2:&6.)562ZFA9"N<G"##?C3-.
M\'ZI:>+DU+S;."W665Y?L[O_ *0&Z!HS\JD=V!YH7^8C3LO'V@WZ*\%T^UM^
MTM&RAMHRV,^@JS:>,-&OI]/AM[Q7DU"-I+<8/S*N<_3H?RKG5\!ZB-(TNT^U
M6OF6?VG><M@^8"%QQVSS6)!\*-9L'$EGJ-F)$3RH6<O^Z0QE7QQUW,2*3O=V
M_K^M!K7<[A_'&AIHQU5;LR60D,1DC0MM8=<XZ5"OQ!T-WC1);AWD0.$6W<G:
M> 2,<"L6R^'E_I>D:SI=KJ,4UKJ%JJ)YB;"DH&W) &,$ >]27W@G49->AOXQ
M9SHEE%;%'NIH2&7JV4'(]C5*UQJUF^O_  WZ?D=#K7B[2_#\L,>HR2HTX!CV
MQ,P.>W'?VI$\9:-)&K"ZP[3&#RRI#AP,D%>O3G-+XAT:YUB/2Q#)%&UI>QW,
MFXG!"@Y ]^:IW/A(2^++S6$6W!GL3;KG.X2'(W'M]WCUJ7HOO_K]!?U_7YB1
M_$;P[+;O,MX^%"L%,3!G!. 5&.1DCI6UIFL6NK6XFMBZJ25"RH48XZ\'FN(;
MX7>5X9M[>&59M5C$2O+//)LVHP8HA RH..PKI-%T:[LOL@N+.Q00-(=RW,LS
M(& ^Z7&>>^:?5BN[)EW4/$6GZ9<>1<RMYBKOD"(6\M?[S8Z"KWVJ#YAYT>5
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M,G_Q-;WFZ5Z6O_? H\W2O2U_[X% &#_PM;P;_P!!N/\ [\R?_$T?\+6\&_\
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M_G@?S%']E7G_ #P/YB@#)L-,L]+B:.R@6%&Y(!)SQ[UG_#'_ )$6U_Z[3?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !113!-&93$)$\P#.S<,X^E #Z*8D
ML<I81R(Q4X;:<X/O0)HS(8Q(AD R5W#(_"@!]%1K<0LC.LL913@L&&!3HY$E
M7=&ZNOJIR* '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\/4FC\,+'-;K"B32+"1#Y)E3/#E.Q-=113[@UL%%%% PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **Y[7M8U"RU>UM-/A\U
MI())2NS=DJR@ G^$?,>:R$\;W%S<26RF"%B7ECD*DYB"@C@XR221^!HZ7"QW
M%%<K8>)9[[4I%1XFA2.-E3A ^X<_,3D<]JNZGJ]Q9:W90(\30S2B-TQRF03D
MG/7ICCUH$G=7-VBN4U'Q?*EW]CLK3,C70MED:1>H.&)7M[9ZUJSW-X/$-M:P
MS1F%HVDE0IR%''7U)(_(T#>AK4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 45ROBCQ/?Z/K%E9:?:1W+7";MA1F9OF
M P,<#@DY/%<U;_%#5)"H>PM-SA6QAUV98KM)/WNF<CB@#T^BO.X/B#JNH1I]
MDM+*&:-K>&YBN-Y*2RLPXQU7 !_&IK;QGKES$S"WT^,M?BR1I%D"9W,"V<\_
M=Z>] '?45SN@>(;O7](N98[>*&YAR@D8EH7<$@D8YV\?K6;9>+M6NM-LR+6S
M>]O996@4%E0VZ#_6-GE<G&/K0!VE%>9WGQ+U.S@ED:VT]XHW91=1ES%,5&2B
M=\YXW=*UK_QO>FSN;[3XK!+*W"JTUU(WS2%-S(H'+')1>.Y/I0!VU%<!#X\U
M:>4?Z#8P^8\D"Q32D/%(BABTAZ!.OO4$'Q'U*53(;6R\F J\C[G4W,;2! T(
M//J>?:@#T:BD!R ?6EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M &&)&<.44N 5#$<X/45%-I]I< ":U@D   #Q@X Z#FK%% %0Z78%PYLK8N
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
'!1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" ,K G,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"O?7T&G6<EU=/LAC&6;!./RK#_X3[P__P _C?\ ?I_\*W;NTAO[
M9[>Y0/$XPRGO7G/Q T.PTB"Q-A;K"9'<,03S@#%;T(0F^65[G)BJE6E'GA:R
M.J_X3[P__P _C?\ ?I_\*3_A/O#_ /S^-_WZ?_"N$\3:?9VZ:=/9QK'%.H^4
M'ENF2?K7H$?@S0FC4FP3) _B/^-:3IT8)-WU,:=;$5).*MIZEW3?$.F:L=ME
M=QR/_</#?D>:TJ\^\6^#H-,LSJFC;X'MSN=0QZ>H],5U'A35VUO08;F7_7#,
M<F.[#O\ RK*=./+SP>AT4JTW-TZBL]]-F;-%%%8G2%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4HM7L9I9(T
MN8RT8);GH!U-6Y$\R-DSC<",USXTB_ETS^SY([9(XXBBR@Y9SD$<=NG- &G'
MK>GR0O*MU'L0@,?3/2GSZM96Q(EG52&"D=>2,_RK&O-%O=3W-<101?NTB"*^
M0P!R23C\J9#X:NENL239A6?<KJY#[ I 'UZ"@#9?6]/C4,]RH!QV/<9'Z42:
MU81K&6N4(E&Y"O.1^%9EQHUXFJK=6ZQRHDBL!))@L F.3@\U#'H%[!-'+M#D
MARZQSF/:68' ('(XH#H;O]JV9C9_M";5?8WLWI446N:?,Y6.Y4D$*>#U/05C
M_P#".7?VQ;I61&:Y$DL>_(*CISCJ.:MRZ/<D7&T1Y>\6=>?X1CVIV7]?(4M-
MOZW-4W]L))X_.3? NZ09^Z.O-3(ZR(KH<JPR".XKF?\ A']1626Y\V%IKE9%
ME3I@,./F[XP*V],%U';)#=0)'Y:!05DW;OT&*2V![EVBBB@84444 %%%% !1
M110 4444 %%%% !117&Q^,+G4/&$>GZ; );-&*ROCD^K9[ 5<(.=[=#.I5C3
MMS=3LJX'XI_\>VF_[\G\A7?5P/Q3_P"/;3?]^3^0K3"_Q488[^!+^NIA^*W@
MF72YHF4.R@&-3]P#&,^YKU:,XA3)Q\HKRKQE-O33'D#"Z\H%E/11Q@"M.ST'
MQ)XFC6YU#4'M(&'R)R./]T8_6NBI!2IQ;=EJ<E&JX59J,;MV-WQUKMM8Z%-:
M"16N+E=BH#D@=R:D\!6$EAX8B$P*M,YEVGJ <8_E7(ZQX&U#15%_;S+?+$=[
M@IR,>HYR*[?PIXAC\0Z9YFU8YXL+*@Z#T(]C6=2*C1M!W5]36E.4\1>JK.VB
M-RBBBN0]$**** "BBB@ HHHH **** "BBB@ K(UCQ3I.@W$4&I70ADE4NHVD
M_*#@DXZ"M>N4\0^#F\0^)K:[GN)(K&.T>"1892CN68'!X^[@4=09<3QOH#Z@
MMFNH1F5G5%.#L+, 0-W3)R*EM/%VBWVJMIUM?QO<@E0O.&(ZA3T)'M7*-\-K
MB&_-S:S)Y27ZRQV;3/Y+0A%49']\8R#ST%2V_A#7XX-+L"VG);Z3.\\%P"Q>
M4\[ RX&.O)S2B[I-@]['2W_C'1=,N)(+J\ FCD$;(JEB&(W 8'L*9=>-=#LD
MMFN;Y8_M*[T!4Y"YQN(QP,]S7)7'@;7KW43JMTMD;F2Z$TD$-W)$,"(IQ(%W
M#).<>E::^'M?LKV2]T^&P:2ZM$MI8[JX>40[2<,&*Y<$'D''-/\ K\/\QNU]
M/ZU-J'QIHD^KC3(KO==DX"!&_/.,8]ZV;BZAM;9[FXE2."-=S.QP /7-<^/#
M]X/$MUJ+BVEBETU;41Y*[G!R>,<+6J=/$V@"RE@A4F 1^5]Y%.. "1R >])Z
M1TW_ .''9778<NLV#R6L:W49>[0R0KGEU R2/;%51XITMK:2X69VAC?8SB-B
M,\^WL:ICPY,&T9\6_F64,D4K<Y8,F  <9(S]*HVGAC4XK"\M4\FTAN$BA\F.
MYDD7:&_>,"PRI*D@ ?G3>[2)7PILW;/Q+IFH7$4-I<>:\JAUVJ<8(R,GMQ3I
MO$6G6]\;22?$JD*Q"DJK'HI/0$^E93^';I/$D=U9Q06T"RH[S1SN&=%3;L,?
MW?3GVJ.]T#4I?$7VJVCMXD:=)&G2=UW(.JM%@JQ[;N#1V#H;%UXDTRSL;>[F
MNE$-PH:(@$EP<=!^(_.I;/6[&^CN&BFV_9N9ED!5HQC.2#TXKF;KP5=W$-]
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ME3N8*HR2P[574#I)/$6F17DEK)=HDD8.[=P 0,D9Z9 YQ4/_  EFC^4DAO%
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M'UK+/@O5+"[LI"D5]MN,,LLI,<@PYWR )QU'7=R: L>@QZA:S74EM'<1-/&
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M(QP/X:72_B-X9L[R[EN-?M62X?S"$MY00>G]WIBNR\S2?2U_[X%'F:3Z6O\
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M:_\ ? H\S2?2U_[X% &#_P +6\&_]!N/_OS+_P#$T?\ "UO!O_0;C_[\R_\
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M #/^%K>#?^@W'_WYE_\ B:/^%K>#?^@W'_WYE_\ B:?_ ,)OX)_Z"NF?D/\
M"C_A-_!/_05TS\A_A0 S_A:W@W_H-Q_]^9?_ (FC_A:W@W_H-Q_]^9?_ (FG
M_P#";^"?^@KIGY#_  H_X3?P3_T%=,_(?X4 ,_X6MX-_Z#<?_?F7_P")H_X6
MMX-_Z#<?_?F7_P")J6/QGX,FE2./4],9W(50 .2>G:MHR:4#C%K_ -\"@# _
MX6MX-_Z#<?\ WYE_^)H_X6MX-_Z#<?\ WYE_^)K>\S2?2U_[X%'F:3Z6O_?
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M=E3G (Y#&F_Z^_\ I@=9'(DT:R1.KHPR&4Y!_&E9@JEF( '))[5Q-SI'B?\
MM2=;>[FCL]P$?E-&B"/ & .H;.3TIQTOQ$CS1,]U-'B1;=OM* *-S8W@\MP5
MH [0$$ @Y!Z$4M<!=6NOZ58PW%W=W1B* 7*K<*,-N& IQA>,UUGAQ[B3P_9/
M>&4SM&"WFG+?C[T;AUL:=%%% !1110 4444 %%%% !1110 4444 (S*BEF(
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M1PHK1Q@R#+8_>9&W]-U1^%+76+7[4FKM,ZE@8GEE5B>.>%X _G20,Z&BBB@
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MHQ88_N]><=:ZNGI;^OZ[BZA1112&%%%% !1110 4444 %%%% !1110 4444
M%%%% !14$=G%%>2W*AO-E #'<<<=.*GH @GNX[>6"-]Q:=]B@#/."<GVXJ>J
MTEFLNH0W;.<PHR*G;YL9/Z59H **** "BBB@ HHHH **** "BBB@!&8*I9C@
M 9)K)T'Q-8>(A.;$R@PD9$B;25(RK#V-:KH)$9&&58$'Z5A>&/"D7AKSRMU+
M<M*J1J74#8B#"KQU^M"W=P>VAOT444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %84?B9'%R
MWV9@L*LWWQNX..1U%;E8S^&HIG=IKJ9\HR*2!E0W7G'/XT #Z]-').KV+!88
M_-9O,'W3G'\J;%XF0A&EB54?(#)*KX(&<''3-7)=(BF^T9D<>?"L+8QP!GD?
MG5>;P\ES9BVN+J1T5U92$12-OT'>D"(8_%4$L43);R&21 1'D9#%L!:=-XC^
MSJ4FM3'<K($:-I  ,C(.[IBI3X<M=]TZO(CSR+("N/W;+TVTH\/PO)YMS*\\
MID#NS@?/@8 QC&*8%?\ X2RV6)'DB=2X;: 0=S XP/7.>M;<+.\*-(FQR,E<
MYQ[5DKX9M,*KN\D:(\:*V/D#'/!]NU:EM";>VCB:1I2B[=[]3]:8B6BBBD,*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[5-773
M"B^2\K,"Y"D<*.IYK1K/U/2(]2*,TLD3*"I*8^93U'- $>I:W'IYM\Q-()^0
M00../7J>>E+8:U'?W;0K"Z#!:-VQAP#@_3FF7>@I>;-]S*-@*C 'W"0=O3VZ
M]:DT_1(=/N3+'+(X"E8T;&$!.3B@6I8OKY+%(VDZ.^W.>G!)/Y"JDNOVX:U6
MW#2FXD\L<$8]SFK=Y8)>LAD9@%5@ ,8R1C-4K+P[#9M$RS2,8Y3(!@ 9(QC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-S'=-"@8^067.2#A,\'&*[[29;B?2K:2\1TN&C!D5P P/?(' JPL\3)N#KC
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU/S<_,>3R:?#X5TB"0O%:[6*LA.]NC9SW]S7-P77C"YU)+><M%;F21976UZ
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MCCVJK)X9TR5X6>%SY( 5?-;;MX^4C.".!QTI:_UZ?Y@_(BT/Q VJLPFA6'=
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M23[BR2!2WT!ZT$G&#QGJ%WK<5K$D,=L+J,-(%;)0LRE2".#P*GU#4M;,U[%
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M8U+5/MPO[B2X1/+;=(NWRY"N7C'L#5);V_K^OZW)>G]?U_7H=M1112&%%%%
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M!'Y$0Q^[3Y3N'RC@^M2444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4SR8]FSRTVYSC:,9I]% $36L#X#0QG#;AE!U]?
MK2I!%$S-'$B,WWBJ@$_6I** &M&CG+(K'!'(SP>M,CM8(@!'#&@4Y 5 ,&I:
M* "BBB@ HHHH **** "BBB@!GEI\WR+\_P![C[WUJ,V5NS,S0QMN4*05!! Z
M#%3T4 1"VA$BN(8PZC"L%&0/0&GJBIG:H7)R<#J:=10 4444 %%%% !1110
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MM@HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 45!;23R!_M$*Q8;"[7W9'KTXJ>@!*"0.IK-UDSMY"6X;<I:4D D?*I
MP/S(_*L:W:_U*2P^T^?MCN3N.P@,-N<]!QGVH6K!Z'64444 %%%% !1110 4
M444 %%%% !2=:AO1(;&<09\TQMLQZXXK)\,I(B7&5F6([-HESG=M^;K[T S=
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-,MQ]D8M#Q]TDY/UY ZU;TS1-.T83#3K2.W$S;Y-@^\:I"?D7J***0PHHHH
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.-I"X'UJ!M!G.GK8)?NELJ@9V@LWKGV-;=% &'+X92X?]]<$QL%\Q%0*&(!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M04445(!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWKESJ3L+HQN'M8[M?+&/+#Y_=GU(QU]ZJZ?XLN-8URUM+>V-M&&?[0LI4O@
M[1C.1GUKI+:QM;+S/LMM##YC;G\M NX^IQUIEMI=C9.7M;.WA<G):.,*<_A3
MZB>Q;HHHI#"BBB@ HHHH *S];OI-.TN2>$#S,JBENBEF W'V&<UH4R:&.XA>
M*9%DC<;61AD$>A%#!')WOB6_@T%7A,<MX+Q[;<BYWA2WS!<XYVCO3M#\3W>I
MZC;B3RO)GDD@\M5Y0HFXOGT)XQ6^VBZ:\ @;3[4Q  !#$N .O3'N?SJ6+3K.
M"Y-Q#:01S%0AD6,!MH[9]*:\P92US5Y-+,/DQ-,V&D>-1EF11SCWRRU2\.>(
MI]?U.[(C6*T@C0!<AFWGDY(/&.F*W9K2"Y!$\,<@92AWJ#D'J/I3;6PM;%2M
MI;0P ]1&@7/Y4D'0L4444 %%%% !1110 4444 %<KIOB'4+J'7A>&RM9K&8Q
MQ%V/EJ-N06/?UXKJJS[K0M,O6W7-C;R?.9&#(,.Q&"6'?CUH[C.+B\9:TEAI
MUY-)8/!+=")B%(:6)F"K+MS\HY]^U;WA/7;S5+W5+34)+:1[613') /E=&7(
M(]1VS6I'X<T:$Q&+2K%#"Q>/;;J-A]1QP>!5BRTVRTT2"QM(+82-N<11A=Q]
M3CK3$RU1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT])F:*3:$8D99EQ\^.?E%'_"=:@))T-K;A$8HDA+$Y#8#,H' 8<@UWE%'_!
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MH],OAJ6G078B>'S5W>6_5?:C?45RU1110 4444 %%%% !1110 4444 %%%%
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M-X&\37VOM=K?>2Q18Y4:(8"!QG8?<4+78ENVYUU%%% PHHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFXK>J&:TM[C=YT$4FY2AWH#E3U'TXZ4 <LWB#4Y_#<<MN8A>_:FAD)* A%+
ML QVYX'?%.T3Q/<ZEJD"[U>WFED@$93:Z[$W>8?J>,=*Z!M'TYH!"UA:F(#
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M].A_$5O6MPEW:Q3QA@DBA@&&#@^HHZ"ZDM%%% PHHHH **** "BBB@ HHHH
MI:QI_P#:NDW%GO"&9=H8KG'OBL;6?#-UK5]%-+-;QI =L?RL2%RIW#D?-E3U
MR.E=-118+Z6.-3P3=Q-!*E_ 9K:W-I"6B./*.<[AGEN>HP/:K=SX4N9DAA6\
MB6 0"UD!B.YHP5/!SPW!]N:TO$&N)H6G&<H)9F.(XMP7<>_)Z "JNI^))+%X
MC';I)$L N)V+8(0D#Y?4\Y_"DVF]?ZT?Z7!O2S':#X?ETHL9[A)2MNEK%L0K
MB-,XW<G+?,<U1T#P8VCZH+MYX'5"Q1$B.5!!S\Q))ZU?T/Q ^J,PGA2(-;I=
MQ%6S^Z?.-W^U\IS58>/M&:WEF1KADC/.(6Z>OTXJG=.[W%:ZL=+14=O.EU;1
M3Q',<J!U/J",BI*35A[A1110 4444 %-=0Z,I ((Q@U2UF]GL-/>>W2%F7[Q
MF?:JCN3W/T%<^WC2Y24>=8_9T<+'")0P,LK 8 ;&,<Y]< T 6Y_#,\FA6FF[
M[*5+95Q]H@+ L 1G&>.O%-TCPI-IE_#))>B:&&1YU!0[S(Z[3DY^Z!TXJ1O$
M5S_9T9CMHC>M<O;%"Y\O<F<G/7'R\?6F:1XL;5;V%1;A+>>22!&W?.)$7<V1
MTQZ4XWN[ WKJ7];T4ZPNUI%"")T",#C<V.>"#QCMZU4\+^&6\/M</+-%-),%
M&4BV;0HP!UY^IYJ]K.M0Z,D4D^/+)+2'NJ <D#OR5'XU0C\;Z3*;;:9P+B7R
ME)B("MG&#Z<TEY ]M3HJ*** "BBB@ HHHH **** $.<'&,]LURFE>'M;TRYN
MI9+VRN9;Z1C-<&%E=5P0H W$87T&*ZRN7A\8L=.UV[N+!X?[*D*>66&Y\#(/
MMFCOZ#,^Z^'9F73XX[U$2*%(KK,63*5<2%E.?E)8'.<]:T_"7A23PXURT]TE
MPTB1Q)LC*!408&>3D^IK#3XFS+,L,^F*LENX6^VRY" LJJ4_O?>%;OA+Q6_B
M-KE9K46[QJDJ!7W;HW&5)]#ZTUUL2_/^OZ_R.DHHHI#"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"":S@N)X
M)I8PTEN2T;9/RDC!_2J%[X8TK4=_VJUW;V9VQ(RY+ !NA[@"M:B@#+'AK2A$
ML?V-=BQB,*6;[H)('7U)JNW@[1GM_):V?R\8_P!?)G;TVYSG;[=*W** ,N\\
M.:;?W:W-Q [2JBQY65U#*#D @'!&2>M1-X3TAF=OLI4L>-LKC9SGY<'Y>?3%
M;-% %&TT:PLK6:VM[95AG_UJ$DA^ ISGV%9MQX,TR58U03)LD1RWGNS$+G"A
MB<@<]JZ"B@#'3PII$<A=+3;G!*B1MI([XSC/'7K4@\-Z4+B2<6B^;('#-N;D
M,26[]\FM2B@#F8O!%DNH332NYMV4K'"CNFP''<-[=L>^:Z"SM(+"TBMK6,1P
MQ+M11V%344>0!1110 4444 %%%% !17/:]K&H66KVMII\/FM)!)*5V;LE64
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M,--MQ#YS!G^9FSCH.2< >@XKC(/B#JNH1I]DM+*&:-K>&YBN-^4EE9AQCJN
M#^-36WC/7+F)F%OI\9:_%DC2+($SN8%LYY^[T]Z .^HKG= \0W>OZ1<RQV\4
M-S#E!(Q+0NX)!(QSMX_6LVR\7:M=:;:$6MF][>RRM JEE0VZ#_6-GE<G&/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" ,K G,# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"O?7T&G6<EU=/LAC&6;!./RK$_X3[P__P _C?\ ?I_\*W+NTAO[
M9[>Y0/$XPRGO7G/Q!T.PTB"Q-A;K"9'<,03S@#%;T(0F^65[G)BJE6E'GA:R
M.J_X3[P__P _C?\ ?I_\*3_A/O#_ /S^-_WZ?_"N$\3:?9VZ:=/9QK'%.H&T
M=6Z9)^M>@1^#-":-2;!,D#^(UI.G1@DW?4QIUL14DXJVGJ7--\0Z9JQVV5W'
M(_\ </#?D>:TZ\^\6^#H-,LSJFC;H'MSN=0QZ>H],5U'A35VUO08;F7_ %RY
MCDQW8=_Y5E.G'EYX/0Z*5:;FZ=16>^FS-FBBBL3I"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %\]@>R_K^NX1?$/P]-:37"WC!(D5R&B8%E)"@J,<C) XK7TK6[36(3):F0
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M9T2/=]S;]TX]\&@#HX+6"V&+>&.(>B*!4U9%^);_ %5+!)GA@6+S93&<,W.
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MR,;OTJPGA;7+&[:[TJ?38)KBU2VG23S)$CV$[63/)X/1J(MO?^M/\Q_U^/\
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M6\&_]!N/_OS+_P#$T?\ "UO!O_0;C_[\R_\ Q-;WF:3Z6O\ WP*/,TGTM?\
MO@4 8/\ PM;P;_T&X_\ OS+_ /$T?\+6\&_]!N/_ +\R_P#Q-;WF:3Z6O_?
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M^%K>#?\ H-Q_]^9?_B:EC\9^#)I4CCU/3&=R%4 #DGIVK:,FE XQ:_\ ? H
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MX-_Z#<?_ 'YE_P#B:/\ A:W@W_H-Q_\ ?F7_ .)K>\S2?2U_[X%'F:3Z6O\
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M^8H J45;_LJ\_P">!_,4?V5>?\\#^8H J45;_LJ\_P">!_,4?V5>?\\#^8H
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MPUQ:QD8^6%'14QW4;N_?-22^ )'MO*^WAEC\OR8V5@BX W@X.<,0&^HKM:*
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MB+6Z7<6ULYB?.W/HWRG-)H?BJTUJ46\:R+<A-SKM.U>3QG\*IIMZ[_\ #_\
M!"]C5T^W:STZVMI'\QX8EC9_[Q  S5BBBAN[NP2MH%%%%( HHHH S->LK[4-
M.-OIUU%;2,PWO(A;*=P,$$$^M8,W@B:697BEL[;8RR PPL"[*  KG/*9 /KQ
MUK=\0:I/I.GK-:VS7$KR+&%"LVT'JQ"@G ]JQ'\<%0LBV\4L,DWV.-T<_-/M
M#=QPO.,]?:A=;#++>&]0^R($N[47"W#W.XQ-LWN6W#&>F&&/I2:-X2ETJ^A8
MW226T$LDZ*$(<R.NULG.-OI4S>([G^SHVCM8S>M<O;%"YV!DSDYQG'R\?6F:
M1XL.JWL*"V"6\\CP(V[YO,1=S9'3'I3CN^4E[Z[ES7]#?6XC&+@PKY3H, _>
M)'/Y C\37/1> +F.6S9;RW5;>7S=H1R0=V>"6SCV/%=)KFL'2(H3'$)7=N5+
M8PO=OS(_.G:-KUIKL4DEEYA6-MI+H5Y]LTEOH-ZJS-.BBB@ HHHH **** "B
MBB@ JIJEE_:.EW-IE!YT93YUW+SZCN*MU5U.\.GZ9<W:Q-*88RXC7JQ Z"D]
MM1QO=6.$B^&%PKINU"!(I&'G0QPD*B!U<+%D_+RO.<]36_X1\*2^'&N7N+J.
M=I$CB3RT*@(@P,\G)]:PX/B=*P@\_3E5E(-X@D(: %E4#!&=V6R1Z5O>$_%;
M>)#<K+:BW>-4E0!]VZ-QE2?0^HJEY?U_7^9+\_Z_K_(Z2BBBD,**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHIDI*Q.1G(!Q@9_2AZ /HKSO3?$M[9JX^U-=%M@DN92S0Q9W98KC<A
MX V].:@DUG7KF[DOW>:*+RRRVJ%U&0IQV[]:.HF['I=4M2TFUU:.-+M9"(FW
MH8Y6C93]5(-<U=ZMJUQX4MHK1W?5+N5XQ)"F/+"L<G!]@!^-9J>+-4-REQLD
M1"_ER1S(VR ^6-Q; Z ^GK0K/0=]O,Z8^"M#)&;+("[2#*^".>HSR?F/)]:E
M'A+2-Q=K=WD(VF1YG9B.>,DYQR>*YT^.-562*/\ LM9-XR)5#[&!)1,?5MN?
M8TR+QOK%UJ,UK;VEJ52)IA(R2#[N[*D=C\OZT7"QOW_A*RGLHX;-1;R0C;$^
MYCM&02."#V]:U-+T]-+TRWLHV9UA0+N;J?>N1F\;:BMM)*EM;>8&53"P<-$#
MCYF.,8YKK-(O);_2;:ZN(UCEE0,RH<@?0^E"VT%U+M%%% PHK"\974UGX<FE
MMY7B<.@+HQ4@%AGD=/K6'%XIN+ 006<;7\+([/,TCRE&'1"Q'\7:DGN%CN:*
MXB/Q==1ZC!+/+!+9L DLD2.(TR"<\C.<@#\:H3^.-6=[>XCMXU*I*QM-KAF
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MX.&7CUQP<TV!Z#15?3TGCTZV2Z;=<+$HE;.<M@9Y^M6*;5G82"BBBD,****
M"BBB@ HJ"..X6[E=YPT# ;(]@&T]^>]3T -:1$*AV52YVKDXR?04ZL3Q'IM_
MJ4:K82B%HXW*/G!$AP!CTXW#/O7/1:!XF2:Q/VF79#+O8O>9(&[)4C&",?C0
M@>BN=Y1110 4444 %%%% !1110 4444 %0VUY;7@<VL\4P1BC&-PVUO0X[T^
M5#)$Z [2RD ^E<EX#\-7_A_[6;](8]Z1QJL3[@^Q<%SP,$^E"W8/8["BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% ',6_CFR*-]JAN$9&VNR1ED4G.T9]3BK47B_3I[-KA?."
MA5;#1D'YFVC]35D>&]*6-T6T4*[K(V'8?,O0]>V:@'@[1 %_T+[K;_\ 6O\
M,V0<MS\W('6EK8;M?0S)?B!:0V:,UM.UT\(E$2J=IY&<-[9JW_PFNGPVK37
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M$E_+Y?V .K0H\JNJ;OG& HV]^"W'M5#PE;ZG)J%Y?ZQ'<+*T<<4?G*HR .2
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MX5TB9F8VFQF9F8QR.F[=]X'!'!].E7[>PMK65Y((5C=U5#M_NK]T8]LU8HH
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M]C6TRAT*L,JPP16/X>\+6?AOS_LLL\IEVKF9@2J*,*HP!P*%OJ#VT-JBBB@
MHHHH **** "BBB@ HHHH **** "BJU]J-GID(FO[J&VC+;0\KA03Z9-+:7UK
M?(7M+B*=1C)C<,!GD=* +%%%1QSQ2M(L<BNT;;7"G.T^AH DHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** .>\6^'IO$*Z9%#+Y26]V)I7!PP4*P^7(()R17/7_@[6TNKIK";
M,$L^]42Z:!C^["J[%1V89V]#7H5%*W]?=_D.YYK+X0\7RR,KZJY9BOG7"WCK
MYZY7@)C$9&&Y'7-3W?@S7SJ-X]I?R1VV2UL!>.#N 0+N]>C=<]:]#HJKA<\\
M\#IK*^*[I-0^V-'% ZRRRRN4DD,@((4\+\OIFO0Z**70FVK"BBB@84444 %%
M%% !1110 4444 %%%% !1110 4444 %%8^L>(/[+O[2S2U,\URKNH\U(P I
M/+$?WA2V_BC3)4B\VY2"20$B.1N1_G% &O169;^(]*NYHH8+Z%Y9B1&@/+8Z
M\?B*S5\;6<=TZ7L36ML))(EN'D4@E&VG(!RO/3- '2T5DMXIT5=X.I6^8R P
M#<@DX''U-:5O<174"3V\BR12#<K*<@B@"2BBB@ HHHH **** "BBB@ HHHH
M**HZQJD6C:;+>SQRR1QXRL2[CR<?E5;5?$,.EW]E:-'OEN\E<R*@ ! ZGO\
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M=10MT 'Q;IR231R+=1R0D!D>W<-SW QR,<_2K-QKVGVK6XDFR+A0Z,JD@*<
M,3V&2.3ZUGW7A>657DAO%6[>>60RO%N&UQMVXR.BX /M4=QX4FF2*%;U%@6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%26/8VX&-QE<^_K0M78'H=-1110 4444 %%%% !1110 4444 %%%% !1110
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MT0R12 D,3ES[ #T[UUFD74][I-M<74:1S2(&94SC/MGFA:J_]=P>CL7:***
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M12K%;AIH<&*.1OM"ER&P<?* !SGUKO*?3^O(74****0PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH :$4.7"J&/4XY-.J".>5KR6)K=EB0 K+N&']1BIZ
M (C;Q-<K<% 944JK>@.,_P A4M9]Y),^JV5O$75/FED9>A & I^N[/X5H4=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<@*O&<XZ[?\ :H ZBBL)?&_AUEA(U>UQ,^Q,MC)H/C#2'G2*VNXYSYWDN5;
M0X8Y]_NGI0!NT5R=[\2= M/)=+@W$,A93)"-VQA_"1USS5R#QOH<CK'-J%O!
M,[,$C>09(4XS[=* .@HJCI6M6&N6S7&F74=S$K;2Z=,U>H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/N]:T=?T_4+[1]+-S;37=U&C&41QHR%RO\2$C\P<BCI<2WL=4+.UPH6WAPN
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M"W@W_9XHH]S9?RU R?4X[U'_ &98$$?8K8ACN/[I>3Z]*P/"FGWMH9OM%O)
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'--';PM+,ZQQJ,LS'
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M:G9.UE#I]I:N4MRC$KMY'^SGC/UHZ!U-UKB)%5FD0!ONDGKWI(;F&Y!,$J2
M==ISBN;AT?4Q=:;)-' T4 "&/=]Q=I!R.AS6QHMC]CM7:2%(IIG+NJ@ #T''
MH* -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*Y>2.VD>&,22JI*H6VACZ9[5+2$9&*3VT P1KEU+X3MM446L$TJ!W$I)5/4
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MF83AA_I//F!=W;[O3BL@^*/$WV1V:T"RER%VVDAV$ G:W'?'49KM[34K2_\
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M.*R/^$I\3?9'9K15E+D+MM)3L(!.UN/;J,TWH!WT,,=O!'#"@2.-0B*.@ X
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M>L;>RB1YK&.)5G.YG0?>-2K=P/#)*DJLD9978<X*\$?A7%7/@2_"1I9W:I$
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MJ_EJKQK&BG ;/W\K@_@ ?SJ7P]I1T71+>Q8H6C!R4)P23GO0!IT444 %%%%
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M]-B5MKN!\6Z7+I5W?V=PMS':@&0(>0#T-1IXTTEKF>)I\+$0 P4G=\H8G '
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M% ##$C.'**7 *AB.<'J*BFT^TN !-:P2   !XP< =!S5BB@"H=+L"X<V5L7
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M38=UJVZ$G)V'CU/L.#6S10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" ,K G,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %\]@>R_K^NX1?$/P]-:37"WC!(D5R&B8%E)"@J,<C) XK7TK6[36(3):F0
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M9T2/=]S;]TX]\&@#HX+6"V&+>&.(>B*!4U9%^);_ %5+!)GA@6+S93&<,W.
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MR,;OTJPGA;7+&[:[TJ?38)KBU2VG23S)$CV$[63/)X/1J(MO?^M/\Q_U^/\
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M6\&_]!N/_OS+_P#$T?\ "UO!O_0;C_[\R_\ Q-;WF:3Z6O\ WP*/,TGTM?\
MO@4 8/\ PM;P;_T&X_\ OS+_ /$T?\+6\&_]!N/_ +\R_P#Q-;WF:3Z6O_?
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M^%K>#?\ H-Q_]^9?_B:EC\9^#)I4CCU/3&=R%4 #DGIVK:,FE XQ:_\ ? H
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MX-_Z#<?_ 'YE_P#B:/\ A:W@W_H-Q_\ ?F7_ .)K>\S2?2U_[X%'F:3Z6O\
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M^8H J45;_LJ\_P">!_,4?V5>?\\#^8H J45;_LJ\_P">!_,4?V5>?\\#^8H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNQ\PDX/56/XUZ7157 \OTSX>:OI$UJR1PSQPQ-'MBOY+<\ON!RJ\\=C4EO\
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MJ"=E8XN#X?/#J=A+_:KFRT^Y:>WA$6' )W;"^[E<^U=I111TL 4444 %%%%
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M!SNV_-U]Z 9N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7TBP_LO2K:S\PR&% I=NK'N:$#W+E%%% !1110 4444 %%%% !1110 4444
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M1@&!'<>M)!/%<Q"2%U="2 PZ<'!_44-:6$M#AM0U;Q&3]G99!)%,1&8K1_\
M2 &/4@X48 ^M/N?%&NNR-;6L@B"QAP;.3>SE3N"@\<'U('O7;&XB$AC\Q=X3
M>5SSM]?I36NX$@$SRJL9Q\QXZ\"@#B+;4_$*Z=;RS)-,(2@=3:N)&;8Q8]1G
M! &.AJQH%[K6L:A.NHI-$GV5U1Q$\2DEAM.#_%753:K96[E)KF-&$JPD,<?.
MPRJ_4BI%O;=H&F$R>4F=SYX&.M+U'?4X6TD\0-<027"WICNN)%VG]SY ]/\
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M>)?M 6UDMFB".H=@=\;#*M[?2A;NP/;4Z"BBB@ HHHH **** "BBB@ HHHH
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MJ:X[X?>(-0UO[:+ZX6X5!&X=5 \MV7+1\>GYT+=V![':4444 %%%% !1110
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MHY(;L*/,CDE5;=0'*,6&/[O7G'6NLIZ6_K^NXNH4444AA1110 4444 %%%%
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M9:_!J$%[%;WCJF%DCFN8VD=<'(STQN(-49M*\73&"9C<?;(DD(D\Z,HH9<
M?W_?I7:PZWI]Q=K;PW44CLNX%7!!]L^O'2F2^(--ANX;9KR$R2AF&'!  &23
MSP*?]?F+K_78Y:/2O$DTUJMZUW/$DT3IF6-0@5R6\P _-QC&*[NLZXU[3K<0
M;KN)C.ZI&J."6).!Q]:T:?3^O(74****0PHHHH R/$^F/JVA36T2%Y259%#[
M>0P/6LK7]+U#4-05H;,L/+\J.8R*/);<I\P<YZ ].>*ZRBE8'JK',>%M*O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#K[ 'U'%)7MK_6__  !_U^7_  ?ZVRM/\8R:Q##'IUI$U[(SAHY)L(BKSDL
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MM6MH;AVM4N8K>54.=PD?>S 8&,8&*[NFI(DB[HV5EZ94YI=1WT.+C\8SQZE
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MT#Q \]K]K>>XB2:)U\RZ'[D*Y+;@!\^1C'TKNZR9O$VE1?9PMY%*UPZI&L;
MDDMC^?\ *M:GT_KR%U"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
M *\<=P+R5WF5H& V1A<%3WY[U8I*6@"C<VLMQJEG(0IMX [G)YW\!?T+?G5Z
MJ]Q=I;S6\;!BT[[%"]N"<GVX_6K% !1110 4444 %%%% !1110 4444 ,E4O
M$ZJ=I92 ?2N1\ ^&]0T'[8;^*.$.L<:K')O$A5<&0^A-=@S!%+,< #)-8_A_
MQ19>(Q/]D69#"0<2K@LK#*L/8T+=V![:FS1110 4444 %%%% !1110 4444
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M<CKSQ6)_8?B[[(\;7-P[NY+,;I1@X.&7CIG'!IO01W\<:11K'&JHB *JJ,
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M<9&.#26P&XWB'25:13J-J&C&7'F#CG'\S5^&:.XA26%UDC<;E93D$>QKB(?
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MR(KHP96&00<@BG5!96JV5C;VJ,66"-8PS=2 ,<_E4]-VOH)>84444AA1110
M4444 )2U!'9PQW<MRB8FE #MGJ!TJ>@"K>ZC!I_E?:&VK(Q7<3@* "22>PXJ
M%=?TMVA5=0MBTQQ&!(/F.<8_.F:QH5OK:%+EW"F)HP%QQD@Y_P#'16,G@"U2
M2W;[9-B&3S=BQHJEMV<X X/;BA ]M#K**** "BBB@ HHHH **** "BBB@!&8
M(I9C@ 9)K'\/^*++Q&)_L:S(82#B5<%E895A[&M=T$B,C#*L,$5B>&_"EOX:
M\\PW$UPTH5 TN/D11A5& .GKUH6^H/;0W:*** "BBB@ HHHH **** "BBB@
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M@!@V,]LCBH1H6EB(Q#3K01DY*^2N#^E7(HHX(EBA18XT&%51@ >PH ?1110
M5QT7COR8IFO+-VC@D"2S1D8&XD* N<GI78U5&FV0# 6=OAB&8>6.2.A-+J/2
MQ@Q^+G&L6]M<VPA28!0/-5MI(+ D@XQ@=*HS_$-1]GN8;*0V3>:KG<I=F4=
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MA"2B1S(T0P%#C.P^XKK:K6>G6>G"065K!;B1M[B*,+N;U..IH6[![%FBBB@
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MS[3%;VLEJ;7[00&;>G90>QRV< <X%-Z-I] .PHKFH_$]S<:-;3PVT?VN>=X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP:-@-BBFQR)-&DD;!D<!E8="#T-.H **** "BBB@ HHHH @CBG6[ED>?="P
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MM58FYU5%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M206T%L"+>&.('LB!?Y54NX9;C5;(;#]GAW2LV?X\84?D6K0H **** "BBB@
MHHHH **** "JL^FV=S.DTUM$\B-N#%1G.,?RXJU10!2&BZ8/+QIUF/+Y3]PO
MR]^..*FM;2UM XM((80S981(%R?4X[U)*&:)Q&<.5.T^AKC/AWI6IZ9]N_M"
M">W1Q&-LK!C)*%^=QR>":%JV#V.VHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S/^$AL
M3J!M TA(?RS*(SY8?^Z7Z9]JTZYY_#U^GVN&TU18+2YE>8K]G#.&;J,DXVY]
ML^] &T+ZU(!%S#@YQ\XYQUJJ^O:>FF7.H&X!M;9F620#(!4X/UKF[3X=1P"<
MR743N^XIBWP$8[.Q)X^3D=P2*OQ^$,Z2MA<72B)KMKJ5;>+RU;)SL R<"@$;
MT=];2QQ.L\>)D#IE@"PQG.*5;RV?;MN(CNZ8<<URP\!NL<T U!7AEB\D-+!N
MEC4;L;6SQ]XYXYP*CE^'_P!IOA<SW%KDH$9([8HHQG&T!N,YYZT =:+RV;;M
MN(CN.%PXY-3UQ=MX >VDLW6]A!M92ZE;?[JY!VC+'TZG)KM* "BBB@"IJ6HP
M:59-=7.\QJ0,(I9B2<  "BSU*&\A$FV2 DXV3KY;_D:K^(-(.MZ2]FLJQ%F5
M@S)N'!SR,C^=8D_@B2[FAEGOHT>&-XU$,!52K=2<L22.QSQ25]0.D34[26Z%
MO'.C2%=P"G((Z=?PILNJV4-U#;O<1^;,&* -V R3[<5SP\&7"SPW,=[:Q7$#
M H([3;'PI7E0W/!]:I-\-R]NL#:A&457R_V?]XS,,$%MWW?]G]:8'7W&J6=L
ML1DN(_WK*B8.2Q)P,?C5NN.M? 7V6>&1+F  21R./LY."C%OD)8E<YYZUV-/
MH+J%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%01VBQW<MP))2
MT@ *E\J,>@[5/0!#/=16[PI(2&F?8@ SDX)_I4U59;/S=2@NF?Y8490F.I;'
M/X8_6K5 !1110 4444 %%%% !1110 4444 (2 "2< 5FZ-XAT[7UF.G3>9Y+
M;6RI'7H1GJ#V-:,B"2-D;HP(-<]X4\)GPT;AI+S[2TBI$A$>S;&@PH/)R?>A
M;NX/;0Z.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "L7Q)K%QI$=H+5(C)<S>7ND5F"_*3G"\G
MI6U5/4=*L]6CC2]A\Q8VWIAV4J<8R""#WH8U8P7\;0Z=-Y&J(3*5#+]GB8[A
M@%CM/( R*EN/&UM';PW,-G=RVLK@"81X5E[L/6K[>%](?9NLP63HQD?=^><]
MJ1_"NC2;PUBI#L&(WMC(.>!GC\*3N(JVOBZ&YN'A%K=F0-S&(<-&N%.6R?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" ,K G,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^'^8W;I_6IM0^--$GU<:9%=[KLG 0(WYYQC'O6S<74-K:O<W$J1P1KN:1C@
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MSPWJ*QS\.]:CU2+5(M2M_M5G+$MM&RG!B0;<,W4$C.0!BDM=_P"OZT8KN_\
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MQJ3QGMFN&M?&>J:!<26OB&SED^8E77@_AV(J)*5=MQZ=#6#AA8I3Z[OS/06
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M #UQA:H7/CCP@^F6\-OK-E%<Q%291:R_P^GRYKNO-TKTM?\ O@4>;I7I:_\
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M'_WYD_\ B:/^%K>#?^@W'_WYD_\ B:WO-TKTM?\ O@4>;I7I:_\ ? H P?\
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M#<?_ 'YD_P#B:/\ A:W@W_H-Q_\ ?F3_ .)K>\W2O2U_[X%'FZ5Z6O\ WP*
M,'_A:W@W_H-Q_P#?F3_XFC_A:W@W_H-Q_P#?F3_XFM[S=*]+7_O@5SUI\0?!
M5W;B7[?9P$DC9-'L88..1B@!_P#PM;P;_P!!N/\ [\R?_$T?\+6\&_\ 0;C_
M ._,G_Q-/_X3CP3_ -!73/R'^%'_  G'@G_H*Z9^0_PH 9_PM;P;_P!!N/\
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M:_\ ? H\W2O2U_[X% &#_P +6\&_]!N/_OS)_P#$T?\ "UO!O_0;C_[\R?\
MQ-;WFZ5Z6O\ WP*/-TKTM?\ O@4 8/\ PM;P;_T&X_\ OS)_\31_PM;P;_T&
MX_\ OS)_\36]YNE>EK_WP*/-TKTM?^^!0!@_\+6\&_\ 0;C_ ._,G_Q-'_"U
MO!O_ $&X_P#OS)_\36]YNE>EK_WP*/-TKTM?^^!0!@_\+6\&_P#0;C_[\R?_
M !-'_"UO!O\ T&X_^_,G_P 36]YNE>EK_P!\"CS=*]+7_O@4 8/_  M;P;_T
M&X_^_,G_ ,31_P +6\&_]!N/_OS)_P#$UO>;I7I:_P#? H\W2O2U_P"^!0!@
M_P#"UO!O_0;C_P"_,G_Q-'_"UO!O_0;C_P"_,G_Q-;WFZ5Z6O_? H\W2O2U_
M[X% &#_PM;P;_P!!N/\ [\R?_$T?\+6\&_\ 0;C_ ._,G_Q-;WFZ5Z6O_? H
M\W2O2U_[X% &#_PM;P;_ -!N/_OS)_\ $U8T_P"(WA;5;^&RL=626YG;;&@B
MD&X^F2N*UO-TKTM?^^!3X9-.,JB$6_F$_+M49S0!>HHHH **** "BBB@ HHH
MH **** "BBB@#G]>_P"/Y/\ KF/YFLRM/7O^/Y/^N8_F:S* "BBB@ HHHH *
M*** "BBB@ HKG_$%S>?VWH]C:WKV:71E\QU52?E (ZUB6WCZ>UMDAN8!>3QM
M())4.T.BMM!  //Y"@#NZ*Y ^/TCGNQ<6)BCA5FC#/\ /+CT&,=_7BK;^)K^
M)K."33(?M=U.(D1;H%<%0P)...M '245Q5KXSNTMB!9FYD1)II&DF5-J(V"!
M@<^U,7Q=>SO+.Z^59B\A2/RR"VQDW8((].:!-V5SN**Y!_';16XGET[;'/"T
M]KMF!+JK8(;CY36UHFLRZG+>07-J+:XM'"NJR;P<C(P<>]"U&]#5HHHH ***
M* "BBB@ HHHH **** "BN2CU"_OKW4+G^V(K"*SO/LZP21J4*C^]WR>V*>?&
MSJWF?V<3;2&5+=EF&]VC!R"O;.*5]+@=517%P^,[[4)M-CMK6&*2:[$4T32'
M<%VY'4#'_P!:K^J7E[=>)9=,M]1_LZ&"T^T>;M4F1B>^>P[XI_U^H?U^ATM%
M<HWC"2V+IY,=[#:+$+JZ1P@8OC!1>XYS5.X\<7'GVM\+<Q:9^_. X+S!!W&/
MEYH>@';^OTKG/AOIEC<^"K:6XL;660S39>2%68_.>Y%6/#?B+^WX[C=;&"2'
M;G!)5@PR,$@4OPQ_Y$6U_P"NTW_H9K2FO>U(F]#6U'2;:*RD>PTG2Y)UY"S0
MJJX[\A37/:;J^GG0(M6UC0]/A@GYB6UMO-8 9R6^7BNU=0T;ACA2""?3-<U=
M>!+.YT:PTTWERL5D&"-M5MX;KD$8SZ&M6GK8S3UU*EGKWARYU6:T.G6&W"-;
MLELI,B%=Q8C;P!ZU*FO^$9('E%G;#:5"H;$!Y=W"E!MRV<=J=;_#S3;9XY$N
M;KSD54$ORAB@4J5/'0@\TRV^'&GVL.V&ZG69'1X)E1 T13..@^;KSFDD^H:&
M?J7B?1H+BU33M"M;A)$D>;=98:/9U7&W(.>N>E;WAR"RUG0[>_N=&T^%YQN"
M+;+P.W513;?P7:0R>:;JYDF*3++(VW,AE^\QXZ^E;6GV2:=IUO9Q,SI!&(U9
MNI ]:<4]>83>UCD?B!IUE:Z3ITEM96T+_P!IP#='"JG&3QD"NF?[[?6L'XC_
M /(%T[_L*0?S-;S_ 'V^M95-S6&PVBBBLRPHHKD;74;^_N+J]?68K**WOC;+
M;/&"A4'&#WW'M0!UU%<F?&[A/..FDP3+*;;;,"SF/J&&.*AM_&%]J-[I45O;
M01F>X:.XC,AW !<]P"..?PH6H'945F)=33>)I[='/V>VM@77'61CD?I7/1^(
MK[^R=)G-P&EFOY(I@ ,LB[N/;H*5_P"OG8'I_7E<[2BN,E\:7$UEE[-K1I84
MN(6CE#DH7"G.1Q6QX6U2]U6UO);Y(U\NZ>*,H>P[?A36H7-NBBB@ HHHH **
M9/$TT#QQRM"[C D4 E?<9XKC=.UN^L;*ZN[R[FOW%\UC! P1%+;L!BP''2A:
MNP':T5QC^,KW^UH(?LL,20^<MVC2C&Y!U#8Z4V+QE<ZD]JD40MG6_CAEVG<K
MHRD\9 /:FE?83=E<[6BN-\9^*Y]&U6VMK.9$\I?/N%*[MZYP$Z<'&34USXUE
M6^>*STY9X1/' LAG"[F=<KQCIZTEJKE69UE%<@OCJ26W,D.F[F@B::Z5IP-B
MJQ4[>/F.0:FE\;(D9D6T9E^U_9AE\$_+NW?_ %J+Z7%UL=35G3O^0C!_O5Y_
M>>-M1:S'D:?'!<2)#-&6F# QNV.>.#_C7?Z9N-];%@ Q(R <X.*!73.KHHHH
M&%%%% !1110 4444 %%%% !1110!S^O?\?R?]<Q_,UF5M:O97%S=J\,990F,
MY'J:H_V5>?\ / _F* *=%7/[*O/^>!_,4?V5>?\ / _F* *=%7/[*O/^>!_,
M4?V5>?\ / _F* *=%7/[*O/^>!_,4?V5>?\ / _F* *=%7/[*O/^>!_,4?V5
M>?\ / _F* ,?4-'T_5O+.H6L<YBSL+9!7/7&#[5$_AW29(X$:PAV6XVQ!<C:
M,YQP>?QK=_LJ\_YX'\Q1_95Y_P \#^8H PO^$=TG[1).;"$R2!@Q.3D'KQG
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M'<8( )[UU/@/5K[5=$F.J.S7<%S)"ZR*JR( > ^WC./2K-MX)\/6EM/;0:7
MD$Z[9(P3AAG/3/'/I6CIFE66C6@MM.MT@AW%MJYY)ZDD\DTT39ERBBBD,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_003.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.gif
M1TE&.#=AW@%M G<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M.9 #X"-B%;B'_E+2 $A=\CV%JJ-9U'B2!CC#= ^8@$ LL  $Y,-T"QC:0(J
M 97LBU "<*/A\EB2#:S,2<VJVA<% H(B.*DD?P,9';URQX$PT26'(^5 /C80
M#B3@D0SP(TC"UT<BML1;%C!(-'>9CT>B$9N5VP\AERC_ $.FI ,0.P@YJ6E-
M@B@ '[(,B3-RU\XW%M$D(( 70N8) 'H51 /CZ"9'&I#/;<KD8@4T ,>2)+"3
MT!(E%H! ^02J324Q0)P F, #6(D[9"K3)1Q E"(G +I]4E, 4,B(1C,YD@8D
MDAX*H2@ ,(".D]%KI29)GAG9^!(-<%(@@Z. 0 Y0A '^R #.>  $XFF2DY;$
MJD4(EJ/X0=:!2)0@1TCKHTQWDH[NT ($8Y]&-S*R@1PN2>!J #[BQH&A/2"H
M)B&J2!@W)3:QZ84 &YX&"K#7BC2@8 +;Y ,JNYY"&2H!# !M @0@3)9PH(P"
M$>P+']!6DJ1LIF11P&A#&]K1_QKJE>Z)ZP- T"]7N2JAKKVJ-SU($-:>1+%>
M&0!O?>NJ(R0*M^[A;$D4  %=$D2U!3'N1?9J5B*AI0/XR,'PJ#J0PQZ7F=[]
MRFG;9K-[ D"[)>EN>L>24JCB$8'P)0ERYTL3>$CW(D<00#J4-(#+XO&%"Q!O
M6>M5E@;\EU *QB8$$%6$"B.J;PW(QPMKBI&AHC<K!]@L@R90VEHZ^,0%(<!!
M_&'2#V/%8P_.#P9:&Y;]<J4 18@Q?C 08;'4P\57Z< J%S0!&DN% YI*LI*5
M7*@'J'@L&M/Q?7A\E4UR"@,9P+*6LVPK!I.E D6@VH+V 0465Z4!P/4K=*^2
MC@4\6?]!5&9.!XJ 5"(C=CE19E"<EP-F,2MH CU.3IO?G* ]PT3*@P$SHNLS
M8Y8L&C%"?O1\]B%>,__)3YB^M*8SS>F! ,K3J>7TIIG4 3B9VM31,W-"&B"K
M>;BJMPCCBJ+U_(X'V/K6N,ZUKG?-ZU[O6I&^#O:MT3'A"J/#P@+ !T,.I[1[
M.,H!SZ; DJ=-[6I;^]K8SK:VKXV!!61TQ EX@"(I+.YR*_+<YDXWNM>M;G,O
MX-WH)C>YW]UN=#\ 4??V=1$@<,>O55C<\ 9VON4]\((3_. &3SC"%Z[PAC.<
MPN^& +\9E $C1R6ERQ8 3,,2:3U;'"H6>,<=D[9QL,R:R!__?XH%SKF0<):E
MXPLR]%1"?D<$:+PL)__SG:FR\HR7_"LPAW.@I0*%!(S\YE]> !_'O/.90\#G
M94E'CO4\](L;?2$VGP?.IX[R*K^#(3;_N5>"7NBJ@_SJ"DE:2\62\[)7F>4*
M<3E9VBQI^<A<*BD]^MK#TG8$9<#L(NG $8X@A9\-P )S% @"+'"$B&&DYRU'
M.DDZD ,,@&!RK,; $1AI <NO&2,'^';,&1K5#10A!Q;XI#@U4*H?@:"Z4,#
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MC% ")4>22@G6?-^Q6R_1 *.%:G ".CRT#P*0 U(  E"@C3JH$.$'B_#W$0L
M,=I8CC&35B"04B7F,-9%$:QV)*&V)&!2BICF:0>#>X2RBRH1?!B  1/@CQB
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M%-7G#L[Z*@Q0K6II.:7FDAH !;2#G>^! *9S,\Z*5<EY7=UJ$RE5 /[9?07
M %&Y%+TX4JU"10T !6LGGO:! *!I)"N$,PT3L3IQE"U8L4/1 !=@$.G_H+ (
M07FV8[+UX;"J>0 O! ] JYH$^Q-%=T=IV10T*SS*15>]R &$)A \2Q\HFQ <
M"28(L#<'T97F:I@(D;3M6K,(H0$,4R2.=Q =\)K\X;,)\312$[$R8ZYHU[8"
M@(]/ 0\7@$38"B4@@$3TRA\P )J/)*"D6;0^ ;/B)[-"X:YQMP$80$5RN1\(
M0)@) 8PO Y<)$;=#89>Q@Y,JR0%(= !]:P!GRY8,ZQY_.SQ#BU74LI<=^Q '
MT*9].[A]HP"I5[IB" $5:!!@Z[&""P #0+*>%K)H>[KM@:UW4YM5H[6+8[CV
M:7HY  *J5TZM1TT08'E'  &_.X1SRY">BYJ@_VL0'6 !_G.P8FF\[&&O_QF<
M=X.YU_6Z#)%W T&$D:0!]T>0*V55KDJ$B6L2B 1H7=, J9>%C'D$P.>2-A.&
M3YNY<4*#Z+L>;"NQW@FQS5L1\C YAS,C?7*_A8C !\&Y3E.9(%&21= JHL10
M"E $$_ J*CP0KQ<]HO3 2^M7N#NV RFU#ZP>50NN>\6M)], ,K 1D3A<WS,
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MCQ&0 @+9"">([#GH" 5"4TH,P-A[F8S38L\@D+?ZD:3O4 3C8&')=Q+\0-+
M*X$ T.D"8?$9H=P D'4.F0/[L&0_PFHD!E62C1( =2G5SAXM5,+;V*$@D ':
MWA!_@\6*%^UP13<&2.(-H>[!G>S6VM]S,J3( @'F;!\YWQ(#L  .P+3$]22@
MU,H?XY&[3.8?]-.0^0 QCQ+49>M!H]80<&^(HH</\.*5C^=+O!9_0_GMD4TK
MX3';.P"3/A#^<&+T\#&/1O<TKQ8-(.-$4P28/Q&GA7@A_ZD "*#4TV00^$#\
M"\&_3I_]53$X4BT??X/^"ME5\'9O#]O[>[D!6;Z" /_T8%'][A\>K=3_  %
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MY N*T#J!EW_Z;R,!Y%$ GY&/N$=L".C!BJ./XY:;VZK\>4=9[JX&0(,B%"C
MQ9*V/@BQI*#(IW,("J(:'@ 0@, "?B.C &;*/S7*]IPV]O5UD0GB@(%][EG
M =%%0G?,Z88:&[LCVB:H WP@?T  ##)XP($*JI+M]J2-A0H#"(X'8$;.!UA'
M( /Y(XET@[H>"@0!4 ,!<(*<:J!Y]2W AWRF'8";]W(U-ZC(K @L\QT"!^(/
M".!M)'/YEE!NMCV!U*\@\RB"41PXD/\'_ PJ[!+@L"B6%)4X $6;4P@_T/9
M;PG,:SG)P 'O-SZ"8& ##8" 72:PPL74+H3.@D<.E3(?#QY$ 0RH5P,^AL,
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M(?I!:_:RS#:(=MG+7P9SF,4\9C)[>0,T=#%^ &L<S#8YI$6X!P@.L##2#N0
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MT%2!. *[,M6#6"/6S(@^4HC_(T"'XFQ39O5/1.55=_75"+!7'^!5=;T&7HT
MD56&:P@"D*50( U.?G569VW4)7A/@=4*:A6-7 I"2_Q6<&6 9%R(0'79".!7
MXMS-H771ERW96E6&?15:'UC:=K52E T >:U2*&W1H.5-HSW0!*79D("6JZ@0
M/FI8O#H1HEBK+(P!&\7:K&5;H77;JFW9WO0!7T54 !#:EWW:=Q56CTW9M^U-
MK:U:K W:EX76K@V);2G2F*E ELE9#MK9SF@@ALB!W&S;RK7<H37:P<W:>!56
M7]W5N\W;6B59>=5<WT1:RZU<P U8P_T(3DR*HGD ^X@(!#H EXJB5CV(+S7=
MMSU=_[_E7;_%7%[UU7N=6P#85;QE5\]UUJ<%W-YEV])MV]Z%4];M3IO%"9V)
MP<8%@ ?( :60A\^3W/ATV\R%V],EW^?-5]*U4J8M6<_U56.U58&0VO']6_JM
MW^>]W .-5L,MF4UMB352P_O!0#LKV]<%WY^UT=W%W[7]7<&-@'55!A^0@(V]
MU7EU5WBXAF3M3>8EV?L-7 \&7DEE@ "F7HHX$ 'H5IS@DB-@$S-"@,UH7$5:
M# 805T 57_/U7=]EX. UUD=5!F50APA>VBD(XG55U+MU6ZJU7Z1UWA"^7WYM
M E#ZRQ(NB S8CRD^"<(0N"94%E<:F0Z(W0_"78-XU7+-7__RU5HT/EE@M54,
M%F(,#E9D[6"A/=GC56#@9.+H=>((4 ,K@5@.S9_P<(^;8;S[X#J?G5@(*%?,
MU>$<QF&7W5B2?5E>E0"0#5DSWN$0SN,[/E^W38,9B#/Q$ \H2&&:_0\ @4
M^>.I&N."T%W4==Y-SM^[C>3@W=@S;F3AC&7\]5T)\%4X:1,LIN)/H8<#5H@D
MU5PTCMLG1MT<;F!=7F#[76).=EM?'>:X41O)3>"X5>9'+E\][EU&EF7 !>$]
MUF%KOF:+"1HO5>1H5N9EYF4/;MX[AEOZ]69&GF9G1>=T=I=L7H@R'LY='N</
M9F9OMN??A6:"[N3TY6>*N"-A?H[_!FAEF$C@/'YG/([F^F7@6:YGB]9H<\[<
M !#2AEZ(#L@'G*L4B2U*;#!CC.YF<Y;F9RY=67;F9F[DTD4'KB7IA$  "UP6
M :AAA" ,97#GW27GFS;J9NYD7O;H@X;>'%[=G4:("C#+3_'G8P[/HQ;H?$[J
M@G[FF*[IL+YHI)U>J7X?G]82>8C<?Q: C]YJ>(YI'*;GE\YHIXYGRQUILS8(
MJBX;3KGJA.@ 1B#.K3;HNW[JI?YH>J[G@W;;?UA/O08YM,Z2!C!FA9@"26;L
MNYYK3<9EKGYKCWYJWXUJR!X(JE[EW/CKA#AB:'[IP^[HQ=;J7$YHPXX Q][?
MKNUIB&:._W6FB,L&[:Z&;9D&YSUN:GFVZ[CVVQ@E;8*@:MU>CM1&"*AE[:1&
M['EV9KEV:82>;>0NW.6^(LE6$8D.:H2X[*).[,0>Z+4=:/,V[J9^ZP@8[>56
M@*KF%)5.B'OUUWANXGG&Y^M6[/,.Z\YFV^[V[M?)H$\A@,I&B&O @5O0! ?_
M!$U( 4WXA F5T D&64O6<'<-60[/\ [?< _?6.4N\ H8!RAP!P*3 A5G<2EH
M#&P291!8\1B?\?&H<?&X<1EG<1K?<1OO<1S_<0*;:-$3@ 5 N"6@ "1/\G/0
MS"8G B>'\B>7\BBG\BFW<BAG<D35\BWG\B[W\B]7AR!8 $3V[O\9Z4L3B09&
M2',<8(0J.?,WAW.XS$+JP@<&L/,[+Y$XCW,&@88'B((H6( ^__- ]W- AX9[
M,/1"#W1$7P!#9_0H$  R7^XU>H44L/1+Q_1,U_1,E_!-]_1/!_50%_51#W5-
M&'*%+0(8, !57_565_57=_58A_59E_5:IW58-P!7(JD),*Q]P ##P@!?!W9?
MY_4)$'9C__4="O9D1_:=DW32UAD+%U1IIW;R_ <:9HB;:8L#<>ZT]-]T5H!\
MT(=J)_=ROTXA8( L/((%: O]Z-./\(>REN\B$ ();6)SQ_?C/'4 T':V<'?G
M_/9KK@!Q5U( _=<,/>I\5WC]1'=UOSK_M="/HBN]!WAVR*Z (MA10=71H8W4
M,L5/^@3YCQ=YCR?YCC?Y00WYDJ]? =!I0#WPM?AWG:#X A<($Z_W?L78C5[X
MG>_---CW=6_W]HH>1+, 2.L 1 ,!%%$ #&BQK:AXO=:9<<=8J]5C98W2$Z7Z
MB[UZ<\5Z)14"!<]=G#EME(AY -"YV'$'PG"@F[$ =Q"?U]H* 2#AF:?Y@4\#
M*C7XS09KK>?[K/?[KN?ZC.?-!+  Y1@ =V![R(%XOIL:""C#VF6O>NGW@<B
ME0K@K4B+L9=1G;GY -?[B^9Y<Q]/(4B [SH,\2L"*.CVM%G];Q/ZBRF\%LF
M16R !%B>CF-W_W[H7G!:@( ?YH&7>K=6:D?&:,Y.7>)&_OX.Y_,6YQ0E?-):
M!PNXF:27P2+8?;)_?8.P@ P:AQ=Z@.E3@'&XC >P+:>G>0"X>  ?[G?>9-=&
M[O??9?C/Y?B/@#0H?0[8-CF"@AQ8  LX2QP"B!P !A(L:/ @0H(;!"A(>$!
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M88E)(394DA0J,\44Z@3!881/7A<$E.IH.&'_A2,J"9D$W[7HDF[GC40/!#W
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M(*X^.0CZ<P#MEAS#ZTC 5ULN\QV"931HGGEQ665PG/.\YS<&R9M]+O2A#W4
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MA\]<$DR6A +@0P;LQP$4P46PR@;L_X=:M,=CUH,"T <C.H1&<I  5.;@M2(
M1-\&(( \="9!:,#MF>-)K$-=WJ5>$*4OXB9?XM$#08 2'D$>DF 1 $!8!9:,
MW$@#C.- 1)AG#)M* &%!V$@#*!E!@  $9"4:;=-(H"5?I-QT"D!U%N=U9B<
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J,;B&YS>'=SB(A[B(C[AQ?#B)Q[>)G[B*KSB+M[B+[UV*KV&,YU%    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_004.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.gif
M1TE&.#EAQP)I 7< ,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "'Y
M! $     +     #' FD!AP          ,P  9@  F0  S   _P S   S,P S
M9@ SF0 SS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9
M_P#,  #,,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S,
M9C, F3, S#, _S,S #,S,S,S9C,SF3,SS#,S_S-F #-F,S-F9C-FF3-FS#-F
M_S.9 #.9,S.99C.9F3.9S#.9_S/, #/,,S/,9C/,F3/,S#/,_S/_ #/_,S/_
M9C/_F3/_S#/__V8  &8 ,V8 9F8 F68 S&8 _V8S &8S,V8S9F8SF68SS&8S
M_V9F &9F,V9F9F9FF69FS&9F_V:9 &:9,V:99F:9F6:9S&:9_V;, &;,,V;,
M9F;,F6;,S&;,_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D S)D
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MN^[JWL.+_U_]?/OX\^@I@T_/OCUBW\!_NY]/'_#Z^OCSTRV/6[___Z8-U!^
M!!88EG;R&:C@@EO=Q^"#$#Y57H(15FAA4@Y>J.&&/<$7&H<@AFB08[Y1:)R
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MRTRQ?/#CXA>I6+\X9A&/AY1&\;KHQOI%48QUC*09>:=&-"*RD)(L8R'#J"_
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M/_[9(O>'J(H/3T&231J^\8.T 1R6XCL_PUL*+5N_KLL/S>",F+ KFU.@Z[-
M[+- =@NF*X@"C_@:*<,A]<L5$8P0GUH_]"L;$DR]YP.3/T.FUZL_0V$X_8M!
M&K3!_.LUW;.G#^*@31DAX M!4S) _T+ %53 %%RYQ%NCXN*B[8HTC[JY"Y1"
M#"0O[0,Z*$(?4Y 5^@(RDY,F/C&_%6P;[4I"K7N^X_.G+UDP_[B3)+&+L+9C
M0PH3,3ALP[2K0SJ40SO,0SR<)!.;N_&1"NU8-@%B0-$:PBTK0M)KN:@KPY@+
MEQ\:-\A+B.JCPBFT1%X*)LP#FQ!"$CT+O\AHQ-!009L(0T4$J.4)Q6T[PZ!
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%?T   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>22
<FILENAME>aemd-20201231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_q3%2D20201231.xfr; Date: 2021%2D02%2D09T13:56:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80020000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:aemd="http://aethlonmedical.com/20201231">
    <link:schemaRef xlink:href="aemd-20201231.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_custom_CommonStockSalesAgrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aemd:CommonStockSalesAgrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_custom_CommonStockSalesAgrMember_custom_WainwrightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">aemd:CommonStockSalesAgrMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:WainwrightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccruedLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AccruedLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-12-31_custom_VestingOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:VestingOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-12-31_custom_VestingOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:VestingOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-12-31_custom_ShareBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:ShareBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-12-31_custom_ShareBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:ShareBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-12-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-12-31_custom_AethlonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:AethlonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-12-31_custom_ESIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:ESIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-12-31_custom_AethlonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:AethlonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-12-31_custom_ESIMember547542546">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:ESIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_AethlonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:AethlonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ESIMember22701499">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:ESIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_AethlonMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:AethlonMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_ESIMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">aemd:ESIMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_GraniteRidgeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">aemd:GraniteRidgeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-04-03_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">aemd:NonEmployeeDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-04-03_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember_custom_Plan2010Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">aemd:NonEmployeeDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aemd:Plan2010Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-04-03_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember_custom_Equity2020PlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">aemd:NonEmployeeDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aemd:Equity2020PlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-04-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_VestingOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:VestingOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_custom_VestingOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:VestingOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_custom_ShareBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:ShareBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_custom_ShareBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">aemd:ShareBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-01to2020-09-30_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember_custom_Equity2020PlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">aemd:NonEmployeeDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aemd:Equity2020PlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-01to2020-09-30_us-gaap_RestrictedStockUnitsRSUMember_custom_Equity2020PlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aemd:Equity2020PlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-01to2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-01to2020-09-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-09-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_NoncontrollingInterestMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-01to2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">aemd:NonEmployeeDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-01to2020-09-30_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">aemd:NonEmployeeDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">aemd:NonEmployeeDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_TimothyRodellMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:TimothyRodellMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-12-31_custom_MelanomaCancerContractPhase2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aemd:MelanomaCancerContractPhase2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-12-31_custom_BreastCancerGrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aemd:BreastCancerGrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-12-31_custom_SubawardWithUniversityOfPittsburghMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aemd:SubawardWithUniversityOfPittsburghMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-10-30_custom_TimothyRodellMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:TimothyRodellMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeparationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aemd:SeparationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-01to2020-10-30_custom_CharlesJFisherJrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">aemd:CharlesJFisherJrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-10-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-01to2020-12-31_custom_LeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aemd:LeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aemd:LeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_MelanomaCancerContractPhase2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">aemd:MelanomaCancerContractPhase2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-01to2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_RestrictedCashMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">aemd:RestrictedCashMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-12-31_custom_TimothyRodellMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aemd:TimothyRodellMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-01to2020-05-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-01</xbrli:startDate>
        <xbrli:endDate>2020-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_Equity2020PlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">aemd:Equity2020PlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-01to2020-12-31_custom_DrRodellMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">aemd:DrRodellMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-02-04" unitRef="Shares" decimals="INF">12123524</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-03-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:Assets contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">12669749</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">10387686</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-12-31_custom_AethlonMember" unitRef="USD" decimals="0">12669552</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-12-31_custom_ESIMember22701499" unitRef="USD" decimals="0">197</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-12-31_custom_AethlonMember" unitRef="USD" decimals="0">4682294</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-12-31_custom_ESIMember" unitRef="USD" decimals="0">197</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">4682491</us-gaap:Assets>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-04-01to2020-06-30_custom_CommonStockSalesAgrMember" unitRef="Shares" decimals="INF">2685600</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2685600</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3087</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2019-07-01to2019-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">59340</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:Cash contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">12131593</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">9604780</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-12-31_custom_AethlonMember" unitRef="USD" decimals="0">12131396</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-12-31_custom_ESIMember22701499" unitRef="USD" decimals="0">197</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-12-31_custom_AethlonMember" unitRef="USD" decimals="0">4058456</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-12-31_custom_ESIMember" unitRef="USD" decimals="0">197</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">4058653</us-gaap:Cash>
    <dei:EntityRegistrantName contextRef="From2020-04-01to2020-12-31">AETHLON MEDICAL INC</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2020-04-01to2020-12-31">0000882291</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2020-04-01to2020-12-31">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2020-04-01to2020-12-31">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2020-04-01to2020-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-04-01to2020-12-31">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="From2020-04-01to2020-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2020-04-01to2020-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-04-01to2020-12-31">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2020-04-01to2020-12-31">2021</dei:DocumentFiscalYearFocus>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">38981</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">106391</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="From2020-06-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember" unitRef="USD" decimals="0">24251</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="From2020-09-01to2020-09-30_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember" unitRef="USD" decimals="0">16128</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="From2020-12-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember" unitRef="USD" decimals="0">31802</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="From2020-04-01to2020-12-31_custom_DrRodellMember" unitRef="USD" decimals="0">34209</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">131746</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">111707</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2020-12-31_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" unitRef="USD" decimals="0">69292</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2020-03-31_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" unitRef="USD" decimals="0">69750</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2020-12-31_us-gaap_AccruedLiabilitiesMember" unitRef="USD" decimals="0">62454</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2020-03-31_us-gaap_AccruedLiabilitiesMember" unitRef="USD" decimals="0">41957</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2020-12-31_custom_TimothyRodellMember" unitRef="USD" decimals="0">20260</us-gaap:DueToRelatedPartiesCurrent>
    <dei:EntitySmallBusiness contextRef="From2020-04-01to2020-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-04-01to2020-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-04-01to2020-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-04-01to2020-12-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2020-04-01to2020-12-31">001-37487</dei:EntityFileNumber>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">64750</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">136426</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-04-02" unitRef="USD" decimals="0">228694</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">12123524</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">9366873</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF">12123524</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-03-31" unitRef="Shares" decimals="INF">9366873</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:InterestExpenseDebt contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">23759</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpense contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">54046</us-gaap:InterestExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2020-04-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="From2020-04-01to2020-06-30_custom_CommonStockSalesAgrMember" unitRef="USD" decimals="0">7260869</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PaymentsForCommissions contextRef="From2020-04-01to2020-06-30_custom_CommonStockSalesAgrMember_custom_WainwrightMember" unitRef="USD" decimals="0">224825</us-gaap:PaymentsForCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="From2020-04-01to2020-06-30_custom_CommonStockSalesAgrMember_custom_WainwrightMember" unitRef="USD" decimals="0">8472</us-gaap:PaymentsOfStockIssuanceCosts>
    <aemd:SaleOfStockPricePerShare1 contextRef="From2020-04-01to2020-06-30_custom_CommonStockSalesAgrMember" unitRef="USDPShares" decimals="INF">2.70</aemd:SaleOfStockPricePerShare1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2020-04-01to2020-04-03_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember" unitRef="Shares" decimals="INF">24822</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2020-04-01to2020-04-03_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember_custom_Plan2010Member" unitRef="Shares" decimals="INF">23893</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2020-04-01to2020-04-03_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember_custom_Equity2020PlanMember" unitRef="Shares" decimals="INF">929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2020-09-01to2020-09-30_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember_custom_Equity2020PlanMember" unitRef="Shares" decimals="INF">929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2020-09-01to2020-09-30_us-gaap_RestrictedStockUnitsRSUMember_custom_Equity2020PlanMember" unitRef="Shares" decimals="INF">4645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <aemd:RsusExchangedForCommonStockRsusExchanged contextRef="From2020-06-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember" unitRef="Shares" decimals="INF">29866</aemd:RsusExchangedForCommonStockRsusExchanged>
    <aemd:RsusExchangedForCommonStockRsusExchanged contextRef="From2020-09-01to2020-09-30_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember" unitRef="Shares" decimals="INF">29866</aemd:RsusExchangedForCommonStockRsusExchanged>
    <aemd:RsusExchangedForCommonStockRsusExchanged contextRef="From2020-12-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember" unitRef="Shares" decimals="INF">32189</aemd:RsusExchangedForCommonStockRsusExchanged>
    <aemd:RsusExchangedForCommonStockCommonStockIssued contextRef="From2020-06-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember" unitRef="Shares" decimals="INF">29866</aemd:RsusExchangedForCommonStockCommonStockIssued>
    <aemd:RsusExchangedForCommonStockCommonStockIssued contextRef="From2020-09-01to2020-09-30_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember" unitRef="Shares" decimals="INF">29866</aemd:RsusExchangedForCommonStockCommonStockIssued>
    <aemd:RsusExchangedForCommonStockCommonStockIssued contextRef="From2020-12-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember" unitRef="Shares" decimals="INF">32189</aemd:RsusExchangedForCommonStockCommonStockIssued>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="From2020-06-01to2020-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember" unitRef="Shares" decimals="INF">11947</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="From2020-09-01to2020-09-30_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember" unitRef="Shares" decimals="INF">11947</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="From2020-12-01to2020-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember" unitRef="Shares" decimals="INF">12876</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">460119</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">472420</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">602323</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-03-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">51124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">602323</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">32.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-03-31_us-gaap_OptionMember" unitRef="USDPShares" decimals="INF">44.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_us-gaap_OptionMember" unitRef="USDPShares" decimals="INF">3.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2020-12-31_us-gaap_OptionMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">2240000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2020-04-01to2020-12-31">P1Y5M23D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="From2020-04-01to2020-12-31_custom_MelanomaCancerContractPhase2Member" unitRef="USD" decimals="0">436427</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="From2020-04-01to2020-12-31_custom_BreastCancerGrantMember" unitRef="USD" decimals="0">188444</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:OperatingLeaseExpense contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">130000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">144000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">50000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">44000</us-gaap:OperatingLeaseExpense>
    <dei:EntityShellCompany contextRef="From2020-04-01to2020-12-31">false</dei:EntityShellCompany>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2020-04-02" unitRef="USD" decimals="0">228694</us-gaap:OperatingLeaseLiability>
    <us-gaap:ProfitLoss contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">-4594850</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">-5626925</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-04-01to2020-12-31_custom_AethlonMember" unitRef="USD" decimals="0">-5610994</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-04-01to2020-12-31_custom_ESIMember" unitRef="USD" decimals="0">-15931</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-04-01to2019-12-31_custom_AethlonMember" unitRef="USD" decimals="0">-4575811</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-04-01to2019-12-31_custom_ESIMember547542546" unitRef="USD" decimals="0">-19039</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">-2444390</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-820939</us-gaap:ProfitLoss>
    <aemd:GrantDateFairValue contextRef="From2020-04-01to2020-04-03_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember" unitRef="USD" decimals="0">35000</aemd:GrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2020-04-01to2020-04-03_us-gaap_RestrictedStockUnitsRSUMember_custom_NonEmployeeDirectorsMember" unitRef="USDPShares" decimals="INF">1.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">11434186</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">9277426</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">2299078</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">3804182</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">9368</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">12125</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1267</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4781</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">121426563</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">129207491</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">108076275</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">114172714</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-112026381</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-117650120</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-105652433</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-110243475</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-03-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-132124</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-12-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-135310</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-03-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-126031</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-129838</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">12089</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1339</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">128895581</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">109571708</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-115207228</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-109423894</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-09-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-133812</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-09-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-128480</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-09-30" unitRef="USD" decimals="0">13566630</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">20672</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">12072</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1274</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">128744684</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">108862666</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-113436664</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-107718857</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-06-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-132987</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-06-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-126891</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2020-06-30" unitRef="USD" decimals="0">15187105</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">1018192</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:Revenues contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">443458</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">624871</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2020-04-01to2020-12-31_custom_AethlonMember" unitRef="USD" decimals="0">624871</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2020-04-01to2020-12-31_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2019-04-01to2019-12-31_custom_AethlonMember" unitRef="USD" decimals="0">443458</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2019-04-01to2019-12-31_custom_ESIMember547542546" unitRef="USD" decimals="0">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">624871</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">413458</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">-4144797</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">-5625395</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2020-04-01to2020-12-31_custom_AethlonMember" unitRef="USD" decimals="0">-5609464</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2020-04-01to2020-12-31_custom_ESIMember" unitRef="USD" decimals="0">-15931</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-04-01to2019-12-31_custom_AethlonMember" unitRef="USD" decimals="0">-4125758</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-04-01to2019-12-31_custom_ESIMember547542546" unitRef="USD" decimals="0">-19039</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">-2443588</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-876406</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndDebtExpense contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">54232</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">1530</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2020-04-01to2020-12-31_custom_AethlonMember" unitRef="USD" decimals="0">1530</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2020-04-01to2020-12-31_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2019-04-01to2019-12-31_custom_AethlonMember" unitRef="USD" decimals="0">54232</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2019-04-01to2019-12-31_custom_ESIMember547542546" unitRef="USD" decimals="0">0</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">802</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">126</us-gaap:InterestAndDebtExpense>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">9366873</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">12123524</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1266979</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4779614</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">12088313</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1337259</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">12070393</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1273605</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2686</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">7258183</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">36619</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-04-01to2020-06-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-04-01to2019-06-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">7260869</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">36622</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-07-01to2019-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">60</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-07-01to2019-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">386552</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-07-01to2019-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-07-01to2019-09-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2019-07-01to2019-09-30" unitRef="USD" decimals="0">386612</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">447011</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2019-04-01to2019-06-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">447011</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">17920</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">35211</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3539</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3439</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">17920</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="From2019-07-01to2019-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3236</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">-66012</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-6769</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">18</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">36</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-24269</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-66048</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-23775</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-6772</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-04-01to2020-06-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-10-01to2020-12-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2019-04-01to2019-06-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2019-10-01to2019-12-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">-24251</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-23771</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">17</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2019-07-01to2019-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-16145</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2019-07-01to2019-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-8448</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2019-07-01to2019-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-07-01to2020-09-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2019-07-01to2019-09-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2020-07-01to2020-09-30" unitRef="USD" decimals="0">-16128</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="From2019-07-01to2019-09-30" unitRef="USD" decimals="0">-8445</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">377958</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">102576</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">84207</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">377958</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">326536</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">102576</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-04-01to2020-06-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-10-01to2020-12-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2019-06-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-10-01to2019-12-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">84207</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">326536</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-07-01to2019-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">167042</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-07-01to2019-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">326536</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-07-01to2019-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-07-01to2020-09-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-07-01to2019-09-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2020-07-01to2020-09-30" unitRef="USD" decimals="0">167042</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2019-07-01to2019-09-30" unitRef="USD" decimals="0">326536</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <aemd:IssuanceOfCommonSharesUponWarrantExchangesValue contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-55593</aemd:IssuanceOfCommonSharesUponWarrantExchangesValue>
    <aemd:IssuanceOfCommonSharesUponWarrantExchangesValue contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3</aemd:IssuanceOfCommonSharesUponWarrantExchangesValue>
    <aemd:IssuanceOfCommonSharesUponWarrantExchangesValue contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-55596</aemd:IssuanceOfCommonSharesUponWarrantExchangesValue>
    <aemd:IssuanceOfCommonSharesUponWarrantExchangesValue contextRef="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <aemd:IssuanceOfCommonSharesUponWarrantExchangesValue contextRef="From2019-10-01to2019-12-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <aemd:IssuanceOfCommonSharesUponWarrantExchangesValue contextRef="From2019-07-01to2019-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1</aemd:IssuanceOfCommonSharesUponWarrantExchangesValue>
    <aemd:IssuanceOfCommonSharesUponWarrantExchangesValue contextRef="From2019-07-01to2019-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4402</aemd:IssuanceOfCommonSharesUponWarrantExchangesValue>
    <aemd:IssuanceOfCommonSharesUponWarrantExchangesValue contextRef="From2019-07-01to2019-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <aemd:IssuanceOfCommonSharesUponWarrantExchangesValue contextRef="From2019-07-01to2019-09-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <aemd:IssuanceOfCommonSharesUponWarrantExchangesValue contextRef="From2019-07-01to2019-09-30" unitRef="USD" decimals="0">4403</aemd:IssuanceOfCommonSharesUponWarrantExchangesValue>
    <aemd:IssuanceOfCommonSharesUponWarrantExchangesShares contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2914</aemd:IssuanceOfCommonSharesUponWarrantExchangesShares>
    <aemd:IssuanceOfCommonSharesUponWarrantExchangesShares contextRef="From2019-07-01to2019-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1078</aemd:IssuanceOfCommonSharesUponWarrantExchangesShares>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">-2444390</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-820939</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-04-01to2020-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-10-01to2020-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-04-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-04-01to2020-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-10-01to2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-04-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-04-01to2020-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-1410283</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-10-01to2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-2442892</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-04-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-2066424</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-819581</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-04-01to2020-06-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-863</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-10-01to2020-12-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-1498</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-04-01to2019-06-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-860</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-10-01to2019-12-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-1358</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-04-01to2020-06-30" unitRef="USD" decimals="0">-1411146</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-04-01to2019-06-30" unitRef="USD" decimals="0">-2067284</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-07-01to2020-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-07-01to2019-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-07-01to2020-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-07-01to2019-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-07-01to2020-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-1770564</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-07-01to2019-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-1705037</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-07-01to2020-09-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-825</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-07-01to2019-09-30_us-gaap_NoncontrollingInterestMember" unitRef="USD" decimals="0">-1589</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2020-07-01to2020-09-30" unitRef="USD" decimals="0">-1771389</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2019-07-01to2019-09-30" unitRef="USD" decimals="0">-1706626</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">12159</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">12159</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:RestrictedCash contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">46726</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">0</us-gaap:RestrictedCash>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">57092</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">57504</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">166751</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">140484</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">12322271</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">10041113</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">75829</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">229604</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">114849</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">206729</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">1235563</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">1110260</us-gaap:Liabilities>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">42540</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">1235563</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">1067720</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">860697</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">472420</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">67698</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">98557</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">175422</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">285036</us-gaap:AccountsPayableCurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2020-03-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">12669749</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">10387686</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:MinorityInterest contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">-135310</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">-132124</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">11569496</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">9409550</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">-117650120</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">-112026381</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">129207491</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">121426563</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">12125</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">9368</us-gaap:CommonStockValue>
    <us-gaap:OperatingExpenses contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">4588255</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">6250266</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">3068459</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">1289864</us-gaap:OperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">998465</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">1883802</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">919830</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">273510</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">1609942</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">2520805</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">1523650</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">406421</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ProfessionalFees contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">1979848</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">1845659</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">624979</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">609933</us-gaap:ProfessionalFees>
    <us-gaap:NetIncomeLoss contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">-4591042</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">-5623739</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">-2442892</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-819581</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">-3808</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">-3186</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">-1498</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-1358</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">-450053</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">-1530</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">-802</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">55467</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">-447011</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">-3577253</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">-4526309</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">27558</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">20039</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">100000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">-100000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">-271533</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">278663</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">-169691</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">-153775</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">206729</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">-91880</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">30287</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <aemd:AccretionOfRightofuseLeaseAsset contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">-862</aemd:AccretionOfRightofuseLeaseAsset>
    <aemd:AccretionOfRightofuseLeaseAsset contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">1723</aemd:AccretionOfRightofuseLeaseAsset>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">15992</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">28775</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">-148064</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">-54630</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">148064</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">54630</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">3955896</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">7154478</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">992591</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">4987468</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">7260869</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:InterestPaidNet contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">83332</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">0</us-gaap:InterestPaidNet>
    <us-gaap:StockIssued1 contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">4</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">0</us-gaap:StockIssued1>
    <aemd:InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">228694</aemd:InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability>
    <aemd:InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">0</aemd:InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">230579</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">2573539</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">12178319</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">9604780</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-03-31" unitRef="USD" decimals="0">3828074</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">4058653</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">12131593</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">4058653</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3432056</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">4564234</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">3432</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4560802</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-10-01to2019-12-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">3946</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <aemd:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2019-10-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <aemd:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4</aemd:StockIssuedDuringPeriodValueReverseStockSplits>
    <aemd:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-4</aemd:StockIssuedDuringPeriodValueReverseStockSplits>
    <aemd:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <aemd:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2019-10-01to2019-12-31_us-gaap_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;1. NATURE OF BUSINESS AND BASIS OF PRESENTATION&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;ORGANIZATION&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Aethlon Medical, Inc. and its subsidiary (collectively,&#13;&amp;#8220;Aethlon&amp;#8221;, the &amp;#8220;Company&amp;#8221;, &amp;#8220;we&amp;#8221; or &amp;#8220;us&amp;#8221;), is a medical technology company focused&#13;on developing products to diagnose and treat life and organ threatening diseases. The Aethlon Hemopurifier&amp;#174;, or Hemopurifier,&#13;is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier&#13;is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis&#13;and inhibit the benefit of leading cancer therapies. The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier&#13;as a &amp;#8220;Breakthrough Device&amp;#8221; for&amp;#160;two independent indications:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px; font: 12pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 48px; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 48px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 48px"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;the treatment of life-threatening viruses that are not addressed with approved therapies.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We believe the Hemopurifier can be a substantial&#13;advance in the treatment of patients with advanced and metastatic cancer through the clearance of exosomes that promote the growth&#13;and spread of tumors through multiple mechanisms. We are currently preparing for the initiation of clinical trials in patients&#13;with advanced and metastatic cancers. We are initially focused on the treatment of solid tumors, including head and neck cancer,&#13;gastrointestinal cancers and other cancers. As we advance our clinical trials, we are in close contact with our clinical sites&#13;to navigate and assess the impact of the COVID-19 global pandemic on our clinical trials and current timelines.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 4, 2019, the FDA approved our Investigational&#13;Device Exemption, or IDE, application to initiate an Early Feasibility Study, or EFS, of the Hemopurifier in patients with head&#13;and neck cancer in combination with standard of care pembrolizumab (Keytruda) (NCT # 04453046).&amp;#160; The primary endpoint for&#13;the EFS, which is designed to enroll 10-12 subjects at a single center, will be safety, with secondary endpoints including measures&#13;of exosome clearance and characterization, as well as response and survival rates. This study, which will be conducted at the UPMC&#13;Hillman Cancer Center in Pittsburgh, PA, has been approved by the Institutional Review Board, or IRB, and is now open for patient&#13;enrollment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We also believe the Hemopurifier can be a part&#13;of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed&#13;with an already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used to treat&#13;individuals infected with human immunodeficiency virus, or HIV, Hepatitis C, and Ebola.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Additionally, &lt;i&gt;in vitro,&lt;/i&gt; the Hemopurifier&#13;has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus,&#13;Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, and the&#13;reconstructed Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government&#13;or non-government research institutes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 17, 2020, the FDA approved a supplement&#13;to the Company&amp;#8217;s open IDE for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients&#13;with SARS-CoV-2/COVID-19 in a New Feasibility Study. &lt;font style="background-color: white"&gt;That study&amp;#8217;s plan is to enroll&#13;up to 40 subjects at up to 20 centers in the U.S. Subjects will have established laboratory diagnosis of COVID-19, be admitted&#13;to an intensive care unit, or ICU and will have acute lung injury and/or severe or life threatening disease, among other criteria.&#13;Endpoints for this study, in addition to safety, will include reduction in circulating virus as well as clinical outcomes (NCT&#13;# 04595903). The first sites for this trial, Hoag Memorial Hospital Presbyterian in Newport Beach, CA and Hoag Hospital &amp;#8211;&#13;Irvine in Irvine, CA now have IRB approval and are preparing to open for patient enrollment. Under Single Patient Emergency Use&#13;regulations, the Company has also recently treated a patient with COVID-19 who successfully completed eight daily treatments with&#13;the Hemopurifier.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We are also the majority owner of Exosome Sciences,&#13;Inc., or ESI, a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases. Included&#13;among ESI&amp;#8217;s activities is the advancement of a TauSome&amp;#8482; biomarker candidate to diagnose chronic traumatic encephalopathy,&#13;or CTE, in the living. ESI previously documented TauSome levels in former NFL players to be nine times higher than same age-group&#13;control subjects. Through ESI, we are also developing exosome based biomarkers in patients with, or at risk for, a number of cancers.&#13;We consolidate ESI&amp;#8217;s activities in our consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Successful outcomes of human trials will also&#13;be required by the regulatory agencies of certain foreign countries where we plan to sell the Hemopurifier. Some of our patents&#13;may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications&#13;and/or other patents issued more recently will help protect the proprietary nature of the Hemopurifier treatment technology.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition to the foregoing, we are monitoring&#13;closely the impact of the COVID-19 global pandemic on our business and have taken steps designed to protect the health and safety&#13;of our employees while continuing our operations. Given the level of uncertainty regarding the duration and impact of the COVID-19&#13;pandemic on capital markets and the U.S. economy, we are unable to assess the impact of the worldwide spread of SARS-CoV-2 and&#13;the resulting COVID-19 pandemic on our timelines and future access to capital. We are continuing to monitor the spread of COVID-19&#13;and its potential impact on our operations. The full extent to which the COVID-19 pandemic will impact our business, results of&#13;operations, financial condition, clinical trials, and preclinical research will depend on future developments that are highly uncertain,&#13;including actions taken to contain or treat COVID-19 and their effectiveness, as well as the economic impact on national and international&#13;markets.&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our executive offices are located at 9635 Granite&#13;Ridge Drive, Suite 100, San Diego, California 92123. Our telephone number is (858) 459-7800. Our website address is www.aethlonmedical.com.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our common stock is listed on the Nasdaq Capital&#13;Market under the symbol &amp;#8220;AEMD.&amp;#8221;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;REVERSE STOCK SPLIT&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Following the approval of a reverse stock split&#13;at our 2019 Annual Meeting of Stockholders&amp;#8217; held on October 14, 2019, our Board of Directors approved a 1-for-15 reverse&#13;stock split. Accordingly, 15 shares of outstanding common stock then held by stockholders were combined into one share of common&#13;stock. Any fractional shares resulting from the reverse split were rounded up to the next whole share. Authorized common stock&#13;remained at 30,000,000 shares. The accompanying unaudited condensed consolidated financial statements and accompanying notes have&#13;been retroactively revised to reflect such reverse stock split as if it had occurred on April 1, 2019. All shares and per share&#13;amounts have been revised accordingly.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the nine months ended December 31,&#13;2020, there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal&#13;year ended March 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Basis of Presentation and Use of Estimates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated&#13;financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP,&#13;for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission,&#13;or SEC Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto&#13;for the fiscal year ended March 31, 2020, included in the Company's Annual Report on Form 10-K filed with the SEC on June 25, 2020.&#13;The accompanying unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its majority-owned&#13;subsidiary. All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed&#13;consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are&#13;necessary to present fairly the condensed consolidated financial statements as of and for the three and nine months ended December&#13;31, 2020, and the condensed consolidated statement of cash flows for the nine months ended December 31, 2020. Estimates were made&#13;relating to useful lives of fixed assets, impairment of assets, share-based compensation expense and accruals for clinical trial&#13;and research and development expenses. Actual results could differ materially from those estimates. The accompanying condensed&#13;consolidated balance sheet at March 31, 2020 has been derived from the audited consolidated balance sheet at March 31, 2020, contained&#13;in the above referenced 10-K. The results of operations for the three and nine months ended December 31, 2020 are not necessarily&#13;indicative of the results to be expected for the full year or any future interim periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain prior year balances within the unaudited&#13;condensed consolidated financial statements have been reclassified to conform to the current year presentation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Restricted Cash&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;To comply with the terms of our new laboratory&#13;and office lease (see Note 13), we caused our bank to issue a standby letter of credit, or the L/C, in the amount of $46,726 in&#13;favor of the landlord. The L/C is in lieu of a security deposit. In order to support the L/C, we agreed to have our bank withdraw&#13;$46,726 from our operating accounts and to place that amount in a restricted certificate of deposit. We have classified that amount&#13;as restricted cash, a long-term asset, on our balance sheet.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;LIQUIDITY&#13;AND GOING CONCERN&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Management expects existing cash&#13;as of December 31, 2020 to be sufficient to fund the Company&amp;#8217;s operations for at least twelve months from the issuance date&#13;of these condensed consolidated financial statements.&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;2. LOSS PER COMMON SHARE&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic loss per share is computed by dividing&#13;net loss by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is&#13;computed similar to basic loss per share, except that the denominator is increased to include the number of additional dilutive&#13;common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were&#13;dilutive. Since we had net losses for all periods presented, basic and diluted loss per share are the same, and additional potential&#13;common shares have been excluded, as their effect would be antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2020, and 2019, an aggregate&#13;of 2,626,485 and 3,779,301 potential common shares, respectively, consisting of shares underlying outstanding stock options, warrants&#13;and unvested restricted stock units, were excluded, as their inclusion would be antidilutive.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;3. RESEARCH AND DEVELOPMENT EXPENSES&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our research and development costs are expensed&#13;as incurred. We incurred research and development expenses during the three and nine month periods ended December 31, 2020 and&#13;2019, which are included in various operating expense line items in the accompanying condensed consolidated statements of operations.&#13;Our research and development expenses in those periods were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 67%"&gt;&lt;font style="font-size: 10pt"&gt;Three months ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;461,176&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;218,571&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Nine months ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,367,333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;692,022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;4. &lt;font style="text-transform: uppercase"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We do not expect the adoption of any recent&#13;accounting pronouncement to have a material impact on our financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:LongTermDebtTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;5. CONVERTIBLE NOTES PAYABLE, NET&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2019, all of our previously outstanding&#13;convertible notes, in the aggregate amount of $992,591, were paid in full.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For the nine months ended December 31, 2019,&#13;we recorded interest expense of $23,759 related to the contractual interest rates of our convertible notes and interest expense&#13;of $30,287 related to the amortization of the note discount for a total interest expense of $54,046 related to our convertible&#13;notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the nine months ended December 31, 2019,&#13;prior to paying off the notes, we reduced the conversion price on the convertible notes from $45.00 per share to $10.20 per share.&#13;The modification of the convertible notes was evaluated under ASC 470-50-40 and the instruments were determined to be substantially&#13;different, and the transaction qualified for extinguishment accounting. Under the extinguishment accounting we recorded a loss&#13;on debt extinguishment of $447,011.&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;6. EQUITY TRANSACTIONS&amp;#160;IN THE NINE MONTHS ENDED DECEMBER 31,&#13;2020&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Common Stock Sales Agreement with H.C. Wainwright &amp;#38; Co.,&#13;LLC&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 28, 2016, we entered into a Common&#13;Stock Sales Agreement, or the Agreement, with H.C. Wainwright &amp;#38; Co., LLC, or Wainwright, which established an at-the-market&#13;equity program pursuant to which we may offer and sell shares of our common stock from time to time as set forth in the Agreement.&#13;The Agreement provided for the sale of shares of our common stock having an aggregate offering price of up to $12,500,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 30, 2020, we executed Amendment No.&#13;2 to the Agreement with Wainwright, effective as of the same date. The amendment provides that references in the Agreement to the&#13;registration statement shall refer to the registration statement on Form S-3 (File No. 333-237269), originally filed with the SEC&#13;on March 19, 2020, declared effective by the SEC on March 30, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Subject to the terms and conditions set forth&#13;in the Agreement, Wainwright agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices&#13;to sell the shares under the Agreement from time to time, based upon our instructions. We provided Wainwright with customary indemnification&#13;rights under the Agreement, and Wainwright is entitled to a commission at a fixed rate equal to three percent of the gross proceeds&#13;per share sold. In addition, we agreed to pay certain expenses incurred by Wainwright in connection with the Agreement, including&#13;up to $50,000 of the fees and disbursements of their counsel. The Agreement will terminate upon the sale of all of the shares under&#13;the Agreement, unless terminated earlier by either party as permitted under the Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Sales of the shares, if any, under the Agreement&#13;will be made in transactions that are deemed to be &amp;#8220;at the market offerings&amp;#8221; as defined in Rule 415 under the Securities&#13;Act of 1933, as amended, or the Securities Act, including sales made by means of ordinary brokers&amp;#8217; transactions, including&#13;on the Nasdaq Capital Market, at market prices or as otherwise agreed with Wainwright. We have no obligation to sell any of the&#13;shares, and, at any time, we may suspend offers under the Agreement or terminate the Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the three months ended June 30, 2020, we&#13;raised aggregate net proceeds of $7,260,869, net of $224,825 in commissions to Wainwright and $8,472 in other offering expenses,&#13;under the Agreement, through the sale of 2,685,600 shares at an average price of $2.70 per share of net proceeds.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Restricted Stock Unit Grants &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In 2012, as amended through July 16, 2020,&#13;our Board of Directors established the Non-Employee Directors Compensation Program, to provide for cash and equity compensation&#13;for persons serving as non-employee directors of the Company. Under this program, each new director receives either stock options&#13;or a grant of restricted stock units, or RSUs, as well as an annual grant of RSUs at the beginning of each fiscal year. The RSUs&#13;are subject to vesting and represent the right to be issued on a future date shares of our common stock upon vesting.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 3, 2020, pursuant to the terms of&#13;the Company&amp;#8217;s Non-Employee Directors Compensation Program, the Compensation Committee of the Board of Directors granted RSUs&#13;to each non-employee director of the Company. The Non-Employee Directors Compensation Program provided for a grant of RSUs with&#13;a grant date fair value of $35,000, priced at the average of the closing prices for the five trading days ending on the date of&#13;grant, which was $1.41 per share, so that the total number of RSUs to be granted to each non-employee director for fiscal year&#13;2020 would be 24,822 shares of our common stock.&amp;#160;&amp;#160;On April 3, 2020, each eligible director was granted an RSU for 23,893&#13;shares under the Company&amp;#8217;s 2010 Stock Plan, or the 2010 Plan, as the number of shares that remained available for grant under&#13;the 2010 Plan was not sufficient for each director&amp;#8217;s full RSU grant. The Compensation Committee also granted to each eligible&#13;director a contingent grant under our 2020 Equity Incentive Plan, or the 2020 Plan, for the remaining portion of the annual RSU&#13;grants, or 929 RSU&amp;#8217;s to each eligible director, contingent upon stockholder approval of the 2020 Plan at the Company&amp;#8217;s&#13;2020 Annual Meeting of Stockholders, or the Annual Meeting. These grants are subject to vesting as follows: 50% of the RSUs subject&#13;to the grants will vest on December 31, 2020 and 50% of the RSUs will vest on March 31, 2021, subject in each case to the continuous&#13;service of each director, through such vesting dates, as well as approval of the 2020 Plan by the stockholders at the Annual Meeting,&#13;which was obtained at the Annual Meeting.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2020, 29,866 vested RSUs held by our&#13;non-employee directors were exchanged into the same number of shares of our common stock. All five non-employee directors elected&#13;to return 40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resulting&#13;in 11,947 of the vested RSUs being cancelled in exchange for $24,251 in aggregate cash proceeds to those independent directors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2020, 29,866 vested RSUs held&#13;by our non-employee directors were exchanged into the same number of shares of our common stock. All five non-employee directors&#13;elected to return 40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances,&#13;resulting in 11,947 of the vested RSUs being cancelled in exchange for $16,128 in aggregate cash proceeds to those independent&#13;directors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Also in September 2020, our stockholders approved&#13;the 2020 Plan at the Annual Meeting, at which point the grants of 929 RSUs to each of our eligible independent directors for a&#13;total of 4,645 RSUs were considered effective and no longer contingent as of that date (See Note 9).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2020, 32,189 vested RSUs held by&#13;our non-employee directors were exchanged into the same number of shares of our common stock. All five non-employee directors elected&#13;to return 40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resulting&#13;in 12,876 of the vested RSUs being cancelled in exchange for $31,802 in aggregate cash proceeds to those independent directors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;RSUs outstanding that have vested as of, and&#13;are expected to vest subsequent to, December 31, 2020 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Number of RSUs&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 84%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Expected to vest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;32,189&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;32,189&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;7. RELATED PARTY TRANSACTIONS&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended December 31,&#13;2020, we accrued unpaid fees of $69,292 owed to our non-employee directors as of December 31, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As a result of entering into a Separation Agreement&#13;on October 30, 2020 with our former Chief Executive Officer, or CEO, Timothy Rodell, M.D., or the Separation Agreement, we paid&#13;out accrued vacation of $20,260 to Dr. Rodell in the three months ended December 2020 (see Note 8 and Note 13). That accrued vacation&#13;was previously recorded in the due to related parties account.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amounts due to related parties were comprised&#13;of the following items:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31, &lt;br /&gt;&#13;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;March 31, &lt;br /&gt;&#13;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 68%"&gt;&lt;font style="font-size: 10pt"&gt;Accrued Board fees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;69,292&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;69,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Accrued vacation to all employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,454&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;41,957&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total due to related parties&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;131,746&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;111,707&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;8. OTHER CURRENT LIABILITIES&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Other current liabilities were comprised of the following items:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;March 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 68%"&gt;&lt;font style="font-size: 10pt"&gt;Accrued separation expenses for former executive&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;400,578&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Accrued professional fees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;460,119&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;472,420&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total other current liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;860,697&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;472,420&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;9. STOCK COMPENSATION&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following tables summarize share-based&#13;compensation expenses relating to RSUs and stock options and the effect on basic and diluted loss per common share during the three&#13;and nine month periods ended December 31, 2020 and 2019:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Three Months &lt;br /&gt;&#13;Ended &lt;br /&gt;&#13;December 31, &lt;br /&gt;&#13;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Three Months&lt;br /&gt;&#13;Ended&lt;br /&gt;&#13;December 31, &lt;br /&gt;&#13;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Nine Months &lt;br /&gt;&#13;Ended &lt;br /&gt;&#13;December 31,&lt;br /&gt;&#13;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Nine Months&lt;br /&gt;&#13;Ended &lt;br /&gt;&#13;December 31,&lt;br /&gt;&#13;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 44%; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Vesting of stock options and restricted stock units&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;377,958&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;102,576&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;629,207&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;755,648&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;377,958&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;102,576&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;629,207&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;755,648&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average number of common shares outstanding &amp;#8211; basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,093,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,887,883&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;11,265,725&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,821,557&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Basic and diluted loss per common share attributable to stock-based compensation expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.41&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All of the stock-based compensation expense&#13;recorded during the nine months ended December 31, 2020 and 2019, which totaled $629,207 and $755,648, respectively, is included&#13;in payroll and related expense in the accompanying condensed consolidated statements of operations.&amp;#160; Stock-based compensation&#13;expense recorded during the nine months ended December 31, 2020 and 2019 represented an impact on basic and diluted loss per common&#13;share of $(0.06) and $(0.41), respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We review share-based compensation on a quarterly&#13;basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of&#13;adjusting the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The&#13;effect of forfeiture adjustments for the nine months ended December 31, 2020 was insignificant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Stock Option Activity and Approval of 2020 Plan&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From February 2020 through May 2020, our compensation&#13;committee granted options to purchase 521,476 shares of our common stock that were contingent upon stockholder approval of the&#13;2020 Plan. Upon approval of the 2020 Plan at the Annual Meeting, these option grants were considered effective and no longer contingent&#13;as of that date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2020 Plan approved by our stockholders&#13;at the Annual Meeting, authorizes up to 1,842,556 shares for issuance pursuant to stock option grants, RSUs or other forms of stock-based&#13;compensation. No future grants will be made under the 2010 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We issued an option to purchase shares 239,122&#13;shares of our common stock pursuant to the 2020 Plan to our Chief Executive Officer during the three months ended December 31,&#13;2020, in connection with the appointment of Dr. Fisher as our Chief Executive Officer, effective as of October 30, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the Separation Agreement&#13;and pursuant to Dr. Rodell&amp;#8217;s employment agreement with the Company, the vesting was accelerated on 50% of outstanding and&#13;unvested options to purchase shares of our common stock held by Dr. Rodell as of the Separation Date of October 30, 2020, such&#13;that the accelerated stock options were fully vested and exercisable as of the Separation Date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2020, Dr. Rodell elected to net&#13;exercise a portion of his stock options. As a result, we issued Dr. Rodell an aggregate of 15,896 shares of our common stock and&#13;we paid the estimated withholding taxes of $34,209 related to the net exercise.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Options outstanding that were vested as of&#13;December 31, 2020 and options that are expected to vest subsequent to December 31, 2020 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br /&gt;&#13;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br /&gt;&#13;Average&lt;br /&gt;&#13;Exercise&lt;br /&gt;&#13;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br /&gt;&#13;Average&lt;br /&gt;&#13;Remaining&lt;br /&gt;&#13;Contractual&lt;br /&gt;&#13;Term in&lt;br /&gt;&#13;Years&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font-size: 10pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;34,509&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;32.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.84&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Expected to vest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;567,814&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.67&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;602,323&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;A summary of stock option activity during the nine months ended&#13;December 31, 2020 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Range of&lt;br /&gt;&#13;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br /&gt;&#13;Average &lt;br /&gt;&#13;Exercise&lt;br /&gt;&#13;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 53%"&gt;&lt;font style="font-size: 10pt"&gt;Stock options outstanding at March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;51,124&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$18.75 - $187.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;44.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(15,896&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;770,094&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.28 &amp;#8211; $2.45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Cancelled/Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(202,999&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.28 - $187.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Stock options outstanding at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;602,323&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.28 - $187.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.29&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Stock options exercisable at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;34,509&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.28 - $187.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;32.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 31, 2020, our outstanding stock&#13;options had no intrinsic value since the closing price on that date of $2.47 per share was below the weighted average exercise&#13;price of our outstanding stock options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2020, there was approximately&#13;$2,240,000 of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted&#13;average period of 1.48 years.&lt;/p&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <aemd:WarrantsTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;10. WARRANTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;During the nine months ended December 31, 2020 and 2019, we did&#13;not issue any warrants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;A summary of warrant activity during the nine months ended December&#13;31, 2020 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Range of&lt;br /&gt;&#13;Exercise&lt;br /&gt;&#13;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br /&gt;&#13;Average&lt;br /&gt;&#13;Exercise&lt;br /&gt;&#13;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 53%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Warrants outstanding at March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,021,368&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.50 - $125.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Cancelled/Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(29,395&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$90.75 &amp;#8211; $135.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;97.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Warrants outstanding at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,991,973&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.50 &amp;#8211; $99.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.23&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Warrants exercisable at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,991,973&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.50 &amp;#8211; $99.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.23&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</aemd:WarrantsTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;11. GOVERNMENT CONTRACTS AND RELATED REVENUE RECOGNITION&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have recognized revenue under the following&#13;two contracts/grants with the National Cancer Institute, or NCI, part of the National Institutes of Health, or NIH, over the past&#13;two years:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Phase 2 Melanoma Cancer Contract&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 12, 2019, the NCI awarded to us&#13;an SBIR Phase II Award Contract, for NIH/NCI Topic 359, entitled &amp;#8220;A Device Prototype for Isolation of Melanoma Exosomes for&#13;Diagnostics and Treatment Monitoring&amp;#8221;, or the Award Contract. The Award Contract amount is $1,860,561 and runs for the period&#13;from September 16, 2019 through September 15, 2021.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The work to be performed pursuant to this Award&#13;Contract focuses on melanoma exosomes. This work follows from our completion of a phase I contract for the Topic 359 solicitation&#13;that ran from September 2017 through June 2018, as described below. Following on the phase I work, the deliverables in the phase&#13;II program involve the design and testing of a pre-commercial prototype of a more advanced version of the exosome isolation platform.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the period ended December 31, 2020,&#13;we completed all of the milestones relevant to that time period. As a result, we recorded $436,427 of government contract revenue&#13;on the Phase 2 Melanoma Cancer Contract in the nine months ended December 31, 2020.&amp;#160;&amp;#160; Of the total revenue recognized&#13;during the current period relating to this grant, a total of $117,849 was invoiced to the NCI during the three months ended December&#13;31, 2020 and we recorded $318,578 which had previously been recognized as deferred revenue.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Breast Cancer Grant&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the nine months ended December 31, 2020,&#13;we completed and submitted the final reports applicable to this NCI grant (number 1R43CA232977-01). The title of this Small Business&#13;Innovation Research, or SBIR, Phase I grant is &amp;#8220;The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from&#13;the Blood Circulation,&amp;#8221; or the Breast Cancer Grant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;This NCI Phase I grant period originally ran&#13;from September 14, 2018 through August 31, 2019. In August 2019, we applied for and received a no cost, twelve month extension&#13;on this grant; through August 31, 2020. The total amount of the firm grant was $298,444. The grant called for two subcontractors&#13;to work with us. Those subcontractors were University of Pittsburgh and Massachusetts General Hospital. As of December 31, 2020,&#13;we have received all of the funds allocated to the Breast Cancer Grant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the nine months ended December 31, 2020,&#13;we recorded the remaining $188,444 of revenue related to the Breast Cancer Grant, as we achieved two of the three milestones related&#13;to the Breast Cancer Grant. We concluded in our final report to the SBIR that our pre-clinical results demonstrated that our work&#13;under the grant provided support that the Hemopurifier has the capacity to clear exosomes from breast cancer patients. That amount&#13;previously was recorded as deferred revenue.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2020, we received all of&#13;the funds allocated to the Breast Cancer Grant and have submitted the final reports applicable to this grant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Subaward with University of Pittsburgh&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, we are completing the logistical&#13;elements of documentation and billing the University of Pittsburgh in connection with a cost reimbursable subaward arrangement&#13;under an NIH project entitled &amp;#8220;Depleting Exosomes to Improve Responses to Immune Therapy in HNNCC.&amp;#8221; Our share of the&#13;award is $256,750. We have not recorded any revenues as of December 31, 2020 related to the subaward. We anticipate billing and&#13;recognizing revenue under this subaward in future periods.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;12. SEGMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We operate our businesses principally through&#13;two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic&#13;business activities. Our reportable segments have been determined based on the nature of the potential products being developed.&#13;We record discrete financial information for ESI and our chief operating decision maker reviews ESI&amp;#8217;s operating results in&#13;order to make decisions about resources to be allocated to the ESI segment and to assess its performance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Aethlon&amp;#8217;s revenue is generated primarily&#13;from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead&#13;to the ESI segment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following tables set forth certain information regarding our&#13;segments:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Nine Months Ended December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Revenues:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 68%; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;624,871&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;443,458&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Total Revenues&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;624,871&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;443,458&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Operating Losses:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,609,464&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(4,125,758&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(15,931&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(19,039&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Total Operating Loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,625,395&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(4,144,797&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Net Losses:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,610,994&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(4,575,811&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(15,931&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(19,039&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Net Loss Before Non-Controlling Interests&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,626,925&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(4,594,850&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Cash:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,131,396&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,058,456&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;197&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;197&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Total Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,131,593&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,058,653&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Total Assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,669,552&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,682,294&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;197&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;197&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Total Assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,669,749&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,682,491&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Capital Expenditures:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;54,630&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;148,064&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Capital Expenditures&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;54,630&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;148,064&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Depreciation and Amortization:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;28,775&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,992&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Total Depreciation and Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;28,775&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,992&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Interest Expense:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,530&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(54,232&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Total Interest Expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,530&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(54,232&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;13. COMMITMENTS AND CONTINGENCIES&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;CONTRACTUAL OBLIGATIONS AND COMMITMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;There have been no material changes to our&#13;contractual obligations and commitments outside the ordinary course of business from those disclosed under the heading &amp;#8220;Management&amp;#8217;s&#13;Discussion and Analysis of Financial Condition and Results of Operations-Contractual Obligations and Commitments&amp;#8221; as contained&#13;in our Annual Report on Form 10-K for the year ended March 31, 2020, filed by us with the SEC on June 25, 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 30, 2020, we entered into a Separation&#13;Agreement with Timothy Rodell, M.D., our former Chief Executive Officer, or the Separation Agreement. Under this agreement, we&#13;agreed to pay Dr. Rodell a total of $444,729 and to cover his medical insurance costs over a twelve-month period that began on&#13;November 1, 2020, all in accordance with the terms of his employment agreement with the Company. We also paid Dr. Rodell accrued&#13;vacation in the amount of $20,260 in November 2020.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The total expense accrued at December 31, 2020&#13;relating to the Separation Agreement, was $400,578 (see Note 7 and Note 8).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 30, 2020, we entered into an Executive&#13;Employment Agreement, or Agreement, with Charles J. Fisher Jr., M.D. The Agreement provides Dr. Fisher with (i) an initial annualized&#13;base salary of $430,000 per year; (ii) eligibility for a discretionary annual cash bonus, (iii) eligibility for a one-time cash&#13;bonus and additional equity grant upon attaining a specified performance goal, (iv) eligibility to participate in and receive additional&#13;stock options or equity award grants under the Company&amp;#8217;s equity incentive plans from time to time, in the discretion of the&#13;Board or the Compensation Committee, and in accordance with the terms and conditions of such plans; and (iv) severance payments&#13;in the event that Dr. Fisher&amp;#8217;s employment is terminated by the Company for any reason other than Cause (as defined in the&#13;Agreement) or if it is terminated by Dr. Fisher for Good Reason (as defined in the Agreement).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;LEASE COMMITMENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We currently lease approximately 2,600 square&#13;feet of executive office space at 9635 Granite Ridge Drive, Suite 100, San Diego&lt;i&gt;, &lt;/i&gt;California 92123 under a 39-month gross&#13;plus utilities lease that commenced on December 1, 2014 and expires on August 31, 2021. The current rental rate under the lease&#13;extension is $8,265 per month.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We also rent approximately 1,700 square feet&#13;of laboratory space at 11585 Sorrento Valley Road, Suite 109, San Diego, California 92121 at the rate of $6,148 per month on a&#13;one-year lease that originally was to expire on November 30, 2020. In December 2020, we entered into a short-term lease extension&#13;running from December 1, 2020 through the completion date of our construction of our planned new laboratory space which is adjacent&#13;to our current laboratory.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Rent expense, which is included in general&#13;and administrative expenses, approximated $50,000 and $44,000 for the three month periods ended December 31, 2020 and 2019, respectively.&#13;For the nine month periods ended December 31, 2020 and 2019, rent expense approximated $144,000 and $130,000, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Future minimum lease payments under the Granite Ridge Lease as of&#13;December 31, 2020, are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 84%"&gt;&lt;font style="font-size: 10pt"&gt;January 1, 2021 through March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;25,663&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;April 1, 2021 through August 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;43,670&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Total future minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;69,333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Less: discount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,635&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total lease liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;67,698&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the fiscal year ended March 31, 2020,&#13;we adopted ASU Topic 842 on April 1, 2019 utilizing the alternative transition method allowed for under this guidance. As a result,&#13;we recorded lease liabilities and right-of-use lease assets of $228,694 on our balance sheet as of April 1, 2019. The lease liabilities&#13;represent the present value of the remaining lease payments of our corporate headquarters lease, discounted using our incremental&#13;borrowing rate as of April 1, 2019. The corresponding right-of-use lease assets are recorded based on the lease liabilities and&#13;the cumulative difference between rent expense and amounts paid under its corporate headquarters lease. We also elected the short-term&#13;lease recognition exemption for its laboratory lease. For the laboratory lease that qualified as short-term, we did not recognize&#13;right-of-use assets or lease liabilities at adoption.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2020, we entered into an agreement&#13;to lease approximately 2,823 square feet of office space and 1,807 square feet of laboratory space. The agreement carries a term&#13;of 63 months and we will commence paying rent when we take occupancy of those spaces, which is expected to occur in the second&#13;quarter of 2021. Upon taking occupancy of the space, we will record lease liabilities and right-of-use lease assets related to&#13;this agreement on our balance sheet. We estimate that the present value of the contractual payments under the lease agreement to&#13;be approximately $806,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition, the new lease agreement required&#13;us to post a standby letter of credit in favor of the landlord in the amount of $46,726 in lieu of a security deposit. We arranged&#13;for our bank to issue the standby letter of credit in the three months ended December 31, 2020 and transferred a like amount to&#13;a restricted certificate of deposit which secured the bank&amp;#8217;s risk in issuing that letter of credit. We have classified that&#13;restricted certificate of deposit on our balance sheet as restricted cash .&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;LEGAL MATTERS&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From time to time, claims are made against&#13;us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent&#13;uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from&#13;selling one or more products or engaging in other activities.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The occurrence of an unfavorable outcome in&#13;any specific period could have a material adverse effect on our results of operations for that period or future periods. We are&#13;not presently a party to any pending or threatened legal proceedings.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;14. SUBSEQUENT EVENTS&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management has evaluated events subsequent&#13;to December 31, 2020 through the date that the accompanying condensed consolidated financial statements were filed with the SEC&#13;for transactions and other events which may require adjustment of and/or disclosure in such financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2021, we hired two senior executives,&#13;Guy Cipriani as Senior Vice President, Chief Business Officer, and Steven LaRosa, M.D., as Chief Medical Officer and entered into&#13;employment agreements with each executive. Mr. Cipriani will oversee business development and partnerships, while also contributing&#13;to fundraising and corporate development. Mr. Cipriani&amp;#8217;s initial annual base salary is $340,000 and Mr. Cipriani also is&#13;eligible for a discretionary annual cash bonus.&amp;#160; Mr. Cipriani also is eligible for reimbursement of relocation expenses in&#13;the aggregate amount of up to $75,000. &amp;#160;Dr. LaRosa will be responsible for the clinical development of Aethlon's Hemopurifier&amp;#174;,&#13;including leading clinical operations and regulatory strategy. In addition to a one-time signing bonus of $100,000, subject to&#13;repayment if Dr. LaRosa leaves Aethlon prior to two years with the Company, Dr. LaRosa&amp;#8217;s initial annual base salary is $400,000.&#13;Dr. LaRosa also is eligible for a discretionary annual cash bonus and relocation expense reimbursement of up to $50,000.&amp;#160;&#13;Upon commencement of employment each of Mr. Cipriani and Dr. LaRosa was granted an option to purchase 120,883 shares of the Company&amp;#8217;s&#13;Common Stock, with an exercise price equal to the fair market value on the date of grant, subject to a four-year vesting schedule&#13;and other terms and conditions of the Company&amp;#8217;s 2020 Equity Incentive Plan.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Basis of Presentation and Use of Estimates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited condensed consolidated&#13;financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP,&#13;for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission,&#13;or SEC Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto&#13;for the fiscal year ended March 31, 2020, included in the Company's Annual Report on Form 10-K filed with the SEC on June 25, 2020.&#13;The accompanying unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its majority-owned&#13;subsidiary. All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed&#13;consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are&#13;necessary to present fairly the condensed consolidated financial statements as of and for the three and nine months ended December&#13;31, 2020, and the condensed consolidated statement of cash flows for the nine months ended December 31, 2020. Estimates were made&#13;relating to useful lives of fixed assets, impairment of assets, share-based compensation expense and accruals for clinical trial&#13;and research and development expenses. Actual results could differ materially from those estimates. The accompanying condensed&#13;consolidated balance sheet at March 31, 2020 has been derived from the audited consolidated balance sheet at March 31, 2020, contained&#13;in the above referenced 10-K. The results of operations for the three and nine months ended December 31, 2020 are not necessarily&#13;indicative of the results to be expected for the full year or any future interim periods.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain prior year balances within the unaudited&#13;condensed consolidated financial statements have been reclassified to conform to the current year presentation.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Restricted Cash&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;To comply with the terms of our new laboratory&#13;and office lease (see Note 13), we caused our bank to issue a standby letter of credit, or the L/C, in the amount of $46,726 in&#13;favor of the landlord. The L/C is in lieu of a security deposit. In order to support the L/C, we agreed to have our bank withdraw&#13;$46,726 from our operating accounts and to place that amount in a restricted certificate of deposit. We have classified that amount&#13;as restricted cash, a long-term asset, on our balance sheet.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our research and development expenses in those&#13;periods were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 67%"&gt;&lt;font style="font-size: 10pt"&gt;Three months ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;461,176&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;218,571&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Nine months ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,367,333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;692,022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;RSUs outstanding that have vested as of, and&#13;are expected to vest subsequent to, December 31, 2020 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Number of RSUs&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 84%; padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Expected to vest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;32,189&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;32,189&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amounts due to related parties were comprised&#13;of the following items:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31, &lt;br /&gt;&#13;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;March 31, &lt;br /&gt;&#13;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 68%"&gt;&lt;font style="font-size: 10pt"&gt;Accrued Board fees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;69,292&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;69,750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Accrued vacation to all employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,454&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;41,957&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total due to related parties&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;131,746&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;111,707&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Other current liabilities were comprised of the following items:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;March 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 68%"&gt;&lt;font style="font-size: 10pt"&gt;Accrued separation expenses for former executive&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;400,578&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Accrued professional fees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;460,119&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;472,420&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total other current liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;860,697&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;472,420&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following tables summarize share-based&#13;compensation expenses relating to RSUs and stock options and the effect on basic and diluted loss per common share during the three&#13;and nine month periods ended December 31, 2020 and 2019:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Three Months &lt;br /&gt;&#13;Ended &lt;br /&gt;&#13;December 31, &lt;br /&gt;&#13;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Three Months&lt;br /&gt;&#13;Ended&lt;br /&gt;&#13;December 31, &lt;br /&gt;&#13;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Nine Months &lt;br /&gt;&#13;Ended &lt;br /&gt;&#13;December 31,&lt;br /&gt;&#13;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Nine Months&lt;br /&gt;&#13;Ended &lt;br /&gt;&#13;December 31,&lt;br /&gt;&#13;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 44%; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Vesting of stock options and restricted stock units&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;377,958&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;102,576&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;629,207&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;755,648&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;377,958&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;102,576&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;629,207&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;755,648&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average number of common shares outstanding &amp;#8211; basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,093,361&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,887,883&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;11,265,725&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,821,557&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Basic and diluted loss per common share attributable to stock-based compensation expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.06&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.41&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Options outstanding that were vested as of&#13;December 31, 2020 and options that are expected to vest subsequent to December 31, 2020 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br /&gt;&#13;Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br /&gt;&#13;Average&lt;br /&gt;&#13;Exercise&lt;br /&gt;&#13;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br /&gt;&#13;Average&lt;br /&gt;&#13;Remaining&lt;br /&gt;&#13;Contractual&lt;br /&gt;&#13;Term in&lt;br /&gt;&#13;Years&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 58%"&gt;&lt;font style="font-size: 10pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;34,509&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;32.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.84&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Expected to vest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;567,814&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.67&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;602,323&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;A summary of stock option activity during the nine months ended&#13;December 31, 2020 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Range of&lt;br /&gt;&#13;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br /&gt;&#13;Average &lt;br /&gt;&#13;Exercise&lt;br /&gt;&#13;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 53%"&gt;&lt;font style="font-size: 10pt"&gt;Stock options outstanding at March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;51,124&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$18.75 - $187.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;44.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(15,896&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;770,094&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.28 &amp;#8211; $2.45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.45&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Cancelled/Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(202,999&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.28 - $187.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Stock options outstanding at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;602,323&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.28 - $187.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.29&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Stock options exercisable at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;34,509&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.28 - $187.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;32.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;A summary of warrant activity during the nine months ended December&#13;31, 2020 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Range of&lt;br /&gt;&#13;Exercise&lt;br /&gt;&#13;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br /&gt;&#13;Average&lt;br /&gt;&#13;Exercise&lt;br /&gt;&#13;Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 53%; padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Warrants outstanding at March 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,021,368&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.50 - $125.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Cancelled/Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(29,395&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$90.75 &amp;#8211; $135.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;97.17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Warrants outstanding at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,991,973&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.50 &amp;#8211; $99.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.23&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; text-indent: -10pt"&gt;&lt;font style="font-size: 10pt"&gt;Warrants exercisable at December 31, 2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,991,973&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;$1.50 &amp;#8211; $99.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.23&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following tables set forth certain information regarding our&#13;segments:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Nine Months Ended December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Revenues:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 68%; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;624,871&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;443,458&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Total Revenues&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;624,871&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;443,458&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Operating Losses:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,609,464&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(4,125,758&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(15,931&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(19,039&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Total Operating Loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,625,395&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(4,144,797&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Net Losses:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,610,994&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(4,575,811&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(15,931&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(19,039&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Net Loss Before Non-Controlling Interests&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(5,626,925&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(4,594,850&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Cash:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,131,396&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,058,456&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;197&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;197&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Total Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,131,593&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,058,653&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Total Assets:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,669,552&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,682,294&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;197&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;197&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Total Assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,669,749&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,682,491&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Capital Expenditures:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;54,630&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;148,064&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Capital Expenditures&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;54,630&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;148,064&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Depreciation and Amortization:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;28,775&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,992&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Total Depreciation and Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;28,775&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,992&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Interest Expense:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Aethlon&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,530&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(54,232&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;ESI&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8211;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;&lt;font style="font-size: 10pt"&gt;Total Interest Expense&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,530&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(54,232&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2020-04-01to2020-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Future minimum lease payments under the Granite Ridge Lease as of&#13;December 31, 2020, are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="width: 84%"&gt;&lt;font style="font-size: 10pt"&gt;January 1, 2021 through March 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;25,663&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;April 1, 2021 through August 31, 2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;43,670&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Total future minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;69,333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;Less: discount&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,635&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #EEEEEE"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total lease liability&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;67,698&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">12178319</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">4058653</us-gaap:RestrictedCashAndCashEquivalents>
    <aemd:LetterOfCredit contextRef="AsOf2020-12-31_custom_LeaseAgreementMember" unitRef="USD" decimals="0">46726</aemd:LetterOfCredit>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-04-01to2019-12-31" unitRef="Shares" decimals="INF">3779301</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2020-04-01to2020-12-31" unitRef="Shares" decimals="INF">2626485</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">692022</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">1367333</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">461176</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">218571</us-gaap:ResearchAndDevelopmentExpense>
    <aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">32189</aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">32189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <aemd:AccruedSeparationExpenses contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">400578</aemd:AccruedSeparationExpenses>
    <aemd:AccruedSeparationExpenses contextRef="AsOf2020-03-31" unitRef="USD" decimals="0">0</aemd:AccruedSeparationExpenses>
    <us-gaap:ShareBasedCompensation contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">755648</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">629207</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-04-01to2020-12-31_custom_VestingOptionsMember" unitRef="USD" decimals="0">629207</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-04-01to2019-12-31_custom_VestingOptionsMember" unitRef="USD" decimals="0">755648</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">377958</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">102576</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2020-10-01to2020-12-31_custom_VestingOptionsMember" unitRef="USD" decimals="0">377958</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-10-01to2019-12-31_custom_VestingOptionsMember" unitRef="USD" decimals="0">102576</us-gaap:ShareBasedCompensation>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-04-01to2019-12-31" unitRef="Shares" decimals="INF">1821557</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-04-01to2020-12-31" unitRef="Shares" decimals="INF">11265725</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2020-10-01to2020-12-31" unitRef="Shares" decimals="INF">12093361</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2019-10-01to2019-12-31" unitRef="Shares" decimals="INF">2887883</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-04-01to2019-12-31" unitRef="USDPShares" decimals="INF">-2.52</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-04-01to2020-12-31" unitRef="USDPShares" decimals="INF">-0.50</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-04-01to2020-12-31_custom_ShareBasedCompensationMember" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-04-01to2019-12-31_custom_ShareBasedCompensationMember" unitRef="USDPShares" decimals="INF">-0.41</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-10-01to2020-12-31" unitRef="USDPShares" decimals="INF">-0.20</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-10-01to2019-12-31" unitRef="USDPShares" decimals="INF">-0.28</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2020-10-01to2020-12-31_custom_ShareBasedCompensationMember" unitRef="USDPShares" decimals="INF">-0.03</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2019-10-01to2019-12-31_custom_ShareBasedCompensationMember" unitRef="USDPShares" decimals="INF">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2020-04-01to2020-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">34509</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2020-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">567814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2020-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">1.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-04-01to2020-12-31_us-gaap_StockOptionMember">P5Y10M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-04-01to2020-12-31_us-gaap_StockOptionMember">P9Y8M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="From2020-04-01to2020-12-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">770094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-04-01to2020-12-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">15896</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-04-01to2020-12-31_custom_DrRodellMember" unitRef="Shares" decimals="INF">15896</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2020-04-01to2020-12-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">202999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-12-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">34509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <aemd:RangeOfExercisePricesOptionBeginning contextRef="From2020-04-01to2020-12-31_us-gaap_OptionMember">$18.75 - $187.50</aemd:RangeOfExercisePricesOptionBeginning>
    <aemd:RangeOfExercisePricesOptionExercisable contextRef="From2020-04-01to2020-12-31_us-gaap_OptionMember">$1.28 - $187.50</aemd:RangeOfExercisePricesOptionExercisable>
    <aemd:RangeOfExercisePricesOptionEnding contextRef="From2020-04-01to2020-12-31_us-gaap_OptionMember">$1.28 - $187.50</aemd:RangeOfExercisePricesOptionEnding>
    <aemd:RangeOfExercisePricesOptionCancelledexpired contextRef="From2020-04-01to2020-12-31_us-gaap_OptionMember">$1.28 - $187.50</aemd:RangeOfExercisePricesOptionCancelledexpired>
    <aemd:RangeOfExercisePricesOptionGranted contextRef="From2020-04-01to2020-12-31_us-gaap_OptionMember">$1.28 - $2.45</aemd:RangeOfExercisePricesOptionGranted>
    <aemd:RangeOfExercisePricesOptionExercised contextRef="From2020-04-01to2020-12-31_us-gaap_OptionMember">$1.28</aemd:RangeOfExercisePricesOptionExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2020-04-01to2020-12-31_us-gaap_OptionMember" unitRef="USDPShares" decimals="INF">6.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2020-04-01to2020-12-31_us-gaap_OptionMember" unitRef="USDPShares" decimals="INF">1.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2020-04-01to2020-12-31_us-gaap_OptionMember" unitRef="USDPShares" decimals="INF">1.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-12-31_us-gaap_OptionMember" unitRef="USDPShares" decimals="INF">32.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2020-03-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">2021368</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2020-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1991973</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2020-04-01to2020-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">29395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations>
    <aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber contextRef="AsOf2020-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1991973</aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber>
    <aemd:RangeOfWeightedAverageExercisePriceExercisable contextRef="From2020-04-01to2020-12-31_us-gaap_WarrantMember">$1.50 - $99.00</aemd:RangeOfWeightedAverageExercisePriceExercisable>
    <aemd:RangeOfWeightedAverageExercisePriceOutstandingEnding contextRef="From2020-04-01to2020-12-31_us-gaap_WarrantMember">$1.50 - $99.00</aemd:RangeOfWeightedAverageExercisePriceOutstandingEnding>
    <aemd:RangeOfWeightedAverageExercisePriceExpired contextRef="From2020-04-01to2020-12-31_us-gaap_WarrantMember">$90.75 - $135.00</aemd:RangeOfWeightedAverageExercisePriceExpired>
    <aemd:RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="From2020-04-01to2020-12-31_us-gaap_WarrantMember">$1.50 - $125.25</aemd:RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-03-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">5.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2020-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">5.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <aemd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2020-04-01to2020-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">97.17</aemd:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">5.23</aemd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice>
    <aemd:AwardContractAmount contextRef="From2020-04-01to2020-12-31_custom_MelanomaCancerContractPhase2Member" unitRef="USD" decimals="0">1860561</aemd:AwardContractAmount>
    <aemd:AwardContractAmount contextRef="From2020-04-01to2020-12-31_custom_SubawardWithUniversityOfPittsburghMember" unitRef="USD" decimals="0">256750</aemd:AwardContractAmount>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">148064</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">54630</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="From2020-04-01to2020-12-31_custom_AethlonMember" unitRef="USD" decimals="0">54630</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="From2020-04-01to2020-12-31_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="From2019-04-01to2019-12-31_custom_AethlonMember" unitRef="USD" decimals="0">148064</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="From2019-04-01to2019-12-31_custom_ESIMember547542546" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:DepreciationAndAmortization contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">15992</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">28775</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2020-04-01to2020-12-31_custom_AethlonMember" unitRef="USD" decimals="0">28775</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2020-04-01to2020-12-31_custom_ESIMember" unitRef="USD" decimals="0">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2019-04-01to2019-12-31_custom_AethlonMember" unitRef="USD" decimals="0">15992</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2019-04-01to2019-12-31_custom_ESIMember547542546" unitRef="USD" decimals="0">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2020-12-31_custom_GraniteRidgeMember" unitRef="USD" decimals="0">67698</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2020-12-31_custom_GraniteRidgeMember" unitRef="USD" decimals="0">1635</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <aemd:LesseeOperatingLeaseLiabilityPaymentsGross contextRef="AsOf2020-12-31_custom_GraniteRidgeMember" unitRef="USD" decimals="0">69333</aemd:LesseeOperatingLeaseLiabilityPaymentsGross>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2020-12-31_custom_GraniteRidgeMember" unitRef="USD" decimals="0">43670</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2020-12-31_custom_GraniteRidgeMember" unitRef="USD" decimals="0">25663</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:OperatingLeasePayments contextRef="From2020-10-01to2020-10-30_custom_TimothyRodellMember" unitRef="USD" decimals="0">444729</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="From2020-12-01to2020-12-31_custom_LeaseAgreementMember" unitRef="USD" decimals="0">806000</us-gaap:OperatingLeasePayments>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31_custom_SeparationAgreementMember" unitRef="USD" decimals="0">400578</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:SalariesAndWages contextRef="From2020-10-01to2020-10-30_custom_CharlesJFisherJrMember" unitRef="USD" decimals="0">430000</us-gaap:SalariesAndWages>
    <us-gaap:DeferredRevenue contextRef="AsOf2020-12-31_custom_MelanomaCancerContractPhase2Member" unitRef="USD" decimals="0">318578</us-gaap:DeferredRevenue>
    <aemd:GainOnShareForWarrantExchanges contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">51190</aemd:GainOnShareForWarrantExchanges>
    <aemd:GainOnShareForWarrantExchanges contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">0</aemd:GainOnShareForWarrantExchanges>
    <aemd:GainOnShareForWarrantExchanges contextRef="From2020-10-01to2020-12-31" unitRef="USD" decimals="0">0</aemd:GainOnShareForWarrantExchanges>
    <aemd:GainOnShareForWarrantExchanges contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">55593</aemd:GainOnShareForWarrantExchanges>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2019-04-01to2020-03-31">On October 14, 2019, our Board of Directors approved a 1-for-15 reverse stock split. Accordingly, 15 shares of outstanding common stock then held by stockholders were combined into one share of common stock.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SecurityDeposit contextRef="AsOf2020-12-31_custom_RestrictedCashMember" unitRef="USD" decimals="0">46726</us-gaap:SecurityDeposit>
    <aemd:AccruedDirectorFees contextRef="AsOf2020-12-31" unitRef="USD" decimals="0">69292</aemd:AccruedDirectorFees>
    <us-gaap:NoninterestExpenseDirectorsFees contextRef="From2020-04-01to2020-12-31_custom_TimothyRodellMember" unitRef="USD" decimals="0">20260</us-gaap:NoninterestExpenseDirectorsFees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2020-02-01to2020-05-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">521476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2020-12-31_custom_Equity2020PlanMember" unitRef="Shares" decimals="INF">1842556</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <aemd:ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise contextRef="From2019-04-01to2019-12-31" unitRef="USD" decimals="0">10</aemd:ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise>
    <aemd:ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise contextRef="From2020-04-01to2020-12-31" unitRef="USD" decimals="0">71</aemd:ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>23
<FILENAME>aemd-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_q3%2D20201231.xfr; Date: 2021%2D02%2D09T13:56:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80020000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaeDOaPty5526YkxvmR9fQnq3yQhoXdpyyJ37tlmEUYF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:aemd="http://aethlonmedical.com/20201231" elementFormDefault="qualified" targetNamespace="http://aethlonmedical.com/20201231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://aethlonmedical.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" id="CondensedConsolidatedStatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
	  <link:definition>00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/ReconciliationOfCashCashEquivalentsAndRestrictedCash" id="ReconciliationOfCashCashEquivalentsAndRestrictedCash">
	  <link:definition>00000007 - Statement - RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation" id="NatureOfBusinessAndBasisOfPresentation">
	  <link:definition>00000008 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/LossPerCommonShare" id="LossPerCommonShare">
	  <link:definition>00000009 - Disclosure - 2. LOSS PER COMMON SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses" id="ResearchAndDevelopmentExpenses">
	  <link:definition>00000010 - Disclosure - 3. RESEARCH AND DEVELOPMENT EXPENSES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
	  <link:definition>00000011 - Disclosure - 4. RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableNet" id="ConvertibleNotesPayableNet">
	  <link:definition>00000012 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/EquityTransactions" id="EquityTransactions">
	  <link:definition>00000013 - Disclosure - 6. EQUITY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000014 - Disclosure - 7. RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
	  <link:definition>00000015 - Disclosure - 8. OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/StockCompensation" id="StockCompensation">
	  <link:definition>00000016 - Disclosure - 9. STOCK COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/Warrants" id="Warrants">
	  <link:definition>00000017 - Disclosure - 10. WARRANTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognition" id="GovernmentContractsAndGrantsAndRelatedRevenueRecognition">
	  <link:definition>00000018 - Disclosure - 11. GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/Segments" id="Segments">
	  <link:definition>00000019 - Disclosure - 12. SEGMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000020 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000021 - Disclosure - 14. SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" id="NatureOfBusinessAndBasisOfPresentationPolicies">
	  <link:definition>00000022 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables" id="ResearchAndDevelopmentExpensesTables">
	  <link:definition>00000023 - Disclosure - 3. RESEARCH AND DEVELOPMENT EXPENSES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/EquityTransactionsTables" id="EquityTransactionsTables">
	  <link:definition>00000024 - Disclosure - 6. EQUITY TRANSACTIONS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
	  <link:definition>00000025 - Disclosure - 7. RELATED PARTY TRANSACTIONS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
	  <link:definition>00000026 - Disclosure - 8. OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationTables" id="StockCompensationTables">
	  <link:definition>00000027 - Disclosure - 9. STOCK COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/WarrantsTables" id="WarrantsTables">
	  <link:definition>00000028 - Disclosure - 10. WARRANTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/SegmentsTables" id="SegmentsTables">
	  <link:definition>00000029 - Disclosure - 12. SEGMENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000030 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative" id="NatureOfBusinessAndBasisOfPresentationDetailsNarrative">
	  <link:definition>00000031 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/LossPerCommonShareDetails-Narrative" id="LossPerCommonShareDetails-Narrative">
	  <link:definition>00000032 - Disclosure - 2. LOSS PER COMMON SHARE (Details- Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails" id="ResearchAndDevelopmentExpensesDetails">
	  <link:definition>00000033 - Disclosure - 3. RESEARCH AND DEVELOPMENT EXPENSES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative" id="ConvertibleNotesPayableDetailsNarrative">
	  <link:definition>00000034 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/EquityTransactionsDetails-RsusOutstanding" id="EquityTransactionsDetails-RsusOutstanding">
	  <link:definition>00000035 - Disclosure - 6. EQUITY TRANSACTIONS (Details - RSU's outstanding)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative" id="EquityTransactionsDetailsNarrative">
	  <link:definition>00000036 - Disclosure - 6. EQUITY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
	  <link:definition>00000037 - Disclosure - 7. RELATED PARTY TRANSACTIONS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000038 - Disclosure - 7. RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" id="OtherCurrentLiabilitiesDetails">
	  <link:definition>00000039 - Disclosure - 8. OTHER CURRENT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation" id="StockCompensationDetails-StockCompensation">
	  <link:definition>00000040 - Disclosure - 9. STOCK COMPENSATION (Details - Stock compensation)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" id="StockCompensationDetails-OptionsVestedAndExpectedToVest">
	  <link:definition>00000041 - Disclosure - 9. STOCK COMPENSATION (Details - Options vested and expected to vest)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" id="StockCompensationDetails-OptionActivity">
	  <link:definition>00000042 - Disclosure - 9. STOCK COMPENSATION (Details - Option activity)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/StockCompensationDetails-Narrative" id="StockCompensationDetails-Narrative">
	  <link:definition>00000043 - Disclosure - 9. STOCK COMPENSATION (Details- Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/WarrantsDetails" id="WarrantsDetails">
	  <link:definition>00000044 - Disclosure - 10. WARRANTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognitionDetailsNarrative" id="GovernmentContractsAndGrantsAndRelatedRevenueRecognitionDetailsNarrative">
	  <link:definition>00000045 - Disclosure - 11. GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/SegmentsDetails" id="SegmentsDetails">
	  <link:definition>00000046 - Disclosure - 12. SEGMENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetails-Rent" id="CommitmentsAndContingenciesDetails-Rent">
	  <link:definition>00000047 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Details - Rent)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000048 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="aemd-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aemd-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aemd-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="aemd-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="aemd_SaleOfStockPricePerShare1" name="SaleOfStockPricePerShare1" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RsusExchangedForCommonStockRsusExchanged" name="RsusExchangedForCommonStockRsusExchanged" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RsusExchangedForCommonStockCommonStockIssued" name="RsusExchangedForCommonStockCommonStockIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_GrantDateFairValue" name="GrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_IssuanceOfCommonSharesUponWarrantExchangesValue" name="IssuanceOfCommonSharesUponWarrantExchangesValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_IssuanceOfCommonSharesUponWarrantExchangesShares" name="IssuanceOfCommonSharesUponWarrantExchangesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AccretionOfRightofuseLeaseAsset" name="AccretionOfRightofuseLeaseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability" name="InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_StockIssuedDuringPeriodValueReverseStockSplits" name="StockIssuedDuringPeriodValueReverseStockSplits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarrantsTextBlock" name="WarrantsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_LetterOfCredit" name="LetterOfCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AccruedSeparationExpenses" name="AccruedSeparationExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfExercisePricesOptionBeginning" name="RangeOfExercisePricesOptionBeginning" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfExercisePricesOptionExercisable" name="RangeOfExercisePricesOptionExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfExercisePricesOptionEnding" name="RangeOfExercisePricesOptionEnding" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfExercisePricesOptionCancelledexpired" name="RangeOfExercisePricesOptionCancelledexpired" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfExercisePricesOptionGranted" name="RangeOfExercisePricesOptionGranted" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfExercisePricesOptionExercised" name="RangeOfExercisePricesOptionExercised" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfWeightedAverageExercisePriceExercisable" name="RangeOfWeightedAverageExercisePriceExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfWeightedAverageExercisePriceOutstandingEnding" name="RangeOfWeightedAverageExercisePriceOutstandingEnding" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfWeightedAverageExercisePriceExpired" name="RangeOfWeightedAverageExercisePriceExpired" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" name="RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AwardContractAmount" name="AwardContractAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_LesseeOperatingLeaseLiabilityPaymentsGross" name="LesseeOperatingLeaseLiabilityPaymentsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_GainOnShareForWarrantExchanges" name="GainOnShareForWarrantExchanges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AccruedDirectorFees" name="AccruedDirectorFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" name="ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_CommonStockSalesAgrMember" name="CommonStockSalesAgrMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WainwrightMember" name="WainwrightMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_VestingOptionsMember" name="VestingOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ShareBasedCompensationMember" name="ShareBasedCompensationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_MelanomaCancerContractPhase2Member" name="MelanomaCancerContractPhase2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_AethlonMember" name="AethlonMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_ESIMember" name="ESIMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_GraniteRidgeMember" name="GraniteRidgeMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_Plan2010Member" name="Plan2010Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_Equity2020PlanMember" name="Equity2020PlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_TimothyRodellMember" name="TimothyRodellMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_BreastCancerGrantMember" name="BreastCancerGrantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_SubawardWithUniversityOfPittsburghMember" name="SubawardWithUniversityOfPittsburghMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_SeparationAgreementMember" name="SeparationAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_CharlesJFisherJrMember" name="CharlesJFisherJrMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_LeaseAgreementMember" name="LeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_RestrictedCashMember" name="RestrictedCashMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_DrRodellMember" name="DrRodellMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_NumberOfWarrantsAbstract" name="NumberOfWarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="aemd_WarrantsWeightedAverageExercisePriceAbstract" name="WarrantsWeightedAverageExercisePriceAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>24
<FILENAME>aemd-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_q3%2D20201231.xfr; Date: 2021%2D02%2D09T13:56:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80020000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aethlonmedical.com/role/DocumentAndEntityInformation" xlink:href="aemd-20201231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:href="aemd-20201231.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="aemd-20201231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="aemd-20201231.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="aemd-20201231.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="aemd-20201231.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ReconciliationOfCashCashEquivalentsAndRestrictedCash" xlink:href="aemd-20201231.xsd#ReconciliationOfCashCashEquivalentsAndRestrictedCash" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:href="aemd-20201231.xsd#NatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/LossPerCommonShare" xlink:href="aemd-20201231.xsd#LossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses" xlink:href="aemd-20201231.xsd#ResearchAndDevelopmentExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RecentAccountingPronouncements" xlink:href="aemd-20201231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableNet" xlink:href="aemd-20201231.xsd#ConvertibleNotesPayableNet" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactions" xlink:href="aemd-20201231.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:href="aemd-20201231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:href="aemd-20201231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensation" xlink:href="aemd-20201231.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Warrants" xlink:href="aemd-20201231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognition" xlink:href="aemd-20201231.xsd#GovernmentContractsAndGrantsAndRelatedRevenueRecognition" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Segments" xlink:href="aemd-20201231.xsd#Segments" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:href="aemd-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SubsequentEvents" xlink:href="aemd-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" xlink:href="aemd-20201231.xsd#NatureOfBusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables" xlink:href="aemd-20201231.xsd#ResearchAndDevelopmentExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsTables" xlink:href="aemd-20201231.xsd#EquityTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsTables" xlink:href="aemd-20201231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:href="aemd-20201231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationTables" xlink:href="aemd-20201231.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsTables" xlink:href="aemd-20201231.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SegmentsTables" xlink:href="aemd-20201231.xsd#SegmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesTables" xlink:href="aemd-20201231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:href="aemd-20201231.xsd#NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/LossPerCommonShareDetails-Narrative" xlink:href="aemd-20201231.xsd#LossPerCommonShareDetails-Narrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails" xlink:href="aemd-20201231.xsd#ResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="aemd-20201231.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsDetails-RsusOutstanding" xlink:href="aemd-20201231.xsd#EquityTransactionsDetails-RsusOutstanding" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative" xlink:href="aemd-20201231.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetails" xlink:href="aemd-20201231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="aemd-20201231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:href="aemd-20201231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation" xlink:href="aemd-20201231.xsd#StockCompensationDetails-StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:href="aemd-20201231.xsd#StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:href="aemd-20201231.xsd#StockCompensationDetails-OptionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-Narrative" xlink:href="aemd-20201231.xsd#StockCompensationDetails-Narrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsDetails" xlink:href="aemd-20201231.xsd#WarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognitionDetailsNarrative" xlink:href="aemd-20201231.xsd#GovernmentContractsAndGrantsAndRelatedRevenueRecognitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SegmentsDetails" xlink:href="aemd-20201231.xsd#SegmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetails-Rent" xlink:href="aemd-20201231.xsd#CommitmentsAndContingenciesDetails-Rent" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aemd-20201231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_GainOnShareForWarrantExchanges" xlink:label="loc_aemdGainOnShareForWarrantExchanges" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_aemdGainOnShareForWarrantExchanges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_AccretionOfRightofuseLeaseAsset" xlink:label="loc_aemdAccretionOfRightofuseLeaseAsset" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_aemdAccretionOfRightofuseLeaseAsset" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_GainOnShareForWarrantExchanges" xlink:label="loc_aemdGainOnShareForWarrantExchanges" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_aemdGainOnShareForWarrantExchanges" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ReconciliationOfCashCashEquivalentsAndRestrictedCash" xlink:title="00000007 - Statement - RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:title="00000008 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/LossPerCommonShare" xlink:title="00000009 - Disclosure - 2. LOSS PER COMMON SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses" xlink:title="00000010 - Disclosure - 3. RESEARCH AND DEVELOPMENT EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RecentAccountingPronouncements" xlink:title="00000011 - Disclosure - 4. RECENT ACCOUNTING PRONOUNCEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableNet" xlink:title="00000012 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactions" xlink:title="00000013 - Disclosure - 6. EQUITY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:title="00000014 - Disclosure - 7. RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:title="00000015 - Disclosure - 8. OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensation" xlink:title="00000016 - Disclosure - 9. STOCK COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Warrants" xlink:title="00000017 - Disclosure - 10. WARRANTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognition" xlink:title="00000018 - Disclosure - 11. GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Segments" xlink:title="00000019 - Disclosure - 12. SEGMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - 14. SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" xlink:title="00000022 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables" xlink:title="00000023 - Disclosure - 3. RESEARCH AND DEVELOPMENT EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsTables" xlink:title="00000024 - Disclosure - 6. EQUITY TRANSACTIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsTables" xlink:title="00000025 - Disclosure - 7. RELATED PARTY TRANSACTIONS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000026 - Disclosure - 8. OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationTables" xlink:title="00000027 - Disclosure - 9. STOCK COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsTables" xlink:title="00000028 - Disclosure - 10. WARRANTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SegmentsTables" xlink:title="00000029 - Disclosure - 12. SEGMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingenciesTables" xlink:title="00000030 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="00000031 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/LossPerCommonShareDetails-Narrative" xlink:title="00000032 - Disclosure - 2. LOSS PER COMMON SHARE (Details- Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails" xlink:title="00000033 - Disclosure - 3. RESEARCH AND DEVELOPMENT EXPENSES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000034 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsDetails-RsusOutstanding" xlink:title="00000035 - Disclosure - 6. EQUITY TRANSACTIONS (Details - RSU&apos;s outstanding)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative" xlink:title="00000036 - Disclosure - 6. EQUITY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsDetails" xlink:title="00000037 - Disclosure - 7. RELATED PARTY TRANSACTIONS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000038 - Disclosure - 7. RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000039 - Disclosure - 8. OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_AccruedSeparationExpenses" xlink:label="loc_aemdAccruedSeparationExpenses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_aemdAccruedSeparationExpenses" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation" xlink:title="00000040 - Disclosure - 9. STOCK COMPENSATION (Details - Stock compensation)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:title="00000041 - Disclosure - 9. STOCK COMPENSATION (Details - Options vested and expected to vest)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:title="00000042 - Disclosure - 9. STOCK COMPENSATION (Details - Option activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-Narrative" xlink:title="00000043 - Disclosure - 9. STOCK COMPENSATION (Details- Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsDetails" xlink:title="00000044 - Disclosure - 10. WARRANTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognitionDetailsNarrative" xlink:title="00000045 - Disclosure - 11. GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SegmentsDetails" xlink:title="00000046 - Disclosure - 12. SEGMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetails-Rent" xlink:title="00000047 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Details - Rent)">
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_LesseeOperatingLeaseLiabilityPaymentsGross" xlink:label="loc_aemdLesseeOperatingLeaseLiabilityPaymentsGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_aemdLesseeOperatingLeaseLiabilityPaymentsGross" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_aemdLesseeOperatingLeaseLiabilityPaymentsGross" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000048 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>25
<FILENAME>aemd-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_q3%2D20201231.xfr; Date: 2021%2D02%2D09T13:56:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80020000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aethlonmedical.com/role/DocumentAndEntityInformation" xlink:href="aemd-20201231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:href="aemd-20201231.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="aemd-20201231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="aemd-20201231.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="aemd-20201231.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="aemd-20201231.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ReconciliationOfCashCashEquivalentsAndRestrictedCash" xlink:href="aemd-20201231.xsd#ReconciliationOfCashCashEquivalentsAndRestrictedCash" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:href="aemd-20201231.xsd#NatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/LossPerCommonShare" xlink:href="aemd-20201231.xsd#LossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses" xlink:href="aemd-20201231.xsd#ResearchAndDevelopmentExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RecentAccountingPronouncements" xlink:href="aemd-20201231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableNet" xlink:href="aemd-20201231.xsd#ConvertibleNotesPayableNet" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactions" xlink:href="aemd-20201231.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:href="aemd-20201231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:href="aemd-20201231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensation" xlink:href="aemd-20201231.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Warrants" xlink:href="aemd-20201231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognition" xlink:href="aemd-20201231.xsd#GovernmentContractsAndGrantsAndRelatedRevenueRecognition" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Segments" xlink:href="aemd-20201231.xsd#Segments" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:href="aemd-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SubsequentEvents" xlink:href="aemd-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" xlink:href="aemd-20201231.xsd#NatureOfBusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables" xlink:href="aemd-20201231.xsd#ResearchAndDevelopmentExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsTables" xlink:href="aemd-20201231.xsd#EquityTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsTables" xlink:href="aemd-20201231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:href="aemd-20201231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationTables" xlink:href="aemd-20201231.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsTables" xlink:href="aemd-20201231.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SegmentsTables" xlink:href="aemd-20201231.xsd#SegmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesTables" xlink:href="aemd-20201231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:href="aemd-20201231.xsd#NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/LossPerCommonShareDetails-Narrative" xlink:href="aemd-20201231.xsd#LossPerCommonShareDetails-Narrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails" xlink:href="aemd-20201231.xsd#ResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="aemd-20201231.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsDetails-RsusOutstanding" xlink:href="aemd-20201231.xsd#EquityTransactionsDetails-RsusOutstanding" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative" xlink:href="aemd-20201231.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetails" xlink:href="aemd-20201231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="aemd-20201231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:href="aemd-20201231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation" xlink:href="aemd-20201231.xsd#StockCompensationDetails-StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:href="aemd-20201231.xsd#StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:href="aemd-20201231.xsd#StockCompensationDetails-OptionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-Narrative" xlink:href="aemd-20201231.xsd#StockCompensationDetails-Narrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsDetails" xlink:href="aemd-20201231.xsd#WarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognitionDetailsNarrative" xlink:href="aemd-20201231.xsd#GovernmentContractsAndGrantsAndRelatedRevenueRecognitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SegmentsDetails" xlink:href="aemd-20201231.xsd#SegmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetails-Rent" xlink:href="aemd-20201231.xsd#CommitmentsAndContingenciesDetails-Rent" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aemd-20201231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapNoncontrollingInterestMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_IssuanceOfCommonSharesUponWarrantExchangesShares" xlink:label="loc_aemdIssuanceOfCommonSharesUponWarrantExchangesShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdIssuanceOfCommonSharesUponWarrantExchangesShares_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_IssuanceOfCommonSharesUponWarrantExchangesValue" xlink:label="loc_aemdIssuanceOfCommonSharesUponWarrantExchangesValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdIssuanceOfCommonSharesUponWarrantExchangesValue_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="loc_aemdStockIssuedDuringPeriodValueReverseStockSplits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdStockIssuedDuringPeriodValueReverseStockSplits_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic_60" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ReconciliationOfCashCashEquivalentsAndRestrictedCash" xlink:title="00000007 - Statement - RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:title="00000008 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/LossPerCommonShare" xlink:title="00000009 - Disclosure - 2. LOSS PER COMMON SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses" xlink:title="00000010 - Disclosure - 3. RESEARCH AND DEVELOPMENT EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RecentAccountingPronouncements" xlink:title="00000011 - Disclosure - 4. RECENT ACCOUNTING PRONOUNCEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableNet" xlink:title="00000012 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactions" xlink:title="00000013 - Disclosure - 6. EQUITY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:title="00000014 - Disclosure - 7. RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:title="00000015 - Disclosure - 8. OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensation" xlink:title="00000016 - Disclosure - 9. STOCK COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Warrants" xlink:title="00000017 - Disclosure - 10. WARRANTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognition" xlink:title="00000018 - Disclosure - 11. GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Segments" xlink:title="00000019 - Disclosure - 12. SEGMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - 14. SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" xlink:title="00000022 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables" xlink:title="00000023 - Disclosure - 3. RESEARCH AND DEVELOPMENT EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsTables" xlink:title="00000024 - Disclosure - 6. EQUITY TRANSACTIONS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsTables" xlink:title="00000025 - Disclosure - 7. RELATED PARTY TRANSACTIONS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000026 - Disclosure - 8. OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationTables" xlink:title="00000027 - Disclosure - 9. STOCK COMPENSATION (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsTables" xlink:title="00000028 - Disclosure - 10. WARRANTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SegmentsTables" xlink:title="00000029 - Disclosure - 12. SEGMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingenciesTables" xlink:title="00000030 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="00000031 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RestrictedCashMember" xlink:label="loc_aemdRestrictedCashMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_aemdRestrictedCashMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSecurityDeposit_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/LossPerCommonShareDetails-Narrative" xlink:title="00000032 - Disclosure - 2. LOSS PER COMMON SHARE (Details- Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails" xlink:title="00000033 - Disclosure - 3. RESEARCH AND DEVELOPMENT EXPENSES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000034 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsDetails-RsusOutstanding" xlink:title="00000035 - Disclosure - 6. EQUITY TRANSACTIONS (Details - RSU&apos;s outstanding)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative" xlink:title="00000036 - Disclosure - 6. EQUITY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_CommonStockSalesAgrMember" xlink:label="loc_aemdCommonStockSalesAgrMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_aemdCommonStockSalesAgrMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_WainwrightMember" xlink:label="loc_aemdWainwrightMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_aemdWainwrightMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_NonEmployeeDirectorsMember" xlink:label="loc_aemdNonEmployeeDirectorsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="loc_aemdNonEmployeeDirectorsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_Plan2010Member" xlink:label="loc_aemdPlan2010Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_aemdPlan2010Member_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_Equity2020PlanMember" xlink:label="loc_aemdEquity2020PlanMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_aemdEquity2020PlanMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForCommissions" xlink:label="loc_us-gaapPaymentsForCommissions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForCommissions_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_SaleOfStockPricePerShare1" xlink:label="loc_aemdSaleOfStockPricePerShare1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdSaleOfStockPricePerShare1_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_GrantDateFairValue" xlink:label="loc_aemdGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdGrantDateFairValue_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RsusExchangedForCommonStockRsusExchanged" xlink:label="loc_aemdRsusExchangedForCommonStockRsusExchanged_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRsusExchangedForCommonStockRsusExchanged_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RsusExchangedForCommonStockCommonStockIssued" xlink:label="loc_aemdRsusExchangedForCommonStockCommonStockIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRsusExchangedForCommonStockCommonStockIssued_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation_110" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsDetails" xlink:title="00000037 - Disclosure - 7. RELATED PARTY TRANSACTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaapAccruedLiabilitiesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_us-gaapAccruedLiabilitiesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000038 - Disclosure - 7. RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_TimothyRodellMember" xlink:label="loc_aemdTimothyRodellMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_aemdTimothyRodellMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_AccruedDirectorFees" xlink:label="loc_aemdAccruedDirectorFees_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdAccruedDirectorFees_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaapNoninterestExpenseDirectorsFees_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoninterestExpenseDirectorsFees_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000039 - Disclosure - 8. OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation" xlink:title="00000040 - Disclosure - 9. STOCK COMPENSATION (Details - Stock compensation)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaapNatureOfExpenseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapNatureOfExpenseAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_VestingOptionsMember" xlink:label="loc_aemdVestingOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdVestingOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ShareBasedCompensationMember" xlink:label="loc_aemdShareBasedCompensationMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdShareBasedCompensationMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_130" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:title="00000041 - Disclosure - 9. STOCK COMPENSATION (Details - Options vested and expected to vest)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_30" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:title="00000042 - Disclosure - 9. STOCK COMPENSATION (Details - Option activity)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionBeginning" xlink:label="loc_aemdRangeOfExercisePricesOptionBeginning_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionBeginning_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionExercised" xlink:label="loc_aemdRangeOfExercisePricesOptionExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionExercised_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionGranted" xlink:label="loc_aemdRangeOfExercisePricesOptionGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionGranted_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionCancelledexpired" xlink:label="loc_aemdRangeOfExercisePricesOptionCancelledexpired_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionCancelledexpired_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionEnding" xlink:label="loc_aemdRangeOfExercisePricesOptionEnding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionEnding_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionExercisable" xlink:label="loc_aemdRangeOfExercisePricesOptionExercisable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionExercisable_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-Narrative" xlink:title="00000043 - Disclosure - 9. STOCK COMPENSATION (Details- Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_Equity2020PlanMember" xlink:label="loc_aemdEquity2020PlanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_aemdEquity2020PlanMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_DrRodellMember" xlink:label="loc_aemdDrRodellMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_aemdDrRodellMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation_80" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsDetails" xlink:title="00000044 - Disclosure - 10. WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_NumberOfWarrantsAbstract" xlink:label="loc_aemdNumberOfWarrantsAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdNumberOfWarrantsAbstract_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:label="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_WarrantsWeightedAverageExercisePriceAbstract" xlink:label="loc_aemdWarrantsWeightedAverageExercisePriceAbstract_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdWarrantsWeightedAverageExercisePriceAbstract_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_aemdRangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfWeightedAverageExercisePriceExpired" xlink:label="loc_aemdRangeOfWeightedAverageExercisePriceExpired_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfWeightedAverageExercisePriceExpired_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfWeightedAverageExercisePriceOutstandingEnding" xlink:label="loc_aemdRangeOfWeightedAverageExercisePriceOutstandingEnding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfWeightedAverageExercisePriceOutstandingEnding_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfWeightedAverageExercisePriceExercisable" xlink:label="loc_aemdRangeOfWeightedAverageExercisePriceExercisable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfWeightedAverageExercisePriceExercisable_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_aemdShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognitionDetailsNarrative" xlink:title="00000045 - Disclosure - 11. GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_MelanomaCancerContractPhase2Member" xlink:label="loc_aemdMelanomaCancerContractPhase2Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aemdMelanomaCancerContractPhase2Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_BreastCancerGrantMember" xlink:label="loc_aemdBreastCancerGrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aemdBreastCancerGrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_SubawardWithUniversityOfPittsburghMember" xlink:label="loc_aemdSubawardWithUniversityOfPittsburghMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aemdSubawardWithUniversityOfPittsburghMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_AwardContractAmount" xlink:label="loc_aemdAwardContractAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdAwardContractAmount_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRevenue_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SegmentsDetails" xlink:title="00000046 - Disclosure - 12. SEGMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_AethlonMember" xlink:label="loc_aemdAethlonMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_aemdAethlonMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ESIMember" xlink:label="loc_aemdESIMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_aemdESIMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestAndDebtExpense_130" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetails-Rent" xlink:title="00000047 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Details - Rent)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_GraniteRidgeMember" xlink:label="loc_aemdGraniteRidgeMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_aemdGraniteRidgeMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_LesseeOperatingLeaseLiabilityPaymentsGross" xlink:label="loc_aemdLesseeOperatingLeaseLiabilityPaymentsGross_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdLesseeOperatingLeaseLiabilityPaymentsGross_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue_20" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000048 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_TimothyRodellMember" xlink:label="loc_aemdTimothyRodellMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_aemdTimothyRodellMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_CharlesJFisherJrMember" xlink:label="loc_aemdCharlesJFisherJrMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_aemdCharlesJFisherJrMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_SeparationAgreementMember" xlink:label="loc_aemdSeparationAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aemdSeparationAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_LeaseAgreementMember" xlink:label="loc_aemdLeaseAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aemdLeaseAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalariesAndWages_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_LetterOfCredit" xlink:label="loc_aemdLetterOfCredit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdLetterOfCredit_120" xlink:type="arc" order="7" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>26
<FILENAME>aemd-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_q3%2D20201231.xfr; Date: 2021%2D02%2D09T13:56:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80020000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_CommonStockSalesAgrMember" xlink:label="aemd_CommonStockSalesAgrMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_CommonStockSalesAgrMember" xlink:to="aemd_CommonStockSalesAgrMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_CommonStockSalesAgrMember_lbl" xml:lang="en-US">Common Stock Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_WainwrightMember" xlink:label="aemd_WainwrightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WainwrightMember" xlink:to="aemd_WainwrightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WainwrightMember_lbl" xml:lang="en-US">H.C. Wainwright [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesMember_lbl" xml:lang="en-US">Accrued board fees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="us-gaap_AccruedLiabilitiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesMember" xlink:to="us-gaap_AccruedLiabilitiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesMember_lbl" xml:lang="en-US">Accrued vacation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfExpenseAxis_lbl" xml:lang="en-US">Nature of Expense [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_VestingOptionsMember" xlink:label="aemd_VestingOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_VestingOptionsMember" xlink:to="aemd_VestingOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_VestingOptionsMember_lbl" xml:lang="en-US">Vesting of stock options and restricted stock units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ShareBasedCompensationMember" xlink:label="aemd_ShareBasedCompensationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ShareBasedCompensationMember" xlink:to="aemd_ShareBasedCompensationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ShareBasedCompensationMember_lbl" xml:lang="en-US">Share-Based Compensation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_AethlonMember" xlink:label="aemd_AethlonMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AethlonMember" xlink:to="aemd_AethlonMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AethlonMember_lbl" xml:lang="en-US">Aethlon [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ESIMember" xlink:label="aemd_ESIMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ESIMember" xlink:to="aemd_ESIMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ESIMember_lbl" xml:lang="en-US">ESI [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_GraniteRidgeMember" xlink:label="aemd_GraniteRidgeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_GraniteRidgeMember" xlink:to="aemd_GraniteRidgeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_GraniteRidgeMember_lbl" xml:lang="en-US">9635 Granite Ridge Drive [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_NonEmployeeDirectorsMember" xlink:label="aemd_NonEmployeeDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_NonEmployeeDirectorsMember" xlink:to="aemd_NonEmployeeDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_NonEmployeeDirectorsMember_lbl" xml:lang="en-US">Non Employee Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_Plan2010Member" xlink:label="aemd_Plan2010Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_Plan2010Member" xlink:to="aemd_Plan2010Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_Plan2010Member_lbl" xml:lang="en-US">2010 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_Equity2020PlanMember" xlink:label="aemd_Equity2020PlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_Equity2020PlanMember" xlink:to="aemd_Equity2020PlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_Equity2020PlanMember_lbl" xml:lang="en-US">2020 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_TimothyRodellMember" xlink:label="aemd_TimothyRodellMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_TimothyRodellMember" xlink:to="aemd_TimothyRodellMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_TimothyRodellMember_lbl" xml:lang="en-US">Timothy Rodell [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type Of Arrangement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_MelanomaCancerContractPhase2Member" xlink:label="aemd_MelanomaCancerContractPhase2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_MelanomaCancerContractPhase2Member" xlink:to="aemd_MelanomaCancerContractPhase2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_MelanomaCancerContractPhase2Member_lbl" xml:lang="en-US">Melanoma Cancer Contract Phase 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_BreastCancerGrantMember" xlink:label="aemd_BreastCancerGrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_BreastCancerGrantMember" xlink:to="aemd_BreastCancerGrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_BreastCancerGrantMember_lbl" xml:lang="en-US">Breast Cancer Grant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_SubawardWithUniversityOfPittsburghMember" xlink:label="aemd_SubawardWithUniversityOfPittsburghMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_SubawardWithUniversityOfPittsburghMember" xlink:to="aemd_SubawardWithUniversityOfPittsburghMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_SubawardWithUniversityOfPittsburghMember_lbl" xml:lang="en-US">Subaward with University of Pittsburgh [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_SeparationAgreementMember" xlink:label="aemd_SeparationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_SeparationAgreementMember" xlink:to="aemd_SeparationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_SeparationAgreementMember_lbl" xml:lang="en-US">Separation Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_CharlesJFisherJrMember" xlink:label="aemd_CharlesJFisherJrMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_CharlesJFisherJrMember" xlink:to="aemd_CharlesJFisherJrMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_CharlesJFisherJrMember_lbl" xml:lang="en-US">Charles J. Fisher Jr [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_LeaseAgreementMember" xlink:label="aemd_LeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LeaseAgreementMember" xlink:to="aemd_LeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_LeaseAgreementMember_lbl" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RestrictedCashMember" xlink:label="aemd_RestrictedCashMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RestrictedCashMember" xlink:to="aemd_RestrictedCashMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RestrictedCashMember_lbl" xml:lang="en-US">Restricted Cash [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_DrRodellMember" xlink:label="aemd_DrRodellMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_DrRodellMember" xlink:to="aemd_DrRodellMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_DrRodellMember_lbl" xml:lang="en-US">Dr. Rodell [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity's Reporting Status Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging growth</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use lease asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Patents, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability, less current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 13)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.001 per share; 30,000,000 shares authorized; 12,123,524 and 9,366,873 shares issued and outstanding as of December 31, 2020 and March 31, 2020, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Aethlon Medical, Inc. stockholders' equity before noncontrolling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interests</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders' Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Government contract revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Payroll and related expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="us-gaap_InterestAndDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Interest and other debt expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_GainOnShareForWarrantExchanges" xlink:label="aemd_GainOnShareForWarrantExchanges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_GainOnShareForWarrantExchanges" xlink:to="aemd_GainOnShareForWarrantExchanges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aemd_GainOnShareForWarrantExchanges_lbl" xml:lang="en-US">(Gain) on share for warrant exchanges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">BASIC AND DILUTED LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuances of common stock for cash under at the market program, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuances of common stock for cash under at the market program, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, value</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_IssuanceOfCommonSharesUponWarrantExchangesShares" xlink:label="aemd_IssuanceOfCommonSharesUponWarrantExchangesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_IssuanceOfCommonSharesUponWarrantExchangesShares" xlink:to="aemd_IssuanceOfCommonSharesUponWarrantExchangesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_IssuanceOfCommonSharesUponWarrantExchangesShares_lbl" xml:lang="en-US">Issuance of common shares upon warrant exchanges, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_IssuanceOfCommonSharesUponWarrantExchangesValue" xlink:label="aemd_IssuanceOfCommonSharesUponWarrantExchangesValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_IssuanceOfCommonSharesUponWarrantExchangesValue" xlink:to="aemd_IssuanceOfCommonSharesUponWarrantExchangesValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_IssuanceOfCommonSharesUponWarrantExchangesValue_lbl" xml:lang="en-US">Issuance of common shares upon warrant exchanges, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Par value of DTC roundup of shares following reverse split, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="aemd_StockIssuedDuringPeriodValueReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="aemd_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xml:lang="en-US">Par value of DTC roundup of shares following reverse split, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Proceeds from the issuance of common stock, net, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Proceeds from the issuance of common stock, net, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows used in operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_GainOnShareForWarrantExchanges" xlink:to="aemd_GainOnShareForWarrantExchanges_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="aemd_GainOnShareForWarrantExchanges_2_lbl" xml:lang="en-US">Gain on share for warrant exchanges</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_AccretionOfRightofuseLeaseAsset" xlink:label="aemd_AccretionOfRightofuseLeaseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccretionOfRightofuseLeaseAsset" xlink:to="aemd_AccretionOfRightofuseLeaseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="aemd_AccretionOfRightofuseLeaseAsset_lbl" xml:lang="en-US">Accretion of right-of-use lease asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net provided by (used in) financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from the issuance of common stock, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Principal payments on convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units and net stock option exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net increase in cash and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and restricted cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and restricted cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplement disclosures of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental information of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability" xlink:label="aemd_InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability" xlink:to="aemd_InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability_lbl" xml:lang="en-US">Initial recognition of right-of-use lease asset and lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Par value of shares issued for round up following reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" xlink:label="aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" xlink:to="aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise_lbl" xml:lang="en-US">Par value of shares issued for vested restricted stock units and net stock option exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">NATURE OF BUSINESS AND BASIS OF PRESENTATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Convertible Notes Payable [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTES PAYABLE, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_WarrantsTextBlock" xlink:label="aemd_WarrantsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsTextBlock" xlink:to="aemd_WarrantsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarrantsTextBlock_lbl" xml:lang="en-US">WARRANTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_RevenueRecognitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAbstract_lbl" xml:lang="en-US">Revenue Recognition [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Basis of Presentation and Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock_lbl" xml:lang="en-US">Research and Development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of RSU activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Due to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Other Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Share-based compensation expense relating to RSUs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xml:lang="en-US">Options outstanding that have vested and are expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of segments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Lease commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_2_lbl" xml:lang="en-US">Repayment of convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense, debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_2_lbl" xml:lang="en-US">Amortization of debt discounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Total interest expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">RSU's vested</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" xlink:label="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" xlink:to="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">RSU's expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Total RSU's outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForCommissions" xlink:label="us-gaap_PaymentsForCommissions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForCommissions" xlink:to="us-gaap_PaymentsForCommissions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForCommissions_lbl" xml:lang="en-US">Payment of commissions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment of stock issuance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock issued new, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_SaleOfStockPricePerShare1" xlink:label="aemd_SaleOfStockPricePerShare1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_SaleOfStockPricePerShare1" xlink:to="aemd_SaleOfStockPricePerShare1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_SaleOfStockPricePerShare1_lbl" xml:lang="en-US">Stock sale - average price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_GrantDateFairValue" xlink:label="aemd_GrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_GrantDateFairValue" xlink:to="aemd_GrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_GrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">RSU's granted</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RsusExchangedForCommonStockRsusExchanged" xlink:label="aemd_RsusExchangedForCommonStockRsusExchanged" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RsusExchangedForCommonStockRsusExchanged" xlink:to="aemd_RsusExchangedForCommonStockRsusExchanged_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RsusExchangedForCommonStockRsusExchanged_lbl" xml:lang="en-US">RSU's exchanged for common stock, RSU's exchanged</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RsusExchangedForCommonStockCommonStockIssued" xlink:label="aemd_RsusExchangedForCommonStockCommonStockIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RsusExchangedForCommonStockCommonStockIssued" xlink:to="aemd_RsusExchangedForCommonStockCommonStockIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RsusExchangedForCommonStockCommonStockIssued_lbl" xml:lang="en-US">RSU's exchanged for common stock, Common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Stock cancelled in exchange for withholding tax, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xml:lang="en-US">Payments to satify tax withholding</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_AccruedDirectorFees" xlink:label="aemd_AccruedDirectorFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedDirectorFees" xlink:to="aemd_AccruedDirectorFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AccruedDirectorFees_lbl" xml:lang="en-US">Accrued director fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="us-gaap_NoninterestExpenseDirectorsFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseDirectorsFees" xlink:to="us-gaap_NoninterestExpenseDirectorsFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseDirectorsFees_lbl" xml:lang="en-US">Director fees</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_AccruedSeparationExpenses" xlink:label="aemd_AccruedSeparationExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedSeparationExpenses" xlink:to="aemd_AccruedSeparationExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AccruedSeparationExpenses_lbl" xml:lang="en-US">Accrued separation expenses for former executive</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total other current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">Weighted average number of common shares outstanding- basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xml:lang="en-US">Basic and diluted loss per common share attributable to stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Options expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Total options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price options expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term options expected to vest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Stock options Outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Stock options cancelled/forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Stock options outstanding, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Stock options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionBeginning" xlink:label="aemd_RangeOfExercisePricesOptionBeginning" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionBeginning" xlink:to="aemd_RangeOfExercisePricesOptionBeginning_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfExercisePricesOptionBeginning_lbl" xml:lang="en-US">Range of exercise prices, Option beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionExercised" xlink:label="aemd_RangeOfExercisePricesOptionExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionExercised" xlink:to="aemd_RangeOfExercisePricesOptionExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfExercisePricesOptionExercised_lbl" xml:lang="en-US">Range of exercise prices, Option Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionGranted" xlink:label="aemd_RangeOfExercisePricesOptionGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionGranted" xlink:to="aemd_RangeOfExercisePricesOptionGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfExercisePricesOptionGranted_lbl" xml:lang="en-US">Range of exercise prices, Option Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionCancelledexpired" xlink:label="aemd_RangeOfExercisePricesOptionCancelledexpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionCancelledexpired" xlink:to="aemd_RangeOfExercisePricesOptionCancelledexpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfExercisePricesOptionCancelledexpired_lbl" xml:lang="en-US">Range of exercise prices, Option cancelled/expired</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionEnding" xlink:label="aemd_RangeOfExercisePricesOptionEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionEnding" xlink:to="aemd_RangeOfExercisePricesOptionEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfExercisePricesOptionEnding_lbl" xml:lang="en-US">Range of exercise prices, Option ending</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionExercisable" xlink:label="aemd_RangeOfExercisePricesOptionExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionExercisable" xlink:to="aemd_RangeOfExercisePricesOptionExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfExercisePricesOptionExercisable_lbl" xml:lang="en-US">Range of exercise prices, Option exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding, Weighted Average Exercise Price, beginning price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled/Forfeited, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Outstanding Weighted Average Exercise Price, ending price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Unrecognized compensation cost amortization period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Options authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Stock issued for exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_NumberOfWarrantsAbstract" xlink:label="aemd_NumberOfWarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_NumberOfWarrantsAbstract" xlink:to="aemd_NumberOfWarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_NumberOfWarrantsAbstract_lbl" xml:lang="en-US">Number of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of Warrants Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of Warrants Cancelled/Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Number of Warrants Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:label="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:to="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Warrants Exercisable, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_WarrantsWeightedAverageExercisePriceAbstract" xlink:label="aemd_WarrantsWeightedAverageExercisePriceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsWeightedAverageExercisePriceAbstract" xlink:to="aemd_WarrantsWeightedAverageExercisePriceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_WarrantsWeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Range of Exercise Price Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfWeightedAverageExercisePriceExpired" xlink:label="aemd_RangeOfWeightedAverageExercisePriceExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfWeightedAverageExercisePriceExpired" xlink:to="aemd_RangeOfWeightedAverageExercisePriceExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfWeightedAverageExercisePriceExpired_lbl" xml:lang="en-US">Range of Exercise Price Cancelled/Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfWeightedAverageExercisePriceOutstandingEnding" xlink:label="aemd_RangeOfWeightedAverageExercisePriceOutstandingEnding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfWeightedAverageExercisePriceOutstandingEnding" xlink:to="aemd_RangeOfWeightedAverageExercisePriceOutstandingEnding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfWeightedAverageExercisePriceOutstandingEnding_lbl" xml:lang="en-US">Range of Exercise Price Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfWeightedAverageExercisePriceExercisable" xlink:label="aemd_RangeOfWeightedAverageExercisePriceExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfWeightedAverageExercisePriceExercisable" xlink:to="aemd_RangeOfWeightedAverageExercisePriceExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_RangeOfWeightedAverageExercisePriceExercisable_lbl" xml:lang="en-US">Range of Exercise Price Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Cancelled/Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:to="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_2_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_AwardContractAmount" xlink:label="aemd_AwardContractAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AwardContractAmount" xlink:to="aemd_AwardContractAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AwardContractAmount_lbl" xml:lang="en-US">Award Contract amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Contract revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_3_lbl" xml:lang="en-US">Net Losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US">Capital Expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestAndDebtExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Operating lease payments year 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Operating lease payments year 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_LesseeOperatingLeaseLiabilityPaymentsGross" xlink:label="aemd_LesseeOperatingLeaseLiabilityPaymentsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LesseeOperatingLeaseLiabilityPaymentsGross" xlink:to="aemd_LesseeOperatingLeaseLiabilityPaymentsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="aemd_LesseeOperatingLeaseLiabilityPaymentsGross_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Lease payment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Annual Base salary</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_LetterOfCredit" xlink:label="aemd_LetterOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LetterOfCredit" xlink:to="aemd_LetterOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_LetterOfCredit_lbl" xml:lang="en-US">Letter of credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccretionOfRightofuseLeaseAsset" xlink:to="aemd_AccretionOfRightofuseLeaseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_AccretionOfRightofuseLeaseAsset_doc" xml:lang="en-US">Accretion of right-of-use lease asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AethlonMember" xlink:to="aemd_AethlonMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_AethlonMember_doc" xml:lang="en-US">Information by business segments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ESIMember" xlink:to="aemd_ESIMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ESIMember_doc" xml:lang="en-US">The set of legal entities associated with a report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_GraniteRidgeMember" xlink:to="aemd_GraniteRidgeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_GraniteRidgeMember_doc" xml:lang="en-US">Information by property that could be leased or is available for lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_GrantDateFairValue" xlink:to="aemd_GrantDateFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_GrantDateFairValue_doc" xml:lang="en-US">Grant date fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability" xlink:to="aemd_InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability_doc" xml:lang="en-US">Initial recognition of right-of-use lease asset and lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_IssuanceOfCommonSharesUponWarrantExchangesShares" xlink:to="aemd_IssuanceOfCommonSharesUponWarrantExchangesShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_IssuanceOfCommonSharesUponWarrantExchangesShares_doc" xml:lang="en-US">Issuance of common shares upon warrant exchanges, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_IssuanceOfCommonSharesUponWarrantExchangesValue" xlink:to="aemd_IssuanceOfCommonSharesUponWarrantExchangesValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_IssuanceOfCommonSharesUponWarrantExchangesValue_doc" xml:lang="en-US">Issuance of common shares upon warrant exchanges, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LesseeOperatingLeaseLiabilityPaymentsGross" xlink:to="aemd_LesseeOperatingLeaseLiabilityPaymentsGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_LesseeOperatingLeaseLiabilityPaymentsGross_doc" xml:lang="en-US">Total lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_NumberOfWarrantsAbstract" xlink:to="aemd_NumberOfWarrantsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_NumberOfWarrantsAbstract_doc" xml:lang="en-US">Number of warrants [Abstract}</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_doc" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionBeginning" xlink:to="aemd_RangeOfExercisePricesOptionBeginning_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RangeOfExercisePricesOptionBeginning_doc" xml:lang="en-US">Range of exercise prices, Option beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionCancelledexpired" xlink:to="aemd_RangeOfExercisePricesOptionCancelledexpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RangeOfExercisePricesOptionCancelledexpired_doc" xml:lang="en-US">Range of exercise prices, Option cancelled/expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionEnding" xlink:to="aemd_RangeOfExercisePricesOptionEnding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RangeOfExercisePricesOptionEnding_doc" xml:lang="en-US">Range of exercise prices, Option ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfExercisePricesOptionExercisable" xlink:to="aemd_RangeOfExercisePricesOptionExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RangeOfExercisePricesOptionExercisable_doc" xml:lang="en-US">Range of exercise prices, Option exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfWeightedAverageExercisePriceExercisable" xlink:to="aemd_RangeOfWeightedAverageExercisePriceExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RangeOfWeightedAverageExercisePriceExercisable_doc" xml:lang="en-US">Weighted Average Exercise Price Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfWeightedAverageExercisePriceExpired" xlink:to="aemd_RangeOfWeightedAverageExercisePriceExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RangeOfWeightedAverageExercisePriceExpired_doc" xml:lang="en-US">Weighted Average Exercise Price Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RangeOfWeightedAverageExercisePriceOutstandingEnding" xlink:to="aemd_RangeOfWeightedAverageExercisePriceOutstandingEnding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RangeOfWeightedAverageExercisePriceOutstandingEnding_doc" xml:lang="en-US">Weighted Average Exercise Price Outstanding, Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RsusExchangedForCommonStockCommonStockIssued" xlink:to="aemd_RsusExchangedForCommonStockCommonStockIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RsusExchangedForCommonStockCommonStockIssued_doc" xml:lang="en-US">RSU's exchanged for common stock, Common stock issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_RsusExchangedForCommonStockRsusExchanged" xlink:to="aemd_RsusExchangedForCommonStockRsusExchanged_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_RsusExchangedForCommonStockRsusExchanged_doc" xml:lang="en-US">RSU's exchanged for common stock, RSU's exchanged</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_SaleOfStockPricePerShare1" xlink:to="aemd_SaleOfStockPricePerShare1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_SaleOfStockPricePerShare1_doc" xml:lang="en-US">Stock sale - average price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:to="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber_doc" xml:lang="en-US">Warrants exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:to="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Warrants Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" xlink:to="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber_doc" xml:lang="en-US">Number of RSU's expected to vest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Warrants - Weighted Average Exercise Price Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WainwrightMember" xlink:to="aemd_WainwrightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WainwrightMember_doc" xml:lang="en-US">Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsTextBlock" xlink:to="aemd_WarrantsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WarrantsTextBlock_doc" xml:lang="en-US">Warrants [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_WarrantsWeightedAverageExercisePriceAbstract" xlink:to="aemd_WarrantsWeightedAverageExercisePriceAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_WarrantsWeightedAverageExercisePriceAbstract_doc" xml:lang="en-US">Weighted average exercise price of warrants [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="aemd_StockIssuedDuringPeriodValueReverseStockSplits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_StockIssuedDuringPeriodValueReverseStockSplits_doc" xml:lang="en-US">Par value of DTC roundup of shares following reverse split, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedSeparationExpenses" xlink:to="aemd_AccruedSeparationExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_AccruedSeparationExpenses_doc" xml:lang="en-US">Accrued separation expenses for former executive</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_GainOnShareForWarrantExchanges" xlink:to="aemd_GainOnShareForWarrantExchanges_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_GainOnShareForWarrantExchanges_doc" xml:lang="en-US">(Gain) on share for warrant exchanges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccruedDirectorFees" xlink:to="aemd_AccruedDirectorFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_AccruedDirectorFees_doc" xml:lang="en-US">Accrued director fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" xlink:to="aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise_doc" xml:lang="en-US">Par value of shares issued for vested restricted stock units and net stock option exercise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_GainOnShareForWarrantExchanges" xlink:to="aemd_GainOnShareForWarrantExchanges_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_GainOnShareForWarrantExchanges_4_lbl" xml:lang="en-US">GainOnShareForWarrantExchanges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_AccretionOfRightofuseLeaseAsset" xlink:to="aemd_AccretionOfRightofuseLeaseAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_AccretionOfRightofuseLeaseAsset_3_lbl" xml:lang="en-US">AccretionOfRightofuseLeaseAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_2_lbl" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_2_lbl" xml:lang="en-US">Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="aemd_LesseeOperatingLeaseLiabilityPaymentsGross" xlink:to="aemd_LesseeOperatingLeaseLiabilityPaymentsGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="aemd_LesseeOperatingLeaseLiabilityPaymentsGross_3_lbl" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentsGross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>27
<FILENAME>aemd-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Source; Value: aethlon_q3%2D20201231.xfr; Date: 2021%2D02%2D09T13:56:21Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80020000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://aethlonmedical.com/role/DocumentAndEntityInformation" xlink:href="aemd-20201231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:href="aemd-20201231.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="aemd-20201231.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="aemd-20201231.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="aemd-20201231.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="aemd-20201231.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ReconciliationOfCashCashEquivalentsAndRestrictedCash" xlink:href="aemd-20201231.xsd#ReconciliationOfCashCashEquivalentsAndRestrictedCash" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:href="aemd-20201231.xsd#NatureOfBusinessAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/LossPerCommonShare" xlink:href="aemd-20201231.xsd#LossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses" xlink:href="aemd-20201231.xsd#ResearchAndDevelopmentExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RecentAccountingPronouncements" xlink:href="aemd-20201231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableNet" xlink:href="aemd-20201231.xsd#ConvertibleNotesPayableNet" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactions" xlink:href="aemd-20201231.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:href="aemd-20201231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:href="aemd-20201231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensation" xlink:href="aemd-20201231.xsd#StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Warrants" xlink:href="aemd-20201231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognition" xlink:href="aemd-20201231.xsd#GovernmentContractsAndGrantsAndRelatedRevenueRecognition" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/Segments" xlink:href="aemd-20201231.xsd#Segments" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:href="aemd-20201231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SubsequentEvents" xlink:href="aemd-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" xlink:href="aemd-20201231.xsd#NatureOfBusinessAndBasisOfPresentationPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables" xlink:href="aemd-20201231.xsd#ResearchAndDevelopmentExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsTables" xlink:href="aemd-20201231.xsd#EquityTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsTables" xlink:href="aemd-20201231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:href="aemd-20201231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationTables" xlink:href="aemd-20201231.xsd#StockCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsTables" xlink:href="aemd-20201231.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SegmentsTables" xlink:href="aemd-20201231.xsd#SegmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesTables" xlink:href="aemd-20201231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:href="aemd-20201231.xsd#NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/LossPerCommonShareDetails-Narrative" xlink:href="aemd-20201231.xsd#LossPerCommonShareDetails-Narrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails" xlink:href="aemd-20201231.xsd#ResearchAndDevelopmentExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:href="aemd-20201231.xsd#ConvertibleNotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsDetails-RsusOutstanding" xlink:href="aemd-20201231.xsd#EquityTransactionsDetails-RsusOutstanding" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative" xlink:href="aemd-20201231.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetails" xlink:href="aemd-20201231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="aemd-20201231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:href="aemd-20201231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation" xlink:href="aemd-20201231.xsd#StockCompensationDetails-StockCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:href="aemd-20201231.xsd#StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:href="aemd-20201231.xsd#StockCompensationDetails-OptionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/StockCompensationDetails-Narrative" xlink:href="aemd-20201231.xsd#StockCompensationDetails-Narrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/WarrantsDetails" xlink:href="aemd-20201231.xsd#WarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognitionDetailsNarrative" xlink:href="aemd-20201231.xsd#GovernmentContractsAndGrantsAndRelatedRevenueRecognitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/SegmentsDetails" xlink:href="aemd-20201231.xsd#SegmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetails-Rent" xlink:href="aemd-20201231.xsd#CommitmentsAndContingenciesDetails-Rent" xlink:type="simple" />
    <link:roleRef roleURI="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="aemd-20201231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaapMinorityInterest" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapMinorityInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaapLaborAndRelatedExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapLaborAndRelatedExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_GainOnShareForWarrantExchanges" xlink:label="loc_aemdGainOnShareForWarrantExchanges" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_aemdGainOnShareForWarrantExchanges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaapNoncontrollingInterestMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapNoncontrollingInterestMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_IssuanceOfCommonSharesUponWarrantExchangesShares" xlink:label="loc_aemdIssuanceOfCommonSharesUponWarrantExchangesShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdIssuanceOfCommonSharesUponWarrantExchangesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_IssuanceOfCommonSharesUponWarrantExchangesValue" xlink:label="loc_aemdIssuanceOfCommonSharesUponWarrantExchangesValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdIssuanceOfCommonSharesUponWarrantExchangesValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="loc_aemdStockIssuedDuringPeriodValueReverseStockSplits" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdStockIssuedDuringPeriodValueReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_GainOnShareForWarrantExchanges" xlink:label="loc_aemdGainOnShareForWarrantExchanges" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_aemdGainOnShareForWarrantExchanges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_AccretionOfRightofuseLeaseAsset" xlink:label="loc_aemdAccretionOfRightofuseLeaseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_aemdAccretionOfRightofuseLeaseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability" xlink:label="loc_aemdInitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_aemdInitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" xlink:label="loc_aemdParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_aemdParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ReconciliationOfCashCashEquivalentsAndRestrictedCash" xlink:title="00000007 - Statement - RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaapRestrictedCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="loc_us-gaapRestrictedCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation" xlink:title="00000008 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/LossPerCommonShare" xlink:title="00000009 - Disclosure - 2. LOSS PER COMMON SHARE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses" xlink:title="00000010 - Disclosure - 3. RESEARCH AND DEVELOPMENT EXPENSES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RecentAccountingPronouncements" xlink:title="00000011 - Disclosure - 4. RECENT ACCOUNTING PRONOUNCEMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableNet" xlink:title="00000012 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactions" xlink:title="00000013 - Disclosure - 6. EQUITY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactions" xlink:title="00000014 - Disclosure - 7. RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilities" xlink:title="00000015 - Disclosure - 8. OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensation" xlink:title="00000016 - Disclosure - 9. STOCK COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Warrants" xlink:title="00000017 - Disclosure - 10. WARRANTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_WarrantsTextBlock" xlink:label="loc_aemdWarrantsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_aemdWarrantsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognition" xlink:title="00000018 - Disclosure - 11. GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaapRevenueRecognitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueRecognitionAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Segments" xlink:title="00000019 - Disclosure - 12. SEGMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SubsequentEvents" xlink:title="00000021 - Disclosure - 14. SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationPolicies" xlink:title="00000022 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables" xlink:title="00000023 - Disclosure - 3. RESEARCH AND DEVELOPMENT EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:label="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsTables" xlink:title="00000024 - Disclosure - 6. EQUITY TRANSACTIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsTables" xlink:title="00000025 - Disclosure - 7. RELATED PARTY TRANSACTIONS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000026 - Disclosure - 8. OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationTables" xlink:title="00000027 - Disclosure - 9. STOCK COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsTables" xlink:title="00000028 - Disclosure - 10. WARRANTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SegmentsTables" xlink:title="00000029 - Disclosure - 12. SEGMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingenciesTables" xlink:title="00000030 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative" xlink:title="00000031 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RestrictedCashMember" xlink:label="loc_aemdRestrictedCashMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_aemdRestrictedCashMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaapSecurityDeposit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSecurityDeposit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/LossPerCommonShareDetails-Narrative" xlink:title="00000032 - Disclosure - 2. LOSS PER COMMON SHARE (Details- Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails" xlink:title="00000033 - Disclosure - 3. RESEARCH AND DEVELOPMENT EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative" xlink:title="00000034 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsDetails-RsusOutstanding" xlink:title="00000035 - Disclosure - 6. EQUITY TRANSACTIONS (Details - RSU&apos;s outstanding)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative" xlink:title="00000036 - Disclosure - 6. EQUITY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_CommonStockSalesAgrMember" xlink:label="loc_aemdCommonStockSalesAgrMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_aemdCommonStockSalesAgrMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCounterpartyNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_WainwrightMember" xlink:label="loc_aemdWainwrightMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_aemdWainwrightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_NonEmployeeDirectorsMember" xlink:label="loc_aemdNonEmployeeDirectorsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="loc_aemdNonEmployeeDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_Plan2010Member" xlink:label="loc_aemdPlan2010Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_aemdPlan2010Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_Equity2020PlanMember" xlink:label="loc_aemdEquity2020PlanMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_aemdEquity2020PlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForCommissions" xlink:label="loc_us-gaapPaymentsForCommissions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForCommissions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_SaleOfStockPricePerShare1" xlink:label="loc_aemdSaleOfStockPricePerShare1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdSaleOfStockPricePerShare1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_GrantDateFairValue" xlink:label="loc_aemdGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RsusExchangedForCommonStockRsusExchanged" xlink:label="loc_aemdRsusExchangedForCommonStockRsusExchanged" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRsusExchangedForCommonStockRsusExchanged" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RsusExchangedForCommonStockCommonStockIssued" xlink:label="loc_aemdRsusExchangedForCommonStockCommonStockIssued" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRsusExchangedForCommonStockCommonStockIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsDetails" xlink:title="00000037 - Disclosure - 7. RELATED PARTY TRANSACTIONS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaapAccruedLiabilitiesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_us-gaapAccruedLiabilitiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000038 - Disclosure - 7. RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_TimothyRodellMember" xlink:label="loc_aemdTimothyRodellMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_aemdTimothyRodellMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_AccruedDirectorFees" xlink:label="loc_aemdAccruedDirectorFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdAccruedDirectorFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoninterestExpenseDirectorsFees" xlink:label="loc_us-gaapNoninterestExpenseDirectorsFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNoninterestExpenseDirectorsFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000039 - Disclosure - 8. OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_AccruedSeparationExpenses" xlink:label="loc_aemdAccruedSeparationExpenses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_aemdAccruedSeparationExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation" xlink:title="00000040 - Disclosure - 9. STOCK COMPENSATION (Details - Stock compensation)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="loc_us-gaapNatureOfExpenseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapNatureOfExpenseAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="loc_us-gaapInterimPeriodCostsNotAllocableDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNatureOfExpenseAxis" xlink:to="loc_us-gaapInterimPeriodCostsNotAllocableDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_VestingOptionsMember" xlink:label="loc_aemdVestingOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdVestingOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ShareBasedCompensationMember" xlink:label="loc_aemdShareBasedCompensationMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInterimPeriodCostsNotAllocableDomain" xlink:to="loc_aemdShareBasedCompensationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest" xlink:title="00000041 - Disclosure - 9. STOCK COMPENSATION (Details - Options vested and expected to vest)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity" xlink:title="00000042 - Disclosure - 9. STOCK COMPENSATION (Details - Option activity)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionBeginning" xlink:label="loc_aemdRangeOfExercisePricesOptionBeginning" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionBeginning" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionExercised" xlink:label="loc_aemdRangeOfExercisePricesOptionExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionGranted" xlink:label="loc_aemdRangeOfExercisePricesOptionGranted" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionCancelledexpired" xlink:label="loc_aemdRangeOfExercisePricesOptionCancelledexpired" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionCancelledexpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionEnding" xlink:label="loc_aemdRangeOfExercisePricesOptionEnding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionEnding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfExercisePricesOptionExercisable" xlink:label="loc_aemdRangeOfExercisePricesOptionExercisable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfExercisePricesOptionExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/StockCompensationDetails-Narrative" xlink:title="00000043 - Disclosure - 9. STOCK COMPENSATION (Details- Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_Equity2020PlanMember" xlink:label="loc_aemdEquity2020PlanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_aemdEquity2020PlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_DrRodellMember" xlink:label="loc_aemdDrRodellMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_aemdDrRodellMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/WarrantsDetails" xlink:title="00000044 - Disclosure - 10. WARRANTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWarrantsAndRightsNoteDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_NumberOfWarrantsAbstract" xlink:label="loc_aemdNumberOfWarrantsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdNumberOfWarrantsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:label="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_WarrantsWeightedAverageExercisePriceAbstract" xlink:label="loc_aemdWarrantsWeightedAverageExercisePriceAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdWarrantsWeightedAverageExercisePriceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_aemdRangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfWeightedAverageExercisePriceExpired" xlink:label="loc_aemdRangeOfWeightedAverageExercisePriceExpired" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfWeightedAverageExercisePriceExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfWeightedAverageExercisePriceOutstandingEnding" xlink:label="loc_aemdRangeOfWeightedAverageExercisePriceOutstandingEnding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfWeightedAverageExercisePriceOutstandingEnding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_RangeOfWeightedAverageExercisePriceExercisable" xlink:label="loc_aemdRangeOfWeightedAverageExercisePriceExercisable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdRangeOfWeightedAverageExercisePriceExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_aemdShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognitionDetailsNarrative" xlink:title="00000045 - Disclosure - 11. GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="loc_us-gaapRevenueRecognitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueRecognitionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_MelanomaCancerContractPhase2Member" xlink:label="loc_aemdMelanomaCancerContractPhase2Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aemdMelanomaCancerContractPhase2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_BreastCancerGrantMember" xlink:label="loc_aemdBreastCancerGrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aemdBreastCancerGrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_SubawardWithUniversityOfPittsburghMember" xlink:label="loc_aemdSubawardWithUniversityOfPittsburghMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aemdSubawardWithUniversityOfPittsburghMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_AwardContractAmount" xlink:label="loc_aemdAwardContractAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdAwardContractAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/SegmentsDetails" xlink:title="00000046 - Disclosure - 12. SEGMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_AethlonMember" xlink:label="loc_aemdAethlonMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_aemdAethlonMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_ESIMember" xlink:label="loc_aemdESIMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_aemdESIMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireProductiveAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireProductiveAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetails-Rent" xlink:title="00000047 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Details - Rent)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:label="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_GraniteRidgeMember" xlink:label="loc_aemdGraniteRidgeMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="loc_aemdGraniteRidgeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_LesseeOperatingLeaseLiabilityPaymentsGross" xlink:label="loc_aemdLesseeOperatingLeaseLiabilityPaymentsGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdLesseeOperatingLeaseLiabilityPaymentsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000048 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_TimothyRodellMember" xlink:label="loc_aemdTimothyRodellMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_aemdTimothyRodellMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_CharlesJFisherJrMember" xlink:label="loc_aemdCharlesJFisherJrMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_aemdCharlesJFisherJrMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_SeparationAgreementMember" xlink:label="loc_aemdSeparationAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aemdSeparationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_LeaseAgreementMember" xlink:label="loc_aemdLeaseAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_aemdLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="aemd-20201231.xsd#aemd_LetterOfCredit" xlink:label="loc_aemdLetterOfCredit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_aemdLetterOfCredit" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206589421016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AETHLON MEDICAL INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity's Reporting Status Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,123,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging growth</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206589129144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 12,131,593<span></span>
</td>
<td class="nump">$ 9,604,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">114,849<span></span>
</td>
<td class="nump">206,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">75,829<span></span>
</td>
<td class="nump">229,604<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">12,322,271<span></span>
</td>
<td class="nump">10,041,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">166,751<span></span>
</td>
<td class="nump">140,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use lease asset</a></td>
<td class="nump">64,750<span></span>
</td>
<td class="nump">136,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">57,092<span></span>
</td>
<td class="nump">57,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">46,726<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
<td class="nump">12,159<span></span>
</td>
<td class="nump">12,159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">12,669,749<span></span>
</td>
<td class="nump">10,387,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">175,422<span></span>
</td>
<td class="nump">285,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">131,746<span></span>
</td>
<td class="nump">111,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">67,698<span></span>
</td>
<td class="nump">98,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">860,697<span></span>
</td>
<td class="nump">472,420<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,235,563<span></span>
</td>
<td class="nump">1,067,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, less current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42,540<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,235,563<span></span>
</td>
<td class="nump">1,110,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 per share; 30,000,000 shares authorized; 12,123,524 and 9,366,873 shares issued and outstanding as of December 31, 2020 and March 31, 2020, respectively</a></td>
<td class="nump">12,125<span></span>
</td>
<td class="nump">9,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">129,207,491<span></span>
</td>
<td class="nump">121,426,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(117,650,120)<span></span>
</td>
<td class="num">(112,026,381)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Aethlon Medical, Inc. stockholders' equity before noncontrolling interests</a></td>
<td class="nump">11,569,496<span></span>
</td>
<td class="nump">9,409,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(135,310)<span></span>
</td>
<td class="num">(132,124)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">11,434,186<span></span>
</td>
<td class="nump">9,277,426<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 12,669,749<span></span>
</td>
<td class="nump">$ 10,387,686<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206596883384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="nump">12,123,524<span></span>
</td>
<td class="nump">9,366,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">12,123,524<span></span>
</td>
<td class="nump">9,366,873<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206588035400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Government contract revenue</a></td>
<td class="nump">$ 624,871<span></span>
</td>
<td class="nump">$ 413,458<span></span>
</td>
<td class="nump">$ 624,871<span></span>
</td>
<td class="nump">$ 443,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">624,979<span></span>
</td>
<td class="nump">609,933<span></span>
</td>
<td class="nump">1,845,659<span></span>
</td>
<td class="nump">1,979,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Payroll and related expenses</a></td>
<td class="nump">1,523,650<span></span>
</td>
<td class="nump">406,421<span></span>
</td>
<td class="nump">2,520,805<span></span>
</td>
<td class="nump">1,609,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">919,830<span></span>
</td>
<td class="nump">273,510<span></span>
</td>
<td class="nump">1,883,802<span></span>
</td>
<td class="nump">998,465<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,068,459<span></span>
</td>
<td class="nump">1,289,864<span></span>
</td>
<td class="nump">6,250,266<span></span>
</td>
<td class="nump">4,588,255<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="num">(2,443,588)<span></span>
</td>
<td class="num">(876,406)<span></span>
</td>
<td class="num">(5,625,395)<span></span>
</td>
<td class="num">(4,144,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER EXPENSE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest and other debt expenses</a></td>
<td class="nump">802<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="nump">1,530<span></span>
</td>
<td class="nump">54,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_GainOnShareForWarrantExchanges', window );">(Gain) on share for warrant exchanges</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(55,593)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(51,190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">447,011<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="nump">802<span></span>
</td>
<td class="num">(55,467)<span></span>
</td>
<td class="nump">1,530<span></span>
</td>
<td class="nump">450,053<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
<td class="num">(2,444,390)<span></span>
</td>
<td class="num">(820,939)<span></span>
</td>
<td class="num">(5,626,925)<span></span>
</td>
<td class="num">(4,594,850)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">LOSS ATTRIBUTABLE TO NONCONTROLLING INTERESTS</a></td>
<td class="num">(1,498)<span></span>
</td>
<td class="num">(1,358)<span></span>
</td>
<td class="num">(3,186)<span></span>
</td>
<td class="num">(3,808)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS ATTRIBUTABLE TO AETHLON MEDICAL, INC.</a></td>
<td class="num">$ (2,442,892)<span></span>
</td>
<td class="num">$ (819,581)<span></span>
</td>
<td class="num">$ (5,623,739)<span></span>
</td>
<td class="num">$ (4,591,042)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED LOSS PER COMMON SHARE</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (2.52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED</a></td>
<td class="nump">12,093,361<span></span>
</td>
<td class="nump">2,887,883<span></span>
</td>
<td class="nump">11,265,725<span></span>
</td>
<td class="nump">1,821,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_GainOnShareForWarrantExchanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>(Gain) on share for warrant exchanges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_GainOnShareForWarrantExchanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118262090&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206585809464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2019</a></td>
<td class="nump">1,266,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value at Mar. 31, 2019</a></td>
<td class="nump">$ 1,267<span></span>
</td>
<td class="nump">$ 108,076,275<span></span>
</td>
<td class="num">$ (105,652,433)<span></span>
</td>
<td class="num">$ (126,031)<span></span>
</td>
<td class="nump">$ 2,299,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock for cash under at the market program, shares</a></td>
<td class="nump">3,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuances of common stock for cash under at the market program, value</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">36,619<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Loss on debt extinguishment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">447,011<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">447,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, shares</a></td>
<td class="nump">3,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, value</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(23,775)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(23,771)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">326,536<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">326,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,066,424)<span></span>
</td>
<td class="num">(860)<span></span>
</td>
<td class="num">(2,067,284)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2019</a></td>
<td class="nump">1,273,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Jun. 30, 2019</a></td>
<td class="nump">$ 1,274<span></span>
</td>
<td class="nump">108,862,666<span></span>
</td>
<td class="num">(107,718,857)<span></span>
</td>
<td class="num">(126,891)<span></span>
</td>
<td class="nump">1,018,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock for cash under at the market program, shares</a></td>
<td class="nump">59,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuances of common stock for cash under at the market program, value</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">386,552<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">386,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, shares</a></td>
<td class="nump">3,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, value</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(8,448)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_IssuanceOfCommonSharesUponWarrantExchangesShares', window );">Issuance of common shares upon warrant exchanges, shares</a></td>
<td class="nump">1,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_IssuanceOfCommonSharesUponWarrantExchangesValue', window );">Issuance of common shares upon warrant exchanges, value</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,402<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">326,536<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">326,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,705,037)<span></span>
</td>
<td class="num">(1,589)<span></span>
</td>
<td class="num">(1,706,626)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2019</a></td>
<td class="nump">1,337,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Sep. 30, 2019</a></td>
<td class="nump">$ 1,339<span></span>
</td>
<td class="nump">109,571,708<span></span>
</td>
<td class="num">(109,423,894)<span></span>
</td>
<td class="num">(128,480)<span></span>
</td>
<td class="nump">20,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, shares</a></td>
<td class="nump">3,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, value</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(6,772)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,769)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_IssuanceOfCommonSharesUponWarrantExchangesShares', window );">Issuance of common shares upon warrant exchanges, shares</a></td>
<td class="nump">2,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_IssuanceOfCommonSharesUponWarrantExchangesValue', window );">Issuance of common shares upon warrant exchanges, value</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(55,596)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(55,593)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Par value of DTC roundup of shares following reverse split, shares</a></td>
<td class="nump">3,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_StockIssuedDuringPeriodValueReverseStockSplits', window );">Par value of DTC roundup of shares following reverse split, value</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Proceeds from the issuance of common stock, net, shares</a></td>
<td class="nump">3,432,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Proceeds from the issuance of common stock, net, value</a></td>
<td class="nump">$ 3,432<span></span>
</td>
<td class="nump">4,560,802<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,564,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">102,576<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">102,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(819,581)<span></span>
</td>
<td class="num">(1,358)<span></span>
</td>
<td class="num">(820,939)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2019</a></td>
<td class="nump">4,779,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 4,781<span></span>
</td>
<td class="nump">114,172,714<span></span>
</td>
<td class="num">(110,243,475)<span></span>
</td>
<td class="num">(129,838)<span></span>
</td>
<td class="nump">3,804,182<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2020</a></td>
<td class="nump">9,366,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 9,368<span></span>
</td>
<td class="nump">121,426,563<span></span>
</td>
<td class="num">(112,026,381)<span></span>
</td>
<td class="num">(132,124)<span></span>
</td>
<td class="nump">9,277,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuances of common stock for cash under at the market program, shares</a></td>
<td class="nump">2,685,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuances of common stock for cash under at the market program, value</a></td>
<td class="nump">$ 2,686<span></span>
</td>
<td class="nump">7,258,183<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,260,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, shares</a></td>
<td class="nump">17,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, value</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">(24,269)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(24,251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">84,207<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">84,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,410,283)<span></span>
</td>
<td class="num">(863)<span></span>
</td>
<td class="num">(1,411,146)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2020</a></td>
<td class="nump">12,070,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Jun. 30, 2020</a></td>
<td class="nump">$ 12,072<span></span>
</td>
<td class="nump">128,744,684<span></span>
</td>
<td class="num">(113,436,664)<span></span>
</td>
<td class="num">(132,987)<span></span>
</td>
<td class="nump">15,187,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, shares</a></td>
<td class="nump">17,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, value</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="num">(16,145)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(16,128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">167,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">167,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,770,564)<span></span>
</td>
<td class="num">(825)<span></span>
</td>
<td class="num">(1,771,389)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2020</a></td>
<td class="nump">12,088,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 12,089<span></span>
</td>
<td class="nump">128,895,581<span></span>
</td>
<td class="num">(115,207,228)<span></span>
</td>
<td class="num">(133,812)<span></span>
</td>
<td class="nump">13,566,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, shares</a></td>
<td class="nump">35,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common shares upon vesting of restricted stock units and net stock option exercise, value</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="num">(66,048)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(66,012)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">377,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">377,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,442,892)<span></span>
</td>
<td class="num">(1,498)<span></span>
</td>
<td class="num">(2,444,390)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="nump">12,123,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 12,125<span></span>
</td>
<td class="nump">$ 129,207,491<span></span>
</td>
<td class="num">$ (117,650,120)<span></span>
</td>
<td class="num">$ (135,310)<span></span>
</td>
<td class="nump">$ 11,434,186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_IssuanceOfCommonSharesUponWarrantExchangesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares upon warrant exchanges, shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_IssuanceOfCommonSharesUponWarrantExchangesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_IssuanceOfCommonSharesUponWarrantExchangesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares upon warrant exchanges, value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_IssuanceOfCommonSharesUponWarrantExchangesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_StockIssuedDuringPeriodValueReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Par value of DTC roundup of shares following reverse split, value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_StockIssuedDuringPeriodValueReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206588081880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (5,626,925)<span></span>
</td>
<td class="num">$ (4,594,850)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">28,775<span></span>
</td>
<td class="nump">15,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">629,207<span></span>
</td>
<td class="nump">755,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">447,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_GainOnShareForWarrantExchanges', window );">Gain on share for warrant exchanges</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(51,190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccretionOfRightofuseLeaseAsset', window );">Accretion of right-of-use lease asset</a></td>
<td class="num">(1,723)<span></span>
</td>
<td class="nump">862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">91,880<span></span>
</td>
<td class="num">(206,729)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">153,775<span></span>
</td>
<td class="nump">169,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="nump">278,663<span></span>
</td>
<td class="num">(271,533)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Due to related parties</a></td>
<td class="nump">20,039<span></span>
</td>
<td class="nump">27,558<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,526,309)<span></span>
</td>
<td class="num">(3,577,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(54,630)<span></span>
</td>
<td class="num">(148,064)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(54,630)<span></span>
</td>
<td class="num">(148,064)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Net provided by (used in) financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net</a></td>
<td class="nump">7,260,869<span></span>
</td>
<td class="nump">4,987,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Principal payments on convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(992,591)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units and net stock option exercise</a></td>
<td class="num">(106,391)<span></span>
</td>
<td class="num">(38,981)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,154,478<span></span>
</td>
<td class="nump">3,955,896<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash and restricted cash</a></td>
<td class="nump">2,573,539<span></span>
</td>
<td class="nump">230,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash at beginning of period</a></td>
<td class="nump">9,604,780<span></span>
</td>
<td class="nump">3,828,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash at end of period</a></td>
<td class="nump">12,178,319<span></span>
</td>
<td class="nump">4,058,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplement disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">83,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental information of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability', window );">Initial recognition of right-of-use lease asset and lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">228,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Par value of shares issued for round up following reverse stock split</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise', window );">Par value of shares issued for vested restricted stock units and net stock option exercise</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_AccretionOfRightofuseLeaseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of right-of-use lease asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_AccretionOfRightofuseLeaseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_GainOnShareForWarrantExchanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>(Gain) on share for warrant exchanges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_GainOnShareForWarrantExchanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial recognition of right-of-use lease asset and lease liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_InitialRecognitionOfRightofuseLeaseAssetAndLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Par value of shares issued for vested restricted stock units and net stock option exercise</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_ParValueOfSharesIssuedForVestedRestrictedStockUnitsAndNetStockOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssetsAndLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206595185048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 12,131,593<span></span>
</td>
<td class="nump">$ 4,058,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">46,726<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Cash and restricted cash</a></td>
<td class="nump">$ 12,178,319<span></span>
</td>
<td class="nump">$ 4,058,653<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206667305864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>1. NATURE OF BUSINESS AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">NATURE OF BUSINESS AND BASIS OF PRESENTATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1. NATURE OF BUSINESS AND BASIS OF PRESENTATION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">ORGANIZATION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Aethlon Medical, Inc. and its subsidiary (collectively,
&#8220;Aethlon&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221; or &#8220;us&#8221;), is a medical technology company focused
on developing products to diagnose and treat life and organ threatening diseases. The Aethlon Hemopurifier&#174;, or Hemopurifier,
is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier
is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression, seed the spread of metastasis
and inhibit the benefit of leading cancer therapies. The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier
as a &#8220;Breakthrough Device&#8221; for&#160;two independent indications:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px; font: 12pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 48px; font: 12pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#183;</font></td>
    <td style="font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt">the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 48px"><font style="font: 10pt Symbol">&#183;</font></td>
    <td><font style="font-size: 10pt">the treatment of life-threatening viruses that are not addressed with approved therapies.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe the Hemopurifier can be a substantial
advance in the treatment of patients with advanced and metastatic cancer through the clearance of exosomes that promote the growth
and spread of tumors through multiple mechanisms. We are currently preparing for the initiation of clinical trials in patients
with advanced and metastatic cancers. We are initially focused on the treatment of solid tumors, including head and neck cancer,
gastrointestinal cancers and other cancers. As we advance our clinical trials, we are in close contact with our clinical sites
to navigate and assess the impact of the COVID-19 global pandemic on our clinical trials and current timelines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 4, 2019, the FDA approved our Investigational
Device Exemption, or IDE, application to initiate an Early Feasibility Study, or EFS, of the Hemopurifier in patients with head
and neck cancer in combination with standard of care pembrolizumab (Keytruda) (NCT # 04453046).&#160; The primary endpoint for
the EFS, which is designed to enroll 10-12 subjects at a single center, will be safety, with secondary endpoints including measures
of exosome clearance and characterization, as well as response and survival rates. This study, which will be conducted at the UPMC
Hillman Cancer Center in Pittsburgh, PA, has been approved by the Institutional Review Board, or IRB, and is now open for patient
enrollment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also believe the Hemopurifier can be a part
of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed
with an already approved treatment. In small-scale or early feasibility human studies, the Hemopurifier has been used to treat
individuals infected with human immunodeficiency virus, or HIV, Hepatitis C, and Ebola.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, <i>in vitro,</i> the Hemopurifier
has been demonstrated to capture Zika virus, Lassa virus, MERS-CoV, cytomegalovirus, Epstein-Barr virus, Herpes simplex virus,
Chikungunya virus, Dengue virus, West Nile virus, smallpox-related viruses, H1N1 swine flu virus, H5N1 bird flu virus, and the
reconstructed Spanish flu virus of 1918. In several cases, these studies were conducted in collaboration with leading government
or non-government research institutes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 17, 2020, the FDA approved a supplement
to the Company&#8217;s open IDE for the Hemopurifier in viral disease to allow for the testing of the Hemopurifier in patients
with SARS-CoV-2/COVID-19 in a New Feasibility Study. <font style="background-color: white">That study&#8217;s plan is to enroll
up to 40 subjects at up to 20 centers in the U.S. Subjects will have established laboratory diagnosis of COVID-19, be admitted
to an intensive care unit, or ICU and will have acute lung injury and/or severe or life threatening disease, among other criteria.
Endpoints for this study, in addition to safety, will include reduction in circulating virus as well as clinical outcomes (NCT
# 04595903). The first sites for this trial, Hoag Memorial Hospital Presbyterian in Newport Beach, CA and Hoag Hospital &#8211;
Irvine in Irvine, CA now have IRB approval and are preparing to open for patient enrollment. Under Single Patient Emergency Use
regulations, the Company has also recently treated a patient with COVID-19 who successfully completed eight daily treatments with
the Hemopurifier.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are also the majority owner of Exosome Sciences,
Inc., or ESI, a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases. Included
among ESI&#8217;s activities is the advancement of a TauSome&#8482; biomarker candidate to diagnose chronic traumatic encephalopathy,
or CTE, in the living. ESI previously documented TauSome levels in former NFL players to be nine times higher than same age-group
control subjects. Through ESI, we are also developing exosome based biomarkers in patients with, or at risk for, a number of cancers.
We consolidate ESI&#8217;s activities in our consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Successful outcomes of human trials will also
be required by the regulatory agencies of certain foreign countries where we plan to sell the Hemopurifier. Some of our patents
may expire before FDA approval or approval in a foreign country, if any, is obtained. However, we believe that certain patent applications
and/or other patents issued more recently will help protect the proprietary nature of the Hemopurifier treatment technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the foregoing, we are monitoring
closely the impact of the COVID-19 global pandemic on our business and have taken steps designed to protect the health and safety
of our employees while continuing our operations. Given the level of uncertainty regarding the duration and impact of the COVID-19
pandemic on capital markets and the U.S. economy, we are unable to assess the impact of the worldwide spread of SARS-CoV-2 and
the resulting COVID-19 pandemic on our timelines and future access to capital. We are continuing to monitor the spread of COVID-19
and its potential impact on our operations. The full extent to which the COVID-19 pandemic will impact our business, results of
operations, financial condition, clinical trials, and preclinical research will depend on future developments that are highly uncertain,
including actions taken to contain or treat COVID-19 and their effectiveness, as well as the economic impact on national and international
markets.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our executive offices are located at 9635 Granite
Ridge Drive, Suite 100, San Diego, California 92123. Our telephone number is (858) 459-7800. Our website address is www.aethlonmedical.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock is listed on the Nasdaq Capital
Market under the symbol &#8220;AEMD.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">REVERSE STOCK SPLIT</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following the approval of a reverse stock split
at our 2019 Annual Meeting of Stockholders&#8217; held on October 14, 2019, our Board of Directors approved a 1-for-15 reverse
stock split. Accordingly, 15 shares of outstanding common stock then held by stockholders were combined into one share of common
stock. Any fractional shares resulting from the reverse split were rounded up to the next whole share. Authorized common stock
remained at 30,000,000 shares. The accompanying unaudited condensed consolidated financial statements and accompanying notes have
been retroactively revised to reflect such reverse stock split as if it had occurred on April 1, 2019. All shares and per share
amounts have been revised accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended December 31,
2020, there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal
year ended March 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Basis of Presentation and Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP,
for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission,
or SEC Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto
for the fiscal year ended March 31, 2020, included in the Company's Annual Report on Form 10-K filed with the SEC on June 25, 2020.
The accompanying unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its majority-owned
subsidiary. All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed
consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are
necessary to present fairly the condensed consolidated financial statements as of and for the three and nine months ended December
31, 2020, and the condensed consolidated statement of cash flows for the nine months ended December 31, 2020. Estimates were made
relating to useful lives of fixed assets, impairment of assets, share-based compensation expense and accruals for clinical trial
and research and development expenses. Actual results could differ materially from those estimates. The accompanying condensed
consolidated balance sheet at March 31, 2020 has been derived from the audited consolidated balance sheet at March 31, 2020, contained
in the above referenced 10-K. The results of operations for the three and nine months ended December 31, 2020 are not necessarily
indicative of the results to be expected for the full year or any future interim periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Reclassifications</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior year balances within the unaudited
condensed consolidated financial statements have been reclassified to conform to the current year presentation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Restricted Cash</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To comply with the terms of our new laboratory
and office lease (see Note 13), we caused our bank to issue a standby letter of credit, or the L/C, in the amount of $46,726 in
favor of the landlord. The L/C is in lieu of a security deposit. In order to support the L/C, we agreed to have our bank withdraw
$46,726 from our operating accounts and to place that amount in a restricted certificate of deposit. We have classified that amount
as restricted cash, a long-term asset, on our balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">LIQUIDITY
AND GOING CONCERN</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="margin: 0"><font style="font: 10pt Times New Roman, Times, Serif">Management expects existing cash
as of December 31, 2020 to be sufficient to fund the Company&#8217;s operations for at least twelve months from the issuance date
of these condensed consolidated financial statements.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206596830216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2. LOSS PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Earnings Per Share, Basic and Diluted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER COMMON SHARE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2. LOSS PER COMMON SHARE</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic loss per share is computed by dividing
net loss by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share is
computed similar to basic loss per share, except that the denominator is increased to include the number of additional dilutive
common shares that would have been outstanding if potential common shares had been issued, if such additional common shares were
dilutive. Since we had net losses for all periods presented, basic and diluted loss per share are the same, and additional potential
common shares have been excluded, as their effect would be antidilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2020, and 2019, an aggregate
of 2,626,485 and 3,779,301 potential common shares, respectively, consisting of shares underlying outstanding stock options, warrants
and unvested restricted stock units, were excluded, as their inclusion would be antidilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206676793640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. RESEARCH AND DEVELOPMENT EXPENSES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">3. RESEARCH AND DEVELOPMENT EXPENSES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development costs are expensed
as incurred. We incurred research and development expenses during the three and nine month periods ended December 31, 2020 and
2019, which are included in various operating expense line items in the accompanying condensed consolidated statements of operations.
Our research and development expenses in those periods were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2019</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 67%"><font style="font-size: 10pt">Three months ended</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">461,176</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">218,571</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Nine months ended</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1,367,333</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">692,022</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206676664872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">4. <font style="text-transform: uppercase">Recent Accounting Pronouncements</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not expect the adoption of any recent
accounting pronouncement to have a material impact on our financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=SL108384541-122693<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31137-122693<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206595485592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. CONVERTIBLE NOTES PAYABLE, NET<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">CONVERTIBLE NOTES PAYABLE, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">5. CONVERTIBLE NOTES PAYABLE, NET</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2019, all of our previously outstanding
convertible notes, in the aggregate amount of $992,591, were paid in full.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the nine months ended December 31, 2019,
we recorded interest expense of $23,759 related to the contractual interest rates of our convertible notes and interest expense
of $30,287 related to the amortization of the note discount for a total interest expense of $54,046 related to our convertible
notes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended December 31, 2019,
prior to paying off the notes, we reduced the conversion price on the convertible notes from $45.00 per share to $10.20 per share.
The modification of the convertible notes was evaluated under ASC 470-50-40 and the instruments were determined to be substantially
different, and the transaction qualified for extinguishment accounting. Under the extinguishment accounting we recorded a loss
on debt extinguishment of $447,011.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206595260472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. EQUITY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">6. EQUITY TRANSACTIONS&#160;IN THE NINE MONTHS ENDED DECEMBER 31,
2020</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Common Stock Sales Agreement with H.C. Wainwright &#38; Co.,
LLC</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 28, 2016, we entered into a Common
Stock Sales Agreement, or the Agreement, with H.C. Wainwright &#38; Co., LLC, or Wainwright, which established an at-the-market
equity program pursuant to which we may offer and sell shares of our common stock from time to time as set forth in the Agreement.
The Agreement provided for the sale of shares of our common stock having an aggregate offering price of up to $12,500,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 30, 2020, we executed Amendment No.
2 to the Agreement with Wainwright, effective as of the same date. The amendment provides that references in the Agreement to the
registration statement shall refer to the registration statement on Form S-3 (File No. 333-237269), originally filed with the SEC
on March 19, 2020, declared effective by the SEC on March 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to the terms and conditions set forth
in the Agreement, Wainwright agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices
to sell the shares under the Agreement from time to time, based upon our instructions. We provided Wainwright with customary indemnification
rights under the Agreement, and Wainwright is entitled to a commission at a fixed rate equal to three percent of the gross proceeds
per share sold. In addition, we agreed to pay certain expenses incurred by Wainwright in connection with the Agreement, including
up to $50,000 of the fees and disbursements of their counsel. The Agreement will terminate upon the sale of all of the shares under
the Agreement, unless terminated earlier by either party as permitted under the Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales of the shares, if any, under the Agreement
will be made in transactions that are deemed to be &#8220;at the market offerings&#8221; as defined in Rule 415 under the Securities
Act of 1933, as amended, or the Securities Act, including sales made by means of ordinary brokers&#8217; transactions, including
on the Nasdaq Capital Market, at market prices or as otherwise agreed with Wainwright. We have no obligation to sell any of the
shares, and, at any time, we may suspend offers under the Agreement or terminate the Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the three months ended June 30, 2020, we
raised aggregate net proceeds of $7,260,869, net of $224,825 in commissions to Wainwright and $8,472 in other offering expenses,
under the Agreement, through the sale of 2,685,600 shares at an average price of $2.70 per share of net proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Restricted Stock Unit Grants </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2012, as amended through July 16, 2020,
our Board of Directors established the Non-Employee Directors Compensation Program, to provide for cash and equity compensation
for persons serving as non-employee directors of the Company. Under this program, each new director receives either stock options
or a grant of restricted stock units, or RSUs, as well as an annual grant of RSUs at the beginning of each fiscal year. The RSUs
are subject to vesting and represent the right to be issued on a future date shares of our common stock upon vesting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 3, 2020, pursuant to the terms of
the Company&#8217;s Non-Employee Directors Compensation Program, the Compensation Committee of the Board of Directors granted RSUs
to each non-employee director of the Company. The Non-Employee Directors Compensation Program provided for a grant of RSUs with
a grant date fair value of $35,000, priced at the average of the closing prices for the five trading days ending on the date of
grant, which was $1.41 per share, so that the total number of RSUs to be granted to each non-employee director for fiscal year
2020 would be 24,822 shares of our common stock.&#160;&#160;On April 3, 2020, each eligible director was granted an RSU for 23,893
shares under the Company&#8217;s 2010 Stock Plan, or the 2010 Plan, as the number of shares that remained available for grant under
the 2010 Plan was not sufficient for each director&#8217;s full RSU grant. The Compensation Committee also granted to each eligible
director a contingent grant under our 2020 Equity Incentive Plan, or the 2020 Plan, for the remaining portion of the annual RSU
grants, or 929 RSU&#8217;s to each eligible director, contingent upon stockholder approval of the 2020 Plan at the Company&#8217;s
2020 Annual Meeting of Stockholders, or the Annual Meeting. These grants are subject to vesting as follows: 50% of the RSUs subject
to the grants will vest on December 31, 2020 and 50% of the RSUs will vest on March 31, 2021, subject in each case to the continuous
service of each director, through such vesting dates, as well as approval of the 2020 Plan by the stockholders at the Annual Meeting,
which was obtained at the Annual Meeting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2020, 29,866 vested RSUs held by our
non-employee directors were exchanged into the same number of shares of our common stock. All five non-employee directors elected
to return 40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resulting
in 11,947 of the vested RSUs being cancelled in exchange for $24,251 in aggregate cash proceeds to those independent directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2020, 29,866 vested RSUs held
by our non-employee directors were exchanged into the same number of shares of our common stock. All five non-employee directors
elected to return 40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances,
resulting in 11,947 of the vested RSUs being cancelled in exchange for $16,128 in aggregate cash proceeds to those independent
directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Also in September 2020, our stockholders approved
the 2020 Plan at the Annual Meeting, at which point the grants of 929 RSUs to each of our eligible independent directors for a
total of 4,645 RSUs were considered effective and no longer contingent as of that date (See Note 9).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2020, 32,189 vested RSUs held by
our non-employee directors were exchanged into the same number of shares of our common stock. All five non-employee directors elected
to return 40% of their vested RSUs in exchange for cash, in order to pay their withholding taxes on the share issuances, resulting
in 12,876 of the vested RSUs being cancelled in exchange for $31,802 in aggregate cash proceeds to those independent directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RSUs outstanding that have vested as of, and
are expected to vest subsequent to, December 31, 2020 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Number of RSUs</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 84%; padding-bottom: 1pt"><font style="font-size: 10pt">Expected to vest</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid">&#160;</td>
    <td style="width: 13%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">32,189</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">32,189</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206595220440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">7. RELATED PARTY TRANSACTIONS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended December 31,
2020, we accrued unpaid fees of $69,292 owed to our non-employee directors as of December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of entering into a Separation Agreement
on October 30, 2020 with our former Chief Executive Officer, or CEO, Timothy Rodell, M.D., or the Separation Agreement, we paid
out accrued vacation of $20,260 to Dr. Rodell in the three months ended December 2020 (see Note 8 and Note 13). That accrued vacation
was previously recorded in the due to related parties account.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amounts due to related parties were comprised
of the following items:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">December 31, <br />
2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">March 31, <br />
2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><font style="font-size: 10pt">Accrued Board fees</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">69,292</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">69,750</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Accrued vacation to all employees</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">62,454</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">41,957</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total due to related parties</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">131,746</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">111,707</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206595344328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">8. OTHER CURRENT LIABILITIES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other current liabilities were comprised of the following items:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">March 31,</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><font style="font-size: 10pt">Accrued separation expenses for former executive</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">400,578</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Accrued professional fees</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">460,119</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">472,420</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total other current liabilities</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">860,697</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">472,420</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206595448280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. STOCK COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">STOCK COMPENSATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">9. STOCK COMPENSATION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables summarize share-based
compensation expenses relating to RSUs and stock options and the effect on basic and diluted loss per common share during the three
and nine month periods ended December 31, 2020 and 2019:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Three Months <br />
Ended <br />
December 31, <br />
2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Three Months<br />
Ended<br />
December 31, <br />
2019</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Nine Months <br />
Ended <br />
December 31,<br />
2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Nine Months<br />
Ended <br />
December 31,<br />
2019</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 44%; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Vesting of stock options and restricted stock units</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">377,958</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">102,576</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">629,207</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">755,648</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Total stock-based compensation expense</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">377,958</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">102,576</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">629,207</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">755,648</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Weighted average number of common shares outstanding &#8211; basic and diluted</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">12,093,361</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,887,883</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">11,265,725</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,821,557</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Basic and diluted loss per common share attributable to stock-based compensation expense</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.03</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.04</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.06</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.41</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the stock-based compensation expense
recorded during the nine months ended December 31, 2020 and 2019, which totaled $629,207 and $755,648, respectively, is included
in payroll and related expense in the accompanying condensed consolidated statements of operations.&#160; Stock-based compensation
expense recorded during the nine months ended December 31, 2020 and 2019 represented an impact on basic and diluted loss per common
share of $(0.06) and $(0.41), respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We review share-based compensation on a quarterly
basis for changes to the estimate of expected award forfeitures based on actual forfeiture experience. The cumulative effect of
adjusting the forfeiture rate for all expense amortization is recognized in the period the forfeiture estimate is changed. The
effect of forfeiture adjustments for the nine months ended December 31, 2020 was insignificant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Stock Option Activity and Approval of 2020 Plan</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From February 2020 through May 2020, our compensation
committee granted options to purchase 521,476 shares of our common stock that were contingent upon stockholder approval of the
2020 Plan. Upon approval of the 2020 Plan at the Annual Meeting, these option grants were considered effective and no longer contingent
as of that date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2020 Plan approved by our stockholders
at the Annual Meeting, authorizes up to 1,842,556 shares for issuance pursuant to stock option grants, RSUs or other forms of stock-based
compensation. No future grants will be made under the 2010 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We issued an option to purchase shares 239,122
shares of our common stock pursuant to the 2020 Plan to our Chief Executive Officer during the three months ended December 31,
2020, in connection with the appointment of Dr. Fisher as our Chief Executive Officer, effective as of October 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Separation Agreement
and pursuant to Dr. Rodell&#8217;s employment agreement with the Company, the vesting was accelerated on 50% of outstanding and
unvested options to purchase shares of our common stock held by Dr. Rodell as of the Separation Date of October 30, 2020, such
that the accelerated stock options were fully vested and exercisable as of the Separation Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2020, Dr. Rodell elected to net
exercise a portion of his stock options. As a result, we issued Dr. Rodell an aggregate of 15,896 shares of our common stock and
we paid the estimated withholding taxes of $34,209 related to the net exercise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Options outstanding that were vested as of
December 31, 2020 and options that are expected to vest subsequent to December 31, 2020 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Number of<br />
Shares</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted<br />
Average<br />
Remaining<br />
Contractual<br />
Term in<br />
Years</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 58%"><font style="font-size: 10pt">Vested</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">34,509</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">32.53</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">5.84</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Expected to vest</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">567,814</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">1.51</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">9.67</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">602,323</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of stock option activity during the nine months ended
December 31, 2020 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Amount</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Range of<br />
Exercise Price</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted<br />
Average <br />
Exercise<br />
Price</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 53%"><font style="font-size: 10pt">Stock options outstanding at March 31, 2020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">51,124</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 16%; text-align: center"><font style="font-size: 10pt">$18.75 - $187.50</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">44.12</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(15,896</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt">$1.28</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.28</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">770,094</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt">$1.28 &#8211; $2.45</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.45</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Cancelled/Expired</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(202,999</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 10pt">$1.28 - $187.50</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">6.76</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Stock options outstanding at December 31, 2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">602,323</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 10pt">$1.28 - $187.50</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">3.29</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Stock options exercisable at December 31, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">34,509</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center"><font style="font-size: 10pt">$1.28 - $187.50</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">32.53</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 31, 2020, our outstanding stock
options had no intrinsic value since the closing price on that date of $2.47 per share was below the weighted average exercise
price of our outstanding stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2020, there was approximately
$2,240,000 of unrecognized compensation cost related to share-based payments, which is expected to be recognized over a weighted
average period of 1.48 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206693334760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. WARRANTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarrantsTextBlock', window );">WARRANTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">10. WARRANTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the nine months ended December 31, 2020 and 2019, we did
not issue any warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of warrant activity during the nine months ended December
31, 2020 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Amount</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Range of<br />
Exercise<br />
Price</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 53%; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Warrants outstanding at March 31, 2020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2,021,368</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 16%; text-align: center"><font style="font-size: 10pt">$1.50 - $125.25</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">5.21</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Cancelled/Expired</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(29,395</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 10pt">$90.75 &#8211; $135.00</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">97.17</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Warrants outstanding at December 31, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,991,973</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center"><font style="font-size: 10pt">$1.50 &#8211; $99.00</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">5.23</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Warrants exercisable at December 31, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,991,973</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center"><font style="font-size: 10pt">$1.50 &#8211; $99.00</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">5.23</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206595260472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">11. GOVERNMENT CONTRACTS AND RELATED REVENUE RECOGNITION</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have recognized revenue under the following
two contracts/grants with the National Cancer Institute, or NCI, part of the National Institutes of Health, or NIH, over the past
two years:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Phase 2 Melanoma Cancer Contract</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 12, 2019, the NCI awarded to us
an SBIR Phase II Award Contract, for NIH/NCI Topic 359, entitled &#8220;A Device Prototype for Isolation of Melanoma Exosomes for
Diagnostics and Treatment Monitoring&#8221;, or the Award Contract. The Award Contract amount is $1,860,561 and runs for the period
from September 16, 2019 through September 15, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The work to be performed pursuant to this Award
Contract focuses on melanoma exosomes. This work follows from our completion of a phase I contract for the Topic 359 solicitation
that ran from September 2017 through June 2018, as described below. Following on the phase I work, the deliverables in the phase
II program involve the design and testing of a pre-commercial prototype of a more advanced version of the exosome isolation platform.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the period ended December 31, 2020,
we completed all of the milestones relevant to that time period. As a result, we recorded $436,427 of government contract revenue
on the Phase 2 Melanoma Cancer Contract in the nine months ended December 31, 2020.&#160;&#160; Of the total revenue recognized
during the current period relating to this grant, a total of $117,849 was invoiced to the NCI during the three months ended December
31, 2020 and we recorded $318,578 which had previously been recognized as deferred revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Breast Cancer Grant</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the nine months ended December 31, 2020,
we completed and submitted the final reports applicable to this NCI grant (number 1R43CA232977-01). The title of this Small Business
Innovation Research, or SBIR, Phase I grant is &#8220;The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from
the Blood Circulation,&#8221; or the Breast Cancer Grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This NCI Phase I grant period originally ran
from September 14, 2018 through August 31, 2019. In August 2019, we applied for and received a no cost, twelve month extension
on this grant; through August 31, 2020. The total amount of the firm grant was $298,444. The grant called for two subcontractors
to work with us. Those subcontractors were University of Pittsburgh and Massachusetts General Hospital. As of December 31, 2020,
we have received all of the funds allocated to the Breast Cancer Grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended December 31, 2020,
we recorded the remaining $188,444 of revenue related to the Breast Cancer Grant, as we achieved two of the three milestones related
to the Breast Cancer Grant. We concluded in our final report to the SBIR that our pre-clinical results demonstrated that our work
under the grant provided support that the Hemopurifier has the capacity to clear exosomes from breast cancer patients. That amount
previously was recorded as deferred revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2020, we received all of
the funds allocated to the Breast Cancer Grant and have submitted the final reports applicable to this grant.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Subaward with University of Pittsburgh</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, we are completing the logistical
elements of documentation and billing the University of Pittsburgh in connection with a cost reimbursable subaward arrangement
under an NIH project entitled &#8220;Depleting Exosomes to Improve Responses to Immune Therapy in HNNCC.&#8221; Our share of the
award is $256,750. We have not recorded any revenues as of December 31, 2020 related to the subaward. We anticipate billing and
recognizing revenue under this subaward in future periods.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206595193144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. SEGMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">12. SEGMENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We operate our businesses principally through
two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic
business activities. Our reportable segments have been determined based on the nature of the potential products being developed.
We record discrete financial information for ESI and our chief operating decision maker reviews ESI&#8217;s operating results in
order to make decisions about resources to be allocated to the ESI segment and to assess its performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Aethlon&#8217;s revenue is generated primarily
from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead
to the ESI segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following tables set forth certain information regarding our
segments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Nine Months Ended December 31,</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2019</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 10pt">Revenues:</font></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">624,871</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">443,458</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total Revenues</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">624,871</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">443,458</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Operating Losses:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">(5,609,464</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">(4,125,758</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(15,931</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(19,039</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total Operating Loss</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(5,625,395</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(4,144,797</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Net Losses:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">(5,610,994</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">(4,575,811</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(15,931</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(19,039</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Net Loss Before Non-Controlling Interests</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(5,626,925</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(4,594,850</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Cash:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">12,131,396</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4,058,456</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">197</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">197</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total Cash</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">12,131,593</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,058,653</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Total Assets:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">12,669,552</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4,682,294</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">197</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">197</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total Assets</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">12,669,749</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,682,491</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Capital Expenditures:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">54,630</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">148,064</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Capital Expenditures</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">54,630</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">148,064</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Depreciation and Amortization:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">28,775</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">15,992</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total Depreciation and Amortization</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">28,775</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">15,992</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Interest Expense:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">(1,530</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">(54,232</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total Interest Expense</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(1,530</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(54,232</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206595284856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>13. COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">13. COMMITMENTS AND CONTINGENCIES</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">CONTRACTUAL OBLIGATIONS AND COMMITMENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been no material changes to our
contractual obligations and commitments outside the ordinary course of business from those disclosed under the heading &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations-Contractual Obligations and Commitments&#8221; as contained
in our Annual Report on Form 10-K for the year ended March 31, 2020, filed by us with the SEC on June 25, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 30, 2020, we entered into a Separation
Agreement with Timothy Rodell, M.D., our former Chief Executive Officer, or the Separation Agreement. Under this agreement, we
agreed to pay Dr. Rodell a total of $444,729 and to cover his medical insurance costs over a twelve-month period that began on
November 1, 2020, all in accordance with the terms of his employment agreement with the Company. We also paid Dr. Rodell accrued
vacation in the amount of $20,260 in November 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total expense accrued at December 31, 2020
relating to the Separation Agreement, was $400,578 (see Note 7 and Note 8).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 30, 2020, we entered into an Executive
Employment Agreement, or Agreement, with Charles J. Fisher Jr., M.D. The Agreement provides Dr. Fisher with (i) an initial annualized
base salary of $430,000 per year; (ii) eligibility for a discretionary annual cash bonus, (iii) eligibility for a one-time cash
bonus and additional equity grant upon attaining a specified performance goal, (iv) eligibility to participate in and receive additional
stock options or equity award grants under the Company&#8217;s equity incentive plans from time to time, in the discretion of the
Board or the Compensation Committee, and in accordance with the terms and conditions of such plans; and (iv) severance payments
in the event that Dr. Fisher&#8217;s employment is terminated by the Company for any reason other than Cause (as defined in the
Agreement) or if it is terminated by Dr. Fisher for Good Reason (as defined in the Agreement).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">LEASE COMMITMENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently lease approximately 2,600 square
feet of executive office space at 9635 Granite Ridge Drive, Suite 100, San Diego<i>, </i>California 92123 under a 39-month gross
plus utilities lease that commenced on December 1, 2014 and expires on August 31, 2021. The current rental rate under the lease
extension is $8,265 per month.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also rent approximately 1,700 square feet
of laboratory space at 11585 Sorrento Valley Road, Suite 109, San Diego, California 92121 at the rate of $6,148 per month on a
one-year lease that originally was to expire on November 30, 2020. In December 2020, we entered into a short-term lease extension
running from December 1, 2020 through the completion date of our construction of our planned new laboratory space which is adjacent
to our current laboratory.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rent expense, which is included in general
and administrative expenses, approximated $50,000 and $44,000 for the three month periods ended December 31, 2020 and 2019, respectively.
For the nine month periods ended December 31, 2020 and 2019, rent expense approximated $144,000 and $130,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Future minimum lease payments under the Granite Ridge Lease as of
December 31, 2020, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 84%"><font style="font-size: 10pt">January 1, 2021 through March 31, 2021</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">25,663</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">April 1, 2021 through August 31, 2021</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">43,670</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Total future minimum lease payments</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">69,333</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Less: discount</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(1,635</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total lease liability</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">67,698</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended March 31, 2020,
we adopted ASU Topic 842 on April 1, 2019 utilizing the alternative transition method allowed for under this guidance. As a result,
we recorded lease liabilities and right-of-use lease assets of $228,694 on our balance sheet as of April 1, 2019. The lease liabilities
represent the present value of the remaining lease payments of our corporate headquarters lease, discounted using our incremental
borrowing rate as of April 1, 2019. The corresponding right-of-use lease assets are recorded based on the lease liabilities and
the cumulative difference between rent expense and amounts paid under its corporate headquarters lease. We also elected the short-term
lease recognition exemption for its laboratory lease. For the laboratory lease that qualified as short-term, we did not recognize
right-of-use assets or lease liabilities at adoption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2020, we entered into an agreement
to lease approximately 2,823 square feet of office space and 1,807 square feet of laboratory space. The agreement carries a term
of 63 months and we will commence paying rent when we take occupancy of those spaces, which is expected to occur in the second
quarter of 2021. Upon taking occupancy of the space, we will record lease liabilities and right-of-use lease assets related to
this agreement on our balance sheet. We estimate that the present value of the contractual payments under the lease agreement to
be approximately $806,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the new lease agreement required
us to post a standby letter of credit in favor of the landlord in the amount of $46,726 in lieu of a security deposit. We arranged
for our bank to issue the standby letter of credit in the three months ended December 31, 2020 and transferred a like amount to
a restricted certificate of deposit which secured the bank&#8217;s risk in issuing that letter of credit. We have classified that
restricted certificate of deposit on our balance sheet as restricted cash .</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">LEGAL MATTERS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, claims are made against
us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent
uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from
selling one or more products or engaging in other activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The occurrence of an unfavorable outcome in
any specific period could have a material adverse effect on our results of operations for that period or future periods. We are
not presently a party to any pending or threatened legal proceedings.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206595193144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>14. SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">14. SUBSEQUENT EVENTS</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has evaluated events subsequent
to December 31, 2020 through the date that the accompanying condensed consolidated financial statements were filed with the SEC
for transactions and other events which may require adjustment of and/or disclosure in such financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2021, we hired two senior executives,
Guy Cipriani as Senior Vice President, Chief Business Officer, and Steven LaRosa, M.D., as Chief Medical Officer and entered into
employment agreements with each executive. Mr. Cipriani will oversee business development and partnerships, while also contributing
to fundraising and corporate development. Mr. Cipriani&#8217;s initial annual base salary is $340,000 and Mr. Cipriani also is
eligible for a discretionary annual cash bonus.&#160; Mr. Cipriani also is eligible for reimbursement of relocation expenses in
the aggregate amount of up to $75,000. &#160;Dr. LaRosa will be responsible for the clinical development of Aethlon's Hemopurifier&#174;,
including leading clinical operations and regulatory strategy. In addition to a one-time signing bonus of $100,000, subject to
repayment if Dr. LaRosa leaves Aethlon prior to two years with the Company, Dr. LaRosa&#8217;s initial annual base salary is $400,000.
Dr. LaRosa also is eligible for a discretionary annual cash bonus and relocation expense reimbursement of up to $50,000.&#160;
Upon commencement of employment each of Mr. Cipriani and Dr. LaRosa was granted an option to purchase 120,883 shares of the Company&#8217;s
Common Stock, with an exercise price equal to the fair market value on the date of grant, subject to a four-year vesting schedule
and other terms and conditions of the Company&#8217;s 2020 Equity Incentive Plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206592262936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Basis of Presentation and Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Basis of Presentation and Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated
financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP,
for interim financial information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission,
or SEC Regulation S-X. Accordingly, they should be read in conjunction with the audited financial statements and notes thereto
for the fiscal year ended March 31, 2020, included in the Company's Annual Report on Form 10-K filed with the SEC on June 25, 2020.
The accompanying unaudited condensed consolidated financial statements include the accounts of Aethlon Medical, Inc. and its majority-owned
subsidiary. All significant inter-company transactions and balances have been eliminated in consolidation. The unaudited condensed
consolidated financial statements contain all normal recurring accruals and adjustments that, in the opinion of management, are
necessary to present fairly the condensed consolidated financial statements as of and for the three and nine months ended December
31, 2020, and the condensed consolidated statement of cash flows for the nine months ended December 31, 2020. Estimates were made
relating to useful lives of fixed assets, impairment of assets, share-based compensation expense and accruals for clinical trial
and research and development expenses. Actual results could differ materially from those estimates. The accompanying condensed
consolidated balance sheet at March 31, 2020 has been derived from the audited consolidated balance sheet at March 31, 2020, contained
in the above referenced 10-K. The results of operations for the three and nine months ended December 31, 2020 are not necessarily
indicative of the results to be expected for the full year or any future interim periods.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Reclassifications</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior year balances within the unaudited
condensed consolidated financial statements have been reclassified to conform to the current year presentation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Restricted Cash</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To comply with the terms of our new laboratory
and office lease (see Note 13), we caused our bank to issue a standby letter of credit, or the L/C, in the amount of $46,726 in
favor of the landlord. The L/C is in lieu of a security deposit. In order to support the L/C, we agreed to have our bank withdraw
$46,726 from our operating accounts and to place that amount in a restricted certificate of deposit. We have classified that amount
as restricted cash, a long-term asset, on our balance sheet.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206667384472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. RESEARCH AND DEVELOPMENT EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock', window );">Research and Development expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development expenses in those
periods were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2019</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 67%"><font style="font-size: 10pt">Three months ended</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">461,176</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">218,571</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Nine months ended</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1,367,333</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">692,022</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature and amounts of capitalized costs of a research and development nature that were acquired in a transaction other than a business combination, the amount of such assets charged to expense during the period, and identification of the income statement caption in which the charges are included.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206595484472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. EQUITY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of RSU activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RSUs outstanding that have vested as of, and
are expected to vest subsequent to, December 31, 2020 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Number of RSUs</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 84%; padding-bottom: 1pt"><font style="font-size: 10pt">Expected to vest</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid">&#160;</td>
    <td style="width: 13%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">32,189</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">32,189</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206667341512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Due to related parties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amounts due to related parties were comprised
of the following items:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">December 31, <br />
2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">March 31, <br />
2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><font style="font-size: 10pt">Accrued Board fees</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">69,292</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">69,750</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Accrued vacation to all employees</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">62,454</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">41,957</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total due to related parties</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">131,746</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">111,707</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206688052120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Other Current Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other current liabilities were comprised of the following items:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">March 31,</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%"><font style="font-size: 10pt">Accrued separation expenses for former executive</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">400,578</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Accrued professional fees</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">460,119</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">472,420</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total other current liabilities</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">860,697</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">472,420</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206592257768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. STOCK COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Share-based compensation expense relating to RSUs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables summarize share-based
compensation expenses relating to RSUs and stock options and the effect on basic and diluted loss per common share during the three
and nine month periods ended December 31, 2020 and 2019:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Three Months <br />
Ended <br />
December 31, <br />
2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Three Months<br />
Ended<br />
December 31, <br />
2019</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Nine Months <br />
Ended <br />
December 31,<br />
2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Nine Months<br />
Ended <br />
December 31,<br />
2019</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 44%; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Vesting of stock options and restricted stock units</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">377,958</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">102,576</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">629,207</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">755,648</font></td>
    <td style="width: 1%; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Total stock-based compensation expense</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">377,958</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">102,576</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">629,207</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">755,648</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Weighted average number of common shares outstanding &#8211; basic and diluted</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">12,093,361</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,887,883</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">11,265,725</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,821,557</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Basic and diluted loss per common share attributable to stock-based compensation expense</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.03</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.04</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.06</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.41</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock', window );">Options outstanding that have vested and are expected to vest</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Options outstanding that were vested as of
December 31, 2020 and options that are expected to vest subsequent to December 31, 2020 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Number of<br />
Shares</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted<br />
Average<br />
Remaining<br />
Contractual<br />
Term in<br />
Years</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 58%"><font style="font-size: 10pt">Vested</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">34,509</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">32.53</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">5.84</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Expected to vest</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">567,814</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">1.51</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">9.67</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">602,323</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of stock option activity during the nine months ended
December 31, 2020 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Amount</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Range of<br />
Exercise Price</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted<br />
Average <br />
Exercise<br />
Price</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 53%"><font style="font-size: 10pt">Stock options outstanding at March 31, 2020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">51,124</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 16%; text-align: center"><font style="font-size: 10pt">$18.75 - $187.50</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">44.12</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(15,896</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt">$1.28</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.28</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">770,094</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><font style="font-size: 10pt">$1.28 &#8211; $2.45</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">1.45</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Cancelled/Expired</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(202,999</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 10pt">$1.28 - $187.50</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">6.76</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Stock options outstanding at December 31, 2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">602,323</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 10pt">$1.28 - $187.50</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">3.29</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Stock options exercisable at December 31, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">34,509</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center"><font style="font-size: 10pt">$1.28 - $187.50</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">32.53</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206595344328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of warrant activity during the nine months ended December
31, 2020 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Amount</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Range of<br />
Exercise<br />
Price</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted<br />
Average<br />
Exercise<br />
Price</b></font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 53%; padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Warrants outstanding at March 31, 2020</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2,021,368</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 16%; text-align: center"><font style="font-size: 10pt">$1.50 - $125.25</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">5.21</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Cancelled/Expired</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(29,395</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: center"><font style="font-size: 10pt">$90.75 &#8211; $135.00</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 1pt; text-align: right"><font style="font-size: 10pt">97.17</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Warrants outstanding at December 31, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,991,973</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center"><font style="font-size: 10pt">$1.50 &#8211; $99.00</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">5.23</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; text-indent: -10pt"><font style="font-size: 10pt">Warrants exercisable at December 31, 2020</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,991,973</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: center"><font style="font-size: 10pt">$1.50 &#8211; $99.00</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td>
    <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">5.23</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206670134776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. SEGMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following tables set forth certain information regarding our
segments:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">Nine Months Ended December 31,</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2020</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 10pt">2019</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 10pt">Revenues:</font></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 68%; padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">624,871</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">443,458</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total Revenues</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">624,871</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">443,458</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Operating Losses:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">(5,609,464</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">(4,125,758</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(15,931</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(19,039</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total Operating Loss</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(5,625,395</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(4,144,797</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Net Losses:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">(5,610,994</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">(4,575,811</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(15,931</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(19,039</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Net Loss Before Non-Controlling Interests</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(5,626,925</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(4,594,850</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Cash:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">12,131,396</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4,058,456</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">197</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">197</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total Cash</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">12,131,593</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,058,653</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Total Assets:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">12,669,552</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4,682,294</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">197</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">197</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total Assets</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">12,669,749</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,682,491</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Capital Expenditures:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">54,630</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">148,064</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Capital Expenditures</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">54,630</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">148,064</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Depreciation and Amortization:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">28,775</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">15,992</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total Depreciation and Amortization</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">28,775</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">15,992</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Interest Expense:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Aethlon</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">(1,530</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">(54,232</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 1pt; padding-left: 10pt"><font style="font-size: 10pt">ESI</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">&#8211;</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt"><font style="font-size: 10pt">Total Interest Expense</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(1,530</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(54,232</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206596810952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>13. COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Lease commitments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Future minimum lease payments under the Granite Ridge Lease as of
December 31, 2020, are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="width: 84%"><font style="font-size: 10pt">January 1, 2021 through March 31, 2021</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 13%; text-align: right"><font style="font-size: 10pt">25,663</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">April 1, 2021 through August 31, 2021</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">43,670</font></td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td><font style="font-size: 10pt">Total future minimum lease payments</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">&#160;</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">69,333</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">Less: discount</font></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: black 1pt solid"><font style="font-size: 10pt">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 10pt">(1,635</font></td>
    <td style="padding-bottom: 1pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #EEEEEE">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total lease liability</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">67,698</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206592270216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">On October 14, 2019, our Board of Directors approved a 1-for-15 reverse stock split. Accordingly, 15 shares of outstanding common stock then held by stockholders were combined into one share of common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=aemd_RestrictedCashMember', window );">Restricted Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,726<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=aemd_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=aemd_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206585797768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2. LOSS PER COMMON SHARE (Details- Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">2,626,485<span></span>
</td>
<td class="nump">3,779,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206592186200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. RESEARCH AND DEVELOPMENT EXPENSES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 461,176<span></span>
</td>
<td class="nump">$ 218,571<span></span>
</td>
<td class="nump">$ 1,367,333<span></span>
</td>
<td class="nump">$ 692,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206588100776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. CONVERTIBLE NOTES PAYABLE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 992,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Total interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (447,011)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206595440648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. EQUITY TRANSACTIONS (Details - RSU's outstanding) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSU's vested</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber', window );">RSU's expected to vest</a></td>
<td class="nump">32,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Total RSU's outstanding</a></td>
<td class="nump">32,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of RSU's expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206589972072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. EQUITY TRANSACTIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments to satify tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,391<span></span>
</td>
<td class="nump">$ 38,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | 2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSU's granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Non Employee Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_GrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value per share</a></td>
<td class="nump">$ 1.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSU's granted</a></td>
<td class="nump">24,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_RsusExchangedForCommonStockRsusExchanged', window );">RSU's exchanged for common stock, RSU's exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,189<span></span>
</td>
<td class="nump">29,866<span></span>
</td>
<td class="nump">29,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_RsusExchangedForCommonStockCommonStockIssued', window );">RSU's exchanged for common stock, Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,189<span></span>
</td>
<td class="nump">29,866<span></span>
</td>
<td class="nump">29,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Stock cancelled in exchange for withholding tax, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,876<span></span>
</td>
<td class="nump">11,947<span></span>
</td>
<td class="nump">11,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments to satify tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,802<span></span>
</td>
<td class="nump">$ 16,128<span></span>
</td>
<td class="nump">$ 24,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Non Employee Directors [Member] | 2010 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSU's granted</a></td>
<td class="nump">23,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Non Employee Directors [Member] | 2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSU's granted</a></td>
<td class="nump">929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aemd_CommonStockSalesAgrMember', window );">Common Stock Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,260,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued new, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,685,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_SaleOfStockPricePerShare1', window );">Stock sale - average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=aemd_CommonStockSalesAgrMember', window );">Common Stock Sales Agreement [Member] | H.C. Wainwright [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Payment of commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_GrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant date fair value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_GrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RsusExchangedForCommonStockCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>RSU's exchanged for common stock, Common stock issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RsusExchangedForCommonStockCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RsusExchangedForCommonStockRsusExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>RSU's exchanged for common stock, RSU's exchanged</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RsusExchangedForCommonStockRsusExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_SaleOfStockPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock sale - average price per share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_SaleOfStockPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aemd_Equity2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aemd_Equity2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=aemd_NonEmployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=aemd_NonEmployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aemd_Plan2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aemd_Plan2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=aemd_CommonStockSalesAgrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=aemd_CommonStockSalesAgrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=aemd_WainwrightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=aemd_WainwrightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206687528120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>7. RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 131,746<span></span>
</td>
<td class="nump">$ 111,707<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accrued board fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">69,292<span></span>
</td>
<td class="nump">69,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued vacation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 62,454<span></span>
</td>
<td class="nump">$ 41,957<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206592091688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. RELATED PARTY TRANSACTIONS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedDirectorFees', window );">Accrued director fees</a></td>
<td class="nump">$ 69,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aemd_TimothyRodellMember', window );">Timothy Rodell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoninterestExpenseDirectorsFees', window );">Director fees</a></td>
<td class="nump">$ 20,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_AccruedDirectorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued director fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_AccruedDirectorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseDirectorsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseDirectorsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aemd_TimothyRodellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aemd_TimothyRodellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206592270216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>8. OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AccruedSeparationExpenses', window );">Accrued separation expenses for former executive</a></td>
<td class="nump">$ 400,578<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">460,119<span></span>
</td>
<td class="nump">472,420<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">$ 860,697<span></span>
</td>
<td class="nump">$ 472,420<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_AccruedSeparationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued separation expenses for former executive</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_AccruedSeparationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206585684536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. STOCK COMPENSATION (Details - Stock compensation) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 377,958<span></span>
</td>
<td class="nump">$ 102,576<span></span>
</td>
<td class="nump">$ 629,207<span></span>
</td>
<td class="nump">$ 755,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding- basic and diluted</a></td>
<td class="nump">12,093,361<span></span>
</td>
<td class="nump">2,887,883<span></span>
</td>
<td class="nump">11,265,725<span></span>
</td>
<td class="nump">1,821,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per common share attributable to stock-based compensation expense</a></td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (2.52)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=aemd_VestingOptionsMember', window );">Vesting of stock options and restricted stock units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 377,958<span></span>
</td>
<td class="nump">$ 102,576<span></span>
</td>
<td class="nump">$ 629,207<span></span>
</td>
<td class="nump">$ 755,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=aemd_ShareBasedCompensationMember', window );">Share-Based Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per common share attributable to stock-based compensation expense</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=aemd_VestingOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=aemd_VestingOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=aemd_ShareBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=aemd_ShareBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206585724888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. STOCK COMPENSATION (Details - Options vested and expected to vest) - Options [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested</a></td>
<td class="nump">34,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options expected to vest</a></td>
<td class="nump">567,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Total options outstanding</a></td>
<td class="nump">602,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price options vested | $ / shares</a></td>
<td class="nump">$ 32.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price options expected to vest | $ / shares</a></td>
<td class="nump">$ 1.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term options vested</a></td>
<td class="text">5 years 10 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term options expected to vest</a></td>
<td class="text">9 years 8 months 2 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206585756744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. STOCK COMPENSATION (Details - Option activity) - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options Outstanding, beginning balance | shares</a></td>
<td class="nump">51,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised | shares</a></td>
<td class="num">(15,896)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted | shares</a></td>
<td class="nump">770,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Stock options cancelled/forfeited | shares</a></td>
<td class="num">(202,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding, ending balance | shares</a></td>
<td class="nump">602,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable | shares</a></td>
<td class="nump">34,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_RangeOfExercisePricesOptionBeginning', window );">Range of exercise prices, Option beginning</a></td>
<td class="text">$18.75 - $187.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_RangeOfExercisePricesOptionExercised', window );">Range of exercise prices, Option Exercised</a></td>
<td class="text">$1.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_RangeOfExercisePricesOptionGranted', window );">Range of exercise prices, Option Granted</a></td>
<td class="text">$1.28 - $2.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_RangeOfExercisePricesOptionCancelledexpired', window );">Range of exercise prices, Option cancelled/expired</a></td>
<td class="text">$1.28 - $187.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_RangeOfExercisePricesOptionEnding', window );">Range of exercise prices, Option ending</a></td>
<td class="text">$1.28 - $187.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_RangeOfExercisePricesOptionExercisable', window );">Range of exercise prices, Option exercisable</a></td>
<td class="text">$1.28 - $187.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Weighted Average Exercise Price, beginning price | $ / shares</a></td>
<td class="nump">$ 44.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">1.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">1.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled/Forfeited, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">6.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding Weighted Average Exercise Price, ending price | $ / shares</a></td>
<td class="nump">3.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 32.53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfExercisePricesOptionBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices, Option beginning</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfExercisePricesOptionBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfExercisePricesOptionCancelledexpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices, Option cancelled/expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfExercisePricesOptionCancelledexpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfExercisePricesOptionEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices, Option ending</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfExercisePricesOptionEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfExercisePricesOptionExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise prices, Option exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfExercisePricesOptionExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfExercisePricesOptionExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfExercisePricesOptionExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfExercisePricesOptionGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfExercisePricesOptionGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206592369576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. STOCK COMPENSATION (Details- Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">$ 377,958<span></span>
</td>
<td class="nump">$ 102,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 629,207<span></span>
</td>
<td class="nump">$ 755,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="nump">$ 2,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 5 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments to satify tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,391<span></span>
</td>
<td class="nump">$ 38,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aemd_DrRodellMember', window );">Dr. Rodell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued for exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments to satify tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=aemd_Equity2020PlanMember', window );">2020 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Options authorized</a></td>
<td class="nump">1,842,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,842,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_OptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued for exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aemd_DrRodellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=aemd_DrRodellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=aemd_Equity2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=aemd_Equity2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206589922456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. WARRANTS (Details) - Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_NumberOfWarrantsAbstract', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding, Beginning | shares</a></td>
<td class="nump">2,021,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Warrants Cancelled/Expired | shares</a></td>
<td class="num">(29,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants Outstanding, Ending | shares</a></td>
<td class="nump">1,991,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber', window );">Number of Warrants Exercisable, Ending | shares</a></td>
<td class="nump">1,991,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_WarrantsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of Exercise Price Outstanding, Beginning</a></td>
<td class="text">$1.50 - $125.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_RangeOfWeightedAverageExercisePriceExpired', window );">Range of Exercise Price Cancelled/Expired</a></td>
<td class="text">$90.75 - $135.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_RangeOfWeightedAverageExercisePriceOutstandingEnding', window );">Range of Exercise Price Outstanding, Ending</a></td>
<td class="text">$1.50 - $99.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_RangeOfWeightedAverageExercisePriceExercisable', window );">Range of Exercise Price Exercisable</a></td>
<td class="text">$1.50 - $99.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price Outstanding, Beginning | $ / shares</a></td>
<td class="nump">$ 5.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Cancelled/Expired | $ / shares</a></td>
<td class="nump">97.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price Outstanding, Ending | $ / shares</a></td>
<td class="nump">5.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercisable | $ / shares</a></td>
<td class="nump">$ 5.23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_NumberOfWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants [Abstract}</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_NumberOfWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Outstanding, Beginning</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfWeightedAverageExercisePriceExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfWeightedAverageExercisePriceExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfWeightedAverageExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfWeightedAverageExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_RangeOfWeightedAverageExercisePriceOutstandingEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Outstanding, Ending</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_RangeOfWeightedAverageExercisePriceOutstandingEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercisable, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants - Weighted Average Exercise Price Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOtherThanOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_WarrantsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of warrants [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_WarrantsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206589130696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aemd_MelanomaCancerContractPhase2Member', window );">Melanoma Cancer Contract Phase 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AwardContractAmount', window );">Award Contract amount</a></td>
<td class="nump">$ 1,860,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Contract revenue</a></td>
<td class="nump">436,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">318,578<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aemd_BreastCancerGrantMember', window );">Breast Cancer Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Contract revenue</a></td>
<td class="nump">188,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aemd_SubawardWithUniversityOfPittsburghMember', window );">Subaward with University of Pittsburgh [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_AwardContractAmount', window );">Award Contract amount</a></td>
<td class="nump">$ 256,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_AwardContractAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_AwardContractAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aemd_MelanomaCancerContractPhase2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aemd_MelanomaCancerContractPhase2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aemd_BreastCancerGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aemd_BreastCancerGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aemd_SubawardWithUniversityOfPittsburghMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aemd_SubawardWithUniversityOfPittsburghMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206590105992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. SEGMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 624,871<span></span>
</td>
<td class="nump">$ 413,458<span></span>
</td>
<td class="nump">$ 624,871<span></span>
</td>
<td class="nump">$ 443,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Losses</a></td>
<td class="num">(2,443,588)<span></span>
</td>
<td class="num">(876,406)<span></span>
</td>
<td class="num">(5,625,395)<span></span>
</td>
<td class="num">(4,144,797)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Losses</a></td>
<td class="num">(2,444,390)<span></span>
</td>
<td class="num">(820,939)<span></span>
</td>
<td class="num">(5,626,925)<span></span>
</td>
<td class="num">(4,594,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">12,131,593<span></span>
</td>
<td class="nump">4,058,653<span></span>
</td>
<td class="nump">12,131,593<span></span>
</td>
<td class="nump">4,058,653<span></span>
</td>
<td class="nump">$ 9,604,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">12,669,749<span></span>
</td>
<td class="nump">4,682,491<span></span>
</td>
<td class="nump">12,669,749<span></span>
</td>
<td class="nump">4,682,491<span></span>
</td>
<td class="nump">$ 10,387,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital Expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,630<span></span>
</td>
<td class="nump">148,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,775<span></span>
</td>
<td class="nump">15,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest Expense</a></td>
<td class="num">(802)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="num">(1,530)<span></span>
</td>
<td class="num">(54,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aemd_AethlonMember', window );">Aethlon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624,871<span></span>
</td>
<td class="nump">443,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,609,464)<span></span>
</td>
<td class="num">(4,125,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,610,994)<span></span>
</td>
<td class="num">(4,575,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">12,131,396<span></span>
</td>
<td class="nump">4,058,456<span></span>
</td>
<td class="nump">12,131,396<span></span>
</td>
<td class="nump">4,058,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">12,669,552<span></span>
</td>
<td class="nump">4,682,294<span></span>
</td>
<td class="nump">12,669,552<span></span>
</td>
<td class="nump">4,682,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital Expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,630<span></span>
</td>
<td class="nump">148,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,775<span></span>
</td>
<td class="nump">15,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,530)<span></span>
</td>
<td class="num">(54,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=aemd_ESIMember', window );">ESI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,931)<span></span>
</td>
<td class="num">(19,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,931)<span></span>
</td>
<td class="num">(19,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital Expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aemd_AethlonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aemd_AethlonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=aemd_ESIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=aemd_ESIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206592094568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>13. COMMITMENTS AND CONTINGENCIES (Details - Rent) - 9635 Granite Ridge Drive [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating lease payments year 2020</a></td>
<td class="nump">$ 25,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Operating lease payments year 2021</a></td>
<td class="nump">43,670<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_LesseeOperatingLeaseLiabilityPaymentsGross', window );">Total lease payments</a></td>
<td class="nump">69,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Discount</a></td>
<td class="num">(1,635)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease liability</a></td>
<td class="nump">$ 67,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_LesseeOperatingLeaseLiabilityPaymentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total lease payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_LesseeOperatingLeaseLiabilityPaymentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_GraniteRidgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=aemd_GraniteRidgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140206585530360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>13. COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 02, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 131,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">$ 44,000<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use lease asset</a></td>
<td class="nump">64,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 228,694<span></span>
</td>
<td class="nump">$ 136,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 228,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aemd_SeparationAgreementMember', window );">Separation Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">400,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=aemd_LeaseAgreementMember', window );">Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payment</a></td>
<td class="nump">806,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aemd_LetterOfCredit', window );">Letter of credit</a></td>
<td class="nump">46,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=aemd_TimothyRodellMember', window );">Timothy Rodell [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 444,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">$ 20,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=aemd_CharlesJFisherJrMember', window );">Charles J. Fisher Jr [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Annual Base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aemd_LetterOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">aemd_LetterOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>aemd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aemd_SeparationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aemd_SeparationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=aemd_LeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=aemd_LeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=aemd_TimothyRodellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=aemd_TimothyRodellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=aemd_CharlesJFisherJrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=aemd_CharlesJFisherJrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M<VAE971S+W-H965T,RYX;6R-E6M/VS 4AO^*%4T:2%MS:U- ::32=@*)E8K
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MM2Q5,ELW6F1#'(9\N$C2?'!YOO[;37EY7JSJ+,W531E4J\4B*?_W3F7%T\4
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M.CA^_E3H>UU9:@$4>'1-D" \)R0?RRK\]$V2,B76S]7P8'=X2*']V5#^)MJ
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M'3X+&$O^G^@ESF?JL%P3T/3]<_C8Z.]2HY\EW;%\((M>X#%0=F.7CVZX]+%
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M\AIJ=[N\S OV6Z*PA!H+/'JP]^+9CJKD!5GY4KLUOY0Z=W7M"OY(;Q^8BF[
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MF0ROKV^'D_'%.9V'U/9]A;%QZ_<A;=)CX ,?#H%U#&IJ-TZ_Q\6CTZ/.F;^
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MD=>P9C#NT8O&RG#(MV0+!T?]0@5&AE32!%P#(X:U-7XBJU)))$:A>^Z$<!;
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MTKZ$VTNQ5-6N[8ZW#<$GKP_VA?B0+J"PBV_G]@4#,#1(Z:U&0<I0P2G8NU$
MVBG'RCC[7:"/7+NF];K0[-^\FAS,/@QZVF:FS<7O!G=HJKT-#FY:KQY*!S1;
MHZ*#5Z1112Y7*>55GNMD&C@K<I;?1ER3%'1I!2YY37B\GHQ3) ;2)/[&+0B!
MGN=&=>FGBUU#0085LN%.\+98Z5(AK5CY\%#KYUW;&.R(?VMNS#I&P]Z.YB<C
M^K]IL?;0O\/\WU18QW9_K?@&842VU]C.MF=VBC(5(98>)QUT[28%RKU$HY,.
MJ2S"MHD&8IU58O)D.AX<'NY1J!0R1_!V'+=Q5@_S&H+SZ++;0>=?)9:PSS1
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M965T<R]S:&5E=#(T+GAM;'V47V_:,!# W_D4ITR:-@D1"+2C#")!RS0>VG5
M.TW3'DQR(5$=.[4=:+_]SD[(V%1X(;Y_O[LS=Q[OI7K2*:*!EYP+/?%28XJ1
M[^LHQ9SICBQ0D"61*F>&1+7U=:&0Q2XHYW[0[5[Z.<N$%XZ=[EZ%8UD:G@F\
M5Z#+/&?J=89<[B=>SSLHEMDV-5;AA^.";7&%YJ&X5R3Y#27.<A0ZDP(4)A-O
MVAO-!M;?.3QFN-='9["=;*1\LL(BGGA=6Q!RC(PE,/KL\!HYMR JX[EF>DU*
M&WA\/M"_N-ZIEPW3>"WYCRPVZ<0;>A!CPDINEG+_%>M^+BPODER[7]A7OOW
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M29C?M)C#P$RYN@#G&\9DOU &AA'\[']02P,$%     @ [HE*4FR/>"[0 @
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MGP2X3E#K*\;D8:(%VG]3^ =02P,$%     @ [HE*4C",'#4" P  YP@  !D
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MC?#;=OBONZ@5?O<Q^.>/<;_O#(>C8[@F2R6O%Y37"TK\F0W^%OA-=B[!@:"
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M>?1/+K<$>X0I _E^3:EXOU'G__PCU_1?4$L#!!0    ( .Z)2E)<IC^^4 (
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MS*SN&>N)H ?=%&VHD"V6'NYEFXV9 LC]+:7B=:(<M(W[[%]02P,$%     @
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M!<PY$KL\I_S'+61L/W:P<UAX3-<;J1>\R6A+U[  ^?=VSM7,,UJ2-(="I*Q
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M7O3XQ4"R5=Z3/C.I.MS\,5+?191K _5^P9C<#72 ZDMK^!M02P,$%     @
M[HE*4L>3M&U" P  !@P  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL
MI9;?;]HP$,?_%2OJPR:U)$X:(!4@0=MI>VB'Z#8>ICV8Y("HB<UL\V/2_OC9
M#H1T!%/:E\1V?-_[G&.?K[-F_%G, 23:Y!D576<NY>+&=44\AYR(!EL 55^F
MC.=$JBZ?N6+!@23&*,]<W_.:;DY2ZO0Z9FS(>QVVE%E*8<B16.8YX7\&D+%U
MU\'.;F"4SN92#[B]SH+,X GD]\60JYY;JB1I#E2DC"(.TZ[3QS<#W-0&9L:/
M%-:BTD8ZE ECS[KS)>DZGB:"#&*I)8AZK> 6LDPK*8[?6U&G]*D-J^V=^B<3
MO IF0@3<LFR<)G+>==H.2F!*EID<L?5GV 84:KV89<(\T;J8VU23XZ60+-\:
M*X(\I<6;;+8+43$(O",&_M; -]R%(T-Y1R3I=3A;(ZYG*S7=,*$::P674OU7
MGB177U-E)WO8:Z!Q?S3J/WY[0A_N0)(T$Q_1%1H3S@F5 OU\@'P"_%?'E<J?
MMG+CK?:@T/:/:$?H@5$Y%^B>)I"\M'<59PGK[V 'OE7P#N(&"O E\CW?NT N
M$G/"011/BWY0+D9@](,C^H]+'2EBTS)ZB^AU*7IM1*]?+8J^+J60A"8IG5VB
M <Q22E43_45UD10+4_@(C0]]TE8]M08X:+8[[JH&+BSAPG/A;@F-U2&!Q+W?
M+%(.B94K/."Z\J,@"NNQFB56\UUK=F_>5K#F 1B.(ARU@GJR5DG6.I?L?@,\
M3@699/ JLM9Y9.V2K&W=O&.3@-3OZJ^ JX2ZXP(TY&D,EIT<E1XB:^PC0I6L
M"OVE\I'M7!>Z7?\"-T)/I9X+[(<-/[008V^?WKPW,1_L\MKT9M>^B+Q&*S3
M0=CP/!MP)1_C]R]RL<MJD>WJY1)'T0E@?P_LOPFX<BQJ0>VJKP?=)W<<6"5/
M')#C67E_T]0&4GAM5\ZSVKVX_C#C_:V![=?&*=JZ-'T"M' 854"C5@.WCI#N
MKQ!LOT/.6M<R/YY@#0]8U:(>R9!X?ZU@^[UR"K6R9T\C-NO^^_^(;J4TRX'/
M3 $J4,R65!956CE:%KG]HK3;3R\JY ?"U9X4*(.I,M6IQT&\*#J+CF0+4^A-
MF%1EHVG.5:$.7$]0WZ>,R5U'.RA+_]X_4$L#!!0    ( .Z)2E*$1B;'T0(
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MX:RJX=5 T&-9-W=4R"I<=F/Y[@%3&^3ZGE)Q'BA \Y(.?@-02P,$%     @
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MIEP9@Y7)"WKG!E_6+T(=:%&Y6[@0VMQIU]V81Q2D76#F5T+HU\!>[/99SOX
M4$L#!!0    ( .Z)2E(655/$&00  "$0   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0X+GAM;*586V_B.!3^*U:T#S/2EL0A%T 4B5M:1@M3E<[LPVH?3'*
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MD*U/^KB5/3PP)2#?KRD5'P-%4/PK,/@?4$L#!!0    ( .Z)2E)6P1^Y. (
M ( *   -    >&PO<W1Y;&5S+GAM;-5676O;,!3]*T(=HX51V\F2T=4V;(7"
M8"N%YF%O1;&O;8$^/%G.G/[ZZ<-QG+09H0];^F+=>^[5N4=7PE+<Z#6#API
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ [HE*4AKL1W3O P  ,PX  !@              ("!#@@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .Z)2E).TS>.% 8  .L6   8
M              " @3,,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " #NB4I29IW?O($"  "5!@  &               @(%]$@  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ [HE*4N0JQVFZ!0
M3Q4  !@              ("!-!4  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( .Z)2E).4W*X2 H  #M$   8              " @20;
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #NB4I24J-K
M.P<'  !S&@  &               @(&B)0  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ [HE*4I5Z!7&  @  'P8  !@
M ("!WRP  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( .Z)
M2E)63#5L6Q(  +$L   8              " @94O  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " #NB4I2K3NO:HD#   '"   &
M        @($F0@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ [HE*4H9+=&KS @  DP8  !D              ("!Y44  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #NB4I20,(('U8"   6!0
M&0              @($/20  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( .Z)2E+"_'6ZG0,   T(   9              " @9Q+  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ [HE*4B9[C:[B
M"@  XAT  !D              ("!<$\  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " #NB4I2"0:(M74#  ![!P  &0
M@(&)6@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( .Z)
M2E*/<Y& G0(  )0%   9              " @35>  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ [HE*4OTMG(1:"   .!4  !D
M         ("!"6$  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " #NB4I288'"VMD"  !:!@  &0              @(&::0  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( .Z)2E+F%LJ.VP<  . 2
M   9              " @:IL  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ [HE*4G^E!0K>!   ( L  !D              ("!O'0
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #NB4I25I#.
MPWT+  !3&P  &0              @('1>0  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( .Z)2E*WM0%&#@4   @+   9
M  " @86%  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M[HE*4@-CD.U_!@  RP\  !D              ("!RHH  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " #NB4I21;S!:GX"  !"!0  &0
M            @(& D0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( .Z)2E)&#DB <P(  !0%   9              " @364  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ [HE*4J86UAR3 @
M6@4  !D              ("!WY8  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " #NB4I2$(O&F:0"  " !0  &0              @(&I
MF0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( .Z)2E)/
M_VW&C00  (X+   9              " @82<  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ [HE*4FR/>"[0 @  $@8  !D
M     ("!2*$  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M" #NB4I23018!(H#  !&"   &0              @(%/I   >&PO=V]R:W-H
M965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( .Z)2E)RM\RPO0(  *@%   9
M              " @1"H  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L!
M A0#%     @ [HE*4J=BVW;) @  ,@8  !D              ("!!*L  'AL
M+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #NB4I2&#T@ICT"
M   -!0  &0              @($$K@  >&PO=V]R:W-H965T<R]S:&5E=#,R
M+GAM;%!+ 0(4 Q0    ( .Z)2E*31]"8@0(  *<&   9              "
M@7BP  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ [HE*
M4C",'#4" P  YP@  !D              ("!,+,  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " #NB4I20W58 $$"   <!0  &0
M        @(%IM@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( .Z)2E*^"W7!JP0  / 2   9              " @>&X  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ [HE*4ERF/[Y0 @  "08
M !D              ("!P[T  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " #NB4I2]&$F>3$"  #/!   &0              @(%*P
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( .Z)2E*V/]33
M<0(  -T%   9              " @;+"  !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ [HE*4@[3Z()] P  Q L  !D
M ("!6L4  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #N
MB4I2YJ2QH\\"   5"   &0              @($.R0  >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( .Z)2E*:PRWJU@,  "</   9
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M970T-BYX;6Q02P$"% ,4    " #NB4I2QZI65V$"  "B!0  &0
M    @(']WP  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M .Z)2E(655/$&00  "$0   9              " @97B  !X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ [HE*4E;!'[DX @  @ H   T
M             ( !Y>8  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #NB4I2
MEXJ[',     3 @  "P              @ %(Z0  7W)E;',O+G)E;'-02P$"
M% ,4    " #NB4I28,TM T@$  !?(   #P              @ $QZ@  >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ [HE*4I(LH):X 0  YQP  !H
M         ( !INX  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ [HE*4HQ/ZH^Z 0  [AP  !,              ( !EO   %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     #@ .  _#P  @?(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>131</ContextCount>
  <ElementCount>284</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>30</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/ReconciliationOfCashCashEquivalentsAndRestrictedCash</Role>
      <ShortName>RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>1. NATURE OF BUSINESS AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - 2. LOSS PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/LossPerCommonShare</Role>
      <ShortName>2. LOSS PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - 3. RESEARCH AND DEVELOPMENT EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses</Role>
      <ShortName>3. RESEARCH AND DEVELOPMENT EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - 4. RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/RecentAccountingPronouncements</Role>
      <ShortName>4. RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE, NET</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlonmedical.com/role/ConvertibleNotesPayableNet</Role>
      <ShortName>5. CONVERTIBLE NOTES PAYABLE, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - 6. EQUITY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/EquityTransactions</Role>
      <ShortName>6. EQUITY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - 7. RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/RelatedPartyTransactions</Role>
      <ShortName>7. RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - 8. OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/OtherCurrentLiabilities</Role>
      <ShortName>8. OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - 9. STOCK COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensation</Role>
      <ShortName>9. STOCK COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - 10. WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/Warrants</Role>
      <ShortName>10. WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - 11. GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognition</Role>
      <ShortName>11. GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - 12. SEGMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/Segments</Role>
      <ShortName>12. SEGMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CommitmentsAndContingencies</Role>
      <ShortName>13. COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - 14. SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/SubsequentEvents</Role>
      <ShortName>14. SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationPolicies</Role>
      <ShortName>1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - 3. RESEARCH AND DEVELOPMENT EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables</Role>
      <ShortName>3. RESEARCH AND DEVELOPMENT EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/ResearchAndDevelopmentExpenses</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - 6. EQUITY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/EquityTransactionsTables</Role>
      <ShortName>6. EQUITY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/EquityTransactions</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - 7. RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>7. RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/RelatedPartyTransactions</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - 8. OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>8. OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - 9. STOCK COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationTables</Role>
      <ShortName>9. STOCK COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/StockCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - 10. WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/WarrantsTables</Role>
      <ShortName>10. WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/Warrants</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - 12. SEGMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/SegmentsTables</Role>
      <ShortName>12. SEGMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/Segments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>13. COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>1. NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/NatureOfBusinessAndBasisOfPresentationPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - 2. LOSS PER COMMON SHARE (Details- Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/LossPerCommonShareDetails-Narrative</Role>
      <ShortName>2. LOSS PER COMMON SHARE (Details- Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/LossPerCommonShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - 3. RESEARCH AND DEVELOPMENT EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>3. RESEARCH AND DEVELOPMENT EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/ResearchAndDevelopmentExpensesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - 5. CONVERTIBLE NOTES PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://aethlonmedical.com/role/ConvertibleNotesPayableDetailsNarrative</Role>
      <ShortName>5. CONVERTIBLE NOTES PAYABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/ConvertibleNotesPayableNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - 6. EQUITY TRANSACTIONS (Details - RSU's outstanding)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/EquityTransactionsDetails-RsusOutstanding</Role>
      <ShortName>6. EQUITY TRANSACTIONS (Details - RSU's outstanding)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/EquityTransactionsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - 6. EQUITY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/EquityTransactionsDetailsNarrative</Role>
      <ShortName>6. EQUITY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/EquityTransactionsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - 7. RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>7. RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - 7. RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>7. RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - 8. OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/OtherCurrentLiabilitiesDetails</Role>
      <ShortName>8. OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/OtherCurrentLiabilitiesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - 9. STOCK COMPENSATION (Details - Stock compensation)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationDetails-StockCompensation</Role>
      <ShortName>9. STOCK COMPENSATION (Details - Stock compensation)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/StockCompensationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - 9. STOCK COMPENSATION (Details - Options vested and expected to vest)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationDetails-OptionsVestedAndExpectedToVest</Role>
      <ShortName>9. STOCK COMPENSATION (Details - Options vested and expected to vest)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/StockCompensationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - 9. STOCK COMPENSATION (Details - Option activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationDetails-OptionActivity</Role>
      <ShortName>9. STOCK COMPENSATION (Details - Option activity)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/StockCompensationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - 9. STOCK COMPENSATION (Details- Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/StockCompensationDetails-Narrative</Role>
      <ShortName>9. STOCK COMPENSATION (Details- Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/StockCompensationTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - 10. WARRANTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/WarrantsDetails</Role>
      <ShortName>10. WARRANTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/WarrantsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - 11. GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognitionDetailsNarrative</Role>
      <ShortName>11. GOVERNMENT CONTRACTS AND GRANTS AND RELATED REVENUE RECOGNITION (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/GovernmentContractsAndGrantsAndRelatedRevenueRecognition</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - 12. SEGMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/SegmentsDetails</Role>
      <ShortName>12. SEGMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/SegmentsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Details - Rent)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CommitmentsAndContingenciesDetails-Rent</Role>
      <ShortName>13. COMMITMENTS AND CONTINGENCIES (Details - Rent)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="aemd-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - 13. COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>13. COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://aethlonmedical.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aemd-20201231.xml</File>
    <File>aemd-20201231.xsd</File>
    <File>aemd-20201231_cal.xml</File>
    <File>aemd-20201231_def.xml</File>
    <File>aemd-20201231_lab.xml</File>
    <File>aemd-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001683168-21-000475-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-21-000475-xbrl.zip
M4$L#!!0    ( .Z)2E*;S!\LFH0  -$P!@ 1    865M9"TR,#(P,3(S,2YX
M;6SLO6UWXDB2*/S]GG/_@Y[:GKW=YV 7$N*M:F;NH6Q7M6>J;*_MZMZY7_8(
M2$#30F+T8A?SZY^(R$PI!0(C$"!L]>Z4;9 R(R,CXRWCY<__]\?4T9Z8']B>
M^Y=W^GG]G<;<@3>TW?%?WGU_..L]7%Q?O]/^[U__]__2X+\__W]G9]IGFSG#
M#]JE-SB[=D?>1^W&FK(/VA?F,M\*/?^C]IOE1/B)]]EVF*]=>-.9PT(&7_"9
M/FC-\U9?.SO;8-C?F#OT_._WU_&PDS"<?7C__OGY^=SUGJQGS_\C.!]XT\W&
M>_ B?\#BP2P63AS/_9]_-?YD7!IUHZX;#?W\QPA6<6F%\ !\IL-7=0/_Z3[J
MC0_-U@=#_W\;SA9:813$L]5_=.HP!_S'7__SC[[OV!_P7PUVP@T^_ CLO[Q3
M5OC<./?\\7MX1W__W]^^/@PF;&J=V6X06NZ O9-O.;;[1]9[>K?;?4_?RD>7
MGL3)Y1R-]_AUWPJ2D1' -<\O00+?#L/X!?7AYGO^9>I1._/1%G_4EH\.V<)S
M 1N<C[VG]_#%>]RUL[I^UM#EXSX;K02Y]1Z^E0_:@6<:>GO=^O@3\H4H.!M;
MUBQ^860%?7I8?)$!#'SC>PX+,M^A;S)><CW7C:;9< U#_WTXG['W\- 9/,5\
M>Q"_]_)+Z1< !OPX&SKZ)@.Z@1>YH3_/WA+Q9<9K@1\N3P,?9CQJL>DP?E:<
MT2D;V@/+P:/^7I[4=_(,(MU^".ATW+.11B3_84*$@&.=)4<[&+X37^/R_O(N
ML)$[O=/>RZ'XF1QX;LA^A)H-</2"VQ'!J!MGR9SQH\P-[7 >?QI_;@_QFY$-
M+) @8ZFMD?BZN/[[N[\B2^AT#*.K__G]XLO)=.\SYQ.SS6!;O6$&%'1"P[\F
M"XBG$-\LCI\:27XH\+$:29]];PHX[I[53=C+T*/?3Q%A@!0_1.;_UV0Y<J3D
MNZ770$XE+Z7P++\I$L]X8"2>3Y0P53S+Y>3"\R(]%XOG^-#7&Z>'V]2AIP7L
M\]!G$>/_"(GX/_<L"$'@A&SX$'J#/[Z[=AC</WS_QJ9]YA\-K0D5LO&4*?B(
MOQH",#]FCCVP0PZK-K3A2:XIB\5]Z#U;_O 1Y$COAQV\^ZO\>.V:__P^<W@5
MM/?9L+WN<U:13:G(YK!ZPP(+J;?.&O7_&41!Z$W_!^S'J><22AXLT)=[8_]U
MD,%#U _LH6WY<US7[8B6R$D"E=8/*Q=^BBR$MO2 *M%F)"0?^-VRW6??'D_"
MBK1>(*U-P "K#J8 0Y#Y,R"/.7I#E-D7L5W1\R8BL3<@VSJXL^96WV$]=PB?
M^!$;?K6MONW8H<V"UT&]]\P!; [OD'0>?<L-K$$(#Z2EY>;H>*VB,VVB5'1R
MTG2R1RMM-3]YTU11/AHX"J^H:*!4-' <;XU0@W\#"]1VQ[<S1-8K(84;*XQ\
M4(&O?LS@*U4-S5KM*:JB>_<V9WGU*Y(I \F<U 6%))F'B>6S3U; AA@: !BV
M$)NOG736K;KB.CFY3D5"92*AT^)"4O<E[Q?GY*^#<%9<*RRML^(VFYC'%7F\
M,A-X Y;P!K:[8@1Y?2054;P*[\<*-E_M[EMA[K];O@\3ONJM3JVQ8N^;L/>*
M+%XW@Z_V]_6S>.$5ZO%,@=>QU9@[Q/#]3U%@NRP('OAP@>(02BVX8O<YR>7J
MX?KMD$J\V(I,<OJ:*ZY2^95SD$M\T)IFNVD:3;/U%FBF%.REA/2RH)16+.45
M*ZC9>QV?#,-HUW6SVWT+^WTT=G#8O:Y4A7*<ZT4>?HB]KJR'U[?'B[S[BV^Y
M=LCN[>&8O8[-OO,]0% X?XCZ_V2#\-&[]7M/ENU@:/QGS[^=81$7VQU_958J
M]&09$Z^;LPM+U3CIQ&]<P %]<?A[8[,,7GG ;CSW:CISO#ECE[8/!.GYKR2&
M=#\YOGD@N&0CYOOI6+$>^HG'Q.U_M\/)M3NTG^QA9#E):-F=-2?N_VF.T-^.
M,H=)&,/J'3Q%1Q.1\#XM03113[J@A%S (52M4T;2X7-YE)S>U\%"8\7TZE\1
MP(T,R',3Q50^MK3N-W;!6>U[&?;]$/9G==Y+MN^'%(;5OI=JWX^0JSL<VJA\
M6\Z=90^OW0MK9H>6\Z9H8"T.WIC<K^BAS/1P>'V@HH?2TL-1](2*'LI,#X?7
M'^Y9:-DN&UY9OFN[XU?B9]V0$+(7_\8TAHH"RD4!A]<1*@HH$04<12NH**!<
M%'!X/>#&<_$IWW,<P,$U%NEDP2O)C]F0#M:AX(WI!!4UE)<:#J\?5-104FHX
MBJY044-YJ>'@)?F+#.Z23]PYE@NKJ;\.DJI"OHI=#5+'0N7X-,$<^@"6/,+L
M<.>6\TP<'S>D.KW5Z=WH]&:1376&L\^P7G]5[=UH.7GQ?(@\WAC/)QITNI#_
MFA_/!ZK#N43/50'I,A20/JFC69%,&4CF)+E,53"Z3 6C3Y+K5"14)A(J,Q>J
M=Q7[NXM]""O[N[*_*_L[R_[N;F-_=P_02W2W,UR=T(JFRT?32_UQJYRB(^<4
M%>*./$!KY67#JB*=<I%.:0TJM5)BQ75*1SK;%DW<.]?)M,4KTBD7Z93-!D]B
M7KL5IRD!N:2C6U4==U_QC-6^EVO?Y9[L9]\WL&VJ/,B2Y4&>OLU3D52Y2>H$
M;:&*I$I,4J=I(U4D56Z2.A';J2*CDI'1D6VJBAY*2P]'M[6J[/*C9Y>?OG55
M$5'9B.@$[:F*B$I%1*=I055$5#8B.A&;J2*<HQ/.D:VDB@)*1 %'MXNJ2AJE
MJJ1Q^C9215!E)J@3M)<J@BHM09VF[5015)D)ZD3LJ(J(2D5$1[:I*FHH*34<
MR[XZX5HMI34[LK3$$\9S"96GM*P[,=P>1P2<+)+VRQD%)>EG=0.H_&21)!>P
M;_'17I727:4)E"";2.Y0;HFX[\QI/,-M12)6I%,VTI$[E%O([X]T$B%?I;R6
M@5S2>DOK 'I+M>_EVO=%I?[@6D85.%NRP-G3USXJDBHQ29V.5E*14<G(Z,C:
M2D4/I:6'HVLQ56#;T0/;3E]OJ8BH5$1T.II*13A')YPCZR85!92( HZNC50A
M(:4*"3E]S:0BJ-(2U.EH*141E8J(CJRQ5-104FHXEO9R8H$Z)RO43QC/I9=U
M)X;;XXB DT72H3AC:W4AH9T:)9VZ6#U^JY7R-T/:K^7:*F-L_CY[BU5'ICHR
MNQV9LK8]THW5E<:J(U,=F2/6"3#*52<@5O%3C4\?[:D73N;WWI Y)QX#$OCA
MAPLO0O_##+ ]7V@FE['2H_JJ4EM]@*3*U+9_8X[E>E/KPG('S+] ]XTU".\F
M< "-TZ8"R7TX\U#XC4(*+Z_^V.)VF^S1@W2_7450GWQF!2%'Z!? ^2MQ@:ZC
MHA5+KD@G)^D\1'T+E154"$ ?>6)^ ,N_'=W981CT(W\\>?VTM"D.*N+:H)A6
M'2WG2K\Y.K5L5RFKOG\G=YK],, FMRK&/J.#>=ITLA&_6;7H5Z\2K^04%V"!
M.BSXVV<[F##_;_YI$\$+S")[L16_V-3))&CF*VB [ VQC:SU'IMH3L+-4A'*
MZQ4MV3M>>5C*Y6$YK**A%MI"NZD!\YU8P,#.A;;DN@_)9Y/KC0LK>"5^@T^6
M@Z?H8<)8^-4;+%Z 9"WY=1^N=<ZD5V3O)U=V#AR;X1VJ\8_ ; /@I/! \&FN
M?E-J3T!I_49U1;.O-]7KX]L9(OEU4-"*NV!UB<<FD&VT>-JP0TH7'@>-G]\!
M2WX=M($K67 .9"WS[4J42_]-"Y/T\H_-)DH@1R+7YJ3S_>%RB1JF8/=&/ONK
M'7BFH;<_P#-R,/E5>@H<;<7X%!(3K)Q"(($>VGH.@.]NQ3P4F9.!6WSW)IHR
MWPJ]C-"@'#A8A#%K5&722P86I>V^-.W+>%F<-VM@^7T*"UD('3+[PQ71M%(.
MC:/T-@J150UM=ZP)4KIGHZ7*KAH.1U^(G="&;&!/+2?XR[OKF\_O_JH;NM%H
M&N:?WV\VF00MHTX;G.Y;G_)ZAK]93L3NF$^O9\$G3HX"GT(MBS#6S^MX,G-,
M61B4W+@^/)1\CEX43CS?_C<;;H;#%9 UZOR_3. 69]H9J$64[0.H7A"P,-B8
ML-3)ZTCSK5:W;7:3J?EX>6;)((S%6>J-3KO5:>TR2TI9Z+%PXL1FPXL+;#:-
MPJ:^>KCFTQI&NZZ;W>[ZZ;OMK6>.V\'D7K390C7'+&SF>,U[7^N+RS*[^DN3
MT+&Y#H*(#2\C'QCU'2D=_"#=L&?Z*@W$FO9S\MI2.9&6 P=R["^A9,7Q-EJ=
M9DL]W9L!N-]EK2ZJ6OKUK.W!M<5Z&O5.^ZB+R5$8^\7%-+L-<^>M00_G]A)%
M;^@ A2+,8+3-9WA9FG1;=;/=J6\[P=:"!-;5Z+8*F78'(9)CUAT$2+W9,9O;
MK;4 X;'%;"\NI]5<09*)LG_/QG808H@I>FI>YJ1\XK_VKAY__7I[HWV[NKR^
MZ'W5KF\N5!,B/6J&/</PULZY=H?LQ]_9?.-I57?&RM'4Z2Z]082^ O10;CR+
M7C_[+SZ^^GK6L)RS7''#?^/Q5=?!RM'4Z7KP[1"?^.Q8XXVG&0$I,#Y#:@!U
MY(O(]_%C.QA8SC^8Y>==RYF\B%LW6@8!\"?OV<SS0V#1:!Y%&PAR,>L_T/Y^
M:;3E63_;#O,O *"QYV].=#>>>V8-!LQ!#P*8/32*.GUJV"PRX0CAV_L9/MM\
MH?_52)/(TDBKIT/\YYL,'0=9T\4C+?(GF4\E_'N/WJ/U \.,)YZ#SH+/GI_D
M7JDY5B\K."_SMT:GVU'4XFU!V>.2,I&\WF1L-;KE7]/>DN_7X<8PC6;Y4;.W
M).NU9-/2C4[94;._9-JU3$+OU(VRHV;3ZZ&U"S6->K?XA5Y&[-%3;F]L%@A9
MN[6IU-#;IJ)DKYYA5U@V<-'I>KO>/@0L:8KO#088/AW +EE]A_7<(7SB@[GZ
MU;;ZMF/C<!OL>:MK=(V#8;)XZ-O-^E%POP6LAMDTCX+I_+":>K=Y0)I>$QNU
M5IS7C5:NW4^T[0<8Q/D4!;;+@LUUVQ PJ>KLJ5&6)[F:,G\,G/*+[SV'$V21
MEKNYQ:!87FN&6YZ5"MSAK?D3 [/)RD)_#JLH>[2L60>>#Y8320"ZIZ+L#G]^
M ;NYN97T6WKN-6-F&V8W$046;.X*T,\:;1/=F%GC+%+W[0RM-]@""A^_M\>3
M\';T/6#D3M]6F+7,% ];.T<! &T@T1HMTV@=$"+8%V/]03<Z+?56)A=$2U>"
MW*N[TVUH<N/]PBP[ ;/A+6BWT6IUVHW=87DA'J!([&P6#; A6(7A:0U4LFSH
MU0_4<]DEZV>QU-P."*/1;BHJ=\8L+P!2!!!-LZYJTPLS+-W89"K]2IK%I_E2
ML1P*\.1A>]<N6&KD%PINPPGS'R>6RP,]@]]@4C:\=KEG:E,[9R,3\&7J4.]^
M#K3")8O0]P:,#0-<+!Y9C*J_]?'6]';$A][#W>LR.;1!JP)^JQB"+\*URK8%
M&Q%AL ,,\BOLYE@^\+MEN\\^<O]-E$7#[!C-9>LV#>*JA=R.X@M!7/V%%X3'
M74[';&?X)++ E$OB>=6T:3RB" Y+'$:D[X>R5L4Y&>=M.&_K(3H<WZ'B*,'F
M? =_;^S!];0*64"XQB&X4QH/;P3_\@D,)0=Y6=]X5QH=]:Z^VI6][$IF1L/+
MFI[1??,[LZ];A&IGCKLSV^'=;)G-XR&>YX$&47#U8S#!.89"ZQ(J1.JKXUT8
MKN+TW4ZK);2531=1Y,H/<!]8SI4?XKIO56BCH7>Z>UJY\FN&]^>$*'YI(45C
MH/24OV\,E/\$K,1 2M8$V,887BQ]S,@JCZ;>-=L+\C/GFO:(E^,=DU+CY8B'
M1S<Z[5:Q>!'WN'>^-V+DJ[*<SVSG2 JS58<]5!)#ULY2!$POWS^9;<,TZMO"
MM+5N*S18Y0X@XS)Q14  D5&J(L.+)-*J&PVC" ?"*KB/A)AT]$$^G#1U7;TU
M>BTH2=/*VR&3WQDZL]FP]\1\:\RN?C!_8 >,W+R[GJHUSN6&<=[<#\;6+:A4
M>-SH$*Y!H6F>ZT6XG$\8A1L=VG54>%Z(JZLT&+QV065R WM Z>>[X6Q!X!=Q
M]?H2P(N8D:K= _.?;"Q>EC4OJ(!/=&-+4P2/7F@YZO=XOW;CA?]@L+*!-W8W
MS[+/O)],I[+O#<*#H4)FF/CB(WQN@XM&$9MUI_^C^<UH7!X (YF +J+IGCTQ
M-V((LJP7B7K\!5D+S+]V!TZ$=(=!2/#_0]#S<X9J;U"2<ZW>C'%;BC6V!<"'
M7_.JOAQK ]0Z'=,T"UUH.J*LP-@:O9$^U9D3;0M-_N0@T]PK-*GBY2_''>T1
M-;@Y]3P;E0<S2@3PA#G.SI&]ZBCK%RS#N.<K]+X=0RGCX3-"DT9V^-7+#);.
M?2C.S&;7[*A1K\GXN6;.?0#.FBVCU4W% 14W<_YT<0!'KW?5_=@#.)OED9]A
M[0%]9T"R:&$+O)C-=K.C[Q><&"]-L]TTC:;9>@%!W7JC6\1.Y>.29P8(NT9W
M]\.2FR6>=8QZ=_V2Z7J Y#:F:'^V;'_9/#AH#%5&5EN3&/L*2(\5&[!@Q94,
MA:N,6OW<U \?1O BKC*+RJ"#G?F!G$OH@'>8W ] AH"L?A1B\MFC!VA!;/N>
MXW##D>*?M\Y.U,V&J:M%NXJ!YY"KW*"8C-%NI])$3FR1*!E>7*1A=+OU=N>4
M%[E)$80ZD*MQLHM<\G>NJ_Z40<B-UNEN\)+3+=_:,5.G>;*+ET=XZ\6W%LN7
MG=3:=]EXLZW6/3FQM2_G. ^'Y+.S'+QCOW8OK)D=6IND$,,! "'6;#5.&1D+
MR>D[(*-KU-NI0I$GAHPECK #,NJ=>KMEM$^:/19&&;JIMXVV;IXL,I9XQCT+
M+=MEPRO+=^'532S),UW'D@.-TV:=BZ%0VZ"AW6K6=6.Q7.;IH&&)3VR%AGJS
MU33,QNG*CB4.L1TUU $)Y@DSRB7>D/WF1LAH&.D0II/#1)H@=L%$LZ&_(@ZQ
M R:,5KUQNB)CB4GL@HENIW'2QO;F9::SU.MZIWNRB\]58SOK'KQQNFM?VOA=
M;*Q.I]MLGK *N40(N]A8W69;;]=?$4O83H-J@MUM&*>+AB6:V$Z?[IJ857_2
MZE,:#;NH3V!FGJY/?HD@=E$:.F;G=!5)21,O2,=FJ]5JG.XJY7Z_4*^QU3Y=
MDE[*.LRM_9WPXG.UB\E:?/NTN7JK,.VO;9JMSNDB8XD0=O*P=UI&JW6Z,009
MB<C;:'\-LP%8>$4TL9WVUV[KG4[S=*]DEZAA)S=B=ZFWUNE@8HD@=G*>=4[X
M0E+2Q'I&V-0[;;U^N@YTN=\OL'N]HW?WK@*)9)!"XM1-LV$V%:M<CIUCSMP1
MZBW#!&(H?,[\,=A[!F2SJ/3Z3O,7$XQ> !44&(:^&T9R1Y\70 7Y4W'TS1 >
MYZY@H?@I*RX[13?-MMI6+V.B[6#9*E^EV>@V#P3+5ADL]:[9RLHHVB> V^6T
M% 9:45DNNH%Y+@<&<,>\ER+W-W\F3*/9V1.^\N;&M%MF/:M+PFI0I,K2<X=8
MV;W0"NY&0]&LLB?:&IS\::9-U95Y &CRG[VC@9A;[RD8MF)8UWX);C_J4O&;
MG(]]I;K(%8^Q?/Q+-S(Z/JP')D\WCETZ<2_UZ7BQ.4>>]B6[0+;<V*00T'+E
M,:P$K=7JMA<KSA0 V<Y(,]OM;DLO&F>Y8G%6XJS>Z33THBFMB&[T>J/1-II%
M;V>N*ZS52&N#/K@/I.T.6KO1JB_6N5X+65*W]#+RT?%$":>45'K#GNF;C?M\
M;'<U9K26,D5? JBH52R(V5U6L1@#?:@EK-V([:^FX.QU],ZQ%K5V7[9?%(A5
M?3$&KQ3[M-EUT8_ _N#:SE_>81?&=]K[@V#[N*"MQ5J>.Y6CX*X, &9A,%_S
MJZ.?_)?.M+%XI7)(8-L*L#M$![<6(Y]*L88=6&VGU6R6<E^.SVM7@E8&?I$%
MX$L[W5J*T\R[T[WA/Z,@I$HHC]X*JJ,2*84K<2_A<6^0;7^V3+-=5RM#;0SB
MP=96S!G;&WA%GK.B@3S,SJ\XI-Q<O, "HC[6F;\=\=]#N^^P!S: 1[&I>)'V
MX"I+MMU=RJ[=&MY#K'[)$[K+ZAM-0U\,^2GOZK=FP"M7OY0I5>K%+_F==UJ\
M>4*+QY/>5D[]SDZ_DSKU6ZO_*\OV-UYVA!6[>-+*BN)XZZ^+6ZWZIFKBT5>7
M_S*\U=[49#[ZX@ITW>J+"7LE7O-V CK+X7 B:R[0N;T8F5_B)6\GC+?VYQ]]
MR7OR_Y\9IG%*'&WUZ=X!!R"RS%/A<'OR-9P9C?9289L2XV#U\=^%#MI+B8ME
M1<&1KYD*/[WE!/G(-V:%GXUR@ER*R[_"*;K,@)?B-K-PZBXSX+FO9U$Q:[[L
M&RR'-,KMX"9UXU16M[7W*\.07DQU+>N:"[SR/A6C<NTV[Z!5ZBW=/"'->A]1
M F<=\V0,K+5D4$X%ZLAQ$(5CN<R"O!2!'45A_$7&M52IK:RG-G<X"[*D?7'E
M3:[KZ7ZGO]A2Z)[]*[(#.Y2=/SD42K/.-1V3\MW3@/[551,R]PUS"7"4/W6H
M;C3;K3>%H]TNC8H(HCG P3CI!1T_#.X Q_*D%[2GJYJ.:=3;;XT9[>.^YVV*
MOKTDVABM9N-M"<@]W3U5JL:Q(HL/>=).>57[OE4J&P4>.GC\D++SQ-=6JJ#_
M0YZT$U];[DNPMZ?RYL^+?'LJV&[W<24\%[M=MI5P07NZ2M-;[;IIO"E:WU?:
M[MOC&@>X)"O;23MQ=>%@5VTEV;>*]^V:HGXDKF:QZ? #7AY:[H#A'2%);$K@
M^C[SW-\MW[?<\.K'8&*Y8Q84=C]UUFPVL3[5-O,? /;M,S+*OJ =(F%PRUKE
M7^%N O$0$!8A (J#LZA@.;TLI+$/K=,TL3!HV==7%M+?K^ZS1SA?HH'#,GC^
MS0$R^HTNUO[<"KH]+*W0C'6]WN[LN#2ID]VP,*D;WGNR;(?W/%&@$IU2/EF!
M/2BJFKK9Z"H%!W("4?P:\JMZ':/>52M&''T)^XT4V@^9E F^_<;Q[(=$RP1?
M<5$V1Z;%DL%:7*C(D6FT9+ 6$.ZP$)YMZG5#+=U;!I&P:X;ODN V.FHGM:,O
ML8#PCH4EUELM4RVT7X8E[NH76%!=]&ZSHY=HA87%?2RLLW4RAW&'-I5FMU.B
M5186"K*XE66W%@KIO=HLTU;F3Y$&":CK9JM$:]@B$1I;Q7?*Q/_W&UY1#([W
M%RVQ9_R53"DMSM%[9+QNI4"WV_5FJTQ'KP"_].(2Z\UZHUVB)186L+#H'FN6
M:)&%>>\7FWQVRN8!S)E1W&[KC5*M(7_>,!RI5LLH3NFX9#,OL,.@%P0L#) X
M(M]G[HH>ZYOTN]/5=EJKAM\-#.KBM@\P[N$H^/8@9,,+*YALBP,3="IEA]*#
M;C/ER^NM;SK=9QL&85_M)P8B-;3<,>:2"[2PK7>]V:ZK?I+UDQ0!TLL8:;:;
M=7-;D.Y\;\;\<'[G6"YV:[SZ5V3/,))G!QSIK59;+:FT;H[=X=G@B)AU4]7\
M\\##$7>Q*ZMH&(:AUF%*#;O%G!LLNEY'JZVQX9QW/IN!\BD:=0)2J,U!(:MO
M-SM&5\7^BS,5!MS+:#*,;JMN[@1=;S#P(C<,[MF V4\HDX".=J48'2A60=JZ
M.7:'9P,TH?6\)3Q?;:MO.\L%1?(=H&93]?HI8^:>;H.SH^MU0_5,K9DN[M+]
ME5D!DP_.=]<OE.E?G*,@H%[&#+9'W@4P!9&[\]25)/$R(>[,7+&$;3:!K)B<
M^$AQR^^TZJVN8F^N&'XG*#8@A[9AJFC8%(ILLMD1)=@RH/,B;18(TLOXZ7::
MS?:V(%V@\6H-PM_M<')!K<H3W.Z**V7/-IFF.- V4ES@O]W@D^+ISIJC;-J5
MU6!;>&-9^*5'WP6&#01PIUE/A=QO! .:QC8/S =5!C$)Q,?<03Y1_)++,?<L
MF<M]:1:%K< LJKF/^GLXWUZ08)]S5=EZ::9B(-OD)#0Z[50SY[R0?;-=SX?/
MI?-K6QSA%59#5P[EXL#;3?PR"F!B0U=O[5^:N$"ZT)NMKME=[$ZR%M_%[7W7
MK'>;S<7>36LG7_1; XN(II%CA6QXR4;VP-YA^_5VJUG7C93SY:79BH)O$RH!
MT(Q60PU^R _?BFN8[?E*UZ@#7TFU%\R<82= -O(0FD8KI2MO"(CB65V.2\_G
M*E6O#1:'W6[:#<Y0H]79?-98.1.V_P;UMS=PD#8[':/9S% !Y2S;@+%P@[^!
M:FPTX7RTB@<C9RW,>JMCJM[J0L#(7V[2Z'0[ZGWDBV!\82X\X8#,[0VGMFL'
M(3[_Q,3S15!*M]LQ6PJAO##E[A#F)B*]TVETZL9A0<Q'8%V]VVG4#PAA;MHS
MVHVFOCV$7ZV^Y\/#]XPD68'TI[?JW:Z:^)P]U=8 Y28WHVG4._7F/@'*1UQZ
MTVBT5)6L8(!RTY)9;YF&GA>>.]\;L2 @Z?^9%2/F]&X;V)<B;!<GV0*(+?B3
MV6PUNT4#D8](6H8)N"@4AMQT@2>YT=@<AM3%>A'D< 9"7D]544A-D7?^W)1P
MUFP9C?;*+*XMYL^?"+<FGGX+_.=-8EL7";X^N",,?;L?A3RT(CN$IA 2 55B
M95#L!C#L8Q'YZ:RA=U8&J!QO$3F)=5VD^9$6D9_BU\58;[,(S_6D4<!'*E#5
M O98KS?5'(95L^T"5GYJUINJ[KPOH')29\KBV M,N8FMV31;[2V ^F+9;H 4
MR8);]^H'/A_9P00=Y[>C2]8OAK&:9KNN*[S_Q5F+ #,WL=4/#V ^PCLT@+FI
M<!< ,5C#"B:@&#[90S;\-/\>8+18[ ?I#< &7=<")J>L;[;;1C.=M+7A_(5"
MGI\EFDVCU:AWBX <6(./U[Z7C/^\=A?N\(39=F?Y12'>:#=5J9@3@N(7D-\'
M4*^K6GSA"[AD(^;[#"SF)^9N4B=VDUXVZ>OK%R<M LHM9'WQ8"[L!;JT!@,_
M8L-5$5G;LA.C#9I*(P=99(*RMP7EI_)VI]4ZP'I$;*/<V,P8QT(V2&]U6^J]
MUW:@[&U!6VG&J:[M^UK0<EAE(6)@(7ASDWD+@C4_JKMZI[.6+[T,:V_J ?__
M-Q68Y/K/I1W02[!+4SN:%H'41MWHJ"737YJS""!WT;(W!I"J3R%[8?S1>WL\
M";U1%#"*6B-2+H1+=%JR2-T+L^T(67Y'<MMHY(-,(OF2S7P8B9 ,OSOT*G)K
M!?F%*!G-KNI=W&3:@D#-+]PZ*<ZY#:@K=.YK]XD%>[!6=+-37\A6W7#Z0@'?
MPNMMMAKU(N &-4,6\QW\*[)]MC)CIA!B7L#WYK,7"G=N?"^@>WNP5VS49]NU
MW$'A]-WH@E'8;;U()QG3%PIX;GR#UF^:[4X1@-^#LL9W*]5IMB@?'##G9C<5
MB[9RNMT@VT4AR $48'C V## 29?J4F) 52&A4MU.VVRE[Y#7SUH$F/FIT&C5
M.ZWN#F#*.P<,O5O,:MP2=YU&HV&H2G-JAOP [$)7+TRN-(#6"R&;A1!9,73.
M:7=9<-:TO(0KO&Y;CE+-/EN+!-F03@@IQ.@S@$KC.KG;0K*W]6R#\&*6$L>#
M@NC = 7X@9+YR7*0%_(&!(M69R$;TJ@WU<B0//,7#/L6L5CM1K-1(/ ++Z8S
M^2F$2?U >7*'$.1VIZ$O+&%K, ZPI@WBFUMUT(?J)[(D/# O+JG1,3KUMGDZ
M2]HD2J_9::F77X4O:?D@]D Q]OTYZ,"[QNTW=.I\DFNZ F'<( 4U"[VY051D
M^&7DPU.<E?'2ZN3"W?#*=I?J[PVS8=2;BPE':Z':<!VTYCS+>"&IH64:C6S%
M*WO6?8&Y;><;4]66CP_]#IT^FF"-U$NUF&):O!4.5I%]S-:>2[PO]0-&SSS,
M0/,\1$^,1M?<E&\LPY=2\M<A?NNE;8K@_4&P):>0!E0^F ZXG!TZ9)5^;04T
M"-HO@$7R%*Q9!UK/'8P ^HHEKD4>;#!R1_8 /<C\WA/7X#DV)M<_ JB?G!Q^
MK;_^IQ-^G&E!.'?87]Z-X*4/FEZ?A=JC/66!=L.>M7MO:KDU_D%->P!LC3YJ
M4\L?V^X'K?[N/\?A1_U<N^D]?K^_TFX_:Y^^/US?7#T\:+V;2^U3[^'Z 3^]
MN[]ZN+IY[#U>W][@G.]G^.)__H?>$/\4 <=_6M/9Q__06_6/>YOB]OY+[^;Z
M_YWR.CYJ2!EGE@.4]$'#/HWV:$[S]E@X<3Q7^\:&0&!.30/#_5RSW*&&1R&(
M^H$]M"U_KOT\  )GZ$QGSKS&H2*8.X91E\/$G^@?:QH(:$UY!'CNS'+GJ4>4
MKY^9\HWF^>IW4:!\]TM-LP/-TJ8<8EC98.)ZCC=&#Q--H8V\012P(0$):QO"
M&7>\&1P:;>9[PV@ *PL]#=8U=KV T6I#GUFAYM@C_J?GCRT75H"?,N0[\'2
M?HS@7'N$=4FT_<JFW@QXRLAFOMC"M@D+ _C5KSB^".P!< F$^RP(K3'3[.DT
M<CW49:P9BT)[@-#: P8_ M@L-D1(85U]@&Z 7F6?X$- SU3PGFP?<&&[(]PB
MSP4PKUWQ M^)%*0"&G6.(=W#,GIV1OP'@/!&VL#V!Y@QCY.$T=3SSX9 7$_P
M$OOA!1[27S@!X "S4R\4"V) .3,<!?.-:EK < X8.(#/K"$..P6V#A@ =D?
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MVR"%E _)X3AA!(*/7!X6SSGJPPP5RDGR,)Y$O:MW^%% RY>TL$!0.C!O0?C
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M5AT Q!V?(XAXCIYL+PJ 'H> )P0&4"4@ <W@B7$W%)PN.#+:S>>OR-CG D_
M6ET\N2%M.MH"Y&5#S=N"UZTQ.T.I,2,H1$!$S/F1Y7#G&6W8L[+MRN6L-&'[
M%NZALDV+?@#:>A FOAW\@> B";@1!EQP6Y][I B2WTDG(L\7(G3=5@DW4?(T
MZ&P\BPP=4B%\0"?XC:A!#S%72Z0)()?;1<*%1F(*=Y%@Z:.HHJ3'V)P7G!8E
MMB6;0> .,1^#>G#K@$NBHAH!O9 2.T$Q"_1!*@5*1!1M2ZQ2(Y*%D7#'\*I(
M:D!3:PYD- ,8@&!Q>$5Q0[GH)[^33I2&  4RG$YW3B$&7I]''IV#-'M&^4^$
MFQC9>",O%L)!4/U?\;4V:@]<)Q!PPM 8B02\QF>)H.$Z"'-FZ)(.X<R(BWAO
M!G@)T0GD6F049>F!B=V>!$.\$3*]3BM0B!K<TS&H6^.8T0BV#A]Q[H3.9V>^
MA0^Y'P7H)>;.8])80NL/O+T,V2SM^U-W<<(LAUP=0Z'@21<,#LE 7_#FC&C?
M%N4S;#<BE1^^%D7E**+C"ZBP@JTCTT2@(U>0(,A,6+7EDW5'LB\2=A^YRS)7
M26"H2QR('@/$=\- VJE<.4<[U9O.8Z1&+MUDHHJ]RB7_[/G.\-D>JH$?B7E"
M][52$P+5$J]5 /AX#Q:1'SOI":Y11,?!(BXEO 8(?'(5DR 2OI62/1V%DL*$
M#'J:>7A.D>G+U;A+6T$:-"A\P&SHY,,,W$F:HJ)X!5R?%Z,I=%03ZT:NR(DB
MGJ.F"!^TZFWNOEVZ4T&HL9J"_#PVW&E.'HV"*Q#X4N[2%>><<.W%U"3BE6)G
ML\6#B@2U4T222XS/$\PG6;.@&1LH>S3B\6)\I8J=@DCBY 2X29#LBEL&3K)H
M'LI/!&\GJE2<\\=B.D=S32"_^,' 2$5CUAN-[ &>!MA QQM8PB/?;36:VA??
M GKGYLZ]/1PS[1*#MF"R"#[&, 'X%23LI0VL$FPPF S8IFM;6M?0C<:YAE.%
MS ']T@.E3RA7(!1_[C0[OVA@2IZU._4Z?^Z9]=&.E.Y=?.SY^?G<XC%R(D[O
M'%2(O<BDH^_(@(+)87@,PH6U.W80)C;(C14,K7]I(B2;P/E&A RG;<@$0Z)
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M0/&PRC 4V6V4AXTFE_S2]ZM>]W>!KS:[NG"NSBR;O% 8X_1&$IT_;QI="%M
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M-52LMF*U945_Q6K7L]HDPN'/[[.O5>6EJ[RTO6=/S(T87K#*NI&_V^'D(@H
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M$QMA)9D;SSVC+"2/ISQ=8X@E"\+*C"_>C&_5NKF;0E1F?)EV$;2+KEGK%-G
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M@&,%_XHLGU/+B#&2ZBQ6HCQ2HH!M6/ O4'&WU6AJ7X#@;6 (]_9PS(!ZX$&
M*\*/=)!CV@-0Y:7-QAZNS490:F3KOZ??+P!4(#/7MK2NH1L-P10LK=$5RM#8
MQ^9K"-#, 08'D  [ J-:+(*.$YHM8&H#60*5QN*7I*]NTO$$,6W[\!)*VV@,
M>)'"6><B0.!&PW^ ;_K(XA+^1%,1#(!=8""D_8"@[H"ZTR0N3["^$0U>*HF$
ML#01Z;5V3$0:$A"! D3D6'T/D.J!E(O)1]>;G:;VX!'F/>TWT&49JO36,"&@
MKD) -6V!6G0<!?>'M@L%;ZNFFYUD0W"[+0X"R$LRTA2J\7R0;B"Q &Y4NP $
M3B7X5JR_2GWD7+M62&N5U1),P$0\0X8J)HKIA>N D4NBEX18FDZ-.@#E>]&8
MBQV@Z)G#A=E0+ ZM&Y!!0>A' RGE\#,40LB17=C2)30_3VR04VC/#/]IH20E
M.+@W(";ZY*TW0L'WN&JAN=<2'(&NX41#+MS&S 51SK49KE2!C+0!^1:Q0O$R
MS*H<@*'V4Y,K?O@&V(+TN_01P/:".J]:>(%P&2P9#/0^\"Z@?F!:H*7AG [L
M#D+S68P'E+3-<,G*%T#7!;P$N\XUV,7Y3U,JTA2?(TS&TW 7IY$\GE)-4WA]
M6IY]Y9(253[NGUK$+1" 3P^,/,?QGD59@^/@B!S9V@ ,=CS\P&C^\J[^COX6
M[G3Z.PV&\3(8S_8PG"#$]3]]U,1EP0!6:\T"]D&3OR5W;WN\;A>@=,P_;7P7
M\#<+C"I_+KBL'G/9E)\N;^$5B9(_Y;[G67AS#]<Y<H;&GW:*1&W66JV\%50W
M0<NQ[GOS]$CJS7S;6:*8!<6QI'$:&U_MQU/N>%-82+2!V:BUVKO>\QX[$#]?
MX,!HG4#:$!.;$M#>*6/[G6]U:XW&IHSFM-G*5Q8$'\A/A1[SBG\4VD>OUFKL
MFCCQ*MKHY0Q?XFS'L2WNYMT1@U7L2YJWM6NM;F?/.,V@MR2DY51,M-6V^F7D
MTZT9F&8CX)Q LJLOVPF49[R-\&9HT_8>OFN/WLP>@,5@D.\O4>ST+O<E_EN.
M;CDA\UUNWH.9[P8\Q&#*PHDWQ(M6[QF&1&L^2JZ)QY%-%P;G6B_0++26(R>,
MX? 97BC 6^E3AMY+NCQ!8CKS1F?HLQ<^6:I]RB]3C0Y0CXE@H[.F;SETLQ!,
MT"]+%FEZ.=R1N323N'R< 6C\^@&4#/'[D^5$3%R6 *Q3<3&T8!K'KB=_YI&C
M#2,ZT,,'Z!)>V%HLU##T(\!!\!7;'?AT.2#\*'#8?.\9OZ5Q5JYA@"[!8(;W
M+?CL2BRAY1VC&._@R/\;9F$!\<U=7^3LG48.W^BA/1HQ'WW'6I^%SQ@^DW:1
MH.N'+K@#?BG.]]X.@[4(26[2F<,&B!6<-_$.$B@<2%S V.6TQGZP*=V9$9GA
M)(I#3PPLW3^+WW"?YK_P6I*N] "[R7SDJQP"^*X7RAG_S3W:*?1*\O.S,!CR
M<P7@O1$WX08>7S<)IY">U>S+E8[14/WB=*I2URE :'JM4V\O/K7HTN5') GB
M&%B^3]NCQ80%;[4:W#7(&<TS7F@Z3GQ/@H>;CA9%@4R Z.&)T/H#F,%@$,V
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M<[T;&;*;M2V #7'].I>A:@,9&\LWC/B5E42[6\,GAA3&0*D?Q#S)3P+$O3A
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MC \4OR@0"_] O@!T2Q"T#UD6J_S[>XCK?#?8MLQ2; BL"]Z43P%IC-N53+E
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M"5VCY_E'G_\%W/!RQJ,?E+F8#.WR3!/3C\IIFI<I-7Y2;=6*K1NRJ32>BST
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MKK%?E7?Q9M'=,N?609_+(U]\>7S_D[0 <V_CKB/DH_RF:JH]U55G#_ZIE?A
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MD+U<!WI&;-.P34.#>Z$SJN?'Y,_\17Y(/A<Q83I.KGJW9K5V@#%+!FUJV^9
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MH@:N  AUP=>U6T)AN<,O]T.DA%^I&KM8M +%%<QB2'-YC)60AMU)][P_?G\
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M\L)YWTA$4=HNJ]YZ/%M4^:P5'(F&QS\!4$L#!!0    ( .Z)2E*L+6^.2A
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MY!Y,EW( #FB"2. [%C!&OQ,AJD)SG]A&$!-]9,PO0^)XB-"'7IK$ 9&.?42
M#2D_7([*/OD?8D+&R(>T9HF]Z0+<CHC7XA[[M1F"3-]:@"3ZZ &Y>$4M57]:
M43,6VKM<[SW;.(VCEH5#"*3>_=C''OQHQ0-,PIHE>N_9MT#F'#AW+AKA $'
M>3;ISRB0\"6"GOOD,_:N,]_TB&E)A:/B'OO5MTM]*,3I<MR)^NV31P,2"+\7
M^C25&#KF'7C+P!$/'D&W?7(8Q5$ZI8)Q*>4H"SOLDZMOI@^:$8_:;+M]\G"-
M89!Y=/C#> M\L!(:%*ZCYT6!+3*C"3@W+T0T&-Y[CHP J]+=J_;1O91WS+;;
MKQ]<+IU@F>0+5";@?A%D%N)Q(M%UK](*[PCZ$=(X]B EM8+V]6<_8\@X902Z
M&[7ZLHX9C7,5<X]M&H>-E'+\BOK5$35E)2O3NX8(*L>N5.>#1E,Y/@7=#A%9
MY1C+;WV(""0IJ-S6-44C.1:E"=0?!?HH,!V7C*A2 ^=!.,^L1O6P<^3DJ2UI
M,"5(U!?/$A:J!;0,D1KFJ&4-J229P\;D5.T3$A(C#**]*1BBY8.T@% M**15
M($^ACFQ#VNZENM?(L;2\R]*I(6>2%+I<[X-F3>G(JKXX(:14"PYC%>G^%A$P
M";K3!YZ;+HG/,/UH9U!R9&M$V 4;?Y#8W2E)IA8$TB-;GL(A\G;)05S07(7U
ML;*>=-_/.<3L15(K!<UKFK^L\Q7XLL(L)H],O0A*Y)VE2?&0 )M6Z$9C?@B_
M;_5 3P'R;&2G="B4O12.P,>4TDG\IZ.UM+37YH^0>FHQ"6V+QH$!E*@%V8)Q
M"KRO-[_AYYXQZNNCJ=ZG/TV-X:#?G<$OE]UA=]33M>D779]-M3<WGAG:#CSB
MY[1@)T7F8FL+C4LKAK"_;2 )F*@L:&Z2NZ@V*"2M>]-<'5/#.49N0-)/(E-J
MG722$J&?DH__[!("N)($*7V :]XA-WKLGTF[3+/CYAC>W'AG^8R_S;*W82E=
MW]*P;R/_\U$G)0.3T2W[8*NMDA;')%S&MM@"O2W3_G,?+WG22B2#<SC=%!H\
MY$A[1,[](HB8:U#(R<XQH?O(SD.R'2LV$FXO.:6<-JH4&=S**6OLHY7IV,D"
M"GC?:,XC.;"E.LNI[JQ1U960@G(:C+D4>5]5_%K1V'D5HA[[>(7\X'D,43W*
M5'Z$3K3^N%%ODC=*>+W4\&R%XT(,6#DM73DPZT%#R&3M@1>8WCU=;(UA<O4D
MZJ>&(RO0E!QHY7351RM,')B3Q)QBSQ+%G.(><OHY;T8_(J#*:2:ID_;NA\@D
M:$)9,N8W)+:I8O4(NLGIZ&TS.I*"K)RB\LN*6<UDV\FIXETSJN#52BLD^XU-
M 6&RG-=6@5E:L@$I/3_+MF\ZK2Q60<'T+!^P<J;5#]$,;VR=R9@8KT_3>::T
MGL3 E=-5-%LLXPL*.S2=8TIK20!9/15MQ?:4\6>QI@3]FDXZY14F)0#E])9N
M='US@D4O) %>OIB=6'MRO9M.2J5U6$88RFDRY_0&-TE2*K4H4,CK=X R4VZ)
MK@IE%^7\WRN8B1>?[V55E=>V4>\=E9A2IJ*+&GB>.MNRZ='/.5:=]<KY()4S
MI*YM1^4@ICLV'7O@]<R5$[R<Z,^9\Q5U:'JX2^M& %DY%4UH+8:';-WT/?!5
M!":MX3*,YD)]-'<LA^.F9?HV/;^05IR\()33(8MQX%EN2 NBQ]B/1!T$OG,7
M!G0=8H9I"**)'7:!E?N!%R!_HV91QL?O1E\]!UM%3AG[$5V*H9"]?'4\[$?H
M19IG6ZKGB/>HPR+!**?!C>RSZ]EE\C5QSZ9'J2PVX?BK9!A2&F]PTE%&-(77
M&!3A^W2<A3>$WYLN9\R_%6JKMO&L:FVC]F;K*3\W4\4IN#YJ"_*Y'.3I#/[[
MJH\ KG&E&6-]TIT-H($BA9WKR7+VEAK.XL!+TV8K=.:(D"CCOT(\OMF637O:
M0J&S13FY&-4+B^8=]E_.)22P.,&PH'W3?EY6,7R\RJDGOE?4!8:[]M+Q'!+$
M]?]"/0D[-CW+E%68I 24T]P:'^14>(GH>6X)![W9N-$ECNAX$H?CEQ;*N&16
MT,QZQ38J-3-6>3S%0X@%UFIV-,#4 6_C$GHP3I<&@:2SGNAN@[M B**H?=.C
M1JB0C*WQ<:MG<->FXQ$Z=A Q//V)P@P=LJ 9OS&G"#BA4]RU:1]15GO2TMAC
M&&7/-])/(L48\8TF5]A/#O[J3];"].YS P[M)>K4=#(CK0\9,(HF-'1*XP3\
M/&:S3=,>CN6W*'SF!%HE,P,A(K$9JF94(Q3(Y,>99DV;5B[7.2L &64I+?QJ
M^UT[D&IZ-,DH<6<)"1(B95:+)>^HWUH^?;O+\NET9O3^]<48]O7)]!_F"I-?
M-?W?-X/9'UNKJ8TO';/7VF]!?[<+]%YW^D6[&AK?5%DYID>> 2=XJ <')'CY
M?$/HB;1U/$PNM.$6 9:A\?^DI8Q3*JF:UQ=V^FCE(\M)+B.B+T>BTO7L[I)N
M.OYWZSJ1W+.%$KT5""[5]%A&2,II6(7)]P$G>U5U6V4VWO"R2C1KO32C",K>
M3I=3!U70ONDC&95UR!>$<B,2LEB?UE3W4?S_P$NNT^BC.?)]E'^M!F]9<S=Z
M31_CJ*SW:H)4;T"S>#)G,&G,L2P_1+;4X9!=Z35]TOD AE%&D*_ 863@;)_^
MK& 064)REO#^%5M"ONB4,X'-5#/.2_H.B8" RULZX;)8Z1)=Y=3\05TU2XM'
M.<6R!IH&KV2'O,QH9KK**?:CNHJ5%L_A-\MHP$"Q@457G>!Y2%!T.*[HBA?:
M3=A+<I7C1$$=2>%[?<G6RWV$NT32S=Z2NE5X":N,E/:I8_4VK#LJ+E!5VL)N
MN@PI'_7 >T"DXLIW+HTF5[[-Y_C=0[AK_0@='Q7>$\A9&2]!0]&5<XYJLROG
MI07V:NS[RO%,SZIFW[DTFMW9L1"RR148PH"0D!YZ,>8;Y[RY&SZBKHI:,T>1
M[#Z0G'B4FYU,T"H9B93?]9N8^-L&W$Z*;@;)*U-").KYHM2?)JL=,SPSG^BE
M.+3" $!#WE!V,V%WBHIN&948SA6%J9YY4'G0MUS ?S2P/I@NQ3=&OH/M[ R@
MV"3*46G:J^^"F:U(*INW*UG+>#A1\#*^"J(XG',XG"AX_D6YT\ST74C K.LD
M*ZH44$8FT;F]W$MGMZJTWF>JM"9ZSQCU!L-!='XW+<GZ)2[,HE5HM]UA5*S5
M'?6A\70V&?1H&5?TO1HE6]NP66OA94:BGLH%@2X8L^\_@]V*+J22Z]ZTVY=5
M7LX+9*2%HV :?\@KKP\7F'94UBZ783?A9>5>DISO5S_05W@YQ'(Q 1KP2Z>M
MC;JSFXE.?>KES70PTJ>Q%[WL3@=1\>L8_"GXULCS'KR\EWUI<CZ0CUD@IVUM
M: #K8WVB]8RO7R%*3+]T)_K!.>:_*CF7^\Y)EONS-HU:>G?2^Q()OZ_?ZD-C
M3 N0-?WW,2U0GM: Q**OAHM7ZND-,C[VX$<KKJS.1]+)(CFG2'J4[VZO9]R,
M9H/1-9B0,8*?>W%%=1TUXGEO?]Y\0\<6B-,LB+=M6@U^JT]F@\NAKHV,F0Z6
MU?VC"[_]HHWTV<$AL&]/SF?]+,OZNW9:E3^;=$?3;B^Z\*0&V\E_^W ^U^=9
MKM]3JQE&E??C[J1NY@M>0)S/^]LL[Q_:FC'[0MW.S61"#1^RU$M(56>#&L9L
M\6N&MYA^EV7Z8SL^ST%])74O]7CW]"6Q^4R^9X+325O[UIV *=3@-'9]ZVL^
M%C;00J2]-L"EC"*G#NX%3+R7S%BN(XC)Y"4>!A.( *,;/9KY7(\&M:@G?5ML
M/B0FY'8@YD[UZ[I\>N&;57/9/65B;.>L'64&@]G7]521J@$"E YSRSH&:WA'
MT(^0I@</A7(^94)J!V+J].9R"GX]R@=N:Q&X7)HYQJY3K ,FL)9,-[4W*?W#
M'RSCYW$SFD 4H&1BL$PVI[V)21X>&)M*\, PH3D_H:B/_:+,@@>"B='<_*(^
M+ 6)!@\*$[EYZ49]2)B\@X>!">RYV4=]S*=I"(]G-H!O)",URCD)R3Q6N8&Y
M/E8Y$9K#_5GY.%T?)+D86/AF]RV<;%@O&PN3YVCK!QU> .QR3,)$2X"6B?Q%
MZS-K6*TZ<?&#?<)1/K(=HWU"LY8#\GF+'W)&RD1_WDI((Q;)9C.I_4Q(2(PP
M(('IT0WU?(!,9E"4WJ306MID>A-?=T T_$*^0:0"'3(9@PABK>,N/YGCCC@F
M?1!D<[4--0$:@9Z8#$,.5IWJ*LA7N=IBLA%^PKI65H/W?![LO8)U'O6*#R9F
M;RV6>>$HMU_3.Z^B-R R;Q^5D$(]IWZ CRE:F?$]YIP;OM/S, 7MF]Y-E52
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MO$_/!ME$ /2?.Q H?/(_4$L#!!0    ( .Z)2E* ]BBL>1T  %SM 0 5
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M35;)LO3NP(*RD<O4N55KRD9G0;<V+"L;8?FMV[! C(+*;=V1-6(CD7F [JW
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MZ@PUX(XP8WY9BN>W57A>J\O)W[\LYU-EM?X?[1ZZOTK*_UW-U-]3(H@$$(O
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M*BFO$WG]13J?+[]WFN9;JT9ABNGW>TRO%,3L9#:?!;G+,8=_"?G$R;S?Y'G
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M]IMUGF99Z>V !0P0S0[?.-A/G#C N1I][W=[A\0!4;RSWJN2D.9V2!SH-G&
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M[V1YL9BE[QP>BGD-B2RO/Y$%;]0M;Q.3$SVAA=!<[,06*H^B[7XEERAHBEQ
M6WOY)'F0MF@7N?1 ?-)2Z.# >BP)FGG""V.1\T5:U(-.SXU_16L:&ZE\<%^*
M$R][+C=HL7="/4M>W)%3*DC5MPZ6Y:VCO(\S!VBN%Y)R0<W'P<T)K7D5)VL
M#!I'Q FSZ2B*?Z-AEP=GRU_9:)'MN*;WO+R]-#W/O?&=NPT5%-;NUWEO=S]0
M*L4B<7)K&+; 38U?7WD+?9NTMYK3DE>=)C:OG40P2;2\Z\8$+O,YXC6F&2O*
MQ'<]N 7.S-8M'^]=R*X+T'^&JCV15Q$5!A,7RYH\B>D43,$M<)Q=I(0,Y5Y#
MX6'*HY=H@[C6D ^7K_2#4>\R :F30VFM7.!HU' P:H@G_03QI!WM9[Z+V'3=
M^,6AQY4*NHD=7V+B6323$M%8>&PEW8Q/C(A-P)!&N*"1H"HHB!S%J8U4I[$:
M.33V5%<SU8;789Q<7884(CL*I2CK&;U<;_Q]"SK;C.32%!+%QKLN;[ ZIE;=
M#5M<CSE%/,HZ9A&E8MK&)5H@:%Y0.0\Y &!.+:.4TUA\%(A$,SA?/&J2./#6
M].@XO+017_S[M!(-'M^,1<W=4!(0T;?B2_J%2I*,^9;HPO$GCU9!(OA>?#DG
MZ21)FF\-J[A8CPIE_8=O.@"]A(:OXPR?(A *NXJ/#R,+).CXEJ2:@GL'Z&:8
M1V<;\A8ZGOFO@JI3E$[BPU5(/ FHJF=]F@%JAKQ%![@>(GD*;CSE":<_4F)U
M^>W%AX=&-PF9#SS#UQ.XW9I>O!^)=T30V@_8N@GBB/9HE?#KTV'M]YFP]NDA
MO@+UZTP-(]LXIQ(G6\X6%\IB,E->8MVH,1YW"'D/(>]7&_)&EA1Y4][SVK_Y
M)] ]%2X=^0$I/^;D'#H[5VL.-+?H!K7R0XD=&J\L&]%" J48*;PXK,I@G&YU
MJPQ@#440/&C/6Q=$W@#@J"^=;AW@Q#G3 RO3N /4$'BV(:=-A#IO("SB1\Q)
M>XY3>T":L[FIW9B6Z3W''O'4!PNDX>HCL![ 5Z3N&XJ!KCHBM[ML61=@M1@C
MH<]WFF9EZ7>@.>HCK ]Z--"KP3K)3T<;BDRDD>ZUP".P#R N3!7X$'/;ALK$
ME6V8KH[S;(&A/.FH*3&AF$5O2<.)"W-MKL3<-6*=7>K/M_V&=I\1AOTI$>.&
M!6>T/]2('0XGL(?P8>_"AZ[C)1!"O^VC@SZZG@0SNG./;VS=OY<]@0]JFM]2
MT* ?D=Y.W$,FR:_ O>_H^."A?.< $):F2)-,C-B@_B6Z=QRO*Y(]K,)#-P$X
MH8 3,KC6 KB=1LM4<PN]S3/#C=HY+;N.EU5Z16 A"QUYT).-YEC _=NYZ6Z
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M1JGHQ /:M(WT@]5O0[]W@Q#?J#N&0L+#%L&4H*\FW5>/UM%8-I/145D!8-@
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M\?7\/%E^Z.DE_*53FF.*KCKF1!/\#+A%:S 5U3.ONFOZ;A/%&^R[RP ]T?W
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MNPNB5XP7.'XB]D'<)],HS&^F,_435DVK_CU]OGX:I7_&Z1ROHH?0_YOT^MN
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MA!)M"*G^G;NA.GU"G_[Q@MHK0.+5C>QFY9[R82W!&L)#U> G)&L/Q?L&59X
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MTDWAFF;(TZ^6$?VHYC0?VRH>(L4W MPC=('\#*_TFO)64!JA)]*.D_RS_WZ
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M0!%C :--RUMJH@O<=8LY^<QQ\\ALGY-=Z)D;:K!362#1U/-39*Y4M+]$=\4
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M4+),T2:!6NP7%.1(_US#-ZA%!O3)/7AR#Y[<@Z_6/>A[008!^J\\]^F/Z!H
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M.Z$$ 3R .O#(RF(5)<LWTC_QIVS63#ZR[W^3W\!_[BDH]"?_"U!+ 0(4 Q0
M   ( .Z)2E*;S!\LFH0  -$P!@ 1              "  0    !A96UD+3(P
M,C Q,C,Q+GAM;%!+ 0(4 Q0    ( .Z)2E("R/_&00X  *B(   1
M      "  <F$  !A96UD+3(P,C Q,C,Q+GAS9%!+ 0(4 Q0    ( .Z)2E*L
M+6^.2A   -^Z   5              "  3F3  !A96UD+3(P,C Q,C,Q7V-A
M;"YX;6Q02P$"% ,4    " #NB4I2@/8HK'D=  !<[0$ %0
M@ &VHP  865M9"TR,#(P,3(S,5]D968N>&UL4$L! A0#%     @ [HE*4AFY
M^ GU0   EI\# !4              ( !8L$  &%E;60M,C R,#$R,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( .Z)2E(H%Q4 %R\   \2 P 5              "
M 8H" 0!A96UD+3(P,C Q,C,Q7W!R92YX;6Q02P4&      8 !@"* 0  U#$!
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
